PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DAVIS, SF; BYERS, RH; LINDEGREN, ML; CALDWELL, MB; KARON, JM; GWINN, M				DAVIS, SF; BYERS, RH; LINDEGREN, ML; CALDWELL, MB; KARON, JM; GWINN, M			PREVALENCE AND INCIDENCE OF VERTICALLY ACQUIRED HIV-INFECTION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS	Objective.-To estimate human immunodeficiency virus (HIV) type I prevalence among childbearing women, HIV incidence in infants, and the number of children living with HIV infection and acquired immunodeficiency syndrome as a result of transmission from mother to infant (vertical transmission). Design.-The national HIV serosurvey of childbearing women was used to estimate the incidence of vertically acquired HIV infection in children born between 1988 and 1993. Data from the national acquired immunodeficiency syndrome case surveillance system and a multicenter pediatric HIV surveillance project were modeled to estimate incidence in children born between 1978 and 1987. Setting.-Surveillance conducted by the Centers for Disease Control and Prevention, Atlanta, Ga, in collaboration with state and local health departments. Results.-Approximately 14920 HIV-infected infants were born in the United States between 1978 and 1993. Of these, an estimated 12240 children were living at the beginning of 1994; 26% were younger than 2 years, 35% were aged 2 to 4 years, and 39% were aged 5 years or older. Approximately 6530 HIV-infected women gave birth in the United States in 1993, and, based on a 25% vertical transmission rate, an estimated 1630 of their infants were HIV infected. Conclusions-These results provide a basis for estimating medical and other resource needs for HIV-infected women and their children and for measuring the impact of interventions to reduce vertical transmission of HIV.			DAVIS, SF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,E46,ATLANTA,GA 30333, USA.							AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; CALDWELL MB, 1992, PEDIATRICS, V90, P603; CALDWELL MB, 1992, PEDIATRICS, V90, P482; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; KARON JM, 1992, HIVNCID1092028 US DE; LINDSAY MK, 1991, OBSTET GYNECOL, V77, P599; LYON L, 1993, 9TH INT C AIDS BERL; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; SCHABLE B, 1995, PEDIATRICS, V95, P511; WANG MC, 1992, J AM STAT ASSOC, V87, P397, DOI 10.2307/2290270; 1989, MMWR MORB MORTAL SS7, V38, P1; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, HIV AIDS SURVEILLANC, V6, P1; IN PRESS VITAL STATI, V1; 1990, VITAL STATISTICS US, V1; 1994, VITAL STATISTICS US, V1; 1993, ANN SUMMARY BIRTHS M; 1993, VITAL STATISTICS US, V1; 1993, MMWR-MORBID MORTAL W, V42, P869	25	107	107	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					952	955		10.1001/jama.274.12.952	http://dx.doi.org/10.1001/jama.274.12.952			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674525				2022-12-01	WOS:A1995RV73400029
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CENTER FOR DRUGS INAUGURATES FAX-ON-DEMAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-01	WOS:A1995RV73400006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALPROSTADIL APPROVED AS IMPOTENCE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-01	WOS:A1995RV73400004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW SAFETY STANDARD FOR MEDICAL DEVICE WIRES PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-01	WOS:A1995RV73400005
J	BEVERS, RFM; BAKKER, DJ; KURTH, KH				BEVERS, RFM; BAKKER, DJ; KURTH, KH			HYPERBARIC-OXYGEN TREATMENT FOR HEMORRHAGIC RADIATION CYSTITIS	LANCET			English	Article							THERAPY	Radiation-induced severe haemorrhagic cystitis is difficult to treat. Conventional treatments may decrease haematuria but do not affect the radiocystitis itself. Hyperbaric oxygen treatment has been reported to do both. We report the results of a prospective study of hyperbaric oxygen (20 sessions of 100% oxygen inhalation at 3 bar for 90 min in a multiplace hyperbaric chamber) to 40 patients with biopsy-proven radiation cystitis and severe haematuria. Haematuria disappeared completely or improved in 37 patients after treatment. Mean follow-up was 23.1 months (range 1-74); and the recurrence rate was 0.12/year. There were no adverse effects. Hyperbaric oxygen treatment should be considered for patients with severe radiation-induced haematuria.	UNIV AMSTERDAM,ACAD MED CTR,DEPT UROL,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam								Akiyama A, 1994, Nihon Hinyokika Gakkai Zasshi, V85, P1269; FELDMEIER JJ, 1994, UNDERSEA HYPERBAR M, V21, P467; GABB G, 1987, CHEST, V92, P1074, DOI 10.1378/chest.92.6.1074; GRIM PS, 1990, JAMA-J AM MED ASSOC, V263, P2216; KINDWALL EP, 1993, CLIN PLAST SURG, P589; LEE HC, 1994, UNDERSEA HYPERBAR M, V21, P321; MOSS WT, 1979, RAD ONCOLOGY RATIONA, P246; NAKADA T, 1992, EUR UROL, V22, P294; Noordzij JW., 1993, INT UROGYNECOL J, V4, P160; NORKOOL DM, 1993, J UROLOGY, V150, P332, DOI 10.1016/S0022-5347(17)35476-9; PARSONS CL, 1986, J UROLOGY, V136, P813, DOI 10.1016/S0022-5347(17)45087-7; RIJKMANS BG, 1989, EUR UROL, V16, P354; SCHOENROCK GJ, 1986, UROLOGY, V27, P271, DOI 10.1016/0090-4295(86)90289-X; WEISS JP, 1994, J UROLOGY, V151, P1514, DOI 10.1016/S0022-5347(17)35289-8	14	131	138	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					803	805		10.1016/S0140-6736(95)91620-2	http://dx.doi.org/10.1016/S0140-6736(95)91620-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674746				2022-12-01	WOS:A1995RW25800011
J	DECOSAS, J; KANE, F; ANARFI, JK; SODJI, KDR; WAGNER, HU				DECOSAS, J; KANE, F; ANARFI, JK; SODJI, KDR; WAGNER, HU			MIGRATION AND AIDS	LANCET			English	Editorial Material							INFECTION		CTR COOPERAT INT SANTE & DEV,ABIDJAN,COTE IVOIRE; UNIV GHANA,INST STAT SOCIAL & ECON RES,LEGON,GHANA; FORCES ACT MIEUX ETRE MERE & ENFANT,LOME,TOGO; GTZ,DIV HLTH POPULAT & NUTR,ESCHBORN,GERMANY	University of Ghana	DECOSAS, J (corresponding author), GTZ REG AIDS PROGRAMME W & CENT AFRICA,BOX 9698 KIA,ACCRA,GHANA.							ANARFI JK, 1982, THESIS REGIONAL I PO; ASHITEY GA, 1994, EPIDEMIOLOGY DISEASE; KALE K, 1994, ACTES S SIDA MIGRATI, P32; KANE F, 1993, AIDS, V7, P1261, DOI 10.1097/00002030-199309000-00017; LALOU R, 1994, MIGRATION SIDA AFRIQ; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; Odotei I., 1992, MARITIME ANTHR STUDI, V5, P88; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RICH V, 1995, LANCET, V346, P432, DOI 10.1016/S0140-6736(95)92797-2; SUDARKASA N, 1977, SIGNS, V3, P178, DOI 10.1086/493450	10	177	178	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					826	828		10.1016/S0140-6736(95)91631-8	http://dx.doi.org/10.1016/S0140-6736(95)91631-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674750				2022-12-01	WOS:A1995RW25800022
J	FRAISE, AP				FRAISE, AP			DISINFECTION IN ENDOSCOPY	LANCET			English	Editorial Material							GLUTARALDEHYDE				FRAISE, AP (corresponding author), CITY HOSP,NHS TRUST,HOSP INFECT RES LAB,BIRMINGHAM,W MIDLANDS,ENGLAND.							BRADLEY CR, 1995, J HOSP INFECT, V29, P143, DOI 10.1016/0195-6701(95)90196-5; BROADLEY SJ, 1993, J HOSP INFECT, V23, P189, DOI 10.1016/0195-6701(93)90024-T; CALDER IM, 1992, LANCET, V339, P433, DOI 10.1016/0140-6736(92)90124-L; COATES D, 1992, J HOSP INFECT, V21, P241, DOI 10.1016/0195-6701(92)90135-9; COWAN RE, 1994, GUT, V35, P717, DOI 10.1136/gut.35.5.717-a; LYNAM PA, 1995, J HOSP INFECT, V30, P237, DOI 10.1016/S0195-6701(95)90322-4; LYNCH DA, 1994, ENDOSCOPY, V26, P351; TYLER R, 1990, J HOSP INFECT, V15, P339, DOI 10.1016/0195-6701(90)90090-B; VANKLINGEREN B, 1993, J HOSP INFECT, V25, P147, DOI 10.1016/0195-6701(93)90107-B	9	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					787	788		10.1016/S0140-6736(95)91613-X	http://dx.doi.org/10.1016/S0140-6736(95)91613-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674739				2022-12-01	WOS:A1995RW25800004
J	HESLOP, HE; BENAIM, E; BRENNER, MK; KRANCE, RA; STRICKLIN, LM; ROCHESTER, RJ; BILLING, R				HESLOP, HE; BENAIM, E; BRENNER, MK; KRANCE, RA; STRICKLIN, LM; ROCHESTER, RJ; BILLING, R			RESPONSE OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE TO LYMPHOBLAST ANTIBODY CBL1	LANCET			English	Note								Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA; CV CANC CTR, SAN MARCOS, CA USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	HESLOP, HE (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38101 USA.		Brenner, Malcolm/Y-2509-2019; Heslop, Helen/AAC-9500-2020		NATIONAL CANCER INSTITUTE [P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21745, CA 20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANASETTI C, 1994, BLOOD, V84, P1320; ANTIN JH, 1994, BLOOD, V84, P1342, DOI 10.1182/blood.V84.4.1342.bloodjournal8441342; BILLING R, 1982, HYBRIDOMA, V1, P303, DOI 10.1089/hyb.1.1982.1.303; BLAISE D, 1995, LANCET, V345, P1144, DOI 10.1016/S0140-6736(95)90978-8; BYERS VS, 1990, BLOOD, V75, P1426; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; HERVE P, 1992, BLOOD, V79, P3362; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; PRENTICE HG, 1984, LANCET, V1, P472; TAKAHASHI H, 1983, LANCET, V2, P1155	10	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 23	1995	346	8978					805	806		10.1016/S0140-6736(95)91621-0	http://dx.doi.org/10.1016/S0140-6736(95)91621-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674747				2022-12-01	WOS:A1995RW25800012
J	HILL, MR; JAMES, AL; FAUX, JA; RYAN, G; HOPKIN, JM; LESOUEF, P; MUSK, AW; COOKSON, WOCM				HILL, MR; JAMES, AL; FAUX, JA; RYAN, G; HOPKIN, JM; LESOUEF, P; MUSK, AW; COOKSON, WOCM			FC-EPSILON-RI-BETA POLYMORPHISM AND RISK OF ATOPY IN A GENERAL-POPULATION SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							SINGLE AMINO-ACID; BRONCHIAL HYPERRESPONSIVENESS; SERUM IGE; RESPONSES; ASTHMA; CHROMOSOME-11Q13; LINKAGE; ALLERGY; INFANCY; ADULTS	Objective-To establish the prevalence of Fc epsilon RI-beta polymorphisms Leu181 and Leu181/Leu183 on chromosome 11q13 in the general population and to examine whether when maternally inherited they confer a risk of atopy. Design-A population based survey for measures of atopy (skin prick test reactions, specific IgE titres, total serum IgE concentration), bronchial hyperresponsiveness, and carriage of Fc epsilon RI-beta Leu181 and Leu181/Leu183. Setting-The rural coastal town of Busselton, Western Australia. Subjects-1004 members of 230 two generation families identified through adults aged under 55. Results-Fc epsilon RI-beta Leu181/Leu183 was identified in 45 subjects (4.5%). All 13 children who had inherited the variant maternally were atopic. Six had asthma and nine rhinitis. The odds ratio of a positive Skin prick test reaction to house dust mite or grass pollen in these children compared with the other 523 children was 7.37 (95% confidence interval 1.62 to 33.60). The 95% confidence interval for the odds ratio of a positive specific IgE response (radio-allergosorbent test) was 3.00 to infinity and the odds ratio for bronchial hyperresponsiveness was 3.70 (1.21 to 11.60). By contrast, the eight children mho had derived the variant paternally had negative skin prick and radioallergosorbent test results and did not have increased bronchial responsiveness. Conclusion-Fc epsilon R triple prime beta Leu181/Leu183 when inherited maternally identifies a genetic risk factor for atopy and bronchial hyperresponsiveness.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; QUEEN ELIZABETH II MED CTR,DEPT RESP MED,PERTH,WA 6009,AUSTRALIA; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA,AUSTRALIA	University of Oxford; University of Western Australia; University of Oxford; University of Western Australia			Le Souef, Peter N/H-5256-2014; Hill, Michael/C-4861-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERG N, 1994, CLIN EXP ALLERGY, V23, P829; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	25	132	135	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					776	779		10.1136/bmj.311.7008.776	http://dx.doi.org/10.1136/bmj.311.7008.776			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580438	Green Published			2022-12-01	WOS:A1995RX10700019
J	MANT, J; HICKS, N				MANT, J; HICKS, N			DETECTING DIFFERENCES IN QUALITY OF CARE - THE SENSITIVITY OF MEASURES OF PROCESS AND OUTCOME IN TREATING ACUTE MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; UNITS	The merits or otherwise of publishing hospital specific death rates are much debated. This article compares the relative sensitivity of measures of process and outcome to differences in quality of care for the hospital treatment of myocardial infarction. Aspects of hospital care that have a proved impact on mortality from myocardial infarction are identified, and the results from meta-analysis and large randomised controlled trials are used to estimate the impact that optimal use of these interventions would have on mortality in a typical district general hospital. Sample size calculations are then performed to determine how many years of data would be needed to detect significant differences between hospitals. A comparison is then made with the amount of data that would be needed to detect significant differences if information about process of care was being collected. Process measures based on the results of randomised controlled trials were found to be able to detect relevant differences between hospitals that would not be identified by comparing hospital specific mortality, which is an insensitive indicator of the quality of care.	OXFORDSHIRE HLTH, HEADINGTON, OXON, ENGLAND		MANT, J (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND.			Hicks, Nicholas/0000-0002-7214-9678				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CLARKE A, 1993, BRIT MED J, V307, P1436, DOI 10.1136/bmj.307.6917.1436; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; DILLNER L, 1994, BRIT MED J, V309, P1599, DOI 10.1136/bmj.309.6969.1599a; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; Moher M., 1995, EVIDENCE EFFECTIVENE; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROBINSON R, 1995, BRIT MED J, V310, P755, DOI 10.1136/bmj.310.6982.755; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Sheldon T A, 1993, Qual Health Care, V2, P149, DOI 10.1136/qshc.2.3.149; 1995, ASSESSING OPTIONS CO; 1992, LANCET, V239, P753; 1993, LANCET, V341, P1183	21	221	222	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	1995	311	7008					793	796		10.1136/bmj.311.7008.793	http://dx.doi.org/10.1136/bmj.311.7008.793			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580444	Green Published			2022-12-01	WOS:A1995RX10700026
J	NEWTON, JN; HENDERSON, J; GOLDACRE, MJ				NEWTON, JN; HENDERSON, J; GOLDACRE, MJ			WAITING LIST DYNAMICS AND THE IMPACT OF EARMARKED FUNDING	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To determine how changes in the number of admissions from waiting lists and changes in the number of additions to the lists are related to list size and waiting times, in the context of local waiting list initiatives. Design-Review of national and Korner statistics. Setting-England (1987-94) and districts of the former Oxford region (1987-91). Main outcome measures-Correlation of quarterly changes in the number of admissions from waiting Lists in England with changes in total list size, numbers of patients waiting one to two, or over two years, and number of additions to the lists; examination of changes in waiting list statistics for individual district specialties in one region in relation to funding for waiting list initiatives. Results-Nationally, changes in the number of admissions to hospital from lists closely correlated with changes in the number of additions to lists (r=0.84; P<0.01). After adjusting for changes in the number of additions to lists, changes in the number of admissions correlated inversely with changes in List size (r=-0.62; P<0.001), Decreases in the number of patients waiting from one to two years were significantly associated with increases in the number of admissions (r=-0.52; P<0.01); locally, only six of 44 waiting list initiatives were followed by an increase in admissions and a fall in list size, although a further 11 were followed by a fall in list size without a corresponding increase in admissions. Conclusions-An increase in admissions improved waiting times but did not reduce list size because additions to the list tended to increase at the same time. The appropriateness of waiting list initiatives as a method of funding elective surgery should be reviewed.			NEWTON, JN (corresponding author), UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.		Newton, John/HCH-8693-2022	Henderson, Jane/0000-0001-7527-694X; Newton, John/0000-0002-5641-6457				Arnstein P M, 1991, Br J Plast Surg, V44, P553, DOI 10.1016/0007-1226(91)90029-J; Frankel S, 1989, Health Trends, V21, P56; GOLDACRE MJ, 1987, BRIT MED J, V295, P1105, DOI 10.1136/bmj.295.6606.1105; HEMINGWAY H, 1995, BRIT MED J, V310, P818, DOI 10.1136/bmj.310.6983.818; MILLS RP, 1991, J ROY SOC MED, V84, P405, DOI 10.1177/014107689108400709; Naylor C D, 1994, Qual Health Care, V3, P221, DOI 10.1136/qshc.3.4.221; PARMAR JR, 1993, ANN ROY COLL SURG, V75, P4; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; POPE C, 1992, BRIT MED J, V305, P577, DOI 10.1136/bmj.305.6853.577; Umeh H N, 1994, Ann R Coll Surg Engl, V76, P4; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA; 1992, HLTH SERVICE CHARTER; 1994, EL9490 NHS EX; 1992, 4TH REPORT PROGR NHS; 1987, HOSPITAL WAITING STA; 1909, REVISED EXPANDED PAT; 1995, BRIT MED J, V310, P1045	17	27	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					783	785		10.1136/bmj.311.7008.783	http://dx.doi.org/10.1136/bmj.311.7008.783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580440	Green Published			2022-12-01	WOS:A1995RX10700021
J	REZZA, G; PEZZOTTI, P; AIUTI, F				REZZA, G; PEZZOTTI, P; AIUTI, F			ACQUIRED IMMUNODEFICIENCY WITHOUT HIV-INFECTION - EPIDEMIOLOGY AND CLINICAL OUTCOME IN ITALY	BRITISH MEDICAL JOURNAL			English	Article							CD4+ T-LYMPHOCYTOPENIA		UNIV ROMA LA SAPIENZA,CATTEDRA ALLERGOL & IMMUNOL CLIN,I-00162 ROME,ITALY	Sapienza University Rome	REZZA, G (corresponding author), IST SUPER SANITA,CTR OPERAT AIDS,I-00161 ROME,ITALY.		PEZZOTTI, PATRIZIO/C-6480-2016; rezza, giovanni/D-4393-2016	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; rezza, giovanni/0000-0003-0268-6790				ABENI DD, 1993, GIORNALE ITALIANO AI, V4, P16; HO DD, 1993, NEW ENGL J MED, V328, P380, DOI 10.1056/NEJM199302113280602; MCNULTY A, 1994, BRIT MED J, V308, P825, DOI 10.1136/bmj.308.6932.825; MONTELLA F, 1994, AIDS, V8, P390, DOI 10.1097/00002030-199403000-00018; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					785	786		10.1136/bmj.311.7008.785	http://dx.doi.org/10.1136/bmj.311.7008.785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580441	Green Published			2022-12-01	WOS:A1995RX10700022
J	SAUNDERS, N; HAMMERSLEY, B				SAUNDERS, N; HAMMERSLEY, B			MAGNESIUM FOR ECLAMPSIA	LANCET			English	Editorial Material							PREECLAMPSIA-ECLAMPSIA; SULFATE				SAUNDERS, N (corresponding author), PRINCESS ANNE HOSP,SOUTHAMPTON,HANTS,ENGLAND.							BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; COTTON DB, 1992, AM J OBSTET GYNECOL, V166, P1127, DOI 10.1016/S0002-9378(11)90599-7; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; GOODWIN JS, 1984, JAMA-J AM MED ASSOC, V251, P2387, DOI 10.1001/jama.251.18.2387; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; SADEH M, 1989, STROKE, V20, P1273, DOI 10.1161/01.STR.20.9.1273; Sibai B M, 1992, Int J Obstet Anesth, V1, P167, DOI 10.1016/0959-289X(92)90024-X; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P728, DOI 10.1016/0002-9378(84)90676-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V163, P1049, DOI 10.1016/0002-9378(90)91123-T; The Eclampsia Trial Collaborative Group, 1995, LANCET, V345, P1445	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					788	789		10.1016/S0140-6736(95)91614-8	http://dx.doi.org/10.1016/S0140-6736(95)91614-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674740				2022-12-01	WOS:A1995RW25800005
J	VERSCHUREN, WMM; KROMHOUT, D				VERSCHUREN, WMM; KROMHOUT, D			TOTAL CHOLESTEROL CONCENTRATION AND MORTALITY AT A RELATIVELY YOUNG AGE - DO MEN AND WOMEN DIFFER	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; FOLLOW-UP; PLASMA-CHOLESTEROL; PAISLEY SURVEY; CANCER; POPULATION; RENFREW; COHORT; RISK	Objective-To investigate the relation between total cholesterol concentration and mortality from coronary heart disease, cardiovascular diseases, non-cardiovascular causes, and all causes. Design-Population based cohort study. Subjects-23000 men and 26000 women aged 30-51 years examined between 1974 and 1980. Main outcome measures-Mortality for the above mentioned end points for fifths of cholesterol distribution, and relative risks estimated by using Cox's proportional hazard (survival) analysis. Adjustment was made for age, smoking, systolic blood pressure, and body mass index. Results-Mortality from coronary heart disease in men was five times higher than that in women. A strong positive association between total cholesterol concentration and mortality from coronary heart disease and cardiovascular diseases was observed in both men and women, The relative risk for the highest compared with the lowest fifth of the cholesterol distribution was for mortality from coronary heart disease (3.0 (95% confidence interval 1.8 to 5.1) in men and 3.8 (1.1 to 13.1) in women) and for mortality from cardiovascular disease (2.8 (1.8 to 4.2) in men and 2.9 (1.4 to 6.0) in women). No increase of non-cardiovascular mortality at low cholesterol concentration was observed. All cause mortality was significantly higher in the highest compared with the lowest fifth of the cholesterol distribution: relative risk 1.6 (1.3 to 2.0) in men and 1.5 (1.1 to 1.9) in women. Conclusion-Total cholesterol concentration is a strong predictor of mortality from coronary heart disease, cardiovascular diseases, and all causes in women as well as in men. Low cholesterol concentrations are not associated with increased mortality from non-cardiovascular causes,			VERSCHUREN, WMM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Kromhout, Daan/A-8566-2014					ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1993, NETH J CARDIOL; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MEIJER J, 1976, HART B, V7, P42; NEATON JD, 1992, ARCH INTERN MED, V152, P1480; PERSSON B, 1984, ACTA MED SCAND, V216, P485; RUWAARD D, 1993, PUBLIC HLTH STATUS F, P377; SCHATZKIN A, 1988, CANCER RES, V48, P452; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; VERSCHUREN WMM, 1991, AM J EPIDEMIOL, V134, P1290, DOI 10.1093/oxfordjournals.aje.a116032; 1989, SAS STAT USERS GUIDE, V1; 1994, WOMEN CARDIOVASCULAR; 1982, JAMA-J AM MED ASSOC, V248, P2853; 1990, HART B S, V23, P9	28	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					779	783		10.1136/bmj.311.7008.779	http://dx.doi.org/10.1136/bmj.311.7008.779			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580439	Green Published, Green Accepted			2022-12-01	WOS:A1995RX10700020
J	WALLEY, T; BARTON, S				WALLEY, T; BARTON, S			A PURCHASER PERSPECTIVE OF MANAGING NEW DRUGS - INTERFERON-BETA AS A CASE-STUDY	BRITISH MEDICAL JOURNAL			English	Article								Many new drugs in the future will be very expensive and have major resource implications. Given current structures and legislation covering the prescribing of drugs, there are no clear means of controlling the use of these drugs to avoid diverting money away from other health care services and into drug treatment. This paper considers what mechanisms might be used by a purchaser to manage the introduction of an expensive new drug and uses interferon beta-1b for treating multiple sclerosis as an example. The most likely mechanism is the prescribing of the drug by a general practitioner on the advice of a neurologist. This would achieve a good benefit for the resources invested but would not control total expenditure. Devolving a limited budget for the drug to a specialist centre so that neurologists may prescribe it directly would be preferable, as this would link clinical, prescribing, and budgetary responsibility. These issues need to be addressed urgently by purchasers if major disruptions of services are to be avoided.			WALLEY, T (corresponding author), UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; CRUMP BJ, 1995, BRIT MED J, V310, P509, DOI 10.1136/bmj.310.6978.509; GOODKIN DE, 1994, LANCET, V344, P1702, DOI 10.1016/S0140-6736(94)90484-7; GOODKIN DE, 1994, LANCET, V344, P1057, DOI 10.1016/S0140-6736(94)91713-2; GOULD J, 1994, BRIT MED J, V309, P1657, DOI 10.1136/bmj.309.6969.1657b; HAYCOX A, 1995, PURCHASER DECISION M; JONES R, 1992, BRIT MED J, V304, P4, DOI 10.1136/bmj.304.6818.4; LEUFKENS H, 1994, BRIT MED J, V309, P1137, DOI 10.1136/bmj.309.6962.1137; MOONEY G, 1994, KEY ISSUES HLTH EC; NISHIMURA LY, 1994, PHARMACOECONOMICS, V6, P498, DOI 10.2165/00019053-199406060-00003; ORME M, 1991, BRIT MED J, V303, P593, DOI 10.1136/bmj.303.6803.593; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WALLEY T, 1994, PHARMACOECONOMICS, V5, P93, DOI 10.2165/00019053-199405020-00003; 1994, GUIDELLINES CONDUCT; 1994, BETA INTERFERON 1B P; 1995, EL955 NHS EX DEP HLT; 1994, PRIORITY SETTING NHS, V1; 1991, EL91127 NHS MAN EX D; 1994, NEW TREATMENTS MULTI; 1994, NEUROLOGY, V44, P1537; 1994, EL9472 NHS EX DEP HL; 1944, GUIDELINES TREATMENT	23	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					796	799		10.1136/bmj.311.7008.796	http://dx.doi.org/10.1136/bmj.311.7008.796			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580445	Green Published			2022-12-01	WOS:A1995RX10700027
J	WELLIVER, RC				WELLIVER, RC			RSV AND CHRONIC ASTHMA	LANCET			English	Editorial Material							VIRUS-SPECIFIC IGE; RESPIRATORY SYNCYTIAL VIRUS; INFECTION; PATHOGENESIS; SUBSEQUENT; CHILDHOOD; CHILDREN		CHILDRENS HOSP,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	WELLIVER, RC (corresponding author), SUNY BUFFALO,DEPT PEDIAT,DIV INFECT DIS,BUFFALO,NY 14260, USA.							BUI RHD, 1987, J PEDIATR-US, V110, P87; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; SIGURS N, 1995, PEDIATRICS, V95, P500; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEMPEL DA, 1981, MED CLIN N AM, V65, P1045, DOI 10.1016/S0025-7125(16)31488-2; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; WELLIVER RC, 1986, AM J DIS CHILD, V140, P34, DOI 10.1001/archpedi.1986.02140150036029	11	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					789	790		10.1016/S0140-6736(95)91615-6	http://dx.doi.org/10.1016/S0140-6736(95)91615-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674741				2022-12-01	WOS:A1995RW25800006
J	WHINCUP, P; COOK, D; PAPACOSTA, O; WALKER, M				WHINCUP, P; COOK, D; PAPACOSTA, O; WALKER, M			BIRTH-WEIGHT AND BLOOD-PRESSURE - CROSS-SECTIONAL AND LONGITUDINAL RELATIONS IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION INUTERO; ADULT LIFE; CHILDREN; INITIATION; MORTALITY; FETAL; SIZE; RISK	Objective-To examine cross sectional and longitudinal relations between birth weight and blood pressure in childhood. Design-Cross sectional study of primary school children aged 9-11 years, with analysis in relation to previous measurements at 5-7 years in a subgroup. Setting-20 primary schools in Guildford and Carlisle. Subjects-1511 children measured at 9-11 years (response rate 79%), including 549 who had been measured at 5-7 years. Main outcome measures-Blood pressure at 9-11 years, change in blood pressure between 5-7 and 9-11 years, birth weight (based on maternal recall), and placental weight (based on birth records). Results-At 9-11 years birth weight was inversely related both to systolic blood pressure (regression coefficient -2.80 mm Hg/kg; 95% confidence interval -3.84 to -1.76) and to diastolic blood pressure (regression coefficient -1.42 mm Hg/kg; -2.14 to -0.70) once current height and body mass index were taken into account. Placental weight was inversely related to blood pressure after adjustment for current height and body mass index but placental ratio (placental weight to birth weight) was unrelated to blood pressure. Between 5-7 and 9-11 years systolic blood pressure rose more rapidly in children of lower birth weight (regression coefficient -1.71 mm Hg/kg; -3.35 to -0.07). This effect seemed to be stronger in girls. Conclusions-Birth weight rather than placental ratio is the early Life factor most importantly related to blood pressure in childhood. The results support the possibility of ''amplification'' of the relation between birth weight and blood pressure, particularly in girls.	UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND	St Georges University London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Papacosta, Olia/0000-0001-8781-6747; Whincup, Peter/0000-0002-5589-4107				BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; CARTER J, 1984, LOW BIRTHWEIGHT MED, P191; FROHLICH ED, 1988, CIRCULATION, V77, P502; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F SYMP, V156, P38; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337; WHINCUP PH, 1988, LANCET, V2, P890; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WHINCUP PH, 1989, J HYPERTENS, V7, P845, DOI 10.1097/00004872-198910000-00010; WHINCUP PH, 1993, BRIT MED J, V306, P584, DOI 10.1136/bmj.306.6877.584; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; 1985, SAS USERS GUIDE BASI	22	141	147	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					773	776		10.1136/bmj.311.7008.773	http://dx.doi.org/10.1136/bmj.311.7008.773			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580437	Green Published			2022-12-01	WOS:A1995RX10700018
J	ACHARYA, U; JACOBS, R; PETERS, JM; WATSON, N; FARQUHAR, MG; MALHOTRA, V				ACHARYA, U; JACOBS, R; PETERS, JM; WATSON, N; FARQUHAR, MG; MALHOTRA, V			THE FORMATION OF GOLGI STACKS FROM VESICULATED GOLGI MEMBRANES REQUIRES 2 DISTINCT FUSION EVENTS	CELL			English	Article							GTP-BINDING PROTEINS; VESICLE FUSION; STOMATITIS-VIRUS; TRANSPORT; PURIFICATION; ENDOCYTOSIS; INVITRO; FAMILY; YEAST; NSF	We have reconstituted the fusion and assembly of vesiculated Golgi membranes (VGMs) into functionally active stacks of cisternae. A kinetic analysis of this assembly process revealed that highly dispersed VGMs of 60-90 nm diameter first fuse to form larger vesicles of 200-300 nm diameter that are clustered together. These vesicles then fuse to form tubular elements and short cisternae, which finally assemble into stacks of cisternae. We now provide evidence that the sequential stack formation from VGMs reflects two distinct fusion processes: the first event is N-ethylmaleimide (NEM)-sensitive factor (NSF) dependent, and the second fusion event requires an NSF-like NEM-sensitive ATPase called p97. Interestingly, while the earliest steps in stack formation share some similarities with events catalyzing fusion of transport vesicles to its target membrane, neither GTP IS nor Rab-GDI, inhibitors of vesicular protein traffic, inhibit stack formation.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,MOLEC & NEUROBIOL LABS,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of California System; University of California San Diego; Salk Institute; Harvard University; Harvard Medical School	ACHARYA, U (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM46224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	31	178	179	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					895	904		10.1016/0092-8674(95)90269-4	http://dx.doi.org/10.1016/0092-8674(95)90269-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553850	Bronze			2022-12-01	WOS:A1995RW69300006
J	AITTOMAKI, K; LUCENA, JLD; PAKARINEN, P; SISTONEN, P; TAPANAINEN, J; GROMOLL, J; KASKIKARI, R; SANKILA, EM; LEHVASLAIHO, H; ENGEL, AR; NIESCHLAG, E; HUHTANIEMI, I; DELACHAPELLE, A				AITTOMAKI, K; LUCENA, JLD; PAKARINEN, P; SISTONEN, P; TAPANAINEN, J; GROMOLL, J; KASKIKARI, R; SANKILA, EM; LEHVASLAIHO, H; ENGEL, AR; NIESCHLAG, E; HUHTANIEMI, I; DELACHAPELLE, A			MUTATION IN THE FOLLICLE-STIMULATING-HORMONE RECEPTOR GENE CAUSES HEREDITARY HYPERGONADOTROPIC OVARIAN FAILURE	CELL			English	Article							LUTEINIZING-HORMONE; MOLECULAR-CLONING; GONADOTROPIN-DEFICIENCY; CHORIONIC-GONADOTROPIN; FUNCTIONAL EXPRESSION; PRECOCIOUS PUBERTY; CYCLIC-AMP; CDNA; RAT; LOCALIZATION	Hypergonadotropic ovarian dysgenesis (ODG) with normal karyotype is a heterogeneous condition that in some cases displays Mendelian recessive inheritance, By systematically searching for linkage in multiplex affected families, we mapped a locus for ODG to chromosome 2p, As the previously cloned follicle-stimulating hormone receptor (FSHR) gene had been assigned to 2p, we searched it for mutations, A C566T transition in exon 7 of FSHR predicting an Ala to Val substitution at residue 189 in the extracellular ligand-binding domain segregated perfectly with the disease phenotype. Expression of the gene in transfected cells demonstrated a dramatic reduction of binding capacity and signal transduction, but apparently normal ligand-binding affinity of the mutated receptor. We conclude that the mutation causes ODG in these families.	UNIV TURKU,DEPT PHYSIOL,SF-20520 TURKU,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND; UNIV OULU,CENT HOSP,DEPT OBSTET & GYNECOL,SF-90220 OULU,FINLAND; UNIV MUNSTER,INST REPROD MED,D-48149 MUNSTER,GERMANY; UNIV MALAGA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,E-29080 MALAGA,SPAIN; UNIV HELSINKI,CENT HOSP,DEPT CLIN GENET,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,SF-00290 HELSINKI,FINLAND	University of Turku; University of Oulu; University of Munster; Universidad de Malaga; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	AITTOMAKI, K (corresponding author), UNIV HELSINKI,DEPT MED GENET,HAARTMANINKATU 3,SF-00290 HELSINKI,FINLAND.		Gromoll, Joerg/AAB-2146-2019	Gromoll, Joerg/0000-0002-7788-8138; REYES ENGEL, ARMANDO/0000-0002-7294-8103				AIMAN J, 1985, OBSTET GYNECOL, V66, P9; AITTOMAKI K, 1994, AM J HUM GENET, V54, P844; BROOKER G, 1979, ADV CYCLIC NUCLEOTID, P1; CATT K, 1976, METHODS RECEPTOR RES, P175; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUZINET B, 1988, J CLIN ENDOCR METAB, V66, P552, DOI 10.1210/jcem-66-3-552; DAVIS D, 1995, MOL ENDOCRINOL, V9, P169; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GRANAT M, 1983, FERTIL STERIL, V40, P215; GROMOLL J, 1994, J MOL ENDOCRINOL, V12, P265, DOI 10.1677/jme.0.0120265; GROMOLL J, 1993, BIOCHEM BIOPH RES CO, V196, P1066, DOI 10.1006/bbrc.1993.2359; GROMOLL J, 1992, BIOCHEM BIOPH RES CO, V188, P1077, DOI 10.1016/0006-291X(92)91341-M; GUDERMANN T, 1994, ENDOCRINOLOGY, V135, P2204, DOI 10.1210/en.135.5.2204; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALPIN DMG, 1986, J REPROD FERTIL, V78, P119, DOI 10.1530/jrf.0.0780119; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; JONES GS, 1969, AM J OBSTET GYNECOL, V104, P597, DOI 10.1016/S0002-9378(16)34255-7; KARONEN SL, 1975, ANAL BIOCHEM, V67, P1, DOI 10.1016/0003-2697(75)90266-3; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LAPOLT PS, 1992, ENDOCRINOLOGY, V130, P1289, DOI 10.1210/en.130.3.1289; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEACH FS, 1994, HUM MOL GENET, V3, P2082; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; MATSUMOTO AM, 1989, TESTIS, P181; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; MAXSON WS, 1983, SEMIN REPROD ENDOCR, V1, P147, DOI 10.1055/s-2007-1022585; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; Myers R. M., 1988, Genome analysis: a practical approach., P95; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NEVANLINNA HR, 1972, HEREDITAS-GENETISK A, V71, P195; Norio R., 1981, BIOCULTURAL ASPECTS, P359; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; RANNIKKO AS, 1995, MOL CELL ENDOCRINOL, V107, P196; REBAR RW, 1990, FERTIL STERIL, V53, P804; REINDOLLAR RH, 1984, J REPROD MED, V29, P391; RICHARDS JS, 1995, ENDOCR REV, V15, P725; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V54, P77, DOI 10.1159/000132962; ROUSSEAUMERCK MF, 1993, GENOMICS, V15, P222, DOI 10.1006/geno.1993.1041; Sambrook J., 1989, MOL CLONING LAB MANU; SANKILA EM, 1995, HUM MOL GENET, V4, P93, DOI 10.1093/hmg/4.1.93; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIMPSON J L, 1971, Birth Defects Original Article Series, V7, P215; SIMPSON JL, 1979, GENETIC MECHANISMS S, P365; SMITH A, 1979, FERTIL STERIL, V32, P528; SOKKA T, 1990, J ENDOCRINOL, V127, P297, DOI 10.1677/joe.0.1270297; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TILLY JL, 1992, ENDOCRINOLOGY, V130, P1296, DOI 10.1210/en.130.3.1296; VANCAMPENHOUT J, 1972, OBSTET GYNECOL, V40, P6; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; WEINBAUER GF, 1993, MOL BIOL MALE REPROD, P99; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; YARNEY TA, 1993, MOL CELL ENDOCRINOL, V93, P219, DOI 10.1016/0303-7207(93)90127-6; ZIRKIN BR, 1994, J ANDROL, V15, P273	64	685	716	0	24	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					959	968		10.1016/0092-8674(95)90275-9	http://dx.doi.org/10.1016/0092-8674(95)90275-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553856	Bronze			2022-12-01	WOS:A1995RW69300012
J	BACON, KB; PREMACK, BA; GARDNER, P; SCHALL, TJ				BACON, KB; PREMACK, BA; GARDNER, P; SCHALL, TJ			ACTIVATION OF DUAL T-CELL SIGNALING PATHWAYS BY THE CHEMOKINE RANTES	SCIENCE			English	Article							LYMPHOCYTES-T; TYROSINE PHOSPHORYLATION; COUPLED RECEPTORS; CALCIUM CURRENT; G-PROTEIN; INTERLEUKIN-8; FLUORESCENCE; DEPLETION; STORES	The chemokine RANTES induced biphasic mobilization of Ca2+ in T cells. The initial peak, a transient increase in cytosolic Ca2+ mediated by a heterotrimeric guanine nucleotide-binding protein (G protein)-coupled pathway, was associated predominantly with chemotaxis. The second peak, Ca2+ release and sustained influx dependent on protein tyrosine kinases, was associated with a spectrum of cellular responses--Ca2+ channel opening, interleukin-2 receptor expression, cytokine release, and T cell proliferation-characteristic of T cell receptor activation. Other chemokines did not produce these responses. Thus, in addition to inducing chemotaxis, RANTES can act as an antigenin-dependent activator of T cells in vitro.	STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Stanford University	BACON, KB (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.				NIGMS NIH HHS [GM07065] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON KB, 1995, J IMMUNOL, V154, P3654; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BACON KB, 1993, BLOOD, V81, P430; BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAY LS, 1989, J IMMUNOL, V142, P1631; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MODESTO J, 1991, CELL SIGNAL, V3, P25, DOI 10.1016/0898-6568(91)90004-E; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PREMACK BA, 1994, ADV EXP MED BIOL, V365, P91; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1115; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RONCAROLO MG, 1989, J EXP MED, V168, P2139; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1994, CYTOKINE HDB, P419; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SOZZANI S, 1994, J IMMUNOL, V152, P3615; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	35	396	409	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1727	1730		10.1126/science.7569902	http://dx.doi.org/10.1126/science.7569902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569902				2022-12-01	WOS:A1995RV94800040
J	BOLSHAKOV, VY; SIEGELBAUM, SA				BOLSHAKOV, VY; SIEGELBAUM, SA			REGULATION OF HIPPOCAMPAL TRANSMITTER RELEASE DURING DEVELOPMENT AND LONG-TERM POTENTIATION	SCIENCE			English	Article							MINIATURE SYNAPTIC CURRENTS; QUANTAL ANALYSIS; PYRAMIDAL CELLS; NEURONS; PROBABILITY; AMPLITUDE; SLICES; TRANSMISSION; SYNAPSES; PAIRS	Developmental changes in rat hippocampal transmitter release and synaptic plasticity were investigated. Recordings from pairs of pyramidal neurons in slices showed that an action potential in a CA3 neuron released only a single quantum of transmitter onto a CAI neuron. Failures of synaptic transmission reflected probabilistic transmitter release. The probability of release (P-r) was 0.9 in 4- to 8-day-old rats and decreased to less than 0.5 at 2 to 3 weeks. Long-term potentiation (LTP) in 2- to 3-week-old rats was associated with an increase in P-r from a single synaptic site. The high initial P-r in 4- to 8-day-old rats normally occludes the expression of LTP at this stage.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	BOLSHAKOV, VY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PHARMACOL,722 W 168TH ST,NEW YORK,NY 10032, USA.							ARANCIO O, 1994, J PHYSIOL-LONDON, V481, P395, DOI 10.1113/jphysiol.1994.sp020448; BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P1229; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; JESSELL TM, 1993, NEURON S, V10, P1; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Katz B., 1969, RELEASE NEURAL TRANS; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; PURVES D, 1985, PRINCIPLES NEURAL DE; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SAYER RJ, 1990, J NEUROSCI, V10, P826; SORRA KE, 1993, J NEUROSCI, V13, P3736; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	43	300	303	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1730	1734		10.1126/science.7569903	http://dx.doi.org/10.1126/science.7569903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569903				2022-12-01	WOS:A1995RV94800041
J	BURRIGHT, EN; CLARK, HB; SERVADIO, A; MATILLA, T; FEDDERSEN, RM; YUNIS, WS; DUVICK, LA; ZOGHBI, HY; ORR, HT				BURRIGHT, EN; CLARK, HB; SERVADIO, A; MATILLA, T; FEDDERSEN, RM; YUNIS, WS; DUVICK, LA; ZOGHBI, HY; ORR, HT			SCA1 TRANSGENIC MICE - A MODEL FOR NEURODEGENERATION CAUSED BY AN EXPANDED CAG TRINUCLEOTIDE REPEAT	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; SPINOCEREBELLAR ATAXIA; PURKINJE-CELLS; LARGE KINDREDS; EXPRESSION; DEFINITION; DELETION; PROMOTER; ANTIGEN	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant inherited disorder characterized by degeneration of cerebellar Purkinje cells, spinocerebellar tracts, and selective brainstem neurons owing to the expansion of an unstable CAG trinucleotide repeat. To gain insight into the pathogenesis of the SCA1 mutation and the intergenerational stability of trinucleotide repeats in mice, we have generated transgenic mice expressing the human SCA1 gene with either a normal or an expanded CAG tract. Both transgenes were stable in parent to offspring transmissions. While all six transgenic lines expressing the unexpanded human SCA1 allele had normal Purkinje cells, transgenic animals from five of six lines with the expanded SCA1 allele developed ataxia and Purkinje cell degeneration. These data indicate that expanded CAG repeats expressed in Purkinje cells are sufficient to produce degeneration and ataxia and demonstrate that a mouse model can be established for neurodegeneration caused by CAG repeat expansions.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine	BURRIGHT, EN (corresponding author), UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA.		MATILLA-DUEÑAS, ANTONI/C-7980-2011	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033718, R01NS027699] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33718, NS09724-01, NS27699] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BANFI S, 1993, GENOMICS, V18, P627, DOI 10.1016/S0888-7543(05)80365-9; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; FEDDERSEN RM, 1995, MOL CELL NEUROSCI, V6, P153, DOI 10.1006/mcne.1995.1014; GACY AM, 1995, CELL, V81, P533; GANDELMAN KY, 1992, AM J HUM GENET, V51, P571; HAINES JL, 1984, NEUROLOGY, V34, P1542, DOI 10.1212/WNL.34.12.1542; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Hogan B., 1986, MANIPULATING MOUSE E; JODICE C, 1994, AM J HUM GENET, V54, P959; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOEPPEN AH, 1984, OLIVOPONTOCEREBELLAR, P13; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KWIATKOWSKI TJ, 1993, AM J HUM GENET, V53, P391; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lebowitz P, 1979, Curr Top Microbiol Immunol, V87, P43; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MATILLA T, 1993, HUM MOL GENET, V2, P2123, DOI 10.1093/hmg/2.12.2123; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; QUIGLEY CA, 1992, J CLIN ENDOCR METAB, V74, P927, DOI 10.1210/jc.74.4.927; RANUM LPW, 1994, AM J HUM GENET, V55, P244; RANUM LPW, 1991, AM J HUM GENET, V49, P31; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SMEYNE RJ, 1991, SCIENCE, V254, P719, DOI 10.1126/science.1948052; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Zoghbi H. Y., 1995, METABOLIC MOL BASES, P4559; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8; ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609; ZOGHBI HY, 1991, AM J HUM GENET, V49, P23	41	480	506	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					937	948		10.1016/0092-8674(95)90273-2	http://dx.doi.org/10.1016/0092-8674(95)90273-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553854	Bronze			2022-12-01	WOS:A1995RW69300010
J	DAVID, M; PETRICOIN, E; BENJAMIN, C; PINE, R; WEBER, MJ; LARNER, AC				DAVID, M; PETRICOIN, E; BENJAMIN, C; PINE, R; WEBER, MJ; LARNER, AC			REQUIREMENT FOR MAP KINASE (ERK2) ACTIVITY IN INTERFERON-ALPHA-STIMULATED AND INTERFERON-BETA-STIMULATED GENE-EXPRESSION THROUGH STAT PROTEINS	SCIENCE			English	Article							ACTIVATION; CELLS	Activation of early response genes by interferons (IFNs) requires tyrosine phosphorylation of STAT (signal transducers and activators of transcription) proteins. It was found that the serine-threonine kinase mitogen-activated protein kinase (MAPK) [specifically, the 42-kilodalton MAPK or extracellular signal-regulated kinase 2 (ERK2)] interacted with the alpha subunit of IFN-alpha/beta receptor in vitro and in vivo. Treatment of cells with IFN-beta induced tyrosine phosphorylation and activation of MAPK and caused MAPK and Stat1 alpha to coimmunoprecipitate. Furthermore, expression of dominant negative MAPK inhibited IFN-beta-induced transcription. Therefore, MAPK appears to regulate IFN-alpha and IFN-beta activation of early response genes by modifying the Jak-STAT signaling cascade.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; BIOGEN INC,CAMBRIDGE,MA 02142; PUBL HLTH RES INST,NEW YORK,NY 10016; UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908	US Food & Drug Administration (FDA); Biogen; University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, UNPUB; FINBLOOM DS, UNPUB; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	16	519	536	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1721	1723		10.1126/science.7569900	http://dx.doi.org/10.1126/science.7569900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569900				2022-12-01	WOS:A1995RV94800038
J	EHLERS, MD; TINGLEY, WG; HUGANIR, RL				EHLERS, MD; TINGLEY, WG; HUGANIR, RL			REGULATED SUBCELLULAR-DISTRIBUTION OF THE NR1 SUBUNIT OF THE NMDA RECEPTOR	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CULTURED HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; RAT-BRAIN; PROTEIN-KINASE; CHANNEL; SYNAPSES; PHOSPHORYLATION; LOCALIZATION; POLYAMINES	NMDA (N-methyl-D-aspartate) receptors are selectively localized at the postsynaptic membrane of excitatory synapses in the mammalian brain. The molecular mechanisms underlying this localization were investigated by expressing the NR1 subunit of the NMDA receptor in fibroblasts. NR1 splice variants containing the first COOH-terminal exon cassette (NR1A and NR1D) were located in discrete, receptor-rich domains associated with the plasma membrane. NR1 splice variants lacking this exon cassette (NR1C and NR1E) were distributed throughout the cell, with large amounts of NR1 protein present in the cell interior. Insertion of this exon cassette into the COOH-terminus of the GluR1 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor was sufficient to cause GluR1 to be localized to discrete, receptor-rich domains. Furthermore, protein kinase C phosphorylation of specific serines within this exon disrupted the receptor-rich domains. These results demonstrate that amino acid sequences contained within the NR1 molecule serve to localize this receptor subunit to discrete membrane domains in a manner that is regulated by alternative splicing and protein phosphorylation.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P129; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCK DM, 1992, MOL PHARMACOL, V42, P157; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883	36	250	254	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1734	1737		10.1126/science.7569904	http://dx.doi.org/10.1126/science.7569904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569904				2022-12-01	WOS:A1995RV94800042
J	FENG, GP; DEAK, P; CHOPRA, M; HALL, LM				FENG, GP; DEAK, P; CHOPRA, M; HALL, LM			CLONING AND FUNCTIONAL-ANALYSIS OF TIPE, A NOVEL MEMBRANE-PROTEIN THAT ENHANCES DROSOPHILA PARA SODIUM-CHANNEL FUNCTION	CELL			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; CYCLOPHILIN HOMOLOG NINAA; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; RAT-BRAIN; RETINOTECTAL PROJECTION; SEQUENCE-ANALYSIS; NERVE-CONDUCTION; SKELETAL-MUSCLE; GENE	Voltage-dependent sodium channels are involved in the initiation and propagation of action potentials in many excitable cells. Here we report that tipE, a gene defined by a temperature-sensitive paralytic mutation in Drosophila, encodes a novel integral membrane protein that dramatically stimulates functional expression in Xenopus oocytes of the Drosophila sodium channel a subunit encoded by the paralytic (para) locus. Using a heat shock promoter to control tipE(+) gene expression in transgenic flies, we demonstrate that tipE(+) gene expression is required during pupal development to rescue adult paralysis. In addition, we demonstrate a role for the tipE gene product in adults.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Deák, Péter/M-5674-2018; Feng, Guoping/Y-2827-2019; Deak, Peter/F-7751-2012	Deak, Peter/0000-0002-8849-0352	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016204] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16204] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 1978, GENETICS BIOL DROS A, P1; AURON PE, 1987, BIOTECHNIQUES, V5, P672; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BROADIE K, 1993, NEURON, V11, P607, DOI 10.1016/0896-6273(93)90073-Z; BURG MG, 1993, J NEUROBIOL, V24, P803, DOI 10.1002/neu.480240608; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAWCETT JW, 1985, TRENDS NEUROSCI, V8, P201, DOI 10.1016/0166-2236(85)90079-7; FENG GP, 1995, GENETICS, V139, P1679; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GANETZKY B, 1986, J NEUROGENET, V3, P19, DOI 10.3109/01677068609106892; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hille B., 1992, IONIC CHANNELS EXCIT; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HONG CS, 1994, J NEUROSCI, V14, P5160; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ITOH N, 1985, DROS INF SERVICE, V61, P89; JACKSON FR, 1985, J NEUROSCI, V5, P1144; JACKSON FR, 1986, J NEUROGENET, V3, P1, DOI 10.3109/01677068609106891; JACKSON FR, 1984, NATURE, V308, P189, DOI 10.1038/308189a0; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KULKARNI SJ, 1982, GENET RES, V40, P191, DOI 10.1017/S0016672300019054; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MEYER RL, 1982, SCIENCE, V218, P589, DOI 10.1126/science.7123262; MEYER RL, 1983, DEV BRAIN RES, V6, P293, DOI 10.1016/0165-3806(83)90068-8; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODOWD DK, 1988, J NEUROSCI, V8, P3633; ODOWD DK, 1989, NEURON, V2, P1301, DOI 10.1016/0896-6273(89)90068-8; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; SUZUKI DT, 1971, P NATL ACAD SCI USA, V68, P890, DOI 10.1073/pnas.68.5.890; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel C., 1992, DROS INFORM SERV, V71, P150; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TRUMAN JW, 1993, DEV DROSOPHILA MELAN, V2, P1245; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; YOST CS, 1983, CELL, V34, P759; ZHENG W, 1995, J NEUROSCI, V15, P1132	65	179	189	3	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1001	1011		10.1016/0092-8674(95)90279-1	http://dx.doi.org/10.1016/0092-8674(95)90279-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553842	Bronze			2022-12-01	WOS:A1995RW69300016
J	GOGA, A; MCLAUGHLIN, J; AFAR, DEH; SAFFRAN, DC; WITTE, ON				GOGA, A; MCLAUGHLIN, J; AFAR, DEH; SAFFRAN, DC; WITTE, ON			ALTERNATIVE SIGNALS TO RAS FOR HEMATOPOIETIC TRANSFORMATION BY THE BCR-ABL ONCOGENE	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; BONE-MARROW; SH2 DOMAIN; CELL LINE; C-ABL; PROTEIN; MICE; BCR/ABL	Biological function of the BCR-ABL oncogene is dependent on its activated tyrosine kinase. Mutations that Inactivate the SRC homology 2 (SH2) domain, the GRB2-binding site in BCR, or the major autophosphorylation site of the kinase domain selectively disrupt downstream signaling but not tyrosine kinase activity. Despite a loss of fibroblast transformation activity, all three mutants retain the ability to render hematopoietic cell lines growth factor independent and transform primary bone marrow cells in vitro. In vivo tests of malignant potential reveal a most critical role for signals dependent on the BCR-ABL SH2 domain. The efficiency of both fibroblast and hematopoietic transformation by BCR-ABL is strongly affected by increased dosage of the SHC adapter protein, which can connect tyrosine kinase signals to RAS. The BCR-ABL oncogene activates multiple alternative pathways to RAS for hematopoietic transformation.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	GOGA, A (corresponding author), UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R35CA053867] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AFAR DEH, 1995, IN PRESS P NATL ACAD; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RENNICK D, 1987, BLOOD, V69, P682; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SALCINI AE, 1994, ONCOGENE, V9, P2827; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TENHOEVE J, 1994, BLOOD, V84, P1731; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	45	248	251	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					981	988		10.1016/0092-8674(95)90277-5	http://dx.doi.org/10.1016/0092-8674(95)90277-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553858	Bronze			2022-12-01	WOS:A1995RW69300014
J	GONG, XH; DUBOIS, DH; MILLER, DJ; SHUR, BD				GONG, XH; DUBOIS, DH; MILLER, DJ; SHUR, BD			ACTIVATION OF A G-PROTEIN COMPLEX BY AGGREGATION OF BETA-1,4-GALACTOSYLTRANSFERASE ON THE SURFACE OF SPERM	SCIENCE			English	Article							NUCLEOTIDE REGULATORY PROTEIN; PERTUSSIS TOXIN; MOUSE SPERM; ACROSOME REACTION; ZONA-PELLUCIDA; RAT HEPATOCYTES; BINDING; RECEPTOR; ZP3; MEMBRANES	Fertilization is initialed by the species-specific binding of sperm to the extracellular coat of the egg. One sperm receptor for the mouse egg is beta-1,4-galactosyltransferase (GalTase), which binds O-linked oligosaccharides on the egg coat glycoprotein ZP3. ZP3 binding induces acrosomal exocytosis through the activation of a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein (G protein). The cytoplasmic domain of sperm surface GalTase bound to and activated a heterotrimeric G protein complex that contained the G(i alpha) subunit. Aggregation of GalTase by multivalent ligands elicited G protein activation. Sperm from transgenic mice that overexpressed GalTase had higher rates of G protein activation than did wild-type sperm, which rendered transgenic sperm hypersensitive to their ZP3 ligand. Thus, the cytoplasmic domain of cell surface GalTase appears to enable it to function as a signal-transducing receptor for extracellular oligosaccharide ligands.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324, R01HD022590, R01HD023479] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07324, R01 HD23479, R01 HD22590] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; EVANS SC, 1995, BIOESSAYS, V17, P261, DOI 10.1002/bies.950170313; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; GONG X, UNPUB; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KALAB P, 1994, J BIOL CHEM, V269, P3810; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LIANG M, 1991, J BIOL CHEM, V266, P13342; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; Miller David J., 1994, Seminars in Developmental Biology, V5, P255, DOI 10.1006/sedb.1994.1033; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NGUYEN TTM, 1994, J BIOL CHEM, V269, P28000; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; PRATT SA, 1993, DEV BIOL, V156, P80, DOI 10.1006/dbio.1993.1060; ROLDAN ERS, 1994, SCIENCE, V266, P1578, DOI 10.1126/science.7985030; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; STROUS GJ, 1987, EUR J BIOCHEM, V169, P307, DOI 10.1111/j.1432-1033.1987.tb13613.x; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; WARD CR, 1992, J BIOL CHEM, V267, P14061; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YOUAKIM A, 1994, J CELL BIOL, V126, P1573, DOI 10.1083/jcb.126.6.1573	32	152	157	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1718	1721		10.1126/science.7569899	http://dx.doi.org/10.1126/science.7569899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569899				2022-12-01	WOS:A1995RV94800037
J	GUILLOT, T				GUILLOT, T			CONDENSATION OF METHANE, AMMONIA, AND WATER AND THE INHIBITION OF CONVECTION IN GIANT PLANETS	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MOIST CONVECTION; JUPITERS ATMOSPHERE; VERTICAL STRUCTURE; PARA-HYDROGEN; TROPOSPHERE; ABUNDANCE; NEPTUNE; URANUS; VOYAGER-2	The condensation of chemical species of high molecular mass such as methane, ammonia, and water can inhibit convection in the hydrogen-helium atmospheres of the giant planets. Convection is inhibited in Uranus and Neptune when methane reaches an abundance of about 15 times the solar value and in Jupiter and Saturn if the abundance of water is more than about five times the solar value. The temperature gradient consequently becomes superadiabatic, which is observed in temperature profiles inferred from radio-occultation measurements. The planetary heat flux is then likely to be transported by another mechanism, possibly radiation in Uranus, or diffusive convection.			GUILLOT, T (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.			Guillot, Tristan/0000-0002-7188-8428				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAINES KH, 1995, ICARUS, V114, P328, DOI 10.1006/icar.1995.1065; BAINES KH, 1994, ICARUS, V109, P20, DOI 10.1006/icar.1994.1075; BJORAKER GL, 1986, ICARUS, V66, P579, DOI 10.1016/0019-1035(86)90093-X; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; CARLSON BE, 1988, J ATMOS RES, V45, P2067; CONRATH BJ, 1984, ICARUS, V57, P184, DOI 10.1016/0019-1035(84)90065-4; DELGENIO AD, 1990, ICARUS, V84, P29, DOI 10.1016/0019-1035(90)90156-4; Emanuel K.A., 1994, ATMOSPHERIC CONVECTI; FLASAR FM, 1988, JUN UR C PAS; FLASAR FM, COMMUNICATION; GAUTIER D, IN PRESS NEPTUNE; GIERASCH PJ, 1987, J GEOPHYS RES, V92, P15019, DOI 10.1029/JA092iA13p15019; GUILLOT T, 1994, ICARUS, V112, P37; GUILLOT T, 1994, ICARUS, V112, P57; GUILLOTEAU S, 1993, ASTRON ASTROPHYS, V279, P661; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; Kippenhahn R., 1990, STELLAR STRUCTURE EV; LEDOUX P, 1947, ASTROPHYS J, V125, P242; LEWIS JS, 1969, ICARUS, V10, P365, DOI 10.1016/0019-1035(69)90091-8; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LINDAL GF, 1985, ASTRON J, V90, P1136, DOI 10.1086/113820; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; LODDERS K, 1994, ICARUS, V112, P368, DOI 10.1006/icar.1994.1190; LUNINE JI, 1989, PLANET SPACE SCI, V37, P151, DOI 10.1016/0032-0633(89)90003-2; LUNINE JI, 1987, ICARUS, V69, P566, DOI 10.1016/0019-1035(87)90025-X; MARTEN A, 1981, ICARUS, V46, P233, DOI 10.1016/0019-1035(81)90211-6; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; MASSIE ST, 1982, ICARUS, V49, P213, DOI 10.1016/0019-1035(82)90073-2; NEAL VT, 1969, SCIENCE, V166, P373, DOI 10.1126/science.166.3903.373; RAGES K, 1991, ICARUS, V89, P359, DOI 10.1016/0019-1035(91)90183-T; ROSSOW WB, 1978, ICARUS, V36, P1, DOI 10.1016/0019-1035(78)90072-6; SCHMITT RW, 1994, ANNU REV FLUID MECH, V26, P255, DOI 10.1146/annurev.fl.26.010194.001351; SHIRTCLIFFE TG, 1967, NATURE, V213, P489, DOI 10.1038/213489a0; STEVENSON DJ, 1979, MON NOT R ASTRON SOC, V187, P129, DOI 10.1093/mnras/187.2.129; STOKER CR, 1989, GEOPHYS RES LETT, V16, P929, DOI 10.1029/GL016i008p00929; STOKER CR, 1986, ICARUS, V67, P106, DOI 10.1016/0019-1035(86)90179-X; Turner J. S., 1973, BUOYANCY EFFECTS FLU; VERONIS G, 1968, J FLUID MECH, V34, P315, DOI 10.1017/S0022112068001916; YAIR Y, 1992, ICARUS, V98, P72, DOI 10.1016/0019-1035(92)90208-O; [No title captured]	42	61	61	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1697	1699		10.1126/science.7569896	http://dx.doi.org/10.1126/science.7569896			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569896				2022-12-01	WOS:A1995RV94800029
J	HOSOYA, T; TAKIZAWA, K; NITTA, K; HOTTA, Y				HOSOYA, T; TAKIZAWA, K; NITTA, K; HOTTA, Y			GLIAL-CELLS MISSING - A BINARY SWITCH BETWEEN NEURONAL AND GLIAL DETERMINATION IN DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GROWTH CONES; GENE ENCODES; NEUROGENESIS; MELANOGASTER; EXPRESSION; PROTEINS; SEQUENCE; CNS; CONSENSUS	In the Drosophila CNS, both neurons and glia are derived from neuroblasts. We have identified a gene, glial cells missing (gcm), that encodes a novel nuclear protein expressed transiently in early glial cells. Its mutation causes presumptive glial cells to differentiate into neurons, whereas its ectopic expression forces virtually all CNS cells to become glial cells. Thus, gem functions as a binary switch that turns on glial fate while inhibiting default neuronal fate of the neuroblasts and their progeny. Similar results are also obtained in the PNS. Analyses of the mutant revealed that ''pioneer neurons'' can find correct pathways without glial cells and that neurons and glia have a common molecular basis for individual identity.	UNIV TOKYO,GRAD SCH SCI,DEPT PHYS,TOKYO 113,JAPAN	University of Tokyo			Hosoya, Toshihiko/Q-2514-2018	Hosoya, Toshihiko/0000-0001-8559-8344				BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Campos-Ortega JAVH, 1985, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CONDRON BG, 1994, NEURON, V13, P541, DOI 10.1016/0896-6273(94)90024-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; GIANGRANDE A, 1994, DEVELOPMENT, V120, P523; GIANGRANDE A, 1993, DEVELOPMENT, V117, P895; Goodman C. S., 1993, DEV DROSOPHILA MELAN, VII, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1993, J NEUROBIOL, V24, P611, DOI 10.1002/neu.480240507; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; KANIA A, 1995, GENETICS, V139, P1663; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; UDOLPH G, 1993, DEVELOPMENT, V118, P765; Waddington C. H, 1940, ORG AND GENES; WINBERG ML, 1992, DEVELOPMENT, V115, P903; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981	48	359	365	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1025	1036		10.1016/0092-8674(95)90281-3	http://dx.doi.org/10.1016/0092-8674(95)90281-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553844	Bronze			2022-12-01	WOS:A1995RW69300018
J	HUA, J; CHANG, C; SUN, Q; MEYEROWITZ, EM				HUA, J; CHANG, C; SUN, Q; MEYEROWITZ, EM			ETHYLENE INSENSITIVITY CONFERRED BY ARABIDOPSIS ERS GENE	SCIENCE			English	Article							2-COMPONENT REGULATORS; PLANT TRANSFORMATION; SIGNAL-TRANSDUCTION; THALIANA; PATHWAY	ERS (ethylene response sensor), a gene in the Arabidopsis thaliana ethylene hormone-response pathway, was uncovered by cross-hybridization with the Arabidopsis ETR1 gene. The deduced ERS protein has sequence similarity with the amino-terminal domain and putative histidine protein kinase domain of ETR1, but it does not have a receiver domain as found in ETR1. A missense mutation identical to the dominant etr1-4 mutation was introduced into the ERS gene. The altered ERS gene conferred dominant ethylene insensitivity to wild-type Arabidopsis. Double-mutant analysis indicates that ERS acts upstream of the CTR1 protein kinase gene in the ethylene-response pathway.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009					Abeles F.B., 2012, ETHYLENE PLANT BIOL; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; FUNKE G. L., 1938, BIOLOGISCH JAARBOEK, V5, P335; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HUA J, UNPUB; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMAN G, 1995, GENETICS, V139, P1393; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VANANDEL OM, 1978, J EXP BOT, V29, P638; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	22	455	494	1	54	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1712	1714		10.1126/science.7569898	http://dx.doi.org/10.1126/science.7569898			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569898				2022-12-01	WOS:A1995RV94800035
J	JONES, BW; FETTER, RD; TEAR, G; GOODMAN, CS				JONES, BW; FETTER, RD; TEAR, G; GOODMAN, CS			GLIAL-CELLS MISSING - A GENETIC SWITCH THAT CONTROLS GLIAL VERSUS NEURONAL FATE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; RAT CEREBRAL-CORTEX; DROSOPHILA EMBRYOS; COMMON PROGENITOR; NEURAL CREST; LINEAGE; MIDLINE; CNS; EXPRESSION	The glial cells missing (gem) gene in Drosophila encodes a novel nuclear protein that is transiently expressed early in the development of nearly all glia, In loss-of-function gem mutant alleles, nearly all glia fail to differentiate, and, where we can follow them in the PNS, are transformed into neurons. In gain-of-function gem conditions using transgenic constructs that drive ectopic gem expression, many presumptive neurons are transformed into glia. Thus, gem appears to function as a binary genetic switch for glia versus neurons. In the presence of gem protein, presumptive neurons become glia, while in its absence, presumptive glia become neurons.			JONES, BW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.		Tear, Guy/C-5444-2009					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Campos-Ortega Jose A., 1993, P1091; CONDRON BG, 1994, J NEUROSCI, V14, P5766; CONDRON BG, 1995, CURR BIOL, V5, P51, DOI 10.1016/S0960-9822(95)00016-9; CONDRON BG, 1994, NEURON, V13, P541, DOI 10.1016/0896-6273(94)90024-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FRANK E, 1991, DEVELOPMENT, V111, P895; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; Goodman Corey S., 1993, P1131; GROVE EA, 1993, DEVELOPMENT, V117, P553; HALTER DA, 1995, DEVELOPMENT, V121, P317; HATTEN ME, 1988, DEV BIOL, V125, P280, DOI 10.1016/0012-1606(88)90211-4; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; Jan Yuh Nung, 1993, P1207; KANIA A, 1995, GENETICS, V139, P1663; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOPCZYNSKI CC, 1992, J CELL BIOL, V199, P503; LANE ME, 1993, GENE DEV, V7, P1228; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEDOUARIN N, 1991, GLIA, V4, P175; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEPASS U, 1994, DEVELOPMENT, V120, P1829; TROPEA M, 1988, GLIA, V1, P380, DOI 10.1002/glia.440010605; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; UDOLPH G, 1993, DEVELOPMENT, V118, P765; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, DEV BIOL, V136, P254; WILLIAMS BP, 1995, NEURON, V14, P1181, DOI 10.1016/0896-6273(95)90265-1; XIONG WC, 1995, NEURON, V14, P581, DOI 10.1016/0896-6273(95)90314-3; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	52	389	396	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1013	1023		10.1016/0092-8674(95)90280-5	http://dx.doi.org/10.1016/0092-8674(95)90280-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553843	Bronze			2022-12-01	WOS:A1995RW69300017
J	KORNAU, HC; SCHENKER, LT; KENNEDY, MB; SEEBURG, PH				KORNAU, HC; SCHENKER, LT; KENNEDY, MB; SEEBURG, PH			DOMAIN INTERACTION BETWEEN NMDA RECEPTOR SUBUNITS AND THE POSTSYNAPTIC DENSITY PROTEIN PSD-95	SCIENCE			English	Article							AMINO-ACID RECEPTORS; TUMOR SUPPRESSOR GENE; SPINAL-CORD NEURONS; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; DROSOPHILA; SYSTEM; ANTAGONISTS; EXPRESSION; AGONISTS	The N-methyl-D-aspartate (NMDA) receptor subserves synaptic glutamate-induced transmission and plasticity in central neurons. The yeast two-hybrid system was used to show that the cytoplasmic tails of NMDA receptor subunits interact with a prominent postsynaptic density protein PSD-95. The second PDZ domain in PSD-95 binds to the seven-amino acid, COOH-terminal domain containing the terminal tSXV motif (where S is serine, X is any amino acid, and V is valine) common to NR2 subunits and certain NR1 splice forms. Transcripts encoding PSD-95 are expressed in a pattern similar to that of NMDA receptors, and the NR2B subunit co-localizes with PSD-95 in cultured rat hippocampal neurons. The interaction of these proteins may affect the plasticity of excitatory synapses.	UNIV HEIDELBERG,CTR MOLEC BIOL,D-69120 HEIDELBERG,GERMANY; CALTECH,DIV BIOL,PASADENA,CA 91125	Ruprecht Karls University Heidelberg; California Institute of Technology				Kennedy, Mary/0000-0003-1369-0525	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028710] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-28710] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BOURNE HR, 1993, NEURON S, V10, P65; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; ISHII T, 1992, J BIOL CHEM, V268, P2836; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUTSUWADA T, 1993, NATURE, V358, P36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, UNPUB; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER M, 1994, J NEUROSCI, V15, P2354; NOVAK L, 1984, NATURE, V307, P462; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	45	1536	1585	1	79	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1737	1740		10.1126/science.7569905	http://dx.doi.org/10.1126/science.7569905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569905				2022-12-01	WOS:A1995RV94800043
J	KRONTIRIS, TG				KRONTIRIS, TG			MINISATELLITES AND HUMAN-DISEASE	SCIENCE			English	Editorial Material							HUMAN INSULIN GENE; HRAS1 MINISATELLITE; DNA-SEQUENCE; LOCUS; MUTATION; ALLELES; ACTIVATION; REGION; CANCER		TUFTS UNIV,SCH MED,GENET PROGRAM,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111	Tufts University; Tufts Medical Center	KRONTIRIS, TG (corresponding author), TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111, USA.							BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BUARD J, 1994, EMBO J, V13, P3203, DOI 10.1002/j.1460-2075.1994.tb06619.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KASPERCZYK A, 1990, AM J HUM GENET, V47, P854; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OWERBACH D, 1994, AM J HUM GENET, V54, P909; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; Phelan C., 1994, American Journal of Human Genetics, V55, pA67; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WOLFF RK, 1989, GENOMICS, V5, P382, DOI 10.1016/0888-7543(89)90076-1; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7	27	64	64	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1682	1683		10.1126/science.7569893	http://dx.doi.org/10.1126/science.7569893			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569893				2022-12-01	WOS:A1995RV94800026
J	LATTERICH, M; FROHLICH, KU; SCHEKMAN, R				LATTERICH, M; FROHLICH, KU; SCHEKMAN, R			MEMBRANE-FUSION AND THE CELL-CYCLE - CDC48P PARTICIPATES IN THE FUSION OF ER MEMBRANES	CELL			English	Article							DIVISION-CYCLE; VESICULAR TRANSPORT; PUTATIVE ATPASES; GENETIC CONTROL; GOLGI STACK; YEAST; PROTEIN; FAMILY; MEMBER; VCP	The fusion of endoplasmic reticulum (ER) membranes in yeast is an essential process required for normal progression of the nuclear cell cycle, karyogamy, and the maintenance of an intact organellar compartment. We showed previously that this process requires a novel fusion machinery distinct from the classic membrane docking/fusion machinery containing Sec17p (alpha-SNAP) and Sec18p (NSF), Here we show that Cdc48p, a cell-cycle protein with homology to Sec18p, is required in ER fusion. A temperature-sensitive cdc48 mutant is conditionally defective in ER fusion in vitro. Addition of purified Cdc48p restores the fusion of isolated cdc48 mutant ER membranes, We propose that Cdc48p is part of an evolutionarily conserved fusion/docking machinery involved in multiple homotypic fusion events.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV TUBINGEN, DEPT PHYSIOL CHEM, D-72076 TUBINGEN, GERMANY	University of California System; University of California Berkeley; Eberhard Karls University of Tubingen	LATTERICH, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FROHLICH KU, 1995, IN PRESS BIOCH BIOPH; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MOIR D, 1982, GENETICS, V100, P547; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; RSOE MD, 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; SOGAARD M, 1994, CELL, V78, P938; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	35	325	329	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					885	893		10.1016/0092-8674(95)90268-6	http://dx.doi.org/10.1016/0092-8674(95)90268-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553849	Bronze			2022-12-01	WOS:A1995RW69300005
J	LIEM, KF; TREMML, G; ROELINK, H; JESSELL, TM				LIEM, KF; TREMML, G; ROELINK, H; JESSELL, TM			DORSAL DIFFERENTIATION OF NEURAL PLATE CELLS INDUCED BY BMP-MEDIATED SIGNALS FROM EPIDERMAL ECTODERM	CELL			English	Article							FLOOR PLATE; SPINAL-CORD; HOMEOBOX GENE; CREST CELLS; LIMB BUDS; NOTOCHORD; PATTERN; EXPRESSION; INDUCTION; TUBE	The cellular interactions that control the differentiation of dorsal cell types from neural progenitors have been examined in neural plate explants. Certain genes that are expressed in the dorsal neural tube are initially expressed uniformly within the neural plate and appear to achieve their dorsal restriction through a Sonic hedgehog (SHH)-mediated repressive signal from the notochord. The acquisition of definitive dorsal cell fates, however, requires a contact-dependent signal from the epidermal ectoderm, BMP4 and BMP7 are expressed in the epidermal ectoderm, and both proteins mimic its inductive activity, BMP4 and a related gene, DSL1, are subsequently expressed by cells in the dorsal neural tube. The differentiation of dorsal cell types, therefore, appears to be initiated at the neural plate stage and to involve the opponent activities of a BMP-mediated dorsalizing signal from the epidermal ectoderm and a SHH-mediated ventralizing signal from the notochord.			LIEM, KF (corresponding author), COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Roelink, Henk/0000-0002-5260-3634	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-T32-GM07367] Funding Source: Medline; NIMH NIH HHS [IP50 MH5000733-2] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MARTINSGREEN M, 1988, DEVELOPMENT, V103, P607; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MAYOR R, 1995, DEVELOPMENT, V121, P767; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; MOURY JD, 1989, DEV BIOL, V133, P44, DOI 10.1016/0012-1606(89)90295-9; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RANGINI Z, 1991, MECH DEVELOP, V35, P13, DOI 10.1016/0925-4773(91)90037-7; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHERSON T, 1993, DEVELOPMENT, V118, P1049; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TRUEB B, 1988, NUCLEIC ACIDS RES, V16, P4723, DOI 10.1093/nar/16.10.4723; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	53	879	901	2	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					969	979		10.1016/0092-8674(95)90276-7	http://dx.doi.org/10.1016/0092-8674(95)90276-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553857	hybrid			2022-12-01	WOS:A1995RW69300013
J	PAUL, REL; PACKER, MJ; WALMSLEY, M; LAGOG, M; RANFORDCARTWRIGHT, LC; PARU, R; DAY, KP				PAUL, REL; PACKER, MJ; WALMSLEY, M; LAGOG, M; RANFORDCARTWRIGHT, LC; PARU, R; DAY, KP			MATING PATTERNS IN MALARIA PARASITE POPULATIONS OF PAPUA-NEW-GUINEA	SCIENCE			English	Article							ANOPHELES-PUNCTULATUS COMPLEX; PLASMODIUM-FALCIPARUM; GENETIC DIVERSITY; SPOROZOITE RATES; TRANSMISSION; EPIDEMIOLOGY; RESISTANCE; MADANG; AREA	Description of the genetic structure of malaria parasite populations is central to an understanding of the spread of multiple-locus drug and vaccine resistance. The Plasmodium falciparum mating patterns from Madang, Papua New Guinea, where intense transmission of malaria occurs, are described here. A high degree of inbreeding occurs in the absence of detectable linkage disequilibrium. This contrasts with other studies, indicating that the genetic structure of malaria parasite populations is neither clonal nor panmictic but will vary according to the transmission characteristics of the region.	UNIV OXFORD, DEPT ZOOL, WELLCOME CTR EPIDEMIOL INFECT DIS, OXFORD OX1 3PS, ENGLAND; PAPUA NEW GUINEA INST MED RES, MADANG, PAPUA N GUINEA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND; UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, DIV BIOL SCI, EDINBURGH EH9 3JT, MIDLOTHIAN, SCOTLAND	University of Oxford; PNG Institute Of Medical Research; Imperial College London; University of Edinburgh			Ranford-Cartwright, Lisa C/H-4701-2013; Day, Karen/F-3697-2015	Ranford-Cartwright, Lisa C/0000-0003-1992-3940; Day, Karen/0000-0002-6115-6135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITKIN M, 1989, STATISTICAL MODELLIN; BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S; BURKOT TR, 1989, AM J TROP MED HYG, V40, P229, DOI 10.4269/ajtmh.1989.40.229; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; CARTER R, 1975, T ROY SOC TROP MED H, V69, P371, DOI 10.1016/0035-9203(75)90191-1; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; CATTANI JA, 1986, PAPUA NEW GUINEA MED, V29, P11; CAUGANT DA, 1981, GENETICS, V98, P467; CONWAY DJ, 1991, T ROY SOC TROP MED H, V85, P454, DOI 10.1016/0035-9203(91)90217-M; CONWAY DJ, 1991, PARASITOLOGY, V103, P7, DOI 10.1017/S0031182000059229; Crawley M. J., 1993, GLIM ECOLOGISTS; CURTIS CF, 1986, T ROY SOC TROP MED H, V80, P889, DOI 10.1016/0035-9203(86)90248-8; DAY KP, 1992, PARASITOLOGY, V104, pS35, DOI 10.1017/S0031182000075235; DYE C, 1992, MODELLING VECTOR BOR, P165; GUPTA S, 1994, PARASITOL TODAY, V10, P476, DOI 10.1016/0169-4758(94)90160-0; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hartl D. L., 1989, PRINCIPLES POPULATIO; Hartl DL, 1992, CURR OPIN GENET DEV, V2, P937, DOI 10.1016/S0959-437X(05)80119-4; HILL WG, 1995, GENET RES, V65, P53, DOI 10.1017/S0016672300033000; KEMP DJ, 1990, ADV PARASIT, V29, P75; KOELLA JC, 1990, T ROY SOC TROP MED H, V84, P662, DOI 10.1016/0035-9203(90)90135-2; LENSKI RE, 1993, P NATL ACAD SCI USA, V90, P4334, DOI 10.1073/pnas.90.10.4334; MARSHALL VM, 1993, PROTOCOLS MOL PARASI, V21, P223; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V49, P239, DOI 10.1016/0166-6851(91)90067-G; RANFORDCARTWRIGHT LC, 1993, PARASITOLOGY, V107, P11, DOI 10.1017/S003118200007935X; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TIBAYRENC M, 1991, PARASITOL TODAY, V7, P228, DOI 10.1016/0169-4758(91)90234-F; TRIGLIA T, 1992, PARASITOL TODAY, V8, P225, DOI 10.1016/0169-4758(92)90118-L; VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85; WALLIKER D, 1991, PARASITOL TODAY, V7, P232, DOI 10.1016/0169-4758(91)90235-G; WALLIKER D, 1989, EXP PARASITOL, V69, P303, DOI 10.1016/0014-4894(89)90078-7; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x; Wright S., 1984, THEORY GENE FREQUENC	38	267	274	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1709	1711		10.1126/science.7569897	http://dx.doi.org/10.1126/science.7569897			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569897				2022-12-01	WOS:A1995RV94800034
J	RABOUILLE, C; LEVINE, TP; PETERS, JM; WARREN, G				RABOUILLE, C; LEVINE, TP; PETERS, JM; WARREN, G			AN NSF-LIKE ATPASE, P97, AND NSF MEDIATE CISTERNAL REGROWTH FROM MITOTIC GOLGI FRAGMENTS	CELL			English	Article							HELA-CELLS; VESICULAR TRANSPORT; PUTATIVE ATPASES; MEMBRANE-FUSION; PROTEIN; FAMILY; YEAST; GENE; MEMBER; IDENTIFICATION	Golgi cisternae regrew in a cell-free system from mitotic Golgi fragments incubated with buffer alone. Pretreatment with NEM or salt washing inhibited regrowth, but this could be restored either by p97, an NSF-like ATPase, or by NSF together with SNAPs and p115, a vesicle docking protein. The morphology of cisternae regrown with p97 and NSF-SNAPs-p115 differed, suggesting that they play distinct roles in rebuilding Golgi cisternae after mitosis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	RABOUILLE, C (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Levine, Timothy/0000-0002-7231-0775				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KIRSCHNER MW, 1995, CELL, V81, P279; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MISTELI T, 1995, J CELL BIOL, V130, P1; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PETERS JM, 1991, THESIS U HEIDELBERG; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; STUART RA, 1993, J BIOL CHEM, V268, P4050; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	46	304	311	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					905	914		10.1016/0092-8674(95)90270-8	http://dx.doi.org/10.1016/0092-8674(95)90270-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553851	Bronze			2022-12-01	WOS:A1995RW69300007
J	SIVILOTTI, L; COLQUHOUN, D				SIVILOTTI, L; COLQUHOUN, D			ACETYLCHOLINE-RECEPTORS - TOO MANY CHANNELS, TOO FEW FUNCTIONS	SCIENCE			English	Editorial Material							RAT HIPPOCAMPAL-NEURONS; CURRENTS; PERMEABILITY; SUBTYPES; SUBUNIT; CORTEX; BRAIN		UCL, WELLCOME LAB MOLEC PHARMACOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	SIVILOTTI, L (corresponding author), UCL, DEPT PHARMACOL, LONDON WC1E 6BT, ENGLAND.		Sivilotti, Lucia/D-8919-2011; Colquhoun, David/C-1664-2008	Sivilotti, Lucia/0000-0003-2510-8424; Colquhoun, David/0000-0002-4263-017X				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; CLARKE PBS, 1992, TRENDS PHARMACOL SCI, V13, P407, DOI 10.1016/0165-6147(92)90125-P; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; CONNOLLY JG, 1995, J PHYSIOL-LONDON, V484, P87, DOI 10.1113/jphysiol.1995.sp020650; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; Hill AV, 1909, J PHYSIOL-LONDON, V39, P361; Hille B., 1992, IONIC CHANNELS EXCIT; LENA C, 1993, J NEUROSCI, V13, P2680, DOI 10.1523/JNEUROSCI.13-06-02680.1993; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; LESTER RAJ, 1995, J NEUROPHYSIOL, V74, P195, DOI 10.1152/jn.1995.74.1.195; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MCMAHON LL, 1994, J NEUROPHYSIOL, V71, P826, DOI 10.1152/jn.1994.71.2.826; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P155, DOI 10.1111/j.1476-5381.1951.tb00631.x; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SUGAYA K, 1990, J NEUROSCI RES, V27, P349, DOI 10.1002/jnr.490270314; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VIDAL C, 1993, NEUROSCIENCE, V56, P23, DOI 10.1016/0306-4522(93)90558-W; Wonnacott S, 1990, BIOL NICOTINE DEPEND; ZORUMSKI CF, 1992, MOL PHARMACOL, V41, P931	29	49	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	1995	269	5231					1681	1682		10.1126/science.7569892	http://dx.doi.org/10.1126/science.7569892			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569892				2022-12-01	WOS:A1995RV94800025
J	SLATER, S; WOLD, S; LU, M; BOYE, E; SKARSTAD, K; KLECKNER, N				SLATER, S; WOLD, S; LU, M; BOYE, E; SKARSTAD, K; KLECKNER, N			ESCHERICHIA-COLI SEQA PROTEIN BINDS ORIC IN 2 DIFFERENT METHYL-MODULATED REACTIONS APPROPRIATE TO ITS ROLES IN DNA-REPLICATION INITIATION AND ORIGIN SEQUESTRATION	CELL			English	Article							ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; FIS PROTEIN; MEMBRANE; PREVENTS; DOMAINS; HYBRID; SITES; IHF; HU	The seqA gene negatively modulates replication initiation at the E. coli origin, oriC. seqA is also essential for sequestration, which acts at oriC and the dnaA promoter to ensure that replication initiation occurs exactly once per chromosome per cell cycle. Initiation is promoted by full methylation of GATC sites clustered in oriC; sequestration is specific to the hemimethylated forms generated by replication, SeqA protein purification and DNA binding are described. SeqA interacts with fully methylated oriC strongly and specifically, This reaction requires multiple molecules of SeqA and determinants throughout oriC, including segments involved in open complex formation. SeqA interacts more strongly with hemimethylated DNA; in this case, oriC and non-oriC sequences are bound similarly. Also, binding of hemimethylated oriC by membrane fractions is due to SeqA. Direct interaction of SeqA protein with the replication origin is likely to be involved in both replication initiation and sequestration.	INST CANC RES,DEPT BIOPHYS,N-0310 MONTEBELLO,NORWAY		SLATER, S (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BAKER TA, 1902, ANNU REV GENET, V26, P447; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRENDLER T, 1995, IN PRESS EMBO J; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; HORIUCHI K, 1972, P NATL ACAD SCI USA, V69, P3220, DOI 10.1073/pnas.69.11.3220; HWANG DS, 1992, J BIOL CHEM, V267, P23083; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; KOPPES L, 1986, CELL, V44, P117, DOI 10.1016/0092-8674(86)90490-3; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOBNEROLESEN A, 1994, EMBO J, V13, P1856; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MESSER W, 1995, IN PRESS ESCHERICHIA; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; POLACZEK P, 1990, New Biologist, V2, P265; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J., 1989, MOL CLONING LAB MANU; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	35	238	241	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					927	936		10.1016/0092-8674(95)90272-4	http://dx.doi.org/10.1016/0092-8674(95)90272-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553853	Bronze			2022-12-01	WOS:A1995RW69300009
J	TSUGORKA, A; RIOS, E; BLATTER, LA				TSUGORKA, A; RIOS, E; BLATTER, LA			IMAGING ELEMENTARY EVENTS OF CALCIUM-RELEASE IN SKELETAL-MUSCLE CELLS	SCIENCE			English	Article							SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; RYANODINE; FIBERS; CHANNEL; RECEPTORS; CHARGE; BRAIN	In skeletal muscle cells, calcium release to trigger contraction occurs at triads, specialized junctions where sarcoplasmic reticulum channels are opened by voltage sensors in the transverse tubule. Scanning confocal microscopy was used in cells under voltage clamp to measure the concentration of intracellular calcium, [Ca2+](i), at individual triads and [Ca2+](i) gradients that were proportional to calcium release. In cells stimulated with small depolarizations, the [Ca2+](i) gradients broke down into elementary events, corresponding to sing le-chan net currents of about 0.1 picoampere. Because these events were one-tenth to one-fifth the size of calcium sparks (elementary release events of cardiac muscle), skeletal muscle control mechanisms appear to be fundamentally different.	RUSH UNIV,DEPT MOLEC BIOPHYS & PHYSIOL,CHICAGO,IL 60612; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153; AA BOGOMOLETS PHYSIOL INST,KIEV 252601,UKRAINE	Rush University; Loyola University Chicago; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology			Blatter, Lothar/AAC-8431-2020					ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRUM G, 1988, J PHYSIOL-LONDON, V398, P441, DOI 10.1113/jphysiol.1988.sp017052; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P272; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; KOVACS L, 1979, NATURE, V279, P391, DOI 10.1038/279391a0; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042; MEISSNER G, 1994, ANN REV PHYSL, V76, P485; MELZER W, 1984, BIOPHYS J, V45, P637, DOI 10.1016/S0006-3495(84)84203-4; MELZER W, 1987, BIOPHYS J, V51, P849, DOI 10.1016/S0006-3495(87)83413-6; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SATOH H, UNPUB; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SHIROKOVA N, IN PRESS J GEN PHYSL; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SUN XH, 1995, J CELL BIOL, V129, P979; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495	34	251	257	1	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 22	1995	269	5231					1723	1726		10.1126/science.7569901	http://dx.doi.org/10.1126/science.7569901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV948	7569901				2022-12-01	WOS:A1995RV94800039
J	CHAISSON, RE; KERULY, JC; MOORE, RD				CHAISSON, RE; KERULY, JC; MOORE, RD			RACE, SEX, DRUG-USE, AND PROGRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; AIDS; INFECTION; ZIDOVUDINE	Background. The rates of progression of human immunodeficiency virus (HIV) infection and survival have been reported to differ among sociodemographic groups, It is unclear whether these differences reflect biologic differences or differences in access to medical care. Methods. We measured disease progression and survival in a cohort of 1372 patients seropositive for HIV who were treated at a single urban center (median follow-up, 1.6 years). We calculated the rates of survival for the entire cohort and the rates of progression to the acquired immunodeficiency syndrome (AIDS) or death among the 740 patients who presented without AIDS. We used Cox proportional-hazards analysis to examine factors associated with progression to AIDS and death. Results. Progression to AIDS or death was associated with a CD4 cell count of 201 to 350 per cubic millimeter (relative risk, 2.0; P<0.001), the presence of symptoms at base line (relative risk, 2.0; P<0.001), prior antiretroviral therapy (relative risk, 1.7, P=0.003), and older age (relative risk per year of age, 1.02; P=0.03). However, there was no relation between disease progression and sex, race, injection-drug use, income, level of education, or insurance status. In the entire cohort, a lower CD4 cell count, a diagnosis of AIDS, older age, and the receipt of antiretroviral therapy before enrollment were associated with an increased risk of death, whereas the use of prophylaxis against pneumocystis pneumonia, zidovudine use after enrollment, and having a job at base line were associated with lower risks of death, There was no significant difference in survival between men and women, blacks and whites, injection-drug users and those who did not use drugs, or patients whose median annual incomes were $5,000 or less and those whose incomes were more than $5,000. Conclusions. Among patients with HIV infection who received medical care from a single urban center, there were no differences in disease progression or survival associated with sex, race, injection-drug use, or socioeconomic status. Differences found in other studies may reflect differences in the use of medical care.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University					AHRQ HHS [R01-HS0780902] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CHAISSON RE, 1991, AIDS, V5, P177, DOI 10.1097/00002030-199102000-00007; CHAISSON RE, 1993, AIDS, V7, P857, DOI 10.1097/00002030-199306000-00015; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; COX DR, 1972, J R STAT SOC B, V34, P187; EHMANN WC, 1994, J ACQ IMMUN DEF SYND, V7, P1095; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; Lee E.T., 1992, STATISTICAL METHODS; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1994, JAMA-J AM MED ASSOC, V272, P1001, DOI 10.1001/jama.1994.03520130035018; MOORE RD, 1994, 34TH INT C ANT AG CH, P61; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SELIK RM, 1993, JAMA-J AM MED ASSOC, V270, P710; STANTON DL, 1994, J ACQ IMMUN DEF SYND, V7, P1050; TURNER BJ, 1994, J ACQ IMMUN DEF SYND, V7, P1250; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1994, MMWR-MORBID MORTAL W, V43, P644; 1994, LANCET, V343, P871; 1995, MMWR MORB MORTL WKLY, V44, P81; 1992, MMWR-MORBID MORTAL W, V41, P1	34	264	276	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					751	756		10.1056/NEJM199509213331202	http://dx.doi.org/10.1056/NEJM199509213331202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643881				2022-12-01	WOS:A1995RU80900002
J	CHI, TH; LIEBERMAN, P; ELLWOOD, K; CAREY, M				CHI, TH; LIEBERMAN, P; ELLWOOD, K; CAREY, M			A GENERAL MECHANISM FOR TRANSCRIPTIONAL SYNERGY BY EUKARYOTIC ACTIVATORS	NATURE			English	Article							EPSTEIN-BARR-VIRUS; RNA POLYMERASE-II; PREINITIATION COMPLEX; GAL4 DERIVATIVES; DNA-BINDING; PROMOTER; DOMAINS; ZEBRA; INITIATION; INTERACTS	One of the important regulatory concepts to emerge from studies of eukaryotic gene expression is that RNA polymerase II promoters and their upstream activators are composed of functional modules whose synergistic action regulates the transcriptional activity of a nearby gene(1-3). Biochemical analysis of synergy by ZEBRA, a non-acidic activator of the Epstein-Barr virus (EBV) lytic cycle(4), showed that the synergistic transcriptional effect of promoter sites and activation modules correlates with assembly of the TFIID:TFIIA (DA) complex in DNase I footprinting and gel shift assays, The activator-dependent DA complex differs from a basal DA complex by its ability to bind TFIIB stably in an interaction regulated by TATA-binding protein-associated factors (TAFs), TFIIB enhances the degree of synergism by increasing complex stability. Similar findings were made with the acidic activator GAL4-VP16. Our data suggest a unifying mechanism for gene activation and synergy by acidic and non-acidic activators, and indicate that synergy is manifested at the earliest stage of preinitiation complex assembly.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; ROCHE INST MOLEC BIOL,DEPT GENE EXPRESS,NUTLEY,NJ 07110	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Carey, Michael/0000-0003-3899-6280				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MILLER G, 1993, J VIROL, V67, P7472, DOI 10.1128/JVI.67.12.7472-7481.1993; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDYKE MW, 1990, MOL CELL BIOL, V10, P3415, DOI 10.1128/MCB.10.7.3415; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	29	175	180	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					254	257		10.1038/377254a0	http://dx.doi.org/10.1038/377254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675113				2022-12-01	WOS:A1995RV87200047
J	FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M				FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M			DO-NOT-RESUSCITATE ORDERS AT A TEACHING HOSPITAL IN JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CARDIOPULMONARY RESUSCITATION; POLICY; CHOICE; STILL				FUKAURA, A (corresponding author), SHOWA UNIV,SCH MED,TOKYO 142,JAPAN.							[Anonymous], 1990, CRIT CARE MED, V18, P1435; Arai T, 1994, Masui, V43, P600; ARAI T, 1994, ICU CCU, V18, P657; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BERLOWITZ DR, 1991, J AM GERIATR SOC, V39, P472, DOI 10.1111/j.1532-5415.1991.tb02492.x; BROWN BW, 1977, STATISTICS BIOMEDICA; Fukaura Asato, 1994, Journal of Japan Society for Cancer Therapy, V29, P1696; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; Murakami K, 1986, Gan To Kagaku Ryoho, V13, P2693; Murakami K, 1989, Gan To Kagaku Ryoho, V16, P740; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Sato Ikuyo, 1994, Journal of Japan Society for Cancer Therapy, V29, P1677; SCHWARTZ DA, 1986, J AM GERIATR SOC, V34, P807, DOI 10.1111/j.1532-5415.1986.tb03986.x; SHAPIRO GR, 1991, PROG P AM SOC CLIN O, V10, P325; STANLEY DP, 1989, MED J AUSTRALIA, V151, P257, DOI 10.5694/j.1326-5377.1989.tb101190.x; STANLEY DP, 1989, MED J AUSTRALIA, V151, P260; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; TAZAWA H, 1990, Journal of Japan Society for Cancer Therapy, V25, P1448; TAZAWA H, 1986, Journal of Japan Society for Cancer Therapy, V21, P2454; Teshima H, 1987, Nihon Kyobu Shikkan Gakkai Zasshi, V25, P305; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; VANDELDEN JJM, 1993, J MED ETHICS, V19, P200, DOI 10.1136/jme.19.4.200; WITTE KL, 1984, HEART LUNG, V13, P159; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1989, J MED ETHICS, V15, P129; 1995, ASSAHI SHIMBUN  0328, P3; 1991, PUBLIC OPINION POLL, V23, P46; 1992, NIHON ISIKAI ZASSI, V107, P1209; 1974, JAMA-J AM MED ASSOC, V227, P864	34	27	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					805	808		10.1056/NEJM199509213331218	http://dx.doi.org/10.1056/NEJM199509213331218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643902				2022-12-01	WOS:A1995RU80900028
J	GAUTAM, M; NOAKES, PG; MUDD, J; NICHOL, M; CHU, GC; SANES, JR; MERLIE, JP				GAUTAM, M; NOAKES, PG; MUDD, J; NICHOL, M; CHU, GC; SANES, JR; MERLIE, JP			FAILURE OF POSTSYNAPTIC SPECIALIZATION TO DEVELOP AT NEUROMUSCULAR-JUNCTIONS OF RAPSYN-DEFICIENT MICE	NATURE			English	Article							DYSTROPHIN-RELATED PROTEIN; ADULT MUSCLE-FIBERS; ACETYLCHOLINE-RECEPTORS; 43K PROTEIN; CELLS; IDENTIFICATION; EXPRESSION; CLUSTERS	OF numerous synaptic components that have been identified, perhaps the best-studied are the nicotinic acetylcholine receptors (AChRs) of the vertebrate neuromuscular junction(1). AChRs are diffusely distributed on embryonic myotubes, but become highly concentrated (similar to 10,000 mu m(-2)) in the postsynaptic membrane as development proceeds. At least two distinct processes contribute to this accumulation. One is local synthesis: subsynaptic muscle nuclei transcribe AChR subunit genes at higher rates than extrasynaptic nuclei, so AChR messenger RNA is concentrated near synaptic sites(2,3). Second, once AChRs have been inserted in the membrane, they form high-density clusters by tethering to a subsynaptic cytoskeletal complex. A key component of this complex is rapsyn, a peripheral membrane protein of relative molecular mass 43K (refs 4, 5), which is precisely colocalized with AChRs at synaptic sites from the earliest stages of neuromuscular synaptogenesis(6). In heterologous systems, expression of recombinant rapsyn leads to clustering of diffusely distributed AChRs, suggesting that rapsyn may control formation of clusters(7,8). To assess the role of rapsyn in vivo, we generated and characterized mutant mice with a targeted disruption of the Rapsn gene. We report that rapsyn is essential for the formation of AChR clusters, but that synapse-specific transcription of AChR subunit genes can proceed in its absence.	UNIV WASHINGTON,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Chu Gerald C., 1995, Seminars in Developmental Biology, V6, P175, DOI 10.1016/S1044-5781(06)80027-7; CROWDER CM, 1988, MOL CELL BIOL, V8, P5257, DOI 10.1128/MCB.8.12.5257; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1994, GENOMICS, V24, P366, DOI 10.1006/geno.1994.1629; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LAROCHELLE WJ, 1989, DEV BIOL, V132, P130, DOI 10.1016/0012-1606(89)90211-X; LUPA MT, 1989, J NEUROSCI, V9, P3937; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MERLIE JP, 1979, J BIOL CHEM, V254, P6320; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Sanes Joshua R., 1995, Seminars in Developmental Biology, V6, P163, DOI 10.1016/S1044-5781(06)80026-5; SANES JR, 1991, DEVELOPMENT, V113, P1181; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	30	455	463	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					232	236		10.1038/377232a0	http://dx.doi.org/10.1038/377232a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675108				2022-12-01	WOS:A1995RV87200040
J	GORLICH, D; VOGEL, F; MILLS, AD; HARTMANN, E; LASKEY, RA				GORLICH, D; VOGEL, F; MILLS, AD; HARTMANN, E; LASKEY, RA			DISTINCT FUNCTIONS FOR THE 2 IMPORTIN SUBUNITS IN NUCLEAR-PROTEIN IMPORT	NATURE			English	Article							GTP-BINDING PROTEIN; LOCATION; TRANSLOCATION; POLYPEPTIDE; MIGRATION; SEQUENCE; RAN/TC4; STEPS	THE import of nuclear proteins proceeds through the nuclear pore complex and requires nuclear localization signals (NLSs)(1,2), energy(3,4) and soluble factors(5), namely importin-alpha (M(r) 60K)(6-12,28), importin-beta (90K)(8-11,13) and Ran(14,15). Importin-alpha is primarily responsible for NLS recognition(6-12,29) and is a member of a protein family that includes the essential yeast nuclear pore protein SRP1p (ref. 16). As the first event, the complex of importin-alpha and importin-beta binds the import substrate in the cytosols(8,9). Here we show that this nuclear pore targeting complex initially docks as a single entity to the nuclear pore via importin-beta. Then the energy-dependent, Ran-mediated translocation through the pore results in the accumulation of import substrate and importin-alpha in the nucleus. In contrast, importin-beta accumulates at the nuclear envelope, but not in the nucleoplasm. Immunoelectron microscopy detects importin-beta on both sides of the nuclear pore. This suggests that the nuclear pore targeting complex might move as a single entity from its initial docking site through the central part of the nuclear pore before it disassembles on the nucleoplasmic side.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY	University of Cambridge; Helmholtz Association; Max Delbruck Center for Molecular Medicine	GORLICH, D (corresponding author), WELLCOME CRC INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Hartmann, Enno/C-5687-2013; Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P137; HARLOW E, 1988, ANTIBODIES LABORATOR; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	29	422	428	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 21	1995	377	6546					246	248		10.1038/377246a0	http://dx.doi.org/10.1038/377246a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675110				2022-12-01	WOS:A1995RV87200044
J	HUANG, PL; HUANG, ZH; MASHIMO, H; BLOCH, KD; MOSKOWITZ, MA; BEVAN, JA; FISHMAN, MC				HUANG, PL; HUANG, ZH; MASHIMO, H; BLOCH, KD; MOSKOWITZ, MA; BEVAN, JA; FISHMAN, MC			HYPERTENSION IN MICE LACKING THE GENE FOR ENDOTHELIAL NITRIC-OXIDE SYNTHASE	NATURE			English	Article							NADPH DIAPHORASE; RELAXING FACTOR; BLOOD-PRESSURE; L-ARGININE; INHIBITORS; NEURONS; INVIVO; NERVE	NITRIC oxide (NO), a potent vasodilator produced by endothelial cells, is thought to be the endothelium-dependent relaxing factor (EDRF) which mediates vascular relaxation in response to acetylcholine, bradykinin and substance P in many vascular besds(1-6). NO has been implicated in the regulation of blood pressure and regional blood flow(4-6), and also affects vascular smooth-muscle proliferation and inhibits platelet aggregation and leukocyte adhesion. Abnormalities in endothelial production of NO occur in atherosclerosis, diabetes and hypertension(7). Pharmacological blockade of NO production with arginine analogues such as L-nitroarginine (L-NA) or L-N-arginine methyl ester affects multiple isoforms of nitric oxide synthase (NOS), and so cannot distinguish their physiological roles(8,9). To study the role of endothelial NOS (eNOS) in vascular function, we disrupted the gene encoding eNOS in mice. Endothelium-derived relaxing factor activity, as assayed by acetylcholine-induced relaxation, is absent, and the eNOS mutant mice are hypertensive. Thus eNOS mediates basal vasodilation. Responses to NOS blockade in the mutant mice suggest that non-endothelial isoforms of NOS mag be involved in maintaining blood pressure.	MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,MED SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DEPT NEUROL,STROKE RES LAB,BOSTON,MA 02129; UNIV VERMONT,COLL MED,DEPT PHARMACOL,BURLINGTON,VT 05405	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Vermont			Moskowitz, Michael A/D-9916-2011					ANDERSON CR, 1992, NEUROSCI LETT, V139, P280, DOI 10.1016/0304-3940(92)90571-N; AYAJIKI K, 1993, NEUROSCIENCE, V54, P819, DOI 10.1016/0306-4522(93)90251-A; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DASILVA SV, 1994, HYPERTENSION S1, V23, P60; FORSTERMANN U, 1994, METHOD ENZYMOL, V233, P258; FREY C, 1994, J BIOL CHEM, V269, P26083; GARDINER SM, 1992, EUR J PHARMACOL, V213, P449, DOI 10.1016/0014-2999(92)90636-I; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1993, BRAIN RES, V603, P173, DOI 10.1016/0006-8993(93)91318-M; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MATSUDA T, 1995, CIRC RES, V76, P426, DOI 10.1161/01.RES.76.3.426; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEART WS, 1983, HYPERTENSION; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SAKUMA I, 1992, CIRC RES, V70, P607, DOI 10.1161/01.RES.70.3.607; SCROGIN KE, 1994, HYPERTENSION, V23, P982, DOI 10.1161/01.HYP.23.6.982; SNYDER SH, 1994, NATURE, V372, P504, DOI 10.1038/372504a0; TODA N, 1993, J VASC RES, V30, P61, DOI 10.1159/000158976; TOGASHI H, 1992, J PHARMACOL EXP THER, V262, P343; VINCENT SR, 1992, NEUROSCIENCE, V48, P755; [No title captured]	27	1682	1734	1	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					239	242		10.1038/377239a0	http://dx.doi.org/10.1038/377239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7545787				2022-12-01	WOS:A1995RV87200042
J	HUNTER, CP; KENYON, C				HUNTER, CP; KENYON, C			SPECIFICATION OF ANTEROPOSTERIOR CELL FATES IN CAENORHABDITIS-ELEGANS BY DROSOPHILA HOX PROTEINS	NATURE			English	Article							C-ELEGANS; FUNCTIONAL SPECIFICITY; BODY REGION; GENE; HOMEODOMAIN; NEMATODE; EMBRYOS; LARVAE	ANTENNAPEDIA class homeobox (Hox) genes specify cell fates in successive anteroposterior body domains in vertebrates, insects and nematodes(1-3). The DNA-binding homeodomain sequences are very similar between vertebrate and Drosophila Hox proteins, and this similarity allows vertebrate Hox proteins to function in Drosophila(4-7). In contrast, the Caenorhabditis elegans homeodomains are substantially divertent(8). Further, C. elegans differs from both insects and vertebrates in having a non-segmented body as well as a distinctive mode of development that involves asymmetric early cleavages and invariant cell lineages. Here we report that, despite these differences, Drosophila Hox proteins expressed in C. elegans can substitute for C. elegans Hox proteins in the control of three different cell-fate decisions: the regulation of cell migration, the specification of serotonergic neurons, and the specification of a sensory structure. We also show that the specificity of one C. elegans Hox protein is partly determined by two amino acids that have been implicated in sequence-specific DNA binding. Together these findings suggest that factors important for target recognition by specific Hox proteins have been conserved throughout much of the animal kingdom.			HUNTER, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MALICKI J, 1993, MECH DEVELOP, V42, P139, DOI 10.1016/0925-4773(93)90003-G; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1991, EMBO J, V12, P3959; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; ZENG WL, 1993, DEVELOPMENT, V118, P339; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	23	40	43	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					229	232		10.1038/377229a0	http://dx.doi.org/10.1038/377229a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675107				2022-12-01	WOS:A1995RV87200039
J	NISHIZAKA, T; MIYATA, H; YOSHIKAWA, H; ISHIWATA, S; KINOSITA, K				NISHIZAKA, T; MIYATA, H; YOSHIKAWA, H; ISHIWATA, S; KINOSITA, K			UNBINDING FORCE OF A SINGLE MOTOR MOLECULE OF MUSCLE MEASURED USING OPTICAL TWEEZERS	NATURE			English	Article							ACTIN FILAMENT; DIRECTION; MYOSIN; INVITRO; RIGOR; SPEED	THE unbinding and rebinding of motor proteins and their substrate filaments are the main components of sliding movement(1). We have measured the unbinding force between an actin filament and a single motor molecule of muscle, myosin, in the absence of ATP, by pulling the filament with optical tweezers(2). The unbinding force could be measured repeatedly on the same molecule, and was independent of the number of measurements and the direction of the imposed loads within a range of +/-90 degrees. The average unbinding force was 9.2 +/- 4.4 pN, only a few times larger than the sliding force(3-5) but an order of magnitude smaller than other intermolecular forces(6,7). From its kinetics(8) we suggest that unbinding occurs sequentially at the molecular interface, which is an inherent property of motor molecules.	WASEDA UNIV,SCH SCI & ENGN,DEPT PHYS,SHINJUKU KU,TOKYO 169,JAPAN; WASEDA UNIV,ADV RES CTR SCI & ENGN,SHINJUKU KU,TOKYO 169,JAPAN	Waseda University; Waseda University								ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ISHIWATA S, 1993, PHASE TRANSIT, V45, P105, DOI 10.1080/01411599308223720; KINOSITA K, 1991, J CELL BIOL, V115, P67, DOI 10.1083/jcb.115.1.67; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MIYATA H, 1995, BIOPHYS J, V68, pS286; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; NISHIZAKA T, 1993, NATURE, V361, P269, DOI 10.1038/361269a0; NISHIZAKA T, 1995, BIOPHYS J, V68, pS75; SCHOENBERG M, 1985, BIOPHYS J, V48, P863, DOI 10.1016/S0006-3495(85)83847-9; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; TAWADA K, 1986, J MUSCLE RES CELL M, V7, P339, DOI 10.1007/BF01753655; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203	22	202	204	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					251	254		10.1038/377251a0	http://dx.doi.org/10.1038/377251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675112				2022-12-01	WOS:A1995RV87200046
J	SHANER, A; ECKMAN, TA; ROBERTS, LJ; WILKINS, JN; TUCKER, DE; TSUANG, JW; MINTZ, J				SHANER, A; ECKMAN, TA; ROBERTS, LJ; WILKINS, JN; TUCKER, DE; TSUANG, JW; MINTZ, J			DISABILITY INCOME, COCAINE USE, AND REPEATED HOSPITALIZATION AMONG SCHIZOPHRENIC COCAINE ABUSERS - A GOVERNMENT-SPONSORED REVOLVING-DOOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADDICTION SEVERITY INDEX; SUBSTANCE-ABUSE; DRUG-ABUSE; PSYCHIATRIC-PATIENTS; URINE; CHROMATOGRAPHY; VALIDITY	Background. Many patients with serious mental illness are addicted to drugs and alcohol. This comorbidity creates additional problems for the patients and for the clinicians, health care systems, and social-service agencies that provide services to this population. One problem is that disability income, which many people with serious mental illness receive to pay for basic needs, may facilitate drug abuse. In this study, we assessed the temporal patterns of cocaine use, psychiatric symptoms, and psychiatric hospitalization in a sample of schizophrenic patients receiving disability income. Methods. We evaluated 105 male patients with schizophrenia and cocaine dependence at the time of their admission to the hospital. They had severe mental illness and a long-term dependence on cocaine, with repeated admissions to psychiatric hospitals; many were homeless. The severity of psychiatric symptoms and urinary concentrations of the cocaine metabolite benzoylecgonine were evaluated weekly for 15 weeks. Results. Cocaine use, psychiatric symptoms, and hospital admissions all peaked during the first week of the month, shortly after the arrival of the disability payment, on the first day. The average patient spent nearly half his total income on illegal drugs. Conclusions. Among cocaine-abusing schizophrenic persons, the cyclic pattern of drug use strongly suggests that it is influenced by the monthly receipt of disability payments. The consequences of this cycle include the depletion of funds needed for housing and food, exacerbation of psychiatric symptoms, more frequent psychiatric hospitalization, and a high rate of homelessness. The troubling irony is that income intended to compensate for the disabling effects of severe mental illness may have the opposite effect.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SHANER, A (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,116A,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA.		Mintz, Jim/N-7385-2014	Mintz, Jim/0000-0002-8299-5851	NIMH NIH HHS [R01 MH48081] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048081] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTERMAN AI, 1983, J PSYCHIAT TREAT EV, V5, P377; BRADY K, 1990, AM J PSYCHIAT, V147, P1164; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COHEN J, 1992, MENTALLY ILL CHEM AB; CONE EJ, 1989, J FORENSIC SCI, V34, P15; DIXON L, 1991, AM J PSYCHIAT, V148, P224; DRAKE RE, 1991, NEW DIR MENT HLTH SE, V50, P3; FARRELL M, 1992, MENT PHYS DISABIL LA, V16, P236; FERRARA SD, 1992, J ANAL TOXICOL, V16, P217, DOI 10.1093/jat/16.4.217; GALANTER M, 1988, AM J DRUG ALCOHOL AB, V14, P211, DOI 10.3109/00952999809001548; HARTZ D, 1994, HOSP COMMUNITY PSYCH, V45, P491; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; Lukoff D, 1986, SCHIZOPHRENIA B, V12, P594, DOI DOI 10.1093/SCHBUL/12.4.578; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MELTZER HY, 1976, SCHIZOPHRENIA BULL, V2, P19, DOI 10.1093/schbul/2.1.19; OVERALL JE, 1962, PSYCHOL REP, V10, P799; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARD ML, 1985, J CLIN PSYCHIAT, V46, P79; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBERTS LJ, 1992, NEW DIR MENT HLTH SE, V53, P55; SAFER DJ, 1987, HOSP COMMUNITY PSYCH, V38, P511; SATEL S, 1994, NEW REPUBLIC    0530, P18; SEALE JP, 1993, PRIMARY CARE, V20, P167; SHANER A, 1993, AM J PSYCHIAT, V150, P758; SPITZER RL, 1990, USERS GUIDE STRUTURE; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; SVENSSON JO, 1986, J ANAL TOXICOL, V10, P122, DOI 10.1093/jat/10.3.122; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; WATTS VW, 1986, J ANAL TOXICOL, V10, P198, DOI 10.1093/jat/10.5.198; YESAVAGE JA, 1983, J CLIN PSYCHIAT, V44, P259; ZISOOK S, 1992, AM J PSYCHIAT, V149, P552; 1993, DHHS SSA65008 SOC SE, P353; 1987, DIAGNOSTIC STATISTIC; 1994, WALL STREET J   0208, pA18; 1993, WALL STREET J   0128, pA18	39	163	163	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					777	783		10.1056/NEJM199509213331207	http://dx.doi.org/10.1056/NEJM199509213331207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643886				2022-12-01	WOS:A1995RU80900007
J	WALD, A; ZEH, J; SELKE, S; ASHLEY, RL; COREY, L				WALD, A; ZEH, J; SELKE, S; ASHLEY, RL; COREY, L			VIROLOGICAL CHARACTERISTICS OF SUBCLINICAL AND SYMPTOMATIC GENITAL HERPES INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-2; VIRAL-ISOLATION; RISK-FACTORS; WOMEN; ACQUISITION; TRANSMISSION; FREQUENCY; LESIONS	Background. The frequency, pattern, and anatomical sites of subclinical shedding of herpes simplex virus (HSV) in the genital tract, along with factors that predict such shedding, have not been well characterized. Methods. We studied prospectively the clinical and virologic course of genital herpes in 110 women. The women kept symptom diaries and provided daily samples from the vulva, cervix, and rectum for viral culture. Results. During a median follow-up of 105 days, subclinical shedding of Virus was identified in 36 of 65 women (55 percent) with HSV type 2 (HSV-2), in 16 of 31 women (52 percent) with HSV type 1 (HSV-1) and HSV-2, and in 4 of 14 women (29 percent) with only HSV-1. Among women with genital HSV-2 infection, subclinical shedding occurred on a mean of 2 percent of the days. The mean duration of viral shedding during subclinical episodes was 1.5 days, as compared with 1.8 days during symptomatic episodes. HSV was isolated from several sites in the genital tract and rectum in 17 percent of subclinical episodes and 22 percent of symptomatic episodes. Half the episodes of subclinical shedding of HSV occurred within seven days of a symptomatic recurrence. The risk of subclinical shedding increased with the frequency of symptomatic recurrences, Subclinical shedding was more frequent among women with more than 12 recurrences per year than among those with no symptomatic recurrences (odds ratio, 3.3; 95 percent confidence interval, 1.4 to 7.9); it was also more frequent among women who had recently acquired genital herpes (odds ratio for women with HSV acquired in the past year as compared with those who had had the infection for a year or more, 1.85; 95 percent confidence interval, 1.1 to 3.1). Conclusions. Among women with a history of genital herpes infection, subclinical shedding of HSV is common and accounts for nearly one third of the total days of reactivation of HSV infection in the genital tract. Women with frequent symptomatic recurrences also have frequent subclinical shedding and may be at high risk for transmitting HSV.	WASHINGTON UNIV,DEPT MED,DIV VIROL,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT STAT,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT LAB MED,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT MICROBIOL,SEATTLE,WA 98144				Corey, Lawrence/AAE-1796-2020; Wald, Anna/B-6272-2012	Corey, Lawrence/0000-0002-2179-2436; Wald, Anna/0000-0003-3486-6438	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM E, 1979, OBSTET GYNECOL, V54, P171; ADAM E, 1980, AM J OBSTET GYNECOL, V137, P827, DOI 10.1016/0002-9378(80)90893-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1986, GENITOURIN MED, V62, P181; BARTON SE, 1987, GENITOURIN MED, V63, P102; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Bowman C A, 1990, Int J STD AIDS, V1, P174; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1985, AM J OBSTET GYNECOL, V153, P24, DOI 10.1016/0002-9378(85)90584-8; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; JOHNSON RE, 1990, NEW ENGL J MED, V321, P7; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; MCCULLAGH P, 1983, GEN LINEAR MODELS, P73; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; RATTRAY MC, 1978, BRIT J VENER DIS, V54, P262; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107	24	414	421	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					770	775		10.1056/NEJM199509213331205	http://dx.doi.org/10.1056/NEJM199509213331205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643884				2022-12-01	WOS:A1995RU80900005
J	WIJGERDE, M; GROSVELD, F; FRASER, P				WIJGERDE, M; GROSVELD, F; FRASER, P			TRANSCRIPTION COMPLEX STABILITY AND CHROMATIN DYNAMICS IN-VIVO	NATURE			English	Article							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; LOCUS-CONTROL REGION; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITE; ACTIVATION-REGION; ERYTHROID-CELLS; EXPRESSION; ENHANCER	Distant regulatory sequences affect transcription through long-range chromatin interactions. Visualization of transcriptional activity of genes that compete for distant elements, using the globin locus as a model, has revealed the dynamics of chromatin Interactions in vivo. Multiple genes appear to be transcribed alternately rather than at the same time to generate several messenger RNAs in one cell. The regulator may stably complex with one gene at a time and switch back and forth between genes in a flip-flop mechanism.	NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	WIJGERDE, M (corresponding author), ERASMUS UNIV ROTTERDAM,MGC DEPT CELL BIOL & GENET,3015 GE ROTTERDAM,NETHERLANDS.		Fraser, Peter/B-7549-2009	Fraser, Peter/0000-0002-0041-1227				ARNDTJOVIN D, 1985, J HISTOCHEM CYTOCHEM, V25, P585; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; CURTIS PJ, 1977, COLD SPRING HARB SYM, V42, P971; DEVILLIERS J, 1982, COLD SPRING HARB SYM, V47, P911; DILLON N, 1990, NATURE, V350, P252; DIRKS RW, 1993, J CELL SCI, V104, P1187; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRASER P, 1987, GENE DEV, V1, P885; FURUKAWA T, 1994, BLOOD, V83, P1412; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; STROUBOULIS J, 1994, THESIS OPEN U UK; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TERASIMA T, 1963, EXP CELL RES, V30, P344, DOI 10.1016/0014-4827(63)90306-9; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WASYLYK B, 1983, CELL, V32, P503, DOI 10.1016/0092-8674(83)90470-1; ZHANG G, 1994, NATURE, V372, P22	36	420	429	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					209	213		10.1038/377209a0	http://dx.doi.org/10.1038/377209a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675106	Green Submitted			2022-12-01	WOS:A1995RV87200031
J	WU, H; KLINGMULLER, U; BESMER, P; LODISH, HF				WU, H; KLINGMULLER, U; BESMER, P; LODISH, HF			INTERACTION OF THE ERYTHROPOIETIN AND STEM-CELL-FACTOR RECEPTORS	NATURE			English	Article							C-KIT; KINASE; PROTEIN; EXPRESSION; PHOSPHORYLATION	MUTATIONS in the KIT transmembrane protein-tyrosine kinase receptor(1) affect erythropoiesis, resulting in fewer committed late progenitors (colony-forming unit erythroid, CFU-E) in the fetal liver(2). As the survival and proliferation of CFU-Es depend absolutely on erythropoietin (EPO)(3), these results suggest that CFU-Es cannot proliferate or mature further unless both the KIT and EPO receptor(4) signalling pathways are functional. How KIT affects proliferation or differentiation of CFU-Es is not clear. Here we show that the KIT ligand SCF (for stem-cell factor) can replace EPO in supporting the growth and survival of HCD57 cells, an EPO-dependent erythroid-progenitor cell line expressing high levels of KIT5. SCF supports the proliferation of 32D cells(6) that express KIT only if they also express the EPO receptor. In HCD57 cells, SCF rapidly induces tyrosine phosphorylation of the EPO receptor, and KIT physically associates with the extended box 2 region(7) in the cytoplasmic domain of the EPO receptor. Our results indicate that KIT may activate the EPO receptor by tyrosine phosphorylation to induce further proliferation and maturation of CFU-Es.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Memorial Sloan Kettering Cancer Center			Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099				Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; HE TC, 1994, J BIOL CHEM, V269, P18291; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LETWIN K, 1988, ONCOGENE, V3, P621; LIU L, 1994, J BIOL CHEM, V269, P16774; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MIURA Y, 1994, J BIOL CHEM, V269, P29962; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SPIVAK JL, 1991, BLOOD, V77, P1228; TSUJIMURA T, 1994, BLOOD, V83, P2619; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	21	241	245	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					242	246		10.1038/377242a0	http://dx.doi.org/10.1038/377242a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7545788				2022-12-01	WOS:A1995RV87200043
J	XUE, D; HORVITZ, HR				XUE, D; HORVITZ, HR			INHIBITION OF THE CAENORHABDITIS-ELEGANS CELL-DEATH PROTEASE CED-3 BY A CED-3 CLEAVAGE SITE IN BACULOVIRUS P35 PROTEIN	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; C-ELEGANS; GENE CED-3; EXPRESSION; TRANSCRIPTION; PURIFICATION; APOPTOSIS; REQUIRES; ENCODES; HOMOLOG	THE baculovirus protein p35 inhibits programmed cell death in such diverse animals as insects, nematodes and mammals(1-5). Here we show that p35 protein is a substrate for and inhibitor of the Caenorhabditis elegans cell-death protease CED-3 (refs 6, 7) and a substrate for four CED-3-like vertebrate cysteine protease activities implicated in apoptosis in mammals(7-14). A p35 mutation that greatly reduced p35 activity in vitro as a CED-3 substrate and inhibitor abolished p35 activity in vivo in protecting against cell death in C. elegans. Introduction of the CED-3 cleavage site in p35 into the cowpox virus protein crmA, which inhibits mammalian apoptosis(14-19) but not programmed cell death in C. elegans, caused crmA to block CED3-mediated cell death. These observations suggest that p35 may prevent programmed cell death in C. elegans and other species by acting as a competitive inhibitor of cysteine proteases.			XUE, D (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			XUE, DING/0000-0002-8429-8136				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P75; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	435	449	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					248	251		10.1038/377248a0	http://dx.doi.org/10.1038/377248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675111				2022-12-01	WOS:A1995RV87200045
J	COHEN, BM; RENSHAW, PF; STOLL, AL; WURTMAN, RJ; YURGELUNTODD, D; BABB, SM				COHEN, BM; RENSHAW, PF; STOLL, AL; WURTMAN, RJ; YURGELUNTODD, D; BABB, SM			DECREASED BRAIN CHOLINE UPTAKE IN OLDER ADULTS - AN IN-VIVO PROTON MAGNETIC-RESONANCE SPECTROSCOPY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT-BRAIN; CEREBROSPINAL-FLUID; H-1-NMR SPECTROSCOPY; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; BARRIER TRANSPORT; CELL-MEMBRANES; METABOLISM; NEURONS; ACETYLCHOLINE	Objective.-To test the hypothesis that uptake of circulating choline into the brain decreases with age, because alterations in metabolism of choline may be a factor contributing to age-related degenerative changes in the brain. Design.-Cohort comparison in younger and older adults. Participants.-Subjects were chosen consecutively from lists of healthy volunteers screened by medical and psychiatric interviews and laboratory tests. Younger adults (n=12) were between the ages of 20 and 40 years (mean age, 32 years), and older adults (n=16) were between the ages of 60 and 85 years (mean age, 73 years). Interventions.-After fasting overnight, subjects received choline, as the bitartrate, to yield free choline equal to 50 mg/kg of body weight. Blood was drawn for determination of plasma choline concentration by high-performance liquid chromatography, and proton magnetic resonance spectroscopy (H-1-MRS) was performed to determine the relative concentration of cytosolic choline-containing compounds in the brain at baseline and after ingestion of choline. Main Outcome Measures.-Plasma choline and cytosolic choline-containing compounds in the brain, estimated as the ratio of the choline resonance to the creatine resonance on H-1-MRS scans of the basal ganglia, were compared following blinded analyses of data from subject cohorts studied at baseline and 3 hours after choline ingestion. Results.-Levels of plasma choline and cytosolic choline-containing compounds in brain were similar at baseline in younger and older subjects. Following ingestion of choline, plasma choline concentration increased by similar proportions (76% and 80%) in both younger and older subjects. Brain cytosolic choline-containing compounds increased substantially in younger subjects (mean increase, 60%; P<.001 vs baseline). Older subjects showed a much smaller increase in brain choline-containing compounds (mean, 16%, P<.001 vs the increase in younger subjects). Conclusion.-Uptake of circulating choline into the brain decreases with age. Given the key role of choline in neuronal structure and function, this change may be a contributing factor in onset in late life of neurodegenerative, particularly dementing, illnesses in which cholinergic neurons show particular susceptibility to loss.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; MIT,CLIN RES CTR,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,PSYCHOPHARMACOL UNIT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital	COHEN, BM (corresponding author), MCLEAN HOSP,CTR BRAIN IMAGING,115 MILL ST,BELMONT,MA 02178, USA.		Renshaw, Perry/O-1384-2018; Cohen, Bruce M./AAZ-4986-2020		NIMH NIH HHS [MH38313, MH31154, MH28783] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH031154, R01MH028783, R37MH028783] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ansell G B, 1977, Int Rev Neurobiol, V20, P1, DOI 10.1016/S0074-7742(08)60649-2; ARMSTRONG DM, 1993, NEUROBIOL AGING, V14, P457, DOI 10.1016/0197-4580(93)90104-J; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BARTUS RT, 1984, NUTRITION GERONTOLOG, P191; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BRINKMAN SD, 1982, J CLIN PSYCHOPHARM, V2, P281; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P799, DOI 10.1016/0730-725X(93)90197-L; COHEN BM, 1985, LIFE SCI, V37, P1403, DOI 10.1016/0024-3205(85)90079-7; COHEN BM, 1982, AM J PSYCHIAT, V139, P1162; CORNFORD EM, 1978, J NEUROCHEM, V30, P299, DOI 10.1111/j.1471-4159.1978.tb06530.x; FISCHER W, 1992, NEUROBIOL AGING, V13, P9, DOI 10.1016/0197-4580(92)90003-G; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; GRIFFEY RH, 1990, J MAGN RESON, V88, P161, DOI 10.1016/0022-2364(90)90120-X; GRINNA LS, 1977, GERONTOLOGY, V23, P452, DOI 10.1159/000212222; GROWDON JH, 1977, J NEUROCHEM, V28, P229, DOI 10.1111/j.1471-4159.1977.tb07732.x; GROWDON JH, 1977, ANN NEUROL, V1, P418, DOI 10.1002/ana.410010503; GROWDON JH, 1977, NEW ENGL J MED, V297, P524, DOI 10.1056/NEJM197709082971002; GUZE BH, 1991, PSYCHIAT RES-NEUROIM, V40, P195, DOI 10.1016/0925-4927(91)90010-N; HETHERINGTON HP, 1994, MAGNET RESON MED, V32, P565, DOI 10.1002/mrm.1910320504; HOLLISTER LE, 1978, LIFE SCI, V23, P17, DOI 10.1016/0024-3205(78)90319-3; ISHIMARU H, 1991, J PHARMACOBIO-DYNAM, V14, P321, DOI 10.1248/bpb1978.14.321; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P55, DOI 10.1016/0006-3223(91)90210-D; JERNIGAN TL, 1993, ARCH NEUROL-CHICAGO, V47, P27; JOPE RS, 1979, J NEUROSCI RES, V4, P69, DOI 10.1002/jnr.490040110; KANG YS, 1990, J PHARMACOBIO-DYNAM, V13, P353, DOI 10.1248/bpb1978.13.353; KAYE WH, 1982, BIOL PSYCHIAT, V17, P275; KIKINIS R, 1992, JMRI-J MAGN RESON IM, V2, P619, DOI 10.1002/jmri.1880020603; KLEIN J, 1990, J NEUROCHEM, V55, P1231, DOI 10.1111/j.1471-4159.1990.tb03129.x; KLEIN J, 1992, J NEUROCHEM, V58, P870, DOI 10.1111/j.1471-4159.1992.tb09337.x; KLEIN J, 1991, J NEUROCHEM, V57, P370, DOI 10.1111/j.1471-4159.1991.tb03762.x; KLEIN J, 1993, NEUROCHEM INT, V22, P293, DOI 10.1016/0197-0186(93)90058-D; LOFFELHOLZ K, 1993, PROG BRAIN RES, V98, P197; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MILLER LG, 1990, BIOCHEM PHARMACOL, V40, P1179, DOI 10.1016/0006-2952(90)90381-T; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; MOHS RC, 1979, AM J PSYCHIAT, V136, P1275; MOORADIAN AD, 1988, BRAIN RES, V440, P328, DOI 10.1016/0006-8993(88)91002-5; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; PARDRIDGE WM, 1986, FASEB J, V45, P2047; PERRY EK, 1980, AGE AGEING, V9, P1, DOI 10.1093/ageing/9.1.1; PERRY EK, 1992, NEUROBIOL AGING, V13, P393, DOI 10.1016/0197-4580(92)90113-C; PETROFF OAC, 1988, COMP BIOCHEM PHYS B, V90, P249, DOI 10.1016/0305-0491(88)90069-7; PETROFF OAC, 1988, J NEUROCHEM, V51, P163, DOI 10.1111/j.1471-4159.1988.tb04850.x; PETROFF OAC, 1989, NEUROLOGY, V39, P1197, DOI 10.1212/WNL.39.9.1197; Rinn W E, 1988, J Geriatr Psychiatry Neurol, V1, P144, DOI 10.1177/089198878800100304; ROUSER G, 1968, LIPIDS, V3, P284, DOI 10.1007/BF02531202; SCHMIDT DE, 1981, NEUROPHARMACOLOGY, V20, P535, DOI 10.1016/0028-3908(81)90205-7; SCREMIN OU, 1993, PROG BRAIN RES, V98, P191; SHENTON ME, 1991, SCHIZOPHR RES, V5, P103, DOI 10.1016/0920-9964(91)90037-R; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; STOLL AL, 1995, BIOL PSYCHIAT, V37, P170, DOI 10.1016/0006-3223(94)00120-R; THAL LJ, 1983, ANN NEUROL, V13, P491, DOI 10.1002/ana.410130504; TROMMER BA, 1982, J NEUROCHEM, V39, P1704, DOI 10.1111/j.1471-4159.1982.tb08006.x; TUCEK S, 1984, PROG BIOPHYS MOL BIO, V44, P1, DOI 10.1016/0079-6107(84)90011-7; ULUS IH, 1976, SCIENCE, V194, P1060, DOI 10.1126/science.10629; WECKER L, 1978, SCIENCE, V199, P86, DOI 10.1126/science.199.4324.86; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; WURTMAN RJ, 1977, LANCET, V2, P68; WURTMAN RJ, 1985, NEUROCHEM INT, V7, P869; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1992, J AM COLL NUTR, V11, P473	62	116	121	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					902	907		10.1001/jama.274.11.902	http://dx.doi.org/10.1001/jama.274.11.902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674505				2022-12-01	WOS:A1995RU60300030
J	KAYE, D				KAYE, D			DIPSTICKS FOR DIAGNOSIS OF URINARY-TRACT INFECTION IN THE NURSING-HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BACTERIURIA				KAYE, D (corresponding author), MED COLL PENN,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; BALDASSARRE JS, 1991, MED CLIN N AM, V75, P375, DOI 10.1016/S0025-7125(16)30460-6; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1989, ANN INTERN MED, V110, P404, DOI 10.7326/0003-4819-110-5-404; GLECKMAN R, 1982, SOUTHERN MED J, V75, P551, DOI 10.1097/00007611-198205000-00011; PAPPAS PG, 1991, MED CLIN N AM, V75, P313, DOI 10.1016/S0025-7125(16)30456-4	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					868	868		10.1001/jama.274.11.868	http://dx.doi.org/10.1001/jama.274.11.868			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674489				2022-12-01	WOS:A1995RU60300008
J	MILLER, RW				MILLER, RW			LOOKING FOR ADVERSE REPRODUCTIVE OUTCOMES IN ATOMIC VETERANS - ARE SUCH STUDIES FEASIBLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MILLER, RW (corresponding author), INST MED,COMM STUDY FEASIBIL & NEED EPIDEMIOL STUDIES ADVE,WASHINGTON,DC 20418, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					865	865						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674486				2022-12-01	WOS:A1995RU60300004
J	ANDERSSON, N; DASOUSA, CP; PAREDES, S				ANDERSSON, N; DASOUSA, CP; PAREDES, S			SOCIAL COST OF LAND MINES IN 4 COUNTRIES - AFGHANISTAN, BOSNIA, CAMBODIA, AND MOZAMBIQUE	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY	Objectives-To document the effects of land mines on the health and social conditions of communities in four affected countries. Design-A cross design of cluster survey and rapid appraisal methods including a household questionnaire and qualitative data from key informants, institutional reviews, and focus groups of survivors of landmines from the same communities. Setting-206 communities, 37 in Afghanistan, 66 in Bosnia, 38 in Cambodia, and 65 in Mozambique. Subjects-174 489 people living in 32 904 households in the selected communities. Main outcome measures-Effects of land mines on food security, residence, livestock, and land use; risk factors: extent of individual land mine injuries; physical, psychological, social, and economic costs of injuries during medical care and rehabilitation. Results-Between 25% and 87% of households had daily activities affected by land mines. Based on expected production without the mines, agricultural production could increase by 88-200% in different regions of Afghanistan, 11% in Bosnia, 135% in Cambodia, and 3.6% in Mozambique. A total of 54 554 animals was lost because of land mines, with a minimum cash value of $6.5m, or nearly $200 per household. Overall, 6% of households (1964) reported a land mine victim; a third of victims died in the blast. One in 10 of the victims was a child. The most frequent activities associated with land mine incidents were agricultural or pastoral, except in Bosnia where more than half resulted from military activities, usually during patrols. Incidences have more than doubled between 1980-3 and 1990-3, excluding the incidents in Bosnia. Some 22% of victims (455/2100) were from households reporting attempts to remove land mines; in these households there was a greatly increased risk of injury (odds ratio 4.2 and risk difference 19% across the four countries). Lethality of the mines varied; in Bosnia each blast killed an average of 0.54 people and injured 1.4, whereas in Mozambique each blast killed 1.45 people and wounded 1.27. Households with a land mine victim were 40% more likely to experience difficulty in providing food for the family. Family relationships were affected for around one in every four victims and relationships with colleagues in 40%. Conclusions-Land mines seriously undermine the economy and food security in affected countries; they kill and maim civilians at an increasing rate. The expense of medical care and rehabilitation add economic disability to the physical burden. Awareness of land mines can be targeted at high risk attitudes, such as those associated with tampering with mines.			ANDERSSON, N (corresponding author), CIETINT,847A 2ND AVE,SUITE 387,NEW YORK,NY 10017, USA.							Andersson N., 1989, Health Policy and Planning, V4, P197, DOI 10.1093/heapol/4.3.197; ANDERSSON N, 1992, HEALTH POLICY PLANN, V7, P352, DOI 10.1093/heapol/7.4.352; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; Coupland Robin M., 1994, MED GLOBAL SURVIVAL, V1, P18; Kakar F, 1995, DIRECT INDIRECT CONS; LEDOGAR RJ, 1993, THIRD WORLD PLAN REV, V15, P263; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1974, AM J EPIDEMIOL, V100, P515; RUIJTER JM, 1991, CONVERGENCE, V34, P3; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.2307/2334323; 1994, UN A49357 REP; 1993, HIDDEN KILLERS GLOBA; 1994, MAY C DOC CERT CONV; 1993, UNICEF MINE AWARENES; 1994, PROGRAMME TECHNICAL; 1994, INT REV RED CROSS; 1993, LANDMINES DEADLY LEG	19	106	108	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					718	721		10.1136/bmj.311.7007.718	http://dx.doi.org/10.1136/bmj.311.7007.718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549685	Green Published			2022-12-01	WOS:A1995RV87400019
J	ASCHERIO, A; BIELLIK, R; EPSTEIN, A; SNETRO, G; GLOYD, S; AYOTTE, B; EPSTEIN, PR				ASCHERIO, A; BIELLIK, R; EPSTEIN, A; SNETRO, G; GLOYD, S; AYOTTE, B; EPSTEIN, PR			DEATHS AND INJURIES CAUSED BY LAND MINES IN MOZAMBIQUE	LANCET			English	Article							EXPERIENCE; HEALTH	Land mines in Mozambique are still causing death and injuries years after the initial dispute. Since 1980, 3400 people have had an amputation because of land mine injuries, However, there are no direct estimates of the number of deaths or casualties which are not treated in hospitals. In March, 1994, a medical team assembled by Physicians for Human Rights (PHR) conducted household surveys in the province of Manica and in the sub-district of Metuchira, province of Sofala. The object was to assess the frequency and severity of injuries and mortality caused by land mines in the civilian population. We found ratios of 8.1 and 16.7 casualties per 1000 living people in Manica and Metuchira, respectively. The prevalence of amputees was 3.2 per 1000 in Manica, and 2.3 in Metuchira. These figures are several folds higher than suggested by hospital data. The case fatality rate was 48%. Most of the victims were civilians (68%) and were injured by antipersonnel mines (81%). 16% of victims were women, and 7% were under 15 years of age. Our results suggest that the impact of land mines is substantially higher than originally thought.	PHYSICIANS HUMAN RIGHTS,BOSTON,MA 02116; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; WHO,HARARE,ZIMBABWE; MASSACHUSETTS DEPT PUBL HLTH,BOSTON,MA 02116; SAVE THE CHILDREN,WESTPORT,CT; UNIV WASHINGTON,SCH PUBL HLTH,SEATTLE,WA 98195; HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; World Health Organization; Massachusetts Department of Public Health; University of Washington; University of Washington Seattle; Harvard University								Anderson K, 1993, LANDMINES DEADLY LEG; BLAGDEN P, 1993, APR INT COMM RED CRO; BLAGDEN P, 1993, DEFENSE WEEK    0913, P11; CLIFF J, 1993, SOC SCI MED, V36, P843, DOI 10.1016/0277-9536(93)90076-G; CLIFF J, 1988, SOC SCI MED, V27, P717, DOI 10.1016/0277-9536(87)90331-5; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P63; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; SHEEHAN E, 1993, LANDMINE CASUALTIES; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; VINES A, 1944, LANDMINES MOZAMBIQUE, P42; 1993, HIDDEN KILLERS GLOBA	12	53	55	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					721	724		10.1016/S0140-6736(95)91501-X	http://dx.doi.org/10.1016/S0140-6736(95)91501-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658871				2022-12-01	WOS:A1995RU81000007
J	BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B				BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B			USE OF GLYCOSAMINOGLYCANS TO INCREASE EFFICIENCY OF LONG-TERM CONTINUOUS PERITONEAL-DIALYSIS	LANCET			English	Note							CELL-PROLIFERATION; HEPARIN	Long-term continuous ambulatory peritoneal dialysis (CAPD) frequently induces progressive structural changes in the peritoneal membrane, leading to dialysis failure. Because heparin and glycosaminoglycans favourably remodel anatomical barriers exposed to injury, we studied the effect of intraperitoneal administration of glycosaminoglycans on peritoneal dialysis efficiency. 16 CAPD patients received glycosaminoglycans for 30 days followed by a 30-day wash-out. Glycosaminoglycans in urea and creatinine dialysate-to-plasma ratios significantly increased (means 0.86 and 0.78 at baseline, 0.92 and 0.82 at 30 days, respectively). Peritoneal protein loss was reduced, and serum albumin concentration increased. We now need to assess whether glycosaminoglycans can postpone dialysis failure in the long term.	UNIV PADUA,INST INTERNAL MED,PADUA,ITALY; UNIV PADUA,DIV NEPHROL,PADUA,ITALY; UMBERTO I GEN HOSP,DIV NEPHROL,MESTRE,ITALY	University of Padua; University of Padua; ULSS 3 Serenissima								BREBOROWICZ A, 1994, NEPHRON, V67, P346, DOI 10.1159/000187991; CAENAZZO C, 1995, NEPHROL DIAL TRANSPL, V10, P175; CHAIMOVITZ C, 1994, KIDNEY INT, V45, P1226, DOI 10.1038/ki.1994.163; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COFFEY AK, 1985, AM J PATHOL, V120, P248; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; GAMBARO G, 1994, J AM SOC NEPHROL, V5, P448; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369	10	48	49	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					740	741						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658876				2022-12-01	WOS:A1995RU81000012
J	BRAHE, C; SERVIDEI, S; ZAPPATA, S; RICCI, E; TONALI, P; NERI, G				BRAHE, C; SERVIDEI, S; ZAPPATA, S; RICCI, E; TONALI, P; NERI, G			GENETIC HOMOGENEITY BETWEEN CHILDHOOD-ONSET AND ADULT-ONSET AUTOSOMAL RECESSIVE SPINAL MUSCULAR-ATROPHY	LANCET			English	Note								Molecular diagnosis of childhood proximal spinal muscular atrophy has been enhanced by the discovery of the survival motor neuron (SMN) gene, which is absent or truncated in 98.6% of patients. To determine whether deletion analysis of the SMN gene may also be diagnostic for adult-onset disease, we studied six patients and found deletions in all. This finding will facilitate the diagnosis of adult-onset spinal muscular atrophy, and provides evidence for genetic homogeneity between the clinically diverse adult and childhood forms of the disease.	UNIV CATTOLICA SACRO CUORE, A GEMELLI SCH MED, NEUROL INST, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	BRAHE, C (corresponding author), UNIV CATTOLICA SACRO CUORE, A GEMELLI SCH MED, INST MED GENET, I-00168 ROME, ITALY.		Servidei, Serenella/ABC-4262-2021; Ricci, Enzo/AAC-4448-2020	RICCI, Enzo/0000-0003-3092-3597; SERVIDEI, Serenella/0000-0001-8478-2799	Telethon [517] Funding Source: Medline	Telethon(Fondazione Telethon)		KAUSCH K, 1991, HUM GENET, V86, P317; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; PEARN J, 1980, LANCET, V1, P919; PEARN JH, 1978, BRAIN, V101, P591, DOI 10.1093/brain/101.4.591; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1	5	88	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					741	742		10.1016/S0140-6736(95)91507-9	http://dx.doi.org/10.1016/S0140-6736(95)91507-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658877				2022-12-01	WOS:A1995RU81000013
J	COHEN, G; FORBES, J; GARRAWAY, M				COHEN, G; FORBES, J; GARRAWAY, M			INTERPRETING SELF-REPORTED LIMITING LONG-TERM ILLNESS	BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; SF-36	Objective-To examine the association between self reported limiting long term illness and other dimensions of self reported health. Design-Stratified random sample of general population. Setting-Lothian region, Scotland, in 1993. Subjects-6212 men and women aged 16 and over. Main outcome measures-Limiting long term illness was assessed by the same question as used in the 1991 United Kingdom census. The shea form 36 health survey was used to assess other dimensions of health. Results-Rates of limiting long term illness were much higher than reported in the census. Scores on general and physical health scales had strong associations with limiting long term illness, but after adjustment for these associations psychosocial health measures had Little influence on limiting long term illness. Being at the lower rather than the upper quartile on the physical functioning scale more than doubled the odds of having limiting long term illness. Reported prevalence of many common illnesses was between two and three times higher among those with limiting long term illness. Conclusions-A positive response to the question used by the census to define limiting long term illness was strongly associated with physical limitations on activity and less strongly influenced by scores on scales of mental and social wellbeing. Socioeconomic effects on limiting long term illness seem largely mediated through measures of general health and physical limitations on health.			COHEN, G (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							BRAZIER JE, 1993, BRIT MED J, V305, P160; CHARLTON J, 1994, POPULATION TRENDS, V75, P18; COHEN G, 1994, LOTHIAN HLTH SURVEY; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JENKINSON CM, 1993, PUBLIC HEALTH, V107, P305, DOI 10.1016/S0033-3506(05)80122-2; KAPLAN GA, 1988, ANN CLIN RES, V20, P131; LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182; ROSENGREN A, 1993, BRIT MED J, V307, P102; SHELTON TA, 1994, BRIT MED J, V109, P1059; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 1993, SAS P243 I TECHN REP; 1994, GENERAL HOUSEHOLD SU, P33	14	89	90	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					722	724		10.1136/bmj.311.7007.722	http://dx.doi.org/10.1136/bmj.311.7007.722			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549686	Green Published			2022-12-01	WOS:A1995RV87400020
J	COX, JT				COX, JT			HPV DNA TESTING - CLINICAL BOON OR BOONDOGGLE	LANCET			English	Editorial Material							CYTOLOGY; SMEARS				COX, JT (corresponding author), UNIV CALIF SANTA BARBARA, STUDENT HLTH SERV, SANTA BARBARA, CA 93106 USA.							[Anonymous], 1993, ACTA CYTOL, V37, P115; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; HATCH KD, 1995, AM J OBSTET GYNECOL, V172, P1150, DOI 10.1016/0002-9378(95)91473-0; HUTCHINSON ML, 1992, ACTA CYTOL, V36, P499; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LUNGU O, 1995, OBSTET GYNECOL, V85, P337, DOI 10.1016/0029-7844(94)00399-X; Meijer C. J., 1992, EPIDEMIOLOGY CERVICA, P271; SCHIFFMAN MH, 1994, CANCER RES, V54, pS1944; SCHIFFMAN MH, 1993, J NATL CANCER I, V85, P1868, DOI 10.1093/jnci/85.22.1868-a; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L	15	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 16	1995	346	8977					717	719						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658868				2022-12-01	WOS:A1995RU81000004
J	DOUGLAS, JDM; MCSHARRY, C; BLAIKIE, L; MORROW, T; MILES, S; FRANKLIN, D				DOUGLAS, JDM; MCSHARRY, C; BLAIKIE, L; MORROW, T; MILES, S; FRANKLIN, D			OCCUPATIONAL ASTHMA CAUSED BY AUTOMATED SALMON PROCESSING	LANCET			English	Article							LABORATORY-ANIMALS; FLOW; WORKERS; SMOKING; ALLERGY	Within 3 months of the opening of a salmon-processing plant in the UK, some workers complained of symptoms suggestive of occupational asthma. A survey of all 291 employees identified 24 (8.2%) with occupational asthma. The employees worked near machines which generated respirable aerosols containing salmon-serum proteins. The IgE response to these proteins was associated with occupational asthma (p<0.001), with increasing severity of symptoms (p<0.001), and with working distance from the aerosol source (p=0.037). The main factor which predisposed to IgE-antibody production and asthma was cigarette smoking (p<0.001), whereas atopy and a previous allergic history did not. The affected employees were reallocated to a low-exposure worksite and factory ventilation was improved. Eleven showed significant clinical and pulmonary function improvement, and continued in employment. Thirteen who still had symptoms were advised to leave, thereafter becoming symptom-free, and regaining normal respiratory function. Early recognition of symptoms and prompt action to reduce aerosol exposure avoided the long-term reduction in pulmonary functions often associated with occupational asthma.	WESTERN INFIRM & ASSOCIATED HOSP,DEPT IMMUNOL,GLASGOW,LANARK,SCOTLAND; UNILEVER RES & ENGN,SHARNBROOK,BEDS,ENGLAND; RAIGMORE HOSP,INVERNESS,SCOTLAND	Unilever	DOUGLAS, JDM (corresponding author), TWEEDDALE MED PRACTICE,HIGH ST,FT WILLIAM PH33 6EU,SCOTLAND.			McSharry, Charles/0000-0003-4758-9038				BURGE PS, 1993, OCCUP MED, V8, P279; BURGE PS, 1988, CHEST, V81, P105; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; DAVIES GE, 1983, BRIT J IND MED, V40, P442; EDWARDS RG, 1980, INT ARCH ALLER A IMM, V68, P352; GADDIE J, 1980, LANCET, V2, P1350; GANNON PF, 1993, J ALLERGY CLIN IMMUN, V91, P1121; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MALO JL, 1988, AM REV RESPIR DIS, V128, P807; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499, DOI 10.1111/j.1365-2249.1994.tb06116.x; MEGURO T, 1990, IND HEALTH, V28, P133, DOI 10.2486/indhealth.28.133; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; NEWMANTAYLOR A, 1990, CHEST, V98, P209; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; SHERSON D, 1989, ALLERGY, V44, P336, DOI 10.1111/j.1398-9995.1989.tb00455.x; STENTON SC, 1995, BRIT MED J, V310, P1299, DOI 10.1136/bmj.310.6990.1299a; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VENABLES KM, 1988, BRIT J IND MED, V45, P667; 1991, IND INJURIES DISABLE; 1990, HSE HSG61	24	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					737	740		10.1016/S0140-6736(95)91505-2	http://dx.doi.org/10.1016/S0140-6736(95)91505-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658875				2022-12-01	WOS:A1995RU81000011
J	GUPTA, JK; CAVE, M; LILFORD, RJ; FARRELL, TA; IRVING, HC; MASON, G; HAU, CM				GUPTA, JK; CAVE, M; LILFORD, RJ; FARRELL, TA; IRVING, HC; MASON, G; HAU, CM			CLINICAL-SIGNIFICANCE OF FETAL CHOROID-PLEXUS CYSTS	LANCET			English	Article							PRENATAL-DIAGNOSIS; LATERAL VENTRICLE; DOWNS-SYNDROME; AMNIOCENTESIS; FETUSES; TRISOMY-18; PREGNANCY; RISK	Choroid plexus (CP) cysts are commonly detected on routine mid-trimester ultrasound scan. When associated anomalies are detected, the risk is sufficient to justify an invasive diagnostic test such as amniocentesis. However, the risk when no associated anomalies are detected is much less well defined. This information is required to determine the appropriate management in cases of apparently isolated CP cysts. We thought the only way to resolve the difficulties in counselling prospective parents was to conduct a prospective study in a large unselected population. A registry of fetal CP cysts detected over 3 years in the Yorkshire Region was compiled and we identified 524 CP cysts. These cases were then amalgamated and analysed with 1361 cases from prospective studies reported in the world English literature and a further 71 unpublished cases identified from a 2 year prospective series from Ninewells Hospital, Dundee. The risk of chromosomal abnormalities was 1 in 150 (95% CI 1 in 85, 1 in 261) when no fetal anatomic abnormalities, apart from the CP cysts themselves, were detected antenatally. The risk increased to approximately 1 in 3 if any other associated ultrasound abnormalities were detected antenatally. The risk did not appear to be related to whether or not cyst size diminished as gestation progresses, whether they were unilateral or bilateral, and whether they were small or large in size (60-80% <10 mm). 76% of aneuploidic cases were trisomy 18 and 17% were trisomy 21. The risk of Down's syndrome in fetuses with CP cysts but no other anomalies detected antenatally is 1 in 880. The probability of a chromosomal abnormality is high when CP cysts are associated with any other antenatally detected anomaly, indicating a clear need to offering amniocentesis. The predictive value is much lower when no other anomalies are detected. In such cases, it is probably advisable to regard CP cysts as an indication for detailed ultrasound assessment, rather than invasive testing.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV LEEDS,INST EPIDEMIOL & HLTH SERV RES,LEEDS,W YORKSHIRE,ENGLAND; ST JAMES UNIV HOSP,DEPT DIAGNOST RADIOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; LEEDS GEN INFIRM,DEPT OBSTET & GYNAECOL,LEEDS,W YORKSHIRE,ENGLAND	University of Dundee; University of Leeds; Saint James's University Hospital; Leeds General Infirmary; University of Leeds	GUPTA, JK (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OBSTET & GYNAECOL,DUNDEE DD1 9SY,SCOTLAND.			Farrell, Thomas/0000-0001-7775-2866				ACHIRON R, 1991, OBSTET GYNECOL, V78, P815; ANDREUSSI L, 1979, SURG NEUROL, V12, P53; BARKAI G, 1993, PRENATAL DIAG, V13, P843, DOI 10.1002/pd.1970130908; BENACERRAF BR, 1988, AM J OBSTET GYNECOL, V158, P404, DOI 10.1016/0002-9378(88)90165-2; BENACERRAF BR, 1990, AM J OBSTET GYNECOL, V162, P1001, DOI 10.1016/0002-9378(90)91304-U; CAMURRI L, 1989, PRENATAL DIAG, V9, P742, DOI 10.1002/pd.1970091011; CHAN L, 1989, OBSTET GYNECOL, V73, P703; CHINN DH, 1991, J ULTRAS MED, V10, P255; CHITKARA U, 1988, OBSTET GYNECOL, V72, P185; CHITTY LS, 1993, BR MED ULTRASOUND SO, V1, P40; CHUDLEIGH P, 1984, PRENATAL DIAG, V4, P135, DOI 10.1002/pd.1970040207; CLARK SL, 1988, OBSTET GYNECOL, V72, P585; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; FAKHRY J, 1985, J ULTRAS MED, V4, P561, DOI 10.7863/jum.1985.4.10.561; FITZSIMMONS J, 1989, OBSTET GYNECOL, V73, P257; GABRIELLI S, 1989, AM J OBSTET GYNECOL, V160, P1207, DOI 10.1016/0002-9378(89)90192-0; Gupta J. K., 1995, P231; HOWARD RJ, 1992, PRENATAL DIAG, V12, P685, DOI 10.1002/pd.1970120809; LILFORD RJ, 1994, BRIT J OBSTET GYNAEC, V101, P291, DOI 10.1111/j.1471-0528.1994.tb13612.x; NADEL AS, 1992, RADIOLOGY, V185, P545, DOI 10.1148/radiology.185.2.1410370; NYBERG DA, 1993, J ULTRAS MED, V12, P103; OSTLERE SJ, 1990, RADIOLOGY, V175, P753, DOI 10.1148/radiology.175.3.2188298; OSTLERE SJ, 1989, PRENATAL DIAG, V9, P205, DOI 10.1002/pd.1970090310; OSTLERE SJ, 1987, LANCET, V1, P1491; PLATT LD, 1991, AM J OBSTET GYNECOL, V164, P1652, DOI 10.1016/0002-9378(91)91451-2; PORTO M, 1993, J CLIN ULTRASOUND, V21, P103, DOI 10.1002/jcu.1870210205; ROOT S, 1994, AM J MED GENET, V49, P170, DOI 10.1002/ajmg.1320490203; SHUANGSH.S, 1965, ARCH PATHOL, V80, P214; SHUANGSHOTI S, 1966, NEUROLOGY, V16, P887, DOI 10.1212/WNL.16.9.887; TWINING P, 1991, BRIT J RADIOL, V64, P98, DOI 10.1259/0007-1285-64-758-98; WALKINSHAW SA, 1994, PRENATAL DIAG, V14, P663, DOI 10.1002/pd.1970140804; ZERRES K, 1992, HUM GENET, V89, P301	32	63	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					724	729		10.1016/S0140-6736(95)91502-8	http://dx.doi.org/10.1016/S0140-6736(95)91502-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658872				2022-12-01	WOS:A1995RU81000008
J	HISLOP, LJ; WYATT, JP; MCNAUGHTON, GW; IRELAND, AJ; RAINER, TH; OLVERMAN, G; LAUGHTON, LM				HISLOP, LJ; WYATT, JP; MCNAUGHTON, GW; IRELAND, AJ; RAINER, TH; OLVERMAN, G; LAUGHTON, LM			URBAN HYPOTHERMIA IN THE WEST OF SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ROYAL ALEXANDRA HOSP, DEPT ACCID & EMERGENCY MED, PAISLEY PA2 9PL, RENFREW, SCOTLAND; ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G11 6NT, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G4 0SF, LANARK, SCOTLAND; MONKLANDS DIST GEN HOSP, DEPT ACCID & EMERGENCY MED, AIRDRIE, LANARK ML6 0JS, SCOTLAND; VICTORIA INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G42 9TY, LANARK, SCOTLAND; SO GEN HOSP, DEPT ACCID & EMERGENCY MED, GLASGOW G51 4TF, LANARK, SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow			Rainer, Timothy/I-2591-2013	Rainer, Timothy/0000-0003-3355-3237				[Anonymous], 1985, LANCET, V2, P987; OTTY CJ, 1987, BRIT MED J, V295, P419, DOI 10.1136/bmj.295.6595.419; WATT GCM, 1994, BRIT MED J, V309, P1030, DOI 10.1136/bmj.309.6961.1030; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; 1991, POP CENS	5	31	31	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	1995	311	7007					725	725		10.1136/bmj.311.7007.725	http://dx.doi.org/10.1136/bmj.311.7007.725			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549687	Green Published			2022-12-01	WOS:A1995RV87400021
J	KUHEL, WI; WARD, RF				KUHEL, WI; WARD, RF			THYROID-CANCER IN CHILDREN	LANCET			English	Editorial Material											KUHEL, WI (corresponding author), CORNELL UNIV,COLL MED,DEPT CLIN OTOLARYNGOL,NEW YORK,NY 10021, USA.							Baverstock K F, 1993, World Health Stat Q, V46, P204; DEGROOT LJ, 1975, THYROID ITS DISEASES, P666; DUFFY BJ, 1950, J CLIN ENDOCR METAB, V101, P1296; HARNESS JK, 1971, ARCH SURG-CHICAGO, V10, P278; MAZZAFERRI EL, AM J MED; Winship T, 1970, CLIN P CHILDRENS HOS, V26, P327; ZIMMERMAN D, 1988, SURGERY, V10, P1157; ZIMMERMAN D, 1992, TREATMENT THYROID CA	8	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					719	720		10.1016/S0140-6736(95)91499-4	http://dx.doi.org/10.1016/S0140-6736(95)91499-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658869				2022-12-01	WOS:A1995RU81000005
J	PATEL, P; MENDALL, MA; CARRINGTON, D; STRACHAN, DP; LEATHAM, E; MOLINEAUX, N; LEVY, J; BLAKESTON, C; SEYMOUR, CA; CAMM, AJ; NORTHFIELD, TC				PATEL, P; MENDALL, MA; CARRINGTON, D; STRACHAN, DP; LEATHAM, E; MOLINEAUX, N; LEVY, J; BLAKESTON, C; SEYMOUR, CA; CAMM, AJ; NORTHFIELD, TC			ASSOCIATION OF HELICOBACTER-PYLORI AND CHLAMYDIA-PNEUMONIAE INFECTIONS WITH CORONARY HEART-DISEASE AND CARDIOVASCULAR RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CELL COUNT; FIBRINOGEN; PLAQUES; HEALTH; LIFE	Objective-To investigate the relation between seropositivity to chronic infections with Helicobacter pylori and Chlamydia pneumoniae and both coronary heart disease and cardiovascular risk factors. Design-Cross sectional study of a population based random sample of men. Coronary heart disease was assessed by electrocardiography, Rose angina questionnaire, and a history of myocardial infarction; serum antibody levels to H pylori and C pneumoniae were measured, risk factor levels determined, and a questionnaire administered. Setting-General practices in Merton, Sutton, and Wandsworth, south London. Subjects-388 white south London men aged 50-69. Main outcome measures-Evidence of coronary risk factors and infection with H pylori or C pneumoniae. Results-47 men (12.1%) had electrocardiographic evidence of ischaemia or infarction. 36 (76.6%) and 18 (38.3%) were seropositive for H pylori and C pneumoniae, respectively, compared with 155 (45.5%) and 62 (18.2%) men with normal electrocardiograms. Odds ratios for abnormal electrocardiograms were 3.82 (95% confidence interval 1.60 to 9.10) and 3.06 (1.33 to 7.01) in men seropositive for H pylori and C pneumoniae, respectively, after adjustment for a range of socioeconomic indicators and risk factors for coronary heart disease. Cardiovascular risk factors that were independently associated with seropositivity to H pylori included fibrinogen concentration and total leucocyte count. Seropositivity to C pneumoniae was independently associated with raised fibrinogen and malondialdehyde concentrations. Conclusions-Both H pylori and C pneumoniae infections are associated with coronary heart disease. These relations are not explained by a wide range of confounding factors. Possible mechanisms include an increase in risk factor levels due to a low grade chronic inflammatory response.	UNIV LONDON ST GEORGES HOSP,SCH MED,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND	St Georges University London								BAKER RJ, 1978, GLIM SYSTEM; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DAROUGAR S, 1983, BRIT MED BULL, V39, P117, DOI 10.1093/oxfordjournals.bmb.a071801; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; GLYNN JR, 1994, LANCET, V344, P146, DOI 10.1016/S0140-6736(94)92754-5; HENDRIKS T, 1988, CLIN CHIM ACTA, V174, P263, DOI 10.1016/0009-8981(88)90052-6; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KWEIDER M, 1993, SCOT MED J, V38, P73, DOI 10.1177/003693309303800304; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MENDALL MA, 1994, BRIT HEART J, V71, P437; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; MORRISSEY JH, 1993, BLOOD, V81, P734; PATEL P, 1994, LANCET, V343, P1634, DOI 10.1016/S0140-6736(94)93084-8; PUOLAKKAINEN M, 1993, J CLIN MICROBIOL, V31, P2212, DOI 10.1128/JCM.31.8.2212-2214.1993; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSE GA, 1982, WHO MONOGR SER, V56, P123; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; WANG SP, 1994, J INFECT DIS, V130, P388; WILLIAMS D, 1989, INFECT IMMUN, V58, P1351; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1985, SAS USERS GUIDE STAT	32	514	530	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					711	714		10.1136/bmj.311.7007.711	http://dx.doi.org/10.1136/bmj.311.7007.711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549683	Green Published			2022-12-01	WOS:A1995RV87400017
J	SANDVIK, L; ERIKSSEN, G; THAULOW, E				SANDVIK, L; ERIKSSEN, G; THAULOW, E			LONG-TERM EFFECTS OF SMOKING ON PHYSICAL-FITNESS AND LUNG-FUNCTION - A LONGITUDINAL-STUDY OF 1393 MIDDLE-AGED NORWEGIAN MEN FOR 7 YEARS	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; BLOOD-PRESSURE; EXERCISE; SMOKERS; CARDIOMYOPATHY; OBSTRUCTION; EPINEPHRINE; NONSMOKERS; POPULATION; PREDICTOR	Objective-To study association between smoking habits and long term decline in physical fitness and lung function in middle aged men who remained healthy. Design-Baseline and follow up measurements performed during 1972-5 and 1980-2 respectively. Setting-National University Hospital of Oslo, Norway. Subjects-1393 men aged 40-59 at baseline who were all healthy at baseline and at follow up. Main outcome measures-Forced expiratory volume in one second and physical fitness (defined as total work done during a symptom limited bicycle ergometer test divided by body weight. Results-Initial fitness was substantially lower among 347 persistent smokers than among 791 persistent non-smokers (1349 J/kg v 1618 J/kg), as was initial forced expiratory volume (3341 ml v 3638 ml). Mean (95% confidence interval) decline in fitness over 7.2 years was 217 (185 to 249) J/kg among smokers compared with 86 (59 to 113) J/kg among non-smokers (P<0.001). Corresponding declines in forced expiratory volume were 271 (226 to 316) ml in smokers and 116 (85 to 147) ml in non-smokers (P<0.001). Differences between smokers and non-smokers remained practically unchanged after adjustment for age and level of physical activity. Changes in fitness and forced expiratory volume among 199 men who had stopped smoking mimicked the findings for persistent non-smokers, and 56 men who started smoking presented findings close to those of persistent smokers. Conclusion-Decline in physical fitness and lung function among healthy middle aged men was considerably greater among smokers than among nonsmokers and could not be explained by differences in age and physical activity.	CENT HOSP AKERSHUS,DEPT MED,N-1474 NORDBYHAGEN,NORWAY	University of Oslo								Astrand PO., 1986, TXB WORK PHYSL, P391; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; CONWAY TL, 1992, PREV MED, V21, P723, DOI 10.1016/0091-7435(92)90079-W; COOPER MJH, 1968, JAMA-J AM MED ASSOC, V203, P123; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; Dressendorfer R H, 1983, Phys Sportsmed, V11, P108, DOI 10.1080/00913847.1986.11708539; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERIKSSEN G, 1994, 67TH AM HEART ASS AN; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1978, ACTA MED SCAND, V203, P532; ERIKSSEN J, 1978, THESIS U HOSPITAL OS; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; HAF JI, 1974, PROGR CARDIOVASC DIS, V17, P73; HANDA K, 1990, ATHEROSCLEROSIS, V84, P189, DOI 10.1016/0021-9150(90)90090-6; Hoad N A, 1992, J R Army Med Corps, V138, P115; JOHNSON BD, 1992, J APPL PHYSIOL, V73, P874, DOI 10.1152/jappl.1992.73.3.874; LAUSTIOLA KE, 1988, CIRCULATION, V78, P1234, DOI 10.1161/01.CIR.78.5.1234; MCHENRY PI, 1977, AM J CARDIOL, V39, P393; PENNY WJ, 1986, INT J CARDIOL, V11, P293, DOI 10.1016/0167-5273(86)90034-3; POWERS SK, 1989, J APPL PHYSIOL, V66, P2491, DOI 10.1152/jappl.1989.66.6.2491; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHAVER LG, 1973, J AM COLL HEALTH ASS, V21, P489; SIDNEY S, 1993, MED SCI SPORT EXER, V25, P911; SINGAL PK, 1982, CAN J PHYSIOL PHARM, V60, P1390, DOI 10.1139/y82-207; TRAPJENSEN J, 1988, AM HEART J, V115, P263, DOI 10.1016/0002-8703(88)90647-3; YATES JC, 1981, AM HEART J, V102, P210, DOI 10.1016/S0002-8703(81)80012-9; 1990, PHS DHSS CDS908416 P; 1984, DHHS PHS8450205 PUBL	30	64	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					715	718		10.1136/bmj.311.7007.715	http://dx.doi.org/10.1136/bmj.311.7007.715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549684	Green Published			2022-12-01	WOS:A1995RV87400018
J	VANHOUTTE, PM				VANHOUTTE, PM			THE MALE PARADOX	LANCET			English	Editorial Material							17-BETA-ESTRADIOL; RABBIT				VANHOUTTE, PM (corresponding author), INST RECH INT SERVIER,6 PL PLEIADES,F-92415 COURBEVOIE,FRANCE.		Vanhoutte, Paul M/B-4533-2009					FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; LAWRENCE WD, 1986, ENDOCRINOLOGY, V119, P2803, DOI 10.1210/endo-119-6-2803; Luscher T.F., 1990, ENDOTHELIUM MODULATO, V001-228; MILLER VM, 1990, AM J PHYSIOL, V258, pR1502, DOI 10.1152/ajpregu.1990.258.6.R1502; YUE P, 1995, CIRCULATION, V91, P1154, DOI 10.1161/01.CIR.91.4.1154	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					717	717		10.1016/S0140-6736(95)91497-8	http://dx.doi.org/10.1016/S0140-6736(95)91497-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658867				2022-12-01	WOS:A1995RU81000003
J	BOWRING, SA; HOUSH, T				BOWRING, SA; HOUSH, T			THE EARTH EARLY EVOLUTION	SCIENCE			English	Article							SOUTHERN WEST GREENLAND; LOWER CONTINENTAL-CRUST; ND-ISOTOPIC EVIDENCE; MEAN-LIFE; CLASTIC METASEDIMENTS; MANTLE FRACTIONATION; DETRITAL ZIRCONS; GNEISS COMPLEX; HF ISOTOPES; GROWTH	The Archean crust contains direct geochemical information of the Earth's early planetary differentiation. A major outstanding question in the Earth sciences is whether the volume of continental crust today represents nearly all that formed over Earth's history or whether its rates of creation and destruction have been approximately balanced since the Archean. Analysis of neodymium isotopic data from the oldest remnants of Archean crust suggests that crustal recycling is important and that preserved continental crust comprises fragments of crust that escaped recycling. Furthermore, the data suggest that the isotopic evolution of Earth's mantle reflects progressive eradication of primordial heterogeneities related to early differentiation.	UNIV TEXAS, DEPT GEOL SCI, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	BOWRING, SA (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA.							ABBOTT D, 1991, GEOPHYS RES LETT, V18, P585, DOI 10.1029/91GL00813; ALLEGRE CJ, 1989, EARTH PLANET SC LETT, V96, P61, DOI 10.1016/0012-821X(89)90124-6; ANDERSON DL, 1994, GEOLOGY, V22, P39, DOI 10.1130/0091-7613(1994)022<0039:SOS>2.3.CO;2; ANDERSON DL, 1981, SCIENCE, V213, P82, DOI 10.1126/science.213.4503.82; ANDERSON DL, 1994, EARTH PLANET SC LETT, V128, P303, DOI 10.1016/0012-821X(94)90152-X; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; ARMSTRONG RL, 1968, REV GEOPHYS, V6, P175, DOI 10.1029/RG006i002p00175; ARMSTRONG RL, 1991, AUST J EARTH SCI, V38, P613, DOI 10.1080/08120099108727995; ARMSTRONG RL, 1981, GEOCHIM COSMOCHIM AC, V45, P1251, DOI 10.1016/0016-7037(81)90149-6; ARNDT NT, 1989, TECTONOPHYSICS, V161, P201, DOI 10.1016/0040-1951(89)90154-6; ARTH JG, 1975, GEOCHIM COSMOCHIM AC, V39, P325, DOI 10.1016/0016-7037(75)90200-8; BARKER F, 1976, GEOLOGY, V4, P596, DOI 10.1130/0091-7613(1976)4<596:GOTLAA>2.0.CO;2; BENNETT VC, 1993, EARTH PLANET SC LETT, V119, P299, DOI 10.1016/0012-821X(93)90140-5; BLACK LP, 1986, CONTRIB MINERAL PETR, V94, P427, DOI 10.1007/BF00376336; BLICHERTTOFT J, 1994, SCIENCE, V263, P1593, DOI 10.1126/science.263.5153.1593; BOAK JM, 1993, GEOL SOC AM ABSTR, V25, P74; BOWRING SA, 1989, GEOLOGY, V17, P971, DOI 10.1130/0091-7613(1989)017<0971:GGFTSP>2.3.CO;2; BOWRING SA, 1989, NATURE, V340, P222, DOI 10.1038/340222a0; BOWRING SA, UNPUB; BOWRING SA, 1990, ORIGIN EARTH, P319; BOWRING SA, 1994, EOS, V75, P59; CAMPBELL IH, 1983, GEOPHYS RES LETT, V10, P1061, DOI 10.1029/GL010i011p01061; CAMPBELL IH, 1988, EARTH PLANET SC LETT, V90, P11, DOI 10.1016/0012-821X(88)90107-0; CARLSON RW, 1979, EARTH PLANET SC LETT, V45, P123, DOI 10.1016/0012-821X(79)90114-6; CARLSON RW, 1994, REV GEOPHYS, V32, P337, DOI 10.1029/94RG01874; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; CHRISTENSEN NI, 1995, J GEOPHYS RES-SOL EA, V100, P9761, DOI 10.1029/95JB00259; Collerson K.D., 1979, TRONDHJEMITES DACITE, V6, P205; COLLERSON KD, 1991, NATURE, V349, P209, DOI 10.1038/349209a0; CONDIE KC, 1984, GEOPHYS RES LETT, V11, P283, DOI 10.1029/GL011i004p00283; DePaolo D.J., 1988, NEODYMIUM ISOTOPE GE, V20, P1; DEPAOLO DJ, 1980, GEOCHIM COSMOCHIM AC, V44, P1185, DOI 10.1016/0016-7037(80)90072-1; DEPAOLO DJ, 1983, GEOPHYS RES LETT, V10, P705, DOI 10.1029/GL010i008p00705; DEPAOLO DJ, 1984, GEOPHYS RES LETT, V11, P154, DOI 10.1029/GL011i002p00154; DEPAOLO DJ, 1981, GEOCHIM COSMOCHIM AC, V45, P1253, DOI 10.1016/0016-7037(81)90150-2; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; DRUMMOND MS, 1990, J GEOPHYS RES-SOLID, V95, P21503, DOI 10.1029/JB095iB13p21503; ENGLAND P, 1993, TECTONOPHYSICS, V223, P67, DOI 10.1016/0040-1951(93)90158-G; FROST CD, 1993, GEOLOGY, V21, P351, DOI 10.1130/0091-7613(1993)021<0351:NIEFTA>2.3.CO;2; FROUDE DO, 1983, NATURE, V304, P616, DOI 10.1038/304616a0; FYFE WS, 1978, CHEM GEOL, V23, P89, DOI 10.1016/0009-2541(78)90068-2; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Goldstein S. L., 1992, EOS T AM GEOPHYS UN, V73, P323; GOODWIN AM, 1991, PRECAMBRIAN GEOLOGY; GURNIS M, 1986, GEOLOGY, V14, P396, DOI 10.1130/0091-7613(1986)14<396:AECGAF>2.0.CO;2; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1992, P LUNAR PLANET SCI C, V23, P487; HOFFMAN PF, 1989, GEOLOGY, V17, P135, DOI 10.1130/0091-7613(1989)017<0135:SOLSFG>2.3.CO;2; HOUSH TB, UNPUB; HOUSH TB, 1993, GEOL SOC AM ABSTR, V25, P73; HURLEY PM, 1969, SCIENCE, V164, P1229, DOI 10.1126/science.164.3885.1229; JACOBSEN SB, 1981, TECTONOPHYSICS, V75, P163, DOI 10.1016/0040-1951(81)90214-6; JACOBSEN SB, 1988, J GEOPHYS RES-SOLID, V93, P338, DOI 10.1029/JB093iB01p00338; JACOBSEN SB, 1988, EARTH PLANET SC LETT, V90, P315, DOI 10.1016/0012-821X(88)90133-1; JACOBSEN SB, IN PRESS AM GEOPHYS; JACOBSEN SB, 1993, P LUNAR PLANET SCI C, V24, P709; JAHN B, 1984, CONTRIB MINERAL PETR, V86, P398, DOI 10.1007/BF01187143; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; JORDAN TH, 1988, J PETROL, P11, DOI DOI 10.1093/PETROLOGY/SPECIAL_VOLUME.1.11; KAY RW, 1991, GEOL RUNDSCH, V80, P259, DOI 10.1007/BF01829365; LAUBSCHER H, 1990, TECTONOPHYSICS, V182, P9, DOI 10.1016/0040-1951(90)90338-9; LIU DY, 1992, GEOLOGY, V20, P339, DOI 10.1130/0091-7613(1992)020<0339:ROMCIT>2.3.CO;2; LUAIS B, 1994, J PETROL, V35, P43, DOI 10.1093/petrology/35.1.43; Lugmair G.W., 1978, P 9 LUNAR PLANET SCI, P689; MAAS R, 1991, GEOCHIM COSMOCHIM AC, V55, P1915, DOI 10.1016/0016-7037(91)90033-2; MAAS R, 1992, GEOCHIM COSMOCHIM AC, V56, P1281, DOI 10.1016/0016-7037(92)90062-N; MARTIN H, 1986, GEOLOGY, V14, P753, DOI 10.1130/0091-7613(1986)14<753:EOSAGG>2.0.CO;2; MCCULLOCH MT, 1993, LITHOS, V30, P237, DOI 10.1016/0024-4937(93)90038-E; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P4717, DOI 10.1016/0016-7037(94)90203-8; MORGAN P, 1989, 28TH INT GEOL C 1989, V2, P462; MORGAN P, 1985, P LUNAR PLANET SCI C, V15, pC561; MUELLER PA, 1992, GEOLOGY, V20, P327, DOI 10.1130/0091-7613(1992)020<0327:GZFAAQ>2.3.CO;2; NUTMAN AP, 1986, CONTRIB MINERAL PETR, V94, P137, DOI 10.1007/BF00592931; NUTMAN AP, 1993, GEOLOGY, V21, P415, DOI 10.1130/0091-7613(1993)021<0415:AOAEAG>2.3.CO;2; NUTMAN AP, 1991, GEOLOGY, V19, P791, DOI 10.1130/0091-7613(1991)019<0791:VEACAC>2.3.CO;2; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; PATCHETT J, 1984, GEOPHYS RES LETT, V11, P151, DOI 10.1029/GL011i002p00151; RAPP RP, 1991, PRECAMBRIAN RES, V51, P1, DOI 10.1016/0301-9268(91)90092-O; REYMER A, 1984, TECTONICS, V3, P63, DOI 10.1029/TC003i001p00063; SCHREYER W, 1995, J GEOPHYS RES-SOL EA, V100, P8353, DOI 10.1029/94JB02912; SHEARER CK, 1993, GEOCHIM COSMOCHIM AC, V57, P4785, DOI 10.1016/0016-7037(93)90200-G; SHIREY SB, 1986, GEOCHIM COSMOCHIM AC, V50, P2631, DOI 10.1016/0016-7037(86)90215-2; SILVER PG, 1988, ANNU REV EARTH PL SC, V16, P477, DOI 10.1146/annurev.ea.16.050188.002401; SNYDER GA, 1994, GEOCHIM COSMOCHIM AC, V58, P4795, DOI 10.1016/0016-7037(94)90209-7; STEVENSON RK, 1990, GEOCHIM COSMOCHIM AC, V54, P1683, DOI 10.1016/0016-7037(90)90400-F; Taylor S.R., 1974, LUNAR PLANETARY SCI, P1287; Taylor S.R., 1985, CONTINENTAL CRUST IT, P312; TAYLOR SR, 1975, LUNAR SCI POST APOLL; VONHUENE R, 1991, REV GEOPHYS, V29, P279, DOI 10.1029/91RG00969; WARREN PH, 1989, TECTONOPHYSICS, V161, P165, DOI 10.1016/0040-1951(89)90153-4; WILLIAMS IS, 1992, EOS, V73, P324; ZARTMAN RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1327, DOI 10.1016/0016-7037(88)90204-9	93	234	244	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1535	1540		10.1126/science.7667634	http://dx.doi.org/10.1126/science.7667634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667634				2022-12-01	WOS:A1995RU81300030
J	CHEN, BM; GRINNELL, AD				CHEN, BM; GRINNELL, AD			INTEGRINS AND MODULATION OF TRANSMITTER RELEASE FROM MOTOR-NERVE TERMINALS BY STRETCH	SCIENCE			English	Article							CELL-ADHESION; EXTRACELLULAR-MATRIX; SYNAPTIC STRENGTH; CALCIUM; CHANNELS; FIBRONECTIN; GADOLINIUM; JUNCTIONS; RECEPTORS; BLOCK	The stretch of a frog muscle within the physiological range can more than double the spontaneous and evoked release of neurotransmitter from its motor nerve terminals. Here, stretch enhancement of release was suppressed by peptides containing the sequence arginine-glycine-aspartic acid (RGD), which blocks integrin binding. Integrin antibodies also inhibited the enhancement obtained by stretching. Stretch enhancement depended on intraterminal calcium derived both from external calcium and from internal stores. Muscle stretch thus might enhance the release of neurotransmitters either by elevating internal calcium concentrations or by increasing the sensitivity of transmitter release to calcium in the nerve terminal.	UNIV CALIF LOS ANGELES, SCH MED, JERRY LEWIS NEUROMUSCULAR RES CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, AHMANSON LAB NEUROBIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030673] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30673, NS06232] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; [Anonymous], UNPUB; Chen B.-M., 1994, Society for Neuroscience Abstracts, V20, P58; CHEN BM, 1994, ADV SEC MESS PHOSPH, V29, P383; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIPOLO R, 1983, ANNU REV PHYSIOL, V45, P313, DOI 10.1146/annurev.ph.45.030183.001525; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GRINNELL AD, 1983, J PHYSIOL-LONDON, V338, P221, DOI 10.1113/jphysiol.1983.sp014670; GRINNELL AD, 1989, J PHYSIOL-LONDON, V418, P397, DOI 10.1113/jphysiol.1989.sp017848; GRINNELL AD, 1980, J PHYSIOL-LONDON, V307, P301, DOI 10.1113/jphysiol.1980.sp013436; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HUTTER OF, 1956, J PHYSIOL-LONDON, V133, P610, DOI 10.1113/jphysiol.1956.sp005613; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KORNBERG L, 1992, TRENDS PHARMACOL SCI, V13, P93, DOI 10.1016/0165-6147(92)90034-4; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.ne.14.030191.002531; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; SWERUP C, 1991, ACTA PHYSIOL SCAND, V143, P21, DOI 10.1111/j.1748-1716.1991.tb09197.x; TURKANIS SA, 1973, J PHYSIOL-LONDON, V230, P391, DOI 10.1113/jphysiol.1973.sp010194; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	31	106	108	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1578	1580		10.1126/science.7667637	http://dx.doi.org/10.1126/science.7667637			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667637				2022-12-01	WOS:A1995RU81300042
J	COOK, DN; BECK, MA; COFFMAN, TM; KIRBY, SL; SHERIDAN, JF; PRAGNELL, IB; SMITHIES, O				COOK, DN; BECK, MA; COFFMAN, TM; KIRBY, SL; SHERIDAN, JF; PRAGNELL, IB; SMITHIES, O			REQUIREMENT OF MIP-1-ALPHA FOR AN INFLAMMATORY RESPONSE TO VIRAL-INFECTION	SCIENCE			English	Article							STEM-CELL PROLIFERATION; LYMPHOCYTES; CHEMOKINES; MIP-1-BETA; EXPRESSION	Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is a chemokine that has pro-inflammatory and stem cell inhibitory activities in vitro. Its biologic role in vivo was examined in mice in which the gene encoding MIP-1 alpha had been disrupted. Homozygous MIP-1 alpha mutant (-/-) mice were resistant to Coxsackievirus-induced myocarditis seen in infected wildtype (+/+) mice. Influenza virus-infected -/- mice had reduced pneumonitis and delayed clearance of the virus compared with infected +/+ mice. The -/- mice had no overt hematopoietic abnormalities. These results demonstrate that MIP-1 alpha is an important mediator of virus-induced inflammation in vivo.	UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; VET AFFAIRS MED CTR,DEPT INTERNAL MED,DURHAM,NC 27710; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; OHIO STATE UNIV,HLTH SCI CTR,DEPT ORAL BIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,HLTH SCI CTR,DEPT MED MICROBIOL & IMMUNOL,COLUMBUS,OH 43210; CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Beatson Institute	COOK, DN (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.		Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755; Sheridan, John/0000-0002-6927-0266	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037001, R29HL046195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29HL46195, HL37001] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK MA, 1994, J NUTR, V124, P345, DOI 10.1093/jn/124.3.345; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; GILL BM, 1995, DIABETES, V44, P614, DOI 10.2337/diabetes.44.6.614; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HERMANN G, 1995, J NEUROIMMUNOL, V56, P179, DOI 10.1016/0165-5728(94)00145-E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KARPUS W, 1994, J IMMUNOL, V8, P1148; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KIM HS, 1988, NUCLEIC ACIDS RES, V18, P8887; MALTMAN J, 1994, J EXP MED, V178, P925; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PRAGNELL IB, 1988, BLOOD, V72, P196; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; WOODRUFF JF, 1974, J IMMUNOL, V113, P1726; WOODRUFF JF, 1980, AM J PATHOL, V101, P425	17	528	547	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1583	1585		10.1126/science.7667639	http://dx.doi.org/10.1126/science.7667639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667639				2022-12-01	WOS:A1995RU81300044
J	GALAKTIONOV, K; LEE, AK; ECKSTEIN, J; DRAETTA, G; MECKLER, J; LODA, M; BEACH, D				GALAKTIONOV, K; LEE, AK; ECKSTEIN, J; DRAETTA, G; MECKLER, J; LODA, M; BEACH, D			CDC25 PHOSPHATASES AS POTENTIAL HUMAN ONCOGENES	SCIENCE			English	Article							FISSION YEAST; BREAST-CARCINOMA; MITOTIC INDUCER; P34CDC2 KINASE; CDK2 ACTIVITY; CYCLIN; PHOSPHORYLATION; CELLS; ACTIVATION; INHIBITION	Cyclin-dependent kinases (CDKs) are activated by CDC25 phosphatases, which remove inhibitory phosphate from tyrosine and threonine residues. In human cells, CDC25 proteins are encoded by a multigene family, consisting of CDC25A, CDC25B, and CDC25C. In rodent cells, human CDC25A or CDC25B but not CDC25C phosphatases cooperate with either Ha-RAS(G12V) or loss of RB1 in oncogenic focus formation. Such transformants were highly aneuploid, grew in soft agar, and formed high-grade tumors in nude mice. Overexpression of CDC25B was detected in 32 percent of human primary breast cancers tested. The CDC25 phosphatases may contribute to the development of human cancer.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA; HARVARD UNIV, SCH MED, LAHEY CLIN MED CTR, BURLINGTON, MA 01805 USA; MITOTIX, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Harvard University; Lahey Hospital & Medical Center; Harvard University; Harvard Medical School								BOSARI S, 1992, VIRCHOWS ARCH A, V421, P291, DOI 10.1007/BF01660975; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, UNPUB; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE AKC, 1990, J CLIN ONCOL, V8, P1457, DOI 10.1200/JCO.1990.8.9.1457; LEE AKC, 1992, MODERN PATHOL, V5, P61; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MATSUDA M, 1991, JPN J GENET, V66, P701, DOI 10.1266/jjg.66.701; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAGATA A, 1991, NEW BIOL, V3, P959; NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; POLYAK K, 1994, NATURE, V78, P59; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOYOSHIMA H, 1994, NATURE, V78, P67; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	505	529	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1575	1577		10.1126/science.7667636	http://dx.doi.org/10.1126/science.7667636			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667636				2022-12-01	WOS:A1995RU81300041
J	HARRISON, LH; ALI, A; DWYER, DM; LIBONATI, JP; REEVES, MW; ELLIOTT, JA; BILLMANN, L; LASHKERWALA, T; JOHNSON, JA				HARRISON, LH; ALI, A; DWYER, DM; LIBONATI, JP; REEVES, MW; ELLIOTT, JA; BILLMANN, L; LASHKERWALA, T; JOHNSON, JA			RELAPSING INVASIVE GROUP-B STREPTOCOCCAL INFECTION IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; RECURRENCE; ENDOCARDITIS; OSTEOMYELITIS	MULTILOCUS ENZYME ELECTROPHORESIS; DISEASE; PENICILLIN; INFANT; COLONIZATION; ANTIBODY; FAILURE	Objective: To study recurrent group B streptococcal infection in adults. Design: Patients with more than one reported group B streptococcal infection were identified through active surveillance for this infection. Sterile-site group B streptococcal isolates were evaluated for serotype and molecular subtyping using restriction endonuclease analysis of chromosomal DNA (REAC). Setting: All acute-care hospitals in Maryland. Patients: Nonpregnant residents of Maryland 18 years of age or older. Results: 22 adults had at least two group B streptococcal episodes that were separated by 2 to 95 weeks (mean, 24 weeks). Of 395 patients with invasive group B streptococcal infection who survived the first episode and were followed for at least 1 year, 17 (4.3% [95% CI, 2.6% to 6.9%]) had more than one episode. Several patients were found to have endocarditis or osteomyelitis during the second episode. Group B streptococcal isolates from both episodes were obtained from 18 of 22 patients. Of the 18 isolate pairs, 13 (72% [CI, 46% to 90%]) had identical REAC patterns; the probability that at least 13 matches would be found by chance alone was less than 0.00001. Among patients with recurrent infection caused by the same strain, the interval between episodes was shorter (mean, 14 weeks) than that among patients with recurrent infection caused by another strain (mean, 43 weeks; P = 0.05). Conclusions: Recurrent group B streptococcal infection is common among adults and in most cases appears to be caused by relapse. The optimal management of adults with a first episode of group B streptococcal infection needs to be further defined to minimize the likelihood of recurrent disease.	UNIV MARYLAND, VET AFFAIRS MED CTR, SCH MED, BALTIMORE, MD 21201 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; MARYLAND DEPT HLTH & MENTAL HYG, BALTIMORE, MD 21210 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centers for Disease Control & Prevention - USA; Maryland Department of Health & Mental Hygiene	HARRISON, LH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, ROOM 5515, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							BAKER CJ, 1974, JAMA-J AM MED ASSOC, V230, P1158, DOI 10.1001/jama.230.8.1158; BAKER CJ, 1981, PEDIATRICS, V68, P544; BARTON LL, 1982, CLIN PEDIATR, V21, P100, DOI 10.1177/000992288202100206; BINNICK AN, 1980, ARCH DERMATOL, V116, P798, DOI 10.1001/archderm.116.7.798; BLUMBERG HM, 1992, J INFECT DIS, V166, P574, DOI 10.1093/infdis/166.3.574; BRENNER DJ, 1988, J CLIN MICROBIOL, V26, P1524, DOI 10.1128/JCM.26.8.1524-1534.1988; BROUGHTON DD, 1976, J PEDIATR-US, V89, P183, DOI 10.1016/S0022-3476(76)80441-6; Campos A, 1992, Enferm Infecc Microbiol Clin, V10, P59; CHMEL H, 1984, OBSTET GYNECOL, V63, P862; DENNING DW, 1988, PEDIATR INFECT DIS J, V7, P729, DOI 10.1097/00006454-198810000-00013; DORAND RD, 1976, J PEDIATR-US, V89, P188, DOI 10.1016/S0022-3476(76)80444-1; ELLISON RT, 1987, JAMA-J AM MED ASSOC, V257, P3260, DOI 10.1001/jama.257.23.3260; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; Fleiss J. L., 1981, STATISTICAL METHODS, P1; GARDNER SE, 1979, AM J OBSTET GYNECOL, V135, P1062, DOI 10.1016/0002-9378(79)90737-3; HALL MA, 1992, INFECT IMMUN, V60, P5030, DOI 10.1128/IAI.60.12.5030-5035.1992; HAQUE KN, 1986, ANN TROP PAEDIATR, V6, P219, DOI 10.1080/02724936.1986.11748443; HARRISON LH, 1995, J INFECT DIS, V171, P513, DOI 10.1093/infdis/171.2.513; HARRISON LH, 1993, MOL EPIDEMIOLOGY PRI; HUNTER W, 1991, P ANN M AM SOC MICRO; KENNY JF, 1977, J PEDIATR-US, V91, P158, DOI 10.1016/S0022-3476(77)80473-3; Lancefield RC, 1934, J EXP MED, V59, P441, DOI 10.1084/jem.59.4.441; MCCRACKEN GH, 1976, J PEDIATR-US, V89, P313, DOI 10.1016/S0022-3476(76)80477-5; MILLARD DD, 1985, AM J DIS CHILD, V139, P964, DOI 10.1001/archpedi.1985.02140120010009; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; PAREDES A, 1976, J PEDIATR-US, V89, P191, DOI 10.1016/S0022-3476(76)80445-3; Passick J, 1989, J Arthroplasty, V4, P87, DOI 10.1016/S0883-5403(89)80057-9; PRUNIER L, 1988, ARCH MAL COEUR VAISS, V81, P925; REEVES MW, 1989, J CLIN MICROBIOL, V27, P313, DOI 10.1128/JCM.27.2.313-320.1989; RENCH MA, 1993, 33RD INT C ANT AG CH; RUIZGOMEZ D, 1979, SCAND J INFECT DIS, V11, P35, DOI 10.3109/inf.1979.11.issue-1.05; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SIEGEL JD, 1981, J PEDIATR-US, V99, P920, DOI 10.1016/S0022-3476(81)80022-4; TRUOG WE, 1976, J PEDIATR-US, V89, P185, DOI 10.1016/S0022-3476(76)80442-8; WALKER SH, 1976, J PEDIATR-US, V89, P187, DOI 10.1016/S0022-3476(76)80443-X; WALKER SH, 1977, J PEDIATR-US, V90, P333, DOI 10.1016/S0022-3476(77)80686-0; WESSELS MR, 1993, NEW ENGL J MED, V328, P1843, DOI 10.1056/NEJM199306243282510	38	53	56	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					421	427		10.7326/0003-4819-123-6-199509150-00004	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639441				2022-12-01	WOS:A1995RU43700004
J	HUANG, P; WEBER, JT; SOSIN, DM; GRIFFIN, PM; LONG, EG; MURPHY, JJ; KOCKA, F; PETERS, C; KALLICK, C				HUANG, P; WEBER, JT; SOSIN, DM; GRIFFIN, PM; LONG, EG; MURPHY, JJ; KOCKA, F; PETERS, C; KALLICK, C			THE FIRST REPORTED OUTBREAK OF DIARRHEAL ILLNESS ASSOCIATED WITH CYCLOSPORA IN THE UNITED-STATES	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; CYANOBACTERIA; CYCLOSPORA; WATER SUPPLY; DISEASE OUTBREAKS	ORGANISM; PATHOGEN	Objective: To investigate and characterize the epidemiology of a diarrheal outbreak associated with a potentially new pathogen, Cyclospora species (previously referred to as Cyanobacteria [blue-green algae]-like bodies). Design: Three retrospective cohort studies supported by laboratory studies, environmental investigation, and community surveillance. Setting: A hospital in Chicago. Participants: Housestaff physicians and hospital administrative staff. Measurements: Identification of clinical features associated with illness and potential risks for acquisition of infection. Results: Illness was characterized by watery diarrhea, abdominal cramping, decreased appetite, and low-grade fever. Symptoms typically occurred in a distinctive cycle of remissions and exacerbations lasting up to several weeks. Stool cultures and examinations for known ova and parasites were negative. Microscopic examination of stool specimens from 11 ill persons showed many spherical bodies, 8 to 10 mu m in diameter, that were identified as Cyclospora organisms. The organisms disappeared by 9 weeks after onset of illness in the 7 patients from whom follow-up specimens were obtained. Epidemiologic studies implicated tap water from a physicians' dormitory as the most likely source of the outbreak. Environmental investigation suggested that stagnant water in a storage tank may have contaminated the water supply after a pump failure. Conclusions: This is the first reported outbreak of diarrhea associated with Cyclospora in the United States. Cyclospora may be a human enteric pathogen able to produce bouts of acute and relapsing diarrhea, and it should be considered in assessments of patients with unexplained, prolonged diarrheal illness.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA								BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BERLIN OGW, 1994, CLIN INFECT DIS, V18, P606, DOI 10.1093/clinids/18.4.606; CHIODINI PL, 1994, T ROY SOC TROP MED H, V88, P369, DOI 10.1016/0035-9203(94)90385-9; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; DEAU AG, 1990, EPI INFO VERSION 5 W; GUSTAFSON TL, 1991, TRUE EPISTAT; HALE D, 1994, JAMA-J AM MED ASSOC, V271, P144, DOI 10.1001/jama.271.2.144; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; ORTEGA YR, 1994, J PARASITOL, V80, P625, DOI 10.2307/3283201; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; RABOLD JG, 1994, LANCET, V344, P1360, DOI 10.1016/S0140-6736(94)90716-1; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; WURTZ R, 1994, CLIN INFECT DIS, V18, P620, DOI 10.1093/clinids/18.4.620; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; 1991, MMWR-MORBID MORTAL W, V40, P325	23	108	121	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					409	414		10.7326/0003-4819-123-6-199509150-00002	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639439				2022-12-01	WOS:A1995RU43700002
J	JACKSON, LA; HILSDON, R; FARLEY, MM; HARRISON, LH; REINGOLD, AL; PLIKAYTIS, BD; WENGER, JD; SCHUCHAT, A				JACKSON, LA; HILSDON, R; FARLEY, MM; HARRISON, LH; REINGOLD, AL; PLIKAYTIS, BD; WENGER, JD; SCHUCHAT, A			RISK-FACTORS FOR GROUP-B STREPTOCOCCAL DISEASE IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						RISK FACTORS; CROSS INFECTION; COMMUNITY-ACQUIRED INFECTIONS; STREPTOCOCCAL INFECTION; STREPTOCOCCUS AGALACTIAE	TOXOID CONJUGATE VACCINE; NONPREGNANT ADULTS; III POLYSACCHARIDE; INFECTION; BACTEREMIA; ANTIBODY; INFANTS; WOMEN	Objective: To determine risk factors for community-acquired and nosocomial group B streptococcal disease in adults. Design: Case-control study. Setting: 3 metropolitan areas in the United States with an aggregate population of 6.6 million persons. Patients: 219 nonpregnant adults with invasive group B streptococcal infection identified by a population-based surveillance in 1991 and 1992 and 645 hospital-matched controls. Results: The following conditions were associated with a significantly increased risk for community-acquired group B streptococcal infection after controlling for age in multivariate analysis: cirrhosis (odds ratio, 9.7 [95% CI, 3.5 to 26.9]; P <0.001), diabetes (odds ratio, 3.0 [CI, 1.9 to 4.7]; P <0.001), stroke (odds ratio, 3.5 [CI, 1.9 to 6.4]; P <0.001), breast cancer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P =0.002), decubitus ulcer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P =0.002), and neurogenic bladder (odds ratio, 4.6 [CI, 1.4 to 15.1]; P =0.01). Sixty-three percent of community case-patients had at least one of these conditions. Nosocomial infection (48 cases [22%]) was independently associated with the placement of a central venous line (odds ratio, 30.9 [CI, 5.2 to 184.1]; P <0.001), diabetes, congestive heart failure, and seizure disorder. Conclusions: Several chronic conditions were independently associated with group B streptococcal disease, and most case-patients had at least one of these conditions. If group B streptococcal vaccines being developed for prevention of neonatal disease are protective in adults, a vaccination strategy targeting those at highest risk has the potential to substantially reduce the burden of invasive group B streptococcal infection in adults.	CTR DIS CONTROL & PREVENT, CHILDHOOD & RESP DIS BRANCH, ATLANTA, GA 30333 USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA	Centers for Disease Control & Prevention - USA; Emory University; Johns Hopkins University; University of California System; University of California Berkeley								[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ANTHONY BF, 1983, J INFECT DIS, V147, P776, DOI 10.1093/infdis/147.4.776; BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1986, J INFECT DIS, V154, P47, DOI 10.1093/infdis/154.1.47; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; BERKOWITZ K, 1990, J CLIN MICROBIOL, V28, P5, DOI 10.1128/JCM.28.1.5-7.1990; BLUMBERG HM, 1994, CLIN RES, V42, pA298; Breslow NE, 1980, IARC SCI PUBL, V32, P248; CASEY JI, 1982, AM J EPIDEMIOL, V116, P704, DOI 10.1093/oxfordjournals.aje.a113453; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; DILLON HC, 1982, J INFECT DIS, V145, P794, DOI 10.1093/infdis/145.6.794; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; Edwards MS, 1995, PRINCIPLES PRACTICE, V4, P1835; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; FINNEGAN OC, 1981, POSTGRAD MED J, V57, P202, DOI 10.1136/pgmj.57.665.202; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; GALLAGHER PG, 1986, REV INFECT DIS, V8, P175; HARRISON LH, 1995, J INFECT DIS, V171, P513, DOI 10.1093/infdis/171.2.513; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LERNER PI, 1977, MEDICINE, V56, P457, DOI 10.1097/00005792-197711000-00001; MADOFF LC, 1994, J CLIN INVEST, V94, P286, DOI 10.1172/JCI117319; MATHEW P, 1993, NEW ENGL J MED, V329, P1658; MILLER JD, 1982, SOUTHERN MED J, V75, P76, DOI 10.1097/00007611-198201000-00021; MUNOZ P, 1992, CLIN INFECT DIS, V14, P492, DOI 10.1093/clinids/14.2.492; OPAL SM, 1988, ARCH INTERN MED, V148, P641, DOI 10.1001/archinte.148.3.641; PAOLETTI LC, 1994, INFECT IMMUN, V62, P3236, DOI 10.1128/IAI.62.8.3236-3243.1994; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; PAOLETTI LC, 1992, INFECT IMMUN, V60, P4009, DOI 10.1128/IAI.60.10.4009-4014.1992; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; SMALL CB, 1984, AM J MED, V76, P367, DOI 10.1016/0002-9343(84)90653-3; VERGHESE A, 1986, REV INFECT DIS, V8, P912; WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993; WESSELS MR, 1995, J INFECT DIS, V171, P879, DOI 10.1093/infdis/171.4.879; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1992, SAS P229 SAS I TECHN	37	196	198	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					415	420		10.7326/0003-4819-123-6-199509150-00003	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639440				2022-12-01	WOS:A1995RU43700003
J	LINGNER, J; COOPER, JP; CECH, TR				LINGNER, J; COOPER, JP; CECH, TR			TELOMERASE AND DNA END REPLICATION - NO LONGER A LAGGING-STRAND PROBLEM	SCIENCE			English	Editorial Material							TERMINAL TRANSFERASE-ACTIVITY; 3' TERMINUS; S-PHASE; SEQUENCES; MOLECULES; ORIGIN				LINGNER, J (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309, USA.			Lingner, Joachim/0000-0002-2853-5803; cooper, julia promisel/0000-0003-2171-2587				BATEMAN AJ, 1975, NATURE, V253, P379, DOI 10.1038/253379a0; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; CAVALIER.T, 1974, NATURE, V250, P467, DOI 10.1038/250467a0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; LINGNER J, UNPUB; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakamura T., UNPUB; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	20	306	319	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1533	1534		10.1126/science.7545310	http://dx.doi.org/10.1126/science.7545310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545310				2022-12-01	WOS:A1995RU81300029
J	MEREDITH, J; TAKADA, Y; FORNARO, M; LANGUINO, LR; SCHWARTZ, MA				MEREDITH, J; TAKADA, Y; FORNARO, M; LANGUINO, LR; SCHWARTZ, MA			INHIBITION OF CELL-CYCLE PROGRESSION BY THE ALTERNATIVELY SPLICED INTEGRIN BETA(1C)	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; BETA-1; EXPRESSION; ADHESION; VARIANT; SUBUNIT; FORM	Integrins regulate cell growth, differentiation, and behavior in many systems. Integrin beta(1C) (beta(1S)) is an alternatively spliced variant of integrin beta(1) with a specific cytoplasmic domain and is expressed in several human tissues. Human beta(1C) transiently expressed in mouse 10T1/2 fibroblasts showed a diffuse pattern of cell surface staining, whereas beta(1) localized to focal adhesions. Moderate concentrations of beta(1C) had no effect on actin stress fibers or focal adhesions, but markedly inhibited DNA synthesis. Inhibition by beta(1C) mapped to the late G(1) phase of the cell cycle, near the G(1)-S boundary. Thus, alternative splicing of beta(1) results in transmission of distinct signals that may regulate growth in vivo.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA	Yale University	MEREDITH, J (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243; Languino, Lucia/0000-0001-9011-7031; takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01GM47157, R01 GM47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214, R01GM047157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BODARY S C, 1991, Journal of Cell Biology, V115, p289A; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FORNARO M, UNPUB; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LANGUINO LR, UNPUB; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MEREDITH JC, UNPUB; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913	24	116	117	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1570	1572		10.1126/science.7545312	http://dx.doi.org/10.1126/science.7545312			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545312				2022-12-01	WOS:A1995RU81300039
J	ROCHE, S; FUMAGALLI, S; COURTNEIDGE, SA				ROCHE, S; FUMAGALLI, S; COURTNEIDGE, SA			REQUIREMENT FOR SRC FAMILY PROTEIN-TYROSINE KINASES IN G(2) FOR FIBROBLAST CELL-DIVISION	SCIENCE			English	Article							GROWTH-FACTOR; C-SRC; IDENTIFICATION; ASSOCIATION; RECEPTOR	The protein tyrosine kinase c-Src is transiently activated at the transition from the G(2) phase to mitosis in the cell cycle of mammalian fibroblasts. Fyn and Yes, the other members of the Src family present in fibroblasts, were also found to be activated at mitosis. In cells microinjected with a neutralizing antibody specific for Src, Fyn, and Yes (anti-cst.1) during G(2), cell division was inhibited by 75 percent. The block occurred before nuclear envelope breakdown. Antibodies specific for phosphatidylinositol-3 kinase alpha and phospholipase C-gamma 1 had no effect. Microinjection of the Src homology 2 (SH2) domain of Fyn was also inhibitory. Functional redundancy between members of the Src family was observed; a Src-specific antibody had no effect in NIH 3T3 cells but inhibited cell division in fibroblasts in which the only functional Src family kinase was Src itself. Thus, Src family kinases and proteins associating with their SH2 domains are required for entry into mitosis.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			FUMAGALLI, Stefano/C-2914-2019	, Stefano/0000-0001-5832-8680; roche, serge/0000-0003-3413-3859				Atherton-Fessler S, 1993, Semin Cell Biol, V4, P433, DOI 10.1006/scel.1993.1051; CHACKALAPARAMPI.I, 1988, CELL, V52, P801; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DURKIN JP, 1991, CELL SIGNAL, V3, P93, DOI 10.1016/0898-6568(91)90015-M; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUMAGALLI S, UNPUB; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROCHE S, UNPUB; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TAYLOR SJ, 1994, NATURE, V368, P871; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696	23	236	240	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1567	1569		10.1126/science.7545311	http://dx.doi.org/10.1126/science.7545311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545311				2022-12-01	WOS:A1995RU81300038
J	SKEHEL, PA; MARTIN, KC; KANDEL, ER; BARTSCH, D				SKEHEL, PA; MARTIN, KC; KANDEL, ER; BARTSCH, D			A VAMP-BINDING PROTEIN FROM APLYSIA REQUIRED FOR NEUROTRANSMITTER RELEASE	SCIENCE			English	Article							SYNAPTIC PLASTICITY; FUSION; VESICLES; DOCKING; FAMILY	Before the fusion of synaptic vesicles with the plasma membrane, a protein complex is thought to form between VAMP-an integral membrane protein of the vesicle-and two proteins associated with the plasma membrane, SNAP-25 and syntaxin. The yeast two-hybrid interaction cloning system has now been used to identify additional proteins from Aplysia that interact directly with VAMP. A 33-kilodalton membrane protein, termed VAP-33 (VAMP-associated protein of 33 kilodaltons), was identified whose corresponding messenger RNA was detected only in the central nervous system and the gill of Aplysia. Presynaptic injection of antibodies specific for VAP-33 inhibited synaptic transmission, which suggests that VAP-33 is required for the exocytosis of neurotransmitter.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	SKEHEL, PA (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH045923] Funding Source: NIH RePORTER; NIMH NIH HHS [R37 MH45923-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARTSCH D, UNPUB; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHIN GJ, 1989, J NEUROSCI, V9, P38; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1993, J CELL SCI, P75; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.neuro.17.1.219; KLASS MR, 1984, MOL CELL BIOL, V4, P529, DOI 10.1128/MCB.4.3.529; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MARTIN KH, UNPUB; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; RAYPORT SG, 1986, J NEUROSCI, V6, P759; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SKEHEL PA, UNPUB; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688	24	142	148	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1580	1583		10.1126/science.7667638	http://dx.doi.org/10.1126/science.7667638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667638				2022-12-01	WOS:A1995RU81300043
J	SUTO, R; SRIVASTAVA, PK				SUTO, R; SRIVASTAVA, PK			A MECHANISM FOR THE SPECIFIC IMMUNOGENICITY OF HEAT-SHOCK PROTEIN-CHAPERONED PEPTIDES	SCIENCE			English	Article							ANTIGEN; CELLS; CANCER	Endogenously synthesized antigenic determinants are generally presented on major histocompatibility complex (MHC) class I molecules, whereas exogenous determinants are presented by MHC class II molecules. Here, it is shown that exogenous antigens chaperoned by a heat shock protein can be channeled into the endogenous pathway, presented by MHC class I molecules, and recognized by CD8(+) T lymphocytes. This pathway is functional only in a subset of macrophages among the cell types tested. These observations provide a basis for the tumor-specific and virus-specific immunogenicity of cognate heat shock protein preparations and offer a mechanism for the classical phenomenon of cross-priming.	FORDHAM UNIV, DEPT BIOL SCI, BRONX, NY 10458 USA	Fordham University					NATIONAL CANCER INSTITUTE [R01CA044786, R29CA044786] Funding Source: NIH RePORTER; NCI NIH HHS [CA44786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; GOODING LR, 1980, J IMMUNOL, V124, P1258; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Li Z.B., UNPUB; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; PALLADINO MA, 1987, CANCER RES, V47, P5074; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; ROCK KL, 1993, J IMMUNOL, V150, P438; SCHIRMBECK R, 1994, EUR J IMMUNOL, V24, P1088, DOI 10.1002/eji.1830240512; SCHIRMBECK R, 1995, EUR J IMMUNOL, V25, P1063, DOI 10.1002/eji.1830250431; SRIVASTAVA PK, 1984, INT J CANCER, V33, P417, DOI 10.1002/ijc.2910330321; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SRIVASTAVA PK, UNPUB; SUTO RK, UNPUB; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; UDONO H, UNPUB	20	709	823	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1585	1588		10.1126/science.7545313	http://dx.doi.org/10.1126/science.7545313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545313				2022-12-01	WOS:A1995RU81300045
J	WANG, W; MEADOWS, LR; DENHAAN, JMM; SHERMAN, NE; CHEN, Y; BLOKLAND, E; SHABANOWITZ, J; AGULNIK, AI; HENDRICKSON, RC; BISHOP, CE; HUNT, DF; GOULMY, E; ENGELHARD, VH				WANG, W; MEADOWS, LR; DENHAAN, JMM; SHERMAN, NE; CHEN, Y; BLOKLAND, E; SHABANOWITZ, J; AGULNIK, AI; HENDRICKSON, RC; BISHOP, CE; HUNT, DF; GOULMY, E; ENGELHARD, VH			HUMAN H-Y - A MALE-SPECIFIC HISTOCOMPATIBILITY ANTIGEN DERIVED FROM THE SMCY PROTEIN	SCIENCE			English	Article							MASS-SPECTROMETRY; TRANSPLANTATION; HLA-A2.1; BINDING; GRAFT; HLA	H-Y is a transplantation antigen that can lead to rejection of male organ and bone marrow grafts by female recipients, even if the donor and recipient match at the major histocompatibility locus of humans, the HLA (human leukocyte antigen) locus, However, the origin and function of H-Y antigens has eluded researchers for 40 years. One human H-Y antigen presented by HLA-B7 was identified as an 11-residue peptide derived from SMCY, an evolutionarily conserved protein encoded on the Y chromosome, The protein from the homologous gene on the X chromosome, SMCX, differs by two amino acid residues in the same region. The identification of H-Y may aid in transplantation prognosis, prenatal diagnosis, and fertilization strategies.	LEIDEN UNIV HOSP, DEPT IMMUNOHAEMATOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, BLOOD BANK, 2333 AA LEIDEN, NETHERLANDS; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, BEIRNE CARTER CTR IMMUNOL RES, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA; PROMEGA CORP, MADISON, WI 53711 USA; BAYLOR COLL MED, DEPT OBSTET & GYNECOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT HUMAN MOLEC GENET, HOUSTON, TX 77030 USA; UNIV VIRGINIA, DEPT PATHOL, CHARLOTTESVILLE, VA 22903 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Virginia; University of Virginia; University of Virginia; Promega Corporation; Baylor College of Medicine; Baylor College of Medicine; University of Virginia			Hunt, Donald F/I-6936-2012; den Haan, Joke MM/A-4281-2010; Agoulnik, Alexander/AAK-3213-2020	Hunt, Donald F/0000-0003-2815-6368; den Haan, Joke MM/0000-0002-4421-6917; Agoulnik, Alexander/0000-0001-6587-6845; Sherman, Nicholas/0000-0003-3206-3113	NIAID NIH HHS [AI33993, AI20963] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033993, R01AI020963, R37AI033993, R37AI020963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BILLINGHAM RE, 1960, J IMMUNOL, V85, P14; BORTIN MM, 1987, TRANSPLANT P, V19, P2655; CANTRELL MA, 1992, GENOMICS, V13, P1255, DOI 10.1016/0888-7543(92)90043-R; CHEN Y, 1994, J IMMUNOL, V152, P2874; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GOULMY E, 1976, LANCET, V2, P1206; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GOULMY E, 1979, J EXP MED, V149, P545, DOI 10.1084/jem.149.2.545; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HOROWITZ MM, 1989, BONE MARROW TRANSPL, V4, P221; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; MEADOWS LR, UNPUB; PARHAM P, 1977, J BIOL CHEM, V252, P7555; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; SETTE A, 1994, J IMMUNOL, V153, P5586; SHAPIRO M, 1984, J IMMUNOGENET, V11, P209; TOKUDA S, 1977, NATURE, V267, P433, DOI 10.1038/267433a0; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; VANDERHARST D, 1994, BLOOD, V83, P1060; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	35	307	321	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1588	1590		10.1126/science.7667640	http://dx.doi.org/10.1126/science.7667640			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667640	Green Submitted			2022-12-01	WOS:A1995RU81300046
J	WHITEWAY, MS; WU, CL; LEEUW, T; CLARK, K; FOURESTLIEUVIN, A; THOMAS, DY; LEBERER, E				WHITEWAY, MS; WU, CL; LEEUW, T; CLARK, K; FOURESTLIEUVIN, A; THOMAS, DY; LEBERER, E			ASSOCIATION OF THE YEAST PHEROMONE RESPONSE G-PROTEIN BETA-GAMMA-SUBUNITS WITH THE MAP KINASE SCAFFOLD STE5P	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; GENE; PATHWAY; ENCODES; SEQUENCE; MUTANTS; RAS; TRANSCRIPTION	The mating response pathway of the yeast Saccharomyces cerevisiae includes a heterotrimeric guanine nucleotide-binding protein (G protein) that activates a mitogen-activated protein (MAP) kinase cascade by an unknown mechanism. An amino-terminal fragment of the MAP kinase scaffold protein Ste5p that interfered with pheromone-induced cell cycle arrest was identified. A haploid-specific interaction between the amino terminus of Ste5p and the G protein beta subunit Ste4p was also detected in a two-hybrid assay, and the product of a signaling-defective allele of STE4 was defective in this interaction. In cells with a constitutively activated pheromone response pathway, epitope-tagged Ste4p was coimmunoprecipitated with Ste5p, Thus, association of the G protein and the MAP kinase cassette via the scaffolding protein Ste5p may transmit the G protein signal.			WHITEWAY, MS (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,6100 ROYALMOUNT AVE,MONTREAL,PQ H4P 2R2,CANADA.		Fourest-Lieuvin, Anne/AGA-6504-2022; Thomas, David/M-7661-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; Thomas, David/0000-0002-8854-762X				BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARLOW E, 1988, ANTIBODIES LABORATOR; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MUKAI Y, 1993, MOL CELL BIOL, V13, P2050, DOI 10.1128/MCB.13.4.2050; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NEER EJ, 1995, CELL, V80, P247; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; PERLMAN R, 1993, P NATL ACAD SCI USA, V90, P5474, DOI 10.1073/pnas.90.12.5474; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WHITEWAY M, 1992, BIOCHEM CELL BIOL, V70, P1230, DOI 10.1139/o92-169; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	43	155	162	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1572	1575		10.1126/science.7667635	http://dx.doi.org/10.1126/science.7667635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667635				2022-12-01	WOS:A1995RU81300040
J	DEVRIES, A; VANOOSTROM, CTM; HOFHUIS, FMA; DORTANT, PM; BERG, RJW; DEGRUIJL, FR; WESTER, PW; VANKREIJL, CF; CAPEL, PJA; VANSTEEG, H; VERBEEK, SJ				DEVRIES, A; VANOOSTROM, CTM; HOFHUIS, FMA; DORTANT, PM; BERG, RJW; DEGRUIJL, FR; WESTER, PW; VANKREIJL, CF; CAPEL, PJA; VANSTEEG, H; VERBEEK, SJ			INCREASED SUSCEPTIBILITY TO ULTRAVIOLET-B AND CARCINOGENS OF MICE LACKING THE DNA EXCISION-REPAIR GENE XPA	NATURE			English	Article							A XERODERMA-PIGMENTOSUM; DAMAGED DNA; SEQUENCE; AFFINITY; CELLS	XERODERMA pigmentosum patients with a defect in the nucleotide-excision repair gene XPA are characterized by, for example, a >1,000-fold higher risk of developing sunlight-induced skin cancer(1-3). Nucleotide-excision repair (NER) is involved in the removal of a wide spectrum of DNA lesions, The XPA protein functions in a pre-incision step, the recognition of DNA damage(4-7). To permit the functional analysis of the XPA gene in vivo, we have generated XPA-deficient mice by gene targeting in embryonic stem cells, The YPA(-/-) mice appear normal, at least until the age of 13 months, XPA(-/-) mice are highly susceptible to ultraviolet (UV)-B-induced skin and eye tumours and to 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumours, We conclude that the XPA-deficient mice strongly mimic the phenotype of humans with xeroderma pigmentosum.	NATL INST PUBL HLTH & ENVIRONM PROTECT, CARCINOGENESIS & MUTAGENESIS LAB, 3720 BA BILTHOVEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, PATHOL LAB, 3720 BA BILTHOVEN, NETHERLANDS; UNIV UTRECHT, DEPT IMMUNOL, 3584 CX UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT DERMATOL, 3584 CX UTRECHT, NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DEGRUIJL FR, 1991, CANCER RES, V51, P979; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HOELJMAKERS JHJ, 1990, CANCER CELL, V2, P311; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; MAHER VM, 1984, PHARMACOL THERAPEUT, V25, P395, DOI 10.1016/0163-7258(84)90006-8; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SATOKATA I, 1992, HUM GENET, V88, P603, DOI 10.1007/BF02265282; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VANOOSTROM CTM, 1994, NUCLEIC ACIDS RES, V22, P11, DOI 10.1093/nar/22.1.11; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x	17	345	350	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 14	1995	377	6545					169	173		10.1038/377169a0	http://dx.doi.org/10.1038/377169a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675086				2022-12-01	WOS:A1995RU75400054
J	EBERS, GC; SADOVNICK, AD; RISCH, NJ; BULMAN, D; RICE, GPA; HASHIMOTO, SA; PATY, D; OGER, JJF; METZ, L; BELL, R; WARREN, S; HADER, W; AUTY, T; NATH, A; GRAY, T; OCONNOR, P; NELSON, R; FREEDMAN, M; BRUNET, D; PAULSETH, R; FRANCIS, G; DUQUETTE, P; MURRAY, TJ; BAHN, V; PRYSEPHILLIPS, W				EBERS, GC; SADOVNICK, AD; RISCH, NJ; BULMAN, D; RICE, GPA; HASHIMOTO, SA; PATY, D; OGER, JJF; METZ, L; BELL, R; WARREN, S; HADER, W; AUTY, T; NATH, A; GRAY, T; OCONNOR, P; NELSON, R; FREEDMAN, M; BRUNET, D; PAULSETH, R; FRANCIS, G; DUQUETTE, P; MURRAY, TJ; BAHN, V; PRYSEPHILLIPS, W			A GENETIC-BASIS FOR FAMILIAL AGGREGATION IN MULTIPLE-SCLEROSIS	NATURE			English	Article							TWINS; EPIDEMIOLOGY; CONCORDANCE	GENETIC-environmental interactions probably underlie spontaneous human autoimmune disorders, a category of complex traits thought to include multiple sclerosis (MS)(1). The geographical distribution and familiar aggregation of this disease have often been ascribed to the role of infectious agents(2), but there is no consensus, Increased family risks range from 300-fold(3,4) for monozygotic twins to 20-40-fold(5) for biological first-degree relatives over the general population prevalence of 0.1% (ref. 6). We screened a population-based sample of 15,000 individuals with MS by using standardized, personally administered questionnaires to identify adopted index cases and/or those who had adopted relatives, The frequency of MS among first-degree non-biological relatives living with the index case was no greater than expected from Canadian population prevalence data and significantly less than for biological relatives, These findings indicate that familial aggregation of MS is genetically determined: no effect of shared environment was detectable.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1W5,CANADA; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	University of British Columbia; Stanford University	EBERS, GC (corresponding author), UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON N6A 5A5,CANADA.			Sadovnick, Dessa/0000-0003-2987-2008; Ebers, George/0000-0003-4771-4177				BELLAMY N, 1992, ANN RHEUM DIS, V51, P588, DOI 10.1136/ard.51.5.588; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; EBERS G, 1987, NEW ENGL J MED, V315, P1638; EBERS GC, 1994, J NEUROIMMUNOL, V54, P117; Feller William, 1968, INTRO PROBABILITY TH, V1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; KETY SS, 1976, BEHAV GENET, V6, P219, DOI 10.1007/BF01065721; KETY SS, 1994, ARCH GEN PSYCHIAT, V51, P442; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; LEITER EH, 1990, IMMUNOL TODAY, V11, P147, DOI 10.1016/0167-5699(90)90057-G; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309	14	478	485	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					150	151		10.1038/377150a0	http://dx.doi.org/10.1038/377150a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675080				2022-12-01	WOS:A1995RU75400048
J	IRIBARREN, C; SHARP, DS; BURCHFIEL, CM; PETROVITCH, H				IRIBARREN, C; SHARP, DS; BURCHFIEL, CM; PETROVITCH, H			ASSOCIATION OF WEIGHT-LOSS AND WEIGHT FLUCTUATION WITH MORTALITY AMONG JAPANESE-AMERICAN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; BODY-WEIGHT; METABOLIC-RATE; HEALTH; RISK; VARIABILITY; LONGEVITY; STROKE; HAWAII	Background. Weight loss and fluctuations in weight have been associated with increased risks of death from cardiovascular disease and from all causes. The clinical and public health implications of these associations are unclear. Methods. We examined the long-term relation of weight change and fluctuation in weight with mortality over a 6-year period in 6537 middle-aged Japanese American men enrolled in the Honolulu Heart Program, a prospective study (mean follow-up, 14.5 years). Results. Men who had a weight loss of 4.5 kg or more or who had large fluctuations in weight (or both) over a six-year period were, on average, in poorer health than their peers whose weight was more stable. After the exclusion of subjects who died during the first five years of follow-up and after adjustment for confounding factors, a weight loss of more than 4.5 kg was associated with the risk of death from all causes, with the exception of death from cancer. The subjects whose weight fluctuated the most had a significantly higher risk of death from cardiovascular causes (relative risk, 1.41; 95 percent confidence interval, 1.03 to 1.93), death from noncardiovascular and noncancerous causes (relative risk, 1.53; 95 percent confidence interval, 1.12 to 2.10), and death from all causes (relative risk, 1.25; 95 percent confidence interval, 1.05 to 1.48). However, the associations of weight loss and variation in weight with death from cardiovascular causes and from noncardiovascular and noncancerous causes were not found among healthy men who had never smoked. Conclusions. The associations between weight loss or fluctuation and mortality were partially explained by confounding factors and by the presence of preexisting disease. However, weight loss and weight fluctuation were unrelated to death among healthy men who had never smoked. Thus, concern about the health hazards of weight loss and variation may not be applicable to otherwise healthy people.	NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, HONOLULU EPIDEMIOL RES UNIT, BETHESDA, MD 20892 USA; UNIV HAWAII MANOA, JOHN A BURNS SCH MED, DEPT MED, HONOLULU, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Hawaii System; University of Hawaii Manoa	IRIBARREN, C (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC002901] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HV-02901, N01-HC-02901] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; ARCHAMBAULT CM, 1989, PHYSIOL BEHAV, V46, P417, DOI 10.1016/0031-9384(89)90013-9; BELSKY JL, 1971, 1271 AT BOMB CAS COM; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BROWNELL KD, 1986, PHYSIOL BEHAV, V38, P459, DOI 10.1016/0031-9384(86)90411-7; COX DR, 1972, J R STAT SOC B, V34, P187; DRAPER NR, 1981, APPLIED REGRESSION A, P19; FRENCH SA, 1995, INT J OBESITY, V19, P22; GORDON T, 1975, AM J CLIN NUTR, V28, P304, DOI 10.1093/ajcn/28.4.304; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; HO SC, 1994, J GERONTOL, V49, pM269, DOI 10.1093/geronj/49.6.M269; JEBB SA, 1991, INT J OBESITY, V15, P367; JEFFERY RW, 1992, AM J CLIN NUTR, V55, P641, DOI 10.1093/ajcn/55.3.641; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P119, DOI 10.1207/s15324796abm1203_4; KULLER L, 1993, ANN INTERN MED, V119, P630, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00015; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; Reed G W, 1993, Obes Res, V1, P392; RHOADS GG, 1983, LANCET, V1, P492; Rumpel C, 1993, Ann Epidemiol, V3, P343, DOI 10.1016/1047-2797(93)90060-H; RUMPEL C, 1994, INT J OBESITY, V18, P179; SCHOTTE DE, 1990, HEALTH PSYCHOL, V9, P599, DOI 10.1037/0278-6133.9.5.599; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEVENS J, 1990, INT J OBESITY, V14, P385; TAYLOR CB, 1995, AM J EPIDEMIOL, V141, P461, DOI 10.1093/oxfordjournals.aje.a117448; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WATT BK, 1963, DEP AGR HDB, V8; Wing R R, 1993, Obes Res, V1, P390; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; 1994, JAMA-J AM MED ASSOC, V272, P1196; 1987, SAS STAT SOFTWARE VE; 1971, 1970 CENSUS POPULATI	41	109	109	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					686	692		10.1056/NEJM199509143331102	http://dx.doi.org/10.1056/NEJM199509143331102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637745				2022-12-01	WOS:A1995RV22700002
J	KARNI, A; MEYER, G; JEZZARD, P; ADAMS, MM; TURNER, R; UNGERLEIDER, LG				KARNI, A; MEYER, G; JEZZARD, P; ADAMS, MM; TURNER, R; UNGERLEIDER, LG			FUNCTIONAL MRI EVIDENCE FOR ADULT MOTOR CORTEX PLASTICITY DURING MOTOR SKILL LEARNING	NATURE			English	Article							CEREBRAL BLOOD-FLOW; SENSORY STIMULATION; TIME-COURSE; REPRESENTATION; HABITUATION; TASK	PERFORMANCE of complex motor tasks, such as rapid sequences of finger movements, can be improved in terms of speed and accuracy over several weeks by daily practice sessions, This improvement does not generalize to a matched sequence of identical component movements, nor to the contralateral hand, Here we report a study of the neural changes underlying this learning using functional magnetic resonance imaging (MRI) of local blood oxygenation level-dependent (BOLD)(1-4) signals evoked in primary motor cortex (Mi). Before training, a comparable extent of M1 was activated by both sequences, However, two ordering effects were observed: repeating a sequence within a brief time window initially resulted in a smaller area of activation (habituation), but later in a larger area of activation (enhancement), suggesting a switch in M1 processing mode within the first session (fast learning), By week 4 of training, concurrent with asymptotic performance, the extent of cortex activated by the practised sequence enlarged compared with the unpractised sequence, irrespective of order (slow learning), These changes persisted for several months, The results suggest a slowly evolving, long-term, experience-dependent reorganization of the adult M1, which may underlie the acquisition and retention of the motor skill.	NHLBI,CARDIAC ENERGET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	KARNI, A (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 49,ROOM 1B80,BETHESDA,MD 20892, USA.		Turner, Robert/C-1820-2008; Li, Chong/F-4265-2015	Turner, Robert/0000-0001-5055-9644; Jezzard, Peter/0000-0001-7912-2251; Meyer, Gundela/0000-0002-5730-828X				ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; FRISTON KJ, 1994, HUMAN BRAIN MAPPING, V1, P153, DOI DOI 10.1002/HBM.460010207; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; JENKINS IH, 1994, J NEUROSCI, V14, P3775; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEBIHAN D, 1993, P SOC MAGN RESON MED, V1, P11; MILLER EK, 1991, VISUAL NEUROSCI, V7, P357, DOI 10.1017/S0952523800004843; Milliken G. W., 1992, Society for Neuroscience Abstracts, V18, P506; MISHKIN M, 1984, NEUROBIOLOGY LEARNIN, P64; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASCUALLEONE A, 1993, NEUROLOGY, V43, pA157; RADEMACHER J, 1993, CEREB CORTEX, V3, P313, DOI 10.1093/cercor/3.4.313; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; SANES JN, 1992, CEREB CORTEX, V2, P141, DOI 10.1093/cercor/2.2.141; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; STERLING MK, 1991, SCIENCE, V254, P716; WARACH S, 1992, J CEREBR BLOOD F MET, V12, P546, DOI 10.1038/jcbfm.1992.78	25	1344	1363	3	123	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					155	158						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675082				2022-12-01	WOS:A1995RU75400050
J	KATZ, EB; STENBIT, AE; HATTON, K; DEPINHO, R; CHARRON, MJ				KATZ, EB; STENBIT, AE; HATTON, K; DEPINHO, R; CHARRON, MJ			CARDIAC AND ADIPOSE-TISSUE ABNORMALITIES BUT NOT DIABETES IN MICE DEFICIENT IN GLUT4	NATURE			English	Article							FACILITATIVE GLUCOSE TRANSPORTERS; LOCALIZATION; MUSCLE; RATS	THE insulin-sensitive glucose transporter, GLUT4, is the most abundant facilitative glucose transporter in muscle and adipose tissue, the major sites for postprandial glucose disposal, To assess the role of GLUT4 in glucose homeostasis, we have disrupted the murine GLUT4 gene. Because GLUT4 has been shown to be dysregulated in pathological states such as diabetes and obesity, it was expected that genetic ablation of GLUT4 would result in abnormal glucose homeostasis, The mice deficient in GLUT4 (GLUT4-null) are growth-retarded and exhibit decreased longevity associated with cardiac hypertrophy and severely reduced adipose tissue deposits, Blood glucose levels in female GLUT4-null mice are not significantly elevated in either the fasting or fed state; in contrast, male GLUT4-null mice have moderately reduced glycaemias in the fasted state and increased glycaemias in the fed state, However, both female and male GLUT4-null mice exhibit postprandial hyperinsulinaemia, indicating possible insulin resistance. Increased expression of other glucose transporters is observed in the liver (GLUT2) and heart (GLUT1) but not skeletal muscle. Oral glucose tolerance tests show that both female and male GLUT4-null mice clear glucose as efficiently as controls, but insulin tolerance tests indicate that these mice are less sensitive to insulin action, The GLUT4-null mice demonstrate that functional GLUT4 protein is not required for maintaining nearly normal glycaemia but that GLUT4 is absolutely essential for sustained growth, normal cellular glucose and fat metabolism, and expected longevity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BRESSLER R, 1993, CARDIOSCIENCE, V4, P133; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; DEFRONZO RA, 1991, DIABETES CARE, V4, P173; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GARVEY WT, 1993, AM J PHYSIOL, V264, pH837, DOI 10.1152/ajpheart.1993.264.3.H837; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KRAEGEN EW, 1993, BIOCHEM J, V295, P387; LITWAN SE, 1990, AM J PHYSIOL, V258, pH551; LO CW, 1986, J CELL SCI, V81, P143; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MODAN M, 1991, DIABETES CARE, V14, P470, DOI 10.2337/diacare.14.6.470; OLEFSKY JM, 1993, EXPL MED BIOL, V334, P129; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Sambrook J., 1989, MOL CLONING LAB MANU; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1990, DIABETES, V39, P712, DOI 10.2337/diabetes.39.6.712	23	342	352	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					151	155		10.1038/377151a0	http://dx.doi.org/10.1038/377151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675081				2022-12-01	WOS:A1995RU75400049
J	LILLIEN, L				LILLIEN, L			CHANGES IN RETINAL CELL FATE INDUCED BY OVEREXPRESSION OF EGF RECEPTOR	NATURE			English	Article							TGF-ALPHA; DIFFERENTIATION; GENE; PROLIFERATION; CULTURES; LINEAGE; INVITRO; PROTEIN; MOUSE; ENTRY	THE differentiation of multipotential progenitor cells in the vertebrate retina into photoreceptors, neurons and glial cells is regulated in part by cell-cell signalling(1-11). Transforming growth factor (TGF)-alpha is one of the extracellular signals implicated in the control of several aspects of retinal development, including proliferation and cell fate(5,6,11-13). The way cells interpret pleiotropic signals such as TGF-alpha is influenced by the level of expression of epidermal growth factor receptor (EGF-R) in some cell lines(14,15). To address the influence of receptor level on responses of retinal progenitor cells to TGF-alpha, additional copies of EGF-Rs were introduced in vitro and in vivo with a retrovirus. Normally irt vitro, low concentrations of TGF-alpha stimulated proliferation whereas high concentrations biased choice of cell fate, inhibiting differentiation into rod photoreceptors while promoting differentiation into Muller glial cells, We report here that introduction of extra EGF-Rs into progenitor cells in vitro reduced the concentration of TGF-alpha required for changes in rod and Muller cell differentiation but did not enhance proliferation, Introduction of extra EGF-Rs in vivo increased the proportion of clones that contained Muller glial cells, suggesting that receptor level is normally limiting, These findings demonstrate that responsiveness to extracellular signals during development can be modulated by the introduction of additional receptors, and suggest that the level of expression of receptors for these signals contributes to the regulation of cell fate.			LILLIEN, L (corresponding author), MED COLL PENN, DEPT ANAT & NEUROBIOL, 3200 HENRY AVE, PHILADELPHIA, PA 19072 USA.							ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; ALTSHULER D, 1992, DEVELOPMENT, V114, P947; ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BJORKLUND H, 1985, NEUROSCI LETT, V54, P363, DOI 10.1016/S0304-3940(85)80061-6; FERRI RT, 1995, DEVELOPMENT, V121, P1151; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; LEUTTEKE NC, 1993, CELL, V73, P263; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LINSER P, 1984, ANN NY ACAD SCI, V429, P430, DOI 10.1111/j.1749-6632.1984.tb12369.x; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; REH TA, 1992, J NEUROBIOL, V23, P1067, DOI 10.1002/neu.480230811; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SPARROW JR, 1990, DEV BRAIN RES, V51, P69, DOI 10.1016/0165-3806(90)90259-2; TAYLOR M, 1990, J NEUROBIOL, V21, P470, DOI 10.1002/neu.480210308; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WATANABE T, 1990, NEURON, V3, P461; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	30	222	226	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					158	162		10.1038/377158a0	http://dx.doi.org/10.1038/377158a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675083				2022-12-01	WOS:A1995RU75400051
J	MANSON, JE; WILLETT, WC; STAMPFER, MJ; COLDITZ, GA; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; SPEIZER, FE				MANSON, JE; WILLETT, WC; STAMPFER, MJ; COLDITZ, GA; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; SPEIZER, FE			BODY-WEIGHT AND MORTALITY AMONG WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELATIVE WEIGHT; CIGARETTE-SMOKING; UNITED-STATES; MASS INDEX; FOLLOW-UP; OBESITY; HEALTH; DEATH; RISK; MEN	Background. The relation between body weight and overall mortality remains controversial despite considerable investigation. Methods. We examined the association between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and both overall mortality and mortality from specific causes in a cohort of 115,195 U.S. women enrolled in the prospective Nurses' Health Study. These women were 30 to 55 years of age and free of known cardiovascular disease and cancer in 1976. During 16 years of follow-up, we documented 4726 deaths, of which 881 were from cardiovascular disease, 2586 from cancer, and 1259 from other causes. Results. In analyses adjusted only for age, we observed a J-shaped relation between body-mass index and overall mortality. When women who had never smoked were examined separately, no increase in risk was observed among the leaner women, and a more direct relation between weight and mortality emerged (P for trend <0.001). In multivariate analyses of women who had never smoked and had recently had stable weight, in which the first four years of follow-up were excluded, the relative risks of death from all causes for increasing categories of body-mass index were as follows: body-mass index <19.0 (the reference category), relative risk = 1.0, 19.0 to 21.9, relative risk = 1.2; 22.0 to 24.9, relative risk = 1.2; 25.0 to 26.9, relative risk = 1.3; 27.0 to 28.9, relative risk = 1.6; 29.0 to 31.9, relative risk = 2.1; and greater than or equal to 32.0, relative risk = 2.2 (P for trend <0.001). Among women with body-mass indexes of 32.0 or higher who had never smoked, the relative risk of death from cardiovascular disease was 4.1 (95 percent confidence interval, 2.1 to 7.7), and that of death from cancer was 2.1 (95 percent confidence interval, 1.4 to 3.2), as compared with the risk among women with body-mass indexes below 19.0. A weight gain of 10 kg (22 lb) or more since the age of 18 was associated with increased mortality in middle adulthood. Conclusions. Body weight and mortality from all causes were directly related among these middle-aged women. Lean women did not have excess mortality. The lowest mortality rate was observed among women who weighed at least 15 percent less than the U.S. average for women of similar age and among those whose weight had been stable since early adulthood.	HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; [Anonymous], 1982, EPIDEMIOLOGIC RES; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COMSTOCK GW, 1966, AM J EPIDEMIOL, V83, P548, DOI 10.1093/oxfordjournals.aje.a120606; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GARRISON RJ, 1993, INT J OBESITY, V17, P417; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HENNEKENS CH, 1979, LANCET, V1, P1390; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; MANN GV, 1974, NEW ENGL J MED, V291, P178, DOI 10.1056/NEJM197407252910405; MANN GV, 1974, NEW ENGL J MED, V291, P226, DOI 10.1056/NEJM197408012910504; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROMIEU I, 1988, AM J CLIN NUTR, V47, P406, DOI 10.1093/ajcn/47.3.406; SCHROLL M, 1981, DAN MED BULL, V28, P106; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; TROY LM, IN PRESS INT J OBES; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; VANDENBROUCKE JP, 1984, JAMA-J AM MED ASSOC, V252, P2859, DOI 10.1001/jama.252.20.2859; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; WAALER HT, 1984, ACTA MED SCAND, P1; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; [No title captured]; 1990, NUTRITION YOUR HLTH; 1959, STAT B METROP INSUR, V40, P1; [No title captured]; 1987, VITAL HLTH STATIS 11, V238; 1980, BUILD STUDY 1979	41	1450	1495	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					677	685		10.1056/NEJM199509143331101	http://dx.doi.org/10.1056/NEJM199509143331101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637744				2022-12-01	WOS:A1995RV22700001
J	NAKANE, H; TAKEUCHI, S; YUBA, S; SAIJO, M; NAKATSU, Y; MURAI, H; NAKATSURU, Y; ISHIKAWA, T; HIROTA, S; KITAMURA, Y; KATO, Y; TSUNODA, Y; MIYAUCHI, H; HORIO, T; TOKUNAGA, T; MATSUNAGA, T; NIKAIDO, O; NISHIMUNE, Y; OKADA, Y; TANAKA, K				NAKANE, H; TAKEUCHI, S; YUBA, S; SAIJO, M; NAKATSU, Y; MURAI, H; NAKATSURU, Y; ISHIKAWA, T; HIROTA, S; KITAMURA, Y; KATO, Y; TSUNODA, Y; MIYAUCHI, H; HORIO, T; TOKUNAGA, T; MATSUNAGA, T; NIKAIDO, O; NISHIMUNE, Y; OKADA, Y; TANAKA, K			HIGH-INCIDENCE OF ULTRAVIOLET-B-INDUCED OR CHEMICAL-CARCINOGEN-INDUCED SKIN TUMORS IN MICE LACKING THE XERODERMA-PIGMENTOSUM GROUP-A GENE	NATURE			English	Article							REPAIR GENE; DAMAGED DNA; PROTEIN; BINDING; CELLS	XERODERMA pigmentosum (XP) is an autosomal recessive disorder characterized by a high frequency of skin cancer on sun-exposed areas, and neurological complications, XP has a defect in the early step(s) of nucleotide-excision repair (NER) and consists of eight different genetic complementation groups (groups A-G and a variant)(1). We established XPA (group-A XP) gene-deficient mice by gene targeting of mouse embryonic stem (ES) cells. The XPA-deficient mice showed neither obvious physical abnormalities nor pathological alterations, but were defective in NER and highly susceptible to ultraviolet-B- or 9,10-dimethyl-1,2-benz[a]anthracene-induced skin carcinogenesis. These findings provide is vivo evidence that the XPA protein protects mice from carcinogenesis initiated by ultraviolet or chemical carcinogen, The XPA-deficient mice may provide a good in vivo model to study the high incidence of skin carcinogenesis in group A XP patients.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT PATHOL,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,OSAKA 565,JAPAN; KINKI UNIV,COLL AGR,ANIM REPROD LAB,NARA 631,JAPAN; KANSAI MED UNIV,DEPT DERMATOL,OSAKA 570,JAPAN; NATL INST ANIM IND,REPROD BIOCHEM LAB,TSUKUBA,IBARAKI 305,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV RADIAT BIOL,KANAZAWA,ISHIKAWA 920,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,OSAKA 565,JAPAN	Osaka University; University of Tokyo; Osaka University; Kindai University (Kinki University); Kansai Medical University; National Agriculture & Food Research Organization - Japan; Kanazawa University; Osaka University			中根, 裕信/V-9816-2019	Nakatsu, Yoshimichi/0000-0001-7408-7071				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BRADLEY A, 1992, BIO-TECHNOL, V10, P534, DOI 10.1038/nbt0592-534; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; IKAI K, 1986, ARCH DERMATOL RES, V278, P445, DOI 10.1007/BF00455161; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1990, MUTAT RES, V235, P187, DOI 10.1016/0921-8777(90)90073-E; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; TANAKA K, 1980, SOMAT CELL GENET, V6, P739, DOI 10.1007/BF01538973; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561	17	246	250	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					165	168		10.1038/377165a0	http://dx.doi.org/10.1038/377165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675085				2022-12-01	WOS:A1995RU75400053
J	NIKOLOV, DB; CHEN, H; HALAY, ED; USHEVA, AA; HISATAKE, K; LEE, DK; ROEDER, RG; BURLEY, SK				NIKOLOV, DB; CHEN, H; HALAY, ED; USHEVA, AA; HISATAKE, K; LEE, DK; ROEDER, RG; BURLEY, SK			CRYSTAL-STRUCTURE OF A TFIIB-TBP-TATA-ELEMENT TERNARY COMPLEX	NATURE			English	Article							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; FUNCTIONAL DOMAINS; BINDING-PROTEIN; BOX COMPLEX; INITIATION; ACTIVATION	The crystal structure of the transcription factor IIB (TFIIB)/TATA box-binding protein (TBP)/TATA-element ternary complex is described at 2.7 Angstrom resolution, core TFIIB resembles cyclin A, and recognizes the preformed TBP-DNA complex through protein-protein and protein-DNA interactions. The amino-terminal domain of core TFIIB forms the downstream surface of the ternary complex, where it could fix the transcription start site. The remaining surfaces of TBP and the TFIIB can interact with TBP-associated factors, other class II initiation factors, and transcriptional activators and coactivators.	ROCKEFELLER UNIV,MOLEC BIOPHYS LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Princeton University				Burley, Stephen/0000-0002-2487-9713; Hisatake, Koji/0000-0002-5795-3115				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BRUNGER AT, 1992, XPLOR V 3 1 MANUAL; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRALAUKIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MOLDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1994, J BIOL CHEM, V269, P30569; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P6077, DOI 10.1073/pnas.92.13.6077; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	478	487	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					119	128		10.1038/377119a0	http://dx.doi.org/10.1038/377119a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675079				2022-12-01	WOS:A1995RU75400039
J	PATHMANATHAN, R; PRASAD, U; SADLER, R; FLYNN, K; RAABTRAUB, N				PATHMANATHAN, R; PRASAD, U; SADLER, R; FLYNN, K; RAABTRAUB, N			CLONAL PROLIFERATIONS OF CELLS INFECTED WITH EPSTEIN-BARR-VIRUS IN PREINVASIVE LESIONS RELATED TO NASOPHARYNGEAL CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EBV GENE-EXPRESSION; LYMPHOPROLIFERATIVE DISEASE; EPITHELIAL-CELLS; TRANSCRIPTION; INSITU; DNA; RNA; TRANSFORMATION; SPECIMENS; BIOPSIES	Background. The Epstein-Barr virus (EBV) is consistently detected in patients with nasopharyngeal carcinoma. To determine whether EBV infection is an early, initiating event in the development of this malignant tumor, we screened nasopharyngeal-biopsy samples, most of which were archival, for preinvasive lesions, including dysplasia and carcinoma in situ, Preinvasive lesions were found in 11 samples, which were tested for the presence of EBV. Methods. EBV infection was detected with in situ hybridization for EBV-encoded RNAs (EBERs) and by immunohistochemical staining for latent membrane protein 1 (LMP-1). The larger samples were also tested for the EBV genome with the use of Southern blotting. The expression of specific EBV RNAs was determined by the amplification of complementary DNA with the polymerase chain reaction. Results. Evidence of EBV infection was detected in all 11 tissue samples with dysplasia or carcinoma in situ, EBERs were identified in all eight samples tested, and LMP-1 was detected in all six of the tested samples. Six of the seven samples tested for the EBV termini contained clonal EBV DNA. Transcription of the latent EBV gene products, EBV nuclear antigen 1, LMP-1, LMP-2A, and the BamHI-A fragment, was detected in most of the samples. Viral proteins characteristic of lytic lesions were not detected. Conclusions. Preinvasive lesions of the nasopharynx are infected with EBV. The EBV DNA is clonal, indicating that the lesions represent a focal cellular growth that arose from a single EBV-infected cell and that EBV infection is an early, possibly initiating event in the development of nasopharyngeal carcinoma. Preinvasive lesions contain EBV RNAs that are characteristic of latent infection but not the viral proteins that are characteristic of lytic infection. The detection of the EBV-transforming gene, LMP-1, in all the neoplastic cells suggests that its expression is essential for preinvasive epithelial proliferations associated with nasopharyngeal carcinoma.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL,CHAPEL HILL,NC 27599; UNIV MALAYA,DEPT PATHOL,KUALA LUMPUR,MALAYSIA; UNIV MALAYA,DEPT OTORHINOLARYNGOL,KUALA LUMPUR,MALAYSIA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Universiti Malaya; Universiti Malaya			Rajadurai, Pathmanathan A/ L A/W-1817-2019		NATIONAL CANCER INSTITUTE [R01CA032979] Funding Source: NIH RePORTER; NCI NIH HHS [CA32979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MC, 1987, HAINES TAYLOR OBSTET, P225; ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; CRISSMAN JD, 1989, AM J SURG PATHOL, V13, P5; de-The G., 1982, HERPESVIRUSES, P25; DESGRANGES C, 1975, INT J CANCER, V16, P7, DOI 10.1002/ijc.2910160103; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GILLIGAN KJ, 1991, J VIROL, V65, P6252, DOI 10.1128/JVI.65.11.6252-6259.1991; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; LEE ES, 1995, NEW ENGL J MED, V332, P19, DOI 10.1056/NEJM199501053320104; LI ZQ, 1983, NASOPHARYNGEAL CARCI, P17; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RANDHAWA PS, 1992, NEW ENGL J MED, V327, P1710, DOI 10.1056/NEJM199212103272403; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SAM CK, 1993, INT J CANCER, V53, P957; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SUN Y, 1993, ONCOGENE, V8, P791; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WU TC, 1991, AM J PATHOL, V138, P1461; YEUNG WM, 1993, INT J CANCER, V53, P746, DOI 10.1002/ijc.2910530507; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	36	457	479	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					693	698		10.1056/NEJM199509143331103	http://dx.doi.org/10.1056/NEJM199509143331103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637746				2022-12-01	WOS:A1995RV22700003
J	SANDS, AT; ABUIN, A; SANCHEZ, A; CONTI, CJ; BRADLEY, A				SANDS, AT; ABUIN, A; SANCHEZ, A; CONTI, CJ; BRADLEY, A			HIGH SUSCEPTIBILITY TO ULTRAVIOLET-INDUCED CARCINOGENESIS IN MICE LACKING XPC	NATURE			English	Article							PIGMENTOSUM GROUP-C; CLONING; CELLS; GENE	COMPROMISE Of genetic information by mutation may result in the dysregulation of cellular growth control and subsequent tumour formation, Xeroderma pigmentosum (XP) is a rare autosomal disease characterized by hypersensitivity of the skin to sunlight and >1,000-fold increased risk of skin cancers in sun-exposed parts of the body, Cell fusion studies have revealed eight complementation groups In XP (A-G, and an XP-variant form); group C is one of the most common forms of the disease(1). We have isolated a mouse homologue of the human gene for XP group C and generated XPC-deficient mice by using embryonic stem cell technology. Mice homozygous for the XPC mutant allele (xpc(m1)/xpc(m1)) are viable and do not exhibit an increased susceptibility to spontaneous tumour generation at one year of age, However, xpc(m1)/xpc(m1) mice were found to be highly susceptible to ultraviolet-induced carcinogenesis compared with mice heterozygous for the mutant allele (xpc(m1)/+) and wild-type controls. Homozygous xpc(m1) mutant mice also display a spectrum of ultraviolet-exposure-related pathological skin and eye changes consistent with the human disease xeroderma pigmentosum group C.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV TEXAS MD ANDERSON,DEPT CARCINOGENESIS,SMITHVILLE,TX 78959	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center				Bradley, Allan/0000-0002-2349-8839				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1973, CANCER RES, V33, P362; GALIEGUEZOUITINA S, 1989, CARCINOGENESIS, V10, P1961, DOI 10.1093/carcin/10.10.1961; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HURT MA, 1993, PATHOLOGY INCIPIENT, P8; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEVER WF, 1990, HISTOPATHOLOGY SKIN, P523; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; STICH HF, 1973, MUTAT RES, V17, P127, DOI 10.1016/0027-5107(73)90261-3; TAKEBE H, 1972, MUTAT RES, V15, P98, DOI 10.1016/0027-5107(72)90099-1	16	215	223	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					162	165		10.1038/377162a0	http://dx.doi.org/10.1038/377162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675084				2022-12-01	WOS:A1995RU75400052
J	SUN, XJ; WANG, LM; ZHANG, YT; YENUSH, L; MYERS, MG; GLASHEEN, E; LANE, WS; PIERCE, JH; WHITE, MF				SUN, XJ; WANG, LM; ZHANG, YT; YENUSH, L; MYERS, MG; GLASHEEN, E; LANE, WS; PIERCE, JH; WHITE, MF			ROLE OF IRS-2 IN INSULIN AND CYTOKINE SIGNALING	NATURE			English	Article							HEMATOPOIETIC-CELLS; RECEPTOR; PROTEIN; PHOSPHORYLATION; TRANSMISSION; SEQUENCE	THE protein IRS-1 acts as an interface between signalling proteins with Src-homology-2 domains (SH2 proteins) and the receptors for insulin, IGF-1, growth hormone, several interleukins (IL-4, IL-9, IL-13) and other cytokines(1-7). It regulates gene expression acid stimulates mitogenesis, and appears to mediate insulin/IGF-1-stimulated glucose transport(8). Thus, survival of the IRS-1(-/-) mouse with only mild resistance to insulin was surprising(9,10). This dilemma is provisionally resolved with our discovery of a second IRS-signalling protein, We purified and cloned a likely candidate called 4PS from myeloid progenitor cells and, because of its resemblance to IRS-1, we designate it IRS-2. Alignment of the sequences of IRS-2 acid IRS-1 revealed a highly conserved amino terminus containing a pleckstrin-homology domain and a phosphotyrosine-binding domain, and a poorly conserved carboxy terminus containing several tyrosine phosphorylation motifs. IRS-2 is expressed in many cells, including tissues from IRS-1(-/-) mice(11), and may be essential for signalling by several receptor systems.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; NIH,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; Harvard University			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU XJ, IN PRESS MOL CELL BI; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PATTI ME, 1995, DIABETES, V44, pA31; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITFIELD K, 1991, INT J FORECASTING, V7, P65, DOI 10.1016/0169-2070(91)90034-S; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	36	745	765	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					173	177		10.1038/377173a0	http://dx.doi.org/10.1038/377173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675087				2022-12-01	WOS:A1995RU75400055
J	FAUCI, AS				FAUCI, AS			NEW SCIENCE AIMED AT AN ANCIENT KILLER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											FAUCI, AS (corresponding author), NIAID,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							JACOBS WR, 1994, SCIENCE, V263, P227; 1995, P NATL ACAD SCI USA, V92, P1530; 1995, SCIENCE, V267, P1638	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					786	786		10.1001/jama.274.10.786	http://dx.doi.org/10.1001/jama.274.10.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650787				2022-12-01	WOS:A1995RU32400005
J	GROVER, SA; COUPAL, L; HU, XF				GROVER, SA; COUPAL, L; HU, XF			IDENTIFYING ADULTS AT INCREASED RISK OF CORONARY-DISEASE - HOW WELL DO THE CURRENT CHOLESTEROL GUIDELINES WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESEARCH CLINICS PREVALENCE; HEART-DISEASE; LIPOPROTEIN-CHOLESTEROL; SERUM-CHOLESTEROL; FRAMINGHAM; MORTALITY; PREDICTION; LIPIDS; COST; MEN	Objective. To assess the accuracy of lipid screening strategies to identify individuals at increased risk of coronary heart disease mortality. Patients.-The 15% random sample of adults recruited into the Lipid Research Clinic Prevalence and Follow-up Studies, which included 3678 men and women aged 35 to 74 years. Total plasma cholesterol levels, lipoprotein fractions, and other coronary risk factors at study entry were compared with subsequent coronary heart disease mortality (mean follow-up, 12.2 years). Outcome Measures.-The areas under receiver operating characteristic curves for blood lipids, lipid ratios, the screening guidelines proposed by the National Cholesterol Education Program, those of the Canadian Consensus Conference on Cholesterol, and a coronary risk model that used Framingham data. Main Results.-The current National Cholesterol Education Program guidelines (area under the curve, 0.74) were significantly (P=.03) more accurate than the old National Cholesterol Education Program guidelines (area, 0.72). The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level (area, 0.72) was as accurate as current National Cholesterol Education Program guidelines. The coronary risk model (area, 0.85) was superior (P<.003) to all other screening maneuvers, Compared with the current National Cholesterol Education Program guidelines, the risk model demonstrated superior test sensitivity (70% vs 45%) with only slightly reduced specificity (82% vs 86%). Conclusion.-The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level is as accurate as current American screening guidelines, Future guidelines should better incorporate high-density lipoprotein cholesterol levels and nonlipid risk factors to target high-risk individuals accurately.	MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DIV GEN INTERNAL MED,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOSTAT & EPIDEMIOL,MONTREAL,PQ,CANADA	McGill University; McGill University; McGill University; McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,1650 CEDAR AVE,MONTREAL,PQ H3G 1A4,CANADA.			Coupal, Louis/0000-0003-0828-9665				ABBOTT RD, 1982, PREV MED, V11, P131, DOI 10.1016/0091-7435(82)90013-5; ABBOTT RD, 1987, US DHEW NIH872284 PU; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BUSH TL, 1991, CIRCULATION, V83, P1287, DOI 10.1161/01.CIR.83.4.1287; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; HANLEY JA, 1988, RADIOLOGY, V148, P889; HEISS G, 1980, CIRCULATION, V61, P302, DOI 10.1161/01.CIR.61.2.302; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; MARTIN MJ, 1986, LANCET, V2, P933; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; METZ CE, 1984, INFORMATION PROCESSI, P432; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WILSON PWF, 1987, AM J CARDIOL, V59, pG91, DOI 10.1016/0002-9149(87)90165-2; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; 1974, REFERENCE MANUAL LIP, V1; 1981, HLTH CANADIANS REPOR; 1974, REFERENCE MANUAL LIP, V2; 1988, CAN MED ASSOC J, V139, P1; 1988, ARCH INTERN MED, V148, P36; 1978, CORONARY RISK HDB ES; 1993, JAMA-J AM MED ASSOC, V269, P8015; 1989, LIFE TABLES CANADA P; 1974, MANUAL LABORATORY OP, V1; 1984, JAMA-J AM MED ASSOC, V251, P351; 1979, CIRCULATION, V60, P427	35	185	187	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					801	806		10.1001/jama.274.10.801	http://dx.doi.org/10.1001/jama.274.10.801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650803				2022-12-01	WOS:A1995RU32400027
J	LEIBOVICI, L; SAMRA, Z; KONIGSBERGER, H; DRUCKER, M; ASHKENAZI, S; PITLIK, SD				LEIBOVICI, L; SAMRA, Z; KONIGSBERGER, H; DRUCKER, M; ASHKENAZI, S; PITLIK, SD			LONG-TERM SURVIVAL FOLLOWING BACTEREMIA OR FUNGEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULTS	Objective.-To delineate long-term survival after an episode of bacteremia or fungemia and risk factors for mortality. Design.-Cohort study. Setting.-A 900-bed university hospital in Israel. Patients.-Study group comprising 1991 patients 18 years of age or older in whom bacteremia or fungemia were detected between March 1988 and October 1992, and a control group comprising 1991 inpatients without any infectious diseases, matched for age, sex, department, date of admission, and underlying disorders. Interventions.-None. Measurements.-Interval from the date of the first positive blood culture (study group) or from date of the identical hospital day (in the matched control patient) to the date of death as recorded in the Israeli National Population registry or, if alive, to June 1, 1994. Results.-The median age of patients was 72 years. in the study group, the mortality rate was 26% at 1 month, 43% at 6 months, 48% at 1 year, and 63% at 4 years, and the median survival was 16.2 months. In the control group, the mortality rate was 7% at 1 month, 27% at 1 year, and 42% at 4 years, and the median survival was greater than 75 months (P<.001). Factors significantly and independently associated with mortality in bacteremic patients were functional class (median survival, 0.5 month in bedridden patients), septic shock (median survival, 0.2 month), serum albumin (median survival, 1.1 months in the lowest quartile), serum creatinine (median survival, 2.9 months in the highest quartile), age (median survival, 2.9 months in the highest quartile [age >80 years]), inappropriate empirical antibiotic treatment (median survival, 4.9 months), nosocomial infection (median survival, 9.6 months), and malignancy (median survival, 2.4 months). Conclusions.-Bacteremia is associated with high short-term mortality, but also a sign of severely curtailed long-term prognosis, especially in patients with low functional capacity, low serum albumin, high serum creatinine, nosocomial infections, malignancy, inappropriate antimicrobial treatment, and septic shock and in elderly patients.	BEILINSON MED CTR,MICROBIOL LAB,IL-49100 PETAH TIQWA,ISRAEL; BEILINSON MED CTR,INFECT DIS UNIT,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,RAMAT AVIV,ISRAEL	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	LEIBOVICI, L (corresponding author), BEILINSON MED CTR,DEPT MED B,IL-49100 PETAH TIQWA,ISRAEL.		Ashkenazi, Shai/V-7996-2019	Ashkenazi, Shai/0000-0001-7244-0679				AMIT M, 1994, SCAND J INFECT DIS, V26, P605, DOI 10.3109/00365549409011819; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; GEERDES HF, 1992, CLIN INFECT DIS, V15, P991, DOI 10.1093/clind/15.6.991; ISPAHANI P, 1987, Q J MED, V63, P427; LEIBOVICI L, 1991, ARCH INTERN MED, V151, P1801; LEIBOVICI L, 1992, CLIN INFECT DIS, V14, P436, DOI 10.1093/clinids/14.2.436; LEIBOVICI L, 1993, AGE AGEING, V22, P431, DOI 10.1093/ageing/22.6.431; MORIYAMA IM, 1989, AM J PUBLIC HEALTH, V79, P1349, DOI 10.2105/AJPH.79.10.1349; PHILLIPS A, 1989, LANCET, V2, P1434; WASUO Y, 1989, J CLIN EPIDEMIOL, V42, P577; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; 1994, STAT ABSTR ISRAEL 19, P151; 1985, SAS USERS GUIDE STAT, P155	14	140	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					807	812		10.1001/jama.274.10.807	http://dx.doi.org/10.1001/jama.274.10.807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650804				2022-12-01	WOS:A1995RU32400028
J	TOKGOZOGLU, LS; ASHIZAWA, T; PACIFICO, A; ARMSTRONG, RM; EPSTEIN, HF; ZOGHBI, WA				TOKGOZOGLU, LS; ASHIZAWA, T; PACIFICO, A; ARMSTRONG, RM; EPSTEIN, HF; ZOGHBI, WA			CARDIAC INVOLVEMENT IN A LARGE KINDRED WITH MYOTONIC-DYSTROPHY - QUANTITATIVE ASSESSMENT AND RELATION TO SIZE OF CTG REPEAT EXPANSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMISSION COMPUTED-TOMOGRAPHY; TRINUCLEOTIDE CAG REPEAT; MUSCULAR-DYSTROPHY; MESSENGER-RNA; ECHOCARDIOGRAPHIC EVALUATION; CONDUCTION SYSTEM; TRIPLET REPEAT; GCT REPEAT; DISEASE; PROTEIN	Objective.-To evaluate and quantitate cardiac involvement in myotonic dystrophy and assess whether the size of the trinucleotide (cytosine-thymine-guanine [CTG]) repeat expansion is a significant predictor of cardiac abnormalities. Design.-Case-control study of a large kindred with myotonic dystrophy. Patients.-Ninety-one bloodline members of the kindred underwent clinical and cardiac evaluation with electrocardiograms, echocardiography (with Doppler in the majority of cases), and genetic and neurologic evaluations. Affected individuals were age-matched to normal family members. Main Outcome Measures.-Electrocardiographic conduction abnormalities, wall motion abnormalities, mitral valve prolapse, and global parameters of systolic and diastolic function were determined by an observer blinded to all clinical data and genetic analysis. Results.-Compared with age-matched normals, patients with myotonic dystrophy (n=25) were more likely to have conduction abnormality (52% vs 9%), mitral valve prolapse (32% vs 9%), and wall motion abnormality (28% vs 0%) (all P<.05). Left ventricular ejection fraction and stroke volume were reduced compared with normals matched for age and heart rate (P<.05), whereas Doppler indexes of diastolic function were only marginally altered. Using multivariate analysis, the number of CTG repeats (range, 69 to 1367; normal, less than or equal to 37) was the strongest predictor of abnormalities in wall motion and electrocardiographic conduction (odds ratio of 16.5 and 5.07 per 500 repeats, respectively). The relation of mitral valve prolapse to the size of the CTG repeat was of borderline significance, Patients with more extensive neurologic findings (n=12) had a higher incidence of wall motion and/or electrocardiographic conduction abnormalities (83% vs 43%; P=.04). Conclusions.-Cardiac involvement in myotonic dystrophy affects predominantly the conduction system and myocardial function. Alterations in myocardial relaxation and diastolic properties, in contrast to skeletal muscle myotonia, are minor. In this kindred, the number of CTG repeats was a significant predictor of cardiac dysfunction in myotonic dystrophy.	METHODIST HOSP,ECHOCARDIOG LAB,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,CARDIOL SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; VET AFFAIRS MED CTR,HOUSTON,TX 77030	The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ANVRET M, 1993, HUM MOL GENET, V2, P1397, DOI 10.1093/hmg/2.9.1397; ASHIZAWA T, 1993, NEUROLOGY, V43, P2674, DOI 10.1212/WNL.43.12.2674; ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; ASHIZAWA T, 1992, NEUROLOGY, V42, P1877; ASHIZAWA T, 1992, AM J MED GENET, V42, P55, DOI 10.1002/ajmg.1320420113; BHARATI S, 1984, CHEST, V86, P444, DOI 10.1378/chest.86.3.444; BORGESNETO S, 1988, J AM COLL CARDIOL, V11, P962, DOI 10.1016/S0735-1097(98)90052-3; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHURCH SC, 1967, ARCH INTERN MED, V119, P176, DOI 10.1001/archinte.119.2.176; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; FORSBERG H, 1988, CARDIOLOGY, V75, P241, DOI 10.1159/000174380; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GOTTDIENER JS, 1982, AM HEART J, V104, P77, DOI 10.1016/0002-8703(82)90644-5; GRIFFITH TW, 1911, QUART J MED, V5, P229; GRIGGS RC, 1975, AM J MED, V59, P37, DOI 10.1016/0002-9343(75)90319-8; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1992, AM J HUM GENET, V51, P10; HARPER PS, 1989, MYOTONIC DYSTROPHY, P13; HARTWIG GB, 1983, NEUROLOGY, V33, P657, DOI 10.1212/WNL.33.5.657; HIROMASA S, 1987, AM HEART J, V113, P1482, DOI 10.1016/0002-8703(87)90665-X; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JANSEN G, 1994, AM J HUM GENET, V54, P575; KOVICK RB, 1975, CIRCULATION, V52, P447, DOI 10.1161/01.CIR.52.3.447; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; LEWIS JF, 1984, CIRCULATION, V3, P425; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MELACINI P, 1988, CLIN CARDIOL, V11, P231, DOI 10.1002/clc.4960110407; MOORMAN JR, 1985, MEDICINE, V64, P371, DOI 10.1097/00005792-198511000-00002; MOTTA J, 1979, AM J MED, V67, P467, DOI 10.1016/0002-9343(79)90795-2; MULVAGH S, 1992, J AM COLL CARDIOL, V20, P112, DOI 10.1016/0735-1097(92)90146-E; NGUYEN HH, 1988, J AM COLL CARDIOL, V11, P662, DOI 10.1016/0735-1097(88)91547-1; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; NOVELLI G, 1993, BIOCHEM MED METAB B, V50, P85, DOI 10.1006/bmmb.1993.1049; OLOFSSON BO, 1988, BRIT HEART J, V59, P47; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PAYNE CA, 1963, AM HEART J, V65, P436, DOI 10.1016/0002-8703(63)90092-9; PERLOFF JK, 1984, AM J CARDIOL, V54, P1074, DOI 10.1016/S0002-9149(84)80147-2; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; REEVES WC, 1980, ARCH NEUROL-CHICAGO, V37, P273, DOI 10.1001/archneur.1980.00500540051004; RICKER K, 1994, NEUROLOGY, V44, P1448, DOI 10.1212/WNL.44.8.1448; ROKEY R, 1985, CIRCULATION, V71, P543, DOI 10.1161/01.CIR.71.3.543; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SCHILLER NB, 1989, J AM SOC ECHO, V5, P358; SMITH M D, 1991, Cardiology Clinics, V9, P193; STREIB EW, 1985, MUSCLE NERVE, V8, P650, DOI 10.1002/mus.880080804; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; VANREET RE, 1984, J AM COLL CARDIOL, V3, P243, DOI 10.1016/S0735-1097(84)80007-8; VENCO A, 1978, BRIT HEART J, V40, P1262; WEYMAN AE, 1994, PRINCIPLES PRACTICE, P391; WINTERS SJ, 1976, ANN INTERN MED, V85, P19, DOI 10.7326/0003-4819-85-1-19; WINTZEN AR, 1987, J NEUROL SCI, V80, P259, DOI 10.1016/0022-510X(87)90160-2; ZOGHBI WA, 1990, CIRCULATION, V82, P1316, DOI 10.1161/01.CIR.82.4.1316	59	64	65	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					813	819		10.1001/jama.274.10.813	http://dx.doi.org/10.1001/jama.274.10.813			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650805				2022-12-01	WOS:A1995RU32400029
J	DECOCK, KM; WILKINSON, D				DECOCK, KM; WILKINSON, D			TUBERCULOSIS-CONTROL IN RESOURCE-POOR COUNTRIES - ALTERNATIVE APPROACHES IN THE ERA OF HIV	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY; CHEMOTHERAPY; INFECTION; THERAPY; AFRICA		CTR EPIDEMIOL RES S AFRICA,HLABISA 3937,SOUTH AFRICA; HLABISA HOSP,HLABISA 3937,SOUTH AFRICA		DECOCK, KM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; CROFTON J, 1992, CLIN TUBERCULOSIS; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KUMARESAN JA, 1992, BRIT MED J, V305, P340, DOI 10.1136/bmj.305.6849.340; NUNN P, 1991, LANCET, V377, P627; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK AL, 1992, AIDS, V6, P809, DOI 10.1097/00002030-199208000-00007; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; 1995, MMWR-MORBID MORTAL W, V44, P387; 1993, TREATMENT TUBERCULOS; 1995, WHOTB95183 REP; 1993, INVESTING HLTH; 1994, AM J RESP CRIT CARE, V149, P1359; 1992, MMWR-MORBID MORTAL W, V41, P1	28	62	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					675	677		10.1016/S0140-6736(95)92284-9	http://dx.doi.org/10.1016/S0140-6736(95)92284-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658822				2022-12-01	WOS:A1995RU04800013
J	GOODWIN, S				GOODWIN, S			HELICOBACTERS SHED NEW LIGHT ON CHAPERONINS	LANCET			English	Editorial Material							PYLORI; PROTEIN				GOODWIN, S (corresponding author), UNITED ARAB EMIRATES UNIV,FAC MED,DEPT MED MICROBIOL,AL AIN,U ARAB EMIRATES.							AUSTIN JW, 1992, J BACTERIOL, V174, P7470, DOI 10.1128/jb.174.22.7470-7473.1992; COATES ARM, 1993, MOL MICROBIOL, V8, P787, DOI 10.1111/j.1365-2958.1993.tb01624.x; COATES ARM, IN PRESS CHAPERONINS; DOIDGE C, 1994, LANCET, V343, P919; DUNN BE, 1992, INFECT IMMUN, V60, P1946, DOI 10.1128/IAI.60.5.1946-1951.1992; ESCHWEILER B, 1993, ZBL BAKT-INT J MED M, V280, P73, DOI 10.1016/S0934-8840(11)80942-4; Ferrero R. L., 1995, Gut, V37, pA51; Ghiara P., 1995, Gut, V37, pA51; GOODWIN CS, 1990, EUR J CLIN MICROBIOL, V9, P1, DOI 10.1007/BF01969526; Kansau Imad, 1995, Gut, V37, pA65; Monath T. P., 1995, Gut, V37, pA52; Phadnis S. H., 1995, Gut, V37, pA19; SUERBAUM S, 1994, MOL MICROBIOL, V14, P959, DOI 10.1111/j.1365-2958.1994.tb01331.x; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	14	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					653	655		10.1016/S0140-6736(95)92275-X	http://dx.doi.org/10.1016/S0140-6736(95)92275-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658815				2022-12-01	WOS:A1995RU04800004
J	HORTON, R				HORTON, R			WILL DUESBERG NOW CONCEDE DEFEAT	LANCET			English	Editorial Material																		DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DUESBERG P, 1994, INT ARCH ALLERGY IMM, V103, P118, DOI 10.1159/000236617	2	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					656	656		10.1016/S0140-6736(95)92277-6	http://dx.doi.org/10.1016/S0140-6736(95)92277-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658817				2022-12-01	WOS:A1995RU04800006
J	IPUGE, YAI; RIEDER, HL; ENARSON, DA				IPUGE, YAI; RIEDER, HL; ENARSON, DA			ADVERSE CUTANEOUS REACTIONS TO THIACETAZONE FOR TUBERCULOSIS TREATMENT IN TANZANIA	LANCET			English	Article							HYPERSENSITIVITY REACTIONS; PULMONARY TUBERCULOSIS; HIV-INFECTION; CHEMOTHERAPY	Because thiacetazone has been linked with serious adverse cutaneous reactions, we undertook 1 year of systematic surveillance for cutaneous thiacetazone-associated adverse reactions within the national tuberculosis programme of Tanzania, For individual cases, we collected information on age, sex, interval between commencing thiacetazone-containing treatment and occurrence of adverse reaction, most severe clinical presentation (toxic epidermal necrolysis, rash without necrolysis, itching without rash), and outcome (dead or alive) within 2 weeks of onset, Univariate and multivariate analyses were done of variables relevant to outcome. 1273 patients with adverse reactions were reported, The frequency of fatal outcome from any cutaneous reaction was 3.1 per 1000 among all tuberculosis patients, and 19.1% among patients with toxic epidermal necrolysis. About 60% of all adverse reactions and deaths occurred within 20 days of starling thiacetazone. Case fatality from adverse cutaneous reactions was considerably less frequent than reported previously, suggesting that improved management might allow retention of thiacetazone in the armamentarium of national tuberculosis programmes even where infection with HIV is prevalent,	MINIST HLTH,TANZANIA NATL TB LEPROSY PROGRAMME,DAR ES SALAAM,TANZANIA; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE									[Anonymous], 1980, Tubercle, V61, P59; [Anonymous], 1983, Tubercle, V64, P153; Chum H. J., 1994, Tubercle and Lung Disease, V75, P24, DOI 10.1016/0962-8479(94)90769-2; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DOMAGK G, 1946, NATURWISSENSCHAFTEN, V33, P315, DOI 10.1007/BF00624524; DUKES CS, 1992, TROP GEOGR MED, V44, P308; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; KELLY P, 1994, T ROY SOC TROP MED H, V88, P113, DOI 10.1016/0035-9203(94)90529-0; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Miller A B, 1966, Tubercle, V47, P33; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1993, T ROY SOC TROP MED H, V87, P578, DOI 10.1016/0035-9203(93)90096-9; NUNN P, 1991, LANCET, V337, P627; RAVIGLIONE MC, 1988, ARCH INTERN MED, V148, P2683, DOI 10.1001/archinte.148.12.2683; Rouillon A, 1991, Bull Int Union Tuberc Lung Dis, V66, P159; 1960, TUBERCLE, V41, P399; 1987, MANUAL NATIONAL TUBE; 1993, 29 INT UN TUB LUNG D; 1966, TUBERCLE, V47, P315; 1963, TUBERCLE, V44, P301; 1966, TUBERCLE, V47, P1; 1994, 32 INT UN TUB LUNG D; 1970, TUBERCLE, V51, P123; 1985, AM REV RESPIR DIS, V131, P727	29	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					657	660		10.1016/S0140-6736(95)92278-4	http://dx.doi.org/10.1016/S0140-6736(95)92278-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544858				2022-12-01	WOS:A1995RU04800007
J	LANNG, S; HANSEN, A; THORSTEINSSON, B; NERUP, J; KOCH, C				LANNG, S; HANSEN, A; THORSTEINSSON, B; NERUP, J; KOCH, C			GLUCOSE-TOLERANCE IN PATIENTS WITH CYSTIC-FIBROSIS - 5-YEAR PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-MELLITUS; GLYCOSYLATED HEMOGLOBIN; DELTA-F508 MUTATION; PANCREATIC FUNCTION; ENDOCRINE; EXOCRINE; INTOLERANCE; ADOLESCENTS	Objectives-To study prevalence and incidence of diabetes mellitus in patients with cystic fibrosis. Design-Five year prospective study with annual oral glucose tolerance tests. Setting-CF Center Copenhagen, Denmark. Subjects-191 patients with cystic fibrosis aged above 2 years. Main outcome measures-Glucose tolerance, plasma glucose concentrations after fasting and after glucose loading, and haemoglobin A(1c) levels. Results-Prevalence of diabetes increased from 11% (n=21) to 24% (n=46) during study, with annual age dependent incidence of 4-9%. Diabetes was diagnosed at median age of 21 (range 3-40). At diagnosis of diabetes, symptoms of hyperglycaemia were present in 33% of patients, fasting hyperglycaemia (greater than or equal to 7.8 mmol/l was seen in 16%, and increased haemoglobin A(1c) levels (>6.4%) were seen in 16%. Impaired glucose tolerance implied higher risk for development of diabetes than normal glucose tolerance (odds ratio 5.6). In 58% of cases with impaired glucose tolerance, however, glucose tolerance was normal at next annual test. Normal glucose tolerance was found in only 37% of patients at all five tests. Within this group of patients, median plasma glucose concentrations after fasting and after glucose loading and haemoglobin A(1c) levels increased by 6-8% during study. Conclusions-Prevalence and incidence of diabetes in cystic fibrosis patients was high and increased with age. Since hyperglycaemic symptoms, fasting hyperglycaemia, and increased levels of glycated haemoglobin did not reliably identify diabetes mellitus, we recommend annual oral glucose tolerance tests in all cystic fibrosis patients aged over 10 years.	HILLEROD HOSP,DEPT MED F,HILLEROD,DENMARK; STENO DIABET CTR,GENTOFTE,DENMARK	University of Copenhagen; Steno Diabetes Center	LANNG, S (corresponding author), RIGSHOSP,CF CTR COPENHAGEN,DEPT PAEDIAT,DK-2100 COPENHAGEN,DENMARK.							ABDULKARIM FW, 1986, ARCH PATHOL LAB MED, V110, P602; ARRIGO T, 1993, ACTA PAEDIATR, V82, P249, DOI 10.1111/j.1651-2227.1993.tb12653.x; ARTAL R, 1984, AM J OBSTET GYNECOL, V148, P412, DOI 10.1016/0002-9378(84)90717-8; BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BANK S, 1975, AM J GASTROENTEROL, V64, P13; BISTRITZER T, 1983, ISRAEL J MED SCI, V19, P600; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; FINKELSTEIN SM, 1988, J PEDIATR-US, V112, P373, DOI 10.1016/S0022-3476(88)80315-9; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; GEFFNER ME, 1984, PEDIATR RES, V18, P1107, DOI 10.1203/00006450-198411000-00011; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANDWERG.S, 1969, NEW ENGL J MED, V281, P451, DOI 10.1056/NEJM196908282810901; HOIBY N, 1977, ACTA PATHOLOGIC S262, V85, P3; IANNUCCI A, 1984, HUM PATHOL, V15, P278, DOI 10.1016/S0046-8177(84)80191-4; LAMERS CBHW, 1990, PANCREAS, V5, P65; LANNG S, 1994, ACTA PAEDIATR, V83, P72, DOI 10.1111/j.1651-2227.1994.tb12956.x; LANNG S, 1991, CLIN GENET, V40, P345; LANNG S, 1992, EUR J PEDIATR, V151, P684, DOI 10.1007/BF01957574; LANNG S, 1991, ARCH DIS CHILD, V66, P612, DOI 10.1136/adc.66.5.612; LANNG S, 1994, ACTA PAEDIATR, V83, P849, DOI 10.1111/j.1651-2227.1994.tb13156.x; LANNG S, 1993, ACTA ENDOCRINOL-COP, V128, P207, DOI 10.1530/acta.0.1280207; LANNG S, 1993, ACTA PAEDIATR, V82, P150, DOI 10.1111/j.1651-2227.1993.tb12628.x; LITTLE RR, 1994, DIABETOLOGIA, V37, P252, DOI 10.1007/BF00398051; MORAN A, 1991, J PEDIATR-US, V118, P715, DOI 10.1016/S0022-3476(05)80032-0; NIELSEN O H, 1981, Ugeskrift for Laeger, V143, P2302; NIR M, IN PRESS THORAX; POLGAR G, 1971, PULMONARY FUNCTION T, P88; REISMAN J, 1990, PEDIATRICS, V150, P374; ROBERT JJ, 1992, ARCH FR PEDIATR, V49, P17; RODMAN HM, 1986, MEDICINE, V65, P389, DOI 10.1097/00005792-198611000-00004; SCHWARTZ M, 1990, HUM GENET, V85, P427, DOI 10.1007/BF02428297; SOIJIMA K, 1986, PEDIATR PATHOL, V6, P25; STUTCHFIELD PR, 1987, ARCH DIS CHILD, V62, P805, DOI 10.1136/adc.62.8.805; SVENDSEN PA, 1982, DIABETOLOGIA, V23, P403; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; World Health Organization, 1985, DIAB MELL REP WHO ST, V727; WULFF HR, 1988, MEDSTAT VERSION 2; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397	38	175	175	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					655	659		10.1136/bmj.311.7006.655	http://dx.doi.org/10.1136/bmj.311.7006.655			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549632	Green Published			2022-12-01	WOS:A1995RU75300016
J	POTTS, M				POTTS, M			NONSURGICAL ABORTION - WHOS FOR METHOTREXATE	LANCET			English	Editorial Material											POTTS, M (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.							CREININ MD, 1993, CONTRACEPTION, V48, P339, DOI 10.1016/0010-7824(93)90079-M; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; DONNENFELD AE, 1994, TERATOLOGY, V49, P79, DOI 10.1002/tera.1420490202; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; TANAKA T, 1982, FERTIL STERIL, V37, P851; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1398; WINIKOFF B, 1995, FAM PLANN PERSPECT, V27, P142, DOI 10.2307/2136257	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					655	656		10.1016/S0140-6736(95)92276-8	http://dx.doi.org/10.1016/S0140-6736(95)92276-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658816				2022-12-01	WOS:A1995RU04800005
J	PUKKALA, E; AUVINEN, A; WAHLBERG, G				PUKKALA, E; AUVINEN, A; WAHLBERG, G			INCIDENCE OF CANCER AMONG FINNISH AIRLINE CABIN ATTENDANTS, 1967-92	BRITISH MEDICAL JOURNAL			English	Article							RADIATION EXPOSURE; COSMIC-RADIATION; BREAST-CANCER; RISK	Objective-To assess whether occupational exposure among commercial airline cabin attendants are associated with risk of cancer. Design-Record linkage study. Setting-Finland. Subjects-1577 female and 187 male cabin attendants who had worked for the Finnish airline companies. Main outcome measure-Standardised incidence ratio; expected number of cases based on national cancer incidences. Results-A significant excess of breast cancer (standardised incidence ratio 1.87 (95% confidence interval 1.15 to 2.23)) and bone cancer (15.10 (1.82 to 54.40)) was found among female workers. The risk of breast cancer was most prominent 15 years after recruitment. Risks of leukaemia (3.57 (0.43 to 12.9)) and skin melanoma (2.11 (0.43 to 6.15) were not significantly raised. Among men, one lymphoma and one Kaposi's sarcoma were found (expected number of cases 1.6). Conclusions-Although the lifestyle of cabin attendants is different fi om that of the reference population-for example, in terms of social status and parity-concentration of the excess risks to primary sites sensitive to radiation suggests that ionising radiation during flights may add to the cancer risk of all flight personnel. Otherwise the lifestyle of cabin attendants did not seem to affect their risks of cancer. Estimates of the effect of reproductive risk factors only partly explained the increased risk of breast cancer. If present estimates of health hazards due to radiation are also valid for cosmic radiation, then the radiation doses of cabin attendants seem too small to account entirely for the observed excess risk.	FINNISH CTR RADIAT NUCL SAFETY,SF-00881 HELSINKI,FINLAND; FINNISH FLIGHT ATTENDANTS ASSOC,SF-00520 HELSINKI,FINLAND	Radiation & Nuclear Safety Authority (STUK)	PUKKALA, E (corresponding author), FINNISH CANC REGISTRY,LIISANKATU 21 B,SF-00170 HELSINKI,FINLAND.		Auvinen, Anssi/AAD-9311-2020; Auvinen, Anssi/AAL-2111-2020	Auvinen, Anssi/0000-0003-1125-4818				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1994, SOURCES EFFECTS IONI; BAND PR, 1990, AVIAT SPACE ENVIR MD, V61, P299; BOUVILLE A, 1988, RADIAT PROT DOSIM, V24, P293; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; FRIEDBERG W, 1989, AVIAT SPACE ENVIR MD, V60, P1104; HIGGINSON J, 1992, HUMAN CANCER EPIDEMI; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; MONTAGNE C, 1993, RADIAT PROT DOSIM, V48, P79; OBRIEN K, 1972, HEALTH PHYS, V22, P225, DOI 10.1097/00004032-197203000-00002; PARETZKE HG, 1993, RADIAT PROT DOSIM, V48, P33; Pukkala E, 1992, GEOGRAPHICAL ENV EPI, P125; Pukkala E, 1995, CONTRIBUTIONS EPIDEM, V7; SINCLAIR WK, 1985, RADIAT PROT DOSIM, V13, P319; SOINI I, 1977, INT J EPIDEMIOL, V6, P365, DOI 10.1093/ije/6.4.365; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; THOMPSON DE, 1994, RAD RES S, V37, pS17; 1994, LANCET, V344, P1039	18	186	190	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					649	652		10.1136/bmj.311.7006.649	http://dx.doi.org/10.1136/bmj.311.7006.649			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549630	Green Published			2022-12-01	WOS:A1995RU75300014
J	RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ				RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ			ARTERIAL EMBOLIZATION TO TREAT UTERINE MYOMATA	LANCET			English	Note								Haemorrhage, probably related to hypervascularisation, is the commonest complication of uterine myomata and is difficult to treat. 16 patients, aged 34-48 years, with symptomatic uterine myomata, for which a major surgical procedure was planned after failure of medical treatment, were treated by selective free-flow arterial embolisation of the myomata with Ivalon particles. With a mean follow-up of 20 months (range 11-48) in the responders, symptoms resolved in 11 patients; menstrual cycles returned to normal in ten of these. Three patients had partial improvement. Two failures required surgery. In 14 cases embolisation caused pelvic pain, which required analgesia in all.	UNIV PARIS 07,HOP LARIBOISIERE,RADIOL INTERVENT SERV,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	RAVINA, JH (corresponding author), UNIV PARIS 07,HOP LARIBOISIERE,SERV GYNECOL OBSTET,F-75475 PARIS 10,FRANCE.							COHEN J, 1993, 3RD INT S GNRH AN CA, P25; FARRER-BROWN G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P967; HERBRETEAU D, 1993, ACTUALITE REANIMATIO, P17; RAVINA JH, 1994, PRESSE MED, V23, P1540; Sampson JA, 1912, SURG GYNECOL OBSTET, V14, P215	5	719	872	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					671	672		10.1016/S0140-6736(95)92282-2	http://dx.doi.org/10.1016/S0140-6736(95)92282-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544859				2022-12-01	WOS:A1995RU04800011
J	VAINIO, A; OLLILA, J; MATIKAINEN, E; ROSENBERG, P; KALSO, E				VAINIO, A; OLLILA, J; MATIKAINEN, E; ROSENBERG, P; KALSO, E			DRIVING ABILITY IN CANCER-PATIENTS RECEIVING LONG-TERM MORPHINE ANALGESIA	LANCET			English	Article							PAIN; BUPRENORPHINE; PSYCHOMOTOR; OPIOIDS	When given in single doses to healthy volunteers, opioid analgesics impair reaction time, muscle coordination, attention, and short-term memory sufficiently to affect driving and other skilled activities. Despite the increasing use of oral morphine daily, little is known about the effect of long-term opioid therapy on psychomotor performance. To examine the effects of continuous morphine medication, psychological and neurological tests originally designed for professional motor vehicle drivers were conducted in two groups of cancer patients who were similar apart from experience of pain, 24 were on continuous morphine (mean 209 mg oral morphine daily) for cancer pain; and 25 were pain-free without regular analgesics. Though the results were a little worse in the patients taking morphine, there were no significant differences between the groups in intelligence, vigilance. concentration, fluency of motor reactions, or division of attention. Of the neural function tests, reaction times (auditory, visual, associative), thermal discrimination, and body sway with eyes open were similar in the two groups; only balancing ability with closed eyes was worse in the morphine group. These results indicate that, in cancer patients receiving long-term morphine treatment with stable doses, morphine has only a slight and selective effect on functions related to driving.	UNIV HELSINKI,CENT HOSP,DEPT ANAESTHESIA,SF-00290 HELSINKI,FINLAND; FINNISH INST OCCUPAT HLTH,HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; Finnish Institute of Occupational Health								BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BUKASA B, 1985, VERKEHRSPSYCHOLOGISC, V23; Bukasa B, 1990, DIAGNOSTICA, V36, P148; Gardziella M., 1985, WARTEGG PIIRUSTUSTES; GORDON N, 1976, PSYCHOPHARMACOLOGIA, V16, P337; HAKKINEN S, 1979, ACCIDENT ANAL PREV, V11, P7, DOI 10.1016/0001-4575(79)90033-2; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; JOO S, 1994, J TRAFFIC MED, V22, P101; KERR B, 1991, NEUROPSYCHOPHARMACOL, V5, P157; LEQUESNE PM, 1990, J NEUROL NEUROSUR PS, V53, P558, DOI 10.1136/jnnp.53.7.558; LINNOILA M, 1986, DRUGS DRIVING, P29; LOMBARDO WK, 1976, INT J ADDICT, V11, P389, DOI 10.3109/10826087609056158; MACDONALD FC, 1989, BRIT J CLIN PHARMACO, V27, P453, DOI 10.1111/j.1365-2125.1989.tb05393.x; OHANLON JF, 1986, DRUGS DRIVING; OJALA M, 1989, ACTA NEUROL SCAND, V80, P118, DOI 10.1111/j.1600-0404.1989.tb03852.x; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; ROTHENBERG S, 1977, PSYCHOPHARMACOLOGY, V52, P299, DOI 10.1007/BF00426715; SAARIALHOKERE U, 1987, EUR J CLIN PHARMACOL, V33, P139, DOI 10.1007/BF00544557; SJOGREN P, 1989, PAIN, V39, P5, DOI 10.1016/0304-3959(89)90168-1; SVENSSON JO, 1982, J CHROMATOGR, V230, P427, DOI 10.1016/S0378-4347(00)80494-6; TREAT JR, 1977, DOTHS03453577TAC IND; VAINIO A, 1988, ACTA ANAESTH SCAND, V32, P179, DOI 10.1111/j.1399-6576.1988.tb02711.x; WARTEGG E, 1955, TESTS KLINISCHEN PSY, V2, P520; YATES IW, 1980, CANCER, V45, P228	24	152	156	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					667	670		10.1016/S0140-6736(95)92281-4	http://dx.doi.org/10.1016/S0140-6736(95)92281-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658820				2022-12-01	WOS:A1995RU04800010
J	VANDEVEN, PJG; BEUTLER, JJ; KAATEE, R; BEEK, FJA; MALI, WPTM; GEYSKES, GG; KOOMANS, HA				VANDEVEN, PJG; BEUTLER, JJ; KAATEE, R; BEEK, FJA; MALI, WPTM; GEYSKES, GG; KOOMANS, HA			TRANSLUMINAL VASCULAR STENT FOR OSTIAL ATHEROSCLEROTIC RENAL-ARTERY STENOSIS	LANCET			English	Note							RENOVASCULAR HYPERTENSION; ANGIOPLASTY	We implanted transluminal stents in 24 hypertensive patients with a critical atherosclerotic ostial renal artery stenosis (28 arteries). Immediate revascularisation was successful in all. Follow-up angiography at 6 months, available in 18 patients, revealed restenosis twice. In another patient restenosis was suspected and confirmed by angiography at 2 months. Hence, the total restenosis rate was 3 of 19 patients (16%) and 3 of 23 arteries (13%). Two patients developed renal insufficiency due to cholesterol embolism. In the remaining 22 patients renal function improved (n=8) or stabilised (n=14). Although all had to resume antihypertensive treatment, blood pressure normalised in 15 patients, improved in one, remained unchanged in five and worsened in one.	UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT RADIOL,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; DEAN RH, 1991, ANN SURG, V213, P446, DOI 10.1097/00000658-199105000-00010; Martin L G, 1992, J Vasc Interv Radiol, V3, P619, DOI 10.1016/S1051-0443(92)72907-8; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; PICOLI G, 1995, NEPHROL DIAL TRANSPL, V10, P444; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; REES CR, 1991, RADIOLOGY, V181, P505; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; STRANDNESS DE, 1994, AM J KIDNEY DIS, V24, P630, DOI 10.1016/S0272-6386(12)80224-1	10	141	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					672	674		10.1016/S0140-6736(95)92283-0	http://dx.doi.org/10.1016/S0140-6736(95)92283-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658821				2022-12-01	WOS:A1995RU04800012
J	VESPA, J; WATSON, F				VESPA, J; WATSON, F			WHO IS NUTRITIONALLY VULNERABLE IN BOSNIA-HERZEGOVINA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To monitor nutritional status and food security in order to identify nutritionally vulnerable groups. Design-Members of five different household groups (urban and rural residents, displaced people in collective centres and private accommodation, elderly people living without younger family) and ail residents of two old people's homes were prospectively followed. Households were selected from 20 local communities and nine collective centres. Setting-Monitoring carried out in three besieged areas of Bosnia-Hercegovina (Sarajevo, Tuzla, and Zenica). Subjects-1739 individuals sampled. Interventions-Data collected every month from December 1993 to May 1994, Information on household food security was collected through structured questionnaires. AU subjects were weighed and their heights measured, Weight for age Z scores were calculated far children; body mass index was calculated for adults and elderly people. Results-From December 1993 to February 1994, before a temporary cease fire, access to food was reduced, In February 1994 no significant signs of undernutrition were detected among children or adults, but elderly people had higher than expected levels of undernutrition (15.5% with body mass index <18.5), a higher rate of weight loss than adults (1.2 kg over two months), and a higher prevalence of self reported illness. Conclusions-Elderly people in Bosnia-Hercegovina are at greater risk of undernutrition than other age groups, Undernutrition may be precipitated in elderly people by sickness, cold, stress, and problems related to food preparation, The health and welfare of elderly people during the emergency in Bosnia-Hercegovina require special attention, and integrated age care programmes are needed.	WHO,REG OFF EUROPE,ZAGREB AREA OFF,ZAGREB 4100,CROATIA	World Health Organization								BENNET GJ, 1992, ESSENTIALS HLTH CARE, P108; DEAN AD, 1990, EPI INFO SOFTWARE VE; EVNAS JG, 1992, OXFORD TXB GERIATRIC, P4; Gregory F., 1990, DIETARY NUTR SURVEY; JAMES WPT, 1994, J EUR CLIN NUTR S3, V48, P179; MURPHY E, 1985, PREVENTION DISEASE E, P156; ROBERTSON A, 1994, NUTRITION VACCINATIO; SHETTY PS, 1994, FAO56 FOOD NUTR PAP; 1992, REPORT HLTH SOCIAL S, V43; 1976, NCHS GROWTH CHARTS; 1992, MWMK, V41, P809; 1994, REPORT FOOD DELIVERI	12	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					652	654		10.1136/bmj.311.7006.652	http://dx.doi.org/10.1136/bmj.311.7006.652			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549631	Green Published			2022-12-01	WOS:A1995RU75300015
J	WARNER, JO				WARNER, JO			REVIEW OF PRESCRIBED TREATMENT FOR CHILDREN WITH ASTHMA IN 1990	BRITISH MEDICAL JOURNAL			English	Article							BECLOMETHASONE DIPROPIONATE; CHILDHOOD	Objective-To review treatment prescribed to asthmatic children in Great Britain during the 12 months after publication of the first guidelines and to assess effectiveness of prophylactic treatment. Design-Review of prescribing information from January 1990 to June 1991 in a representative sample of general practices in Great Britain with a Compufile/AAH Meditel computer. Subjects-17 846 children with asthma aged 4-17 years. Main outcome measures-Numbers of children prescribed different asthma treatments; estimated use of inhaled beta agonists in those receiving prophylactic treatment. Results-From January to December 1990, 9362 (52.5%) children were prescribed preventive treatments. 16211 (90.8%) children were prescribed bronchodilators of some kind. 3055 (17.1%) were prescribed sodium cromoglycate, and the proportion decreased significantly during the study (from 19.5% (95% confidence interval 18.6% to 20.4%) to 17.2% (16.4% to 18.1%), P<0.001, in children aged 4-11 years and from 14.9% (14.0% to 15.9%) to 11.3% (10.4% to 12.2%), P<0.001, in those aged 12-17 during January-July 1991). 6952 (39.0%) were prescribed inhaled steroids, and the proportion increased during the study (from 35.1% (34.0% to 36.2%) to 44.1% (43.0% to 45.2%), P<0.001, in children aged 4-11 years and hem 38.7% (37.40% to 40.0%) to 44.1% (42.7% to 45.5%), P<0.001, in those aged 12-17 during January-July 1991). Only 1358 of the 9362 children (14.5%) received sufficient repeat prescriptions to suggest that they might be taking the prophylactic treatment regularly. Among these children short acting inhaled beta agonists were being used on average four to eight times a day. Conclusions-These results are useful baseline data for audit of the impact of published clinical guidelines, particularly in terms of reducing the need for short acting inhaled beta agonists with prophylactic treatment.			WARNER, JO (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Warner, John/AAF-9587-2020					ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; [Anonymous], 1993, THORAX S, V48, pS1; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; JONES K, 1989, PRACTITIONER, V233, P265; KAARGAREN RJ, 1994, RESP MED, V88, P883; KAARSGAREN RJ, 1994, RESP MED, V88, P383, DOI 10.1016/0954-6111(94)90045-0; LAW CM, 1986, LANCET, V1, P942; REISER J, 1985, LANCET, V1, P206; ROBERTSON CF, 1993, AM REV RESPIR DIS, V147, pA372; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; WARNER JO, 1989, RESP MED, V83, P33, DOI 10.1016/S0954-6111(89)80248-3; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1994, EUR RESPIR REV, V4, P21; 1993, SCOTTISH HLTH STATIS; 1992, ARCH DIS CHILD, V67, P240; 1992, CLIN EXP ALLERGY S1, V22, P1; 1993, HLTH PERSONAL SOCIAL; 1994, HLTH PERSONAL SOCIAL, V20	22	71	74	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					663	666		10.1136/bmj.311.7006.663	http://dx.doi.org/10.1136/bmj.311.7006.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549637	Green Published			2022-12-01	WOS:A1995RU75300021
J	ASO, T; LANE, WS; CONAWAY, JW; CONAWAY, RC				ASO, T; LANE, WS; CONAWAY, JW; CONAWAY, RC			ELONGIN (SIII) - A MULTISUBUNIT REGULATOR OF ELONGATION BY RNA-POLYMERASE-II	SCIENCE			English	Article							TRANSCRIPTION FACTOR; PURIFICATION; IDENTIFICATION; SEQUENCE; PROTEIN	The Elongin (SIII) complex activates elongation by mammalian RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin is a heterotrimer composed of A, B, and C subunits of 110, 18, and 15 kilodaltons, respectively. Here, the mammalian Elongin A gene was isolated and expressed, and the Elongin (SIII) complex reconstituted with recombinant subunits. Elongin A is shown to function as the transcriptionally active component of Elongin (SIII) and Elongin B and C as regulatory subunits. Whereas Elongin C assembles with Elongin A to form an AC complex with increased specific activity, Elongin B, a member of the ubiquitin-homology gene family, appears to serve a chaperone-like function, facilitating assembly and enhancing stability of the Elongin (SIII) complex.	OKLAHOMA MED RES FDN, PROGRAM MOLEC & CELL BIOL, OKLAHOMA CITY, OK 73104 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Oklahoma Medical Research Foundation; Harvard University				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, UNPUB; ASO T, IN PRESS FASEB J; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GARRETT KP, 1994, GENE, V150, P413, DOI 10.1016/0378-1119(94)90467-7; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1994, TRANSCRIPTION MECHAN, P263; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, BIOTECHNIQUES, V16, P824; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	28	286	295	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1439	1443		10.1126/science.7660129	http://dx.doi.org/10.1126/science.7660129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660129				2022-12-01	WOS:A1995RT80600050
J	BAGBY, S; KIM, SJ; MALDONADO, E; TONG, KI; REINBERG, D; IKURA, M				BAGBY, S; KIM, SJ; MALDONADO, E; TONG, KI; REINBERG, D; IKURA, M			SOLUTION STRUCTURE OF THE C-TERMINAL CORE DOMAIN OF HUMAN TFIIB - SIMILARITY TO CYCLIN-A AND INTERACTION WITH TATA-BINDING PROTEIN	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; NUCLEAR MAGNETIC-RESONANCE; FUNCTIONAL DOMAINS; INITIATION-FACTORS; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE; ACTIVATION; SEQUENCE; ENCODES	TFIIB is an essential component of the machinery that transcribes protein-coding genes. The three-dimensional structure of the human TFIIB core domain (TFIIBc) has been determined using multidimensional heteronuclear magnetic resonance spectroscopy. The molecule consists of two direct repeats that adopt similar alpha-helical folds, conferring pseudo-twofold symmetry. An extensive, central basic surface including an amphipathic alpha helix is critical to the function of TFIIB as a bridge between the TBP-promoter complex and RNA polymerase II and associated general and regulatory transcription factors. Similarities between the TFIIBc and cyclin A folds indicate that elements of the eukaryotic cell cycle control apparatus evolved from more fundamental transcriptional control components, demonstrating a link between the transcription and cell cycle molecular machineries.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	University of Toronto; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	BAGBY, S (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST,TORONTO,ON M4X 1K9,CANADA.			Ikura, Mitsuhiko/0000-0002-9524-1303; Bagby, Stefan/0000-0003-2302-9511; Reinberg, Danny/0000-0003-4288-2016				ALEXANDROV NN, 1992, J MOL BIOL, V225, P5, DOI 10.1016/0022-2836(92)91021-G; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P2409, DOI 10.1021/bi00175a009; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brunger A. T., 1993, X PLOR MANUAL VERSIO; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; COLGAN J, 1995, MOL CELL BIOL, V15, P2311; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE S, 1995, IN PRESS NATURE; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V365, P520; NILGES M, 1991, COMPUTATIONAL ASPECT, P41; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	60	117	122	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					857	867		10.1016/0092-8674(95)90483-2	http://dx.doi.org/10.1016/0092-8674(95)90483-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671313	Bronze			2022-12-01	WOS:A1995RU75500021
J	BRENMAN, JE; CHAO, DS; XIA, HH; ALDAPE, K; BREDT, DS				BRENMAN, JE; CHAO, DS; XIA, HH; ALDAPE, K; BREDT, DS			NITRIC-OXIDE SYNTHASE COMPLEXED WITH DYSTROPHIN AND ABSENT FROM SKELETAL-MUSCLE SARCOLEMMA IN DUCHENNE MUSCULAR-DYSTROPHY	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; MEMBRANE-PROTEIN; REACTIVE OXYGEN; MDX MOUSE; PURIFICATION; BRAIN; CALMODULIN; TORPEDO; TISSUE; KINASE	Nitric oxide (NO) is synthesized in skeletal muscle by neuronal-type NO synthase (nNOS), which is localized to sarcolemma of fast-twitch fibers. Synthesis of NO in active muscle opposes contractile force. We show that nNOS partitions with skeletal muscle membranes owing to association of nNOS with dystrophin, the protein mutated in Duchenne muscular dystrophy (DMD). The dystrophin complex interacts with an N-terminal domain of nNOS that contains a GLGF motif. mdx mice and humans with DMD evince a selective loss of nNOS protein and catalytic activity from muscle membranes, demonstrating a novel role for dystrophin in localizing a signaling enzyme to the myocyte sarcolemma. Aberrant regulation of nNOS may contribute to preferential degeneration of fast-twitch muscle fibers in DMD.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BRENMAN, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Chao, Daniel/0000-0002-3544-5283				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAVISON A, 1988, MOL CELL BIOCHEM, V84, P199, DOI 10.1007/BF00421055; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HAUNG Z, 1994, SCIENCE, V265, P1883; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE KH, 1994, J BIOL CHEM, V269, P14371; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.ne.17.030194.001101; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975	56	807	825	1	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					743	752		10.1016/0092-8674(95)90471-9	http://dx.doi.org/10.1016/0092-8674(95)90471-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545544	Bronze			2022-12-01	WOS:A1995RU75500009
J	CAMACHO, P; LECHLEITER, JD				CAMACHO, P; LECHLEITER, JD			CALRETICULIN INHIBITS REPETITIVE INTRACELLULAR CA2+ WAVES	CELL			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; XENOPUS-LAEVIS OOCYTES; CALCIUM-BINDING PROTEIN; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; RELEASE; STORES; IDENTIFICATION; CALSEQUESTRIN; CHANNELS	Inositol 1,4,5-trisphosphate (IP3)-mediated calcium (Ca2+) signaling is subject to cytosolic and luminal regulatory mechanisms. In Xenopus oocytes, Ca2+-sensitive gating of the IP3 receptor (IP(3)R) produces repetitive waves of Ca2+ release. We examined the role of the luminal Ca2+-binding protein calreticulin (CRT) in IP3-mediated Ca2+ signaling by using Ca2+ wave activity as a sensitive Ca2+ release assay. Overexpression of CRT inhibited repetitive IP3-induced Ca2+ waves. Deletion mutagenesis demonstrated that CRT inhibition was mediated by the high affinity-low capacity Ca2+-binding domain, which contributes little to Ca2+ storage. This novel function of CRT in intracellular Ca2+ signaling may be regulated by Ca2+ occupancy of the high affinity binding site.			CAMACHO, P (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA.				NIGMS NIH HHS [R01 GM48451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAUSEN P, 1981, STAIN TECHNOL, V56, P287, DOI 10.3109/10520298109067329; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIU NG, 1994, J BIOL CHEM, V269, P28635; LONGIN A, 1993, J HISTOCHEM CYTOCHEM, V41, P1833, DOI 10.1177/41.12.8245431; LYTTON J, 1991, HEART CARDIOVASCULAR, P1203; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/edrv-14-5-610; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	41	198	202	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					765	771		10.1016/0092-8674(95)90473-5	http://dx.doi.org/10.1016/0092-8674(95)90473-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671304	Bronze			2022-12-01	WOS:A1995RU75500011
J	DEREGE, PJF; WILLIAMS, SA; THERIEN, MJ				DEREGE, PJF; WILLIAMS, SA; THERIEN, MJ			DIRECT EVALUATION OF ELECTRONIC COUPLING MEDIATED BY HYDROGEN-BONDS - IMPLICATIONS FOR BIOLOGICAL ELECTRON-TRANSFER	SCIENCE			English	Article							PORPHYRIN-QUINONE COMPOUNDS; TUNNELING PATHWAYS; INTRAMOLECULAR ELECTRON; CYTOCHROME-C; DISTANCE DEPENDENCE; BENZENE-DERIVATIVES; CRYSTAL-STRUCTURE; FIXED-DISTANCE; ZINC PORPHYRIN; TRANSFER RATES	Three supramolecular bischromophoric systems featuring zinc(II) and iron(III) porphyrins have been synthesized to evaluate the relative magnitudes of electronic coupling provided by hydrogen, sigma, and pi bonds. Laser flash excitation generates the highly reducing singlet excited state of the (porphinato)zinc chromophore that can subsequently be electron transfer quenched by the (porphinato)iron(III) chloride moiety. Measurement of the photoinduced electron transfer rate constants enables a direct comparison of how well these three types of chemical interactions facilitate electron tunneling, In contrast to generally accepted theory, electronic coupling modulated by a hydrogen-bond interface is greater than that provided by an analogous interface composed entirely of carbon-carbon a bonds. These results bear considerably on the analysis of through-protein electron transfer rate data as well as on the power of theory to predict the path traversed by the tunneling electron in a biological matrix; moreover, they underscore the cardinal role played by hydrogen bonds in biological electron transfer processes.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	University of Pennsylvania			Williams, Scott/AAG-7029-2020					ALMARSSON O, 1993, J AM CHEM SOC, V115, P7093, DOI 10.1021/ja00069a005; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BERATAN DN, 1992, J PHYS CHEM-US, V96, P2852, DOI 10.1021/j100186a014; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BERATAN DN, 1986, J AM CHEM SOC, V108, P4321, DOI 10.1021/ja00275a014; BERATAN DN, 1991, ADV CHEM SER, V228, P71; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; BOBROWSKI K, 1992, J PHYS CHEM-US, V96, P10036, DOI 10.1021/j100203a082; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; CASIMIRO DR, 1993, J PHYS CHEM-US, V97, P13073, DOI 10.1021/j100152a007; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COLAPIETRO M, 1982, ACTA CRYSTALLOGR B, V38, P1953, DOI 10.1107/S0567740882007651; COLAPIETRO M, 1978, ACTA CRYSTALLOGR B, V34, P3277, DOI 10.1107/S056774087801064X; DEREGE PJF, IN PRESS INORG CHIM; DIMAGNO SG, 1993, J ORG CHEM, V58, P5983, DOI 10.1021/jo00074a027; DIMAGNO SG, 1993, J AM CHEM SOC, V115, P2513, DOI 10.1021/ja00059a060; EATON SS, 1977, J AM CHEM SOC, V99, P6594, DOI 10.1021/ja00462a021; FARVER O, 1992, J AM CHEM SOC, V114, P5764, DOI 10.1021/ja00040a043; FRANZEN S, 1993, J PHYS CHEM-US, V97, P3040, DOI 10.1021/j100114a035; GAINES GL, 1991, J AM CHEM SOC, V113, P719, DOI 10.1021/ja00002a076; HARRIMAN A, 1992, J AM CHEM SOC, V114, P388, DOI 10.1021/ja00027a074; HELMS A, 1992, J AM CHEM SOC, V114, P6227, DOI 10.1021/ja00041a047; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; KHUNDKAR LR, 1994, J AM CHEM SOC, V116, P9700, DOI 10.1021/ja00100a040; KOBAYASHI H, 1975, ADV BIOPHYS, V8, P191; LHAYA Y, 1965, B CHEM SOC JPN, V38, P1144; LIN VSY, 1994, SCIENCE, V264, P1105, DOI 10.1126/science.8178169; LONGO FR, 1968, J HETEROCYCLIC CHEM, V6, P927; MARCUS RA, 1986, BIOCHIM BIOPHYS ACTA, V811, P265; MATAGA N, 1989, CHEM PHYS, V131, P473, DOI 10.1016/0301-0104(89)80192-2; MIKKELSEN KV, 1993, P NATL ACAD SCI USA, V90, P5443, DOI 10.1073/pnas.90.12.5443; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; OSUKA A, 1990, J AM CHEM SOC, V112, P4958, DOI 10.1021/ja00168a051; PAULSON BP, UNPUB; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PETERSONKENNEDY SE, 1986, J AM CHEM SOC, V108, P1739, DOI 10.1021/ja00268a004; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; RISSER SM, 1993, J AM CHEM SOC, V115, P2508, DOI 10.1021/ja00059a057; ROTHEMUND P, 1948, J AM CHEM SOC, V70, P1808, DOI 10.1021/ja01185a047; SAKATA Y, 1991, CHEM LETT, P1307, DOI 10.1246/cl.1991.1307; SAKATA Y, 1989, J AM CHEM SOC, V111, P8979, DOI 10.1021/ja00206a065; SCHAUER CK, 1985, INORG CHEM, V24, P4082, DOI 10.1021/ic00218a024; SESSLER JL, 1993, J AM CHEM SOC, V115, P10418, DOI 10.1021/ja00075a091; THERIEN MJ, 1991, ADV CHEM SER, V228, P191; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054; TURRO C, 1992, J AM CHEM SOC, V114, P4013, DOI 10.1021/ja00036a081; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; WASIELEWSKI MR, 1985, J AM CHEM SOC, V107, P1080, DOI 10.1021/ja00290a066; WINKLER JR, 1992, CHEM REV, V92, P369, DOI 10.1021/cr00011a001; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	53	339	342	3	60	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1409	1413		10.1126/science.7660123	http://dx.doi.org/10.1126/science.7660123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660123				2022-12-01	WOS:A1995RT80600040
J	DOBRESCU, D; URSEA, B; POPE, M; ASCH, AS; POSNETT, DN				DOBRESCU, D; URSEA, B; POPE, M; ASCH, AS; POSNETT, DN			ENHANCED HIV-1 REPLICATION IN V-BETA-12 T-CELLS DUE TO HUMAN CYTOMEGALOVIRUS IN MONOCYTES - EVIDENCE FOR A PUTATIVE HERPESVIRUS SUPERANTIGEN	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; ENDOGENOUS SUPERANTIGENS; MICROBIAL SUPERANTIGENS; DENDRITIC CELLS; INFECTION; EXPRESSION; AIDS; STIMULATION	HIV-1 replicates more efficiently in cultured IL-2-dependent CD4 T cells expressing V beta 12 T cell receptors (TCRs) rather than other TCRs (Laurence et al., 1992). A viral reservoir is frequently established in V beta 12 T cells in HIV-1-infected patients. Here we show that cytomegalovirus (CMV) is responsible for V beta 12-selective HIV-1 replication that is indistinguishable from the effect of known superantigens (SAGs). This effect is dependent on direct contact of T cells with CMV-infected monocytes. CMV infection, but not ie1 or ie2 transfection, reproduces this effect in a monocytoid cell line (U937). In HIV-infected patients, the presence of CMV antibodies correlates with an HIV-1 viral load preferentially skewed to the V beta 12 subset. Together, these data suggest that a CMV gene product is responsible for a SAG-driven V beta 12-selective HIV-1 reservoir in vivo.	CORNELL UNIV,GRAD SCH MED SCI,HUMAN MOLEC IMMUNOBIOL LAB,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,DIV HEMATOL & ONCOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT CELL BIOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033322] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33322] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1993, IMMUNOL REV, V131, P5, DOI 10.1111/j.1600-065X.1993.tb01527.x; BACCALA R, 1992, RES IMMUNOL, V143, P288, DOI 10.1016/S0923-2494(92)80122-2; BHARDWAJ N, 1992, J EXP MED, V175, P267, DOI 10.1084/jem.175.1.267; BHARDWAJ N, 1994, INFECT IMMUN, V62, P135, DOI 10.1128/IAI.62.1.135-144.1994; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CLOUSE KA, 1989, J IMMUNOL, V143, P470; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COFFIN JM, 1992, SCIENCE, V255, P411, DOI 10.1126/science.1310360; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DOBRESCU D, 1995, P NATL ACAD SCI USA, V92, P5563, DOI 10.1073/pnas.92.12.5563; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; HELD W, 1994, J EXP MED, V180, P2347, DOI 10.1084/jem.180.6.2347; HIRSCH MS, 1984, REV INFECT DIS, V6, P726; HO WZ, 1991, AIDS RES HUM RETROV, V7, P689, DOI 10.1089/aid.1991.7.689; HOBER D, 1992, CLIN IMMUNOL IMMUNOP, V62, P168, DOI 10.1016/0090-1229(92)90069-Z; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JENKINS DE, 1994, J GEN VIROL, V75, P2337, DOI 10.1099/0022-1317-75-9-2337; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; LAFON M, 1994, J EXP MED, V180, P1207, DOI 10.1084/jem.180.4.1207; LAFON M, 1992, NATURE, V358, P507, DOI 10.1038/358507a0; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; Mocarski Edward S. Jr., 1993, P173; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NUMAZAKI K, 1992, MED MICROBIOL IMMUN, V181, P323; OKSENHENDLER E, 1993, AIDS, V7, P1023, DOI 10.1097/00002030-199307000-00023; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POSNETT DN, 1993, AIDS, V7, P625, DOI 10.1097/00002030-199305000-00003; POSNETT DN, 1993, SUPERANTIGENS PATHOG, P163; POSNETT DN, 1995, IN PRESS ANN NY ACAD, V1017; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SKOLNIK PR, 1994, J INFECT DIS, V157, P508; SMITH LR, 1992, EUR J IMMUNOL, V22, P641, DOI 10.1002/eji.1830220305; SMITH PD, 1992, J CLIN INVEST, V90, P1642, DOI 10.1172/JCI116035; SMITH TJ, 1993, BLOOD, V81, P1521; SODERBERG C, 1993, TRANSPLANT P, V25, P1416; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; TAYLORWIEDEMAN J, 1994, J VIROL, V68, P1597, DOI 10.1128/JVI.68.3.1597-1604.1994; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; WEBSTER A, 1989, LANCET, V2, P63	51	81	83	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					753	763		10.1016/0092-8674(95)90472-7	http://dx.doi.org/10.1016/0092-8674(95)90472-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671303	Bronze			2022-12-01	WOS:A1995RU75500010
J	DUAN, DR; PAUSE, A; BURGESS, WH; ASO, T; CHEN, DYT; GARRETT, KP; CONAWAY, RC; CONAWAY, JW; LINEHAN, WM; KLAUSNER, RD				DUAN, DR; PAUSE, A; BURGESS, WH; ASO, T; CHEN, DYT; GARRETT, KP; CONAWAY, RC; CONAWAY, JW; LINEHAN, WM; KLAUSNER, RD			INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN	SCIENCE			English	Article							FACTOR-SIII; IDENTIFICATION	Germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. Here, a cellular transcription factor, Elongin (SIII), is identified as a functional target of the VHL protein. Elongin (SIII) is a heterotrimer consisting of a transcriptionally active subunit (A) and two regulatory subunits (B and C) that activate transcription elongation by RNA polymerase II. The VHL protein was shown to bind tightly and specifically to the Elongin B and C subunits and to inhibit Elongin (SIII) transcriptional activity in vitro. These findings reveal a potentially important transcriptional regulatory network in which the VHL protein may play a key role.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, SURG BRANCH, UROL ONCOL SECT, BETHESDA, MD 20892 USA; AMER RED CROSS, JEROME H HOLLAND LAB, DEPT BIOL MOLEC, ROCKVILLE, MD 20855 USA; OKLAHOMA MED RES FDN, PROGRAM MOLEC BIOL, OKLAHOMA CITY, OK 73104 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross; Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, UNPUB; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Chen D.-Y., UNPUB; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GAO JZ, 1995, CANCER RES, V55, P743; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lis JT, 1994, TRANSCRIPTION MECH R, P459; SHUIN T, 1994, CANCER RES, V54, P2852; TAN SY, 1994, J BIOL CHEM, V269, P25684; TORY K, 1981, JNCI-J NATL CANCER I, V81, P1079; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	26	475	491	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1402	1406		10.1126/science.7660122	http://dx.doi.org/10.1126/science.7660122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660122	Green Submitted			2022-12-01	WOS:A1995RT80600038
J	EKWALL, K; JAVERZAT, JP; LORENTZ, A; SCHMIDT, H; CRANSTON, G; ALLSHIRE, R				EKWALL, K; JAVERZAT, JP; LORENTZ, A; SCHMIDT, H; CRANSTON, G; ALLSHIRE, R			THE CHROMODOMAIN PROTEIN SWI6 - A KEY COMPONENT AT FISSION YEAST CENTROMERES	SCIENCE			English	Article							HETEROCHROMATIN-ASSOCIATED PROTEIN; POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; ANTIBODIES; DOMAIN	Centromeres attach chromosomes to the spindle during mitosis, thereby ensuring the equal distribution of chromosomes into daughter cells. Transcriptionally silent heterochromatin of unknown function is associated with centromeres in many organisms. In the fission yeast Schizosaccharomyces pombe, the silent mating-type loci, centromeres, and telomeres are assembled into silent heterochromatin-like domains. The Swi6 chromodomain protein affects this silencing, and now it is shown that Swi6p localizes with these three chromosomal regions. In cells lacking Swi6p, centromeres lag on the spindle during anaphase and chromosomes are lost at high rates. Thus, Swi6p is located at fission yeast centromeres and is required for their proper function.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST GENET,D-38106 BRAUNSCHWEIG,GERMANY	University of Edinburgh; Braunschweig University of Technology				Ekwall, Karl/0000-0002-3029-4041; Allshire, Robin/0000-0002-8005-3625	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAGAN IM, 1988, J CELL SCI, V89, P343; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; KLAR AJS, 1992, TRENDS GENET, V8, P208, DOI 10.1016/0168-9525(92)90100-I; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1982, CURR OPIN CELL BIOL, V5, P999; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; WOODS A, 1989, J CELL SCI, V93, P491; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	22	254	255	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1429	1431		10.1126/science.7660126	http://dx.doi.org/10.1126/science.7660126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660126				2022-12-01	WOS:A1995RT80600047
J	FLINT, J; CORLEY, R; DEFRIES, JC; FULKER, DW; GRAY, JA; MILLER, S; COLLINS, AC				FLINT, J; CORLEY, R; DEFRIES, JC; FULKER, DW; GRAY, JA; MILLER, S; COLLINS, AC			A SIMPLE GENETIC-BASIS FOR A COMPLEX PSYCHOLOGICAL TRAIT IN LABORATORY MICE	SCIENCE			English	Article							ELEVATED PLUS-MAZE; ANXIETY; RAT; BEHAVIOR; DISORDER; LINKAGE	Psychological traits are commonly inferred from covariation in sets of behavioral measures that otherwise appear to have little in common. Emotionality in mice is such a trait, defined here by covariation in activity and defecation in a novel environment and emergence into the open arms of an elevated plus maze. Behavioral and quantitative trait analyses were conducted on four measures obtained from 879 mice from an F-2 intercross. Three loci, on murine chromosomes 1, 12, and 15, were mapped that influence emotionality. This trait, inferred from studies of strain, sex, and individual differences in rodents, may be related to human susceptibility to anxiety or neuroticism.	UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of Colorado System; University of Colorado Boulder; University of London; King's College London	FLINT, J (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Flint, Jonathan/0000-0002-9427-4429	NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000197] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-05131, DA-00197] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; BROADHURST PL, 1960, EXPT PERSONALITY, V1, P3; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; Castle W E, 1921, Science, V54, P223, DOI 10.1126/science.54.1393.223; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEFRIES JC, 1978, BEHAV GENET, V8, P3, DOI 10.1007/BF01067700; DeFries JC, 1970, CONTRIBUTIONS BEHAVI, P23; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FANSELOW MS, 1991, MIDBRAIN PERIACQUEDU; GOLDSTEIN RB, 1994, ARCH GEN PSYCHIAT, V51, P383; GRAEFF FG, 1993, REV NEUROSCIENCE, V4, P181; Gray J.A., 1987, PSYCHOL FEAR STRESS, V2nd, P422; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREEN S, 1990, BEHAVIOURAL MODELS P; Hall CS, 1936, J COMP PSYCHOL, V22, P345, DOI 10.1037/h0059253; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P952; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P716; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LeDoux J E, 1992, Curr Opin Neurobiol, V2, P191, DOI 10.1016/0959-4388(92)90011-9; LINCOLN S, 1992, MAPPING GENES CONTRO; LIPP HP, 1989, EXPERIENTIA, V45, P845, DOI 10.1007/BF01954059; MAIER W, 1994, ARCH GEN PSYCHIAT, V51, P871; McGuffin P., 1994, SEMINARS PSYCHIATRIC; Montgomery KM, 1958, J COMP PHYSIOL PSYCH, V48, P254; Ott J., 1991, ANAL HUMAN GENETIC L; PANKSEPP J, 1982, BEHAV BRAIN SCI, V5, P407, DOI 10.1017/S0140525X00012759; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PAULS DL, 1993, NAT GENET, V3, P4, DOI 10.1038/ng0193-4; PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Plomin R, 1991, J Psychopharmacol, V5, P1, DOI 10.1177/026988119100500102; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; REDMOND DE, 1985, ANXIETY ANXIETY DISO, P530; TAYLOR MA, 1992, AM J PSYCHIAT, V149, P22; Wright S., 1968, EVOLUTION GENETICS P, V1; 1982, NEROPSYCHOLOGY ANXIE	41	327	334	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1432	1435		10.1126/science.7660127	http://dx.doi.org/10.1126/science.7660127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RT806	7660127				2022-12-01	WOS:A1995RT80600048
J	GREENWELL, PW; KRONMAL, SL; PORTER, SE; GASSENHUBER, J; OBERMAIER, B; PETES, TD				GREENWELL, PW; KRONMAL, SL; PORTER, SE; GASSENHUBER, J; OBERMAIER, B; PETES, TD			TEL1, A GENE INVOLVED IN CONTROLLING TELOMERE LENGTH IN SACCHAROMYCES-CEREVISIAE, IS HOMOLOGOUS TO THE HUMAN ATAXIA-TELANGIECTASIA GENE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; SCHIZOSACCHAROMYCES-POMBE; SHUTTLE VECTORS; DNA-REPAIR; YEAST; RECOVERY; MUTANTS; VPS34	Yeast chromosomes terminate in tracts of simple repetitive DNA (poly[G(1-3)T]). Mutations in the gene TEL1 result in shortened telomeres. Sequence analysis of TEL1 indicates that it encodes a very large (322 kDa) protein with amio acid motifs found in phosphatidylinositol/protein kinases. The closest homolog to TEL1 is the human ataxia telangiectasia gene.	UNIV N CAROLINA, CURRICULUM GENET & CELL BIOL, CHAPEL HILL, NC 27599 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MUNICH, INST BIOCHEM, D-81375 MUNICH, GERMANY	University of North Carolina; University of North Carolina Chapel Hill; University of Chicago; University of Munich	GREENWELL, PW (corresponding author), UNIV N CAROLINA, DEPT BIOL, CB 3280, CHAPEL HILL, NC 27599 USA.			Gassenhuber, johann/0000-0001-5338-8238	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024110] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24110, GM52319] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Guthrie C, 1991, GUIDE YEAST GENETICS; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; LUSTIG AJ, 1993, GENOME ANAL, V7, P79; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA RK, 1995, CYTOGENET CELL GENET, V71, P86; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STACK JH, 1994, J BIOL CHEM, V269, P31552; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	46	352	362	1	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					823	829		10.1016/0092-8674(95)90479-4	http://dx.doi.org/10.1016/0092-8674(95)90479-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671310	Bronze			2022-12-01	WOS:A1995RU75500017
J	HARI, KL; SANTERRE, A; SEKELSKY, JJ; MCKIM, KS; BOYD, JB; HAWLEY, RS				HARI, KL; SANTERRE, A; SEKELSKY, JJ; MCKIM, KS; BOYD, JB; HAWLEY, RS			THE MEI-41 GENE OF DROSOPHILA-MELANOGASTER IS A STRUCTURAL AND FUNCTIONAL HOMOLOG OF THE HUMAN ATAXIA-TELANGIECTASIA GENE	CELL			English	Article							CELL-CYCLE CHECKPOINT; X-LINKED MUTANTS; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; DNA DAMAGE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-ABERRATIONS; CHROMATID INTERCHANGES; SOMATIC-CELLS	The D. melanogaster mei-41 gene is required for DNA repair, mitotic chromosome stability, and normal levels of meiotic recombination in oocytes. Here we show that the predicted mei-41 protein is similar in sequence to the ATM (ataxia telangiectasia) protein from humans and to the yeast rad3 and Mec1p proteins. There is also extensive functional overlap between mei-41 and ATM. Like ATM-deficient cells, mei-41 cells are exquisitely sensitive to ionizing radiation and display high levels of mitotic chromosome instability. We also demonstrate that mei-41 cells, like ATM-deficient cells, fail to show an irradiation-induced delay in the entry into mitosis that is characteristic of normal cells. Thus, the mei-41 gene of Drosophila may be considered to be a functional homolog of the human ATM gene.			HARI, KL (corresponding author), UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Sekelsky, Jeff/0000-0002-4424-677X; Hawley, R. Scott/0000-0002-6478-0494				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P1; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1976, P NATL ACAD SCI USA, V73, P4140, DOI 10.1073/pnas.73.11.4140; BAKER BS, 1978, GENETICS, V90, P531; BAKER BS, 1972, GENETICS, V71, P255; Baker BS, 1976, GENETICS BIOL DROS B, P351; BANGA SS, 1986, MUTAT RES, V163, P157, DOI 10.1016/0027-5107(86)90044-8; BANGA SS, 1995, MOL GEN GENET, V246, P148, DOI 10.1007/BF00294677; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BOYD JB, 1976, GENETICS, V84, P485; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALVI BR, 1994, EMBO J, V13, P1636, DOI 10.1002/j.1460-2075.1994.tb06427.x; CARPENTER AT, 1974, GENETICS, V76, P453; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIEDBERG EC, 1995, DNA REPAIR; GATTI M, 1980, P NATL ACAD SCI-BIOL, V77, P1575, DOI 10.1073/pnas.77.3.1575; GATTI M, 1974, GENETICS, V77, P701; GATTI M, 1979, P NATL ACAD SCI USA, V76, P1377, DOI 10.1073/pnas.76.3.1377; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWLEY RS, 1989, ANNU REV GENET, V23, P87, DOI 10.1146/annurev.genet.23.1.87; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NGUYEN TD, 1979, MUTAT RES, V63, P67, DOI 10.1016/0027-5107(79)90104-0; PIMPINELLI S, 1976, MUTAT RES, V35, P101, DOI 10.1016/0027-5107(76)90172-X; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YAMAMOTO AH, 1990, MUTAT RES, V29, P17	47	248	259	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					815	821		10.1016/0092-8674(95)90478-6	http://dx.doi.org/10.1016/0092-8674(95)90478-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671309	Bronze			2022-12-01	WOS:A1995RU75500016
J	HARTLEY, KO; GELL, D; SMITH, GCM; ZHANG, H; DIVECHA, N; CONNELLY, MA; ADMON, A; LEESMILLER, SP; ANDERSON, CW; JACKSON, SP				HARTLEY, KO; GELL, D; SMITH, GCM; ZHANG, H; DIVECHA, N; CONNELLY, MA; ADMON, A; LEESMILLER, SP; ANDERSON, CW; JACKSON, SP			DNA-DEPENDENT PROTEIN-KINASE CATALYTIC SUBUNIT - A RELATIVE OF PHOSPHATIDYLINOSITOL 3-KINASE AND THE ATAXIA-TELANGIECTASIA GENE-PRODUCT	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; KU-AUTOANTIGEN; PHOSPHORYLATION; ANTIGEN; REPAIR	DNA-dependent protein kinase (DNA-PK), which is involved in DNA double-stranded break repair and V(D)J recombination, comprises a DNA-targeting component called Ku and an similar to 460 kDa catalytic subunit, DNA-PKcs. Here, we describe the cloning of the DNA-PKcs cDNA and show that DNA-PKcs falls into the phosphatidylinositol (PI) 3-kinase family. Biochemical assays, however, indicate that DNA-PK phosphorylates proteins but has no detectable activity toward lipids, Strikingly, DNA-PKcs is most similar to PI kinase family members involved in cell cycle control, DNA repair, and DNA damage responses. These include the FKBP12-rapamycin-binding proteins Tor1p, Tor2p, and FRAP, S. pombe rad3, and the product of the ataxia telangiectasia gene, mutations in which lead to genomic instability and predisposition to cancer. The relationship of these proteins to DNA-PKcs provides important clues to their mechanisms of action.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; BABRAHAM INST,INOSITIDE LAB,CAMBRIDGE CB2 4AT,ENGLAND; TECHNION ISRAEL INST TECHNOL,IL-32000 HAIFA,ISRAEL	University of Cambridge; United States Department of Energy (DOE); Brookhaven National Laboratory; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Technion Israel Institute of Technology	HARTLEY, KO (corresponding author), UNIV CAMBRIDGE,WELCOME TRUST,CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Lees-Miller, Susan/0000-0001-5809-2516; Gell, David/0000-0003-0382-1181; Admon, Arie/0000-0003-0504-3950; divecha, nullin/0000-0001-9695-6039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, IN PRESS TRENDS BIOC; JEGGO PA, 1995, IN PRESS BIOESSAYS; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	34	668	692	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					849	856		10.1016/0092-8674(95)90482-4	http://dx.doi.org/10.1016/0092-8674(95)90482-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671312	Bronze			2022-12-01	WOS:A1995RU75500020
J	HONG, CC; HASHIMOTO, C				HONG, CC; HASHIMOTO, C			AN UNUSUAL MOSAIC PROTEIN WITH A PROTEASE DOMAIN, ENCODED BY THE NUDEL GENE, IS INVOLVED IN DEFINING EMBRYONIC DORSOVENTRAL POLARITY IN DROSOPHILA	CELL			English	Article							DORSAL-VENTRAL PATTERN; SERINE PROTEASE; BLOOD-COAGULATION; MESSENGER-RNA; LDL-RECEPTOR; MELANOGASTER; SEQUENCE; LOCALIZATION; ACTIVATION; ZYMOGEN	Dorsoventral polarity of the Drosophila embryo is induced by a ventral extracellular signal, which is produced by a locally activated protease cascade within the extraembryonic perivitelline compartment. Local activation of the protease cascade depends on a positional cue that is laid down during oogenesis outside the oocyte. Here we present evidence that the nudel gene encodes an essential component of this cue. The nudel gene, which is expressed in follicle cells covering the oocyte, encodes an unusual mosaic protein resembling an extracellular matrix protein with a central serine protease domain. Our findings suggest that embryonic dorsoventral polarity is defined by a positional cue that requires the nudel protein to anchor and to trigger the protease cascade producing the polarity-inducing signal.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University	HONG, CC (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520, USA.		Hong, Charles/C-9989-2010		NICHD NIH HHS [HD-07149] Funding Source: Medline; NIGMS NIH HHS [GM-49370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049370] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; FARGNOLI J, 1982, DEV BIOL, V92, P306, DOI 10.1016/0012-1606(82)90177-4; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GEHRING WJ, 1984, EMBO J, V3, P2077, DOI 10.1002/j.1460-2075.1984.tb02094.x; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAWLEY RJ, 1988, GENE DEV, V2, P341, DOI 10.1101/gad.2.3.341; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; KAY MA, 1985, MOL CELL BIOL, V5, P3583, DOI 10.1128/MCB.5.12.3583; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Merle J., 1968, DROSOPHILA INFORMATI, V43, P122; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MORISATO D, 1995, IN PRESS ANN REV GEN, V29; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POPODI E, 1988, DEV BIOL, V127, P248, DOI 10.1016/0012-1606(88)90312-0; POWSNER J, 1935, PHYSIOL ZOOL, V8, P474; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERER LJ, 1988, DEV BIOL, V130, P786, DOI 10.1016/0012-1606(88)90367-3; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SMITH C, 1994, GENETICS, V136, P1355; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON D, 1992, CELL, V68, P201; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wieschaus E., 1986, P199; WIGGINS RC, 1979, J EXP MED, V150, P1122, DOI 10.1084/jem.150.5.1122; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	92	96	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					785	794		10.1016/0092-8674(95)90475-1	http://dx.doi.org/10.1016/0092-8674(95)90475-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671306	Bronze			2022-12-01	WOS:A1995RU75500013
J	KIBEL, A; ILIOPOULOS, O; DECAPRIO, JA; KAELIN, WG				KIBEL, A; ILIOPOULOS, O; DECAPRIO, JA; KAELIN, WG			BINDING OF THE VONHIPPEL-LINDAU TUMOR-SUPPRESSOR PROTEIN TO ELONGIN-B AND ELONGIN-C	SCIENCE			English	Article							GENE; IDENTIFICATION; SEQUENCE; PRODUCT	Germ-line mutations of the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of human tumors, and somatic mutations of this gene have been identified in sporadic renal cell carcinomas and cerebellar hemangioblastomas. Two transcriptional elongation factors, Elongin B and C, were shown to bind in vitro and in vivo to a short, colinear region of the VHL protein (pVHL) that is frequently mutated in human tumors. A peptide replica of this region inhibited binding of pVHL to Elongin B and C, whereas a point-mutant derivative, corresponding to a naturally occurring VHL missense mutation, had no effect. These results suggest that the tumor suppression function of pVHL may be linked to its ability to bind to Elongin B and C.	CHILDRENS HOSP, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute								ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GARRETT KP, 1994, GENE, V150, P413, DOI 10.1016/0378-1119(94)90467-7; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, UNPUB; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; McKusick V.A., 1992, MENDELIAN INHERITANC; SHUIN T, 1994, CANCER RES, V54, P2852; WHALEY JM, 1994, AM J HUM GENET, V55, P1092	25	546	567	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1444	1446		10.1126/science.7660130	http://dx.doi.org/10.1126/science.7660130			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660130				2022-12-01	WOS:A1995RT80600051
J	KIM, J; IRVINE, KD; CARROLL, SB				KIM, J; IRVINE, KD; CARROLL, SB			CELL RECOGNITION, SIGNAL INDUCTION, AND SYMMETRICAL GENE ACTIVATION AT THE DORSAL-VENTRAL BOUNDARY OF THE DEVELOPING DROSOPHILA WING	CELL			English	Article							IMAGINAL DISK; ENCODES; SERRATE	Appendage formation in insects and vertebrates depends upon signals from both the anterior-posterior and dorsal-ventral (DV) axes. In Drosophila, wing formation is organized symmetrically around the DV boundary of the growing wing imaginal disc and requires interactions between dorsal and ventral cells. Compartmentalization of the wing disc, dorsal cell behavior, and the expression of two dorsally expressed putative signaling molecules, fringe (fng) and Serrate (Ser), are regulated by the apterous selector gene. Here, we demonstrate that fng and Ser have distinct roles in a novel cell recognition and signal induction process. fng serves as a boundary-determining molecule such that Ser is induced wherever cells expressing fng and cells not expressing fng are juxtaposed. Ser in turn triggers the expression of genes involved in wing growth and patterning on both sides of the DV boundary.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	KIM, J (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, HOWARD HUGHES MED INST, MADISON, WI 53706 USA.				NICHD NIH HHS [5R01-HD22780] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; HIZN U, 1994, CELL, V76, P77; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANICOLA M, 1995, GENETICS, V139, P745; SPREICHER S, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; TIONG SYK, 1995, DEVELOPMENT, V121, P1649; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	39	243	245	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					795	802		10.1016/0092-8674(95)90476-X	http://dx.doi.org/10.1016/0092-8674(95)90476-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671307	Bronze			2022-12-01	WOS:A1995RU75500014
J	KUHN, R; SCHWENK, F; AGUET, M; RAJEWSKY, K				KUHN, R; SCHWENK, F; AGUET, M; RAJEWSKY, K			INDUCIBLE GENE TARGETING IN MICE	SCIENCE			English	Article							INVIVO EXPRESSION; MX GENE; INTERFERON; RECOMBINATION; BACTERIOPHAGE-P1; CELLS; VIRUS	A method of gene targeting that allows the inducible inactivation of a target gene in mice is presented. The method uses an interferon-responsive promoter to control the expression of Cre recombinase, Here, Cre was used to delete a segment of the DNA polymerase beta gene flanked by loxP recombinase recognition sites. Deletion was complete in liver and nearly complete in lymphocytes within a few days, whereas partial deletion was obtained in other tissues. This method can be used for the inducible inactivation of any other gene in vivo.	UNIV ZURICH, INST MOLEC BIOL 1, CH-8093 ZURICH, SWITZERLAND	University of Zurich	KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Rajewsky, Klaus/0000-0002-6633-6370				ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHANG KC, 1990, ARCH VIROL, V110, P151, DOI 10.1007/BF01311285; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; de Clercq E, 1980, Antibiot Chemother (1971), V27, P251; DOUGHERTY TF, 1952, PHYSIOL REV, V32, P379, DOI 10.1152/physrev.1952.32.4.379; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; GRESSER I, 1977, CELL IMMUNOL, V34, P406, DOI 10.1016/0008-8749(77)90262-3; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KUHN R, UNPUB; LOHLER J, UNPUB; MELTON DW, 1994, BIOESSAYS, V16, P633, DOI 10.1002/bies.950160907; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STAEHELI P, 1986, MOL CELL BIOL, V6, P4770, DOI 10.1128/MCB.6.12.4770; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	21	1483	1550	1	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1427	1429		10.1126/science.7660125	http://dx.doi.org/10.1126/science.7660125			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660125				2022-12-01	WOS:A1995RT80600046
J	LEVIN, M; JOHNSON, RL; STERN, CD; KUEHN, M; TABIN, C				LEVIN, M; JOHNSON, RL; STERN, CD; KUEHN, M; TABIN, C			A MOLECULAR PATHWAY DETERMINING LEFT-RIGHT ASYMMETRY IN CHICK EMBRYOGENESIS	CELL			English	Article							AXIAL STRUCTURES; BODY ASYMMETRY; EMBRYO; PATTERN; ACTIVIN; BLASTODERM; EXPRESSION; INDUCTION; MUTATION; HEART	While significant progress has been made in understanding the molecular events underlying the early specification of the antero-posterior and dorso-ventral axes, little information is available regarding the cellular or molecular basis for left-right (LR) differences in animal morphogenesis. We describe the expression patterns of three genes involved in LR determination in chick embryos: activin receptor IIa, Sonic hedgehog (Shh), and cNR-1 (related to the mouse gene nodal). These genes are expressed asymmetrically during and after gastrulation and regulate the expression of one another in a sequential pathway. Moreover, manipulation of the sidedness of either activin protein or Shh expression alters heart situs. Together, these observations identify a cascade of molecular asymmetry that determines morphological LR asymmetry in the chick embryo.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NIH,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	Columbia University; National Institutes of Health (NIH) - USA	LEVIN, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008; Levin, Michael/A-5918-2011; Kuehn, Michael R/A-4573-2014	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X; Levin, Michael/0000-0001-7292-8084; Kuehn, Michael R/0000-0002-7703-9160				BROWN NA, 1991, CIBA F SYMP, V162, P182; CONLON FL, 1994, DEVELOPMENT, V120, P1919; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; DANOS MC, 1995, DEVELOPMENT, V121, P1467; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELDER FF, 1993, SCIENCE, V260, P679; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; FUJINAGA M, 1991, DEV BIOL, V143, P203, DOI 10.1016/0012-1606(91)90067-D; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, ORG MILESTONE HALF C, P221; HOYLE C, 1992, DEVELOPMENT, V115, P1071; Hummel K. P., 1959, Journal of Heredity, V50, P9; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cellbio.8.1.227; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KAUFMAN MH, 1981, J ANAT, V133, P235; KINOSHITA K, 1993, DEV BIOL, V160, P276, DOI 10.1006/dbio.1993.1305; KLAR AJS, 1994, TRENDS GENET, V10, P292; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAYTON WM, 1993, TERATOLOGY, V47, P595, DOI 10.1002/tera.1420470611; MCCAIN ER, 1994, DEVELOPMENT, V120, P395; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSLINK H, 1994, CELL, V76, P761; SALAZAR DEL RIO J, 1974, Journal of Embryology and Experimental Morphology, V31, P199; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHREINER CM, 1993, DEV BIOL, V158, P560, DOI 10.1006/dbio.1993.1214; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; STALSBER.H, 1969, DEV BIOL, V19, P109, DOI 10.1016/0012-1606(69)90051-7; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; Stern CD, 1993, ESSENTIAL DEV BIOL P; STERN CD, 1995, IN PRESS DEV BIOL; STOREY KG, 1992, DEVELOPMENT, V114, P729; STREIT A, 1994, TRENDS GENET, V10, P181, DOI 10.1016/0168-9525(94)90240-2; TOYAMA R, 1995, DEVELOPMENT, V121, P383; VIRAGH S, 1989, J MOL CELL CARDIOL, V21, P123, DOI 10.1016/0022-2828(89)90856-0; Waddington CH, 1933, J EXP BIOL, V10, P38; WADDINGTON CH, 1932, PHILOS T ROY SOC B, V13, P221; Wilhelmi H, 1921, ARCH ENTWICKLUNG ORG, V48, P517, DOI 10.1007/BF02554577; YOKOTA C, 1995, BIOCHEM BIOPH RES CO, V207, P1, DOI 10.1006/bbrc.1995.1144; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0; ZIV T, 1992, DEVELOPMENT, V115, P689	53	635	653	0	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					803	814		10.1016/0092-8674(95)90477-8	http://dx.doi.org/10.1016/0092-8674(95)90477-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671308	Bronze			2022-12-01	WOS:A1995RU75500015
J	MOL, CD; ARVAI, AS; SANDERSON, RJ; SLUPPHAUG, G; KAVLI, B; KROKAN, HE; MOSBAUGH, DW; TAINER, JA				MOL, CD; ARVAI, AS; SANDERSON, RJ; SLUPPHAUG, G; KAVLI, B; KROKAN, HE; MOSBAUGH, DW; TAINER, JA			CRYSTAL-STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE IN COMPLEX WITH A PROTEIN INHIBITOR - PROTEIN MIMICRY OF DNA	CELL			English	Article							BACTERIOPHAGE-PBS2; DEAMINATION; GENE	Uracil-DNA glycosylase inhibitor (Ugi) is a B. subtilis bacteriophage protein that protects the uracil-containing phage DNA by irreversibly inhibiting the key DNA repair enzyme uracil-DNA glycosylase (UDG). The 1.9 Angstrom crystal structure of Ugi complexed to human UDG reveals that the Ugi structure, consisting of a twisted five-stranded antiparallel beta sheet and two alpha helices, binds by inserting a beta strand into the conserved DNA-binding groove of the enzyme without contacting the uracil specificity pocket, The resulting interface, which buries over 1200 Angstrom(2) on Ugi and involves the entire beta sheet and an alpha helix, is polar and contains 22 water molecules. Ugi binds the sequence-conserved DNA-binding groove of UDG via shape and electrostatic complementarity, specific charged hydrogen bonds, and hydrophobic packing enveloping Leu-272 from a protruding UDG loop. The apparent mimicry by Ugi of DNA interactions with UDG provides both a structural mechanism for UDG binding to DNA, including the enzyme-assisted expulsion of uracil from the DNA helix, and a crystallographic basis for the design of inhibitors with scientific and therapeutic applications.	OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, CTR ENVIRONM HLTH SCI, CORVALLIS, OR 97331 USA; UNIV TRONDHEIM, UNIGEN CTR MOLEC BIOL, N-7005 TRONDHEIM, NORWAY	Oregon State University; Oregon State University; Oregon State University	MOL, CD (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES BLVD, LA JOLLA, CA 92037 USA.		Tainer, John/GWQ-4878-2022; Slupphaug, Geir/AAN-3794-2020	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312, R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823, GM46312] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHARDSON JS, 1989, PREDICTION PROTEIN S, P2; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VERRI A, 1992, BIOCHEM J, V287, P1007, DOI 10.1042/bj2871007; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31	33	234	252	1	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					701	708		10.1016/0092-8674(95)90467-0	http://dx.doi.org/10.1016/0092-8674(95)90467-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671300	Bronze			2022-12-01	WOS:A1995RU75500005
J	MORROW, DM; MORROW, M; TAGLE, DA; SHILOH, Y; COLLINS, FS; HIETER, P				MORROW, DM; MORROW, M; TAGLE, DA; SHILOH, Y; COLLINS, FS; HIETER, P			TEL1, AN SACCHAROMYCES-CEREVISIAE HOMOLOG OF THE HUMAN GENE MUTATED IN ATAXIA-TELANGIECTASIA, IS FUNCTIONALLY RELATED TO THE YEAST CHECKPOINT GENE MEC1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; RADIATION SENSITIVITY; PROTEIN; CELLS; CANCER; DNA; RAPAMYCIN; VPS34; IDENTIFICATION	Patients with the genetic disorder ataxia telangiectasia (AT) have mutations in the AT mutated (ATM) gene, which is homologous to TEL1 and the checkpoint gene MEC1. A tel1 deletion mutant, unlike a mec1 deletion, is viable and does not exhibit increased sensitivity to DNA-damaging agents. However, increased dosage of TEL1 rescues sensitivity of a mec1 mutant, mec1-1, to DNA-damaging agents and rescues viability of a mec1 disruption. mec1-1 tel1 Delta 1 double mutants are synergistically sensitive to DNA-damaging agents, including radiomimetic drugs. These data indicate that TEL1 and MEC1 are functionally related and that functions of the ATM gene are apparently divided between at least two S. cerevisiae homologs.	NIH,NATL CTR HUMAN GENOME RES,GENE TRANSFER LAB,BETHESDA,MD 20892; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tel Aviv University; Sackler Faculty of Medicine	MORROW, DM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.				NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline; NIGMS NIH HHS [GM162283] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1984, MOL GEN GENET, V197, P3445; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDBERG EC, 1995, DNA REPAIR; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEHMANN AR, 1979, NUCLEIC ACIDS RES, V6, P1953, DOI 10.1093/nar/6.5.1953; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; PAINTER RB, 1982, MECHANISMS CHEM CARC; PAINTER RB, 1985, ATAXIA TELANGIECTASI; PANDITA TK, 1995, IN PRESS CYTOGENET C; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REENAN RAG, 1992, GENETICS, V132, P963; ROSE MD, 1990, METHODS YEAST GENETI; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIKORSKI RS, 1989, GENETICS, V122, P19; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TAYLOR AMR, 1983, CANCER RES, V43, P2700; TAYLOR AMR, 1979, CANCER RES, V39, P1046; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	48	336	343	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					831	840		10.1016/0092-8674(95)90480-8	http://dx.doi.org/10.1016/0092-8674(95)90480-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545545	hybrid			2022-12-01	WOS:A1995RU75500018
J	NEWMAN, LS; MCKEEVER, MO; OKANO, HJ; DARNELL, RB				NEWMAN, LS; MCKEEVER, MO; OKANO, HJ; DARNELL, RB			BETA-NAP, A CEREBELLAR DEGENERATION ANTIGEN, IS A NEURON-SPECIFIC VESICLE COAT PROTEIN	CELL			English	Article							STIFF-MAN SYNDROME; TRANSMITTER RELEASE; SYNAPTIC VESICLES; MEMBRANE-PROTEINS; BREAST-CANCER; CLATHRIN; SYNAPTOTAGMIN; COMPLEX; CELLS; PHOSPHORYLATION	We have identified a target antigen in autoimmune cerebellar degeneration, beta-NAP, that is closely related to the beta-adaptin and beta-COP coat proteins. beta-NAP is a non-clathrin-associated phosphoprotein expressed exclusively in neurons, from E12 through adulthood. beta-NAP is present in the neuronal soma and nerve terminal as soluble and membrane-bound pools and is associated with a discrete set of nerve-terminal vesicles. These results establish beta-NAP as a neuron-specific vesicle coat protein. We propose a model in which beta-NAP mediates vesicle transport between the soma and the axon terminus and suggest that beta-NAP may represent a general class of coat proteins that mediates apical transport in polarized cells.			NEWMAN, LS (corresponding author), ROCKEFELLER UNIV, NEUROONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088; Okano, Hirotaka James/0000-0003-4611-7098	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001461] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM07739] Funding Source: Medline; NINDS NIH HHS [K08 NS01461] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CAMIDGE DR, 1994, J CELL SCI, V107, P709; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DARNELL RB, 1993, NEUROLOGY, V43, P114, DOI 10.1212/WNL.43.1_Part_1.114; DARNELL RB, 1991, J NEUROSCI, V11, P1224, DOI 10.1523/jneurosci.11-05-01224.1991; DARNELL RB, 1994, CURRENT DIAGNOSIS NE, P137; DAVLETOV B, 1993, J BIOL CHEM, V268, P6816; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; GIBBS RB, 1994, J COMP NEUROL, V341, P324, DOI 10.1002/cne.903410304; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HOWARD FM, 1963, MAYO CLIN PROC, V38, P203; HURTLEY SM, 1993, TRENDS BIOCHEM SCI, V18, P453, DOI 10.1016/0968-0004(93)90001-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IKONEN E, 1993, CURR BIOL, V3, P635, DOI 10.1016/0960-9822(93)90061-R; JACOBSON M, 1991, DEV DEV NEUROBIOLOGY, P252; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, J BIOL CHEM, V269, P21043; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARTINMOUTOT N, 1993, J PHYSIOLOGY-PARIS, V87, P37, DOI 10.1016/0928-4257(93)90022-L; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEVSNER J, 1994, IN PRESS GENE; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; POSNER JB, 1990, RES P ARNMD, V68, P187; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cellbio.8.1.395; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1993, NATURE, V366, P15, DOI 10.1038/366015a0; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	63	132	133	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					773	783		10.1016/0092-8674(95)90474-3	http://dx.doi.org/10.1016/0092-8674(95)90474-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671305	Bronze			2022-12-01	WOS:A1995RU75500012
J	PAULOVICH, AG; HARTWELL, LH				PAULOVICH, AG; HARTWELL, LH			A CHECKPOINT REGULATES THE RATE OF PROGRESSION THROUGH S-PHASE IN SACCHAROMYCES-CEREVISIAE IN RESPONSE TO DNA-DAMAGE	CELL			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; REPAIR; ARREST; GENE; RECOMBINATION; TRANSCRIPTION; REPLICATION	We demonstrate that in S. cerevisiae the rate of ongoing S phase is slowed when the DNA is subjected to alkylation. Slowing of replication is dependent on the MEC1 and RAD53 genes, indicating that lesions alone do not slow replication in vivo and that the slowing is an active process. While it has been shown that a MEC1- and RAD53-dependent checkpoint responds to blocked replication or DNA damage by inhibiting the onset of mitosis, we demonstrate that this checkpoint must also have an additional target within S phase that controls replication rate. MEC1 is a homolog of the human ATM gene, which is mutated in ataxia telangiectasia (AT) patients. Like mec1 yeast, AT cells are characterized by damage-resistant DNA synthesis, highlighting the congruence of the yeast and mammalian systems.			PAULOVICH, AG (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.							Allen JB, 1994, GENE DEV, V8, P2416; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRUNBORG G, 1980, RADIAT RES, V82, P547, DOI 10.2307/3575321; BRUNBORG G, 1978, MOL GEN GENET, V182, P277; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KADYK LC, 1993, GENETICS, V133, P469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LEADON SA, 1992, J BIOL CHEM, V267, P23175; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1993, CURR OPIN GENET DEV, V5, P5; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PAULES RS, 1995, CANCER RES, V55, P1763; PETES TD, 1973, BIOCHEM BIOPH RES CO, V55, P603, DOI 10.1016/0006-291X(73)91186-8; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SINGER B, 1983, MOL BIOL MUTAGENS CA, P68; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; ZAMPETTIBOSSELE.F, 1981, INT J RADIAT BIOL, V39, P547	40	531	537	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					841	847		10.1016/0092-8674(95)90481-6	http://dx.doi.org/10.1016/0092-8674(95)90481-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671311	Bronze			2022-12-01	WOS:A1995RU75500019
J	POWERS, T; WALTER, P				POWERS, T; WALTER, P			RECIPROCAL STIMULATION OF GTP HYDROLYSIS BY 2 DIRECTLY INTERACTING GTPASES	SCIENCE			English	Article							SIGNAL RECOGNITION PARTICLE; ELONGATION FACTOR-TU; 4.5S RNA; RIBONUCLEOPROTEIN; SUBUNIT; MODEL	The Escherichia coli guanosine triphosphate (GTP)-binding proteins Ffh and FtsY have been proposed to catalyze the cotranslational targeting of proteins to the bacterial plasma membrane. A mutation was introduced into the GTP-binding domain of FtsY that altered its nucleotide specificity from GTP to xanthosine triphosphate (XTP). The mutant FtsY protein stimulated GTP hydrolysis by a ribonucleoprotein consisting of Ffh and 4.5S RNA in a reaction that required XTP, and it hydrolyzed XTP in a reaction that required both the Ffh-4.5S ribonucleoprotein and GTP. Thus, nucleotide triphosphate hydrolysis by Ffh and FtsY is likely to occur in reciprocally coupled reactions in which the two interacting guanosine triphosphatases act as regulatory proteins for each other.			POWERS, T (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HWANG YW, 1987, J BIOL CHEM, V262, P13081; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P482; SEGEL IH, 1975, ENZYME; SEGEL IH, COMMUNICATION; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	21	181	182	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1422	1424		10.1126/science.7660124	http://dx.doi.org/10.1126/science.7660124			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660124				2022-12-01	WOS:A1995RT80600044
J	ROTHE, M; SARMA, V; DIXIT, VW; GOEDDEL, DV				ROTHE, M; SARMA, V; DIXIT, VW; GOEDDEL, DV			TRAF2-MEDIATED ACTIVATION OF NF-KAPPA-B BY TNF RECEPTOR-2 AND CD40	SCIENCE			English	Article							NECROSIS-FACTOR RECEPTORS	TNF receptor-associated factor (TRAF) proteins are candidate signal transducers that associate with the cytoplasmic domains of members of the tumor necrosis factor (TNF) receptor superfamily. The role of TRAFs in the TNF-R2 and CD40 signal transduction pathways, which result in the activation of transcription factor NF-kappa B, was investigated. Overexpression of TRAF2, but not TRAF1 or TRAF3, was sufficient to induce NF-kappa B activation. A truncated derivative of TRAF2 lacking an amino-terminal RING finger domain was a dominant-negative inhibitor of NF-kappa B activation mediated by TNF-R2 and CD40. Thus, TRAF2 is a common mediator of TNF-R2 and CD40 signaling.	TULARIK INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 2002, SHORT PROTOCOLS MOL, V5th; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHANG G, 1995, SCIENCE, V267, P1494; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hsu H.-J., UNPUB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PENNICA D, 1992, J BIOL CHEM, V267, P21172; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHE M, UNPUB; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	24	947	982	1	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1424	1427		10.1126/science.7544915	http://dx.doi.org/10.1126/science.7544915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7544915				2022-12-01	WOS:A1995RT80600045
J	SAEZ, E; RUTBERG, SE; MUELLER, E; OPPENHEIM, H; SMOLUK, J; YUSPA, SH; SPIEGELMAN, BM				SAEZ, E; RUTBERG, SE; MUELLER, E; OPPENHEIM, H; SMOLUK, J; YUSPA, SH; SPIEGELMAN, BM			C-FOS IS REQUIRED FOR MALIGNANT PROGRESSION OF SKIN TUMORS	CELL			English	Article							MOUSE SKIN; TRANSGENIC MICE; GENE-EXPRESSION; CELL CARCINOMAS; PHORBOL ESTERS; RETINOIC ACID; NULL MUTATION; BENIGN-TUMORS; HUMAN-BREAST; JUN	The proto-oncogene c-fos is a major nuclear target for signal transduction pathways involved in the regulation of cell growth, differentiation, and transformation. Using the multistep skin carcinogenesis model, we have directly tested the ability of c-fos-deficient mice to develop cancer. Upon treatment with a tumor promoter, c-fos knockout mice carrying a v-H-ras transgene were able to develop benign tumors with similar kinetics and relative incidence as wild-type animals. However, c-fos-deficient papillomas quickly became very dry and hyperkeratinized, taking on an elongated, horny appearance. While wild-type papillomas eventually progressed into malignant tumors, c-fos-deficient tumors failed to undergo malignant conversion. Experiments in which v-H-ras-expressing keratinocytes were grafted onto nude mice suggest that c-fos-deficient cells have an intrinsic defect that hinders tumorigenesis. These results demonstrate that a member of the AP-1 family of transcription factors is required for the development of a malignant tumor.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SAEZ, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIUNNO I, 1988, BRIT J CANCER, V57, P464, DOI 10.1038/bjc.1988.108; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; BUCHMANN A, 1991, CANCER RES, V51, P4097; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DE LUCA LM, 1993, CARCINOGENESIS, V14, P539, DOI 10.1093/carcin/14.3.539; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; FISHER C, 1991, DEVELOPMENT, V11, P253; FRENCH JE, 1994, MOL CARCINOGEN, V11, P215, DOI 10.1002/mc.2940110407; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HONOKI K, 1992, MOL CARCINOGEN, V6, P122, DOI 10.1002/mc.2940060207; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PAWELETZ N, 1994, CRIT REV ONCOGENESIS, V5, P69, DOI 10.1615/CritRevOncog.v5.i1.40; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STRAWHECKER JM, 1992, CARCINOGENESIS, V13, P2075, DOI 10.1093/carcin/13.11.2075; STRICKLAND JE, 1993, CARCINOGENESIS, V14, P205, DOI 10.1093/carcin/14.2.205; URABE A, 1992, J PATHOL, V168, P281, DOI 10.1002/path.1711680307; VOLM M, 1992, INT J ONCOL, V1, P69; WALKER RA, 1991, J PATHOL, V163, P323, DOI 10.1002/path.1711630409; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1976, CANCER RES, V36, P4062; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	60	322	332	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					721	732		10.1016/0092-8674(95)90469-7	http://dx.doi.org/10.1016/0092-8674(95)90469-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545543	Bronze			2022-12-01	WOS:A1995RU75500007
J	SCHNITZER, JE; MCINTOSH, DP; DVORAK, AM; LIU, J; OH, P				SCHNITZER, JE; MCINTOSH, DP; DVORAK, AM; LIU, J; OH, P			SEPARATION OF CAVEOLAE FROM ASSOCIATED MICRODOMAINS OF GPI-ANCHORED PROTEINS	SCIENCE			English	Article							SIGNAL-TRANSDUCING MOLECULE; TRANS-GOLGI-NETWORK; T-CELL ACTIVATION; PLASMA-MEMBRANE; MDCK CELLS; EPITHELIAL-CELLS; TYROSINE KINASES; LINKED PROTEINS; PHOSPHATIDYLINOSITOL; RECEPTOR	In situ coating of the surface of endothelial cells in rat lung with cationic colloidal silica particles was used to separate caveolae from detergent-insoluble membranes rich in glycosyl phosphatidylinositol (GPI)-anchored proteins but devoid of caveolin. Immunogold electron microscopy showed that ganglioside G(M1)-enriched caveolae associated with an annular plasmalemmal domain enriched in GPI-anchored proteins. The purified caveolae contained molecular components required for regulated transport, including various lipid-anchored signaling molecules. Such specialized distinct microdomains may exist separately or together in the plasma membrane to organize signaling molecules and to process surface-bound ligands differentially.			SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL52766, HL43278] Funding Source: Medline; NIAID NIH HHS [AI33372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278, R01HL052766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANEY LK, 1983, J BIOL CHEM, V258, P62; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; DAVIS LS, 1988, J IMMUNOL, V141, P2246; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GARCIA M, 1993, J CELL SCI, V104, P1281; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; JACOBSON BS, 1992, EUR J CELL BIOL, V58, P296; KELLER EA, 1992, EMBO J, V3, P863; KORTY PE, 1991, J IMMUNOL, V146, P4092; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LETARTEMUIRHEAD M, 1974, BIOCHEM J, V143, P51, DOI 10.1042/bj1430051; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PATTON WF, 1990, ELECTROPHORESIS, V11, P79, DOI 10.1002/elps.1150110116; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; RYAN US, 1982, J APPL PHYSIOL, V53, P914, DOI 10.1152/jappl.1982.53.4.914; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1995, AM J PHYSIOL, V37, pH48; SCHNITZER JE, 1992, J BIOL CHEM, V264, P24544; SCHNITZER JE, UNPUB; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P21230; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.bb.14.060185.002045; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231; ZHANG F, 1991, J CELL BIOL, V115, P75, DOI 10.1083/jcb.115.1.75	61	439	449	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1435	1439		10.1126/science.7660128	http://dx.doi.org/10.1126/science.7660128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660128				2022-12-01	WOS:A1995RT80600049
J	VOGEL, KS; BRANNAN, CI; JENKINS, NA; COPELAND, NG; PARADA, LF				VOGEL, KS; BRANNAN, CI; JENKINS, NA; COPELAND, NG; PARADA, LF			LOSS OF NEUROFIBROMIN RESULTS IN NEUROTROPHIN-INDEPENDENT SURVIVAL OF EMBRYONIC SENSORY AND SYMPATHETIC NEURONS	CELL			English	Article							NERVE GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; TRK PROTOONCOGENE PRODUCT; DORSAL-ROOT-GANGLIA; TYPE-1 GENE; CAENORHABDITIS-ELEGANS; PROTEIN PRODUCT; TYROSINE KINASE; RAS P21; MOUSE	Mutations at the neurofibromatosis 1 (NF1) locus in humans and mice result in abnormal growth of neural crest-derived cells, including melanocytes and Schwann cells. We have exploited a targeted disruption of the NF1 gene in mice to examine the role of neurofibromin in the acquisition of neurotrophin dependence in embryonic neurons. We show that both neural crest- and placode-derived sensory neurons isolated from NF1 (-/-) embryos develop, extend neurites, and survive in the absence of neurotrophins, whereas their wild-type counterparts die rapidly unless nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) is added to the culture medium. Moreover, NF1 (-/-) sympathetic neurons survive for extended periods and acquire mature morphology in the presence of NGF-blocking antibodies. Our results are consistent with a model wherein neurofibromin acts as a negative regulator of neurotrophin-mediated signaling for survival of embryonic peripheral neurons.	NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	VOGEL, KS (corresponding author), UNIV TEXAS,SW MED CTR,CTR DEV BIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Parada, luis F/B-9400-2014		NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; DAVIES A, 1984, J COMP NEUROL, V223, P124, DOI 10.1002/cne.902230110; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DEDOUARIN NM, 1992, SENSORY NEURONS DIVE, P143; DICICCOBLOOM E, 1990, J CELL BIOL, V110, P2073, DOI 10.1083/jcb.110.6.2073; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ERNSBERGER U, 1988, DEV BIOL, V126, P420, DOI 10.1016/0012-1606(88)90151-0; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HAN M, 1990, GENETICS, V126, P899; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAWSON SN, 1979, J NEUROCYTOL, V8, P265, DOI 10.1007/BF01236122; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NG NFL, 1993, J BIOL CHEM, V268, P25329; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; ROHRER H, 1988, DEVELOPMENT, V103, P545; RUBIN E, 1985, J NEUROSCI, V5, P673; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THEILER K, 1989, HOUSE MOUSE; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; Vogel Kristine S., 1992, P171; VOGEL KS, 1991, NEURON, V7, P819, DOI 10.1016/0896-6273(91)90284-7; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weston J A, 1970, Adv Morphog, V8, P41; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	58	132	133	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					733	742		10.1016/0092-8674(95)90470-0	http://dx.doi.org/10.1016/0092-8674(95)90470-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671302	Bronze			2022-12-01	WOS:A1995RU75500008
J	BOGUSKI, MS				BOGUSKI, MS			HUNTING FOR GENES IN COMPUTER-DATA BASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											BOGUSKI, MS (corresponding author), NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,8600 ROCKVILLE PIKE,BETHESDA,MD 20894, USA.							BOGUSKI MS, 1994, CURRENT PROTOCOLS HU; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509	4	11	11	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					645	647		10.1056/NEJM199509073331008	http://dx.doi.org/10.1056/NEJM199509073331008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637727				2022-12-01	WOS:A1995RR84000008
J	BRUNS, D; JAHN, R				BRUNS, D; JAHN, R			REAL-TIME MEASUREMENT OF TRANSMITTER RELEASE FROM SINGLE SYNAPTIC VESICLES	NATURE			English	Article							IDENTIFIED LEECH NEURONS; NEUROTRANSMITTER RELEASE; CHROMAFFIN CELLS; TRANSMISSION; CULTURE; FUSION; SYNAPTOBREVIN; ACETYLCHOLINE; TETANUS	NEUROTRANSMITTER release is mediated by Ca2+ dependent exocytosis of synaptic vesicles', Neither the amount of transmitter released from individual synaptic vesicles nor the kinetics of this process have yet been directly determined, Using carbon fibres as electrochemical detectors(2,3), we have measured release of the neurotransmitter serotonin from cultured neurons of the leech(4). This technique allowed us to monitor transmitter discharge from single synaptic vesicles as spike-like oxidation currents at high time resolution, providing new insight into the mechanism of neuronal exocytosis, Two types of signals were characterized, corresponding to exocytosis of small clear and large dense core vesicles present in these cells, A small vesicle discharges about 4,700 transmitter molecules with a time constant in the region of 260 mu s, whereas large vesicles release their content of approximately 80,000 molecules with a time constant of about 1.3 ms, Release from both vesicle types is initiated rapidly, with a rise time of less than 60 mu s, suggesting an abrupt opening of a preassembled fusion pore.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University	BRUNS, D (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.			Jahn, Reinhard/0000-0003-1542-3498				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1989, SECRETION ITS CONTRO, P269; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARTFAI T, 1988, ANNU REV PHARMACOL, V28, P285, DOI 10.1146/annurev.pa.28.040188.001441; BEAUDET A, 1981, J PHYSIOLOGY PARIS, V77, P193; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FUCHS PA, 1982, J PHYSIOL-LONDON, V323, P195, DOI 10.1113/jphysiol.1982.sp014068; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENDERSON L, 1983, J PHYSL, V399, P309; HENDERSON LP, 1983, J PHYSIOL-LONDON, V340, P347, DOI 10.1113/jphysiol.1983.sp014766; KUFFLER DP, 1987, J COMP NEUROL, V256, P516, DOI 10.1002/cne.902560404; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WRONA MZ, 1990, BIOORG CHEM, V18, P291, DOI 10.1016/0045-2068(90)90005-P	21	337	344	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					62	65		10.1038/377062a0	http://dx.doi.org/10.1038/377062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659162				2022-12-01	WOS:A1995RT72500056
J	CALANDRA, T; BERNHAGEN, J; METZ, CN; SPIEGEL, LA; BACHER, M; DONNELLY, T; CERAMI, A; BUCALA, R				CALANDRA, T; BERNHAGEN, J; METZ, CN; SPIEGEL, LA; BACHER, M; DONNELLY, T; CERAMI, A; BUCALA, R			MIF AS A GLUCOCORTICOID-INDUCED MODULATOR OF CYTOKINE PRODUCTION	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL GROWTH-FACTOR; CACHECTIN; ENDOTOXIN; MICE; INTERLEUKIN-1; INHIBITION; PITUITARY; STRESS; SHOCK	GLUCOCORTICOID hormones are important for vital functions and act to modulate inflammatory and immune responses(1,2). Yet, in contrast to other hormonal systems, no endogenous mediators have been identified that can directly counter-regulate their potent anti-inflammatory and immunosuppressive properties. Recent investigations of the protein macrophage migration inhibitory factor (MIF), which was discovered originally to be a T-lymphocyte-derived factor(3,4), have established it to be a pro-inflammatory pituitary and macrophage cytokine and a critical mediator of septic shock(5-7), Here we report the unexpected finding that low concentrations of glucocorticoids induce rather than inhibit MIF production from macrophages. MIF then acts to override glucocorticoid-mediated inhibition of cytokine secretion by lipopolysaccharide (LPS)-stimulated monocytes acid to overcome glucocorticoid protection against lethal endotoxaemia. These observations identify a unique counter-regulatory system that functions to control inflammatory and immune responses.	PICOWER INST MED RES,MANHASSET,NY 11030	Northwell Health			Calandra, Thierry/D-9017-2015; Donnelly, Thomas M/C-2717-2009	Calandra, Thierry/0000-0003-3051-1285; Donnelly, Thomas M/0000-0002-4399-2287; Christine, Metz/0000-0002-1013-1691				ABERNATHY RS, 1957, J LAB CLIN MED, V49, P708; ARYA SK, 1984, J IMMUNOL, V133, P273; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BERRY LJ, 1964, J EXP MED, V120, P721, DOI 10.1084/jem.120.5.721; BERTINI R, 1988, J EXP MED, V167, P1708, DOI 10.1084/jem.167.5.1708; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; GARTNER K, 1980, LAB ANIM, V14, P267, DOI 10.1258/002367780780937454; GELLER P, 1954, P SOC EXP BIOL MED, V86, P716; GILLIS S, 1979, J IMMUNOL, V123, P1624; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOLDSTEIN RA, 1992, INFLAMMATION BASIC P, P1061; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEW W, 1988, J IMMUNOL, V140, P1895; MITCHELL R, 1995, J IMMUNOL, V154, P3863; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Orth DN KW., 1992, WILLIAMS TXB ENDOCRI, V8th Edition ed, P489; SILVERSTEIN R, 1991, J EXP MED, V173, P357, DOI 10.1084/jem.173.2.357; SPINK WW, 1954, J CLIN INVEST, V33, P540, DOI 10.1172/JCI102924; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; WEXLER BC, 1957, ENDOCRINOLOGY, V61, P300, DOI 10.1210/endo-61-3-300	25	988	1040	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					68	71		10.1038/377068a0	http://dx.doi.org/10.1038/377068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659164				2022-12-01	WOS:A1995RT72500058
J	CARPENTER, RHS; WILLIAMS, MLL				CARPENTER, RHS; WILLIAMS, MLL			NEURAL COMPUTATION OF LOG LIKELIHOOD IN CONTROL OF SACCADIC EYE-MOVEMENTS	NATURE			English	Article							SHORT REACTION-TIMES; EXPRESS SACCADES; LATENCIES; MONKEY; FIELD	THE latency between the appearance of a visual target and the start of the saccadic eye movement made to look at it varies from trial to trial to an extent that is inexplicable in terms of ordinary 'physiological' processes such as synaptic delays and conduction velocities. An alternative interpretation is that it represents the time needed to decide whether a target is in fact present: decision processes are necessarily stochastic, because they depend on extracting information from noisy sensory signals(1), In one such model(2), the presence of a target causes a signal in a decision unit to rise linearly at a rate r from its initial value s(0) until it reaches a fixed threshold theta, when a saccade is initiated, One can regard this decision signal as a neural estimate of the log likelihood of the hypothesis that the target is present, the threshold being the significance criterion or likelihood level at which the target is presumed to be present, Experiments manipulating the prior probability of the target's appearing confirm this notion: the latency distribution then changes in the way expected if s(0) simply reflects the prior log likelihood of the stimulus.			CARPENTER, RHS (corresponding author), UNIV CAMBRIDGE, PHYSIOL LAB, DOWNING ST, CAMBRIDGE CB2 3EG, ENGLAND.			Carpenter, Roger/0000-0003-2572-1448				BARLOW HB, 1980, PHILOS T ROY SOC B, V290, P71, DOI 10.1098/rstb.1980.0083; Carpenter R. H. S., 1981, EYE MOVEMENTS COGNIT, P237; CARPENTER RHS, 1994, CONTEMPORARY OCULAR MOTOR AND VESTIBULAR RESEARCH: A TRIBUTE TO DAVID A. ROBINSON, P185; CARPENTER RHS, 1994, J PHYSIOL-LONDON, V488, pP4; DALLOS PJ, 1963, IEEE T AUTOMAT CONTR, P218; Edwards A.W.F., 1972, LIKELIHOOD; FISCHER B, 1984, EXP BRAIN RES, V57, P191; FISCHER B, 1983, BRAIN RES, V260, P21, DOI 10.1016/0006-8993(83)90760-6; Fisher R.A., 1921, METRON, V1, P3; FUCHS AF, 1967, J PHYSIOL-LONDON, V191, P609, DOI 10.1113/jphysiol.1967.sp008271; GRICE GR, 1968, PSYCHOL REV, V75, P359, DOI 10.1037/h0026287; HANES DP, 1995, EXP BRAIN RES, V103, P85; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; NAZIR TA, 1991, PSYCHOL RES-PSYCH FO, V53, P281, DOI 10.1007/BF00920481; RATCLIFF R, 1978, PSYCHOL REV, V85, P59, DOI 10.1037//0033-295X.85.2.59; ROBINSON DA, 1973, KYBERNETIK, V14, P71, DOI 10.1007/BF00288906; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHILLER PH, 1987, J NEUROPHYSIOL, V57, P1033, DOI 10.1152/jn.1987.57.4.1033; WENBANSMITH MG, 1991, EXP BRAIN RES, V87, P218	19	638	640	2	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					59	62		10.1038/377059a0	http://dx.doi.org/10.1038/377059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659161				2022-12-01	WOS:A1995RT72500055
J	CHISHOLM, AD; HORVITZ, HR				CHISHOLM, AD; HORVITZ, HR			PATTERNING OF THE CAENORHABDITIS-ELEGANS HEAD REGION BY THE PAX-6 FAMILY MEMBER VAB-3	NATURE			English	Article							PAIRED BOX; C-ELEGANS; GENE; NEMATODE; ANIRIDIA; MUTATIONS; BODY	THE Pax-6 genes are important for eye development in both vertebrates and Drosophila. Mutations in the human PAX6 gene are found in patients with a variety of eye disorders, including aniridia and Peters' anomaly(1-3), and mutations in the Drosophila Pax-6 homologue cause the eyeless phenotype(4). In the nematode Caenorhabditis elegans, vab-3 mutants display many defects in head-region development, including aberrant morphogenesis, transformation of hypodermal (epidermal-like) cell fates to those of posterior homologues, and abnormal specification of neurons, Here we show that vab-3 is a member of the Pax-6 gene family and is expressed in head-region cells, This C. elegans Pax-6 locus can also encode proteins lacking the paired domain(5). Our results suggest: that. a primordial role of the Pax-6 gene family could have been to pattern part of the head region, and that Pax-6 genes subsequently evolved to be more specifically involved in eye development.			CHISHOLM, AD (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, 68-425, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Chisholm, Andrew/0000-0001-5091-0537				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Burglin Thomas R., 1994, P25; BURR AH, 1985, PHOTOCHEM PHOTOBIOL, V41, P577, DOI 10.1111/j.1751-1097.1985.tb03529.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAMBERLIN HM, 1995, DEV BIOL, V170, P679, DOI 10.1006/dbio.1995.1246; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CLARK SG, 1994, GENETICS, V137, P987; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1993, HUM MOL GENET, V2, P915; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; MARTIN P, 1992, ONCOGENE, V7, P1721; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881	31	134	136	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					52	55		10.1038/377052a0	http://dx.doi.org/10.1038/377052a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659159				2022-12-01	WOS:A1995RT72500053
J	DARBY, SC; EWART, DW; GIANGRANDE, PLF; DOLIN, PJ; SPOONER, RJD; RIZZA, CR				DARBY, SC; EWART, DW; GIANGRANDE, PLF; DOLIN, PJ; SPOONER, RJD; RIZZA, CR			MORTALITY BEFORE AND AFTER HIV-INFECTION IN THE COMPLETE UK POPULATION OF HEMOPHILIACS	NATURE			English	Article							HEMOPHILIA CENTERS; UNITED-KINGDOM; AIDS; COHORT; DIRECTORS; BRITAIN; BEHALF; STATES; DEATH	DURING 1977-91, 6,278 males diagnosed with haemophilia were living in the UK. During 1979-86, 1,227 were infected with the human immunodeficiency virus (HIV-1) as a result of transfusion therapy (median estimated seroconversion date, October 1982). Among 2,448 with severe haemophilia, the annual death rate was stable at 8 per 1,000 during 1977-84; during 1985-92 death rates remained at 8 per 1,000 among HIV-seronegative patients but rose steeply in seropositive patients, reaching 81 per 1,000 in 1991-92. Among 3,830 with mild or moderate haemophilia, the pattern was similar, with an initial death rate of 4 per 1,000 in 1977-84, rising to 85 per 1,000 in 1991-92 in seropositive patients. During 1985-92, there were 403 deaths in HIV seropositive patients, whereas 60 would have been predicted from rates in seronegatives, suggesting that 85% of the deaths in seropositive patients were due to HIV infection. Most of the excess deaths were certified as due to AIDS or to conditions recognized as being associated with AIDS.	CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	University of Oxford	DARBY, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.		Semple, Malcolm Gracie/A-8790-2008	Semple, Malcolm Gracie/0000-0001-9700-0418; Laffan, Michael/0000-0002-8268-3268				ARONSON DL, 1988, AM J HEMATOL, V27, P7, DOI 10.1002/ajh.2830270103; ARONSTAM A, 1993, ARCH DIS CHILD, V68, P521, DOI 10.1136/adc.68.4.521; CHEINSONGPOPOV R, 1986, BRIT MED J, V293, P168, DOI 10.1136/bmj.293.6540.168; CHORBA TL, 1994, AM J HEMATOL, V45, P112, DOI 10.1002/ajh.2830450204; COLOMBO M, 1991, AM J HEMATOL, V37, P243, DOI 10.1002/ajh.2830370406; CUTHBERT RJG, 1990, BMJ-BRIT MED J, V301, P956, DOI 10.1136/bmj.301.6758.956; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JONES P, 1985, BRIT MED J, V291, P695, DOI 10.1136/bmj.291.6497.695; KOUMBARELIS E, 1994, THROMB HAEMOSTASIS, V72, P808; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; MCCORMICK A, 1994, POPULATION TRENDS, V76, P1; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SMITH GM, 1991, CLIN LAB HAEMATOL, V13, P115; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; WILLIAMS MD, 1988, THROMB HAEMOSTASIS, V60, P97; 1994, LANCET, V343, P871; 1971, MANUAL INT STATISTIC; 1989, MORBIDITY MORTALITY, V38, P1; 1989, PHIL T R SOC LOND B, V325, P179	24	103	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					79	82		10.1038/377079a0	http://dx.doi.org/10.1038/377079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659168				2022-12-01	WOS:A1995RT72500061
J	GIOVANNUCCI, E; EGAN, KM; HUNTER, DJ; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; SPEIZER, FE				GIOVANNUCCI, E; EGAN, KM; HUNTER, DJ; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; SPEIZER, FE			ASPIRIN AND THE RISK OF COLORECTAL-CANCER IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; LARGE-BOWEL; INDOMETHACIN TREATMENT; COLON CARCINOGENESIS; INTESTINAL TUMORS; REDUCED RISK; ADENOMAS; POLYPS; RATS	Background. Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists. The effects of the dose and the duration of aspirin consumption on the risk of colorectal cancer are not well understood. Methods. We determined rates of colorectal cancer according to the number of consecutive years of regular aspirin use (defined as two or more tablets per week) among women in the Nurses' Health Study who reported regular aspirin use on three consecutive questionnaires (1980, 1982, and 1984) and compared the rates in this group with the rates among women who said they did not use aspirin. Cases of cancer occurring from 1984 through 1992 (the eight years after the 1984 questionnaire) were included. Results. From 1984 through 1992, we documented 331 new cases of colorectal cancer during 551,651 person-years of follow-up. Women who consistently took two or more aspirin tablets per week had no appreciable reduction in the risk of colorectal cancer as compared with nonusers after four years (relative risk, 1.06; 95 percent confidence interval, 0.78 to 1.45) or after five to nine years (relative risk, 0.84; 95 percent confidence interval, 0.55 to 1.28). There was a slight reduction in risk among women who took aspirin for 10 to 19 years, but it was not statistically significant (relative risk, 0.70; 95 percent confidence interval, 0.41 to 1.20). However, there was a statistically significant reduction after 20 years of consistent use of aspirin (relative risk, 0.56; 95 percent confidence interval, 0.36 to 0.90; P for trend=0.008). The maximal reduction in risk was observed among women who took four to six tablets per week; higher doses had a similar apparent benefit. Controlling for risk factors for colorectal cancer, including diet, did not change the results, and the earlier diagnosis and removal of colorectal adenomas among aspirin users did not account for the results. Conclusions. Regular aspirin use, at doses similar to those recommended for the prevention of cardiovascular disease, substantially reduces the risk of colorectal cancer. However, this benefit may not be evident until after at least a decade of regular aspirin consumption.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	GIOVANNUCCI, E (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, P01CA055075, R01CA040356] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOMALASKI JS, 1986, BIOCHEM BIOPH RES CO, V139, P115, DOI 10.1016/S0006-291X(86)80087-0; CRAVEN PA, 1992, CARCINOGENESIS, V13, P541, DOI 10.1093/carcin/13.4.541; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HEATH CW, 1994, CANCER-AM CANCER SOC, V74, P2885, DOI 10.1002/1097-0142(19941115)74:10<2885::AID-CNCR2820741023>3.0.CO;2-P; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MARNETT LJ, 1992, CANCER RES, V52, P5575; MERETO E, 1994, CANCER LETT, V76, P5, DOI 10.1016/0304-3835(94)90127-9; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NARISAWA T, 1981, CANCER RES, V41, P1954; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; PINCZOWSKI D, 1994, GASTROENTEROLOGY, V107, P117, DOI 10.1016/0016-5085(94)90068-X; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; POWIS G, 1994, EUR J CANCER, V30A, P1138, DOI 10.1016/0959-8049(94)90473-1; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Ruffin M. T., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P600; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; TRUJILLO MA, 1994, DIGEST DIS SCI, V39, P2260; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105	42	879	914	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					609	614		10.1056/NEJM199509073331001	http://dx.doi.org/10.1056/NEJM199509073331001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637720	Bronze			2022-12-01	WOS:A1995RR84000001
J	GREGORIO, CC; WEBER, A; BONDAD, M; PENNISE, CR; FOWLER, VM				GREGORIO, CC; WEBER, A; BONDAD, M; PENNISE, CR; FOWLER, VM			REQUIREMENT OF POINTED-END CAPPING BY TROPOMODULIN TO MAINTAIN ACTIN FILAMENT LENGTH IN EMBRYONIC CHICK CARDIAC MYOCYTES	NATURE			English	Article							TROPOMYOSIN-BINDING; MECHANISMS; PROTEIN; MUSCLE; CELLS	CONTROL of actin filament length and dynamics is important for cell motility and architecture and is regulated in part by capping proteins that block elongation and depolymerization at both the fast-growing (barbed) and slow-growing (pointed) ends(1-4). Tropomodulin is a capping protein for the pointed end of the actin filament(5,6); it is associated with the free, pointed ends of the thin filaments in striated muscle, where it is thought to bind to both tropomyosin and actin(7,8). In embryonic chick cardiac myocytes, tropomodulin assembles after the thin, as well as the thick, filaments have become organized into periodic I and A bands(8), suggesting that tropomodulin might be involved in maintaining actin filament length. Here we show that microinjection of an antibody that inhibits tropomodulin's pointed-end-capping activity in vitro results in a marked elongation of actin filaments from their pointed ends and a >80% reduction in the percentage of beating cells. This demonstrates that pointed-end capping by tropomodulin is required to maintain actin filament length in vivo and that this is essential for contractile function in embryonic chick cardiac myocytes.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania								BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; COLUCCIO LM, 1994, J CELL BIOL, V127, P1497, DOI 10.1083/jcb.127.6.1497; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.biochem.55.1.987; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUNG KLP, 1994, MOL BIOL CELL, V5, pA54; SUNG LA, 1992, J BIOL CHEM, V267, P2616; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; SUSSMAN MA, 1994, DEV BRAIN RES, V80, P45, DOI 10.1016/0165-3806(94)90088-4; URSITTI JA, 1994, J CELL SCI, V107, P1633; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WEBER A, 1973, PHYSIOL REV, V53, P612, DOI 10.1152/physrev.1973.53.3.612; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WOO MK, 1994, J CELL SCI, V107, P1359	21	146	148	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					83	86		10.1038/377083a0	http://dx.doi.org/10.1038/377083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7544875				2022-12-01	WOS:A1995RT72500062
J	HATADA, MH; LU, XD; LAIRD, ER; GREEN, J; MORGENSTERN, JP; LOU, MZ; MARR, CS; PHILLIPS, TB; RAM, MK; THERIAULT, K; ZOLLER, MJ; KARAS, JL				HATADA, MH; LU, XD; LAIRD, ER; GREEN, J; MORGENSTERN, JP; LOU, MZ; MARR, CS; PHILLIPS, TB; RAM, MK; THERIAULT, K; ZOLLER, MJ; KARAS, JL			MOLECULAR-BASIS FOR INTERACTION OF THE PROTEIN-TYROSINE KINASE ZAP-70 WITH THE T-CELL RECEPTOR	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; CYCLOSPORINE-A; SH2 DOMAINS; ZETA-CHAIN; RECOGNITION; CALCINEURIN; COMPLEXES; SUBUNIT; TAIL	The crystal structure of the tandem SH2 domains of human ZAP-70 in complex with a peptide derived from the zeta-subunit of the T-cell receptor reveals an unanticipated interaction between the two domains. A coiled coil of a-helices connects the two SH2 domains, producing apr interface that constitutes one of the two critical phosphotyrosine binding sites. These and other unique features provide the molecular basis for highly selective association of ZAP-70 with the T-cell receptor.			HATADA, MH (corresponding author), ARIAD PHARMACEUT INC,26 LANDSDOWNE ST,CAMBRIDGE,MA 02139, USA.			Green, Jeremy/0000-0003-4544-6412				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CCP4, 1979, CCP4 SUITE PROGRAMS; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; TANIGUCHI T, 1991, J BIOL CHEM, V268, P15790; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	47	301	311	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					32	38		10.1038/377032a0	http://dx.doi.org/10.1038/377032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659156				2022-12-01	WOS:A1995RT72500047
J	LAWSON, MA; MAXFIELD, FR				LAWSON, MA; MAXFIELD, FR			CA2+ AND CALCINEURIN-DEPENDENT RECYCLING OF AN INTEGRIN TO THE FRONT OF MIGRATING NEUTROPHILS	NATURE			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATED PLATELETS; CELL-ADHESION; ALPHA-ACTININ; SUBUNIT; VITRONECTIN; RECEPTOR; FIBRONECTIN; ADHERENCE; LAMININ	CHEMOATTRACTANTS stimulate neutrophil migration by activating signalling pathways(1) including repeated transient increases in intracellular free calcium, [Ca2+](i) (refs 2, 3). A motile neutrophil sends out many pseudopods, some of which adhere to the substrate; to continue moving forward the cell must release these attachments(4,5). Adhesion can be actively regulated, and neutrophils in which [Ca2+](i) transients are inhibited become stuck on fibronectin or vitronectin(6,7), extracellular matrix proteins that neutrophils encounter in vivo. Function-blocking antibodies to beta 3 integrins or the alpha v beta 3 heterodimer restore motility on vitronectin to [Ca2+](i)-buffered cells (B, Hendey, M.A.L., E. Marcantonio and F.R.M., manuscript submitted), indicating that an alpha v beta 3-like integrin is responsible for the [Ca2+](i)-sensitive adhesion. We show that the density of alpha v beta 3 integrins in the adherent membrane of neutrophils migrating on vitronectin is much higher at the leading edge than at the rear, but [Ca2+](i) buffering or inhibition of Ca2+-calmodulin-activated protein phosphatase 2B (calcineurin) leads to accumulation of alpha v beta 3 on the adherent surface at the rear of the cell. We show that the polarized distribution of alpha v beta 3 integrins in migrating neutrophils is maintained by [Ca2+](i)-dependent release of adhesion followed by endocytosis of these integrins and recycling to the leading edge.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University			Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 				ABELDA SM, 1994, FASEB J, V8, P504; ABERCROMBIE M, 1970, EXP CELL RES, V62, P389, DOI 10.1016/0014-4827(70)90570-7; ALTANKOV G, 1993, J CELL BIOL, V120, P1449, DOI 10.1083/jcb.120.6.1449; BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BOYLES J, 1979, J CELL BIOL, V82, P347, DOI 10.1083/jcb.82.2.347; BRETCHER MS, 1988, J CELL BIOL, V106, P235, DOI 10.1083/jcb.106.2.235; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BRETSCHER MS, 1984, SCIENCE, V224, P261; CHAMBERS JD, 1993, J LEUKOCYTE BIOL, V53, P462, DOI 10.1002/jlb.53.4.462; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; GHOSH RN, 1994, J CELL SCI, V107, P2177; HASTON WS, 1987, J CELL SCI, V88, P495; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MAXFIELD F, 1993, TRENDS CELL BIOL, V4, P386; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; SCHMIDT CE, 1994, BIOPHYS J, V67, P461, DOI 10.1016/S0006-3495(94)80502-8; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; YLANNE J, 1990, BLOOD, V76, P570	28	476	479	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					75	79		10.1038/377075a0	http://dx.doi.org/10.1038/377075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7544874				2022-12-01	WOS:A1995RT72500060
J	MACCHI, P; VILLA, A; GILIANI, S; SACCO, MG; FRATTINI, A; PORTA, F; UGAZIO, AG; JOHNSTON, JA; CANDOTTI, F; O'SHEA, JJ; VEZZONI, P; NOTARANGELO, LD				MACCHI, P; VILLA, A; GILIANI, S; SACCO, MG; FRATTINI, A; PORTA, F; UGAZIO, AG; JOHNSTON, JA; CANDOTTI, F; O'SHEA, JJ; VEZZONI, P; NOTARANGELO, LD			MUTATIONS OF JAK-3 GENE IN PATIENTS WITH AUTOSOMAL SEVERE COMBINED IMMUNE-DEFICIENCY (SCID)	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; X-CHROMOSOME INACTIVATION; CARRIERS; CELLS	SEVERE combined immune deficiency (SCID) represents a heterogenous group of hereditary diseases. Mutations in the common gamma-chain (gamma(c)), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID1,2, which is usually(!ly associated with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID), The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown, The Jak-3 protein kinase(3,4) has been found to associate,vith the gamma(c)-chain-containing cytokine receptors(4-9). Therefore Jak-3 or other STAT proteins with which it interacts(10,11) are candidate genes for autosomal recessive T- B+ SCID7. Here we investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3. One patient carries a mutation (Tyr100-->Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes. The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination. Both mutations resulted in markedly reduced levels of Jak-3, These findings show that abnormalities in the Jak/STAT signalling pathway can account for SCID in humans.	CNR, IST TECNOL BIOMED AVANZATE, I-20131 MILAN, ITALY; UNIV BRESCIA, DIPARTIMENTO MATERNO INFANTILE, BRESCIA, ITALY; NIH, NATL CTR HUMAN GENOME RES, CLIN GENE THERAPY BRANCH, BETHESDA, MD 20892 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Frattini, Annalisa/B-7684-2015; Notarangelo, Luigi D/F-9718-2016; Vezzoni, Paolo/K-3197-2018; Giliani, Silvia/AAX-8843-2020; Vezzoni, Paolo/R-3416-2019; Ugazio, Alberto/AAA-6092-2020	Frattini, Annalisa/0000-0002-1166-3091; Notarangelo, Luigi D/0000-0002-8335-0262; Giliani, Silvia/0000-0001-8137-4642; Villa, Anna/0000-0003-4428-9013; Vezzoni, Paolo/0000-0002-6382-3923; Candotti, Fabio/0000-0001-6399-6042				BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; DAMELL JE, 1994, SCIENCE, V264, P1415; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; GOUGEON ML, 1990, J IMMUNOL, V145, P2873; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WENGLER GS, 1993, J IMMUNOL, V150, P700; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	19	679	775	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					65	68		10.1038/377065a0	http://dx.doi.org/10.1038/377065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659163				2022-12-01	WOS:A1995RT72500057
J	RHODES, J; CHEN, H; HALL, SR; BEESLEY, JE; JENKINS, DC; COLLINS, P; ZHENG, B				RHODES, J; CHEN, H; HALL, SR; BEESLEY, JE; JENKINS, DC; COLLINS, P; ZHENG, B			THERAPEUTIC POTENTIATION OF THE IMMUNE-SYSTEM BY COSTIMULATORY SCHIFF-BASE-FORMING DRUGS	NATURE			English	Article							T-CELL ACTIVATION; ANTIGEN; LYMPHOCYTES; EXPRESSION; RESPONSES; RECEPTOR; CLONING; ACID	IMMUNE responses are orchestrated by CD4 T lymphocytes, which receive a cognitive signal when clonally distributed receptors are occupied by major histocompatibility complex (MHC) class II-bound peptides on antigen-presenting cells (APCs)(1,2). The APCs provide costimulatory signals, through macromolecules such as CD80, that regulate outcomes in terms of T-cell activation or anergy(3-6). We have studied essential complementary chemical events in the form of Schiff base formation between carbonyls and amines that are constitutively expressed on presenting cell and T-cell surfaces(7-9) and provide a new target for manipulation of immune responses(10,11). Here we show that small Schiff base-forming molecules can substitute for the physiological donor of carbonyl groups and provide a costimulatory signal to CD4 Th-cells through a mechanism that activates clofilium-sensitive K+ and Na+ transport. One such molecule, tucaresol, enhances CD4 Th-cell responses, selectively favouring a Th1-type profile of cytokine production, in vivo tucaresol potently enhances CD4 Th-cell priming and CD8 cytotoxic T-cell priming to viral antigens, and has substantial therapeutic activity in murine models of disease.	WELLCOME RES LABS,CORE SUPPORT GRP,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,EXPTL BIOL GRP,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories	RHODES, J (corresponding author), WELLCOME RES LABS,MOLEC IMMUNOL GRP,BECKENHAM BR3 3BS,KENT,ENGLAND.							AMARAL MC, 1993, IMMUNOLOGY, V79, P24; ATTALI B, 1992, J BIOL CHEM, V267, P8650; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GAO XM, 1990, J IMMUNOL, V144, P2883; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; Hall T.A., 1986, PRINCIPLES ANAL ELEC, P219; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Hedrick Stephen M., 1993, P383; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.immunol.11.1.191; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MOSMANN TR, 1992, ANNU REV IMMUNOL, V7, P145; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; RHODES J, 1995, ANN NY ACAD SCI, V754, P169, DOI 10.1111/j.1749-6632.1995.tb44450.x; RHODES J, 1990, J IMMUNOL, V145, P463; RHODES J, 1989, J IMMUNOL, V143, P1482; ROLAN PE, 1993, BRIT J CLIN PHARMACO, V35, P419, DOI 10.1111/j.1365-2125.1993.tb04160.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELGRADE MK, 1984, J GEN VIROL, V65, P515, DOI 10.1099/0022-1317-65-3-515; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Weiss Arthur, 1993, P467; Wroblewski Joanna, 1993, P317, DOI 10.1017/CBO9780511600371.023; ZHENG B, 1992, SCIENCE, V256, P1560, DOI 10.1126/science.1598588	25	118	130	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					71	75		10.1038/377071a0	http://dx.doi.org/10.1038/377071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659167				2022-12-01	WOS:A1995RT72500059
J	ZHANG, YH; EMMONS, SW				ZHANG, YH; EMMONS, SW			SPECIFICATION OF SENSE-ORGAN IDENTITY BY A CAENORHABDITIS-ELEGANS PAX-6 HOMOLOG	NATURE			English	Article							C-ELEGANS; NEMATODE; GENE; EXPRESSION; SEQUENCE; PATTERN; MUTANTS; VECTORS; CELL	The Pax-6 transcription-factor gene, containing a paired domain and a paired-type homeodomain, is conserved in structure and ubiquitously present among Metazoa(1-5). It is required for development of the central nervous system, and is mutated in human aniridia, mouse and rat small eye and Drosophila eyeless(6). We identified the Pax-6 gene of the nematode Caenorhabditis elegans in genetic studies of male tail morphology(7,8). C. elegans Pax-6 encodes at least two independent genetic functions. One, like other Pax-6 genes, contains paired and homeodomains; this constitutes the genetic locus vab-3 (ref. 9). The other, described here, is expressed from an internal promoter and contains only the homeodomain portion; this constitutes the genetic locus mab-18 (ref. 7), The mab-18 form of the gene is expressed in a peripheral sense organ and is necessary for specification of sense-organ identity. Its function in this context could be to regulate the expression of cell recognition and adhesion proteins required for sense-organ assembly.			ZHANG, YH (corresponding author), ALBERT EINSTEIN COLL MED, DEPT MOLEC GENET, 1300 MORRIS PK AVE, NEW YORK, NY 10461 USA.			Zhang, Yinhua/0000-0003-0592-9153				BAIRD SE, 1991, DEVELOPMENT, V113, P515; BURR AH, 1985, PHOTOCHEM PHOTOBIOL, V41, P577, DOI 10.1111/j.1751-1097.1985.tb03529.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAMBERLIN HM, 1995, DEV BIOL, V170, P679, DOI 10.1006/dbio.1995.1246; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CHOW KL, 1994, DEVELOPMENT, V120, P2579; CHOW KL, IN PRESS DEVELOPMENT; CLARK SG, 1994, GENETICS, V137, P987; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HEDGECOCK EM, 1985, TRENDS NEUROSCI, V8, P288, DOI 10.1016/0166-2236(85)90104-3; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WALTHER C, 1991, DEVELOPMENT, V113, P1435	24	125	127	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					55	59		10.1038/377055a0	http://dx.doi.org/10.1038/377055a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659160				2022-12-01	WOS:A1995RT72500054
J	ADAMSON, SJ; ALESSANDRI, LM; BADAWI, N; BURTON, PR; PEMBERTON, PJ; STANLEY, F				ADAMSON, SJ; ALESSANDRI, LM; BADAWI, N; BURTON, PR; PEMBERTON, PJ; STANLEY, F			PREDICTORS OF NEONATAL ENCEPHALOPATHY IN FULL-TERM INFANTS	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL-PALSY; BIRTH ASPHYXIA	Objective-Preliminary investigation of the contribution of adverse antepartum and intrapartum factors to neonatal encephalopathy in singleton neonates born full term. Design-Matched case-control study based on incidence density sampling of controls. Setting-Two major teaching hospitals (one paediatric and one obstetric) and three peripheral maternity hospitals in Perth, Western Australia (population 1.2 million). Subjects-89 cases, all the full term singleton neonates born during an eight month period in 1992 who fulfilled one or more of six criteria during the first week of life (seizures, abnormal conscious state, persistent hypertonia or hypotonia, and feeding or respiratory difficulties of central origin). One full term control infant without neonatal encephalopathy was matched to each case by sex, hospital of delivery, time of day and day of the week of birth, and maternal health insurance status. Main outcome measures-Odds ratio estimates of relative risk of neonatal encephalopathy associated with antepartum and intrapartum factors. Results-Estimated incidence of moderate or severe encephalopathy in first week of life was 3.75 per 1000 full term live births. Thirteen cases and no controls had evidence suggestive of important intrapartum hypoxia, and in only five of these cases was the neurological condition at birth attributed to events during the intrapartum period. Univariate conditional logistic regression analysis identified significant differences between cases and controls for maternal vaginal bleeding in pregnancy, maternal thyroxine treatment, congenital abnormalities, induction of labour, interval from membrane rupture to delivery, maternal pyrexia in labour, augmentation of labour, abnormal intrapartum cardiotocograms, and meconium in labour. Family history of convulsions also approached significance. Conclusions-Our preliminary results suggest that intrapartum hypoxia, according to currently used criteria, was not the cause of neonatal encephalopathy in most cases in this population. Our findings suggest that many aetiologies of neonatal encephalopathy originate in the antepartum period.	INST CHILD HLTH RES,PERTH,WA 6872,AUSTRALIA; PRINCESS MARGARET HOSP CHILDREN,DEPT NEONATOL,SUBIACO,WA 6008,AUSTRALIA	Telethon Kids Institute; University of Western Australia			Burton, Paul R/H-7527-2016; Badawi, Nadia/A-3179-2014					ARMITAGE P, 1987, STATISTICAL METHODS; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P302, DOI 10.1111/j.1365-3016.1993.tb00406.x; BLAIR E, 1993, DEV MED CHILD NEUROL, V35, P449; BRESLOW N. E., 1980, STATISTICAL METHODS; BURTON PR, 1994, STAT MED, V13, P1699, DOI 10.1002/sim.4780131702; COORSSEN EA, 1991, DEV MED CHILD NEUROL, V33, P730; COPAS J, 1984, J ROYAL STATISTICA A, V147, P35; DEESCOBAR GM, 1993, AM J CLIN NUTR, V57, pS280; DEMOTT RK, 1990, AM J OBSTET GYNECOL, V162, P1593, DOI 10.1016/0002-9378(90)90925-W; DEVLIN MM, 1990, J MED PRACTICE, V5, P215; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GLUCKMAN PD, 1992, DEV MED CHILD NEUROL, V34, P1010; HAGBERG G, 1976, ACTA PAEDIATR SCAND, V65, P403, DOI 10.1111/j.1651-2227.1976.tb04906.x; HENDERSONSMART D, 1991, MED J AUSTRALIA, V154, P576, DOI 10.5694/j.1326-5377.1991.tb121215.x; Joreskog K. G., 1989, LISREL; LEVENE MI, 1986, LANCET, V2, P67; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; MEYER BA, 1992, AM J OBSTET GYNECOL, V166, P612, DOI 10.1016/0002-9378(92)91685-4; MILLER G, 1989, ARCH DIS CHILD, V64, P557, DOI 10.1136/adc.64.4.557; MULLIGAN JC, 1980, J PEDIATR-US, V96, P903, DOI 10.1016/S0022-3476(80)80575-0; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STEER PJ, 1989, OBSTET GYNECOL, V64, P715; TUCKER JM, 1990, CLIN OBSTET GYNECOL, V33, P515, DOI 10.1097/00003081-199009000-00017; 1989, LANCET, V2, P1251	31	121	122	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					598	602		10.1136/bmj.311.7005.598	http://dx.doi.org/10.1136/bmj.311.7005.598			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663254	Green Published			2022-12-01	WOS:A1995RT72300017
J	AHMED, AEH; NICHOLSON, KG; NGUYENVANTAM, JS				AHMED, AEH; NICHOLSON, KG; NGUYENVANTAM, JS			REDUCTION IN MORTALITY ASSOCIATED WITH INFLUENZA VACCINE DURING 1989-90 EPIDEMIC	LANCET			English	Article							VIRUS VACCINE; IMMUNIZATION; PREVENTION; INFECTION; EFFICACY; DISEASE; DEATHS	Influenza epidemics are associated with excess winter mortality Risk factors for influenza complications and death include chronic illness and living in residential care. In the UK uptake of influenza vaccine among high-risk groups is only 10-40%, partly because of scepticism about vaccine efficacy. We have assessed the efficacy of influenza vaccine in reducing mortality from certified influenza by a case-control study of subjects aged 16 years or older who died between Nov 4, 1989, and Feb 23, 1990, in 36 district health authorities in England. We reviewed general practitioners' records for 315 patients who died of influenza and 777 controls, matched for age, sex, and area of residence, who died a year after the epidemic. Information was collected on demography, the usual place of residence (institutional or noninstitutional), and the existence of chronic illness. Conditional logistic regression analysis for matched case-control studies showed that influenza vaccination reduced mortality by 41% (95% Cl 13-60) for all subjects. Further adjustments showed that among subjects who received the vaccine for the first time in 1989, Vaccination reduced mortality by 9% (0-59); however, among those who bad also been vaccinated previously, mortality was reduced by 75% (31-91). We detected no significant differences in the effect of vaccine between subjects who lived in institutions and in the community (p=0.16), or between subjects with high-risk medical conditions and those without (p=0.76). Influenza Vaccine is effective in reducing mortality from influenza, and efficacy seems to be greater after repeated annual vaccination than after first administration.	UNIV LEICESTER,SCH MED,DEPT MICROBIOL & IMMUNOL,LEICESTER LE1 9HN,LEICS,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Leicester; University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655				ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; Ashley J., 1991, Population Trends, P16; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GUNDELFINGER BF, 1958, NEW ENGL J MED, V259, P1005, DOI 10.1056/NEJM195811202592103; HALL CB, 1987, PEDIATRICS, V80, P275; HOSKINS TW, 1979, LANCET, V1, P33; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; LENNOX IM, 1990, AGE AGEING, V19, P169, DOI 10.1093/ageing/19.3.169; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MORIO S, 1994, J EPIDEMIOL COMMUN H, V48, P46, DOI 10.1136/jech.48.1.46; NGUYENVANTAM JS, 1993, EPIDEMIOL INFECT, V111, P347, DOI 10.1017/S0950268800057058; NGUYENVANTAM JS, 1992, EPIDEMIOL INFECT, V108, P537, DOI 10.1017/S0950268800050032; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1987, VACCINE, V5, P302, DOI 10.1016/0264-410X(87)90156-3; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; 1989, OPCS PP2892 MON; 1992, IMMUNISATION INFECTI	30	170	176	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					591	595		10.1016/S0140-6736(95)91434-X	http://dx.doi.org/10.1016/S0140-6736(95)91434-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651002				2022-12-01	WOS:A1995RT18800007
J	CANNON, J; CULLINAN, P; TAYLOR, AN				CANNON, J; CULLINAN, P; TAYLOR, AN			CONSEQUENCES OF OCCUPATIONAL ASTHMA	BRITISH MEDICAL JOURNAL			English	Article											CANNON, J (corresponding author), NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,DOVEHOUSE ST,LONDON SW3 6LR,ENGLAND.							[Anonymous], CLASSIFICATION OCCUP; GANNON PFG, 1993, BRIT J IND MED, V50, P491; MERIDITH S, 1993, J EPIDEMIOL COMMUNIT, V47, P459; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2	4	60	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					602	603		10.1136/bmj.311.7005.602	http://dx.doi.org/10.1136/bmj.311.7005.602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663255	Green Published			2022-12-01	WOS:A1995RT72300018
J	DODGE, JA				DODGE, JA			MALE-FERTILITY IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material											DODGE, JA (corresponding author), QUEENS UNIV BELFAST,NUFFIELD DEPT CHILD HLTH,BELFAST,ANTRIM,NORTH IRELAND.		Chotirmall, Sanjay Haresh/K-4127-2015	Chotirmall, Sanjay Haresh/0000-0003-0417-7607				ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; AUGARTEN A, 1994, LANCET, V344, P1473, DOI 10.1016/S0140-6736(94)90292-5; BARRETO C, 1991, J MED GENET, V28, P420, DOI 10.1136/jmg.28.6.420; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; DEAN M, 1994, HUM GENET, V93, P364; FOGDESTAM I, 1994, 19TH EUR CYST FIBR C; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; LIU J, 1994, JAMA-J AM MED ASSOC, V272, P1858, DOI 10.1001/jama.272.23.1858; OATES RD, 1992, J ASSIST REPROD GEN, V9, P36, DOI 10.1007/BF01204112; STERN RC, 1995, LANCET, V346, P274, DOI 10.1016/S0140-6736(95)92165-6; STERN RC, 1983, LANCET, V1, P1401; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; 1995, 1995 UK CYST FIBR SU; 1994, HUMAN FERTILISTION E	16	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					587	588		10.1016/S0140-6736(95)91431-5	http://dx.doi.org/10.1016/S0140-6736(95)91431-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650999				2022-12-01	WOS:A1995RT18800004
J	EYPASCH, E; LEFERING, R; KUM, CK; TROIDL, H				EYPASCH, E; LEFERING, R; KUM, CK; TROIDL, H			PROBABILITY OF ADVERSE EVENTS THAT HAVE NOT YET OCCURRED - A STATISTICAL REMINDER	BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE RANDOMIZED TRIAL; LAPAROSCOPIC CHOLECYSTECTOMY; OPEN APPENDECTOMY; SAFETY	The probability of adverse and undesirable events during and after operations that have not yet occurred in a finite number of patients (n) can be estimated with Hanley's simple formula, which gives the upper limit of the 95% confidence interval of the probability of such an event: upper limit of 95% confidence interval=maximum risk=3/n (for n>30). Doctors and surgeons should keep this simple rule in mind when complication rates of zero are reported in the literature and when they have not (yet) experienced a disastrous complication in a procedure.			EYPASCH, E (corresponding author), UNIV COLOGNE,KLINIKEN STADT KOLN,DEPT SURG 2,OSTMERHEIMER STR 200,D-51109 COLOGNE,GERMANY.							ATTWOOD SEA, 1992, SURGERY, V112, P497; COLLET D, 1993, SURG ENDOSC-ULTRAS, V7, P334, DOI 10.1007/BF00725952; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; FRAZEE RC, 1994, ANN SURG, V219, P725, DOI 10.1097/00000658-199406000-00017; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V259, P1743; HEBEBRAND D, 1994, CHIRURG, V65, P112; KUM CK, 1993, BRIT J SURG, V80, P1599, DOI 10.1002/bjs.1800801236; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; MCANENA OJ, 1991, LANCET, V338, P693, DOI 10.1016/0140-6736(91)91267-X; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; Pier A, 1991, Surg Laparosc Endosc, V1, P8; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; TROIDL H, 1992, ENDOSCOPY, V24, P252, DOI 10.1055/s-2007-1010477; TROIDL H, 1993, LANGENBECKS ARCH C S, P59; 1991, NEW ENGL J MED, V324, P1073	15	226	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					619	620		10.1136/bmj.311.7005.619	http://dx.doi.org/10.1136/bmj.311.7005.619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663258	Green Published			2022-12-01	WOS:A1995RT72300025
J	FENTON, JE; HONE, S; GORMLEY, P; ODWYER, TP; MCSHANE, DP; TIMON, CI				FENTON, JE; HONE, S; GORMLEY, P; ODWYER, TP; MCSHANE, DP; TIMON, CI			LESSON OF THE WEEK - HYPOPHARYNGEAL TUMORS MAY BE MISSED ON FLEXIBLE ESOPHAGOGASTROSCOPY	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES HOSP,DEPT OTOLARYNGOL,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT HEAD & NECK SURG,DUBLIN 8,IRELAND; UNIV COLL HOSP GALWAY,GALWAY,IRELAND; MATER MISERICORDIAE HOSP,DUBLIN 7,IRELAND; MANCH HOSP,DUBLIN,IRELAND	Trinity College Dublin; Trinity College Dublin; Ollscoil na Gaillimhe-University of Galway; Mater Misericordiae University Hospital; University College Dublin								ADAMS GL, 1993, OTOLARYNGOLOGY HEAD, V3, P1955; BINGHAM BJ, 1986, ANN ROYAL COLLEGE SU, V68, P22; Logemann J. A., 1983, EVALUATION TREATMENT, V12, P38, DOI 10.1044/nsshla_12_38; MARAN AGD, 1993, STELL MARANS HEAD NE, P161; PAIROLERO PC, 1989, PRINCIPLES SURG, P1103; THOMSON HG, 1989, J LARYNGOL OTOL, V103, P399, DOI 10.1017/S0022215100109053	6	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					623	624		10.1136/bmj.311.7005.623	http://dx.doi.org/10.1136/bmj.311.7005.623			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663260	Green Published			2022-12-01	WOS:A1995RT72300027
J	HOPKINS, DR; AZAM, M; RUIZTIBEN, E; KAPPUS, KD				HOPKINS, DR; AZAM, M; RUIZTIBEN, E; KAPPUS, KD			ERADICATION OF DRACUNCULIASIS FROM PAKISTAN	LANCET			English	Article								In 1986 the World Health Organization targeted dracunculiasis (Guinea-worm disease), which seriously impairs socioeconomic development in 16 African countries, India, Pakistan, and Yemen, to be eradicated globally The target date for eradication by the end of 1995 was established in 1991. Pakistan eradicated dracunculiasis from the country in October, 1993, after a national campaign which began in 1987 with a nationwide village-by-village search for cases. The infection, which is transmitted by drinking water from ponds containing infected water fleas, was eradicated by using health education, cloth fillers, and the cyclopsicide, temephos; and in the later stages, by case containment. Methods pioneered in Pakistan's National Guinea Worm Eradication Program are now being applied in remaining endemic countries.	NATL INST HLTH,GUINEA WORM ERADICAT PROGRAM,ISLAMABAD,PAKISTAN; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	HOPKINS, DR (corresponding author), EMORY UNIV,CARTER CTR INC,1 COPENHILL,ATLANTA,GA 30307, USA.							HOPKINS DR, 1981, SCIENCE, V212, P495, DOI 10.1126/science.6451929; HOPKINS DR, 1991, B WORLD HEALTH ORGAN, V69, P533; KAPPUS K D, 1991, World Health Forum, V12, P220; PAUL JE, 1988, WASH231 WAT SAN HLTH; 1993, WKLY EPIDEMIOL REC, V68, P49; 1992, WKLY EPIDEMIOL REC, V67, P137; 1991, MMWR-MORBID MORTAL W, V40, P5; 1988, WKLY EPIDEMIOL REC, V63, P177; 1995, WKLY EPIDEMIOL REC, V70, P125	9	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					621	624		10.1016/S0140-6736(95)91442-0	http://dx.doi.org/10.1016/S0140-6736(95)91442-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651010				2022-12-01	WOS:A1995RT18800015
J	HORTON, R				HORTON, R			SPINNING THE RISKS AND BENEFITS OF CALCIUM-ANTAGONISTS	LANCET			English	Editorial Material																		BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620	2	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					586	587		10.1016/S0140-6736(95)91429-3	http://dx.doi.org/10.1016/S0140-6736(95)91429-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650997				2022-12-01	WOS:A1995RT18800002
J	HOUETO, P; HOFFMAN, JR; IMBERT, M; LEVILLAIN, P; BAUD, FJ				HOUETO, P; HOFFMAN, JR; IMBERT, M; LEVILLAIN, P; BAUD, FJ			RELATION OF BLOOD CYANIDE TO PLASMA CYANOCOBALAMIN CONCENTRATION AFTER A FIXED-DOSE OF HYDROXOCOBALAMIN IN CYANIDE POISONING	LANCET			English	Article								Hydroxocobalamin combines with cyanide to form cyanocobalamin. We hypothesised that the amount of cyanocobalamin formed after a fixed dose of hydroxocobalamin given for cyanide poisoning would correlate with initial blood cyanide concentration. We determined blood cyanide concentration in 12 patients exposed to residential fires, and compared this with markers of the amount of cyanocobalamin formed after treatment with 5 g intravenous hydroxocobalamin. All relationships were highly correlated (r(2) 0.79-0.95), for the whole group, and there appeared to be an almost linear relationship for the 9 patients with initial cyanide concentration below 40 mu mol/L. Above this concentration, no further cyanocobalamin was formed from a single 5 g dose of hydroxocobalamin. In one patient with initial blood cyanide concentration of 96 mu mol/L, however, plasma cyanocobalamin concentration approximately doubled after a second 5 g dose of hydroxocobalamin. 5 g of hydroxocobalamin appears capable of binding all available cyanide ions for blood cyanide concentrations up to about 40 mu mol/L. Beyond this, more hydroxocobalamin must be given for remaining cyanide ions to be bound. This information will allow clinicians to use rapidly measurable plasma cyanocobalamin concentrations to gauge severity of exposure and evaluate adequacy of treatment.	UNIV PARIS 07,HOP FERNAND WIDAL,TOXICOL LAB,PARIS,FRANCE; BRIGADE SAPEURS POMPIERS,SERV MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite								BARTELHEIMER EW, 1962, ARCH INT PHARMACOD T, V139, P99; BRIGHT JE, 1988, HUM TOXICOL, V7, P183, DOI 10.1177/096032718800700214; EVANS CL, 1964, BRIT J PHARM CHEMOTH, V23, P455, DOI 10.1111/j.1476-5381.1964.tb01603.x; Favier C, 1993, CLIN INT CARE, V4, P69; HOUETO P, 1994, J ANAL TOXICOL, V18, P154, DOI 10.1093/jat/18.3.154; HOUETO P, 1994, THERAPIE, V49, P68; LINELL JC, 1987, CLIN EXPT TOXICOLOGY, P427; MOUREU H, 1957, Arch Mal Prof, V18, P116; RIEDERS F, 1975, METHODOLOGY ANAL TOX, P113; RIOU B, 1990, J NEUROSURG ANESTH, V2, P296, DOI 10.1097/00008506-199012000-00008; SCHWARTZ D, 1963, METHODES STATISTIQUE	11	42	46	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					605	608		10.1016/S0140-6736(95)91437-4	http://dx.doi.org/10.1016/S0140-6736(95)91437-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651005				2022-12-01	WOS:A1995RT18800010
J	LEHMANN, ED; HOPKINS, KD; GOSLING, RG				LEHMANN, ED; HOPKINS, KD; GOSLING, RG			ATHEROSCLEROSIS IN THE ASCENDING AORTA AND RISK OF ISCHEMIC STROKE	LANCET			English	Editorial Material							MAGNETIC-RESONANCE; WAVE VELOCITY		WHITTINGTON HOSP, ACAD DEPT MED, LONDON N19 5NF, ENGLAND; UNIV S BANK, SCH APPL SCI, LONDON, ENGLAND	University of London; University College London; London South Bank University	LEHMANN, ED (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROL, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOPKINS KD, 1994, LANCET, V343, P1447, DOI 10.1016/S0140-6736(94)92577-1; KISTLER JP, 1994, NEW ENGL J MED, V331, P1517, DOI 10.1056/NEJM199412013312211; LANNE T, 1992, ULTRASOUND MED BIOL, V18, P451, DOI 10.1016/0301-5629(92)90084-N; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; LEHMANN ED, 1994, LANCET, V344, P1763, DOI 10.1016/S0140-6736(94)92901-7; LEHMANN ED, IN PRESS CLIN SCI; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WADA T, 1994, ARTERIOSCLER THROMB, V14, P479, DOI 10.1161/01.ATV.14.3.479	15	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 2	1995	346	8975					589	590		10.1016/S0140-6736(95)91433-1	http://dx.doi.org/10.1016/S0140-6736(95)91433-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651001				2022-12-01	WOS:A1995RT18800006
J	PEKKANEN, J; TUOMILEHTO, J; UUTELA, A; VARTIAINEN, E; NISSINEN, A				PEKKANEN, J; TUOMILEHTO, J; UUTELA, A; VARTIAINEN, E; NISSINEN, A			SOCIAL-CLASS, HEALTH BEHAVIOR, AND MORTALITY AMONG MEN AND WOMEN IN EASTERN FINLAND	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; INEQUALITIES; ASSOCIATION; MAGNITUDE; EDUCATION; SMOKING; DEATH; OSLO	Objective-To evaluate the associations between social class as defined by occupation, health behaviour, and mortality from all causes and coronary heart disease among middle aged men and women in eastern Finland. Design-Prospective observational study of two independent, random population samples examined in 1972 and 1977. Setting-North Karelia and Kuopio, Finland. Subjects-8967 men and 9694 women aged 30-64 years at the beginning of the follow up study. The subjects were followed up for mortality up till 1987 by using the National Death Registry. Measurements and main results-Altogether 1429 men and 620 women died during the follow up, 603 men and 164 women of coronary heart disease. Among both sexes, compared with white collar workers unskilled blue collar workers had more adverse risk factors and also higher mortality due to coronary heart disease, other cardiovascular diseases, cancer, violent causes, and all other causes. Among men the age adjusted relative risk for all cause mortality in unskilled blue collar workers v white collar workers was reduced from 1.85 (95% confidence interval 1.55 to 2.22) to 1.47 (1.23 to 1.77) when adjusted for smoking, serum cholesterol concentration, hypertension, body mass index, and physical activity in leisure time. Among women the corresponding reduction in hazard ratio was from 1.49 (1.15 to 1.92) to 1.39 (1.07 to 1.81). The respective hazard ratios for coronary heart disease were 1.54 (1.16 to 2.02) and 1.22 (0.92 to 1.61) among men and 1.74 (1.05 to 2.90) and 1.66 (0.99 to 2.79) among women. Conclusions-Unfavourable cardiovascular risk factors and high mortality are concentrated among lower social classes in Finland. Among men about half of the excess coronary and all cause,mortality among unskilled blue collar workers was associated with their unfavourable risk factor profile. The association was smaller in women.	NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,SF-00300 HELSINKI,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,SF-70211 KUOPIO,FINLAND	Finland National Institute for Health & Welfare; University of Eastern Finland	PEKKANEN, J (corresponding author), NATL PUBL HLTH INST,DEPT ENVIRONM EPIDEMIOL,POB 95,SF-70701 KUOPIO,FINLAND.							ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ARBER S, 1990, NEW DIRECTIONS SOCIO; COX DR, 1972, J R STAT SOC B, V34, P187; CROUSE JR, 1989, LANCET, V1, P318, DOI 10.1016/S0140-6736(89)91320-2; DENNIS BH, 1993, INT J EPIDEMIOL, V22, P420, DOI 10.1093/ije/22.3.420; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HOLME I, 1976, LANCET, V2, P1396; HOLME I, 1980, J EPIDEMIOL COMMUN H, V34, P48, DOI 10.1136/jech.34.1.48; KUNST AE, 1994, INT J EPIDEMIOL, V23, P742, DOI 10.1093/ije/23.4.742; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; LUOTO R, 1994, J EPIDEMIOL COMMUN H, V48, P348, DOI 10.1136/jech.48.4.348; MACKENBACH JP, 1995, BRIT MED J, V310, P1152, DOI 10.1136/bmj.310.6988.1152; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MARTIKAINEN P, IN PRESS SOCIOLOGY H; PEKKANEN J, 1995, J EPIDEMIOL COMMUN H, V49, P144, DOI 10.1136/jech.49.2.144; POCOCK SJ, 1987, LANCET, V2, P197; PUSKA P, 1981, N KARELIA PROJECT EV; ROSENGREN A, 1988, BRIT MED J, V297, P1497, DOI 10.1136/bmj.297.6662.1497; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; SALONEN JT, 1980, 11980 SER OR REP; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1062, DOI 10.1093/oxfordjournals.aje.a115210; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1991, SOC SCI MED, V32, P1297, DOI 10.1016/0277-9536(91)90046-F; Townsend P., 1988, BLACK REPORT HLTH DI; Valkonen T, 1992, Int J Health Sci, V3, P157; VALKONEN T, 1990, SOCIOECONOMIC MORTAL; WING S, 1987, LANCET, V2, P1067; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8; 1987, HLTH ALL YEAR 2000 F; 1973, OFFICIAL STATISTIC C, V6, P104	35	150	151	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					589	593		10.1136/bmj.311.7005.589	http://dx.doi.org/10.1136/bmj.311.7005.589			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663252	Green Published			2022-12-01	WOS:A1995RT72300015
J	SEPKOWITZ, KA; ARMSTRONG, D				SEPKOWITZ, KA; ARMSTRONG, D			TREATMENT OF OPPORTUNISTIC INFECTIONS IN AIDS	LANCET			English	Editorial Material									NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	SEPKOWITZ, KA (corresponding author), MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021, USA.							BROWN AE, 1985, INFECTIOUS COMPLICAT; GLATT AE, 1994, INFECT DIS CLIN N AM, P8; 1993, HIV AIDS SURVEILLANC	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					588	589		10.1016/S0140-6736(95)91432-3	http://dx.doi.org/10.1016/S0140-6736(95)91432-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651000				2022-12-01	WOS:A1995RT18800005
J	ALAVI, A; PARRINELLO, M; FRENKEL, D				ALAVI, A; PARRINELLO, M; FRENKEL, D			AB-INITIO CALCULATION OF THE SOUND-VELOCITY OF DENSE HYDROGEN - IMPLICATIONS FOR MODELS OF JUPITER	SCIENCE			English	Article							SOLID HYDROGEN; GROUND-STATE; OSCILLATIONS; EQUATION	First-priniciples molecular dynamics simulations were used to calculate the sound velocity of dense hydrogen, and the results were compared with extrapolations of experimental data that currently conflict with either astrophysical models or data obtained from recent global oscillation measurements of Jupiter. Excellent agreement with the extrapolated experimental data was obtained. These results strongly support the notion that the existing models for the jovian interior need to be revised.	MAX PLANCK INST FESTKORPERFORSCH,D-70569 STUTTGART,GERMANY; FOM,INST ATOM & MOLEC PHYS,1098 SJ AMSTERDAM,NETHERLANDS	Max Planck Society; AMOLF	ALAVI, A (corresponding author), UNIV CAMBRIDGE,DEPT CHEM,LENSFIELD RD,CAMBRIDGE CB2 1EW,ENGLAND.		Frenkel, Daan/G-2580-2014	Frenkel, Daan/0000-0002-6362-2021				ALVAI A, 1994, PHYS REV LETT, V73, P2599; ANSEN JP, 1986, THEORY SIMPLE LIQUID; BARBEE TW, 1989, PHYS REV LETT, V62, P1150, DOI 10.1103/PhysRevLett.62.1150; CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471; CEPERLEY DM, 1980, PHYS REV LETT, V45, P566, DOI 10.1103/PhysRevLett.45.566; CEPERLEY DM, 1987, PHYS REV B, V36, P2092, DOI 10.1103/PhysRevB.36.2092; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; GYGI F, 1993, PHYS REV B, V48, P11692, DOI 10.1103/PhysRevB.48.11692; HEMLEY RJ, 1990, PHYS REV B, V42, P6458, DOI 10.1103/PhysRevB.42.6458; KOHANOFF J, 1995, PHYS REV LETT, V74, P626, DOI 10.1103/PhysRevLett.74.626; MERMIN ND, 1993, PHYS REV, V137, pA1441; MOSSER B, 1993, ASTRON ASTROPHYS, V267, P604; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NATOLI V, 1993, PHYS REV LETT, V70, P1952, DOI 10.1103/PhysRevLett.70.1952; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; Stanley H.E., 1971, PHASE TRANSITIONS CR; 1994, CRC HDB CHEM PHYSICS, P6	18	42	43	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1252	1254		10.1126/science.7652571	http://dx.doi.org/10.1126/science.7652571			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652571	Green Submitted			2022-12-01	WOS:A1995RR84200029
J	BERGGREN, KK; BARD, A; WILBUR, JL; GILLASPY, JD; HELG, AG; MCCLELLAND, JJ; ROLSTON, SL; PHILLIPS, WD; PRENTISS, M; WHITESIDES, GM				BERGGREN, KK; BARD, A; WILBUR, JL; GILLASPY, JD; HELG, AG; MCCLELLAND, JJ; ROLSTON, SL; PHILLIPS, WD; PRENTISS, M; WHITESIDES, GM			MICROLITHOGRAPHY BY USING NEUTRAL METASTABLE ATOMS AND SELF-ASSEMBLED MONOLAYERS	SCIENCE			English	Article							BEAM; SURFACES	Lithography can be performed with beams of neutral atoms in metastable excited states to pattern self-assembled monolayers (SAMs) of alkanethiolates on gold. An estimated exposure of a SAM of dodecanethiolate (DDT) to 15 to 20 metastable argon atoms per DDT molecule damaged the SAM sufficiently to allow penetration of an aqueous solution of ferricyanide to the surface of the gold. This solution etched the gold and transformed the patterns in the SAMs into structures of gold; these structures had edge resolution of less than 100 nanometers. Regions of SAMs as large as 2 square centimeters were patterned by exposure to a beam of metastable argon atoms. these observations suggest that this system may be useful in new forms of micro- and nanolithography.	HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; NATL INST STAND & TECHNOL,DIV ATOM PHYS,GAITHERSBURG,MD 20899; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; NATL INST STAND & TECHNOL,ELECTRON PHYS GRP,GAITHERSBURG,MD 20899	Harvard University; National Institute of Standards & Technology (NIST) - USA; Harvard University; National Institute of Standards & Technology (NIST) - USA			McClelland, Jabez/A-2358-2015; Prentiss, Mara/AAU-2940-2021; rolston, steven l/L-5175-2013; Sano, Michael/E-1715-2011	McClelland, Jabez/0000-0001-5672-5965; rolston, steven l/0000-0003-1671-4190; 	NIGMS NIH HHS [1-F32 GM16511-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016511] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT NL, 1992, SCIENCE, V257, P1380, DOI 10.1126/science.257.5075.1380; ADAMS CS, 1994, PHYS REP, V240, P143, DOI 10.1016/0370-1573(94)90066-3; BEHRINGER RE, 1994, J OPT SOC AM B, V11, P1166; BOZCO F, 1983, J CHEM PHYS, V78, P4256; BRAIN CD, 1987, J AM CHEM SOC, V114, P7155; BRAND JA, 1992, REV SCI INSTRUM, V63, P163, DOI 10.1063/1.1143000; CALVERT JM, 1992, THIN SOLID FILMS, V211, P359; CONRAD H, 1979, PHYS REV LETT, V42, P1082, DOI 10.1103/PhysRevLett.42.1082; DULCEY CS, 1991, SCIENCE, V252, P551, DOI 10.1126/science.2020853; DUNNING FB, 1971, J PHYS PT B ATOM M P, V4, P1696, DOI 10.1088/0022-3700/4/12/018; FAHEY DW, 1980, J PHYS E SCI INSTRUM, V13, P381, DOI 10.1088/0022-3735/13/4/004; HUANG JY, 1994, LANGMUIR, V10, P626, DOI 10.1021/la00015a005; KIM E, 1995, J ELECTROCHEM SOC, V142, P628, DOI 10.1149/1.2044112; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; MCCLELLAND JJ, 1993, SCIENCE, V262, P877, DOI 10.1126/science.262.5135.877; MCCLELLAND JJ, IN PRESS J OPT SOC B; NUZZO RG, 1987, J AM CHEM SOC, V114, P1990; TIBERIO RC, 1993, APPL PHYS LETT, V62, P476, DOI 10.1063/1.108938; TIMP G, 1992, PHYS REV LETT, V69, P1636, DOI 10.1103/PhysRevLett.69.1636; Webb HW, 1924, PHYS REV, V24, P113, DOI 10.1103/PhysRev.24.113; WHITESIDE GM, IN PRESS HDB SURFACE; WILBUR JL, UNPUB; WILBUR JL, 1994, ADV MATER, V7, P600; WILBUR JL, IN PRESS ADV MATER; XIA Y, UNPUB	26	203	212	1	42	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1255	1257		10.1126/science.7652572	http://dx.doi.org/10.1126/science.7652572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652572				2022-12-01	WOS:A1995RR84200030
J	BLASCO, MA; FUNK, W; VILLEPONTEAU, B; GREIDER, CW				BLASCO, MA; FUNK, W; VILLEPONTEAU, B; GREIDER, CW			FUNCTIONAL-CHARACTERIZATION AND DEVELOPMENTAL REGULATION OF MOUSE TELOMERASE RNA	SCIENCE			English	Article							IDENTIFICATION; SEQUENCES	Telomerase synthesizes telomeric DNA repeats onto chromosome ends de novo. The mouse telomerase RNA component was cloned and contained only 65 percent sequence identity with the human telomerase RNA. Alteration of the template region in vivo generated altered telomerase products. The shorter template regions of the mouse and other rodent telomerase RNAs could account for the shorter distribution of products (processivity) generated by the mouse enzyme relative to the human telomerase. Amounts of telomerase RNA increased in immortal cells derived from primary mouse fibroblasts. RNA was detected in all newborn mouse tissues tested but was decreased during postnatal development.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GERON CORP,MENLO PK,CA 94025	Cold Spring Harbor Laboratory; Geron Corporation			Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X	NIA NIH HHS [AG09383] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009383, R37AG009383] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHADENEAU C, 1995, ONCOGENE, V11, P841; FENG J, UNPUB; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MACIEIRACOELHO A, 1988, ANTICANCER RES, V8, P669; MCEACHEM MJ, 1995, NATURE, V346, P403; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHUMYATSKY G, 1992, NUCLEIC ACIDS RES, V20, P2159, DOI 10.1093/nar/20.suppl.2159; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	15	336	347	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1267	1270		10.1126/science.7544492	http://dx.doi.org/10.1126/science.7544492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544492				2022-12-01	WOS:A1995RR84200035
J	FENG, JL; FUNK, WD; WANG, SS; WEINRICH, SL; AVILION, AA; CHIU, CP; ADAMS, RR; CHANG, E; ALLSOPP, RC; YU, JH; LE, SY; WEST, MD; HARLEY, CB; ANDREWS, WH; GREIDER, CW; VILLEPONTEAU, B				FENG, JL; FUNK, WD; WANG, SS; WEINRICH, SL; AVILION, AA; CHIU, CP; ADAMS, RR; CHANG, E; ALLSOPP, RC; YU, JH; LE, SY; WEST, MD; HARLEY, CB; ANDREWS, WH; GREIDER, CW; VILLEPONTEAU, B			THE RNA COMPONENT OF HUMAN TELOMERASE	SCIENCE			English	Article							U3 SNRNA GENES; HUMAN FIBROBLASTS; TETRAHYMENA; REPEATS; DNA; SENESCENCE; REDUCTION; CELLS	Eukaryotic chromosomes are capped with repetitive telomere sequences that protect the ends from damage and rearrangements. Telomere repeats are synthesized by telomerase, a ribonucleic acid (RNA)-protein complex. Here, the cloning of the RNA component of human telomerase, termed hTR, is described. The template region of hTR encompasses 11 nucleotides (5'-CUAACCCUAAC) complementary to the human telomere sequence (TTAGGG)(n). Germline tissues and tumor cell lines expressed more hTR than normal somatic cells and tissues, which have no detectable telomerase activity. Human cell lines that expressed hTR mutated in the template region generated the predicted mutant telomerase activity. HeLa cells transfected with an antisense hTR lost telomeric DNA and began to die after 23 to 26 doublings. Thus, human telomerase is a critical enzyme for the long-term proliferation of immortal tumor cells.	GERON CORP,MENLO PK,CA 94025; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Geron Corporation; Cold Spring Harbor Laboratory				West, Michael/0000-0002-4842-5468	NIA NIH HHS [AG09383] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009383, R37AG009383] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; AVILION AA, 1992, DEV GENET, V13, P80, DOI 10.1002/dvg.1020130113; AVILION AA, 1995, THESIS STATE U NEW Y; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, IN PRESS P NATL ACAD; CHADENEAU C, 1995, ONCOGENE, V11, P841; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG J, UNPUB; FUNK W, UNPUB; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HOLZMANN K, 1993, GENE CHROMOSOME CANC, V6, P178, DOI 10.1002/gcc.2870060308; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIN JH, 1994, GENE, V147, P287, DOI 10.1016/0378-1119(94)90083-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MARSHALLSAY C, 1992, PLANT MOL BIOL, V19, P973, DOI 10.1007/BF00040529; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MCEACHERN MJ, IN PRESS NATURE; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller HJ., 1938, COLLECT NET, V13, P181; NILSSON P, 1994, ONCOGENE, V9, P3043; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	49	1994	2252	3	169	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1236	1241		10.1126/science.7544491	http://dx.doi.org/10.1126/science.7544491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544491				2022-12-01	WOS:A1995RR84200024
J	GIUGLIANO, D; MARFELLA, R; VERRAZZO, G; ACAMPORA, R; DONZELLA, C; QUATRARO, A; COPPOLA, L; DONOFRIO, F				GIUGLIANO, D; MARFELLA, R; VERRAZZO, G; ACAMPORA, R; DONZELLA, C; QUATRARO, A; COPPOLA, L; DONOFRIO, F			ABNORMAL RHEOLOGIC EFFECTS OF GLYCERYL TRINITRATE IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND REVERSAL BY ANTIOXIDANTS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; ANTIOXIDANTS; NITRATES; RHEOLOGY; HEMODYNAMICS	GLYCEMIC CONTROL; NITRIC-OXIDE; RISK-FACTORS; VISCOSITY; NITRATES; DISEASE	Objective: io evaluate 1) the hemorrheologic and hemodynamic effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and 2) the influence of antioxidants on these effects. Design: Case-control study. Setting: University hospital clinic. Patients: 40 patients with diabetes and no evidence of cardiovascular complications and 40 controls matched for demographic variables and body habitus. Interventions: Sublingual glyceryl trinitrate (0.3 mg) and transdermal glyceryl trinitrate patches (10 mg/d). Vitamin E, 300 mg/d orally for 7 days, and glutathione, 600 mg intravenously or intramuscularly, were given to test the effects of antioxidant supplementation. Measurements: Systolic, diastolic, and mean arterial pressure and heart rate; left ventricular ejection fraction; platelet aggregation, blood viscosity, and blood filterability in vitro and ex vivo. Results: Compared with controls, patients with diabetes had increased platelet aggregation to adenosine diphosphate (P < 0.005), increased blood viscosity (P < 0.001), and decreased blood filterability (P = 0.041) at baseline; blood pressure, heart rate, and ejection fraction were similar in the two groups. In controls, both sublingual glyceryl trinitrate and transdermal glyceryl trinitrate patches significantly reduced platelet aggregation (-38%; 95% CI, -49% to -27%) and blood viscosity (-8%; CI, -11% to -5%) and increased blood filterability (10%; CI, 7.0% to 13.1%). Slight but significant decreases in blood pressure and ejection fraction and an increase in heart rate were also seen in controls after administration of glyceryl trinitrate (both preparations). In patients with diabetes, glyceryl trinitrate paradoxically increased platelet aggregation (24%; CI, 15% to 33%) and blood viscosity (6%; CI, 2.9% to 8.8%) and decreased blood filterability (-7%; CI, -9.5% to -4.4%); hemodynamic values did not change significantly. In both groups, theologic responses to glyceryl trinitrate (end concentration, 100 and 200 ng/mL) in vitro were similar to those seen in ex vivo studies. Vitamin E and glutathione normalized theologic responses to glyceryl trinitrate in patients with diabetes. Conclusions: Organic nitrates have beneficial effects on blood theology in controls but not in patients with diabetes, in whom a paradoxical deterioration is seen. Antioxidant supplementation can normalize primary tolerance to the theologic effects of nitrates in diabetes.	UNIV NAPLES 2, NAPLES, ITALY; DIABET CLIN LEPANTO, NAPLES, ITALY; DIABET CLIN SANTA RITA, TARANTO, ITALY	Universita della Campania Vanvitelli			Marfella, Raffaele/C-6899-2012	Marfella, Raffaele/0000-0003-3960-9270; Giugliano, Dario/0000-0002-9377-873X				ABRAIRA C, 1992, DIABETES CARE, V15, P1560, DOI 10.2337/diacare.15.11.1560; BEKS PJ, 1995, DIABETOLOGIA, V38, P86, DOI 10.1007/BF02369357; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CERIELLO A, 1993, DIABETOLOGIA, V36, P265, DOI 10.1007/BF00399961; COLLIER A, 1989, DIABETES METAB, V15, P420; COLWELL JA, 1993, DIABETES, V42, P8, DOI 10.2337/diab.42.1.8; COOKE JP, 1993, CIRCULATION, V88, P2451, DOI 10.1161/01.CIR.88.5.2451; DENT M T, 1991, Diabetologia, V34, pA74; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; FITZGERALD DJ, 1984, CIRCULATION, V70, P297, DOI 10.1161/01.CIR.70.2.297; FUNG HL, 1992, AM J CARDIOL, V70, pB4, DOI 10.1016/0002-9149(92)90588-P; GIUGLIANO D, 1995, METABOLISM, V44, P363, DOI 10.1016/0026-0495(95)90167-1; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAMPTON J. R., 1967, CARDIOVASC RES, V1, P101, DOI 10.1093/cvr/1.2.101; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; KOENIG W, 1994, LANCET, V344, P711, DOI 10.1016/S0140-6736(94)92207-1; KUNISAKI M, 1993, DIABETES, V42, P1138, DOI 10.2337/diabetes.42.8.1138; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MALMBERG K, 1988, EUR HEART J, V9, P259, DOI 10.1093/oxfordjournals.eurheartj.a062494; MALMBERG KA, 1994, DIABETES CARE, V17, P1007, DOI 10.2337/diacare.17.9.1007; MARFELLA R, 1994, DIABETES, V43, P607, DOI 10.2337/diabetes.43.4.607; MCMILLAN DE, 1988, MAYO CLIN PROC, V63, P517, DOI 10.1016/S0025-6196(12)65652-3; MCVEIGH G, 1994, DIABETOLOGIA, V37, P115, DOI 10.1007/BF00428787; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; REID HL, 1976, J CLIN PATHOL, V29, P855, DOI 10.1136/jcp.29.9.855; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X; UZEL N, 1987, HORM METAB RES, V19, P89, DOI 10.1055/s-2007-1011748; WILBRANDT W, 1956, EXP CELL RES, V11, P59, DOI 10.1016/0014-4827(56)90190-2; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YUSUF S, 1988, LANCET, V1, P1088	34	34	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					338	343		10.7326/0003-4819-123-5-199509010-00003	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625621				2022-12-01	WOS:A1995RQ98800003
J	HEINSOHN, R; PACKER, C				HEINSOHN, R; PACKER, C			COMPLEX COOPERATIVE STRATEGIES IN GROUP-TERRITORIAL AFRICAN LIONS	SCIENCE			English	Article							PRISONERS-DILEMMA GAME; RECIPROCAL ALTRUISM; EVOLUTION; SCROUNGERS; PRODUCERS; FOOD	Female lions (Panthera leo) showed persistent individual differences in the extent to which they participated in group-territorial conflict. When intergroup encounters were simulated by playback of aggressive vocalizations, some individuals consistently led the approach to the recorded intruder, whereas others lagged behind and avoided the risks of fighting, The lead females recognized that certain companions were laggards but failed to punish them, which suggests that cooperation is not maintained by reciprocity. Modification of the ''odds'' in these encounters revealed that some females joined the group response when they were most needed, whereas other lagged even farther behind. The complexity of these responses emphasizes the great diversity of individual behavior in this species and the inadequacy of current theory to explain cooperation in large groups.	UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities	HEINSOHN, R (corresponding author), AUSTRALIAN NATL UNIV,DIV BOT & ZOOL,CANBERRA,ACT 0200,AUSTRALIA.							AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod Robert K., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Barnard C. J., 1984, PRODUCERS SCROUNGERS; BARNARD CJ, 1981, ANIM BEHAV, V29, P543, DOI 10.1016/S0003-3472(81)80117-0; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; BOYD R, 1994, J THEOR BIOL, V168, P29; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; GRINNELL J, 1995, ANIM BEHAV, V49, P95, DOI 10.1016/0003-3472(95)80157-X; LIMA SL, 1989, AM NAT, V134, P828, DOI 10.1086/285015; MCCOMB K, 1993, P ROY SOC B-BIOL SCI, V252, P59, DOI 10.1098/rspb.1993.0046; MCCOMB K, 1994, ANIM BEHAV, V47, P379, DOI 10.1006/anbe.1994.1052; MESTERTONGIBBONS M, 1992, Q REV BIOL, V67, P267, DOI 10.1086/417658; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK M, 1993, P NATL ACAD SCI USA, V90, P5091, DOI 10.1073/pnas.90.11.5091; PACKER C, 1990, AM NAT, V136, P1, DOI 10.1086/285079; PACKER C, 1988, AM NAT, V132, P159, DOI 10.1086/284844; Packer C., 1985, P173; PACKER C, 1977, NATURE, V265, P441, DOI 10.1038/265441a0; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; PUSEY AE, 1987, BEHAVIOUR, V101, P275, DOI 10.1163/156853987X00026; PUSEY AE, 1994, BEHAV ECOL, V5, P362, DOI 10.1093/beheco/5.4.362; Schaller GB., 1972, SERENGETI LION; SCHEEL D, 1991, ANIM BEHAV, V4, P697; STANDER PE, 1992, BEHAV ECOL SOCIOBIOL, V29, P445; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; VICKERY WL, 1991, AM NAT, V137, P847, DOI 10.1086/285197; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0; WILSON DS, 1994, TRENDS ECOL EVOL, V9, P442, DOI 10.1016/0169-5347(94)90134-1	29	255	262	2	122	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1260	1262		10.1126/science.7652573	http://dx.doi.org/10.1126/science.7652573			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652573				2022-12-01	WOS:A1995RR84200032
J	IMRIE, KR; KOVACS, MJ; SELBY, D; LIPTON, J; PATTERSON, BJ; PANTALONY, D; POLDRE, P; NGAN, BY; KEATING, A				IMRIE, KR; KOVACS, MJ; SELBY, D; LIPTON, J; PATTERSON, BJ; PANTALONY, D; POLDRE, P; NGAN, BY; KEATING, A			ISOLATED CHLOROMA - THE EFFECT OF EARLY ANTILEUKEMIC THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							GRANULOCYTIC SARCOMA; LEUKEMIA; TRANSLOCATION	Objective: To evaluate the effect of antileukemic chemotherapy administered at diagnosis on the survival of patients with isolated chloroma. Design: Retrospective review of locally identified patients and analysis of cases from the medical literature. Patients: The records of all patients with isolated chloroma identified at three teaching hospitals in Toronto between 1980 and 1994 were reviewed. A MEDLINE search was done to identify all cases of isolated chloroma reported in the English-language medical literature. Patients with a previous known hematologic disorder were excluded. Measurements: The effect of therapy on 1) the interval between diagnosis of chloroma and diagnosis of acute myeloid leukemia and 2) survival was determined. Results: 7 local patients and 83 published cases were identified, for a total of 90 evaluable patients. For the entire group, the median time to the diagnosis of acute myeloid leukemia was 9 months, and median survival was 22 months. Chemotherapy was administered to 49 patients (54%) at diagnosis of chloroma. Significantly fewer patients treated with chemotherapy subsequently developed acute myeloid leukemia (41% compared with 71%; P = 0.001). Survival was longer in patients treated with chemotherapy (>50% alive with a median follow-up of 25 months compared with a median survival of 13 months for those initially untreated; P = 0.001). Multivariate analysis showed that neither local radiotherapy nor surgery had an effect on survival. Conclusions: Administration of antileukemic chemotherapy at diagnosis of chloroma is associated with a significantly lower probability of developing acute myeloid leukemia and with longer survival.	TORONTO GEN HOSP, TORONTO, ON M5G 2C4, CANADA; PRINCESS MARGARET HOSP, TORONTO, ON, CANADA; VICTORIA HOSP, LONDON, ON, CANADA; SUNNYBROOK HLTH SCI CTR, N YORK, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Victoria; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center			Kovacs, Michael/G-3315-2011					ABE R, 1986, CANCER, V58, P1260, DOI 10.1002/1097-0142(19860915)58:6<1260::AID-CNCR2820580614>3.0.CO;2-O; Dock G., 1893, AM J MED SCI, V106, P152, DOI DOI 10.1097/00000441-189308000-00003; ESHGHABADI M, 1986, J CLIN ONCOL, V4, P912, DOI 10.1200/JCO.1986.4.6.912; HESTON JF, 1986, 45 YEARS CANCER INCI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAUSE JR, 1979, CANCER-AM CANCER SOC, V44, P1017, DOI 10.1002/1097-0142(197909)44:3<1017::AID-CNCR2820440333>3.0.CO;2-I; MEIS JM, 1986, CANCER-AM CANCER SOC, V58, P2697, DOI 10.1002/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO;2-R; NEIMAN RS, 1981, CANCER-AM CANCER SOC, V48, P1426, DOI 10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; WIERNIK PH, 1970, BLOOD-J HEMATOL, V35, P361, DOI 10.1182/blood.V35.3.361.361; YATES J, 1982, BLOOD, V60, P454	11	167	172	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					351	353		10.7326/0003-4819-123-5-199509010-00005	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625623				2022-12-01	WOS:A1995RQ98800005
J	NELLIS, WJ; ROSS, M; HOLMES, NC				NELLIS, WJ; ROSS, M; HOLMES, NC			TEMPERATURE-MEASUREMENTS OF SHOCK-COMPRESSED LIQUID-HYDROGEN - IMPLICATIONS FOR THE INTERIOR OF JUPITER	SCIENCE			English	Article							EQUATION-OF-STATE; MOLECULAR-HYDROGEN; FLUID NITROGEN; GIANT PLANETS; HIGH-DENSITY; DISSOCIATION; DEUTERIUM; KBAR	Shock temperatures of hydrogen up to 5200 kelvin were measured optically at pressures up to 83 gigapascals (830 kilobars). At highest pressures, the measured temperatures are substantially lower than predicted. These lower temperatures are caused by a continuous dissociative phase transition above 20 gigapascals. Because hydrogen is in thermal equilibrium in shock-compression experiments, the theory derived from the shock data can be applied to Jupiter. The planet's molecular envelope is cooler and has much less temperature variation than previously believed. The continuous dissociative phase transition suggests that there is no sharp boundary between Jupiter's molecular mantle and its metallic core. A possible convectively quiescent boundary layer might induce an additional layer in the molecular region, as has been predicted.	LAWRENCE LIVERMORE NATL LAB,DIV H,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	NELLIS, WJ (corresponding author), LAWRENCE LIVERMORE NATL LAB,INST GEOPHYS & PLANETARY PHYS,LIVERMORE,CA 94550, USA.							BARBEE TW, 1991, PHYS REV B, V44, P11563, DOI 10.1103/PhysRevB.44.11563; DICK RD, 1980, J CHEM PHYS, V73, P5264, DOI 10.1063/1.439955; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; HOLMES N, UNPUB; HOLMES NC, 1995, REV SCI INSTRUM, V66, P2615, DOI 10.1063/1.1145597; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; HUBBARD WB, 1980, REV GEOPHYS, V18, P1, DOI 10.1029/RG018i001p00001; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; MITCHELL AC, 1981, REV SCI INSTRUM, V52, P347, DOI 10.1063/1.1136602; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NELLIS WJ, 1984, PHYS REV LETT, V53, P1248, DOI 10.1103/PhysRevLett.53.1248; NELLIS WJ, 1991, J CHEM PHYS, V94, P2244, DOI 10.1063/1.459895; NELLIS WJ, 1983, J CHEM PHYS, V79, P1480, DOI 10.1063/1.445938; NELLIS WJ, 1980, J CHEM PHYS, V73, P6137, DOI 10.1063/1.440105; RADOUSKY HB, 1986, PHYS REV LETT, V57, P2419, DOI 10.1103/PhysRevLett.57.2419; ROSS M, 1987, J CHEM PHYS, V86, P7110, DOI 10.1063/1.452360; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; ROSS M, 1981, PHILOS T R SOC A, V303, P303, DOI 10.1098/rsta.1981.0204; SAUMON D, 1991, PHYS REV A, V44, P5122, DOI 10.1103/PhysRevA.44.5122; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; VANTHIEL M, 1973, PHYS REV LETT, V31, P979, DOI 10.1103/PhysRevLett.31.979; Zharkov V. N., 1992, HIGH PRESSURE RES AP, P393; ZHARKOV VN, 1976, JUPITER, P135	26	87	89	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1249	1252		10.1126/science.7652570	http://dx.doi.org/10.1126/science.7652570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652570				2022-12-01	WOS:A1995RR84200028
J	OLSON, MF; ASHWORTH, A; HALL, A				OLSON, MF; ASHWORTH, A; HALL, A			AN ESSENTIAL ROLE FOR RHO, RAC, AND CDC42 GTPASES IN CELL-CYCLE PROGRESSION THROUGH G(1)	SCIENCE			English	Article							C-JUN ACTIVITY; PROTEIN-KINASE; ACTIVATION DOMAIN; ADP-RIBOSYLATION; GROWTH-FACTORS; PHOSPHORYLATION; SERINE-63; PRODUCT; GENE	Members of the Rho family of small guanosine triphosphatases (GTPases) regulate the organization of the actin cytoskeleton; Rho controls the assembly of actin stress fibers and focal adhesion complexes, Rac regulates actin filament accumulation at the plasma membrane to produce lamellipodia and membrane ruffles, and Cdc42 stimulates the formation of filopodia, When microinjected into quiescent fibroblasts, Rho, Rac, and Cdc42 stimulated cell cycle progression through G(1) and subsequent DNA synthesis. Furthermore, microinjection of dominant negative forms of Rac and Cdc42 or of the Rho inhibitor C3 transferase blocked serum-induced DNA synthesis. Unlike Ras, none of the Rho GTPases activated the mitogen-activated protein kinase (MAPK) cascade that contains the protein kinases c-Raf1, MEK (MAPK or ERK kinase), and ERK (extracellular signal-regulated kinase). Instead, Rac and Cdc42, but not Rho, stimulated a distinct MAP kinase, the c-Jun kinase JNK/SAPK (Jun NH2-terminal kinase or stress-activated protein kinase). Rho, Rac, and Cdc42 control signal transduction pathways that are essential for cell growth.	UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	OLSON, MF (corresponding author), UCL, CRC, SIGNAL TRANSDUCT & ONCOGENE GRP, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND.		Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 				BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QLU RG, 1995, NATURE, V374, P457; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YAN MH, 1994, NATURE, V372, P798	28	1036	1058	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1270	1272		10.1126/science.7652575	http://dx.doi.org/10.1126/science.7652575			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652575				2022-12-01	WOS:A1995RR84200036
J	PAPPAS, PG; KAUFFMAN, CA; PERFECT, J; JOHNSON, PC; MCKINSEY, DS; BAMBERGER, DM; HAMILL, R; SHARKEY, PK; CHAPMAN, SW; SOBEL, JD				PAPPAS, PG; KAUFFMAN, CA; PERFECT, J; JOHNSON, PC; MCKINSEY, DS; BAMBERGER, DM; HAMILL, R; SHARKEY, PK; CHAPMAN, SW; SOBEL, JD			ALOPECIA ASSOCIATED WITH FLUCONAZOLE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							HIGH-DOSE KETOCONAZOLE; FUNGAL-INFECTIONS; PROPHYLAXIS; MENINGITIS; TRIAL	Objective: To describe the association between fluconazole and reversible alopecia. Design: A retrospective survey of 1) patients enrolled in NIAID Mycoses Study Group (MSG) protocols involving the long-term use of fluconazole for treatment of endemic mycoses and 2) patients treated with fluconazole outside of a protocol setting but by the MSG investigators who were MSG members. Setting: 26 MSG sites in the United States. Patients: 33 patients with various deep and superficial mycoses who developed alopecia while receiving fluconazole. Results: 11 of 26 investigators reported a total of 33 patients with substantial alopecia related to fluconazole therapy, Underlying mycoses included blastomycosis, sporotrichosis, histoplasmosis, cryptococcosis, coccidioidomycosis, and mucosal candidiasis. In separate MSG studies, 17 of 136 (12.5%) and 8 of 40 (20%) patients had substantial reversible alopecia associated with fluconazole therapy. Eight patients who were not in the protocol had similar adverse effects. Twenty-nine of 33 patients (88%) received at least 400 mg of fluconazole daily for a mean of 7. 1 months. Alopecia developed a median of 3 months after initiation of fluconazole therapy and involved the scalp in all patients. Other sites were involved in about one third of patients. Three patients required wigs because of extensive hair loss. Alopecia resolved within 6 months of discontinuation of fluconazole therapy or reduction of the daily dose by at least 50%. Conclusions: Alopecia appears to be a common adverse event associated with higher-dose (400 mg/d) fluconazole given for 2 months or longer. This effect may be severe but is reversed by discontinuing fluconazole therapy or substantially reducing the daily dose.	UNIV MICHIGAN, ANN ARBOR, MI USA; DUKE UNIV, MED CTR, DURHAM, NC USA; UNIV TEXAS, MED CTR, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX USA; MED RES CTR, KANSAS CITY, MO USA; UNIV MISSOURI, KANSAS CITY, MO USA; UNIV TEXAS, SAN ANTONIO MED CTR, SAN ANTONIO, TX USA; UNIV MISSISSIPPI, JACKSON, MS USA; WAYNE STATE MED SCH, DETROIT, MI USA	University of Michigan System; University of Michigan; Duke University; University of Texas System; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Mississippi; Wayne State University	PAPPAS, PG (corresponding author), UNIV ALABAMA, DEPT MED, DIV INFECT DIS, 1900 UNIV BLVD, 229 TINSLEY HARRISON TOWER, BIRMINGHAM, AL 35294 USA.		MOORE-MILLAR, KARENA/A-9015-2012; Bamberger, David/GYV-3403-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; Hay R J, 1988, Ann N Y Acad Sci, V544, P580, DOI 10.1111/j.1749-6632.1988.tb40456.x; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; PAPPAS PG, 1995, CLIN INFECT DIS, V20, P267, DOI 10.1093/clinids/20.2.267; PAPPAS PG, 1994, FLUCONAZOLE TREATMEN; PONT A, 1984, ARCH INTERN MED, V144, P2150, DOI 10.1001/archinte.144.11.2150; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SUGAR AM, 1987, ANTIMICROB AGENTS CH, V31, P1874, DOI 10.1128/AAC.31.12.1874; VANCAUTEREN H, 1987, REV INFECT DIS, V9, pS43; WEINROTH SE, 1993, ANN INTERN MED, V119, P637, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00029; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003	15	46	46	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					354	357		10.7326/0003-4819-123-5-199509010-00006	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625624				2022-12-01	WOS:A1995RQ98800006
J	SHAKIL, AO; CONRYCANTILENA, C; ALTER, HJ; HAYASHI, P; KLEINER, DE; TEDESCHI, V; KRAWCZYNSKI, K; CONJEEVARAM, HS; SALLIE, R; DIBISCEGLIE, AM; MELPOLDER, JC; HOOFNAGLE, JH				SHAKIL, AO; CONRYCANTILENA, C; ALTER, HJ; HAYASHI, P; KLEINER, DE; TEDESCHI, V; KRAWCZYNSKI, K; CONJEEVARAM, HS; SALLIE, R; DIBISCEGLIE, AM; MELPOLDER, JC; HOOFNAGLE, JH			VOLUNTEER BLOOD-DONORS WITH ANTIBODY TO HEPATITIS-C VIRUS - CLINICAL, BIOCHEMICAL, VIROLOGICAL, AND HISTOLOGIC FEATURES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; HEPATITIS ANTIBODIES; BLOOD DONORS; ALANINE AMINOTRANSFERASE	NON-B-HEPATITIS; NON-A-HEPATITIS; LIVER-DISEASE; POSTTRANSFUSION HEPATITIS; UNITED-STATES; INFECTION; SERUM; HCV; RNA; HISTORY	Objective: To assess the clinical significance of antibody to hepatitis C virus (anti-HCV) in volunteer blood donors. Design: Prospective cohort study. Setting: National Institutes of Health Clinical Center, a tertiary referral research hospital. Patients: 60 anti-HCV-positive blood donors, divided into three groups of 20 persons each: Group I had normal alanine aminotransferase levels, group II had levels elevated to values less than twice the normal range, and group HI had levels elevated to values greater than twice the normal range. Measurements: Medical history, results of laboratory and virologic testing, and percutaneous liver biopsy findings. Results: Participants with normal alanine aminotransferase levels were older and more often female than those with abnormal levels. The source of infection, duration of disease, symptom score, and amount of alcohol consumed were similar in the three groups. Hepatitis C virus RNA was detectable in 85% of participants, more commonly in the groups with elevated alanine aminotransferase levels (95%) than in the group with normal levels (65%); however, titers were similar in all groups. Examination of liver biopsy specimens showed chronic hepatitis in 54 participants (90%) and cirrhosis in 1 participant. The only normal liver biopsy specimens (n = 3) were those from participants who were HCV RNA negative and had normal alanine aminotransferase levels. Conclusions: Most blood donors with anti-HCV have chronic hepatitis C regardless of their serum alanine aminotransferase levels. Donors with normal alanine aminotransferase levels and no HCV RNA in their serum generally have normal liver histologic findings or minimal changes and have probably recovered from HCV infection.	NIH, LIVER DIS SECT, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA			Shaikh, Obaid/AAL-5339-2021; Kleiner, David E/N-2770-2013	Shaikh, Obaid/0000-0002-4955-9222; Kleiner, David E/0000-0003-3442-4453				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALONSO C, 1994, TRANSFUSION, V34, P527, DOI 10.1046/j.1537-2995.1994.34694295070.x; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CONRYCANTILENA C, 1992, TRANSFUSION, V32, pS46; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; HARDIMAN RP, 1993, AUST NZ J MED, V23, P176, DOI 10.1111/j.1445-5994.1993.tb01813.x; HOOFNAGLE JH, 1994, ADV INTERNAL MED, V39, P241; IRVING WL, 1994, BRIT MED J, V308, P695, DOI 10.1136/bmj.308.6930.695; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI ME, 1993, J MED VIROL, V41, P282, DOI 10.1002/jmv.1890410405; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LELBACH WK, 1975, ANN NY ACAD SCI, V252, P85, DOI 10.1111/j.1749-6632.1975.tb19146.x; MCGUINNESS PH, 1993, HEPATOLOGY, V18, P485, DOI 10.1016/0270-9139(93)90345-N; MUTIMER D, 1993, GUT, pS54; NAITO M, 1994, HEPATOLOGY, V19, P871, DOI 10.1002/hep.1840190411; NORDOY I, 1994, SCAND J GASTROENTERO, V29, P77, DOI 10.3109/00365529409090441; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WANG JT, 1993, ARCH PATHOL LAB MED, V117, P152; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YUN ZB, 1993, J MED VIROL, V39, P57, DOI 10.1002/jmv.1890390111; 1991, MMWR MORBMORTAL WKLY, V40, P1	38	226	234	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					330	337		10.7326/0003-4819-123-5-199509010-00002	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7542854				2022-12-01	WOS:A1995RQ98800002
J	UDOLPH, G; LUER, K; BOSSING, T; TECHNAU, GM				UDOLPH, G; LUER, K; BOSSING, T; TECHNAU, GM			COMMITMENT OF CNS PROGENITORS ALONG THE DORSOVENTRAL AXIS OF DROSOPHILA NEUROECTODERM	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSPLANTED INDIVIDUAL CELLS; LINEAGE ANALYSIS; MIDLINE CELLS; SPINAL-CORD; EMBRYOS; MELANOGASTER; NEUROGENESIS; NEUROBLASTS; GUIDANCE	In the Drosophila embryo, the central nervous system (CNS) develops from a population of neural stem cells (neuroblasts) and midline progenitor cells, Here, the fate and extent of determination of CNS progenitors along the dorsoventral axis was assayed. Dorsal neuroectodermal cells transplanted into the ventral neuroectoderm or into the midline produced CNS lineages consistent with their new position. However, ventral neuroectodermal cells and midline cells transplanted to dorsal sites of the neuroectoderm migrated ventrally and produced CNS lineages consistent with their origin, Thus, inductive signals at the ventral midline and adjacent neuroectoderm may confer ventral identities to CNS progenitors as well as the ability to assume and maintain characteristic positions in the developing CNS. Furthermore, ectopic transplantations of wild-type midline cells into single minded (sim) mutant embryos suggest that the ventral midline is required for correct positioning of the cells.	UNIV MAINZ, INST GENET, D-55122 MAINZ, GERMANY	Johannes Gutenberg University of Mainz				Bossing, Torsten/0000-0002-3277-9130				BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BOSSING T, UNPUB; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; Campos-Ortega J. A., 1993, DEV DROSOPHILA MELAN, VII, P1091; Campos-Ortega JAVH, 1985, EMBRYONIC DEV DROSOP; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DOE CQ, 1992, DEVELOPMENT, V116, P855; Goodman C. S., 1993, DEV DROSOPHILA MELAN, VII, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; NAMBU JR, 1993, COMP BIOCHEM PHYS A, V104, P399, DOI 10.1016/0300-9629(93)90439-B; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PACZEK M, 1993, DEVELOPMENT, V117, P205; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PROKOP A, 1994, DEVELOPMENT, V120, P2567; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SINK H, 1991, DEVELOPMENT, V112, P307; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P389, DOI 10.1007/BF00402872; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P445, DOI 10.1007/BF00375748; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; UDOLPH G, 1993, DEVELOPMENT, V118, P765; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	27	43	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	1995	269	5228					1278	1281		10.1126/science.7652576	http://dx.doi.org/10.1126/science.7652576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652576				2022-12-01	WOS:A1995RR84200038
J	WOLFEL, T; HAUER, M; SCHNEIDER, J; SERRANO, M; WOLFEL, C; KLEHMANNHIEB, E; DEPLAEN, E; HANKELN, T; ZUMBUSCHENFELDE, KHM; BEACH, D				WOLFEL, T; HAUER, M; SCHNEIDER, J; SERRANO, M; WOLFEL, C; KLEHMANNHIEB, E; DEPLAEN, E; HANKELN, T; ZUMBUSCHENFELDE, KHM; BEACH, D			A P16(INK4A)-INSENSITIVE CDK4 MUTANT TARGETED BY CYTOLYTIC T-LYMPHOCYTES IN A HUMAN-MELANOMA	SCIENCE			English	Article							MALIGNANT-MELANOMA; PEPTIDE; CELLS; ANTIGENS; GENE; IDENTIFICATION; INHIBITION; MOLECULES; SUBUNIT; BINDING	A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HL4-A2.1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16(INK4a), but not of p21 or of p27(KIP1). The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16(INK4a).	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; CATHOLIC UNIV LEUVEN,LUDWIG INST CANC RES,B-1200 BRUSSELS,BELGIUM; UNIV MAINZ,INST MOLEK GENET,D-55099 MAINZ,GERMANY	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; KU Leuven; Ludwig Institute for Cancer Research; Johannes Gutenberg University of Mainz	WOLFEL, T (corresponding author), UNIV MAINZ,MED KLIN & POLIKLIN 1,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.		Serrano, Manuel/H-2634-2015; Wölfel, Thomas/G-6519-2012	Serrano, Manuel/0000-0001-7177-9312; 				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; DEBERGEYCK V, 1994, EUR J IMMUNOL, V24, P2203, DOI 10.1002/eji.1830240941; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNUTH A, 1984, P NATL ACAD SCI-BIOL, V81, P3511, DOI 10.1073/pnas.81.11.3511; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIVINGSTON PO, 1979, INT J CANCER, V24, P34, DOI 10.1002/ijc.2910240107; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI T, 1994, CANCER RES, V54, P3396; NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PREHN RT, 1957, J NATL CANCER I, V18, P769; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SRIVASTAVA PK, 1987, P NATL ACAD SCI USA, V84, P3807, DOI 10.1073/pnas.84.11.3807; SZIKORA JP, 1993, IMMUNOGENETICS, V37, P135, DOI 10.1007/BF00216837; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VOLKENANDT M, 1991, J CUTAN PATHOL, V18, P210, DOI 10.1111/j.1600-0560.1991.tb00155.x; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; WOLFEL T, 1994, EUR J IMMUNOL, V24, P759, DOI 10.1002/eji.1830240340; XIONG Y, 1993, CELL, V75, P817	50	866	918	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1281	1284		10.1126/science.7652577	http://dx.doi.org/10.1126/science.7652577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652577				2022-12-01	WOS:A1995RR84200039
J	WYSS, DF; CHOI, JS; LI, J; KNOPPERS, MH; WILLIS, KJ; ARULANANDAM, ARN; SMOLYAR, A; REINHERZ, EL; WAGNER, G				WYSS, DF; CHOI, JS; LI, J; KNOPPERS, MH; WILLIS, KJ; ARULANANDAM, ARN; SMOLYAR, A; REINHERZ, EL; WAGNER, G			CONFORMATION AND FUNCTION OF THE N-LINKED GLYCAN IN THE ADHESION DOMAIN OF HUMAN CD2	SCIENCE			English	Article							CELL-SURFACE LIGAND; LYMPHOCYTE-T; ALTERNATIVE PATHWAY; COUPLING-CONSTANTS; MAGNETIC-RESONANCE; BINDING-SITE; PROTEIN; ACTIVATION; RESOLUTION; GLYCOSYLATION	The adhesion domain of human CD2 bears a single N-linked carbohydrate. The solution structure of a fragment of CD2 containing the covalently bound high-mannose N-glycan [-(N-acetylglucosamine)(2)-(mannose)5-8] was solved by nuclear magnetic resonance. The stem and two of three branches of the carbohydrate structure are well defined and the mobility of proximal glycan residues is restricted. Mutagenesis of all residues in the vicinity of the glycan suggests that the glycan is not a component of the CD2-CD58 interface; rather, the carbohydrate stabilizes the protein fold by counterbalancing an unfavorable clustering of five positive charges centered about lysine-61 of CD2.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; PROCEPT INC,CAMBRIDGE,MA 02139; DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODE W, 1989, BIOCHEMISTRY-US, V28, P1952; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DWEK RA, COMMUNICATION; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GOLLOB JA, IN PRESS J EXP MED; Hahn W. C., 1993, LYMPHOCYTE ADHESION, P105; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MADSEN JC, 1993, J BIOMOL NMR, V3, P239; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; QIN LH, 1994, J EXP MED, V179, P341, DOI 10.1084/jem.179.1.341; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RECNY MA, 1992, J BIOL CHEM, V267, P22428; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; VANDENEIJNDEN DH, 1986, CARBOHYD RES, V151, P329, DOI 10.1016/S0008-6215(00)90352-5; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WOOTEN EW, 1990, EUR BIOPHYS J, V18, P139, DOI 10.1007/BF02427373; WYSS DF, 1995, BIOCHEMISTRY-US, V34, P1622, DOI 10.1021/bi00005a019; WYSS DF, 1993, BIOCHEMISTRY-US, V32, P10995, DOI 10.1021/bi00092a008; WYSS DF, UNPUB; YANG SY, 1986, J IMMUNOL, V137, P1097	50	301	312	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1273	1278		10.1126/science.7544493	http://dx.doi.org/10.1126/science.7544493			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544493				2022-12-01	WOS:A1995RR84200037
J	BLADT, F; RIETHMACHER, D; ISENMANN, S; AGUZZI, A; BIRCHMEIER, C				BLADT, F; RIETHMACHER, D; ISENMANN, S; AGUZZI, A; BIRCHMEIER, C			ESSENTIAL ROLE FOR THE C-MET RECEPTOR IN THE MIGRATION OF MYOGENIC PRECURSOR CELLS INTO THE LIMB BUD	NATURE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; EPITHELIAL INTERACTIONS; TYROSINE KINASE; EXPRESSION; IDENTIFICATION; PROTOONCOGENE; MUSCULATURE; PROTEIN; ORIGIN	LIMB muscles develop from cells that migrate from the somites(1,2). The signal that induces migration of myogenic precursor cells to the limb emanates from the mesenchyme of the limb bud(2,3). Here we report that the c-met-encoded receptor tyrosine kinase is essential for migration of myogenic precursor cells into the limb anlage and for migration into diaphragm and tip of tongue. In c-met homozygous mutant (-/-) mouse embryos, the limb bud and diaphragm are not colonized by myogenic precursor cells and, as a consequence, skeletal muscles of the limb and diaphragm do not form. In contrast, development of the axial skeletal muscles proceeds in the absence of c-met signalling. The specific ligand of the c-met protein, the motility and growth factor scatter factor/hepatocyte growth factor(4-9), is expressed in limb mesenchyme and can thus provide the signal for migration which is received by c-met. We have therefore identified a paracrine signalling system that regulates migration of myogenic precursor cells.	MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY; UNIV ZURICH, INST NEUROPATHOL, CH-8091 ZURICH, SWITZERLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Zurich			Isenmann, Stefan/AAJ-3788-2020; Riethmacher, Dieter/AAP-2227-2021; Aguzzi, Adriano/A-3351-2008; Riethmacher, Dieter/AAB-8690-2022; Riethmacher, Dieter/A-6242-2010	Riethmacher, Dieter/0000-0002-4206-5529; Aguzzi, Adriano/0000-0002-0344-6708				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOBER E, 1994, DEVELOPMENT, V120, P603; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULDING M, 1994, DEVELOPMENT, V120, P957; HAYASHI K, 1995, DEVELOPMENT, V121, P661; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; PAPAIOANNOU V, 1994, GENE TARGETING PRACT, P107; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZAMEGAR R, 1995, J CELL BIOL, V129, P1177	30	1040	1081	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					768	771		10.1038/376768a0	http://dx.doi.org/10.1038/376768a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651534				2022-12-01	WOS:A1995RR83600038
J	GOLDBERG, J; HUANG, HB; KWON, YG; GREENGARD, P; NAIRN, AC; KURIYAN, J				GOLDBERG, J; HUANG, HB; KWON, YG; GREENGARD, P; NAIRN, AC; KURIYAN, J			3-DIMENSIONAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN SERINE/THREONINE PHOSPHATASE-1	NATURE			English	Article							MICROCYSTIN-LR; CALCINEURIN; IDENTIFICATION; MECHANISM; DOMAIN; HYDROLYSIS; REFINEMENT; ISOFORMS; ENZYME; ACID	The crystal structure of mammalian protein phosphatase-1, complexed with the toxin microcystin and determined at 2.1 Angstrom resolution, reveals that it is a metalloenzyme unrelated in architecture to the tyrosine phosphatases. Two metal ions are positioned by a central beta-alpha-beta-alpha-beta scaffold at the active site, from which emanate three surface grooves that are potential binding sites for substrates and inhibitors. The carboxy terminus is positioned at the end of one of the grooves such that regulatory sequences following the domain might modulate function. The fold of the catalytic domain is expected to be closely preserved in protein phosphatases 2A and 2B (calcineurin).	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University				Nairn, Angus/0000-0002-7075-0195				ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGY JR, 1995, NAT STRUCT BIOL, V2, P114, DOI 10.1038/nsb0295-114; BARFORD D, 1994, J MOL BIOL, V235, P763, DOI 10.1006/jmbi.1994.1027; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; COHEN P, 1989, REV BIOCH, V58, P453; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; FISCHER EH, 1982, TRENDS BIOCHEM SCI, V7, P3, DOI 10.1016/0968-0004(82)90051-2; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEMMINGS HCJ, 1995, MOL CELLUAR MECHANIS, P279; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM YH, 1993, J BIOL CHEM, V268, P18513; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1984, J BIOL CHEM, V259, P8847; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cb.10.110194.000415; STONE RL, 1994, J BIOL CHEM, V269, P31323; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; VINCENT JB, 1991, J BIOL CHEM, V266, P17737; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	50	729	745	4	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					745	753		10.1038/376745a0	http://dx.doi.org/10.1038/376745a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651533				2022-12-01	WOS:A1995RR83600032
J	GUADAGNOLI, E; HAUPTMAN, PJ; AYANIAN, JZ; PASHOS, CL; MCNEIL, BJ; CLEARY, PD				GUADAGNOLI, E; HAUPTMAN, PJ; AYANIAN, JZ; PASHOS, CL; MCNEIL, BJ; CLEARY, PD			VARIATION IN THE USE OF CARDIAC PROCEDURES AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							Q-WAVE; PROGNOSTIC-SIGNIFICANCE; MEDICARE POPULATION; PATIENT POPULATION; SAMPLE SELECTION; UNITED-STATES; VALIDITY; ISCHEMIA; CARE; RELIABILITY	Background. There are large geographic differences in the frequency with which coronary angiography and revascularization are performed. We attempted to assess whether differences in case mix or in the treatment of specific groups of patients may explain this variability. We also assessed the consequences of various patterns of treatment. Methods. We studied patients covered by Medicare who were 65 to 79 years of age and were admitted to 478 hospitals with acute myocardial infarctions during 1990 in New York (1852 patients), where the rate of use of cardiac procedures is low, and in Texas (1837 patients), where the rate of use of such procedures is high. We compared the patterns of treatment of clinically similar groups of patients in the two states. We also compared mortality rates and measures of the health-related quality of life. Results. Coronary angiography was performed more often in Texas than in New York (45 percent vs. 30 percent, P<0.001). The frequency of use in Texas was significantly higher than that in New York for all the clinical subgroups of patients analyzed except those at greatest risk for reinfarction. Over a two-year period, the adjusted likelihood of death was lower in New York than in Texas (hazard ratio, 0.87; 95 percent confidence interval, 0.78 to 0.98). Patients from Texas were 41 percent more likely to report angina (P = 0.002) and 62 percent more likely to say they could not perform activities requiring energy expenditure of 5 or more metabolic equivalents than patients from New York approximately two years after infarction (P<0.001). Conclusions. Physicians in Texas were more likely to perform angiography than physicians in New York for patients whose conditions allowed more discretion in the use of cardiac procedures. On average, there appears to be no advantage with respect to mortality or health-related quality of life to performing the procedures at the higher rate used in Texas.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	GUADAGNOLI, E (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115, USA.		Cleary, Paul/AAF-7048-2019		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; BODEN WE, 1989, AM J CARDIOL, V64, P799, DOI 10.1016/0002-9149(89)90768-6; BOSCH X, 1987, CIRCULATION, V75, P988, DOI 10.1161/01.CIR.75.5.988; BRAUNWALD E, 1992, HEART DISEASE TXB CA; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CLEARY PD, 1991, MED CARE, V29, P939, DOI 10.1097/00005650-199110000-00001; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; CLEARY PD, 1992, MED CARE, V30, P76; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GROTZINGER KM, 1994, MED CARE, V32, P989, DOI 10.1097/00005650-199410000-00002; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, P475; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JETTE AM, 1986, J GEN INTERN MED, V1, P427; MAISEL AS, 1985, CIRCULATION, V71, P211, DOI 10.1161/01.CIR.71.2.211; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARMOR A, 1982, CIRCULATION, V66, P415, DOI 10.1161/01.CIR.66.2.415; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SCHUSTER EH, 1981, NEW ENGL J MED, V305, P1101, DOI 10.1056/NEJM198111053051901; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530	30	187	198	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					573	578		10.1056/NEJM199508313330908	http://dx.doi.org/10.1056/NEJM199508313330908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623908				2022-12-01	WOS:A1995RQ75100008
J	HAUSKNECHT, RU				HAUSKNECHT, RU			METHOTREXATE AND MISOPROSTOL TO TERMINATE EARLY-PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ILLEGAL ABORTION; INJECTION; BRAZIL	Background. Although medical termination of pregnancy is available in Europe and China as an alternative to surgical termination, political and social factors have blocked medical approaches to pregnancy termination in the United States, Methotrexate, which is toxic to trophoblastic tissue, has been used safely to treat unruptured ectopic pregnancies, This report describes the use of a single low dose of methotrexate followed by intravaginal misoprostol for the medical termination of early pregnancy. Methods. Women seeking termination of pregnancy were selected for this study on the basis of their good general health, emotional stability, and a pregnancy of 63 days or less in duration, Each woman received an intramuscular dose of methotrexate (50 mg per square meter of body-surface area). Five to seven days later, 800 mu g of misoprostol was administered intravaginally. If abortion did not occur after seven days, the woman was offered a second dose of misoprostol or vacuum aspiration. Successful abortion was defined as a complete termination of pregnancy within seven days after the first or second administration of misoprostol. Results. A total of 171 of the 178 women enrolled in the study (96 percent) had successful medical abortions. Twenty-five women (14 percent) did not have an abortion after the first dose of misoprostol and received a second dose. Eighteen subsequently had complete abortions, but seven required suction curettage. In all seven women who required suction curettage, there was histologic evidence of disruption in the conceptus, No important side effects or complications were noted. Conclusions. The combination of methotrexate and misoprostol represents a safe and effective alternative to invasive methods for the termination of early pregnancy.	MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY	Icahn School of Medicine at Mount Sinai								BARBOSA RM, 1993, STUD FAMILY PLANN, V24, P236, DOI 10.2307/2939191; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; BUCKSHEE K, 1992, INT J GYNECOL OBSTET, V37, P297, DOI 10.1016/0020-7292(92)90334-F; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COELHO HLL, 1993, LANCET, V341, P1486; COOK RJ, 1992, FAM PLANN PERSPECT, V24, P39, DOI 10.2307/2135726; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; FERNANDEZ H, 1993, FERTIL STERIL, V59, P773; FLETCHER HM, 1993, BRIT J OBSTET GYNAEC, V100, P641, DOI 10.1111/j.1471-0528.1993.tb14230.x; GOLDSTEIN SR, 1991, AM J OBSTET GYNECOL, V165, P497, DOI 10.1016/0002-9378(91)90274-U; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HENSHAW R, 1994, ACTA OBSTET GYN SCAN, V73, P812, DOI 10.3109/00016349409072511; HOLE H, 1975, GEBURTSH FRAUENHEILK, V35, P538; ICHINOE K, 1987, AM J OBSTET GYNECOL, V156, P484, DOI 10.1016/0002-9378(87)90315-2; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; NESKET M, 1976, CANCER S, V37, P1048; ONEILL E, 1976, CANCER, V38, P984, DOI 10.1002/1097-0142(197608)38:2<984::AID-CNCR2820380249>3.0.CO;2-Q; Reich E W, 1978, Birth Defects Orig Artic Ser, V14, P139; ROSENFIELD A, 1992, AM J PUBLIC HEALTH, V82, P1325, DOI 10.2105/AJPH.82.10.1325; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; STOVALL TG, 1993, AM J OBSTET GYNECOL, V168, P1759, DOI 10.1016/0002-9378(93)90687-E; STROHMER H, 1992, HUM REPROD, V7, P1027, DOI 10.1093/oxfordjournals.humrep.a137763; THONG KJ, 1992, CONTRACEPTION, V46, P435, DOI 10.1016/0010-7824(92)90147-L; WILSON J, 1970, ANAT REC, V166, P39	27	120	124	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					537	540		10.1056/NEJM199508313330901	http://dx.doi.org/10.1056/NEJM199508313330901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623901	Bronze			2022-12-01	WOS:A1995RQ75100001
J	KHARBANDA, S; REN, RB; PANDEY, P; SHAFMAN, TD; FELLER, SM; WEICHSELBAUM, RR; KUFE, DW				KHARBANDA, S; REN, RB; PANDEY, P; SHAFMAN, TD; FELLER, SM; WEICHSELBAUM, RR; KUFE, DW			ACTIVATION OF THE C-ABL TYROSINE KINASE IN THE STRESS-RESPONSE TO DNA-DAMAGING AGENTS	NATURE			English	Article							CELL-CYCLE; PHOSPHORYLATION; BINDING	THE product of the c-abl gene is a non-receptor tyrosine kinase that is localized to the nucleus and cytoplasm. The precise function of c-Abl is unknown. Here we show that ionizing radiation activates c-Abl. Similar results were obtained with the alkylating agents cis-platinum and mitomycin C. We also demonstrate that cells deficient in c-Abl fail to activate Jun kinase (JNK/SAP kinase) after ionizing radiation or alkylating agent exposure and that reconstitution of c-Abl in these cells restores that response. In contrast, the stress response to tumour-necrosis factor is stimulated by a c-Abl-independent mechanism. These findings indicate that c-abl is involved in the stress response to DNA-damaging agents.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOL,WALTHAM,MA 02254; UNIV WURZBURG,INST RADIOBIOL & CELL BIOL,MOLEC ONCOL LAB,D-97078 WURZBURG,GERMANY; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	Brandeis University; University of Wurzburg; University of Chicago; Harvard University; Harvard Medical School	KHARBANDA, S (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CAN PHARMACOL,BOSTON,MA 02115, USA.							DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MATTIONI T, 1995, ONCOGENE, V10, P1325; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SALEEM A, 1995, J IMMUNOL, V154, P4150; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TOMASZ M, 1988, BIOCHEMISTRY-US, V27, P3182, DOI 10.1021/bi00409a009; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	19	454	470	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					785	788		10.1038/376785a0	http://dx.doi.org/10.1038/376785a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651539				2022-12-01	WOS:A1995RR83600043
J	LEV, S; MORENO, H; MARTINEZ, R; CANOLL, P; PELES, E; MUSACCHIO, JM; PLOWMAN, GD; RUDY, B; SCHLESSINGER, J				LEV, S; MORENO, H; MARTINEZ, R; CANOLL, P; PELES, E; MUSACCHIO, JM; PLOWMAN, GD; RUDY, B; SCHLESSINGER, J			PROTEIN-TYROSINE KINASE PYK2 INVOLVED IN CA2+-INDUCED REGULATION OF ION-CHANNEL AND MAP KINASE FUNCTIONS	NATURE			English	Article							NERVE GROWTH-FACTOR; POTASSIUM CHANNEL; ACETYLCHOLINE-RECEPTOR; PC12 CELLS; RAS; PHOSPHORYLATION; ACTIVATION; GENE; TRANSFORMATION; DOMAINS	The protein tyrosine kinase PYK2, which is highly expressed in the central nervous system, is rapidly phosphorylated on tyrosine residues in response to various stimuli that elevate the intracellular calcium concentration, as well as by protein kinase C activation. Activation of PYK2 leads to modulation of ion channel function and activation of the MAP kinase signalling pathway. PYK2 activation may provide a mechanism for a variety of short- and long-term calcium-dependent signalling events in the nervous system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHYSIOL,NEW YORK,NY 10016; SUGEN INC,REDWOOD CITY,CA 94063	New York University; New York University			Lev, Sima/AAP-7880-2020; PLOWMAN, Greg D/E-2012-2011	Lev, Sima/0000-0002-2108-3330; Plowman, Gregory D/0000-0002-6465-309X; Rudy, Bernardo/0000-0001-5748-6900; Peles, Elior/0000-0002-3325-0597				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMMERS R, 1993, J BIOL CHEM, V248, P24456; LEV S, 1992, J BIOL CHEM, V267, P15970; Levitan IB, 1991, NEURON CELL MOL BIOL; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LI N, 1993, NATURE, V263, P85; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANES E, 1993, NATURE, V363, P364; MARIAS R, 1993, CELL, V73, P381; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MESSING RO, 1989, J NEUROSCI, V9, P507; Moreno H., 1994, Society for Neuroscience Abstracts, V20, P725; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PAWSON A, 1993, CURR BIOL, V3, P4345; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	50	1252	1275	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					737	745		10.1038/376737a0	http://dx.doi.org/10.1038/376737a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7544443				2022-12-01	WOS:A1995RR83600031
J	LOVE, JJ; LI, XA; CASE, DA; GIESE, K; GROSSCHEDL, R; WRIGHT, PE				LOVE, JJ; LI, XA; CASE, DA; GIESE, K; GROSSCHEDL, R; WRIGHT, PE			STRUCTURAL BASIS FOR DNA BENDING BY THE ARCHITECTURAL TRANSCRIPTION FACTOR LEF-1	NATURE			English	Article							ALPHA-ENHANCER; NUCLEOPROTEIN STRUCTURES; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; MINOR-GROOVE; HMG DOMAIN; PROTEINS; BINDING; COMPLEX; TCF-1	LYMPHOID enhancer-binding factor (LEF-1) and the closely related T-cell factor 1 (TCF-1) are sequence-specific and cell-type-specific DNA-binding proteins that play important regulatory roles in organogenesis and thymocyte differentiation(1-5). LEF-1 participates in regulation of the enhancer associated with the T cell receptor (TCR)-alpha gene by inducing a sharp bend in the DNA and facilitating interactions between Ets-1, PEBP2-alpha, and ATF/CREB transcription factors bound at sites flanking the LEF-1 site(1,2,6,7). It seems that LEF-1 plays an architectural role in the assembly and function of this regulatory nucleoprotein complex(7,8). LEF-1 recognizes a specific nucleotide sequence through a high-mobilty-group (HMG) domain(1,2). Proteins containing HMG domains bind DNA in the minor groove, bend the double helix(6,9,10), and recognize four-way junctions and other irregular DNA structures(9,11). Here we report the solution structure of a complex of the LEF-1 HMG domain and adjacent basic region with its cognate DNA. The structure reveals the HMG domain bound in the widened minor groove of a markedly distorted and bent double helix. The basic region binds across the narrowed major groove and contributes to DNA recognition.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, SAN DIEGO, CA 92037 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Wright, Peter/0000-0002-1368-0223				CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GLESE K, 1991, GENE DEV, V5, P2567; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETERS R, 1995, BIOCHEMISTRY-US, V34, P4569, DOI 10.1021/bi00014a009; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SEIP S, 1994, J MAGN RESON SER B, V104, P172, DOI 10.1006/jmrb.1994.1072; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	31	527	536	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					791	795		10.1038/376791a0	http://dx.doi.org/10.1038/376791a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651541				2022-12-01	WOS:A1995RR83600045
J	REEVE, MA; FULLER, CW				REEVE, MA; FULLER, CW			A NOVEL THERMOSTABLE POLYMERASE FOR DNA-SEQUENCING	NATURE			English	Article							DOUBLE-STRANDED DNA; TAQ POLYMERASE; EXONUCLEASE ACTIVITY; GENE; PCR		AMERSHAM LIFE SCI INC,CLEVELAND,OH 44128		REEVE, MA (corresponding author), AMERSHAM INT PLC,AMERSHAM RES LABS,WHITE LION RD,AMERSHAM HP7 9LL,BUCKS,ENGLAND.			Fuller, Carl/0000-0003-2277-2119; Reeve, Michael/0000-0002-0747-9902				AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P498; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; KLENOW H, 1971, EUR J BIOCHEM, V22, P371, DOI 10.1111/j.1432-1033.1971.tb01554.x; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LEVEDAKOU EN, 1989, BIOTECHNIQUES, V7, P438; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; SAMOLS SB, 1995, COMMENTS, V21, P57; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	13	59	90	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					796	797		10.1038/376796a0	http://dx.doi.org/10.1038/376796a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651542				2022-12-01	WOS:A1995RR83600046
J	ROGAEV, EI; SHERRINGTON, R; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; LIANG, Y; CHI, H; LIN, C; HOLMAN, K; TSUDA, T; MAR, L; SORBI, S; NACMIAS, B; PIACENTINI, S; AMADUCCI, L; CHUMAKOV, I; COHEN, D; LANNFELT, L; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH				ROGAEV, EI; SHERRINGTON, R; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; LIANG, Y; CHI, H; LIN, C; HOLMAN, K; TSUDA, T; MAR, L; SORBI, S; NACMIAS, B; PIACENTINI, S; AMADUCCI, L; CHUMAKOV, I; COHEN, D; LANNFELT, L; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH			FAMILIAL ALZHEIMERS-DISEASE IN KINDREDS WITH MISSENSE MUTATIONS IN A GENE ON CHROMOSOME-1 RELATED TO THE ALZHEIMERS-DISEASE TYPE-3 GENE	NATURE			English	Article							LINKAGE	WE report the cloning of a novel gene (E5-1) encoded on chromosome 1 which has substantial nucleotide and amino-acid sequence similarity to the S182 gene on chromosome 14q24.3. Mutations, including three new missense mutations in the S182 gene, are associated with the AD3 subtype of early-onset familial Alzheimer's disease (AD)(1). Both the E5-1 and the S182 proteins are predicted to be integral membrane proteins with seven membrane-spanning domains, and a large exposed loop between the sixth and seventh transmembrane domains. Analysis of the nucleotide sequence of the open reading frame (ORF) of the E5-1 gene led to the discovery of two missense substitutions at conserved amino-acid residues in affected members of pedigrees with a form of familial AD that has a later age of onset than the AD3 subtype (50-70 years versus 30-60 years for AD3). These observations imply that the E5-1 gene on chromosome 1 and the S182 gene on chromosome 14q24.3 are members of a family of genes (presenilins) with related functions, and indicates that mutations in conserved residues of E5-1 could also play a role in the genesis of AD. Our results also indicate that still other AD susceptibility genes exist.	UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED BIOPHYS,TORONTO,ON M5S 1A8,CANADA; TORONTO HOSP,DEPT MED,DIV NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA; UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,FLORENCE,ITALY; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN NEUROSCI GERIATR MED,S-14186 HUDDINGE,SWEDEN	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Florence; Karolinska Institutet			Rogaev, Evgeny/AAN-7662-2020; Nacmias, Benedetta/J-5084-2018	Nacmias, Benedetta/0000-0001-9338-9040; sorbi, sandro/0000-0002-0380-6670; PIACENTINI, SILVIA/0000-0002-2749-6785	Canadian Institutes of Health Research [37920] Funding Source: Medline; NIA NIH HHS [P30 AG10133, U24 AG021886] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U24AG021886, P30AG010133] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; HOLLMANN N, 1994, ANNU REV NEUROSCI, V17, P31; Katzman Robert, 1994, P105; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANNFELT L, 1993, NAT GENET, V4, P218, DOI 10.1038/ng0793-218; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0	9	1652	1733	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					775	778		10.1038/376775a0	http://dx.doi.org/10.1038/376775a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651536				2022-12-01	WOS:A1995RR83600040
J	STUMVOLL, M; NURJHAN, N; PERRIELLO, G; DAILEY, G; GERICH, JE				STUMVOLL, M; NURJHAN, N; PERRIELLO, G; DAILEY, G; GERICH, JE			METABOLIC EFFECTS OF METFORMIN IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAT HEPATOCYTES; SKELETAL-MUSCLE; MECHANISM; GLUCONEOGENESIS; OXIDATION; TURNOVER; LACTATE; BIGUANIDES; THERAPY; ALANINE	Background. The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years. Methods. In 10 obese patients with NIDDM, we used a combination of isotope dilution, indirect calorimetry, bioimpedance, and tissue-balance techniques to assess the effects of metformin on systemic lactate, glucose, and free-fatty-acid turnover, lactate oxidation and the conversion of lactate to glucose; skeletal-muscle glucose and lactate metabolism; body composition; and energy expenditure before and after four months of treatment. Results. Metformin treatment decreased the mean (+/-SD) glycosylated hemoglobin value from 13.2+/-2.2 percent to 10.5+/-1.6 percent (P<0.001) and reduced fasting plasma glucose concentrations from 220+/-41 to 155+/-28 mg per deciliter (12.2+/-0.7 to 8.6+/-0.5 mmol per liter) (P<0.001). Although resting energy expenditure did not change, the patients lost 2.7+/-1.3 kg of weight (P<0.001:), 88 percent of which was adipose tissue. The mean (+/-SE) rate of plasma glucose turnover (hepatic glucose output and systemic glucose disposal) decreased from 2.8+/-0.2 to 2.0+/-0.2 mg per kilogram of body weight per minute (15.3+/-0.9 to 10.8+/-0.9 mu mol per kilogram per minute) (P<0.001), as a result of a decrease in hepatic glucose output; systemic glucose clearance did not change. The rate of conversion of lactate to glucose (gluconeogenesis) decreased by 37 percent (P<0.001), whereas lactate oxidation increased by 25 percent (P<0.001). There were no changes in the plasma lactate concentration, plasma lactate turnover, muscle lactate release, plasma free-fatty-acid turnover or uptake of glucose by muscle. Conclusions. Metformin acts primarily by decreasing hepatic glucose output, largely by inhibiting gluconeogenesis, It also seems to induce weight toss, preferentially involving adipose tissue.	UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14642; SCRIPPS CLIN & RES FDN,DIV ENDOCRINOL & METAB,LA JOLLA,CA	University of Rochester; Scripps Research Institute			Stumvoll, Michael/ABE-1121-2021	Stumvoll, Michael/0000-0001-6225-8240	NCRR NIH HHS [5MO1-RR 000954, 5MO1-RR 00044] Funding Source: Medline; NIDDK NIH HHS [DK-20411] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020411, R37DK020411] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALENGRIN F, 1987, DIABETES METAB, V13, P591; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; CIGOLINI M, 1984, DIABETES METAB, V10, P311; CONSOLI A, 1990, J CLIN INVEST, V86, P2038, DOI 10.1172/JCI114940; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GERICH JE, 1993, BAILLIERE CLIN ENDOC, V7, P551, DOI 10.1016/S0950-351X(05)80207-1; HENDLER R, 1990, INT J OBESITY, V14, P927; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V35, P1192, DOI 10.1093/ajcn/35.5.1192; JACKSON RA, 1987, DIABETES, V36, P632, DOI 10.2337/diabetes.36.5.632; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; KREISBERG RA, 1970, DIABETES, V19, P64, DOI 10.2337/diab.19.1.64; LESLIE P, 1987, CLIN SCI, V73, P41, DOI 10.1042/cs0730041; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; LUKE A, 1992, METABOLISM, V41, P450, DOI 10.1016/0026-0495(92)90083-M; MILES JM, 1987, AM J PHYSIOL, V252, pE431, DOI 10.1152/ajpendo.1987.252.3.E431; NOSADINI R, 1987, DIABETES CARE, V10, P62, DOI 10.2337/diacare.10.1.62; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; SCHAFER G, 1980, PHARMACOL THERAPEUT, V8, P275, DOI 10.1016/0163-7258(80)90049-2; SEARLE GL, 1975, DIABETES, V24, P741, DOI 10.2337/diabetes.24.8.741; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; VIGNERI R, 1987, DIABETES CARE, V10, P118, DOI 10.2337/diacare.10.1.118; WILLIAMS RH, 1959, METABOLISM, V8, P548; WILLIAMS RH, 1975, ANN INTERN MED, V83, P567, DOI 10.7326/0003-4819-83-4-567; WING RR, 1994, DIABETES CARE, V17, P30, DOI 10.2337/diacare.17.1.30; Wolfe RR, 1992, RADIOACTIVE STABLE I; WOLLEN N, 1988, BIOCHEM PHARMACOL, V37, P4353, DOI 10.1016/0006-2952(88)90617-X; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415	34	884	901	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					550	554		10.1056/NEJM199508313330903	http://dx.doi.org/10.1056/NEJM199508313330903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623903				2022-12-01	WOS:A1995RQ75100003
J	VANBIESEN, T; HAWES, BE; LUTTRELL, DK; KRUEGER, KM; TOUHARA, K; PORFIRI, E; SAKAUE, M; LUTTRELL, LM; LEFKOWITZ, RJ				VANBIESEN, T; HAWES, BE; LUTTRELL, DK; KRUEGER, KM; TOUHARA, K; PORFIRI, E; SAKAUE, M; LUTTRELL, LM; LEFKOWITZ, RJ			RECEPTOR-TYROSINE-KINASE-MEDIATED AND G-BETA-GAMMA-MEDIATED MAP KINASE ACTIVATION BY A COMMON SIGNALING PATHWAY	NATURE			English	Article							PROTEIN; P21(RAS); FIBROBLASTS; GRB2; RAS	MITOGEN-ACTIVATED protein (MAP) kinases mediate the phosphorylation and activation of nuclear transcription factors that regulate cell growth(1). MAP kinase activation may result from stimulation of either tyrosine-kinase (RTK) receptors, which possess intrinsic tyrosine kinase activity, or G-protein-coupled receptors (GPCR)(2-4). RTK-mediated mitogenic signalling involves a series of SH2- and SH3-dependent protein-protein interactions between tyrosine-phosphorylated receptor, Shc, Grb2 and Sos, resulting in Ras-dependent MAP kinase activation(5-7). The beta gamma subunits of heterotrimeric G proteins (G beta gamma) also mediate Ras-dependent MAP kinase activations(8-10) by an as-yet unknown mechanism. Here we demonstrate that activation of MAP kinase by G(i)-coupled receptors is preceded by the G beta gamma-mediated tyrosine phosphorylation of Shc, leading to an increased functional association between Shc, Grb2 and Sos. Moreover, disruption of the Shc-Grb2-Sos complex blocks G beta gamma-mediated MAP kinase activation, indicating that G beta gamma does not mediate MAP kinase activation by a direct interaction with Sos. These results indicate that G beta gamma-mediated MAP kinase activation is initiated by a tyrosine phosphorylation event and proceeds by a pathway common to both GPCRs and RTKs.	DUKE UNIV,MED CTR,DEPT MED CARDIOL,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DURHAM,NC 27710; GLAXO WELLCOME INC,DEPT MOLEC CELL BIOL,RES TRIANGLE PK,NC 27709; ONYX PHARMACEUT,RICHMOND,CA 94806; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; GlaxoSmithKline; Kobe University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SPANDIDOS DA, 1984, NATURE, V322, P469; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196	27	401	404	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					781	784		10.1038/376781a0	http://dx.doi.org/10.1038/376781a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651538				2022-12-01	WOS:A1995RR83600042
J	YU, HT; SCHREIBER, SL				YU, HT; SCHREIBER, SL			STRUCTURE OF GUANINE-NUCLEOTIDE-EXCTRANGE FACTOR HUMAN MSS4 AND IDENTIFICATION OF ITS RAB-INTERACTING SURFACE	NATURE			English	Article							BINDING DOMAIN; PROTEIN; P21	GUANINE-NUCLEOTIDE-EXCHANGE factors (GEFs) promote the exchange of GDP for GTP in Ras GTPases, and thereby positively regulate their functions(1,2). Members of the Sec4/Ypt1/Rab branch of the Ras superfamily are essential for vesicular transport(3-6). A GEF for a subset of Rab proteins, termed mammalian suppressor of Sec4 (Mss4), has been identified(7). Here we use multidimensional NMR to determine the structure of human Mss4 (hMss4), which is the first tertiary structure established for a protein with GEF activity. Mss4 contains a central beta-sheet sandwiched between two small sheets. It also binds a Zn ion through Cys 23, Cys 26, Cys 94 and Cys 97. The Rab-binding surface of hMss4 has subsequently been delineated using chemical-shift perturbation experiments and site-directed mutagenesis. The active site of hMss4 involves the Zn2+-binding region and a neighbouring loop.	HARVARD UNIV, DEPT CHEM, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute				Yu, Hongtao/0000-0002-8861-049X				AMOR JC, 1994, NATURE, V372, P704; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Higuchi R., 1990, PCR PROTOCOLS GUIDE, P177; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; LAL CC, 1993, MOL CELL BIOL, V13, P1345; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; MITSOU MY, 1992, EMBO J, V11, P2391; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WATENPAUGH KD, 1980, J MOL BIOL, V138, P615, DOI 10.1016/S0022-2836(80)80020-9; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020	29	51	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					788	791		10.1038/376788a0	http://dx.doi.org/10.1038/376788a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651540				2022-12-01	WOS:A1995RR83600044
J	ZHOU, XJ; BENSON, KF; ASHAR, HR; CHADA, K				ZHOU, XJ; BENSON, KF; ASHAR, HR; CHADA, K			MUTATION RESPONSIBLE FOR THE MOUSE PYGMY PHENOTYPE IN THE DEVELOPMENTALLY-REGULATED FACTOR HMGI-C	NATURE			English	Article							GROUP PROTEIN HMG-I(Y); GENE; EXPRESSION; DOMAIN; LOCUS	GROWTH is one of the fundamental aspects in the development of an organism. Classical genetic studies have isolated four viable, spontaneous mouse mutants' disrupted in growth, leading to dwarfism. Pygmy is unique among these mutants because its phenotype cannot be explained by aberrations in the growth hormone-insulin-like growth factor endocrine pathway(2-5). Here we show that the pygmy phenotype arises from the inactivation of Hmgi-c (ref. 6), a member of the Hmgi family(7) which function as architectural factors in the nuclear scaffolds and are critical in the assembly of stereospecific transcriptional complexes(9). Hmgi-c and another Hmgi family member, Hmgi(y) (ref. 10), were found to be expressed predominantly during embryogenesis. The HMGI proteins are known to be regulated by cell cycle-dependent phosphorylation which alters their DNA binding affinity(11). These results demonstrate the important role of HMGI proteins in mammalian growth and development.			ZHOU, XJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Green MC., 1989, GENETIC VARIANTS STR, P12; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KING J, 1955, GENETICS, V53, P487; LEHRACH H., 1990, GENOME ANAL, P39; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; NISSLEY SP, 1980, HORM METAB RES, V12, P158, DOI 10.1055/s-2007-996230; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SINHA YN, 1979, P SOC EXP BIOL MED, V162, P221, DOI 10.3181/00379727-162-40651; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264	24	531	554	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					771	774		10.1038/376771a0	http://dx.doi.org/10.1038/376771a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651535				2022-12-01	WOS:A1995RR83600039
J	[Anonymous]				[Anonymous]			CARE IN THE COMMUNITY	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					714	714						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651524				2022-12-01	WOS:A1995RR83600002
J	ANDERSON, FH				ANDERSON, FH			THE RECTAL APPROACH TO TREATMENT IN DISTAL ULCERATIVE-COLITIS	LANCET			English	Editorial Material							COLONIC MUCOSA		HLTH SCI CTR,VANCOUVER,BC,CANADA	University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba	ANDERSON, FH (corresponding author), VANCOUVER HOSP,DIV GASTROENTEROL,VANCOUVER,BC,CANADA.							AZADKHAN AK, 1977, LANCET, V2, P892; BJORCK S, 1992, AGENTS ACTIONS, pC60; CEMPIERI M, 1995, GUT, V26, P400; CHAPMAN MAS, 1994, GUT, V35, P73, DOI 10.1136/gut.35.1.73; Fahey J, 1981, ADV INFLAMMAT RES, V2, P21; Grisham M, 1990, CAN J GASTROENTEROL, V4, P295, DOI 10.1155/1990/324287; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; NORDOY A, 1991, DRUGS, V42, P331, DOI 10.2165/00003495-199142030-00001; ROEDIGER WEW, 1980, LANCET, V2, P712; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; VERNIA P, 1995, DIGEST DIS SCI, V40, P305, DOI 10.1007/BF02065414	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					520	521		10.1016/S0140-6736(95)91377-7	http://dx.doi.org/10.1016/S0140-6736(95)91377-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658775				2022-12-01	WOS:A1995RQ98600005
J	CUI, KH; HAAN, EA; WANG, LJ; MATTHEWS, CD				CUI, KH; HAAN, EA; WANG, LJ; MATTHEWS, CD			OPTIMAL POLYMERASE CHAIN-REACTION AMPLIFICATION FOR PREIMPLANTATION DIAGNOSIS IN CYSTIC-FIBROSIS (DELTA-F508)	BRITISH MEDICAL JOURNAL			English	Article							PRENATAL SEX DETERMINATION; GENETIC DIAGNOSIS; DNA AMPLIFICATION; EMBRYO BIOPSY; SINGLE CELLS; IDENTIFICATION; PRECONCEPTION; RELIABILITY; CHROMOSOME; MUTATIONS	Objective-To evaluate direct polymerase chain reaction amplification of mutation on single embryo cells for the routine preimplantation diagnosis of cystic fibrosis. Design-Direct polymerase chain reaction amplification of mutation was performed to identify the cystic fibrosis Delta F508 mutation in human blood DNA, single lymphocytes, embryos, and embryo cells obtained by biopsy. Preimplantation diagnosis was performed for a couple who were heterozygous carriers of the Delta F508 mutation. Setting-Laboratory for preimplantation diagnosis in a reproductive medicine unit. Main outcome measure-Correct diagnosis of homozygous normal, heterozygous, and homozygous abnormal DNA of the cystic fibrosis Delta F508 mutation. Results-45 blood samples (18 homozygous normal, 17 heterozygous, and 10 homozygous abnormal) and 204 single lymphocytes from known sources showed 100% amplification and were diagnosed correctly. 17 human embryos and 52 normal nucleated embryo cells obtained by single cell embryo biopsy also showed 100% amplification. After a miscarriage of the initial pregnancy (diagnosed at preimplantation to be homozygous normal) in the heterozygous carrier couple, fetal tissue was confirmed to be homozygous normal. Conclusion-Direct polymerase chain reaction amplification of mutation is a simple, fast, reliable test for the common cystic fibrosis mutation (Delta F508) in blood DNA and single cells and should be applicable to routine programmes of general screening, maternal blood examination, and preimplantation diagnosis.	WOMENS & CHILDRENS HOSP,DEPT MED GENET,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia	CUI, KH (corresponding author), UNIV ADELAIDE,QUEEN ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5011,AUSTRALIA.							Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CIU KH, 1994, LANCET, V343, P79; COUTELLE C, 1989, BRIT MED J, V299, P22, DOI 10.1136/bmj.299.6690.22; CUI KH, 1993, HUM REPROD, V8, P621, DOI 10.1093/oxfordjournals.humrep.a138107; CUI KH, 1993, THSIS U ADELAIDE, P1; CUI KJH, 1994, 13TH P ANN SCI M FER; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARRIS A, 1992, BRIT MED BULL, V48, P738, DOI 10.1093/oxfordjournals.bmb.a072575; JARMULOWICZ M, 1989, LANCET, V1, P547; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LESKO J, 1991, AM J HUM GENET, V49, P223; LO YMD, 1989, LANCET, V2, P1363; MEYERS RM, 1985, SCIENCE, V230, P1242; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; NAKAGOME Y, 1990, LANCET, V335, P291, DOI 10.1016/0140-6736(90)90109-I; PICKERING SJ, 1992, HUM REPROD, V7, P630, DOI 10.1093/oxfordjournals.humrep.a137710; ROMMENS J, 1990, AM J HUM GENET, V46, P395; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHENK TE, 1975, P NATL ACAD SCI USA, V72, P989, DOI 10.1073/pnas.72.3.989; SIMPSON JL, 1992, NEW ENGL J MED, V327, P951, DOI 10.1056/NEJM199209243271309; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; STROM CM, 1991, PREIMPLANTATION GENETICS, P131; TROUNSON AL, 1992, HUM REPROD, V7, P583; VERLINSKY Y, 1992, PRENATAL DIAG, V12, P103, DOI 10.1002/pd.1970120205; WINSTON RML, 1991, HUM REPROD, V6, P281	30	10	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					536	540		10.1136/bmj.311.7004.536	http://dx.doi.org/10.1136/bmj.311.7004.536			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7545043	Green Published			2022-12-01	WOS:A1995RR73700017
J	HAYLLAR, J; BJARNASON, I				HAYLLAR, J; BJARNASON, I			NSAIDS, COX-2 INHIBITORS, AND THE GUT	LANCET			English	Editorial Material							RISK		UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	HAYLLAR, J (corresponding author), MT ISA BASE HOSP,MT ISA,QLD,AUSTRALIA.							AKARASEREENONT P, 1994, BRIT J PHARMACOL, V110, pP183; ASLANIAN R, 1994, EXPERT OPIN INV DRUG, V3, P1323; Bjarnason I., 1994, Gastroenterology, V106, pA53; EVERSMEYER W, 1993, AM J MED S2A, V95, P10; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEWIS AJ, 1994, NONSTEROIDAL ANTIINF, P1; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114; SOMASUNDARAM S, 1995, SCAND J GASTROENTERO, V30, P289, DOI 10.3109/00365529509093280; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0	13	85	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					521	522		10.1016/S0140-6736(95)91378-5	http://dx.doi.org/10.1016/S0140-6736(95)91378-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658776				2022-12-01	WOS:A1995RQ98600006
J	LANE, RJM; BURGESS, AP; FLINT, J; RICCIO, M; ARCHARD, LC				LANE, RJM; BURGESS, AP; FLINT, J; RICCIO, M; ARCHARD, LC			EXERCISE RESPONSES AND PSYCHIATRIC-DISORDER IN CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RF,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London	LANE, RJM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON W6 8RF,ENGLAND.			Burgess, Adrian P/0000-0002-0977-8105				DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; LANE RJM, 1994, J NEUROL NEUROSUR PS, V57, P662, DOI 10.1136/jnnp.57.5.662-a; NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Wing J. K. C., 1974, MEASUREMENT CLASSIFI	5	18	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					544	545		10.1136/bmj.311.7004.544	http://dx.doi.org/10.1136/bmj.311.7004.544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663210	Green Published			2022-12-01	WOS:A1995RR73700020
J	MILLER, E; WAIGHT, PA; TEDDER, RS; SUTHERLAND, S; MORTIMER, PP; SHAFI, MS				MILLER, E; WAIGHT, PA; TEDDER, RS; SUTHERLAND, S; MORTIMER, PP; SHAFI, MS			INCIDENCE OF HIV-INFECTION IN HOMOSEXUAL MEN IN LONDON, 1988-94	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,LONDON W1P 6DB,ENGLAND; UNIV LONDON KINGS COLL,DULWICH HOSP,SCH MED & DENT,PUBL HLTH LAB,LONDON SE22 8QF,ENGLAND; CENT PUBL HLTH LAB,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND; CENT MIDDLESEX HOSP NHS TRUST,PUBL HLTH LAB,LONDON NW10 7NS,ENGLAND	University of London; University College London; University of London; King's College London; Public Health England	MILLER, E (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.			Shafi, Shuja/0000-0002-4659-8365; Tedder, Richard/0000-0002-9672-5721				HEYWARD WL, 1994, AIDS, V8, P1285, DOI 10.1097/00002030-199409000-00011; Waight P A, 1992, Commun Dis Rep CDR Rev, V2, pR85; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685	3	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					545	545		10.1136/bmj.311.7004.545	http://dx.doi.org/10.1136/bmj.311.7004.545			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663211	Green Published			2022-12-01	WOS:A1995RR73700021
J	PEACOCK, JL; BLAND, JM; ANDERSON, HR				PEACOCK, JL; BLAND, JM; ANDERSON, HR			PRETERM DELIVERY - EFFECTS OF SOCIOECONOMIC-FACTORS, PSYCHOLOGICAL STRESS, SMOKING, ALCOHOL, AND CAFFEINE	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; PSYCHOSOCIAL STRESS; PREGNANCY; CONSUMPTION; CIGARETTE; LABOR	Objective-To examine the relation between preterm birth and socioeconomic and psychological factors, smoking, and alcohol and caffeine consumption. Design-Prospective study of outcome of pregnancy. Setting-District general hospital in inner London. Participants-1860 consecutive white women booking for delivery; 1513 women studied after exclusion because of multiple pregnancy and diabetes, refusals, and loss to follow up. Measurements-Gestational age was determined from ultrasound and maternal dates; preterm birth was defined as less than 37 completed weeks. Independent variables included smoking, alcohol and caffeine consumption, and a range of indicators of socioeconomic status and psychological stress. Main results-Unifactorial analyses showed that lower social class, less education, single marital status, low income, trouble with ''nerves'' and depression, help from professional agencies, and little contact with neighbours were all significantly associated with an increased risk of preterm birth. There were no apparent effects of smoking, alcohol, or caffeine on the length of gestation overall, although there was an association between smoking and delivery before 32 weeks. Cluster analysis indicated three subgroups of women delivering preterm: two predominantly of low social status and a third of older women with higher social status who did not smoke. Mean gestational age was highest in the third group. Conclusions-Adverse social circumstances are associated with preterm birth but smoking is not, apart from an association with very early births. This runs counter to findings for fetal growth (birth weight for gestational age) in this study, where a strong effect of smoking on fetal growth was observed but there was no evidence for any association with psychosocial factors.			PEACOCK, JL (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Peacock, Janet/0000-0002-0310-2518				ABERNATHY JR, 1966, AM J PUBLIC HEALTH N, V56, P626, DOI 10.2105/AJPH.56.4.626; [Anonymous], CLASSIFICATION OCCUP; ARBUCKLE RE, 1989, PAEDIATRIC PERINATAL, V3, P115; BAKKETEIG LS, 1981, PRETERM LABOR, P17; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BERENDES H, 1992, P INT COLLABORATIVE, V3; BERKOWITZ GS, 1981, AM J EPIDEMIOL, V113, P81, DOI 10.1093/oxfordjournals.aje.a113068; BERKOWITZ GS, 1983, J PSYCHOM RES, V27, P282; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; Everitt B., 1980, CLUSTER ANAL; FEDRICK J, 1976, BRIT J OBSTET GYNAEC, V83, P342, DOI 10.1111/j.1471-0528.1976.tb00840.x; FORTIER I, 1993, AM J EPIDEMIOL, V137, P931, DOI 10.1093/oxfordjournals.aje.a116763; GARN SM, 1977, EPIDEMIOLOGY PREMATU, P127; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRIFFIN J, 1993, BORN TOO SOON; HARTIKAINENSORR.AL, 1989, OBSTET GYNECOL, V74, P13; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HEDEGAARD M, 1993, BMJ-BRIT MED J, V307, P234, DOI 10.1136/bmj.307.6898.234; MACNAUGHTONSMIT.P, 1965, SOME STATISTICAL OTH; MAIN DM, 1988, CLIN OBSTET GYNECOL, V31, P521, DOI 10.1097/00003081-198809000-00004; MCDONALD AD, 1992, AM J PUBLIC HEALTH, V82, P87, DOI 10.2105/AJPH.82.1.87; McIntosh I D, 1984, Public Health Rev, V12, P29; MEYER LC, 1994, PAEDIATR PERINAT EP, V8, P145, DOI 10.1111/j.1365-3016.1994.tb00445.x; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; MEYER MB, 1977, EPIDEMIOLOGY PREMATU, P81; NEWTON RW, 1979, BRIT MED J, V2, P411, DOI 10.1136/bmj.2.6187.411; PAYKEL ES, 1969, ARCH GEN PSYCHIAT, V21, P753; PEACOCK JL, 1991, J EPIDEMIOL COMMUN H, V45, P159, DOI 10.1136/jech.45.2.159; PEACOCK JL, 1991, INT J EPIDEMIOL, V20, P405, DOI 10.1093/ije/20.2.405; PICKERING RM, 1991, INT J EPIDEMIOL, V20, P456, DOI 10.1093/ije/20.2.456; ROBERTS WE, 1990, OBSTET GYNECOL, V76, pS85; Rose G., 1992, STRATEGY PREVENTIVE; RUTTER DR, 1990, SOC SCI MED, V30, P553, DOI 10.1016/0277-9536(90)90154-K; STEIN A, 1987, BRIT MED J, V295, P291, DOI 10.1136/bmj.295.6593.291; 1985, SAS USERS GUIDE	35	234	241	0	30	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					531	535		10.1136/bmj.311.7004.531	http://dx.doi.org/10.1136/bmj.311.7004.531			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663207	Green Published			2022-12-01	WOS:A1995RR73700015
J	QUINTERO, RA; JOHNSON, MP; ROMERO, R; SMITH, C; ARIAS, F; GUEVARAZULOAGA, F; COTTON, DB; EVANS, MI				QUINTERO, RA; JOHNSON, MP; ROMERO, R; SMITH, C; ARIAS, F; GUEVARAZULOAGA, F; COTTON, DB; EVANS, MI			IN-UTERO PERCUTANEOUS CYSTOSCOPY IN THE MANAGEMENT OF FETAL LOWER OBSTRUCTIVE UROPATHY	LANCET			English	Article							URINARY-TRACT OBSTRUCTION; CONGENITAL HYDRONEPHROSIS; RENAL-FUNCTION; INTERVENTION; INUTERO; BIOCHEMISTRY; DIAGNOSIS	In fetuses with lower obstructive uropathy, sonography cannot establish the cause of obstruction. We assessed whether percutaneous fetal cystoscopy could be useful in the evaluation and treatment of obstructive defects in utero. We inserted a fibreoptic endoscope through the lumen of the needle or trocar into the fetal bladder at the time of vesicocentesis or vesicoamniotic-shunt placement and looked at the the urethra, bladder neck, and ureteral orifices. Urethral vesicoamniotic shunting was considered in suitable cases; otherwise a percutaneous shunt was inserted. Fetal cystoscopy was possible in 11 of 13 patients referred. The bladder mucosa appeared haemorrhagic or oedematous in three, The ureteral orifices were seen in 9/11 fetuses, dilation was seen in five, but was only suspected in two by ultrasound. Ureteral webs were noted in two other fetuses. Two of seven fetuses underwent urethral vesicoamniotic shunting; urethral patency was achieved with urethral probing alone in one fetus. The remaining four fetuses were shunted with a standard technique. Fetal cystoscopy helps define the underlying conditions responsible for sonographic findings of lower obstructive uropathy, and allows the introduction of new treatments.	WAYNE STATE UNIV,HUTZEL HOSP,DEPT OBSTET & GYNECOL,DETROIT,MI; WAYNE STATE UNIV,HUTZEL HOSP,DEPT PEDIAT UROL,DETROIT,MI; ST JOHNS MERCY HOSP,DEPT OBSTET & GYNECOL,ST LOUIS,MO; CENT UNIV VENEZUELA,HOSP UNIV CARACAS,UNIDAD PERINATOL,CARACAS,VENEZUELA; NICHHD,PERINATOL RES BRANCH,BETHESDA,MD	Wayne State University; Wayne State University; Saint Johns Mercy Medical Center; University of Central Venezuela; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121				BECK AD, 1971, J UROLOGY, V105, P784, DOI 10.1016/S0022-5347(17)61629-X; BERKOWITZ RL, 1982, AM J OBSTET GYNECOL, V144, P367, DOI 10.1016/0002-9378(82)90239-3; BLACHAR A, 1994, PEDIATR NEPHROL, V8, P30, DOI 10.1007/BF00868254; CROMBLEHOLME TM, 1990, AM J OBSTET GYNECOL, V162, P1239, DOI 10.1016/0002-9378(90)90026-4; ELDER JS, 1987, LANCET, V2, P1007; EVANS MI, 1991, OBSTET GYNECOL, V77, P545; GOLBUS MS, 1982, AM J OBSTET GYNECOL, V142, P383, DOI 10.1016/S0002-9378(16)32377-8; GRANNUM PA, 1990, DIAGNOSTIC ULTRASOUN, P433; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P635, DOI 10.1001/jama.246.6.635; JOHNSON MP, 1994, AM J OBSTET GYNECOL, V170, P1770; KEATING M, 1993, PEDIATRIC SURGERY; KRAMER SA, 1983, J UROLOGY, V130, P641, DOI 10.1016/S0022-5347(17)51383-X; MANNING FA, 1983, AM J OBSTET GYNECOL, V145, P819, DOI 10.1016/0002-9378(83)90685-3; MCFADYEN IR, 1983, BRIT J OBSTET GYNAEC, V90, P342, DOI 10.1111/j.1471-0528.1983.tb08921.x; MULLER F, 1993, OBSTET GYNECOL, V82, P813; NAKAYAMA DK, 1986, J PEDIATR SURG, V21, P43, DOI 10.1016/S0022-3468(86)80651-0; NICOLINI U, 1991, PRENATAL DIAG, V11, P159, DOI 10.1002/pd.1970110305; NICOLINI U, 1987, LANCET, V2, P1338; NOIA G, 1989, Fetal Therapy, V4, P40; PADUANO L, 1991, J UROLOGY, V146, P1094, DOI 10.1016/S0022-5347(17)38009-6; QUINTERO RA, 1993, AM J OBSTET GYNECOL, V168, P1552, DOI 10.1016/S0002-9378(11)90797-2; QUINTERO RA, 1995, AM J OBSTET GYNECOL, V172, P206, DOI 10.1016/0002-9378(95)90115-9; REUSS A, 1988, LANCET, V2, P949; WILKINS IA, 1987, AM J OBSTET GYNECOL, V157, P694, DOI 10.1016/S0002-9378(87)80031-5	25	115	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					537	540		10.1016/S0140-6736(95)91381-5	http://dx.doi.org/10.1016/S0140-6736(95)91381-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658779				2022-12-01	WOS:A1995RQ98600009
J	RUSSELL, MB; OLESEN, J				RUSSELL, MB; OLESEN, J			INCREASED FAMILIAL RISK AND EVIDENCE OF GENETIC-FACTOR IN MIGRAINE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-POPULATION; PREVALENCE; AURA; HEADACHE	Objective-To investigate familial occurrence of migraine with and without aura. Design-Familial occurrence of migraine with and without aura among first degree relatives and spouses of probands with migraine with or without aura and those who had never had migraine. All interviews of first degree relatives and spouses were done blindly by a neurological resident. The operational diagnostic criteria of the International Headache Society were used. Setting-General population from Copenhagen County. Subjects-The 378 probands had 1109 first degree relatives and 229 spouses. Main outcome measures-Patterns of familial aggregation of migraine with and without aura as assessed by calculation of the population relative risk. Results-Compared with the general population the first degree relatives of probands with migraine without aura had 1.9 times the risk of migraine without aura and 1.4 times the risk of migraine with aura. The first degree relatives of probands with migraine with aura had nearly four times the risk of migraine with aura and no increased risk of migraine without aura. The first degree relatives of probands who had never had migraine had no increased risk of migraine either with or without aura. Spouses of probands with migraine without aura had 1.4 times the risk of migraine without aura whereas spouses of probands with migraine with aura had no increased risk of migraine with aura. Conclusion-The different familial patterns indicate that migraine without aura and migraine with aura have a different aetiology. Migraine without aura seems to be caused by a combination of genetic and environmental factors whereas migraine with aura is probably determined largely or exclusively by genetic factors.			RUSSELL, MB (corresponding author), UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT NEUROL,DK-2600 GLOSTRUP,DENMARK.			Olesen, Jes/0000-0002-6712-2702				ALLEN W, 1930, ARCH INTERN MED, V13, P590; BAIER WK, 1985, NEUROPEDIATRICS, V16, P84, DOI 10.1055/s-2008-1052549; BAROLIN GS, 1969, FORTSCHR NEUROL P I, V37, P521; CHRISTIANSEN V, 1925, REV NEUROL, V32, P854; DALSGAARDNIELSE.T, 1973, HEADACHE, V12, P168; DALSGAARDNIELSE.T, 1965, ACTA NEUROL SCAND, V41, P287; DAMICO D, 1991, ITAL J NEUROL SCI, V12, P581, DOI 10.1007/BF02336955; DEVOTO M, 1986, CEPHALALGIA, V6, P101, DOI 10.1046/j.1468-2982.1986.0602101.x; GOODELL H, 1954, ARCH NEUROLOGY PSYCH, V72, P375; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; LEONE M, 1994, CEPHALALGIA, V14, P280, DOI 10.1046/j.1468-2982.1994.1404280.x; MOCHI M, 1993, CEPHALALGIA, V13, P389, DOI 10.1046/j.1468-2982.1993.1306389.x; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; RASMUSSEN BK, 1992, INT J EPIDEMIOL, V21, P1138, DOI 10.1093/ije/21.6.1138; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1993, NEUROLOGY, V43, P1369, DOI 10.1212/WNL.43.7.1369; SELBY G, 1960, J NEUROL NEUROSUR PS, V23, P23, DOI 10.1136/jnnp.23.1.23; VILATELA EA, 1992, NEUROEPIDEMIOLOGY, V11, P46, DOI 10.1159/000110908; WATERS WE, 1971, BRIT MED J, V2, P77, DOI 10.1136/bmj.2.5753.77; WEISS KM, 1982, J CHRON DIS, V35, P539, DOI 10.1016/0021-9681(82)90073-X; 1988, CEPHALALGIA S7, V8, P1	25	272	276	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					541	544		10.1136/bmj.311.7004.541	http://dx.doi.org/10.1136/bmj.311.7004.541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663209	Green Published			2022-12-01	WOS:A1995RR73700019
J	SAUNDERS, P; HERXHEIMER, A				SAUNDERS, P; HERXHEIMER, A			WHO MODEL LIST OF ESSENTIAL DRUGS - A BEACON THROUGH 2 DECADES	LANCET			English	Editorial Material									UNITED KINGDOM COCHRANE CTR,OXFORD,ENGLAND	Cochrane Centre	SAUNDERS, P (corresponding author), ESSENTIAL DRUGS PROJECT,LONDON,ENGLAND.		Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380				[Anonymous], 1977, WHO TECH REP SER, V615; 1990, LANCET, V335, P1003; 1995, WHO TECH REP SER, V850; WHODAP901, P13	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	519		10.1016/S0140-6736(95)91375-0	http://dx.doi.org/10.1016/S0140-6736(95)91375-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658773				2022-12-01	WOS:A1995RQ98600003
J	SCHARSCHMIDT, BF				SCHARSCHMIDT, BF			HEPATITIS-E - A VIRUS IN WAITING	LANCET			English	Editorial Material							NON-B HEPATITIS; NON-A		UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SCHARSCHMIDT, BF (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.							BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1995, LANCET, V315, P1025; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1016/0270-9139(93)90171-I; LOK ASF, 1994, J HEPATOL, V20, P567, DOI 10.1016/S0168-8278(05)80341-1; NANDA SK, 1995, GASTROENTEROLOGY, V108, P225, DOI 10.1016/0016-5085(95)90028-4; PAUL DA, 1994, J INFECT DIS, V169, P801, DOI 10.1093/infdis/169.4.801; PURDY MA, 1994, GASTROENTEROL CLIN N, V23, P537; REYES GR, 1990, SCIENCE, V24, P1335; VASHWANATHAN R, 1957, INDIAN J MED RES S, V45, P1; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L	11	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	520		10.1016/S0140-6736(95)91376-9	http://dx.doi.org/10.1016/S0140-6736(95)91376-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658774				2022-12-01	WOS:A1995RQ98600004
J	SUDLOW, CM; RODGERS, H; KENNY, RA; THOMSON, RG				SUDLOW, CM; RODGERS, H; KENNY, RA; THOMSON, RG			SERVICE PROVISION AND USE OF ANTICOAGULANTS IN ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MITRAL-STENOSIS; THROMBOEMBOLIC COMPLICATIONS; SYSTEMIC EMBOLIZATION; RANDOMIZED TRIAL; GENERAL-PRACTICE; STROKE; WARFARIN; PREVENTION; PREVALENCE	Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin. Implementing this research evidence requires not only an understanding of the trials' results and of the changes that they imply for clinicians' treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes. Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment. This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials' results. These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	SUDLOW, CM (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Sudlow, Cathie/0000-0002-7725-7520; Kenny, Rose Anne/0000-0002-9336-8124				[Anonymous], 1994, ARCH INTERN MED, V154, P1449; [Anonymous], 1994, LANCET, V343, P687; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; BARNABY J, 1993, BRIT MED J, V306, P207, DOI 10.1136/bmj.306.6871.207-b; BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; BLACKSHEAR JL, 1993, AM J CARDIOL, V72, P840, DOI 10.1016/0002-9149(93)91079-W; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAMM AJ, 1980, AM HEART J, V99, P598, DOI 10.1016/0002-8703(80)90733-4; CAMPBELL A, 1974, BRIT HEART J, V36, P1005; CAPLAN LR, 1986, ANN NEUROL, V19, P158, DOI 10.1002/ana.410190208; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CHIMOWITZ MI, 1993, STROKE, V24, P1015, DOI 10.1161/01.STR.24.7.1015; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CORBALAN R, 1992, AM HEART J, V124, P149, DOI 10.1016/0002-8703(92)90933-M; DOBLE N, 1987, J ROY SOC MED, V80, P627, DOI 10.1177/014107688708001009; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FLEGEL KM, 1991, J CLIN EPIDEMIOL, V44, P551, DOI 10.1016/0895-4356(91)90219-Y; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; KENNEDY RD, 1972, GERONTOL CLIN, V14, P5, DOI 10.1159/000245366; KITCHIN AH, 1977, BRIT HEART J, V39, P889, DOI 10.1136/hrt.39.8.889; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDAHL S, 1984, EUR HEART J, V5, P326, DOI 10.1093/oxfordjournals.eurheartj.a061659; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; MCINNES GT, 1987, J ROY COLL PHYS LOND, V21, P42; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; NADEAU SE, 1993, STROKE, V24, P2128, DOI 10.1161/01.STR.24.12.2128; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; PELL JP, 1993, BRIT J GEN PRACT, V43, P152; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; ROSE G, 1978, BRIT HEART J, V40, P636; RUOCCO NA, 1986, J AM COLL CARDIOL, V7, pA165; SHAKESPEARE J, 1994, BRIT MED J, V308, P415, DOI 10.1136/bmj.308.6925.415a; TAYLOR F, 1994, BRIT MED J, V307, P1493; TOHGI H, 1991, EUR NEUROL, V31, P126, DOI 10.1159/000116661; 1994, STROKE, V25, P1315; 1991, CIRCULATION, V84, P527; 1993, 1991 CENSUS; 1993, LANCET, V342, P1255; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	48	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					558	560		10.1136/bmj.311.7004.558	http://dx.doi.org/10.1136/bmj.311.7004.558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663216	Green Published			2022-12-01	WOS:A1995RR73700029
J	THORLACIUS, S; TRYGGVADOTTIR, L; OLAFSDOTTIR, GH; JONASSON, JG; OGMUNDSDOTTIR, HM; TULINIUS, H; EYFJORD, JE				THORLACIUS, S; TRYGGVADOTTIR, L; OLAFSDOTTIR, GH; JONASSON, JG; OGMUNDSDOTTIR, HM; TULINIUS, H; EYFJORD, JE			LINKAGE TO BRCA2 REGION IN HEREDITARY MALE BREAST-CANCER	LANCET			English	Note							ANDROGEN RECEPTOR GENE; FAMILIES; RISKS	Breast cancer is rare in men, and family history of the disease is a risk factor. The recently discovered BRCA2 gene on chromosome 13q is thought to account for some families with increased risk of breast cancer, including male breast cancer. We descibe a family with multiple cases of male breast cancer but, interestingly, no increase in female breast cancer. Linkage to the BRCA2 region is demonstrated and all the affected men share the same haplotype for the BCRA2 markers and loss of the other alleles in their tumours.	ICELAND CANC SOC, MOLED & CELL BIOL RES LAB, IS-125 REYKJAVIK, ICELAND; ICELAND CANC SOC, ICELAND CANC REGISTRY, IS-125 REYKJAVIK, ICELAND; UNIV HOSP REYKJAVIK, DEPT PATHOL, REYKJAVIK, ICELAND	Landspitali National University Hospital			Ögmundsdóttir, Helga M/L-6970-2015	Tryggvadottir, Laufey/0000-0001-8067-9030; Jonasson, Jon G./0000-0002-2635-5032				ANDERSON DE, 1992, J NATL CANCER I, V84, P1114, DOI 10.1093/jnci/84.14.1114; BORRESEN AL, 1992, CANCER RES, V52, P3234; COLLINS N, 1995, ONCOGENE, V10, P1673; EASTON DF, 1993, AM J HUM GENET, V52, P678; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; TULINIUS H, 1992, J MED GENET, V29, P158, DOI 10.1136/jmg.29.3.158; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	10	80	84	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	1995	346	8974					544	545		10.1016/S0140-6736(95)91383-1	http://dx.doi.org/10.1016/S0140-6736(95)91383-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658781				2022-12-01	WOS:A1995RQ98600011
J	BECHARA, A; TRANEL, D; DAMASIO, H; ADOLPHS, R; ROCKLAND, C; DAMASIO, AR				BECHARA, A; TRANEL, D; DAMASIO, H; ADOLPHS, R; ROCKLAND, C; DAMASIO, AR			DOUBLE DISSOCIATION OF CONDITIONING AND DECLARATIVE KNOWLEDGE RELATIVE TO THE AMYGDALA AND HIPPOCAMPUS IN HUMANS	SCIENCE			English	Article							MEMORY; FEAR; AMNESIA; SYSTEMS; DAMAGE	A patient with selective bilateral damage to the amygdala did not acquire conditioned autonomic responses to visual or auditory stimuli but did acquire the declarative facts about which visual or auditory stimuli were paired with the unconditioned stimulus. By contrast, a patient with selective bilateral damage to the hippocampus failed to acquire the facts but did acquire the conditioning. Finally, a patient with bilateral damage to both amygdala and hippocampal formation acquired neither the conditioning nor the facts. These findings demonstrate a double dissociation of conditioning and declarative knowledge relative to the human amygdala and hippocampus.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA; MIT, INFORMAT & DECIS SYST LAB, CAMBRIDGE, MA 02139 USA	University of Iowa; Salk Institute; Massachusetts Institute of Technology (MIT)			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389	NINDS NIH HHS [P01 NS19632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS019632] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ADOLPHS R, IN PRESS J NEUROSCI; Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; [Anonymous], 1987, HDB PHYSL 1 NERVOUS; BERGER TW, 1983, BEHAV BRAIN RES, V8, P49, DOI 10.1016/0166-4328(83)90171-7; Damasio AR., 2006, DESCARTES ERROR EMOT; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEBAR KS, IN PRESS J NEUROSCI; LEBAR KS, 1994, SOC NEUR ABSTR, V20, P360; LEDOUX JE, 1994, SCI AM, V270, P50, DOI 10.1038/scientificamerican0694-50; LEE GP, 1988, NEUROPSY NEUROPSY BE, V1, P119; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MISHKIN M, 1994, CURR OPIN NEUROBIOL, V4, P200, DOI 10.1016/0959-4388(94)90073-6; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TRANEL D, 1994, PSYCHOPHYSIOLOGY, V31, P427, DOI 10.1111/j.1469-8986.1994.tb01046.x; TRANEL D, 1989, NEUROPSYCHOLOGIA, V27, P381, DOI 10.1016/0028-3932(89)90046-8; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; VANHOESEN GW, 1985, ANN NY ACAD SCI, V444, P97; Wechsler D., 1987, WMS R WECHSLER MEMOR; Wechsler D., 1991, WECHSLER ADULT INTEL; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	27	905	921	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1115	1118		10.1126/science.7652558	http://dx.doi.org/10.1126/science.7652558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RQ748	7652558				2022-12-01	WOS:A1995RQ74800048
J	CHENN, A; MCCONNELL, SK				CHENN, A; MCCONNELL, SK			CLEAVAGE ORIENTATION AND THE ASYMMETRIC INHERITANCE OF NOTCH1 IMMUNOREACTIVITY IN MAMMALIAN NEUROGENESIS	CELL			English	Article							CEREBRAL-CORTEX; CELL LINEAGE; RADIAL GLIA; PATTERNS; MOUSE; MIGRATION; NEURONS; FATE; GENE	Neurons in the mammalian central nervous system are generated from progenitor cells near the lumen of the neural tube. Time-lapse microscopy of dividing cells in slices of developing cerebral cortex reveals that cleavage orientation predicts the fates of daughter cells. Vertical cleavages produce behaviorally and morphologically identical daughters that resemble precursor cells; these symmetric divisions may serve to expand or maintain the progenitor pool. In contrast, horizontally dividing cells produce basal daughters that behave like young migratory neurons and apical daughters that remain within the proliferative zone. Notch1 immunoreactivity is distributed asymmetrically in mitotic cells, with Notch1 inherited selectively by the basal (neuronal) daughter of horizontal divisions. These results provide cellular and molecular evidence that cortical neurons are generated from asymmetric divisions.			CHENN, A (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM07365] Funding Source: Medline; NIMH NIH HHS [MH51864] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051864] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; BERRY M, 1965, J ANAT, V99, P691; CAVINESS VS, 1995, IN PRESS TRENDS NEUR; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DAILEY ME, 1994, J NEUROSCI, V14, P1060, DOI 10.1523/JNEUROSCI.14-03-01060.1994; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; GRAY GE, 1992, DEVELOPMENT, V114, P271; HICKS SP, 1968, ANAT REC, V160, P619, DOI 10.1002/ar.1091600311; HINDS JW, 1971, Z ZELLFORSCH MIK ANA, V115, P226, DOI 10.1007/BF00391127; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEVINE SM, 1988, J COMP NEUROL, V277, P441, DOI 10.1002/cne.902770309; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MARTIN AH, 1967, NATURE, V215, P1133; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MILLER MW, 1985, DEV BRAIN RES, V23, P187, DOI 10.1016/0165-3806(85)90040-9; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; NYE JS, 1994, DEVELOPMENT, V120, P2421; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; ROBERTS JS, 1993, DEV BIOL, V155, P396, DOI 10.1006/dbio.1993.1038; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SMART IHM, 1973, J ANAT, V116, P67; SPANA EP, 1995, IN PRESS DEVELOPMENT; STENSAAS LJ, 1968, Z ZELLFORSCH MIK ANA, V91, P341, DOI 10.1007/BF00440763; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Woods D F, 1993, J Cell Sci Suppl, V17, P171; ZAMENHOF S, 1986, DEV BRAIN RES, V31, P143	41	609	621	0	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					631	641		10.1016/0092-8674(95)90035-7	http://dx.doi.org/10.1016/0092-8674(95)90035-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664342	Bronze			2022-12-01	WOS:A1995RR73400014
J	DENG, CX; ZHANG, PM; HARPER, JW; ELLEDGE, SJ; LEDER, P				DENG, CX; ZHANG, PM; HARPER, JW; ELLEDGE, SJ; LEDER, P			MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL	CELL			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; GENE AMPLIFICATION; CDK2 ACTIVITY; APOPTOSIS; INHIBITOR; PROTEIN; IRRADIATION; EXPRESSION; DEFICIENT	p21(CIP1/WAF1) is a CDK inhibitor regulated by the tumor suppressor p53 and is hypothesized to mediate G1 arrest. p53 has been suggested to derive anti-oncogenic properties from this relationship. To test these notions, we created mice lacking p21(CIP1/WAF1). They develop normally and (unlike p53(-/-) mice) have not developed spontaneous malignancies during 7 months of observation. Nonetheless, p21(-/-) embryonic fibroblasts are significantly deficient in their ability to arrest in G1 in response to DNA damage and nucleotide pool perturbation. p21(-/-) cells also exhibit a significant growth alteration in vitro, achieving a saturation density as high as that observed In p53(-/-) cells. In contrast, other aspects of p53 function, such as thymocytic apoptosis and the mitotic spindle checkpoint, appear normal. These results establish the role of p21(CIP1/WAF1) in the G1 checkpoint, but suggest that the anti-apoptotic and the anti-oncogenic effects of p53 are more complex.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT HUMAN & MOLEC GENET,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine			deng, chuxia/N-6713-2016	Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG11085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1994, NAT GENET, V5, P225; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REOBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P71; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1993, ONCOGENE, V8, P1; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU F, 1995, P NATL ACAD SCI USA, V92, P1357; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	64	1914	1953	1	42	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					675	684		10.1016/0092-8674(95)90039-X	http://dx.doi.org/10.1016/0092-8674(95)90039-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664346	Bronze			2022-12-01	WOS:A1995RR73400018
J	DU, ZJ; LANG, SM; SASSEVILLE, VG; LACKNER, AA; ILYINSKII, PO; DANIEL, MD; JUNG, JU; DESROSIERS, RC				DU, ZJ; LANG, SM; SASSEVILLE, VG; LACKNER, AA; ILYINSKII, PO; DANIEL, MD; JUNG, JU; DESROSIERS, RC			IDENTIFICATION OF A NEF ALLELE THAT CAUSES LYMPHOCYTE-ACTIVATION AND ACUTE DISEASE IN MACAQUE MONKEYS	CELL			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL ACTIVATION; MOLECULAR CLONE; RHESUS-MONKEYS; ANTIGEN; RETROVIRUS; AIDS; PHOSPHORYLATION; PATHOGENICITY; DETERMINANTS	Residues 17 and 18 in nef of SIVmac239 were changed from RQ to YE to create a translated sequence of SRPSGDLYERLLRARGETYGRLLGEVEDGYSQSP from residues 10-43. The YXXL motifs in this context match very well with consensus sequences for SH2 binding domains and are similar to ones present in nef of the acutely lethal pathogen SIVpbj14. The YE variant of SIVmac239, unlike SIVmac239 but like SIVpbj14, replicated well in resting peripheral blood mononuclear cell cultures, caused extensive T lymphocyte activation, and produced an acute disease in rhesus and pigtailed monkeys characterized by severe diarrhea, rash, and extensive lymphoid proliferation in the gastrointestinal tract. The YEnef gene transformed NIH 3T3 cells in culture. Both 239nef and YEnef were found to associate with src in cotransfected COS cells, and both 60 kDa src and 34 kDa nef were phosphorylated at tyrosine in these cells. The extent of tyrosine phosphorylation of 239nef was considerably less than that of YEnef in these assays. These findings identity an important determinant of the SIVpbj14 phenotype, and they provide evidence of a role for nef in signal transduction and cellular activation.			DU, ZJ (corresponding author), HARVARD UNIV, NEW ENGLAND REG PRIMATE RES CTR, SCH MED, SOUTHBOROUGH, MA 01772 USA.				NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI25328] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; BARBARESCHI M, 1994, AM J CLIN PATHOL, V102, P171, DOI 10.1093/ajcp/102.2.171; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.iy.12.040194.002325; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DITTMAR MT, 1995, P NATL ACAD SCI USA, V92, P1362, DOI 10.1073/pnas.92.5.1362; DOLLARD SC, 1994, J VIROL, V68, P7800, DOI 10.1128/JVI.68.12.7800-7809.1994; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FULTZ PN, 1994, VIRUS RES, V32, P205, DOI 10.1016/0168-1702(94)90042-6; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; ISRAEL ZR, 1993, AIDS RES HUM RETROV, V9, P277, DOI 10.1089/aid.1993.9.277; JUNG JU, 1995, IN PRESS J BIOL CHEM; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LANDBERG G, 1990, EXP CELL RES, V187, P111, DOI 10.1016/0014-4827(90)90124-S; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	223	224	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	1995	82	4					665	674		10.1016/0092-8674(95)90038-1	http://dx.doi.org/10.1016/0092-8674(95)90038-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664345	Bronze			2022-12-01	WOS:A1995RR73400017
J	GERASIMOVA, TI; GDULA, DA; GERASIMOV, DV; SIMONOVA, O; CORCES, VG				GERASIMOVA, TI; GDULA, DA; GERASIMOV, DV; SIMONOVA, O; CORCES, VG			A DROSOPHILA PROTEIN THAT IMPARTS DIRECTIONALITY ON A CHROMATIN INSULATOR IS AN ENHANCER OF POSITION-EFFECT VARIEGATION	CELL			English	Article							GYPSY TRANSPOSABLE ELEMENT; HAIRY-WING PROTEIN; ZINC FINGER PROTEIN; YELLOW LOCUS; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; MELANOGASTER; GENE; EXPRESSION; SUPPRESSOR	The suppressor of Hairy wing (su(Hw)) protein inhibits the function of transcriptional enhancers located distally from the promoter with respect to the location of su(Hw)-binding sites, This polarity is due to the ability of the su(Hw)-binding region to form a chromatin insulator. Mutations in modifier of mdg4 (mod(mdg4)) enhance the effect of su(Hw) by inhibiting the function of enhancers located on both sides of the su(Hw)-binding region. This inhibition results in a variegated expression pattern, and mutations in mod(mdg4) act as classical enhancers of position-effect variegation. The mod(mdg4) and su(Hw) proteins interact with each other. The mod(mdg4) protein controls the nature of the repressive effect of su(Hw): in the absence of mod(mdg4) protein, su(Hw) exerts a bidirectional silencing effect, whereas in the presence of mod(mdg4), the silencing effect is transformed into unidirectional repression.	RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW 117334,RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	GERASIMOVA, TI (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.		Simonova, Olga B/K-8890-2014	Corces, Victor/0000-0001-5140-4337; Simonova, Olga/0000-0001-9439-524X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035463] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35463] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1991, TRENDS GENET, V7, P86, DOI 10.1016/0168-9525(91)90277-W; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; GEORGIEV PG, 1989, MOL GEN GENET, V220, P121, DOI 10.1007/BF00260865; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P8593, DOI 10.1073/pnas.85.22.8593; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GINIGER E, 1994, DEVELOPMENT, V120, P1385; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JACK J, 1991, DEVELOPMENT, V113, P735; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MARTIN M, 1989, MOL GEN GENET, V218, P118, DOI 10.1007/BF00330574; MAZO AM, 1989, EMBO J, V8, P903, DOI 10.1002/j.1460-2075.1989.tb03451.x; MOHLER J, 1982, CHROMOSOMA, V86, P457, DOI 10.1007/BF00330121; PARKHURST SM, 1988, GENE DEV, V2, P1205, DOI 10.1101/gad.2.10.1205; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; PEIFER M, 1988, P NATL ACAD SCI USA, V85, P9650, DOI 10.1073/pnas.85.24.9650; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Sambrook J., 1989, MOL CLONING LAB MANU; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PA, 1992, MOL GEN GENET, V233, P65, DOI 10.1007/BF00587562; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; SPRADLING AC, 1979, CELL, V16, P589, DOI 10.1016/0092-8674(79)90032-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLFFE AP, 1994, CURR BIOL, V4, P85, DOI 10.1016/S0960-9822(00)00022-1; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	42	249	256	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					587	597		10.1016/0092-8674(95)90031-4	http://dx.doi.org/10.1016/0092-8674(95)90031-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664338	hybrid			2022-12-01	WOS:A1995RR73400010
J	HANSEN, SK; TJIAN, R				HANSEN, SK; TJIAN, R			TAFS AND TFIIA MEDIATE DIFFERENTIAL UTILIZATION OF THE TANDEM ADH PROMOTERS	CELL			English	Article							ALCOHOL-DEHYDROGENASE GENE; DROSOPHILA TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; RNA-POLYMERASE; 2 PROMOTERS; CELL-LINES; FAT-BODY; MELANOGASTER; EXPRESSION; ENHANCER	The D. melanogaster alcohol dehydrogenase (Adh) gene is transcribed from two tandem promoters that are differentially utilized at various stages during development. To determine the mechanism of promoter selectivity, we have analyzed the activity of the Adh promoters both in vitro and in transfected cells. We found that selective promoter utilization is controlled by distinct initiator elements. Reconstitution of Adh transcription with purified components requires a specific TBP-TAF complex that, in concert with TFIIA, directs differential Adh promoter transcription. Fractionation of this TBP-TAF complex reveals that TAF(II)150 is required for discrimination between the proximal and distal promoters. We propose a mechanism for regulating differential promoter utilization during Drosophila development that involves the recognition of specific initiator elements by TAFs in the TFIID complex.			HANSEN, SK (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; ABEL T, 1993, DEVELOPMENT, V119, P623; AYER S, 1990, MOL CELL BIOL, V10, P3512, DOI 10.1128/MCB.10.7.3512; AYER S, 1992, MOL CELL BIOL, V12, P661, DOI 10.1128/MCB.12.2.661; BENYAJATI C, 1987, NUCLEIC ACIDS RES, V15, P7903, DOI 10.1093/nar/15.19.7903; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BENYAJATI C, 1992, NUCLEIC ACIDS RES, V20, P4481, DOI 10.1093/nar/20.17.4481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBIN V, 1989, GENE DEV, V3, P2191, DOI 10.1101/gad.3.12b.2191; CORBIN V, 1990, GENETICS, V124, P637; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FRANK DJ, 1995, J BIOL CHEM, V270, P6292, DOI 10.1074/jbc.270.11.6292; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MOSES K, 1990, MOL CELL BIOL, V10, P539, DOI 10.1128/MCB.10.2.539; PETERSON MG, 1991, NATURE, V354, P369; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SIMCOX AA, 1985, SOMAT CELL MOLEC GEN, V11, P63, DOI 10.1007/BF01534735; STJOHNSTON D, 1992, CELL, V68, P201; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEEKS JR, 1982, J BIOL CHEM, V257, P5884; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	43	101	102	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					565	575		10.1016/0092-8674(95)90029-2	http://dx.doi.org/10.1016/0092-8674(95)90029-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664336	Bronze			2022-12-01	WOS:A1995RR73400008
J	HARTWIG, JH; BOKOCH, GM; CARPENTER, CL; JANMEY, PA; TAYLOR, LA; TOKER, A; STOSSEL, TP				HARTWIG, JH; BOKOCH, GM; CARPENTER, CL; JANMEY, PA; TAYLOR, LA; TOKER, A; STOSSEL, TP			THROMBIN RECEPTOR LIGATION AND ACTIVATED RAC UNCAP ACTIN FILAMENT BARBED ENDS THROUGH PHOSPHOINOSITIDE SYNTHESIS IN PERMEABILIZED HUMAN PLATELETS	CELL			English	Article							BINDING PROTEIN-RHO; PHOSPHATIDYLINOSITOL BISPHOSPHATE; STIMULATED PLATELETS; ALPHA-THROMBIN; GROWTH-FACTOR; GELSOLIN; POLYPHOSPHOINOSITIDES; 3-KINASE; PEPTIDE; CELLS	Cells respond to diverse external stimuli by polymerizing cytoplasmic actin, and recent evidence indicates that GTPases can specify where this polymerization takes place, Actin assembly in stimulated blood platelets occurs where sequestered monomers add onto the fast-growing (barbed) ends of actin filaments (F-actin), which are capped in the resting cells, We report that D3 and D4 polyphosphoinositides, PI(4)P, PI(4,5)P-2, PI(3,4)P-2, and PI(3,4,5)P-3, uncap F-actin in resting permeabilized platelets, The thrombin receptor-activating peptide (TRAP), GTP, and GTP gamma S, but not GDP beta S, also uncap F-actin in permeabilized platelets. GDP beta S inhibits TRAP-induced F-actin uncapping, and PI(4,5)P-2 overcomes this inhibition, Constitutively active mutant Rac, but not Rho, activates uncapping of F-actin, PI(4,5)P-2-binding peptides derived from gelsolin inhibit F-actin uncapping by TRAP, Rac, and GTP gamma S. TRAP and Rac induce rapid PI(4,5)P-2 synthesis in permeabilized platelets. The findings establish a signaling pathway for actin assembly involving Rac in which the final message is phosphoinositide-mediated F-actin uncapping.	Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, LA JOLLA, CA 92037 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL, SIGNAL TRANSDUCT LAB, BOSTON, MA 02115 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center	HARTWIG, JH (corresponding author), BRIGHAM & WOMENS HOSP, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19429] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NIGMS NIH HHS [GM4428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CARSON MR, 1992, AM J PHYSIOL, V263, pL664, DOI 10.1152/ajplung.1992.263.6.L664; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DAVIES TA, 1989, J BIOL CHEM, V264, P19600; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; GAUDETTE DC, 1993, J BIOL CHEM, V268, P13773; GOU DM, 1994, J CHEM SOC CHEM COMM, P2125, DOI 10.1039/c39940002125; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HASLAM RJ, 1984, BIOCHEM J, V222, P351, DOI 10.1042/bj2220351; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; REDMOND T, 1994, J BIOL CHEM, V269, P21657; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SULTAN C, 1991, J BIOL CHEM, V266, P23554; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	46	589	602	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					643	653		10.1016/0092-8674(95)90036-5	http://dx.doi.org/10.1016/0092-8674(95)90036-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664343	Bronze			2022-12-01	WOS:A1995RR73400015
J	HEALEY, BG; FORAN, SE; WALT, DR				HEALEY, BG; FORAN, SE; WALT, DR			PHOTODEPOSITION OF MICROMETER-SCALE POLYMER PATTERNS ON OPTICAL IMAGING FIBERS	SCIENCE			English	Article							FABRICATION; ARRAYS	Microstructures were fabricated on optical imaging fibers with a photopolymerization technique. Monodisperse polymeric microarrays were produced containing spots of 2.5 micrometers in diameter spaced 4.5 micrometers apart. Polymer microarrays were also deposited on other substrates by using imaging fibers for light delivery. The technique allows micrometer-scale photopatterning with masks larger than the desired dimensions.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155	Tufts University					NIGMS NIH HHS [GM 48142] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNARD SM, 1991, NATURE, V353, P338, DOI 10.1038/353338a0; BEIN T, 1994, CHEM MATER, V6, P1109; BRONK KS, 1994, ANAL CHEM, V66, P3519, DOI 10.1021/ac00092a035; DABBOUSI BO, 1994, CHEM MATER, V6, P216, DOI 10.1021/cm00038a020; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GORMAN CB, 1995, CHEM MATER, V7, P252, DOI 10.1021/cm00050a003; GRANSTROM M, 1995, SCIENCE, V267, P1479, DOI 10.1126/science.267.5203.1479; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; HEALY BG, UNPUB; KLEIN JD, 1993, CHEM MATER, V5, P902, DOI 10.1021/cm00031a002; LANGER R, 1993, ACCOUNTS CHEM RES, V26, P537, DOI 10.1021/ar00034a004; LIU C, 1993, SCIENCE, V261, P597; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; MOGI M, 1989, P SPIE INT SOC OPT E, V1067, P172; NOBLE D, 1995, ANAL CHEM, V67, pA201; NOGLIK H, 1994, CHEM MATER, V6, P1593, DOI 10.1021/cm00046a003; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; PARTHASARATHY RV, 1994, CHEM MATER, V6, P1627, DOI 10.1021/cm00046a011; ROZSNYAI LF, 1992, ANGEW CHEM INT EDIT, V31, P759, DOI 10.1002/anie.199207591; SHIEH L, 1994, J CONTROL RELEASE, V29, P73, DOI 10.1016/0168-3659(94)90123-6; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; WALLENBERGER FT, 1995, SCIENCE, V267, P1274, DOI 10.1126/science.267.5202.1274; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Y Chigusa, 1986, OPTOELECTRON DEVICES, V1, P203; YAN MD, 1993, J AM CHEM SOC, V115, P814, DOI 10.1021/ja00055a078; ZHOU HS, 1994, CHEM MATER, V6, P1534, DOI 10.1021/cm00045a010	26	54	74	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 25	1995	269	5227					1078	1080		10.1126/science.7652555	http://dx.doi.org/10.1126/science.7652555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652555				2022-12-01	WOS:A1995RQ74800036
J	HENNING, KA; LI, L; IYER, N; MCDANIEL, LD; REAGAN, MS; LEGERSKI, R; SCHULTZ, RA; STEFANINI, M; LEHMANN, AR; MAYNE, LV; FRIEDBERG, EC				HENNING, KA; LI, L; IYER, N; MCDANIEL, LD; REAGAN, MS; LEGERSKI, R; SCHULTZ, RA; STEFANINI, M; LEHMANN, AR; MAYNE, LV; FRIEDBERG, EC			THE COCKAYNE-SYNDROME GROUP-A GENE ENCODES A WD REPEAT PROTEIN THAT INTERACTS WITH CSB PROTEIN AND A SUBUNIT OF RNA-POLYMERASE-II TFIIH	CELL			English	Article							DNA-REPAIR; XERODERMA-PIGMENTOSUM; INCREASED SENSITIVITY; CELLULAR-SENSITIVITY; ULTRAVIOLET-LIGHT; UV IRRADIATION; CELLS; FIBROBLASTS; TRANSFORMATION; TRANSCRIPTION	The hereditary disease Cockayne syndrome (CS) is characterized by a complex clinical phenotype, CS cells are abnormally sensitive to ultraviolet radiation and are defective in the repair of transcriptionally active genes, The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf, We report the cloning of the CSA cDNA, which can encode a WD repeat protein, Mutations in the cDNA have been identified in CS-A cell lines, CSA protein. interacts with CSB protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH. These observations suggest that the products of the CSA and CSB genes are involved in transcription.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; INST GENET BIOCHEM & EVOLUTIONIST,I-27100 PAVIA,ITALY; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND; UNIV SUSSEX,TRAFFORD CTR MED RES,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Sussex; University of Brighton; University of Sussex					NCI NIH HHS [CA-52461, CA-44247, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044247, P30CA016672, R01CA052461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BRUMBACK RA, 1978, ARCH NEUROL-CHICAGO, V35, P337, DOI 10.1001/archneur.1978.00500300011002; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FRIEDBERG EC, 1994, MUTAT RES, V307, P5, DOI 10.1016/0027-5107(94)90272-0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P655; HOAR DI, 1978, AM J HUM GENET, V30, P590; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KENNEDY RM, 1980, NEUROLOGY, V30, P1268, DOI 10.1212/WNL.30.12.1268; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEHMANN AR, 1979, CANCER RES, V39, P4237; LEHMANN AR, 1993, J MED GENET, V30, P679, DOI 10.1136/jmg.30.8.679; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LEHMANN AR, 1994, MUTAT RES, V315, P41, DOI 10.1016/0921-8777(94)90026-4; MARSHALL RR, 1980, MUTAT RES, V69, P107, DOI 10.1016/0027-5107(80)90180-3; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MULLENDERS LHF, 1992, DNA REPAIR MECHANISM, P247; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OTSUKA F, 1984, J INVEST DERMATOL, V82, P480, DOI 10.1111/1523-1747.ep12260999; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHMICKEL RD, 1977, PEDIATRICS, V60, P135; SCHWEIGER M, 1987, EUR J BIOCHEM, V165, P235, DOI 10.1111/j.1432-1033.1987.tb11433.x; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; SUGITA K, 1987, PEDIATR RES, V21, P34, DOI 10.1203/00006450-198701000-00009; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Swirski Richard A., 1992, Methods (Orlando), V4, P133, DOI 10.1016/1046-2023(92)90045-A; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4704; VERMEULEN W, 1995, COLD SPRING HARB SYM, V59, P317; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5	50	383	392	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					555	564		10.1016/0092-8674(95)90028-4	http://dx.doi.org/10.1016/0092-8674(95)90028-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664335	Bronze			2022-12-01	WOS:A1995RR73400007
J	SICINSKI, P; DONAHER, JL; PARKER, SB; LI, TS; GARDNER, H; HASLAM, SZ; BRONSON, RT; ELLEDGE, SJ; WEINBERG, RA				SICINSKI, P; DONAHER, JL; PARKER, SB; LI, TS; GARDNER, H; HASLAM, SZ; BRONSON, RT; ELLEDGE, SJ; WEINBERG, RA			CYCLIN D1 PROVIDES A LINK BETWEEN DEVELOPMENT AND ONCOGENESIS IN THE RETINA AND BREAST	CELL			English	Article							MOUSE MAMMARY-GLAND; GENOMIC ORGANIZATION; CELL-CYCLE; GENES; AMPLIFICATION; EXPRESSION; ONTOGENY; CANCER; PROTOONCOGENE; PIGMENTOSA	Mice lacking cyclin D1 have been generated by gene targeting in embryonic stem cells. Cyclin D1-deficient animals develop to term but show reduced body size, reduced viability, and symptoms of neurological impairment. Their retinas display a striking reduction in cell number due to proliferative failure during embryonic development. In situ hybridization studies of normal mouse embryos revealed an extremely high level of cyclin al in the retina, suggesting a special dependence of this tissue on cyclin D1. In adult mutant females, the breast epithelial compartment fails to undergo the massive proliferative changes associated with pregnancy despite normal levels of ovarian steroid hormones, thus, steroid-induced proliferation of mammary epithelium during pregnancy may be driven through cyclin D1.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOWARD HUGHES MED INST,HOUSTON,TX 77030; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Baylor College of Medicine; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Michigan State University; Tufts University; Tufts University	SICINSKI, P (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA39826] Funding Source: Medline; NIA NIH HHS [AG11085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADNANE J, 1989, ONCOGENE, V4, P1389; BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BARKLEY MS, 1979, BIOL REPROD, V20, P733, DOI 10.1095/biolreprod20.4.733; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRESCIANI FRANCESCO, 1968, CELL TISSUE KINET, V1, P51, DOI 10.1111/j.1365-2184.1968.tb00193.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HALL JE, 1992, J CLIN ENDOCR METAB, V74, P600, DOI 10.1210/jc.74.3.600; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; HASLAM SZ, 1992, J STEROID BIOCHEM, V42, P589, DOI 10.1016/0960-0760(92)90449-S; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HASLAM SZ, 1988, J STEROID BIOCHEM, V31, P9, DOI 10.1016/0022-4731(88)90199-9; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaufman M.H, 1992, ATLAS MOUSE DEV; KIESS M, 1995, ONCOGENE, V10, P159; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nandi S., 1958, J NATL CANCER I, V21, P1040; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Robertson E. J, 1987, TERATOCARCINOMAS EMB, P71; SCHUURING E, 1992, CANCER RES, V52, P5229; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINBERG RH, 1991, PROGR RETINAL RES, P121; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; SUTHERLAND RL, 1993, J STEROID BIOCHEM, V47, P99, DOI 10.1016/0960-0760(93)90062-2; TAMARU T, 1993, NEUROSCI LETT, V153, P169, DOI 10.1016/0304-3940(93)90314-B; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	51	895	910	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					621	630		10.1016/0092-8674(95)90034-9	http://dx.doi.org/10.1016/0092-8674(95)90034-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664341	Bronze			2022-12-01	WOS:A1995RR73400013
J	TSUKIHARA, T; AOYAMA, H; YAMASHITA, E; TOMIZAKI, T; YAMAGUCHI, H; SHINZAWAITOH, K; NAKASHIMA, R; YAONO, R; YOSHIKAWA, S				TSUKIHARA, T; AOYAMA, H; YAMASHITA, E; TOMIZAKI, T; YAMAGUCHI, H; SHINZAWAITOH, K; NAKASHIMA, R; YAONO, R; YOSHIKAWA, S			STRUCTURES OF METAL SITES OF OXIDIZED BOVINE HEART CYTOCHROME-C-OXIDASE AT 2.8 ANGSTROM	SCIENCE			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; RESOLUTION; BINDING; COMPLEX; OXYGEN	The high resolution three-dimensional x-ray structure of the metal sites of bovine heart cytochrome c oxidase is reported. Cytochrome c oxidase is the largest membrane protein yet crystallized and analyzed at atomic resolution. Electron density distribution of the oxidized bovine cytochrome c oxidase at 2.8 Angstrom resolution indicates a dinuclear copper center with an unexpected structure similar to a [2Fe-2S]-type iron-sulfur center. Previously predicted zinc and magnesium sites have been located, the former bound by a nuclear encoded subunit on the matrix side of the membrane, and the latter situated between heme a(3) and Cu-A, at the interface of subunits I and II. The O-2 binding site contains heme a(3) iron and copper atoms (Cu-B) with an interatomic distance of 4.5 Angstrom; there is no detectable bridging ligand between iron and copper atoms in spite of a strong antiferromagnetic coupling between them. A hydrogen bond is present between a hydroxyl group of the hydroxyfarnesylethyl side chain of heme a(3) and an OH of a tyrosine. The tyrosine phenol plane is immediately adjacent and perpendicular to an imidazole group bonded to Cu-B, suggesting a possible role in intramolecular electron transfer or conformational control, the latter of which could induce the redox-coupled proton pumping. A phenyl group located halfway between a pyrrole plane of the heme a(3) and an imidazole plane liganded to the other home (heme a) could also influence electron transfer or conformational control.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University	TSUKIHARA, T (corresponding author), HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGOHRI AKOH,HYOGO 67812,JAPAN.		Yamashita, Eiki/V-6758-2019	Yamashita, Eiki/0000-0002-4278-0039; Aoyama, Hiroshi/0000-0001-7915-8975				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAKER GM, 1987, J BIOL CHEM, V262, P595; BERTAGNOLLI H, 1995, ANGEW CHEM INT EDIT, V34, P771, DOI 10.1002/anie.199507711; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, V32, P832; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1969, J BIOL CHEM, V250, P7602; EINERSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013; EINERSDOTTIR O, 1985, BIOCHEM BIOPH RES CO, V129, P840; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, TRENDS BIOCHEM SCI, V8, P398, DOI 10.1016/0968-0004(83)90302-X; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRONECK PMH, 1988, FEBS LETT, V247, P70; LEE SC, 1993, J AM CHEM SOC, V115, P5833, DOI 10.1021/ja00066a065; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MALMSTROM BG, 1993, FEBS LETT, V325, P49, DOI 10.1016/0014-5793(93)81411-R; NANTHAKUMAR A, 1993, J AM CHEM SOC, V115, P8513, DOI 10.1021/ja00071a097; OBLAD M, 1989, BIOCHIM BIOPHYS ACTA, V975, P267, DOI 10.1016/S0005-2728(89)80257-9; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; OTWINOWSKI Z, 1985, DENZO FILM PROCESSIN; PALMER G, 1976, P NATL ACAD SCI USA, V73, P2206, DOI 10.1073/pnas.73.7.2206; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SEITER CHA, 1980, P NATL ACAD SCI-BIOL, V77, P1806, DOI 10.1073/pnas.77.4.1806; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Warburg O, 1929, BIOCHEM Z, V214, P64; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; YOSHIKAWA S, UNPUB	43	1281	1291	2	136	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 25	1995	269	5227					1069	1074		10.1126/science.7652554	http://dx.doi.org/10.1126/science.7652554			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652554				2022-12-01	WOS:A1995RQ74800034
J	WANG, CR; CASTANO, AR; PETERSON, PA; SLAUGHTER, C; LINDAHL, KF; DEISENHOFER, J				WANG, CR; CASTANO, AR; PETERSON, PA; SLAUGHTER, C; LINDAHL, KF; DEISENHOFER, J			NONCLASSICAL BINDING OF FORMYLATED PEPTIDE IN CRYSTAL-STRUCTURE OF THE MHC CLASS-IB MOLECULE H2-M3	CELL			English	Article							DROSOPHILA-MELANOGASTER CELLS; COMPLEX CLASS-I; HISTOCOMPATIBILITY ANTIGEN; VIRAL PEPTIDES; PROTEIN; RECOGNITION; SPECIFICITY; RESOLUTION; HLA-A2; H-2M3	H2-M3 is a class Ib MHC molecule of the mouse with a 10(4)-fold preference for binding N-formylated peptides. To elucidate the basis of this unusual specificity, we expressed and crystallized a soluble form of M3 with a formylated nonamer peptide, fMYFINILTL, and determined the structure by X-ray crystallography. M3, refined at 2.1 Angstrom resolution, resembles class ia MHC molecules in its overall structure, but differs in the peptide-binding groove. The A pocket, which usually accommodates the free N-terminus of a bound peptide, is closed, and the peptide is shifted one residue, such that the P1 side chain is lodged in the a pocket, The formyl group is coordinated by His-9 and a bound water on the floor of the groove.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute	WANG, CR (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.		Castaño, A. Raul/A-5905-2012	Castaño, A. Raul/0000-0003-2107-8862				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; CHEN W, 1993, J EXP MED, V177, P869, DOI 10.1084/jem.177.3.869; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HERMEL E, 1992, THESIS U TEXAS DALLA; HOGQUIST KA, 1993, EUR J IMMUNOL, V23, P3028, DOI 10.1002/eji.1830231145; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE S, 1994, J EXP MED, V179, P579, DOI 10.1084/jem.179.2.579; KURLANDER RJ, 1992, SCIENCE, V257, P678, DOI 10.1126/science.1496381; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MILLER JEW, 1994, J CELL BIOCHEM, V18, P292; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROHREN EM, 1994, J IMMUNOL, V152, P5337; ROTZSCHKE O, 1993, NATURE, V361, P642, DOI 10.1038/361642a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; SMITH GP, 1994, INT IMMUNOL, V6, P1917, DOI 10.1093/intimm/6.12.1917; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; VYAS JM, 1995, J EXP MED, V181, P1817, DOI 10.1084/jem.181.5.1817; VYAS JM, 1992, J IMMUNOL, V149, P3605; WANG CR, 1993, P NATL ACAD SCI USA, V90, P2784, DOI 10.1073/pnas.90.7.2784; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WANG CR, 1995, IMMUNOGENETICS, V42, P63, DOI 10.1007/BF00164989; YUNG ACM, 1994, CELL, V76, P39; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	51	128	129	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					655	664		10.1016/0092-8674(95)90037-3	http://dx.doi.org/10.1016/0092-8674(95)90037-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664344	Bronze			2022-12-01	WOS:A1995RR73400016
J	WANG, ND; FINEGOLD, MJ; BRADLEY, A; OU, CN; ABDELSAYED, SV; WILDE, MD; TAYLOR, LR; WILSON, DR; DARLINGTON, GJ				WANG, ND; FINEGOLD, MJ; BRADLEY, A; OU, CN; ABDELSAYED, SV; WILDE, MD; TAYLOR, LR; WILSON, DR; DARLINGTON, GJ			IMPAIRED ENERGY HOMEOSTASIS IN C/EBP-ALPHA KNOCKOUT MICE	SCIENCE			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; BROWN ADIPOSE-TISSUE; HEPATOMA-CELLS; GENE; LIVER; TRANSCRIPTION; EXPRESSION; METABOLISM; DISRUPTION	Mice homozygous for the targeted deletion of the c/ebp alpha gene, which expresses the CCAAT/enhancer-binding protein alpha (C/EBP alpha), did not store hepatic glycogen and died from hypoglycemia within 8 hours after birth. In these mutant mice, the amounts of glycogen synthase messenger RNA were 50 to 70 percent of normal and the transcriptional induction of the genes for two gluconeogenic enzymes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, was delayed. The hepatocytes and adipocytes of the mutant mice failed to accumulate lipid and the expression of the gene for uncoupling protein, the defining marker of brown adipose tissue, was reduced. This study demonstrates that C/EBP alpha is critical for the establishment and maintenance of energy homeostasis in neonates.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839	NIDDK NIH HHS [DK 45285] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYNSLEYGREEN A, 1977, ARCH DIS CHILD, V52, P573, DOI 10.1136/adc.52.7.573; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DEVOS P, 1974, BIOCHEM J, V140, P331, DOI 10.1042/bj1400331; ERICKSON RP, 1968, P NATL ACAD SCI USA, V59, P437, DOI 10.1073/pnas.59.2.437; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; HAWDON JM, 1993, ARCH DIS CHILD-FETAL, V68, P280, DOI 10.1136/adc.68.3_Spec_No.280; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KOCHAN Z, 1992, COMP BIOCHEM PHYS B, V101, P283, DOI 10.1016/0305-0491(92)90191-S; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEU J, 1990, EUR J PEDIATR, V150, P2, DOI 10.1007/BF01959470; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PHILIPPIDIS H, 1969, BIOCHEM J, V113, P651, DOI 10.1042/bj1130651; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang N., UNPUB; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	26	805	826	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1108	1112		10.1126/science.7652557	http://dx.doi.org/10.1126/science.7652557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652557				2022-12-01	WOS:A1995RQ74800046
J	WOLOSHIN, P; SONG, KN; DEGNIN, C; KILLARY, AM; GOLDHAMER, DJ; SASSOON, D; THAYER, MJ				WOLOSHIN, P; SONG, KN; DEGNIN, C; KILLARY, AM; GOLDHAMER, DJ; SASSOON, D; THAYER, MJ			MSX1 INHIBITS MYOD EXPRESSION IN FIBROBLAST X 10T1/2 CELL HYBRIDS	CELL			English	Article							REGULATORY ELEMENTS; MOUSE EMBRYOGENESIS; HUMAN-CHROMOSOMES; MYOGENIN GENE; HOMEOBOX GENE; NEURAL-TUBE; MUSCLE; DIFFERENTIATION; 5-AZACYTIDINE; MYOBLASTS	Transfer of human chromosome 11, which contains the myoD locus, from primary fibroblasts into 10T(1/2) cells results in activation of myoD. In contrast, hybrids that retain human chromosome 11 and additional human chromosomes fail to activate myoD. We show that human chromosome 4 inhibits myoD activation. myoD enhancer/promoter reporter constructs show that repression is at the transcriptional level. Chromosome fragment-containing hybrids localize the repressing activity to the region of 4p that contains the homeobox gene MSX1. MSX1 is expressed in primary human fibroblasts and in 10T(1/2) cells containing human chromosome 4, while parental 10T(1/2) cells do not express Msx1, Forced expression of Msx1 represses myoD enhancer activity. Msx1 protein binds to the myoD enhancer and likely represses myoD transcription directly, Antisense MSX1 relieves repression mediated by chromosome 4. We conclude that MSX1 inhibits transcription of myoD and that myoD is a target for homeobox gene regulation.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030; UNIV PENN,SCH MED,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Icahn School of Medicine at Mount Sinai	WOLOSHIN, P (corresponding author), OREGON HLTH SCI UNIV,DEPT MED & MOLEC GENET,PORTLAND,OR 97201, USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X	NIAMS NIH HHS [AR42644] Funding Source: Medline; NICHD NIH HHS [HD27585] Funding Source: Medline; NIGMS NIH HHS [GM49334] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042644] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOBER E, 1994, DEVELOPMENT, V120, P603; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Favaloro J, 1980, Methods Enzymol, V65, P718; Feigner P.L., 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEWITT JE, 1991, GENOMICS, V11, P670, DOI 10.1016/0888-7543(91)90074-O; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RONG PM, 1992, DEVELOPMENT, V115, P657; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785	43	127	129	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					611	620		10.1016/0092-8674(95)90033-0	http://dx.doi.org/10.1016/0092-8674(95)90033-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664340	Bronze			2022-12-01	WOS:A1995RR73400012
J	YOON, CH; LEE, JH; JONGEWARD, GD; STERNBERG, PW				YOON, CH; LEE, JH; JONGEWARD, GD; STERNBERG, PW			SIMILARITY OF SLI-1, A REGULATOR OF VULVAR DEVELOPMENT IN C-ELEGANS, TO THE MAMMALIAN PROTOONCOGENE C-CBL	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; TYROSINE KINASE; SH3 DOMAINS; V-CBL; CELL FATES; GENE; INDUCTION; ENCODES; LET-60; TRUNCATION	Vulval induction during Caenorhabditis elegans development is mediated by LET-23, a homolog of the mammalian epidermal growth factor receptor tyrosine kinase. The sli-1 gene is a negative regulator of LET-23 and is shown here to encode a protein similar to c-Cbl, a mammalian proto-oncoprotein. SLI-1 and c-Cbl share approximately 55 percent amino acid identity over a stretch of 390 residues, which includes a C3HC4 zinc-binding motif known as the RING finger, and multiple consensus binding sites for Src homology 3 (SH3) domains. SLI-1 and c-Cbl may define a new class of proteins that modify receptor tyrosine kinase-mediated signal transduction.	CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL IMMUNOL & BIOCHEM, SAN FRANCISCO, CA 94143 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California San Francisco				Sternberg, Paul/0000-0002-7699-0173				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRENNER S, 1974, GENETICS, V77, P71; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JONGEWARD GD, 1995, GENETICS, V139, P1553; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; VILLENEUVE AM, COMMUNICATION; WILLIAMS BD, 1992, GENETICS, V131, P609; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	277	288	4	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1102	1105		10.1126/science.7652556	http://dx.doi.org/10.1126/science.7652556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652556				2022-12-01	WOS:A1995RQ74800044
J	ZHOU, W; REINES, D; DOETSCH, PW				ZHOU, W; REINES, D; DOETSCH, PW			T7 RNA-POLYMERASE BYPASS OF LARGE GAPS ON THE TEMPLATE STRAND REVEALS A CRITICAL ROLE OF THE NONTEMPLATE STRAND IN ELONGATION	CELL			English	Article							TRANSCRIPTION TERMINATION; DNA; SEQUENCE; ELEMENTS; INVITRO	We show that T7 RNA polymerase can efficiently transcribe DNA containing gaps from one to five bases in the template strand. Surprisingly, broken template strands missing up to 24 bases can still be transcribed, although at reduced efficiency. The resulting transcripts contain the full template sequence with the RNA deleted for the gapped region missing on the template strand. These findings indicate that the end of a downstream template strand can be brought into the polymerase and transcribed as ii it were a part of an intact polynucleotide chain by utilizing the unpaired nontemplate strand. This, as well as transcription of an intact template strand, relies heavily upon the nontemplate strand, suggesting that a duplex DNA-binding site on the leading edge of RNA polymerase is required for RNA chain elongation on DNA templates. This work contributes substantially to the emerging picture that the nontemplate strand is an important element of the transcription elongation complex.	EMORY UNIV,SCH MED,DIV BIOL & BIOMED SCI,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30322	Emory University; Emory University	ZHOU, W (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NCI NIH HHS [CA55896] Funding Source: Medline; NIGMS NIH HHS [GM46311, R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN M, 1964, J MOL BIOL, V8, P297, DOI 10.1016/S0022-2836(64)80139-X; Chamberlin M., 1982, ENZYMES, V15, P87; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JENG ST, 1990, J BIOL CHEM, V265, P3823; JENG ST, 1992, J BIOL CHEM, V267, P19306; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORRIS CE, 1986, RNA POLYM REGULATION, P47; OAKLEY JL, 1977, P NATL ACAD SCI USA, V74, P4266, DOI 10.1073/pnas.74.10.4266; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; ROSA MD, 1979, CELL, V16, P815, DOI 10.1016/0092-8674(79)90097-7; RYAN T, 1987, J BIOL CHEM, V258, P4690; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SAUCIER JM, 1972, NATURE-NEW BIOL, V239, P167, DOI 10.1038/newbio239167a0; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI YB, 1988, J BIOL CHEM, V263, P527; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032	28	48	49	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					577	585		10.1016/0092-8674(95)90030-6	http://dx.doi.org/10.1016/0092-8674(95)90030-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664337	Bronze, Green Accepted			2022-12-01	WOS:A1995RR73400009
J	ZIMMERLY, S; GUO, HT; PERLMAN, PS; LAMBOWITZ, AM				ZIMMERLY, S; GUO, HT; PERLMAN, PS; LAMBOWITZ, AM			GROUP-II INTRON MOBILITY OCCURS BY TARGET DNA-PRIMED REVERSE TRANSCRIPTION	CELL			English	Article							EVOLUTIONARY RELATIONSHIPS; CYTOCHROME-OXIDASE; RNA; MATURASE; YEAST; GENE; RETROVIRUSES; PROTEINS	Mobile group II introns encode reverse transcriptases and insert site specifically into intronless alleles (homing). Here, in vitro experiments show that homing of the yeast mtDNA group II intron aI2 occurs by reverse transcription at a double-strand break in the recipient DNA. A site-specific endonuclease cleaves the antisense strand of recipient DNA at position +10 of exon 3 and the sense strand at the intron insertion site. Reverse transcription of aI2-containing pre-mRNA is primed by the antisense strand cleaved in exon 3 and results in cotransfer of the intron and flanking exon sequences. Remarkably, the DNA endonuclease that initiates homing requires both the aI2 reverse transcriptase protein and aI2 RNA. Parallels in their reverse transcription mechanisms raise the possibility that mobile group II introns were ancestors of nuclear non-long terminal repeat retrotransposons and telomerases.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZIMMERLY, S (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949, R01GM031480] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480, GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; EICKBUSH TH, 1992, NEW BIOL, V4, P430; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; SAINSARDCHANET A, 1994, J MOL BIOL, V242, P630, DOI 10.1006/jmbi.1994.1613; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J., 1989, MOL CLONING LAB MANU; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	31	225	248	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					545	554		10.1016/0092-8674(95)90027-6	http://dx.doi.org/10.1016/0092-8674(95)90027-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664334	Bronze			2022-12-01	WOS:A1995RR73400006
J	BENNETT, PB; YAZAWA, K; MAKITA, N; GEORGE, AL				BENNETT, PB; YAZAWA, K; MAKITA, N; GEORGE, AL			MOLECULAR MECHANISM FOR AN INHERITED CARDIAC-ARRHYTHMIA	NATURE			English	Article							LONG QT SYNDROME; NA+-CHANNEL INACTIVATION; FREE MEMBRANE PATCHES; SODIUM-CHANNELS; CURRENTS	IN the congenital long-QT syndrome, prolongation of the cardiac action potential occurs by an unknown mechanism(1,2) and predisposes individuals to syncope and sudden death as a result of ventricular arrhythmias(3), Genetic heterogeneity has been demonstrated for autosomal dominant long-QT syndrome by the identification of multiple distinct loci(4,5), associated mutations in two candidate genes have recently been reported(6,7). One form of hereditary long QT (LQT3) has been linked to a mutation(7) in the gene encoding the human heart voltage-gated sodium-channel alpha-subunit (SCN5A on chromosome 3p21)(8). Here we characterize this mutation using heterologous expression of recombinant human heart sodium channels, Mutant channels show a sustained inward current during membrane depolarization, Single-channel recordings indicate that mutant channels fluctuate between normal and non-inactivating gating modes. Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a molecular mechanism for this form of congenital long-QT syndrome.	VANDERBILT UNIV, MED CTR, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	BENNETT, PB (corresponding author), VANDERBILT UNIV, MED CTR, DEPT PHARMACOL, NASHVILLE, TN 37232 USA.							ALZHEIMER C, 1993, J NEUROSCI, V13, P660; ATTWELL D, 1988, LANCET, V1, P1136; CARMELIET E, 1993, EUR HEART J, V14, P3, DOI 10.1093/eurheartj/14.suppl_H.3; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1995, CYTOGENET CELL GENET, V68, P67; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Higuchi R., 1989, PCR TECHNOLOGY, P61; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; JU YK, 1994, P ROY SOC B-BIOL SCI, V256, P163, DOI 10.1098/rspb.1994.0065; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KIYOSUE T, 1989, CIRC RES, V64, P389, DOI 10.1161/01.RES.64.2.389; MAKITA N, 1994, J BIOL CHEM, V269, P7571; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; PATLAK J, 1991, PHYSIOL REV, V71, P1047, DOI 10.1152/physrev.1991.71.4.1047; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHWARTZ PJ, 1992, ANN NY ACAD SCI, V644, P112, DOI 10.1111/j.1749-6632.1992.tb31007.x; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VALENZUELA C, 1994, BIOPHYS J, V67, P161, DOI 10.1016/S0006-3495(94)80465-5; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910	25	704	720	1	14	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					683	685		10.1038/376683a0	http://dx.doi.org/10.1038/376683a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651517				2022-12-01	WOS:A1995RQ67200059
J	CHANG, HY; TAKEI, K; SYDOR, AM; BORN, T; RUSNAK, F; JAY, DG				CHANG, HY; TAKEI, K; SYDOR, AM; BORN, T; RUSNAK, F; JAY, DG			ASYMMETRIC RETRACTION OF GROWTH CONE FILOPODIA FOLLOWING FOCAL INACTIVATION OF CALCINEURIN	NATURE			English	Article							GRASSHOPPER PIONEER NEURONS; CYCLOSPORINE-A; NERVE GROWTH; LASER INACTIVATION; FASCICLIN-I; INHIBITION; PHOSPHORYLATION; TRANSDUCTION; PHOSPHATASE; COMPLEXES	THE neuronal growth cone is thought to be the site of decision making in nerve growth and guidance(1,2). One likely mechanism of how the growth cone translates various extracellular cues into directed motility involves rises in intracellular calcium, A variety of physiological cues, such as adhesion molecules and neurotransmitters, increases intracellular calcium(1), and artificial manipulations of growth cone calcium levels affect growth cone morphology and neurite outgrowth(3). The molecular events downstream of calcium fluxes are incompletely understood, Here we show that calcineurin, a protein phosphatase enriched in growth cones that is dependent on calcium ions and calmodulin(4), functions in neurite outgrowth and directed filopodial motility in cultured chick dorsal root ganglia neurons. Cyclosporin A and FK506, inhibitors of calcineurin(5), delayed neuritogenesis and inhibited neurite extension, Chromophore-assisted laser inactivation of calcineurin io regions of growth cones causes localized filopodial and lamellipodial retraction and influences the direction of subsequent outgrowth. We suggest that a spatial distribution of calcineurin activity within the growth cone can regulate motility and direct outgrowth.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	CHANG, HY (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAY D, 1991, CULTURING NERVE CELL, P104; CLARKE MSF, 1992, J CELL SCI, V102, P533; CLIPSTONE NA, 1993, NATURE, V357, P695; DAVENPORT RW, 1993, NATURE, V361, P721, DOI 10.1038/361721a0; DIAMOND P, 1993, NEURON, V11, P409, DOI 10.1016/0896-6273(93)90146-I; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; LINDEN KG, 1992, BIOPHYS J, V61, P956, DOI 10.1016/S0006-3495(92)81902-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMUCKER D, 1994, P NATL ACAD SCI USA, V91, P2664, DOI 10.1073/pnas.91.7.2664; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; SYDOR AM, 1994, ABS SOC NEUR, V20, P1474; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	30	143	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					686	690		10.1038/376686a0	http://dx.doi.org/10.1038/376686a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7544441				2022-12-01	WOS:A1995RQ67200060
J	HACHIYA, N; MIHARA, K; SUDA, K; HORST, M; SCHATZ, G; LITHGOW, T				HACHIYA, N; MIHARA, K; SUDA, K; HORST, M; SCHATZ, G; LITHGOW, T			RECONSTITUTION OF THE INITIAL STEPS OF MITOCHONDRIAL PROTEIN IMPORT	NATURE			English	Article							YEAST MITOCHONDRIA; RECEPTORS	WE have reconstituted the initial steps of mitochondrial protein import with a purified precursor protein, a purified, ATP-dependent, cytosolic chaperone selective for mitochondrial precursors (mitochondrial import stimulating factor; MSF), and either intact mitochondria or intact or solubilized mitochondrial outer membranes. We show that the precursor-MSF complex first binds to the Mas37p/Mas70p subunits of the mitochondrial import receptor. After ATP-dependent release of MSF, the precursor is transferred from Mas37p/Mas70p to the Mas20p/Mas22p subunits of the receptor, and finally delivered to the import channel in the outer membrane, Import in the absence of the MSF bypasses Mas37p/Mas70p. The ATP-mediated transfer of a precursor from MSF to specific subunits of the import receptor is similar to the GTP-mediated transfer of precursors from the signal recognition particle to its receptor on the endoplasmic reticulum.	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	University of Basel; Kyushu University			Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HONLINGER A, IN PRESS MOL CELL BI; KIEBLER M, 1994, J MEMBRANE BIOL, V135, P191; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465	17	154	156	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					705	709		10.1038/376705a0	http://dx.doi.org/10.1038/376705a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651521				2022-12-01	WOS:A1995RQ67200065
J	HOFMANN, J; CETRON, M; FARLEY, MM; BAUGHMAN, WS; FACKLAM, RR; ELLIOTT, JA; DEAVER, KA; BREIMAN, RF				HOFMANN, J; CETRON, M; FARLEY, MM; BAUGHMAN, WS; FACKLAM, RR; ELLIOTT, JA; DEAVER, KA; BREIMAN, RF			THE PREVALENCE OF DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE IN ATLANTA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DAY-CARE-CENTER; UNITED-STATES; ANTIMICROBIAL RESISTANCE; PNEUMOCOCCAL INFECTIONS; PENICILLIN; CHILDREN; DISEASE; VACCINE; MENINGITIS; EFFICACY	Background. Streptococcus pneumoniae is a major cause of illness, and the emergence of drug-resistant strains threatens to complicate the management of pneumococcal infections. We conducted a laboratory-based surveillance for drug-resistant S. pneumoniae among patients with invasive pneumococcal infections in Atlanta. Methods. From January through October 1994, pneumococcal isolates from 431 patients with invasive disease in metropolitan Atlanta were serotyped and tested to determine their susceptibility to various antimicrobial agents. Susceptibility to the antimicrobial agents was defined according to guidelines established by the National Committee for Clinical Laboratory Standards. Results. The annual incidence of invasive pneumococcal infection was 30 cases per 100,000 population, Isolates from 25 percent of the patients were resistant to penicillin (7 percent were highly resistant), and isolates from 26 percent were resistant to trimethoprim-sulfamethoxazole (7 percent highly resistant). Fifteen percent of the isolates were resistant to erythromycin, 9 percent to cefotaxime (4 percent were highly resistant), and 25 percent to multiple drugs. Drug-resistant pneumococci were found in bath children and adults. Children under six years of age were more likely than older children and adults to have isolates resistant to multiple drugs or cefotaxime, Whites were more likely than blacks to have invasive pneumococcal infections caused by drug-resistant organisms. Among white children younger than six years, 41 percent of the S. pneumoniae isolates were resistant to penicillin. Conclusions. Drug-resistant strains of S. pneumoniae are common among both children and adults in Atlanta, Although blacks had a higher incidence of invasive pneumococcal infections than whites, whites were more likely to be infected with a drug-resistant isolate. Control of drug-resistant pneumococci will require more judicious use of antimicrobial agents and wider use of the pneumococcal polysaccharide vaccine.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA; VET AFFAIRS MED CTR,ATLANTA,GA 30033	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System								AMITAI Y, 1985, ISRAEL J MED SCI, V21, P340; [Anonymous], 1993, M7A3 NAT COMM CLIN L; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; BUTLER JC, 1995, J INFECT DIS, V171, P885, DOI 10.1093/infdis/171.4.885; CHESNEY PJ, 1992, AM J DIS CHILD, V146, P912, DOI 10.1001/archpedi.1992.02160200034022; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FORD KL, 1991, J PEDIATR-US, V119, P941, DOI 10.1016/S0022-3476(05)83050-1; FRIEDLAND IR, 1993, PEDIATR INFECT DIS J, V12, P196, DOI 10.1097/00006454-199303000-00004; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P337; GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAGLUND LA, 1993, J INFECT DIS, V168, P1532, DOI 10.1093/infdis/168.6.1532; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; JACKSON MA, 1984, PEDIATR INFECT DIS J, V3, P129, DOI 10.1097/00006454-198403000-00010; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LEGGIADRO RJ, 1994, PEDIATR INFECT DIS J, V13, P320; LEGGIADRO RJ, 1994, PEDIATRICS, V93, P500; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; ORANGE M, 1993, PEDIATR INFECT DIS J, V12, P244, DOI 10.1097/00006454-199303000-00015; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RADETSKY MS, 1981, LANCET, V2, P771; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROBINSBROWNE RM, 1984, J HYG-CAMBRIDGE, V93, P9, DOI 10.1017/S0022172400060873; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; SIMBERKOFF MS, 1986, J INFECT DIS, V153, P78, DOI 10.1093/infdis/153.1.78; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; TAN TQ, 1993, PEDIATRICS, V92, P761; TAN TQ, 1992, PEDIATRICS, V90, P928; THOMPSON JW, 1994, PEDIATR INFECT DIS J, V13, P408, DOI 10.1097/00006454-199405000-00013; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; WELBY PL, 1994, PEDIATR INFECT DIS J, V13, P281, DOI 10.1097/00006454-199404000-00007; WENGER JD, 1991, LANCET, V338, P395; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P216; 1992, CP112 BUR CENS DEP C; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, M7A3 NAT COMM CLIN L	48	413	435	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					481	486		10.1056/NEJM199508243330803	http://dx.doi.org/10.1056/NEJM199508243330803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623880				2022-12-01	WOS:A1995RP75900003
J	IWATA, S; OSTERMEIER, C; LUDWIG, B; MICHEL, H				IWATA, S; OSTERMEIER, C; LUDWIG, B; MICHEL, H			STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF CYTOCHROME-C-OXIDASE FROM PARACOCCUS-DENITRIFICANS	NATURE			English	Article							CRYSTAL-STRUCTURES; PROTEIN STRUCTURES; SUBUNIT; REFINEMENT; 2-SUBUNIT; FEATURES; ACCURACY; COMPLEX; ENERGY; ENZYME	The crystal structure at 2.8 Angstrom resolution of the four protein subunits containing cytochrome c oxidase from the soil bacterium Paracoccus denitrificans, complexed with an antibody F-v fragment, is described. Subunit I contains 12 membrane-spanning, primarily helical segments and binds haem a and the haem a(3)-copper B binuclear centre where molecular oxygen Is reduced to water. Two proton transfer pathways, one for protons consumed in water formation and one for 'proton pumping', could be identified. Mechanisms for proton pumping are discussed.	MAX PLANCK INST BIOPHYS,D-60528 FRANKFURT,GERMANY; UNIV FRANKFURT,BIOZENTRUM,INST BIOCHEM,D-60439 FRANKFURT,GERMANY	Max Planck Society; Goethe University Frankfurt								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; ESSEN LO, 1995, THESIS J WOLFGANG GO; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HALTIA T, 1990, BIOCHEMISTRY-US, V33, P9731; HALTIA T, 1991, EMBO J, V8, P2015; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, BIOENERG BIOMEMBR, V25, P136; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P896; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; MORGAN JE, 1994, BIOENERG BIOMEMBR, V26, P599; OTWINOWSKI Z, 1991, 1991 P CCP4 STUD WEE, P80; OTWINOWSKI Z, 1993, 1991 P CCP4 STUD WEE, P56; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; RAITIO M, 1990, FEBS LETT, V261, P431, DOI 10.1016/0014-5793(90)80609-M; RICH PR, 1994, AUST J PL PHYSL, V22, P479; RIEDER R, 1980, J BIOL CHEM, V255, P4732; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.tb20695.x; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM M, 1996, BIOCHIM BIOPHYS ACTA, V1187, P106	46	1951	1976	4	155	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					660	669		10.1038/376660a0	http://dx.doi.org/10.1038/376660a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651515				2022-12-01	WOS:A1995RQ67200053
J	IZAURRALDE, E; LEWIS, J; GAMBERI, C; JARMOLOWSKI, A; MCGUIGAN, C; MATTAJ, IW				IZAURRALDE, E; LEWIS, J; GAMBERI, C; JARMOLOWSKI, A; MCGUIGAN, C; MATTAJ, IW			A CAP-BINDING PROTEIN COMPLEX MEDIATING U SNRNA EXPORT	NATURE			English	Article							MESSENGER-RNA PRECURSORS; RECOGNITION; INVITRO; NUCLEUS	CAP structures are added cotranscriptionally to all RNA polymerase II transcripts(1,2). They affect several processes including RNA stability(3-5), pre-messenger RNA splicing(6-11), RNA export from the nucleus(12-14) and translation initiation(15-17). The effect of the cap on translation is mediated by the initiation factor eIF-4F (refs 15-19), whereas the effect on pre-mRNA splicing involves a nuclear complex (CBC) composed of two cap binding proteins, CBP80 and CBP20(11). A role for CBC in the nuclear export of capped RNAs has also been proposed(11,13), We report here the characterization of human and Xenopus CBP20s. Antibodies against recombinant CBP20 prevent interaction of CBC with capped RNAs in vitro. Following microinjection into Xenopus oocytes, the antibodies inhibit both pre-mRNA splicing and export of U small nuclear RNAs to the cytoplasm, These results demonstrate that CBC mediates the effect of the cap structure in U snRNA export, and provide direct evidence for the involvement of a cellular RNA-binding factor in the transport of RNA to the cytoplasm.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Izaurralde, Elisa/G-3239-2012; Gamberi, Chiara/L-5740-2013	Gamberi, Chiara/0000-0002-7122-6491; Izaurralde, Elisa/0000-0001-7365-2649; Mattaj, Iain/0000-0002-5537-8284				BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Frohman MA, 1990, PCR PROTOCOLS GUIDE, P28; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LANG V, 1994, J BIOL CHEM, V269, P6117; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; PATZELT E, 1987, NUCLEIC ACIDS RES, V15, P1387, DOI 10.1093/nar/15.4.1387; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SALDITTGEORGIEF.M, 1980, CELL, V19, P69; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0	30	286	295	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					709	712		10.1038/376709a0	http://dx.doi.org/10.1038/376709a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651522				2022-12-01	WOS:A1995RQ67200066
J	KETCHUM, KA; JOINER, WJ; SELLERS, AJ; KACZMAREK, LK; GOLDSTEIN, SAN				KETCHUM, KA; JOINER, WJ; SELLERS, AJ; KACZMAREK, LK; GOLDSTEIN, SAN			A NEW FAMILY OF OUTWARDLY RECTIFYING POTASSIUM CHANNEL PROTEINS WITH 2 PORE DOMAINS IN TANDEM	NATURE			English	Article							EXPRESSION; K+	POTASSIUM channels catalyse the permeation of K+ ions across cellular membranes and are identified by a common structural moth, a highly conserved signature sequence of eight amino acids in the P domain of each channel's pore-forming alpha-subunit(1,2), Here we describe a novel K+ channel (TOK1) from Saccharomyces cerevisiae that contains two P domains within one continuous polypeptide, Xenopus laevis oocytes expressing the channel exhibit a unique, outwardly rectifying, K+-selective current. The channel is permeable to outward how of ions at membrane potentials above the K+ equilibrium potential; its conduction-voltage relationship is thus sensitive to extracellular K+ ion concentration. In excised membrane patches, external divalent cations block the channel in a voltage-dependent manner, and their removal in this configuration allows inward channel current, These attributes are similar to those described for inwardly rectifying K+ channels(3,4), but in the opposite direction, a previously uorecognized channel behaviour. Our results identify a new class of K+ channel which is distinctive in both its primary structure and functional properties. Structural homologues of the channel are present in the genome of Caenorhabditis elegans.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT GENET,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University; Yale University	KETCHUM, KA (corresponding author), YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PEDIAT,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIOSGA T, 1994, YEAST, V10, P965, DOI 10.1002/yea.320100712; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	24	344	359	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					690	695		10.1038/376690a0	http://dx.doi.org/10.1038/376690a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651518	Green Submitted			2022-12-01	WOS:A1995RQ67200061
J	PALLARES, R; LINARES, J; VADILLO, M; CABELLOS, C; MANRESA, F; VILADRICH, PF; MARTIN, R; GUDIOL, F				PALLARES, R; LINARES, J; VADILLO, M; CABELLOS, C; MANRESA, F; VILADRICH, PF; MARTIN, R; GUDIOL, F			RESISTANCE TO PENICILLIN AND CEPHALOSPORIN AND MORTALITY FROM SEVERE PNEUMOCOCCAL PNEUMONIA IN BARCELONA, SPAIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; SYSTEMIC INFECTIONS; BACTEREMIA; CHLORAMPHENICOL; SUSCEPTIBILITY; DIAGNOSIS; DISEASE; THERAPY	Background. Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic therapy for pneumococcal pneumonia due to resistant strains remains controversial. Methods. To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia. Results. Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIG] of penicillin G, 0.12 to 4.0 mu g per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIG of ceftriaxone or cefotaxime, 1.0 to 4.0 mu g per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P = 0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P = 0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P = 0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P = 0.64), The frequency of resistance to cephalosporin increased from 2 percent in 1984-1988 to 9 percent in 1989-1993 (P = 0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P = 0.89), Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P = 0.64). Conclusions. Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia, Hence, these antibiotics remain the therapy of choice for this disease.	HOSP BELLVITGE PRINCEPS ESPANYA, INFECT DIS SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, MICROBIOL SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, INTERNAL MED SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, PULM DIS SERV, BARCELONA, SPAIN; UNIV BARCELONA, BARCELONA, SPAIN	University of Barcelona			Liñares, Josefina/N-9450-2014; PALLARES, Roman/B-5710-2008; Cabellos, Carmen/AAO-3784-2021	PALLARES, Roman/0000-0003-3262-8508; Cabellos, Carmen/0000-0001-7392-7382				AMSDEN GW, 1995, PRINCIPLES PRACTICE, P492; APPELBAUM PC, 1977, LANCET, V2, P995; APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; FENOLL A, 1991, REV INFECT DIS, V13, P56; FINKELSTEIN MS, 1983, J AM GERIATR SOC, V31, P19, DOI 10.1111/j.1532-5415.1983.tb06283.x; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; GRUER LD, 1984, Q J MED, V53, P259; HANSMAN D, 1971, NEW ENGL J MED, V284, P175, DOI 10.1056/NEJM197101282840403; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; JACOBS MR, 1979, ANTIMICROB AGENTS CH, V16, P190, DOI 10.1128/AAC.16.2.190; JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JOHN CC, 1994, CLIN INFECT DIS, V18, P188, DOI 10.1093/clinids/18.2.188; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KRAMER MR, 1987, ISRAEL J MED SCI, V23, P174; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; MANRESA F, 1991, THORAX, V46, P601, DOI 10.1136/thx.46.8.601; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; MYLOTTE JM, 1981, AM REV RESPIR DIS, V123, P265; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; SANCHEZ C, 1992, LANCET, V339, P988, DOI 10.1016/0140-6736(92)91560-U; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; TAN TQ, 1992, PEDIATRICS, V90, P928; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WATANAKUNAKORN C, 1993, CHEST, V103, P1152, DOI 10.1378/chest.103.4.1152; 1994, NCCLS M100S5 NAT COM	40	628	642	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					474	480		10.1056/NEJM199508243330802	http://dx.doi.org/10.1056/NEJM199508243330802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623879	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1995RP75900002
J	RIKLIN, A; KATZ, E; WILLNER, I; STOCKER, A; BUCKMANN, AF				RIKLIN, A; KATZ, E; WILLNER, I; STOCKER, A; BUCKMANN, AF			IMPROVING ENZYME-ELECTRODE CONTACTS BY REDOX MODIFICATION OF COFACTORS	NATURE			English	Article							GLUCOSE-OXIDASE; POLYMERS; CENTERS	EFFICIENT electron transfer of redox proteins to and from their environment is essential for the use of such proteins in biotechnological applications such as amperometric biosensors and photosynthetic biocatalysts(1-3). But most redox enzymes lack pathways that can transport an electron from their embedded redox site to an electrode(4,5) or a diffusing photoexcited species(6). Electrical communication between redox proteins and electrode surfaces has been improved by aligning proteins on chemically modified electrodes(7-9), by attaching electron-transporting groups(10,11) and by immobilizing proteins in polymer matrices tethered by redox groups(12-14). Generally these methods involve contacting the enzymes at random with electron relay units, Here we report an approach that allows site-specific positioning of electron-mediating units in redox proteins, We strip glucose oxidase of its flavin adenine dinucleotide (FAD) cofactors, modify tbe latter with redox-active ferrocene-containing groups, and then reconstitute the apoprotein with these modified cofactors, In this way, electrical contact between an electrode and the resulting enzyme in solution is greatly enhanced in a controlled and reproducible way.	HEBREW UNIV JERUSALEM, INST CHEM, IL-91904 JERUSALEM, ISRAEL; GESELL BIOTECHNOL FORSCH MBH, DEPT ENZYMOL, D-38124 BRAUNSCHWEIG, GERMANY	Hebrew University of Jerusalem; Gesellschaft fur Biotechnologische Forschung mbH			Stocker, Achim/O-5217-2017	Stocker, Achim/0000-0001-6862-7887				ARMSTRONG FA, 1988, ACCOUNTS CHEM RES, V21, P407, DOI 10.1021/ar00155a004; BLUM L, 1991, BIOSENSORS PRINCIPLE; BUCK RP, 1990, BIOSENSOR TECHNOLOGY; Buckmann AF, 1994, FLAVINS AND FLAVOPROTEINS 1993, P597; DEGANI Y, 1989, J AM CHEM SOC, V111, P2357, DOI 10.1021/ja00188a091; DEGANI Y, 1988, J AM CHEM SOC, V110, P2615, DOI 10.1021/ja00216a040; FOULDS NC, 1988, ANAL CHEM, V60, P2473, DOI 10.1021/ac00173a008; GORTON L, 1992, ANALYST, V117, P1235, DOI 10.1039/an9921701235; HELLER A, 1990, ACCOUNTS CHEM RES, V23, P128, DOI 10.1021/ar00173a002; HELLER A, 1992, J PHYS CHEM-US, V96, P3579, DOI 10.1021/j100188a007; LIONDAGAN M, 1994, J CHEM SOC CHEM COMM, P2741, DOI 10.1039/c39940002741; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MORRIS DL, 1983, METHOD ENZYMOL, V92, P413; SCHUHMANN W, 1991, J AM CHEM SOC, V113, P1394, DOI 10.1021/ja00004a048; WILLNER I, 1992, BIOELECTROCH BIOENER, V29, P29, DOI 10.1016/0302-4598(92)80051-H; WILLNER I, 1993, ADV MATER, V5, P912, DOI 10.1002/adma.19930051206; WILLNER I, 1991, TOP CURR CHEM, V159, P153; WILLNER I, 1994, J AM CHEM SOC, V116, P1428, DOI 10.1021/ja00083a031	18	208	216	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					672	675		10.1038/376672a0	http://dx.doi.org/10.1038/376672a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	RQ672	7651516				2022-12-01	WOS:A1995RQ67200055
J	SCHWEITZER, R; HOWES, R; SMITH, R; SHILO, BZ; FREEMAN, M				SCHWEITZER, R; HOWES, R; SMITH, R; SHILO, BZ; FREEMAN, M			INHIBITION OF DROSOPHILA EGF RECEPTOR ACTIVATION BY THE SECRETED PROTEIN ARGOS	NATURE			English	Article							FAINT-LITTLE-BALL; TYROSINE KINASE; GENE ENCODES; HOMOLOG; EXPRESSION; ANTAGONIST; TORPEDO; MELANOGASTER	THE Drosophila homologue of the mammalian epidermal growth factor (EGF) receptor (DER)(1,2) is a receptor tyrosine kinase involved in many stages of fly development, including photoreceptor determination, and wing-vein formation(3-9). Its primary activating ligand is the Spitz protein(10,11), which is similar to mammalian TGF-alpha (ref. 12), Argos is a secreted protein that, like Spitz, contains a single EGF motif(13-15). It is a repressor of cell determination in the eye, and acts in other tissues, including the wing(16-18) Because Argos has the opposite effects to DER in the eye (the former blocks photoreceptor determination, the latter promotes it) we have tested whether it acts by blocking the DER pathway, We show that Argos does indeed repress this pathway in vivo and find that, in vitro, Argos protein can inhibit the activation of DER by Spitz, Thus the determination of cells by the DER pathway is regulated by a balance between extracellular activating and inhibiting signals. This is the first in vivo example of an extracellular inhibitor of a receptor tyrosine kinase.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	MRC Laboratory Molecular Biology; Weizmann Institute of Science			Schweitzer, Ronen/AAY-2127-2020	Schweitzer, Ronen/0000-0002-7425-5028; Freeman, Matthew/0000-0003-0410-5451; Shilo, Ben Zion/0000-0003-4903-8889				BRUNNER A, 1994, MECH DEVELOP, V48, P175, DOI 10.1016/0925-4773(94)90058-2; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; COCHET C, 1984, J BIOL CHEM, V259, P2553; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; XU T, 1993, DEVELOPMENT, V117, P1223; ZAK NB, 1990, ONCOGENE, V5, P1589	30	219	222	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					699	702		10.1038/376699a0	http://dx.doi.org/10.1038/376699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651519				2022-12-01	WOS:A1995RQ67200063
J	SCOTT, DM; EHRMANN, IE; ELLIS, PS; BISHOP, CE; AGULNIK, AI; SIMPSON, E; MITCHELL, MJ				SCOTT, DM; EHRMANN, IE; ELLIS, PS; BISHOP, CE; AGULNIK, AI; SIMPSON, E; MITCHELL, MJ			IDENTIFICATION OF A MOUSE MALE-SPECIFIC TRANSPLANTATION ANTIGEN, H-Y	NATURE			English	Article							UBIQUITIN-ACTIVATING ENZYME-E1; T-CELLS; GENE; EXPRESSION; CHROMOSOME; RESPONSES; LOCATION; EPITOPES; PEPTIDE; MICE	THE male-specific transplantation antigen, H-Y, causes rejection of male tissue grafts by genotypically identical female mice(1) and contributes to the rejection of human leukocyte antigen-matched male organ grafts by human females(2). Although first recognized 40 years ago(1), the identity of H-Y has remained elusive. T cells detect several distinct H-Y epitopes(3-5), and these are probably peptides, derived from intracellular proteins, that are presented at the cell surface with major histocompatibility complex (MHC) molecules(6). In the mouse, the gene(s) controlling H-Y expression (Hya) are located on the short arm of the Y chromosome(7,8) between the zinc-finger genes Zfy-1 and Zfy-2 (ref. 9). We have recently identified Smcy, a ubiquitously expressed gene, in this region(10) and its X-chromosome homologue, Smcx(11). Here we report that Smcy encodes an H-YKk epitope that is defined by the octamer peptide TENSGKDI: no similar peptide is found in Smcx. These findings provide a genetic basis for the antigenic difference between males and females that contributes towards a tissue transplant rejection response.	INSERM, U406, F-13005 MARSEILLE, FRANCE; BAYLOR COLL MED, DEPT OBSTET & GYNAECOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT HUMAN & MOLEC GENET, HOUSTON, TX 77030 USA; UNIV TENNESSEE, DEPT OBSTET & GYNAECOL, MEMPHIS, TN 38105 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Baylor College of Medicine; Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center	SCOTT, DM (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MRC, CTR CLIN SCI, DU CANE RD, LONDON W12 0NN, ENGLAND.		Mitchell, Michael/I-3987-2016; Agoulnik, Alexander/AAK-3213-2020	Mitchell, Michael/0000-0003-2052-7347; Agoulnik, Alexander/0000-0001-6587-6845; Simpson, Elizabeth/0000-0002-2118-3139				AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; CHOMEZ P, 1992, IMMUNOGENETICS, V35, P241, DOI 10.1007/BF00166829; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GAVIN MA, 1994, EUR J IMMUNOL, V24, P2124, DOI 10.1002/eji.1830240929; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PFEFFER PF, 1982, TRANSPLANTATION, V33, P52, DOI 10.1097/00007890-198201000-00011; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; ROOPENIAN DC, 1992, IMMUNOL TODAY, V13, P7, DOI 10.1016/0167-5699(92)90197-F; ROOPENIAN DC, 1989, IMMUNOGENETICS, V30, P335, DOI 10.1007/BF02425273; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SCOTT D, 1991, IMMUNOGENETICS, V33, P54, DOI 10.1007/BF00211696; SCOTT DM, 1992, IMMUNOGENETICS, V36, P86, DOI 10.1007/BF00215284; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SIMPSON E, 1982, IMMUNOL TODAY, V3, P97, DOI 10.1016/S0167-5699(82)80025-X; SIMPSON E, 1989, K IMMUNOLOGY S, V2, P42; SIMPSON EM, 1991, GENOMICS, V11, P601, DOI 10.1016/0888-7543(91)90067-O; TOMONARI K, 1983, J IMMUNOL, V131, P1641; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	28	171	178	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					695	698		10.1038/376695a0	http://dx.doi.org/10.1038/376695a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7544442				2022-12-01	WOS:A1995RQ67200062
J	SIMON, MN; DEVIRGILIO, C; SOUZA, B; PRINGLE, JR; ABO, A; REED, SI				SIMON, MN; DEVIRGILIO, C; SOUZA, B; PRINGLE, JR; ABO, A; REED, SI			ROLE FOR THE RHO-FAMILY GTPASE CDC42 IN YEAST MATING-PHEROMONE SIGNAL PATHWAY	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE GENE; CELL-DIVISION-CYCLE; MOLECULAR-CLONING; BINDING PROTEIN; HUMAN HOMOLOG; POLARITY; ENCODES; KINASE; G25K	IN the budding yeast Saccharomyces cerevisiae, the process of conjugation of haploid cells of genotype MAT alpha and MAT alpha to form MAT alpha/alpha diploids is triggered by pheromones produced by each mating type. These pheromones stimulate a cellular response by interaction with receptors linked to a heterotrimeric G protein. Although genetic analysis indicates that the pheromone signal is transmitted through the G beta gamma dimer, the initial target(s) of G protein activation remain to be determined. Temperature-sensitive cells with mutations of the CDC24 and CDC42 genes, which are incapable of budding and of generating cell polarity at the restrictive temperature(1-3), are also unable to mate(4). Cdc24 acts as a guanylyl-nucleotide-exchange factor for the Rho-type GTPase Cdc42(5), which has been shown to be a fundamental component of the molecular machinery controlling morphogenesis in eukaryotic cells(6-10). Therefore, the inability of cdc24 and cdc42 mutants to mate has been presumed to be due to a requirement for generation of cell polarity and related morphogenetic events during conjugation, But here we show that Cdc42 has a direct signalling role in the mating-pheromone response between the G protein and the downstream protein kinase cascade.	SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill			De Virgilio, Claudio/B-4707-2012	De Virgilio, Claudio/0000-0001-8826-4323				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1992, YEAST, V8, P315, DOI 10.1002/yea.320080409; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN WN, 1993, J BIOL CHEM, V268, P13280; EIBLE R, 1989, BIOTECHNIQUES, V13, P18; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1973, GENETICS, V74, P267; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	30	188	189	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					702	705		10.1038/376702a0	http://dx.doi.org/10.1038/376702a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651520				2022-12-01	WOS:A1995RQ67200064
J	ALBERTSEN, PC; FRYBACK, DG; STORER, BE; KOLON, TF; FINE, J				ALBERTSEN, PC; FRYBACK, DG; STORER, BE; KOLON, TF; FINE, J			LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-ANALYSIS; CO-MORBIDITY; COMORBIDITY; OUTCOMES; DISEASE	Objective.-To determine age-specific, all-cause mortality, disease-specific mortality, and life expectancy for men aged 65 to 75 years who are treated only with immediate or delayed hormonal therapy for newly diagnosed, clinically localized prostate cancer. Design.-A population-based, retrospective cohort study. Setting.-Patient records were abstracted from 37 acute care hospitals and two Veterans Affairs medical centers in Connecticut. Original pathology slides were sent to a referee pathologist who was blinded to case outcomes. Subjects.-All men identified by the Connecticut Tumor Registry with clinically localized prostate cancer diagnosed in 1971 to 1976 who were aged 65 to 75 years at the time of diagnosis and were untreated or treated with immediate or delayed hormonal therapy. Main Outcome Measures.-Parametric proportional hazards models incorporating tumor histologic findings, comorbidity, and age at the time of diagnosis to compare cohort survival with that of men in the general population. Results.-After a mean follow-up of 15.5 years, the age-adjusted survival for men with Gleason score 2 to 4 tumors was not significantly different from that of the general population. Maximum estimated lost life expectancy for men with Gleason score 5 to 7 tumors was 4 to 5 years and for men with Gleason score 8 to 10 tumors was 6 to 8 years. Tumor histologic findings and patient comorbidities were powerful independent predictors of survival. Conclusions.-Compared with the general population, men aged 65 to 75 years with conservatively treated low-grade prostate cancer incur no loss of life expectancy. Men with higher-grade tumors (Gleason scores 5 to 10) experience a progressively increasing loss of life expectancy. Case series reports of survival/ mortality experienced by men with clinically localized prostate cancer that fail to control for age, tumor histologic features, and comorbidities risk significant bias.	UNIV WISCONSIN,DEPT PREVENT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOSTAT,MADISON,WI 53706; YALE UNIV,CTR CANC,NEW HAVEN,CT	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Yale University	ALBERTSEN, PC (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT SURG,DIV UROL,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.			Kolon, Thomas/0000-0002-8740-5021	AHRQ HHS [HS06770] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CATALONA WJ, 1989, J UROLOGY, V142, P1302, DOI 10.1016/S0022-5347(17)39066-3; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; Elandt-Johnson RC., 1980, SURVIVAL MODELS DATA; Fleming C, 1993, JAMA, V269, P2650; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KAPLAN MH, 1974, J CHRON DIS, V27, P387, DOI 10.1016/0021-9681(74)90017-4; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; MOLD JW, 1992, J FAM PRACTICE, V34, P561; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487	21	369	374	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					626	631		10.1001/jama.274.8.626	http://dx.doi.org/10.1001/jama.274.8.626			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637143				2022-12-01	WOS:A1995RP70200030
J	MOHLEBOETANI, JC; MILLER, B; HALPERN, M; TRIVEDI, A; TESSLER, J; SOLOMON, SL; FENSTERSHEIB, M				MOHLEBOETANI, JC; MILLER, B; HALPERN, M; TRIVEDI, A; TESSLER, J; SOLOMON, SL; FENSTERSHEIB, M			SCHOOL-BASED SCREENING FOR TUBERCULOUS INFECTION - A COST-BENEFIT-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-ANALYSIS; PROGNOSIS; CHILDREN; REACTORS	Objective.-To compare tuberculin screening of all kindergartners and high school entrants (screen-all strategy) vs screening limited to high-risk children (targeted screening). Design.-Decision, cost-effectiveness, and cost-benefit analyses. Setting and Subjects.-Students in a large urban and rural county. Definitions.-High risk of tuberculous infection was defined as birth in a country with a high prevalence of tuberculosis. Low risk was defined as birth in the United States. Outcome Measures.-Tuberculosis cases prevented per 10 000 children screened. Net costs, net cost per case prevented, benefit-cost ratio, and incremental cost-effectiveness. Results.-The screen-all strategy would prevent 14.9 cases per 10 000 children screened; targeted screening would prevent 84.9 cases per 10 000 children screened. The screen-all strategy is more costly than no screening; the benefit-cost ratio is 0.58. Targeted screening would result in a net savings; the benefit-cost ratio is 1.2. Screening all children is cost saving only if the reactor rate is 20% or greater. The cost per additional case prevented for screening all children compared with targeted screening ($34 666) is more than twice as high as treatment and contact tracing for a case of tuberculosis ($16 392). Conclusions.-Targeted screening of schoolchildren is much less costly than mass screening and is more efficient in prevention of tuberculosis.	CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,CLIN RES BRANCH,PREVENT EFFECTIVENESS STUDIES UNIT,ATLANTA,GA 30333; CTY SANTA CLARA PUBL HLTH DEPT,DIV DIS CONTROL & PREVENT,SAN JOSE,CA; CTR DIS CONTROL & PREVENT,PREVENT MED RESIDENCY,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,SPECIAL STUDIES ACT,ATLANTA,GA 30333; BATTELLE CTR PUBL HLTH RES & EVALUAT,ARLINGTON,VA; BATTELLE CTR PUBL HLTH RES & EVALUAT,DURHAM,NC	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Mohle-Boetani, Janet/AAH-4221-2019					BARRY MA, 1990, AM J PUBLIC HEALTH, V80, P439, DOI 10.2105/AJPH.80.4.439; BASS JB, 1993, TUBERCULOSIS COMPREH, P139; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; COMSTOCK GW, 1986, JAMA-J AM MED ASSOC, V256, P2729, DOI 10.1001/jama.256.19.2729; COMSTOCK GW, 1975, AM REV RESPIR DIS, V11, P573; DAVIDSON P T, 1990, American Review of Respiratory Disease, V141, pA336; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRZYBOWSKI S, 1964, AM REV RESPIR DIS, V90, P707; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V2442, P736; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SCHECHTER Y, 1990, DIABETES, V39, P1; SHAW BV, 1993, PROFESSIONAL SOFTWAR; SNIDER DE, 1984, AM J PUBLIC HEALTH, V74, P1353, DOI 10.2105/AJPH.74.12.1353; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; 1991, LOTUS 1 2 3 DOS; 1993, DATA MATTERS; 1993, ADV REPORT FINAL MOR, V41, P22; 1982, B WORLD HEALTH ORGAN, V60, P555; 1988, MMWR-MORBID MORTAL W, V37, P663; 1994, AM J RESP CRIT CARE, V149, P1359; 1990, MMWR-MORBID MORTAL W, V39, P10; 1989, CDC898322 US DEP HLT; 1990, PERSONS AGE PLACE BI; 1994, PEDIATRICS, V93, P131; 1991, REPORT COMMITTEE INF, P487	34	78	78	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					613	619						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637141				2022-12-01	WOS:A1995RP70200028
J	PSATY, BM; HECKBERT, SR; KOEPSELL, TD; SISCOVICK, DS; RAGHUNATHAN, TE; WEISS, NS; ROSENDAAL, FR; LEMAITRE, RN; SMITH, NL; WAHL, PW; WAGNER, EH; FURBERG, CD				PSATY, BM; HECKBERT, SR; KOEPSELL, TD; SISCOVICK, DS; RAGHUNATHAN, TE; WEISS, NS; ROSENDAAL, FR; LEMAITRE, RN; SMITH, NL; WAHL, PW; WAGNER, EH; FURBERG, CD			THE RISK OF MYOCARDIAL-INFARCTION ASSOCIATED WITH ANTIHYPERTENSIVE DRUG THERAPIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD-PRESSURE; NIFEDIPINE; DISEASE; ANGINA; TRIAL; PREVENTION; BLOCKERS	Objective.-To assess the association between first myocardial infarction and the use of antihypertensive agents. Design and Setting.-We conducted a population-based case-control study among enrollees of the Group Health Cooperative of Puget Sound (GHC). Patients and Methods.-Cases were hypertensive patients who sustained a first fatal or nonfatal myocardial infarction from 1986 through 1993 among women and from 1989 through 1993 among men. Controls were a stratified random sample of hypertensive GHC enrollees, frequency matched to the cases on age, sex, and calendar year, All 623 cases and 2032 controls had pharmacologically treated hypertension. Data collection included a review of the ambulatory medical record and a brief telephone interview of consenting survivors. Antihypertensive therapy was assessed using the GHC's computerized pharmacy database. Results.-The first analysis included only the 335 cases and 1395 controls initially free of cardiovascular disease. Compared with users of diuretics alone, the adjusted risk ratio of myocardial infarction was increased by about 60% among users of calcium channel blockers with or without diuretics (risk ratio=1.62; 95% confidence interval [CI], 1.11 to 2.34; P=.01). The second analysis was restricted to 384 cases and 1108 controls who were taking either a calcium channel blocker or a beta-blocker. Among these subjects, the use of calcium channel blockers compared with beta-blockers was associated with about a 60% increase in the adjusted risk of myocardial infarction (risk ratio=1.57; 95% CI, 1.21 to 2.04; P<.001). While high doses of beta-blockers were associated with a decreased risk of myocardial infarction (trend P=.04), high doses of calcium channel blockers were associated with an increased risk (trend P<.01). Conclusions.-In this study of hypertensive patients, the use of short-acting calcium channel blockers, especially in high doses, was associated with an increased risk of myocardial infarction. Ongoing targe-scale clinical trials will assess the effect of various antihypertensive therapies, including calcium channel blockers, on several important cardiovascular end points. Until these results are available, the findings of this study support the current guidelines from the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure that recommend diuretics and beta-blockers as first-line agents unless contraindicated, unacceptable; or not tolerated.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98101 USA; UNIV MICHIGAN, SURVEY RES CTR, INST SOCIAL RES, ANN ARBOR, MI USA; LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, LEIDEN, NETHERLANDS; CTR HLTH STUDIES, GRP HLTH COOPERAT PUGET SOUND, SEATTLE, WA USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Leiden University; Leiden University Medical Center (LUMC); Group Health Cooperative; Wake Forest University; Wake Forest Baptist Medical Center	PSATY, BM (corresponding author), UNIV WASHINGTON, DEPT MED, CARDIOVASC HLTH RES UNIT, SEATTLE, WA 98101 USA.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NHLBI NIH HHS [HL40628, HL43201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040628, R29HL040628, R01HL043201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BETO JA, 1992, AM J HYPERTENS, V5, P125, DOI 10.1093/ajh/5.3.125; Breslow NE., 1980, IARC SCI PUBLICATION, V32; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAVIS BR, IN PRESS AM J HYPERT; EGSTRUP K, 1993, AM J CARDIOL, V71, P177, DOI 10.1016/0002-9149(93)90735-U; FERGUSON JJ, 1994, CIRCULATION, V90, P2194; FURBERG CD, 1989, AM J MED, V86, P37, DOI 10.1016/0002-9343(89)90188-5; FURBERG CD, IN PRESS CIRCULATION; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HILLEGASS WB, 1994, AM J CARDIOL, V73, P835, DOI 10.1016/0002-9149(94)90805-2; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MCCLELLAN K, 1994, INPHARMA, V932, P4; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PSATY BM, 1987, J GEN INTERN MED, V2, P381, DOI 10.1007/BF02596362; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; PSATY BM, 1991, STAT MED, V10, P653, DOI 10.1002/sim.4780100416; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; PSATY BM, 1993, HYPERTENSION PRIMER, P197; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; RUZICKA M, 1992, HYPERTENSION PATHOPH, P2815; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SEWESTER CS, 1994, DRUG FACTS COMP; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1993, BLOOD PRESS, V2, P314	38	877	887	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					620	625		10.1001/jama.274.8.620	http://dx.doi.org/10.1001/jama.274.8.620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637142				2022-12-01	WOS:A1995RP70200029
J	WAGNER, A				WAGNER, A			2ND CHILDHOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					606	606						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637134				2022-12-01	WOS:A1995RP70200009
J	AABY, P; SAMB, B; SIMONDON, F; SECK, AMC; KNUDSEN, K; WHITTLE, H				AABY, P; SAMB, B; SIMONDON, F; SECK, AMC; KNUDSEN, K; WHITTLE, H			NONSPECIFIC BENEFICIAL EFFECT OF MEASLES IMMUNIZATION - ANALYSIS OF MORTALITY STUDIES FROM DEVELOPING-COUNTRIES	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD MORTALITY; GUINEA-BISSAU; RURAL BANGLADESH; VACCINATION; COMMUNITY; SURVIVAL; SENEGAL; TITER; AGE	Objective-To examine whether the reduction in mortality after standard titre measles immunisation in developing countries can be explained simply by the prevention of acute measles and its long term consequences. Design-An analysis of all studies comparing mortality of unimmunised children and children immunised with standard titre measles vaccine in developing countries. Studies-10 cohort and two case-control studies from Bangladesh, Benin, Burundi, Guinea-Bissau, Haiti, Senegal, and Zaire. Main outcome measures-Protective efficacy of standard titre measles immunisation against all cause mortality. Extent to which difference in mortality between immunised and unimmunised children could be explained by prevention of measles disease. Results-Protective efficacy against death after measles immunisation ranged from 30% to 86%. Efficacy was highest in the studies with short follow up and when children were immunised in infancy (range 44-100%). Vaccine efficacy against death was much greater than the proportion of deaths attributed to acute measles disease. In four studies from Guinea-Bissau, Senegal, and Burundi vaccine efficacy against death remained almost unchanged when cases of measles were excluded from the analysis. Diphtheria-tetanus-pertussis and polio vaccinations were not associated with reduction in mortality. Conclusion-These observations suggest that standard titre measles vaccine may confer a beneficial effect which is unrelated to the specific protection against measles disease.	ORSTOM,DAKAR,SENEGAL; UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL; MRC LABS,BANJUL,GAMBIA	Institut de Recherche pour le Developpement (IRD); University Cheikh Anta Diop Dakar; MRC Laboratory Molecular Biology	AABY, P (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.			Aaby, Peter/0000-0001-8331-1389; Simondon, Francois/0000-0003-0395-1314				AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1984, J TROP PEDIATRICS, V30, P164, DOI 10.1093/tropej/30.3.164; AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; DULOU A, IN PRESS AM J EPIDEM; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GARENNE M, 1986, ESTIMATION MORTALITE, P515; HARRIS MF, 1979, S AFR MED J, P38; HOLT EA, 1990, PEDIATRICS, V85, P188; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; 1981, LANCET, V1, P764	20	255	256	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					481	485		10.1136/bmj.311.7003.481	http://dx.doi.org/10.1136/bmj.311.7003.481			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647643	Green Published			2022-12-01	WOS:A1995RQ67000014
J	CARTLIDGE, PHT; STEWART, JH				CARTLIDGE, PHT; STEWART, JH			EFFECT OF CHANGING THE STILLBIRTH DEFINITION ON EVALUATION OF PERINATAL-MORTALITY RATES	LANCET			English	Article							PRETERM INFANTS; ATTITUDES; VIABILITY	The perinatal mortality rate is widely used as a summary statistic for evaluating the effectiveness of perinatal care. Since October, 1992, it has been a legal requirement in England and Wales to register fetal deaths at 24-27 completed weeks of gestation as stillbirths (in addition to those after 28 weeks), thereby altering the definition of perinatal death. In a cohort analysis of all babies born to women resident in Wales during 1993, we assessed whether the revised definition of perinatal mortality rate more appropriately measures effectiveness of care. There were 36 793 births and 313 perinatal deaths (221 stillbirths, 92 early neonatal deaths). At 24-27 weeks' gestation there were 59 (39%) survivors and 93 deaths (52 stillbirths, 36 neonatal deaths [28 early, eight late], and 5 postneonatal deaths). 119 babies had a birthweight below 500 g; one survived and 24 were perinatal deaths. Of the 36 late neonatal deaths all were attributed to perinatally related events. Increased survival of infants at 24-27 weeks' gestation emphasises the importance of including all these infants in the perinatal mortality rate, but it would be a more useful measure of the effectiveness of perinatal care if it excluded babies below 500 g, and included late neonatal deaths.			CARTLIDGE, PHT (corresponding author), UNIV WALES COLL MED,DEPT CHILD HLTH,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							[Anonymous], 1978, INT CLASSIFICATION D; [Anonymous], 1988, REGISTRATION MODERN; CARTLIDGE PHT, 1995, BRIT MED J, V310, P155, DOI 10.1136/bmj.310.6973.155; CLARKE M, 1993, BRIT MED J, V306, P824, DOI 10.1136/bmj.306.6881.824; FENTON AC, 1990, BRIT MED J, V300, P434, DOI 10.1136/bmj.300.6722.434; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; MACFARLANE A, 1990, BRIT MED J, V300, P942, DOI 10.1136/bmj.300.6729.942-a; Macfarlane A, 1980, HLTH TRENDS, V12, P45; Mallett R, 1979, Community Med, V1, P6, DOI 10.1007/BF02548737; MUTCH LMM, 1981, BRIT MED J, V282, P119, DOI 10.1136/bmj.282.6258.119; SCOTT MJ, 1981, BRIT MED J, V282, P707, DOI 10.1136/bmj.282.6265.707; WIGGLESWORTH JS, 1980, LANCET, V2, P684; 1993, CONFIDENTIAL ENQUIRY; 1990, REGISTRATION PROPOSA; 1991, LANCET, V337, P331; 1990, LANCET, V336, P782	16	54	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					486	488		10.1016/S0140-6736(95)91327-0	http://dx.doi.org/10.1016/S0140-6736(95)91327-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637485				2022-12-01	WOS:A1995RP85700015
J	CROSLAND, A; JONES, R				CROSLAND, A; JONES, R			RECTAL BLEEDING - PREVALENCE AND CONSULTATION BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							IRRITABLE-BOWEL-SYNDROME; SYMPTOMS; DIAGNOSIS; DYSPEPSIA; DELAY	Objectives-To determine prevalence of rectal bleeding in the community and to examine factors that lead some patients to consult their general practitioner about rectal bleeding while others do not. Design-Questionnaire survey followed by semistructured interviews of sample of respondents with rectal bleeding. Setting-Two general practices on Tyneside. Subjects-2000 adult patients registered with the general practices were sent a validated questionnaire. Respondents with rectal bleeding were divided into consulters and non-consulters, and 30 patients from each group (matched for age, sex, and characteristics of bleeding) were interviewed. Main outcome measures-Prevalence of rectal bleeding, proportion of subjects with rectal bleeding who sought medical advice, and reasons for consulting or not consulting a doctor about rectal bleeding. Results-287 of the 1200 respondents to the questionnaire had noticed rectal bleeding at some time in their lives, and 231 had noticed it within previous 12 months. Only 118 (41%) of all respondents with rectal bleeding had ever sought medical advice for the problem. Those aged over 60 were most likely to have consulted, as were those who reported blood mixed with their stools. Main difference between those who had sought medical advice and those who had not was that consulters were more likely than non-consulters to perceive their symptoms as serious. Conclusions-Although rectal bleeding is common, only minority of patients seek medical advice for their bleeding. Perception of seriousness of symptoms seems to be most important factor in deciding whether to consult a doctor for rectal bleeding.	UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London	CROSLAND, A (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.							BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; BYLES JE, 1992, J EPIDEMIOL COMMUN H, V46, P241, DOI 10.1136/jech.46.3.241; DENT OF, 1990, DIS COLON RECTUM, V33, P851, DOI 10.1007/BF02051921; DENT OF, 1986, DIS COLON RECTUM, V29, P234; GOULSTON K, 1987, MED J AUSTRALIA, V146, P631, DOI 10.5694/j.1326-5377.1987.tb120441.x; GOULSTON KJ, 1986, LANCET, V2, P261; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; JONES RH, 1995, BRIT J CLIN PRACT, V49, P67; JONES RH, 1993, RECTAL BLEEDING GUID; KETTELL J, 1992, BRIT J GEN PRACT, V42, P459; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MANT A, 1989, DIS COLON RECTUM, V32, P191, DOI 10.1007/BF02554525; RAFFERTY T, 1980, AM SURGEON, V46, P600; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; Strauss A., 1990, BASICS QUALITATIVE R; 1993, OPCS MONITOR     JUL	17	113	114	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					486	488		10.1136/bmj.311.7003.486	http://dx.doi.org/10.1136/bmj.311.7003.486			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647645	Green Published			2022-12-01	WOS:A1995RQ67000016
J	PARISH, S; COLLINS, R; PETO, R; YOUNGMAN, L; BARTON, J; JAYNE, K; CLARKE, R; APPLEBY, P; LYON, V; CEDERHOLMWILLIAMS, S; MARSHALL, J; SLEIGHT, P				PARISH, S; COLLINS, R; PETO, R; YOUNGMAN, L; BARTON, J; JAYNE, K; CLARKE, R; APPLEBY, P; LYON, V; CEDERHOLMWILLIAMS, S; MARSHALL, J; SLEIGHT, P			CIGARETTE-SMOKING, TAR YIELDS, AND NONFATAL MYOCARDIAL-INFARCTION - 14000 CASES AND 32000 CONTROLS IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH-HEART-HEALTH; FILTER CIGARETTE; LUNG-CANCER; NICOTINE; RISK; SMOKERS; COTININE	Objectives-To assess the effects of cigarette smoking on the incidence of non-fatal myocardial infarction, and to compare tar in different types of manufactured cigarettes. Methods-In the early 1990s responses to a postal questionnaire were obtained from 13 926 survivors of myocardial infarction (cases) recently discharged from hospitals in the United Kingdom and 32 389 of their relatives (controls). Blood had been obtained from cases soon after admission for the index myocardial infarction and was also sought from the controls. 4923 cases and 6880 controls were current smokers of manufactured cigarettes with known tar yields. Almost all tar yields were 7-9 or 12-15 mg/cigarette (mean 7.5 mg for low tar (<10 mg) and 13.3 for medium tar (greater than or equal to 10 mg)). The cited risk ratios were standardised for age and sex and compared myocardial infarction rates in current cigarette smokers with those in non-smokers who had not smoked cigarettes regularly in the past 10 years. Results-At ages 30-49 the rates of myocardial infarction in smokers were about five times those in non-smokers (as defined); at ages 50-59 they were three times those in non-smokers, and even at ages 60-79 they were twice as great as in non-smokers (risk ratio 6.3, 4.7, 3.1, 2.5, and 1.9 at 30-39, 40-49, 50-59, 60-69, 70-79 respectively; each 2P<0.00001). After standardisation for age, sex, and amount smoked, the rate of non-fatal myocardial infarction was 10.4% (SD 5.4) higher in medium tar than in low tar cigarette smokers (2P=0.06). This percentage was not significantly greater at ages 30-59 (16.6% (7.1)) than at 60-79 (1.0% (8.5)). In both age ranges the difference in risk between cigarette smokers and non-smokers was much larger than the difference between one type of cigarette and another (risk ratio 3.39 and 3.95 at ages 30-59 for smokers of similar numbers of low and of medium tar cigarettes, and risk ratio 2.35 and 2.37 at ages 60-79). Most possible confounding factors that could be tested for were similar in low and medium tar users, with no significant differences in blood lipid or albumin concentrations. Conclusion-The present study indicates that the imminent change of tar yields in the European Union to comply with an upper limit of 12 mg/cigarette will not increase (and may somewhat decrease) the incidence of myocardial infarction, unless they indirectly help perpetuate tobacco use. Even low tar cigarettes still greatly increase rates of myocardial infarction, however, especially among people in their 30s, 40s, and 50s, and far more risk is avoided by not smoking than by changing from one type of cigarette to another.	RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, EPIDEMIOL STUDIES UNIT, OXFORD OX2 6HE, ENGLAND; JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND; OXFORD BIORES LAB, OXFORD OX4 4GA, ENGLAND	Radcliffe Infirmary; University of Oxford; University of Oxford	PARISH, S (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; CASTELLI WP, 1981, LANCET, V2, P109, DOI 10.1016/S0140-6736(81)90297-X; COLLINS R, 1995, LANCET, V345, P669; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HIGENBOTTAM T, 1982, J EPIDEMIOL COMMUN H, V36, P113, DOI 10.1136/jech.36.2.113; HUNT D, 1992, LANCET, V339, P753; KAUFMAN DW, 1983, NEW ENGL J MED, V308, P409, DOI 10.1056/NEJM198302243080801; KAUFMAN DW, 1989, AM J EPIDEMIOL, V129, P703, DOI 10.1093/oxfordjournals.aje.a115185; KNIGHT GJ, 1985, CLIN CHEM, V31, P118; LEE PN, 1981, J EPIDEMIOL COMMUN H, V35, P16, DOI 10.1136/jech.35.1.16; NEGRI E, 1993, BRIT MED J, V306, P1567, DOI 10.1136/bmj.306.6892.1567; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; Peto R, 1994, MORTALITY SMOKING DE; STELLMAN SD, 1989, PREV MED, V18, P518, DOI 10.1016/0091-7435(89)90010-8; VUTUC C, 1983, J NATL CANCER I, V71, P435; WALD N, 1991, UK SMOKING STATISTIC; Wald N, 1989, NICOTINE SMOKING LOW; WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, BRIT J ADDICT, V87, P921; WYNDER EL, 1979, NEW ENGL J MED, V300, P894, DOI 10.1056/NEJM197904193001605; WYNDER EL, 1979, J NATL CANCER I, V62, P471, DOI 10.1093/jnci/62.3.471; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74; 1994, STATISTICAL B DEPT H, V14	29	159	162	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	1995	311	7003					471	477		10.1136/bmj.311.7003.471	http://dx.doi.org/10.1136/bmj.311.7003.471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647641	Green Published			2022-12-01	WOS:A1995RQ67000012
J	RANTAKALLIO, P; LAARA, E; KOIRANEN, M				RANTAKALLIO, P; LAARA, E; KOIRANEN, M			A 28 YEAR FOLLOW-UP OF MORTALITY AMONG WOMEN WHO SMOKED DURING PREGNANCY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING	Objective-To investigate long term mortality among women who smoked during pregnancy and those who stopped smoking. Design-A follow up of a geographically defined cohort from 1966 through to 1993. Subjects-11 994 women in northern Finland expected to deliver in 1966, comprising 96% of all women giving birth in the area during that year. Smoking habits were recorded during pregnancy but not later. Main outcome measure-Mortality by cause (571 deaths). Results-The mortality ratio adjusted for age, place of residence, years of education and marital status was 2.3 (95% confidence interval 1.8 to 2.8) for the women who smoked during pregnancy and 1.6 (1.1 to 2.2) for those who stopped smoking before the second month of pregnancy, both compared with non-smokers. Among the smokers the relative mortality was higher for typical diseases related to tobacco intake, such as respiratory and oesophageal cancer and diseases of the cardiovascular and digestic organs and also for accidents and suicides. Conclusion-The risk of premature death seems to be higher in women who smoke during pregnancy than in other women who smoke. This may be explained either by the low proportion of those who stop later and the high proportion of heavy smokers or by other characteristics of these subjects that increase the risk.			RANTAKALLIO, P (corresponding author), UNIV OULU, DEPT PUBL HLTH SCI & GEN PRACTICE, AAPISTIE 1, SF-90220 OULU, FINLAND.							Breslow NE, 1987, IARC SCI PUBLICATION; BUTLER NR, 1973, BRIT MED J, V4, P573, DOI 10.1136/bmj.4.5892.573; COLBY JP, 1994, SOC SCI MED, V38, P373, DOI 10.1016/0277-9536(94)90407-3; COX DR, 1972, J R STAT SOC B, V34, P187; Dixon W. J., 1990, BMDP STATISTICAL SOF; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; GRAHAM H, 1994, SOC SCI MED, V38, P691, DOI 10.1016/0277-9536(94)90459-6; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; PRITCHARD CW, 1994, J EPIDEMIOL COMMUN H, V48, P377, DOI 10.1136/jech.48.4.377; PUGH H, 1991, SOC SCI MED, V32, P1105, DOI 10.1016/0277-9536(91)90086-R; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; RANTAKALLIO P, 1969, ACTA PAEDIATR SC S, V0193; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RANTAKALLIO P, 1983, PUBLIC HLTH REV, V11, P55; Rimpeld A., 1992, TOB CONTROL, V1, P285; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; THORNTON A, 1994, J CLIN EPIDEMIOL, V47, P1143, DOI 10.1016/0895-4356(94)90101-5; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; [No title captured]	21	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	1995	311	7003					477	480		10.1136/bmj.311.7003.477	http://dx.doi.org/10.1136/bmj.311.7003.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647642	Green Published			2022-12-01	WOS:A1995RQ67000013
J	STROES, ESG; KOOMANS, HA; DEBRUIN, TWA; RABELINK, TJ				STROES, ESG; KOOMANS, HA; DEBRUIN, TWA; RABELINK, TJ			VASCULAR FUNCTION IN THE FOREARM OF HYPERCHOLESTEROLEMIC PATIENTS OFF AND ON LIPID-LOWERING MEDICATION	LANCET			English	Article							ENDOTHELIUM-DEPENDENT VASODILATION; RESISTANCE VESSELS; CORONARY-ARTERIES; NITRIC-OXIDE; L-ARGININE; RELEASE; CHOLESTEROL; HUMANS	To study whether vascular dysfunction in hypercholesterolaemia is reversible, we investigated patients without overt arterial disease who were taking maintenance treatment for hypercholesterolaemia. Medication was stopped for 2 weeks, reinstituted for 12 weeks, and again stopped for 6 weeks. During both maintenance treatment and the 12 weeks of step-up medication the lipid profile was improved but did not return to normal. Dose-response curves for serotonin-induced vasodilatation, an index of nitric oxide-dependent vasodilatation, showed a comparable and significant rightward shift. after a medication-free period of 2 and 6 weeks compared with control subjects, indicating endothelial dysfunction, which was already maximum after 2 weeks. After 12 weeks of lipid-lowering medication, the difference in endothelial function between controls and patients had disappeared. Go-infusion of L-arginine, the substrate for nitric oxide synthase, returned the impaired serotonin response during hypercholesterolaemia to normal, but had no effect on this response in controls or in patients while on lipid-lowering medication. Neither endothelium-independent vasorelaxation, assessed by sodium nitroprusside infusion, nor vasoconstriction induced by the nitric oxide blocker L-NMMA, were different between controls and patients, whether the latter were on or off lipid-lowering medication. Our results show an L-arginine-sensitive, impaired nitric-oxide-mediated vascular relaxation of forearm resistance vessels in hypercholesterolaemia which is reproducible, and reversible after short-term lipid-lowering therapy. Demonstration of such changes in this readily accessible vascular bed will allow larger trials assessing vascular function during lipid-lowering therapy to be done.	UNIV UTRECHT HOSP,DEPT MED,LIPID CLIN,3584 CX UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,3584 CX UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Rabelink, Ton J./A-5316-2008	Rabelink, Ton J./0000-0001-6780-5186				ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BRUNING TA, 1994, J CARDIOVASC PHARM, V24, P454, DOI 10.1097/00005344-199409000-00014; BRUNING TA, 1994, CIRC RES, V74, P912, DOI 10.1161/01.RES.74.5.912; BUSSE R, 1993, CIRCULATION, V87, P18; CALVER A, 1992, J CLIN INVEST, V90, P2448; CASINO PR, 1993, CIRCULATION, V88, P2541, DOI 10.1161/01.CIR.88.6.2541; CHANG PC, 1988, COMPUT BIOL MED, V18, P157, DOI 10.1016/0010-4825(88)90042-X; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; CHOWIENCZYK PJ, 1995, CLIN SCI, V88, P111, DOI 10.1042/cs0880111; CHOWIENCZYK PJ, 1994, LANCET, V344, P305, DOI 10.1016/S0140-6736(94)91342-0; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DUBOISRANDE JL, 1992, J CARDIOVASC PHARM, V20, pA211; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; HARRISON DG, 1995, AM J CARDIOL, V75, pB75, DOI 10.1016/0002-9149(95)80018-N; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; PRITCHARD KA, 1995, ENDOTHELIUM S, V2, pS19; RABELINK AJ, 1988, LANCET, V2, P1335; SHIMOKAWA H, 1991, CIRCULATION, V83, P652, DOI 10.1161/01.CIR.83.2.652; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801	28	373	380	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					467	471		10.1016/S0140-6736(95)91322-X	http://dx.doi.org/10.1016/S0140-6736(95)91322-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637480				2022-12-01	WOS:A1995RP85700010
J	DOUGLAS, RJ; KOCH, C; MAHOWALD, M; MARTIN, KAC; SUAREZ, HH				DOUGLAS, RJ; KOCH, C; MAHOWALD, M; MARTIN, KAC; SUAREZ, HH			RECURRENT EXCITATION IN NEOCORTICAL CIRCUITS	SCIENCE			English	Article							CAT VISUAL-CORTEX; INTRACORTICAL AXON COLLATERALS; LATERAL GENICULATE-NUCLEUS; RECEPTIVE-FIELD PROPERTIES; STRIATE CORTEX; SIMPLE CELLS; ORIENTATION SELECTIVITY; DIRECTIONAL SELECTIVITY; PYRAMIDAL CELLS; AREA 17	The majority of synapses in the mammalian cortex originate from cortical neurons. Indeed, the largest input to cortical cells comes from neighboring excitatory cells. However, most models of cortical development and processing do not reflect the anatomy and physiology of feedback excitation and are restricted to serial feedforward excitation. This report describes how populations of neurons in cat visual cortex can use excitatory feedback, characterized as an effective ''network conductance,'' to amplify their feedforward input signals and demonstrates how neuronal discharge can be kept proportional to stimulus strength despite strong, recurrent connections that threaten to cause runaway excitation. These principles are incorporated into models of cortical direction and orientation selectivity that emphasize the basic design principles of cortical architectures.	ETH ZURICH, CH-8006 ZURICH, SWITZERLAND; CALTECH, COMPUTAT & NEURAL SYST PROGRAM 13974, PASADENA, CA 91125 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, CTR BIOL & MED SYST, LONDON SW7 2BT, ENGLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Imperial College London	DOUGLAS, RJ (corresponding author), UNIV ZURICH, INST NEUROINFORMAT, CH-8006 ZURICH, SWITZERLAND.			Koch, Christof/0000-0001-6482-8067	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; AMIR Y, 1993, J COMP NEUROL, V334, P19, DOI 10.1002/cne.903340103; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743, DOI 10.1152/jn.1994.72.6.2743; BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P625, DOI 10.1113/jphysiol.1971.sp009681; Braitenberg V, 1991, ANATOMY CORTEX; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Churchland P. S., 1994, LARGE SCALE NEURONAL; DOUGLAS R, 1994, IEEE INT C NEUR NETW, P1848; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P217, DOI 10.1113/jphysiol.1985.sp015821; FERSTER D, 1987, J NEUROSCI, V7, P1780; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; GANZ L, 1984, J NEUROPHYSIOL, V51, P294, DOI 10.1152/jn.1984.51.2.294; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRIEVE KL, 1991, EXP BRAIN RES, V87, P521; GROSSBERG S, 1988, NEURAL NETWORKS, V1, P17, DOI 10.1016/0893-6080(88)90021-4; GULYAS B, 1987, J NEUROPHYSIOL, V57, P1767, DOI 10.1152/jn.1987.57.6.1767; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; Hertz J, 1991, INTRO THEORY NEURAL; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; KOCH C, 1990, J NEUROSCI, V10, P1728; LEVAY S, 1986, J NEUROSCI, V6, P3564; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAEX R, 1991, P NATL ACAD SCI USA, V88, P3549, DOI 10.1073/pnas.88.9.3549; MAEX R, 1995, THESIS LEUVEN U BELG; MARR D, 1970, PROC R SOC SER B-BIO, V176, P161, DOI 10.1098/rspb.1970.0040; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASTRONARDE DN, 1987, J NEUROPHYSIOL, V57, P357, DOI 10.1152/jn.1987.57.2.357; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCGUIRE BA, 1984, J NEUROSCI, V4, P3021; MCLEAN J, 1994, VISUAL NEUROSCI, V11, P271, DOI 10.1017/S0952523800001632; MEAD C, 1990, P IEEE, V78, P1629, DOI 10.1109/5.58356; MITCHISON G, 1992, TRENDS NEUROSCI, V15, P122, DOI 10.1016/0166-2236(92)90352-9; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; PETERS A, 1994, CEREB CORTEX, V4, P215, DOI 10.1093/cercor/4.3.215; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; SAUL AB, 1990, J NEUROPHYSIOL, V64, P206, DOI 10.1152/jn.1990.64.1.206; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1977, J PHYSIOL-LONDON, V271, P699, DOI 10.1113/jphysiol.1977.sp012021; SOMERS D, 1995, P NATL ACAD SCI USA, V92, P3844; SUAREZ HH, IN PRESS J NEUROSCI; SUAREZ HH, 1995, THESIS CALTECH; Traub R.D., 1991, NEURONAL NETWORKS HI; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; White E.L., 1989, CORTICAL CIRCUITS SY; WILLSHAW DJ, 1969, NATURE, V222, P960, DOI 10.1038/222960a0; WORGOTTER F, 1991, J NEUROSCI, V11, P1959; XING P, 1991, NEUROREPORT, V2, P485	60	731	734	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	1995	269	5226					981	985		10.1126/science.7638624	http://dx.doi.org/10.1126/science.7638624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638624				2022-12-01	WOS:A1995RP73800037
J	HAGEN, SJ; HOFRICHTER, J; EATON, WA				HAGEN, SJ; HOFRICHTER, J; EATON, WA			PROTEIN REACTION-KINETICS IN A ROOM-TEMPERATURE GLASS	SCIENCE			English	Article							GEMINATE RECOMBINATION; CONFORMATIONAL-CHANGES; NEUTRON-SCATTERING; HEME-PROTEINS; RELAXATION DYNAMICS; SOLVENT VISCOSITY; LIGAND-BINDING; CO BINDING; MYOGLOBIN; TRANSITION	Protein reaction kinetics in aqueous solution at room temperature are often simplified by the thermal averaging of conformational substates. These substates exhibit widely varying reaction rates that are usually exposed by trapping in a glass at low temperature. Here, it is shown that the solvent viscosity, rather than the low temperature, is primarily responsible for the trapping. this was demonstrated by placement of myoglobin in a glass at room temperature and subsequent observation of inhomogeneous reaction kinetics. The high solvent viscosity slowed the rate of crossing the energy barriers that separated the substates and also suppressed any change in the average protein conformation after ligand dissociation.			HAGEN, SJ (corresponding author), NIH,PHYS CHEM LAB,BLDG 5,BETHESDA,MD 20892, USA.		Hagen, Stephen J/E-9737-2015	Hagen, Stephen J/0000-0002-3373-5033				AGMON N, 1988, BIOCHEMISTRY-US, V27, P3507, DOI 10.1021/bi00409a057; AGMON N, 1990, J PHYS CHEM-US, V94, P2959, DOI 10.1021/j100370a041; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1992, J CHEM PHYS, V97, P7270, DOI 10.1063/1.463500; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; CAMPBELL BF, 1987, SCIENCE, V238, P373, DOI 10.1126/science.3659921; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Doster W., 1993, PROTEIN SOLVENT INTE, P375; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1994, PHYS TODAY, V47, P58, DOI 10.1063/1.881414; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; GREEN JL, 1994, J PHYS CHEM-US, V98, P13780, DOI 10.1021/j100102a052; GREEN JL, 1989, J PHYS CHEM-US, V93, P2880, DOI 10.1021/j100345a006; HAGEN SJ, UNPUB; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/revmodphys.62.251; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1983, HEMOGLOBINS STRUCTUR, P193; HOFRICHTER J, 1994, METHOD ENZYMOL, V232, P387; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; JACKLE J, 1986, REP PROG PHYS, V49, P171, DOI 10.1088/0034-4885/49/2/002; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; MAYER E, 1994, BIOPHYS J, V67, P862, DOI 10.1016/S0006-3495(94)80547-8; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SMITH J, 1990, P NATL ACAD SCI USA, V87, P1601, DOI 10.1073/pnas.87.4.1601; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; WOMERSLEY C, 1981, COMP BIOCHEM PHYS B, V70, P669, DOI 10.1016/0305-0491(81)90001-8	42	208	208	1	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					959	962		10.1126/science.7638618	http://dx.doi.org/10.1126/science.7638618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638618				2022-12-01	WOS:A1995RP73800030
J	HELLER, BA; HOLTEN, D; KIRMAIER, C				HELLER, BA; HOLTEN, D; KIRMAIER, C			CONTROL OF ELECTRON-TRANSFER BETWEEN THE L-SIDE AND M-SIDE OF PHOTOSYNTHETIC REACTION CENTERS	SCIENCE			English	Article							RHODOBACTER-SPHAEROIDES R-26; INITIAL CHARGE SEPARATION; BACTERIAL REACTION CENTERS; STARK-EFFECT SPECTROSCOPY; RHODOPSEUDOMONAS-VIRIDIS; PROTEIN INTERACTIONS; TRANSFER DYNAMICS; TRANSIENT STATES; BACTERIOPHEOPHYTIN; MECHANISM	An aspartic acid residue has been introduced near ring V of the L-side accessory bacteriochlorophyll (BChl(L)) of the photosynthetic reaction center in a Rhodobacter capsulatus mutant in which a His also replaces Leu 212 on the M-polypeptide. The initial stage of charge separation in the G(M201)D/L(M212)H double mutant yields similar to 70 percent electron transfer to the L-side cofactors, similar to 15 percent rapid deactivation to the ground state, and similar to 15 percent electron transfer to the so-called inactive M-side bacteriopheophytin (BPh(M)). It is suggested here that the Asp introduced at M201 modulates the reduction potential of BChl(L), thereby changing the energetics of charge separation. The results demonstrate that an individual amino acid residue can, through its influence on the free energies of the charge-separated states, effectively dictate the balance between the forward electron transfer reactions on the L-side of the RC, the charge-recombination processes, and electron transfer to the M-side chromophores.			HELLER, BA (corresponding author), WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130, USA.							ARLT T, 1993, P NATL ACAD SCI USA, V90, P11757, DOI 10.1073/pnas.90.24.11757; BIXON M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P301, DOI 10.1016/S0005-2728(05)80062-3; BIXON M, 1989, BIOCHIM BIOPHYS ACTA, V977, P273, DOI 10.1016/S0005-2728(89)80081-7; BIXON M, 1992, PHOTOSYNTHETIC BACTE, V2, P291; Breton J., 1990, STRUCTURE FUNCTION B; BYLINA EJ, 1988, NATURE, V336, P182, DOI 10.1038/336182a0; CHAN CK, 1991, P NATL ACAD SCI USA, V88, P11202, DOI 10.1073/pnas.88.24.11202; CHEKALIN SV, 1987, FEBS LETT, V216, P245, DOI 10.1016/0014-5793(87)80698-1; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Deisenhofer J., 1993, PHOTOSYNTHETIC REACT, V2; ECCLES J, 1983, P NATL ACAD SCI-BIOL, V80, P4959, DOI 10.1073/pnas.80.16.4959; ELKABBANI O, 1991, BIOCHEMISTRY-US, V30, P5361, DOI 10.1021/bi00236a006; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; FINKELE U, 1990, BIOCHEMISTRY-US, V29, P8517, DOI 10.1021/bi00489a002; FRIESNER RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P99, DOI 10.1016/S0005-2728(89)80062-3; GOLDSTEIN RA, 1988, BIOCHIM BIOPHYS ACTA, V934, P253, DOI 10.1016/0005-2728(88)90189-2; GOTTFRIED DS, 1991, BIOCHIM BIOPHYS ACTA, V1059, P76, DOI 10.1016/S0005-2728(05)80189-6; GRAY KA, 1992, EUR J BIOCHEM, V207, P723, DOI 10.1111/j.1432-1033.1992.tb17102.x; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HANSON LK, 1987, J AM CHEM SOC, V109, P4728, DOI 10.1021/ja00249a050; HELLER B, UNPUB; HELLER BA, 1995, BIOCHEMISTRY-US, V34, P5294, DOI 10.1021/bi00015a045; JIA YW, 1993, J PHYS CHEM-US, V97, P13180, DOI 10.1021/j100152a024; KELLOGG EC, 1989, PHOTOSYNTH RES, V22, P47, DOI 10.1007/BF00114766; KIRMAIER C, 1991, SCIENCE, V251, P922, DOI 10.1126/science.2000491; KIRMAIER C, 1985, BIOCHIM BIOPHYS ACTA, V810, P49, DOI 10.1016/0005-2728(85)90205-1; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8903, DOI 10.1021/j100021a067; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8910, DOI 10.1021/j100021a068; KIRMAIER C, 1991, BIOCHEMISTRY-US, V30, P609, DOI 10.1021/bi00217a003; KIRMAIER C, 1988, P NATL ACAD SCI USA, V85, P7562, DOI 10.1073/pnas.85.20.7562; KORNIYA H, 1988, P NATL ACAD SCI USA, V85, P9012; LAPORTE L, 1993, CHEM PHYS, V176, P615, DOI 10.1016/0301-0104(93)80265-B; LAPORTE L, IN PRESS CHEM PHYS; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; LOSCHE M, 1987, P NATL ACAD SCI USA, V84, P7537, DOI 10.1073/pnas.84.21.7537; MAITI S, 1994, P NATL ACAD SCI USA, V91, P10360, DOI 10.1073/pnas.91.22.10360; MARCHI M, 1993, J AM CHEM SOC, V115, P4178, DOI 10.1021/ja00063a041; MCDOWELL LM, 1991, BIOCHEMISTRY-US, V30, P8315, DOI 10.1021/bi00098a006; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHELBEYERLE ME, 1988, BIOCHIM BIOPHYS ACTA, V932, P52, DOI 10.1016/0005-2728(88)90139-9; MURCHISON HA, 1993, BIOCHEMISTRY-US, V32, P3498, DOI 10.1021/bi00064a038; NAGARAJAN V, 1993, BIOCHEMISTRY-US, V32, P12324, DOI 10.1021/bi00097a008; OGRODNIK A, 1994, J PHYS CHEM-US, V98, P3432, DOI 10.1021/j100064a026; PALANIAPPAN V, 1995, J AM CHEM SOC, V117, P3647, DOI 10.1021/ja00117a048; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; ROBERT B, 1985, FEBS LETT, V183, P326, DOI 10.1016/0014-5793(85)80803-6; SCHENCK CC, 1981, BIOCHIM BIOPHYS ACTA, V635, P383, DOI 10.1016/0005-2728(81)90036-0; SCHERER POJ, 1989, CHEM PHYS, V131, P115, DOI 10.1016/0301-0104(89)87084-3; SCHMIDT S, 1994, CHEM PHYS LETT, V223, P116, DOI 10.1016/0009-2614(94)00429-3; SHKUROPATOV AY, 1993, FEBS LETT, V322, P168, DOI 10.1016/0014-5793(93)81561-D; STEPHAN MA, 1994, SCIENCE, V264, P810; TAGUCHI AKW, 1992, BIOCHEMISTRY-US, V31, P10345, DOI 10.1021/bi00157a024; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11209; WOODBURY NW, 1994, BIOCHEMISTRY-US, V33, P8101, DOI 10.1021/bi00192a015; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	58	192	200	2	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					940	945		10.1126/science.7638616	http://dx.doi.org/10.1126/science.7638616			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638616				2022-12-01	WOS:A1995RP73800025
J	JOSHUATOR, L; XU, HE; JOHNSTON, SA; REES, DC				JOSHUATOR, L; XU, HE; JOHNSTON, SA; REES, DC			CRYSTAL-STRUCTURE OF A CONSERVED PROTEASE THAT BINDS DNA - THE BLEOMYCIN HYDROLASE, GAL6	SCIENCE			English	Article							CYSTEINE PROTEINASE; PAPAIN; RESOLUTION; YEAST; REFINEMENT; CLONING; AMINOPEPTIDASE; SPECIFICITY; COMPLEX; SUBUNIT	Bleomycin hydrolase is a cysteine protease that hydrolyzes the anticancer drug bleomycin. The homolog in yeast, Gal6, has recently been identified and found to bind DNA and to act as a repressor in the Gal4 regulatory system, The crystal structure of Gal6 at 2.2 Angstrom resolution reveals a hexameric structure with a prominent central channel, The papain-like active sites are situated within the central channel, in a manner resembling the organization of active sites in the proteasome. The Gal6 channel is lined with 60 lysine residues from the six subunits, suggesting a role in DNA binding, The carboxyl-terminal arm of Gal6 extends into the active site cleft and may serve a regulatory function. Rather than each residing in distinct, separable domains, the protease and DNA-binding activities appear structurally intertwined in the hexamer, implying a coupling of these two activities.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JOSHUATOR, L (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,147-75CH,PASADENA,CA 91125, USA.			Joshua-Tor, Leemor/0000-0001-8185-8049; Xu, H. Eric/0000-0002-6829-8144	NIGMS NIH HHS [GM45162, GM40700] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM045162, R01GM040700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAPOTCHARTIER MP, 1994, EUR J BIOCHEM, V224, P497, DOI 10.1111/j.1432-1033.1994.00497.x; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; FERNANDEZ L, 1994, APPL ENVIRON MICROB, V60, P333; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE G, 1971, BIOCHEM J, V124, P107, DOI 10.1042/bj1240107; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MISTOU MY, 1994, J MOL BIOL, V237, P160, DOI 10.1006/jmbi.1994.1215; MONDRAGON A, 1994, NATURE, V367, P138; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; MYLIN LM, 1990, METHOD ENZYMOL, V185, P297; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PICKERSGILL RW, 1991, ACTA CRYSTALLOGR B, V47, P766, DOI 10.1107/S0108768191003191; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rossmann M. G., 1972, MOL REPLACEMENT METH; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; SEBTI SM, 1991, CANCER RES, V51, P227; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VESANTO E, 1994, EUR J BIOCHEM, V224, P991, DOI 10.1111/j.1432-1033.1994.00991.x; VRUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330; Wohlrab Y, 1993, INT DAIRY J, V3, P685, DOI 10.1016/0958-6946(93)90083-C; WU A, UNPUB; XU H, UNPUB; XU HE, 1994, J BIOL CHEM, V269, P21177; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zheng W., UNPUB	55	119	120	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					945	950		10.1126/science.7638617	http://dx.doi.org/10.1126/science.7638617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638617				2022-12-01	WOS:A1995RP73800026
J	LEVYLAHAD, E; WIJSMAN, EM; NEMENS, E; ANDERSON, L; GODDARD, KAB; WEBER, JL; BIRD, TD; SCHELLENBERG, GD				LEVYLAHAD, E; WIJSMAN, EM; NEMENS, E; ANDERSON, L; GODDARD, KAB; WEBER, JL; BIRD, TD; SCHELLENBERG, GD			A FAMILIAL ALZHEIMERS-DISEASE LOCUS ON CHROMOSOME-1	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E; LINKAGE ANALYSIS; TYPE-4 ALLELE; BETA-PROTEIN; GENE; HETEROGENEITY; MARKERS; CONSTRUCTION; MUTATION	The Volga German kindreds are a group of seven related families with autosomal dominant early-onset Alzheimer's disease (AD). Linkage to known AD-related loci on chromosomes 21 and 14 has been excluded. Significant evidence for linkage to AD in these families was obtained with D1S479 and there was also positive evidence for linkage with other markers in the region. A 112-base pair allele of D1S479 co-segregated with the disease in five of seven families, which is consistent with a common genetic founder. This study demonstrates the presence of an AD locus on chromosome 1q31-42.	VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; VET AFFAIRS MED CTR,DIV NEUROL,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005635] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00835] Funding Source: Medline; NIA NIH HHS [AG05136, F32 AG05635] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENJAMIN R, 1994, LANCET, V344, P473, DOI 10.1016/S0140-6736(94)91804-X; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, 1992, HETEROGENEITY ALZHEI, P118; BIRD TD, 1991, AM HIST SOC GERM RUS, V49; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROUSSEAU T, 1994, NEUROLOGY, V342; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAVALLISFORZA LL, 1986, AM J HUM GENET, V38, P599; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HIXSON JE, 1990, J LIPID RES, V31, P545; HODGE SE, 1983, AM J HUM GENET, V35, P1139; KAMINO K, 1992, AM J HUM GENET, V51, P998; KONG A, 1993, GENET EPIDEMIOL, V10, P483, DOI 10.1002/gepi.1370100626; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LANNFELT L, 1993, NAT GENET, V4, P218, DOI 10.1038/ng0793-218; LEVYLAHAD E, IN PRESS ANN NEUROL; LIDDELL M, 1994, J MED GENET, V31, P197, DOI 10.1136/jmg.31.3.197; Lin S., 1994, American Journal of Human Genetics, V55, pA40; LIN SL, 1993, IMA J MATH APPL MED, V10, P1; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MORTON NE, 1955, AM J HUM GENET, V7, P277; OTT J, 1974, AM J HUM GENET, V26, P588; OTT J, 1992, AM J HUM GENET, V51, P283; Ott J., 1991, ANAL HUMAN GENETIC L; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; SHERRINGTON, 1995, NATURE, V375, P754; SMITH AD, 1994, LANCET, V344, P473; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TSAI MS, 1994, AM J HUM GENET, V54, P643; VANDUIJN CM, 1994, AM J HUM GENET, V55, P714; YU CE, 1994, AM J HUM GENET, V54, P631; 1993, LANCET, V342, P737	49	629	652	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					970	973		10.1126/science.7638621	http://dx.doi.org/10.1126/science.7638621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638621				2022-12-01	WOS:A1995RP73800034
J	LEVYLAHAD, E; WASCO, W; POORKAJ, P; ROMANO, DM; OSHIMA, J; PETTINGELL, WH; YU, CE; JONDRO, PD; SCHMIDT, SD; WANG, K; CROWLEY, AC; FU, YH; GUENETTE, SY; GALAS, D; NEMENS, E; WIJSMAN, EM; BIRD, TD; SCHELLENBERG, GD; TANZI, RE				LEVYLAHAD, E; WASCO, W; POORKAJ, P; ROMANO, DM; OSHIMA, J; PETTINGELL, WH; YU, CE; JONDRO, PD; SCHMIDT, SD; WANG, K; CROWLEY, AC; FU, YH; GUENETTE, SY; GALAS, D; NEMENS, E; WIJSMAN, EM; BIRD, TD; SCHELLENBERG, GD; TANZI, RE			CANDIDATE GENE FOR THE CHROMOSOME-1 FAMILIAL ALZHEIMERS-DISEASE LOCUS	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; CATHEPSIN-E; LINKAGE; MUTATION; KINDREDS; MARKERS	A candidate gene for the chromosome 1 Alzheimer's disease (AD) locus was identified (STM2). The predicted amino acid sequence for STM2 is homologous to that of the recently cloned chromosome 14 AD gene (S182). A point mutation in STM2, resulting in the substitution of an isoleucine for an asparagine (N141I), was identified in affected people from Volga German AD kindreds. This N141I mutation occurs at an amino acid residue that is conserved in human S182 and in the mouse S182 homolog. The presence of missense mutations in AD subjects in two highly similar genes strongly supports the hypothesis that mutations in both are pathogenic.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; MASSACHUSETTS GEN HOSP,GENET & AGING UNIT,BOSTON,MA 02129; DARWIN MOLEC,BOTHELL,WA 98021; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; VET AFFAIRS MED CTR,DIV NEUROL,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Levy-Lahad, Ephrat/F-2186-2018; Tanzi, Rudolph/AAE-9622-2019; Schmidt, Stephen/B-5398-2012; Schmidt, Stephen/AAC-6967-2019	Levy-Lahad, Ephrat/0000-0002-2637-1921; Tanzi, Rudolph/0000-0002-7032-1454; 	NATIONAL INSTITUTE ON AGING [R01AG011762, R01AG011899] Funding Source: NIH RePORTER; NIA NIH HHS [AG0513C, R01-AG11762, R01-AG11899] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AZUMA T, 1992, J BIOL CHEM, V267, P1609; BERNSTEIN HG, 1994, BRAIN RES, V667, P287, DOI 10.1016/0006-8993(94)91509-1; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, 1991, J AM HISTO SOC GERM, V49, P1; BIRD TD, 1992, HETEROGENEITY ALZHEI, P118; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; KAMINO K, 1992, AM J HUM GENET, V51, P998; KOCH F, 1977, VOLGA GERMANS; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MULLAN M, 1992, NAT GENET, V2, P340, DOI 10.1038/ng1292-340; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAKANISHI H, 1993, EXP NEUROL, V121, P215, DOI 10.1006/exnr.1993.1088; Sambrook J., 1989, MOL CLONING LAB MANU; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; Scheuerman R. D., 1985, VOLGA GERMANS PIONEE; SCHEUNER D, IN PRESS SOC NEUR AB; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SONG XH, IN PRESS SOC NEUR AB	30	2064	2149	1	77	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					973	977		10.1126/science.7638622	http://dx.doi.org/10.1126/science.7638622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638622				2022-12-01	WOS:A1995RP73800035
J	LIM, M; JACKSON, TA; ANFINRUD, PA				LIM, M; JACKSON, TA; ANFINRUD, PA			BINDING OF CO TO MYOGLOBIN FROM A HEME POCKET DOCKING SITE TO FORM NEARLY LINEAR FE-C-O	SCIENCE			English	Article							CARBON-MONOXIDE; INFRARED-SPECTROSCOPY; DIOXYGEN ADDUCT; RESOLUTION; PICOSECOND; CARBONMONOXYMYOGLOBIN; CARBOXYMYOGLOBIN; PHOTOSELECTION; OXYMYOGLOBIN; HEMOPROTEINS	The relative orientations of carbon monoxide (CO) bound to and photodissociated from myoglobin in solution have been determined with time-resolved infrared polarization spectroscopy. The bound CO is oriented less than or equal to 7 degrees from the heme normal, corresponding to nearly linear Fe-C-O. Upon dissociation from the Fe, CO becomes trapped in a docking site that orientationally constrains it to lie approximately in the plane of the heme. Because the bound and ''docked'' CO are oriented in nearly orthogonal directions, CO binding from the docking site is suppressed. These solution results help to establish how myoglobin discriminates against CO, a controversial issue dominated by the misconception that Fe-C-O is bent.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NIDDK NIH HHS [DK45306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045306, R29DK045306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANI J, 1986, CHEM PHYS LETT, V131, P147, DOI 10.1016/0009-2614(86)80533-4; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; ANFINRUD PA, 1994, P SOC PHOTO-OPT INS, V2138, P107, DOI 10.1117/12.181348; ANSARI A, 1993, BIOPHYS J, V64, P838, DOI 10.1016/S0006-3495(93)81445-0; Antonini E., 1971, FRONT BIOL, DOI DOI 10.1126/SCIENCE.178.4058.296; CAUGHEY WS, 1970, ANN NY ACAD SCI, V174, P148, DOI 10.1111/j.1749-6632.1970.tb49781.x; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; CHURG AK, 1978, J CHEM PHYS, V68, P1913, DOI 10.1063/1.435918; COLLMAN J P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1326, DOI 10.1073/pnas.71.4.1326; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; Eaton W A, 1981, Methods Enzymol, V76, P175; HANSEN PA, 1989, CHEM PHYS, V131, P49, DOI 10.1016/0301-0104(89)87080-6; HENRY ER, 1993, BIOPHYS J, V64, P869, DOI 10.1016/S0006-3495(93)81447-4; HU SZ, 1994, J AM CHEM SOC, V116, P11187, DOI 10.1021/ja00103a056; IVANOV D, 1994, J AM CHEM SOC, V116, P4139, DOI 10.1021/ja00088a084; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; JAMESON GB, 1978, INORG CHEM, V17, P850, DOI 10.1021/ic50182a012; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; JEWSBURY P, 1994, J AM CHEM SOC, V116, P11586, DOI 10.1021/ja00104a056; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LANDAW SA, 1970, J CLIN INVEST, V49, P914, DOI 10.1172/JCI106311; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; LOCKE B, 1995, CHEM PHYS, V190, P155, DOI 10.1016/0301-0104(94)00360-M; MOFFAT K, COMMUNICATION; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PENG SM, 1976, J AM CHEM SOC, V98, P8032, DOI 10.1021/ja00441a025; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PISTORIUS CWFT, 1959, J CHEM PHYS, V31, P1439, DOI 10.1063/1.1730631; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rothberg Lewis J., 1991, Proceedings of the SPIE, V1599, P309, DOI 10.1117/12.2322296; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STRYER L, 1988, BIOCHEMISTRY; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TRAYLOR TG, 1981, ACCOUNTS CHEM RES, V14, P102, DOI 10.1021/ar00064a002	38	296	299	4	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					962	966		10.1126/science.7638619	http://dx.doi.org/10.1126/science.7638619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638619				2022-12-01	WOS:A1995RP73800031
J	LIN, CT; ROBERTSON, DE; AHMAD, M; RAIBEKAS, AA; JORNS, MS; DUTTON, PL; CASHMORE, AR				LIN, CT; ROBERTSON, DE; AHMAD, M; RAIBEKAS, AA; JORNS, MS; DUTTON, PL; CASHMORE, AR			ASSOCIATION OF FLAVIN ADENINE-DINUCLEOTIDE WITH THE ARABIDOPSIS BLUE-LIGHT RECEPTOR CRY1	SCIENCE			English	Article							COLI DNA PHOTOLYASE; THALIANA; IDENTIFICATION; CHROMOPHORE; ENZYME	The Arabidopsis thaliana HY4 gene encodes CRY1, a 75-kilodalton flavoprotein mediating blue light-dependent regulation of seedling development. CRY1 is demonstrated here to noncovalently bind stoichiometric amounts of flavin adenine dinucleotide (FAD). The redox properties of FAD bound by CRY1 include an unexpected stability of the neutral radical flavosemiquinone (FADH .). The absorption properties of this flavosemiquinone provide a likely explanation for the additional sensitivity exhibited by CRY1-mediated responses in the green region of the visible spectrum, Despite the sequence homology to microbial DNA photolyases, CRY1 was found to have no detectable photolyase activity.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,JOHNSON FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; HAHNEMANN UNIV,SCH MED,DEPT BIOL CHEM,PHILADELPHIA,PA 19102	University of Pennsylvania; University of Pennsylvania; Drexel University				Ahmad, Margaret/0000-0003-4524-5813	NIGMS NIH HHS [GM51956, GM31704, GM38409] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051956, R01GM038409, R01GM031704] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Briggs W. R., 1976, Light and plant development. [Smith, H.]., P7; DARWIN C, 1881, POWER MOVEMENT PLANT, P462; Dutton P L, 1978, Methods Enzymol, V54, P411; EKER APM, 1990, J BIOL CHEM, V265, P8009; Galland Paul, 1991, P65; GALSTON AW, 1950, SCIENCE, V111, P619, DOI 10.1126/science.111.2893.619; GRESSEL J, 1979, PHOTOCHEM PHOTOBIOL, V30, P749, DOI 10.1111/j.1751-1097.1979.tb07209.x; HANGARTER R, COMMUNICATION; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LIN C, IN PRESS P NATL ACAD; Lin C. H., UNPUB; LIPSON ED, 1991, SENSORY RECEPTORS SI, P1; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; TAKAO M, 1989, J BACTERIOL, V171, P6323, DOI 10.1128/jb.171.11.6323-6329.1989; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	26	354	382	0	53	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					968	970		10.1126/science.7638620	http://dx.doi.org/10.1126/science.7638620			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638620				2022-12-01	WOS:A1995RP73800033
J	OLSON, CR; GETTNER, SN				OLSON, CR; GETTNER, SN			OBJECT-CENTERED DIRECTION SELECTIVITY IN THE MACAQUE SUPPLEMENTARY EYE FIELD	SCIENCE			English	Article							UNILATERAL NEGLECT; VISUAL NEGLECT; RHESUS-MONKEYS; REPRESENTATION; RECOGNITION; MOVEMENTS; POSITION	Object-centered spatial awareness-awareness of the location, relative to an object, of its parts-plays an important role in many aspects of perception, imagination, and action. One possible basis for this capability is the existence in the brain of neurons with sensory receptive fields or motor action fields that are defined relative to an object-centered frame. In experiments described here, neuronal activity was monitored in the supplementary eye field of macaque monkeys making eye movements to the right or left end of a horizontal bar, Neurons were found to fire differentially as a function of the end of the bar to which an eye movement was made. This is direct evidence for the existence of neurons sensitive to the object-centered direction of movements.			OLSON, CR (corresponding author), UNIV MARYLAND,COLL DENT SURG,DEPT ORAL & CRANIOFACIAL BIOL SCI,BALTIMORE,MD 21201, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027287, F32NS009452] Funding Source: NIH RePORTER; NINDS NIH HHS [1 F32 NS09452, R01 NS27287] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGUIN M, 1993, CORTEX, V29, P349, DOI 10.1016/S0010-9452(13)80188-8; BEHRMANN M, 1994, J COGNITIVE NEUROSCI, V6, P1, DOI 10.1162/jocn.1994.6.1.1; BEHRMANN M, 1994, ATTENTION PERFORMANC, V15, pCH14; BISIACH E, 1978, CORTEX, V14, P129, DOI 10.1016/S0010-9452(78)80016-1; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; CARAMAZZA A, 1990, COGNITIVE NEUROPSYCH, V7, P391, DOI 10.1080/02643299008253450; CARAMAZZA A, 1990, NATURE, V346, P267, DOI 10.1038/346267a0; CHEN LL, 1995, J NEUROPHYSIOL, V73, P1104; Connor C. E., 1994, Society for Neuroscience Abstracts, V20, P1054; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; DERENZI E, 1989, CORTEX, V25, P231, DOI 10.1016/S0010-9452(89)80039-5; DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; MCCLELLAND JL, 1986, PARALLEL DISTRIBUTED, V2, pCH16; MITZ AR, 1989, NEUROSCI LETT, V106, P157, DOI 10.1016/0304-3940(89)90219-X; NIKI H, 1974, BRAIN RES, V68, P197, DOI 10.1016/0006-8993(74)90389-8; OGDEN JA, 1985, NEUROPSYCHOLOGIA, V23, P273, DOI 10.1016/0028-3932(85)90112-5; OLSHAUSEN BA, 1993, J NEUROSCI, V13, P4700; REMMEL RS, 1984, IEEE T BIO-MED ENG, V31, P388, DOI 10.1109/TBME.1984.325352; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; RUSSO GS, 1993, J NEUROPHYSIOL, V69, P800, DOI 10.1152/jn.1993.69.3.800; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAG J, 1992, EXP BRAIN RES, V90, P302; TEHOVNIK EJ, 1993, EXP BRAIN RES, V96, P430; YOUNG AW, 1992, BRAIN, V115, P51, DOI 10.1093/brain/115.1.51	26	186	186	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					985	988		10.1126/science.7638625	http://dx.doi.org/10.1126/science.7638625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638625				2022-12-01	WOS:A1995RP73800038
J	PASTERNACK, RF; COLLINGS, PJ				PASTERNACK, RF; COLLINGS, PJ			RESONANCE LIGHT-SCATTERING - A NEW TECHNIQUE FOR STUDYING CHROMOPHORE AGGREGATION	SCIENCE			English	Article							PORPHYRINS	Light scattering experiments are usually performed at wavelengths away from absorption bands, but for species that aggregate,enhancements in light scattering of several orders of magnitude can be observed at wavelengths characteristic of these species. Resonance light scattering is shown to be a sensitive and selective method for studying electronically coupled chromophore arrays. The approach is illustrated with several examples drawn from porphyrin and chlorin chemistry. The physical principles underlying resonance light scattering are discussed, and the advantages and limitations of the technique are reviewed.	SWARTHMORE COLL,DEPT PHYS & ASTRON,SWARTHMORE,PA 19081	Swarthmore College	PASTERNACK, RF (corresponding author), SWARTHMORE COLL,DEPT CHEM,500 COL AVE,SWARTHMORE,PA 19081, USA.							AKINS DL, 1994, J PHYS CHEM-US, V98, P3612, DOI 10.1021/j100065a012; ANGLISTER J, 1981, J CHEM PHYS, V74, P786, DOI 10.1063/1.441179; ANGLISTER J, 1979, CHEM PHYS LETT, V65, P50, DOI 10.1016/0009-2614(79)80123-2; ANGLISTER J, 1983, J CHEM PHYS, V78, P5358, DOI 10.1063/1.445489; ARENA G, 1995, INORG CHEM, V34, P2994, DOI 10.1021/ic00115a030; BAUER DR, 1975, J CHEM PHYS, V63, P588, DOI 10.1063/1.431091; BLANKENSHIP RE, 1988, LIGHT ENERGY TRANSDU, P32; Bohren C.F., 1998, ABSORPTION SCATTERIN, DOI DOI 10.1002/9783527618156; CHIARELLO R, 1988, J CHEM PHYS, V88, P1253, DOI 10.1063/1.454246; DEPAULA JC, 1995, BIOPHYS J, V68, P335, DOI 10.1016/S0006-3495(95)80192-X; DOUGHERTY TJ, 1992, ADV PHOTOCHEM, P275; FORD NC, 1985, DYNAMIC LIGHT SCATTE, P7; GIBBS EJ, 1988, BIOCHEM BIOPH RES CO, V157, P350, DOI 10.1016/S0006-291X(88)80054-8; MAGILL JV, 1985, J PHYS CHEM-US, V89, P734, DOI 10.1021/j100251a003; MILLER GA, 1978, J PHYS CHEM-US, V82, P616, DOI 10.1021/j100494a023; NELSON WH, 1982, INORG CHEM, V21, P1483, DOI 10.1021/ic00134a043; PASTEMACK RF, UNPUB; PASTERNA.RF, 1972, J AM CHEM SOC, V94, P4511, DOI 10.1021/ja00768a016; PASTERNACK RF, 1994, INORG CHEM, V33, P2062, DOI 10.1021/ic00087a053; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P2406, DOI 10.1021/bi00279a016; PASTERNACK RF, 1993, J AM CHEM SOC, V15, P5393; PERKINS WR, 1992, BIOCHIM BIOPHYS ACTA, V1107, P271, DOI 10.1016/0005-2736(92)90414-H; RISEMAN J, 1950, J CHEM PHYS, V18, P512, DOI 10.1063/1.1747672; SCHUELER PA, 1993, ANAL CHEM, V65, P3177, DOI 10.1021/ac00070a003; STANTON SG, 1981, J CHEM PHYS, V75, P5615, DOI 10.1063/1.442000; STANTON SG, 1983, J CHEM PHYS, V78, P3365, DOI 10.1063/1.445212; ZERO K, 1985, DYNAMIC LIGHT SCATTE, P59	27	907	981	4	129	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					935	939		10.1126/science.7638615	http://dx.doi.org/10.1126/science.7638615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638615				2022-12-01	WOS:A1995RP73800024
J	STALEY, KJ; SOLDO, BL; PROCTOR, WR				STALEY, KJ; SOLDO, BL; PROCTOR, WR			IONIC MECHANISMS OF NEURONAL EXCITATION BY INHIBITORY GABA(A) RECEPTORS	SCIENCE			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; GAMMA-AMINOBUTYRIC ACID; GYRUS GRANULE CELLS; SYNAPTIC POTENTIALS; MEDIATED RESPONSES; RAT HIPPOCAMPUS; PH; CONDUCTANCE; CHANNELS; SLICES	Gamma-aminobutyric acid A (GABA(A)) receptors are the principal mediators of synaptic inhibition, and yet when intensely activated, dendritic GABA(A) receptors excite rather than inhibit neurons. The membrane depolarization mediated by GABA(A) receptors is a result of the differential, activity-dependent collapse of the opposing concentration gradients of chloride and bicarbonate, the anions that permeate the GABA(A) ionophore. Because this depolarization diminishes the voltage-dependent block of the N-methyl-D-aspartate (NMDA) receptor by magnesium, the activity-dependent depolarization mediated by GABA is sufficient to account for frequency modulation of synaptic NMDA receptor activation. Anionic gradient shifts may represent a mechanism whereby the rate and coherence of synaptic activity determine whether bendritic GABA(A) receptor activation is excitatory or inhibitory.	UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	STALEY, KJ (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT NEUROL,B182,4200 E 9TH AVE,DENVER,CO 80262, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03527] Funding Source: Medline; NICHD NIH HHS [HD27827] Funding Source: Medline; NINDS NIH HHS [NS01573] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALVAREZLEEFMANS FJ, 1988, J PHYSIOL-LONDON, V406, P225, DOI 10.1113/jphysiol.1988.sp017378; AVOLI M, 1987, BRAIN RES, V400, P191, DOI 10.1016/0006-8993(87)90671-8; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; CHEN JCT, 1992, J NEUROPHYSIOL, V67, P29, DOI 10.1152/jn.1992.67.1.29; DAVIES CH, 1993, J PHYSIOL-LONDON, V472, P245, DOI 10.1113/jphysiol.1993.sp019945; DAVIES CH, 1992, NATURE, V349, P609; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; GROVER LM, 1993, J NEUROPHYSIOL, V69, P1541, DOI 10.1152/jn.1993.69.5.1541; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HUGENARD JR, 1986, J NEUROPHYSIOL, V56, P1; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KAILA K, 1993, J PHYSIOL-LONDON, V464, P273, DOI 10.1113/jphysiol.1993.sp019634; KAILA K, 1992, NEUROREPORT, V3, P105, DOI 10.1097/00001756-199201000-00028; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; LAMBERT NA, 1991, J NEUROPHYSIOL, V66, P1538, DOI 10.1152/jn.1991.66.5.1538; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; MOTT DD, 1992, SCIENCE, V252, P1718; MULLER W, 1991, J NEUROPHYSIOL, V65, P141, DOI 10.1152/jn.1991.65.1.141; MULLER W, 1989, BRAIN RES, V484, P184, DOI 10.1016/0006-8993(89)90361-2; NACHSHEN DA, 1988, J GEN PHYSIOL, V91, P289, DOI 10.1085/jgp.91.2.289; NICOLL RA, 1978, J PHYSIOL-LONDON, V283, P121, DOI 10.1113/jphysiol.1978.sp012491; PASTERNACK M, 1993, ACTA PHYSIOL SCAND, V148, P229, DOI 10.1111/j.1748-1716.1993.tb09553.x; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Russell JM, 1990, CHLORIDE CHANNELS CA; SMITH RL, 1995, J NEUROSCI, V15, P4057; STALEY K, 1994, J NEUROPHYSIOL, V72, P273, DOI 10.1152/jn.1994.72.1.273; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; THALMANN RH, 1988, NEUROSCI LETT, V21, P319; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; Woodbury D. M., 1982, ANTIEPILEPTIC DRUGS, P771; XIE XM, 1993, J PHYSIOL-LONDON, V460, P503, DOI 10.1113/jphysiol.1993.sp019484; [No title captured]	47	654	671	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					977	981		10.1126/science.7638623	http://dx.doi.org/10.1126/science.7638623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638623				2022-12-01	WOS:A1995RP73800036
J	BARANGER, AM; PALMER, CR; HAMM, MK; GIEBLER, HA; BRAUWEILER, A; NYBORG, JK; SCHEPARTZ, A				BARANGER, AM; PALMER, CR; HAMM, MK; GIEBLER, HA; BRAUWEILER, A; NYBORG, JK; SCHEPARTZ, A			MECHANISM OF DNA-BINDING ENHANCEMENT BY THE HUMAN T-CELL LEUKEMIA-VIRUS TRANSACTIVATOR TAX	NATURE			English	Article							TRANSCRIPTION FACTOR-II; PROTEIN; LEUKEMIA; DIMERIZATION; FLEXIBILITY; TRANSITION; SEQUENCE; ELEMENTS; REPEATS; HELICES	Tax protein activates transcription of the human T-cell leukaemia virus type I (HTLV-I) genome through three imperfect cyclic AMP-responsive element (CRE) target sites located within the viral promoter(1). Previous work has shown that Tax interacts with the bZIP element of proteins that bind the CRE target site(2-4) to promote peptide dimerization(3,5), suggesting an association between Tax and the bZIP coiled coil. Here we show that the site of interaction with Tax is not the coiled coil, but the basic segment. This interaction increases tbe stability of the GCN4 bZIP dimer by 1.7 kcal mol(-1) and tbe DNA affinity of the dimer by 1.9 kcal mol(-1). The differential effect of Tax on several bZIP-DNA complexes that differ in peptide sequence or DNA conformation suggests a model for Tax action based on stabilization of a distinct DNA-bound protein structure. This model may explain how Tax interacts with transcription factors of considerable sequence diversity to alter patterns of gene expression.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523	Yale University; Yale University; Colorado State University								ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRANKLIN AA, 1995, J BIOMED SCI, V1, P17; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; Metallo S J, 1994, Chem Biol, V1, P143, DOI 10.1016/1074-5521(94)90004-3; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; O'NEIL KT, 1990, SCIENCE, V249, P774; PAOLELLA DN, 1994, SCIENCE, V264, P110; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	26	159	161	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					606	608		10.1038/376606a0	http://dx.doi.org/10.1038/376606a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637812				2022-12-01	WOS:A1995RP75600055
J	BOHLER, C; NIELSEN, PE; ORGEL, LE				BOHLER, C; NIELSEN, PE; ORGEL, LE			TEMPLATE SWITCHING BETWEEN PNA AND RNA OLIGONUCLEOTIDES	NATURE			English	Article							DIRECTED SYNTHESIS	THE origin of the RNA world(1) is not easily understood, as effective prebiotic syntheses of the components of RNA, the beta-ribofuranoside-5'-phosphates, are hard to envisage(2). Recognition of this difficulty has led to the proposal(1,3) that other genetic systems, the components of which are more easily formed, may have preceded RNA. This raises the question of how transitions between one genetic system and another could occur. Peptide nucleic acid (PNA) resembles RNA in its ability to form double-helical complexes stabilized by Watson-Crick hydrogen bonding between adenine and thymine and between cytosine and guanine(4-6), but has a backbone that is held together by amide rather than by phosphodiester bonds. Oligonucleotides based on RNA are known to act as templates that catalyse the non-enzymatic synthesis of their complements from activated mononucleotides(7-9), we now show that RNA oligonucleotides facilitate the synthesis of complementary PNA strands and vice versa. This suggests that a transition between different genetic systems can occur without less of information.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186; PANUM INST,IMBG,CTR BIOMOLEC RECOGNIT,DK-2100 COPENHAGEN N,DENMARK	Salk Institute								CAIRNSSMITH AG, 1982, GENETIC TAKEOVER; CAIRNSSMITH AG, 1977, ENCY IGNORANCE; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Gesteland RF., 1993, RNA WORLD NATURE MOD; HILL AR, 1993, ORIGINS LIFE EVOL B, V23, P285, DOI 10.1007/BF01582078; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1984, J MOL BIOL, V178, P669, DOI 10.1016/0022-2836(84)90244-4; JOYCE GF, 1984, NATURE, V310, P602, DOI 10.1038/310602a0; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; Joyce GF., 1993, RNA WORLD, P1; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; WITTUNG P, 1994, NATURE, V368, P561, DOI 10.1038/368561a0	15	189	194	4	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					578	581		10.1038/376578a0	http://dx.doi.org/10.1038/376578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7543656				2022-12-01	WOS:A1995RP75600046
J	BURGERING, BMT; COFFER, PJ				BURGERING, BMT; COFFER, PJ			PROTEIN-KINASE-B (C-AKT) IN PHOSPHATIDYLINOSITOL-3-OH INASE SIGNAL-TRANSDUCTION	NATURE			English	Article							REGULATED KINASE-2; MOLECULAR-CLONING; PATHWAYS	A serine/threonine kinase, named protein kinase B (PKB)(1) for its sequence homology to both protein kinase A and C, has previously been isolated. PKB, which is identical to the kinase Rad, was later found to be the cellular homologue of the transforming v-Akt(3). Here we show that PKB is activated by stimuli such as insulin, platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). Activation of PKB was inhibited by the phosphatidylinositol-3-OH kinase (PI(3)K) inhibitor wortmannin and by coexpression of a dominant-negative mutant of PI(3)K. PDGF receptor mutants that lack detectable associated PI(3)K activity also fail to induce PKB activation. PKB kinase activity is correlated with phosphorylation of PKB on serine. Finally, we show that a constructed Gag-PKB fusion protein, homologous to the v-akt oncogene, displays significantly increased ligand-independent kinase activity. Furthermore, this activity is sufficient to activate the p70 S6-kinase (p70(S6k)). These results suggest a role for PKB in PI(3)K-mediated signal transduction.	NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	BURGERING, BMT (corresponding author), UNIV UTRECHT, PHYSIOL CHEM LAB, UNIV WEG 100, 3584 CG UTRECHT, NETHERLANDS.		Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020	Burgering, Boudewijn/0000-0002-4044-9596				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; WENNSTROM S, 1994, ONCOGENE, V9, P651	19	1794	1846	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	1995	376	6541					599	602		10.1038/376599a0	http://dx.doi.org/10.1038/376599a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637810				2022-12-01	WOS:A1995RP75600053
J	KIM, Y; EOM, SH; WANG, JM; LEE, DS; SUH, SW; STEITZ, TA				KIM, Y; EOM, SH; WANG, JM; LEE, DS; SUH, SW; STEITZ, TA			CRYSTAL-STRUCTURE OF THERMUS-AQUATICUS DNA-POLYMERASE	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN STRUCTURES; 3'-5' EXONUCLEASE; MECHANISM; FRAGMENT; DOMAIN; SITE	THE DNA polymerase from Thermus aquaticus (Taq polymerase), famous for its use in the polymerase chain reaction, is homologous to Escherichia coli DNA polymerase I (pol I) (ref. 1). Like pol I, Tag polymerase has a domain at its amino terminus (residues 1-290) that has 5' nuclease activity and a domain at its carboxy terminus that catalyses the polymerase reaction. Unlike pol I, the intervening domain in Taq polymerase has lost the editing 3'-5' exonuclease activity. Although the structure of the Klenow fragment of pol I has been known for ten years(2), that of the intact pol I has proved more elusive. The structure of Tag polymerase determined here at 2.4 Angstrom resolution shows that the structures of the polymerase domains of the thermostable enzyme and of the Klenow fragment are nearly identical, whereas the catalytically critical carboxylate residues that bind two metal ions are missing from the remnants of the 3'-5'-exonuclease active site of Taq polymerase. The first view of the 5' nuclease domain, responsible for excising the Okazaki RNA in lagging-strand DNA replication, shows a cluster of conserved divalent metal-ion-binding carboxylates at the bottom of a cleft. The location of this 5'-nuclease active site some 70 Angstrom from the polymerase active site in this crystal form highlights the unanswered question of how this domain works in concert with the polymerase domain to produce a duplex DNA product that contains only a nick.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; SEOUL NATL UNIV,CTR MOLEC CATALYSIS,DEPT CHEM,SEOUL 151742,SOUTH KOREA; KOREAN INST SCI & TECHNOL,KOREA RES INST BIOSCI & BIOTECHNOL,TAEJON 305333,SOUTH KOREA	Yale University; Howard Hughes Medical Institute; Yale University; Seoul National University (SNU); Korea Institute of Science & Technology (KIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)			Steitz, Thomas A./C-6559-2009; Kim, Youngsoo/D-6046-2012; Suh, Won/H-8306-2013	Suh, Won/0000-0002-1768-4635				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1992, E COMMUNICATION; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EOM SH, IN PRESS ACTA CRYS D, V51; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; JONES TA, 1993, E COMMUNICATION; KANKARE J, 1994, PROTEIN ENG, V7, P823, DOI 10.1093/protein/7.7.823; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TEPLYAKOV A, 1994, PROTEIN SCI, V7, P1098; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	29	336	369	2	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					612	616		10.1038/376612a0	http://dx.doi.org/10.1038/376612a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637814				2022-12-01	WOS:A1995RP75600057
J	LEAKEY, MG; FEIBEL, CS; MCDOUGALL, I; WALKER, A				LEAKEY, MG; FEIBEL, CS; MCDOUGALL, I; WALKER, A			NEW 4-MILLION-YEAR-OLD HOMINID SPECIES FROM KANAPOI AND ALLIA BAY, KENYA	NATURE			English	Article							HADAR FORMATION; ETHIOPIA; AUSTRALOPITHECUS; MORPHOLOGY; TURKANA	Nine hominid dental, cranial and postcranial specimens from Kanapoi, Henya, and 12 specimens from Allia Bay, Kenya, are described here as a new species of Australopithecus dating from between about 3.9 million and 4.2 million years ago. The mosaic of primitive and derived features shows this species to be a possible ancestor to Australopithecus afarensis and suggests that Ardipithecus ramidus is a sister species to this and all later hominids. A tibia establishes that hominids were bipedal at least half a million years before the previous earliest evidence showed.	RUTGERS STATE UNIV, DEPT ANTHROPOL, NEW BRUNSWICK, NJ 08903 USA; AUSTRALIAN NATL UNIV, RES SCH EARTH SCI, CANBERRA, ACT 0200, AUSTRALIA; PENN STATE UNIV, DEPT ANTHROPOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT BIOL, UNIVERSITY PK, PA 16802 USA	Rutgers State University New Brunswick; Australian National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	LEAKEY, MG (corresponding author), NATL MUSEUMS KENYA, POB 40658, NAIROBI, KENYA.		Klein, Richard G/B-5910-2009					Aiello L., 1990, INTRO HUMAN EVOLUTIO, V1st ed.; Brown F. H., 1991, KOOBI FORA RES PROJE, V3, P1; Cebula G.T., 1986, TERRA COGNITA, V6, P139; COFFING K, 1994, AM J PHYS ANTHROPOL, V93, P55, DOI 10.1002/ajpa.1330930104; Day M.H., 1978, EARLY HOMINIDAFRIC, P311; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; Harris J.M., 1987, P524; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; KOHLLARSON L, 1942, SPUREN VORMENSCHEN F; LATIMER B, 1987, AM J PHYS ANTHROPOL, V74, P155, DOI 10.1002/ajpa.1330740204; MCDOUGALL I, 1985, GEOL SOC AM BULL, V96, P159, DOI 10.1130/0016-7606(1985)96<159:KAADOT>2.0.CO;2; MCDOUGALL I, 1988, GEOCHRONOLOGY THERMO; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; NAMWAMBA F, 1983, THESIS U UTAH; PATTERSON B, 1967, SCIENCE, V156, P64, DOI 10.1126/science.156.3771.64; PUECH PF, 1986, J HUM EVOL, V15, P325, DOI 10.1016/S0047-2484(86)80015-X; SENUT B, 1980, COLLEGIUM ANTROPOL, V4, P87; Senut B., 1985, P193; STEVEN TA, 1967, US GEOL SURV PROF D, V575, P47; WARD SC, 1982, AM J PHYS ANTHROPOL, V57, P605, DOI 10.1002/ajpa.1330570407; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	25	343	354	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					565	571		10.1038/376565a0	http://dx.doi.org/10.1038/376565a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP756	7637803				2022-12-01	WOS:A1995RP75600043
J	LECKBAND, D				LECKBAND, D			THE SURFACE FORCE APPARATUS - A TOOL FOR PROBING MOLECULAR PROTEIN INTERACTIONS	NATURE			English	Article							ADHESION; LIQUIDS	Force measurements can probe directly the molecular impact of proteins' electrostatic surface properties, specific bond strengths, membrane composition, and membrane fluidity on biological recognition events.			LECKBAND, D (corresponding author), UNIV ILLINOIS,DEPT CHEM ENGN,URBANA,IL 61801, USA.		Ueno, Hiroshi/C-3301-2009					BALGI G, 1995, BIOPHYS J, V68, P2251, DOI 10.1016/S0006-3495(95)80407-8; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HUNTER RJ, 1989, F COLLOID SCI, V1; ISRAELAC.JN, 1973, J COLLOID INTERF SCI, V44, P259, DOI 10.1016/0021-9797(73)90218-X; ISRAELACHVILI J, 1987, P NATL ACAD SCI USA, V84, P4722, DOI 10.1073/pnas.84.14.4722; ISRAELACHVILI JN, 1978, J CHEM SOC FARAD T 1, V74, P975, DOI 10.1039/f19787400975; ISRAELACHVILI JN, 1992, SURF SCI REP, V14, P109, DOI 10.1016/0167-5729(92)90015-4; Lauffenburger DA., 1993, RECEPTORS MODELS BIN; LECKBAND D, 1993, ENZYME MICROB TECH, V15, P450, DOI 10.1016/0141-0229(93)90077-F; LECKBAND D, IN PRESS BIOCHEMISTR; LECKBAND D, IN PRESS BIOPHYS J; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE CS, 1989, P NATL ACAD SCI USA, V86, P8392, DOI 10.1073/pnas.86.21.8392; MARRA J, 1986, BIOPHYS J, V49, P815; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.bb.18.060189.000553; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; OKUSA H, 1994, LANGMUIR, V10, P3577, DOI 10.1021/la00022a034; PATEL SS, 1989, ANNU REV PHYS CHEM, V40, P597; TABOR D, 1969, PROC R SOC LON SER-A, V312, P435, DOI 10.1098/rspa.1969.0169; TIMBS MM, 1991, BIOCHIM BIOPHYS ACTA, V1064, P219, DOI 10.1016/0005-2736(91)90305-R	23	52	54	2	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					617	618		10.1038/376617a0	http://dx.doi.org/10.1038/376617a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637815				2022-12-01	WOS:A1995RP75600059
J	LEE, S; HAHN, S				LEE, S; HAHN, S			MODEL FOR BINDING OF TRANSCRIPTION FACTOR TFIIB TO THE TBP-DNA COMPLEX	NATURE			English	Article							RNA POLYMERASE-II; CRYSTAL-STRUCTURE; MINOR-GROOVE; TATA-BOX; FUNCTIONAL DOMAINS; ELEMENT	TRANSCRIPTION factor TFIIB is essential for the formation of RNA polymerase II initiation complexes where it binds to the TATA-binding protein (TBP) complex with DNA and recruits RNA polymerase II. TFIIB is probably a target for various activators(1-4). Several models have been proposed for the position of TFIIB in the TFIIB-TBP-DNA complex(1,3,5,6). Here we examine the structure of this Complex using gel mobility-shift assays and hydroxylradical footprinting. TFIIB requires at least seven base pairs of DNA on either side of the TATA box to form a stable TFIIB-TBP-DNA complex. The sugar residues protected from hydroxylradial cleavage by the TFIIB-TBP complex were mapped on the crystal-structure model of the TBP-DNA complex. This analysis suggests that TFIIB binds beneath the concave surface of TBP, contacting DNA both upstream and downstream of the TATA box. Our model predicts that TFIIB binds close to the C-terminal stirrup of TBP and provides one explanation for why TBP needs to bend DNA.			LEE, S (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HA L, 1991, NATURE, V352, P689; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIMBALL AS, 1993, BIOCHEMISTRY-US, V32, P4698, DOI 10.1021/bi00069a002; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TULLIUS TD, 1988, NATURE, V332, P663, DOI 10.1038/332663a0; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911	24	81	81	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					609	612		10.1038/376609a0	http://dx.doi.org/10.1038/376609a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637813				2022-12-01	WOS:A1995RP75600056
J	MACILWAIN, C				MACILWAIN, C			GENE PATENT STUDY DROWNED AS OTA SINKS	NATURE			English	Editorial Material																		1995, NATURE, V375, P711	1	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					541	541						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637791				2022-12-01	WOS:A1995RP75600004
J	MACILWAIN, C				MACILWAIN, C			LAST-MINUTE LIFELINE FOR PRINCETON TOKAMAK TESTS	NATURE			English	Editorial Material																		1995, NATURE, V375, P713; 1995, NATURE, V375, P622	2	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					541	541						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637791				2022-12-01	WOS:A1995RP75600005
J	PERINI, G; WAGNER, S; GREEN, MR				PERINI, G; WAGNER, S; GREEN, MR			RECOGNITION OF BZIP PROTEINS BY THE HUMAN T-CELL LEUKEMIA-VIRUS TRANSACTIVATOR TAX	NATURE			English	Article							DNA-BINDING SPECIFICITY; LEUCINE ZIPPER MOTIF; ZTA TRANSACTIVATOR; YEAST GCN4; DOMAIN; DIMERIZATION; ACTIVATOR; FAMILY; CREB; AP-1	HUMAN T-cell leukaemia virus type I(HTLV-I) Tax protein increases the DNA binding of many cellular transcription factors that contain a basic region-leucine zipper (bZIP) DNA-binding domain(1-3). bZIP domains comprise a leucine-rich dimerization motif and a basic region that mediates DNA contact. How Tax recognizes diverse bZIPs is not understood. Here we show that no specific sequence of the leucine zipper is required for a Tax response. In contrast, the basic region is essential for the Tax-mediated DNA-binding increase, which can be eliminated by single substitutions of several conserved amino acids. Surprisingly, Tax alters the relative affinity of a bZIP for different DNA binding sites. Thus, through recognition of the conserved basic region, Tax increases DNA binding and modifies DNA site selection. Tax provides a model for how a single auxiliary factor can regulate multiple sequence-specific DNA-binding proteins.			PERINI, G (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.							ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEI D, 1994, P NATL ACAD SCI USA, V91, P11318; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	16	136	136	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					602	605		10.1038/376602a0	http://dx.doi.org/10.1038/376602a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637811				2022-12-01	WOS:A1995RP75600054
J	SCHACTER, DL; REIMAN, E; UECKER, A; POLSTER, MR; YUN, LS; COOPER, LA				SCHACTER, DL; REIMAN, E; UECKER, A; POLSTER, MR; YUN, LS; COOPER, LA			BRAIN-REGIONS ASSOCIATED WITH RETRIEVAL OF STRUCTURALLY COHERENT VISUAL INFORMATION	NATURE			English	Article							MEMORY; OBJECTS; RECOGNITION; MECHANISMS; ACTIVATION; IMPLICIT	AN object's global, three-dimensional structure may be represented by a specialized brain system involving regions of inferior temporal cortex(1-3). This system's role in object representation can be understood by experiments in which people study drawings of novel objects with possible or impossible three-dimensional structures, and later make either possible/impossible object decisions or old/new recognition decisions about briefly flashed studied and nonstudied objects. Although object decisions about possible objects are facilitated by prior study, there is no corresponding facilitation for impossible objects, thereby implicating a system that is specifically involved in the representation of structurally coherent visual objects(4). Here we show, by positron emission tomography (PET), that increases in blood flow in inferior temporal regions are associated with object decisions about possible but not impossible objects, and that there are increases in the vicinity of the hippocampal formation associated with episodic recognition of possible objects.	UNIV ARIZONA,DEPT PSYCHIAT,TUCSON,AZ 85721; GOOD SAMARITAN REG MED CTR,CTR POSITRON EMISS TOMOG,PHOENIX,AZ 85006; UNIV ARIZONA,DIV NEURAL SYST MEMORY & AGING,TUCSON,AZ 85721; UNIV VICTORIA,DEPT PSYCHOL,WELLINGTON,NEW ZEALAND; ARIZONA STATE UNIV,DEPT COMP SCI & ENGN,TEMPE,AZ 85287; COLUMBIA UNIV,DEPT PSYCHOL,NEW YORK,NY 10027	University of Arizona; University of Arizona; Victoria University Wellington; Arizona State University; Arizona State University-Tempe; Columbia University	SCHACTER, DL (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.			Schacter, Daniel/0000-0002-2460-6061				ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BUCKNER RL, 1995, J NEUROSCI, V15, P12; BUCKNER RL, 1995, HDB NEUROPSYCHOLOGY, P439; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; COOPER LA, 1992, J EXP PSYCHOL LEARN, V18, P43, DOI 10.1037/0278-7393.18.1.43; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1991, J CEREB BLOOD FLOW M, V10, P458; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; Gray J., 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; GROSS CG, 1992, PHIL T R SOC B, V335, P245; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Jones-Gotman M., 1993, Society for Neuroscience Abstracts, V19, P1002; KOSSLYN SM, IN PRESS BRAIN; MINTUN MA, 1991, J NUCL MED, V31, P816; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; SCHACTER DL, 1993, J EXP PSYCHOL LEARN, V19, P995, DOI 10.1037/0278-7393.19.5.995; SCHACTER DL, 1990, J EXP PSYCHOL GEN, V119, P5, DOI 10.1037/0096-3445.119.1.5; SCHACTER DL, 1991, J COGNITIVE NEUROSCI, V3, P118; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; STEM C, 1994, SOC NEUR ABSTR, V20, P530; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; VINOGRADA OS, 1978, HIPPOCAMPUS, V2	29	261	261	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					587	590		10.1038/376587a0	http://dx.doi.org/10.1038/376587a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637806				2022-12-01	WOS:A1995RP75600049
J	STANDAERT, SM; DAWSON, JE; SCHAFFNER, W; CHILDS, JE; BIGGIE, KL; SINGLETON, BS; GERHARDT, RR; KNIGHT, ML; HUTCHESON, RH				STANDAERT, SM; DAWSON, JE; SCHAFFNER, W; CHILDS, JE; BIGGIE, KL; SINGLETON, BS; GERHARDT, RR; KNIGHT, ML; HUTCHESON, RH			EHRLICHIOSIS IN A GOLF-ORIENTED RETIREMENT COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN INFECTION; TICKS; CANIS	Background. Ehrlichiosis due to Ehrlichia chaffeensis usually occurs sporadically or in small clusters, with an annual incidence estimated at 3 to 5 cases per 100,000 population in areas of endemic disease. The putative principal vector is the Lone Star tick (Amblyomma americanum). We investigated an outbreak of ehrlichiosis that occurred in June 1993 among members of a golf-oriented retirement community (community A) in Tenessee. The community is densely wooded and borders a wildlife-management area where deer are numerous. Methods. We conducted a case-control study, using medical-history reviews, serologic testing, and testing with the polymerase chain reaction for E. chaffeensis infection. We also surveyed a sample of 10 percent of the households in community A and in another golf-oriented community (community B) more than 20 miles (32 km) from the wildlife-management area. Survey participants completed a questionnaire and provided specimens for serologic testing. In both communities, searches for ticks were undertaken. Results. Eleven cases of symptomatic ehrlichiosis were identified in the case-control study, 10 of which were in community A (attack rate, 330 per 100,000). Of 311 surveyed residents of community-A, 12.5 percent had serologic evidence of past E. chaffeensis infection, as compared with 3.3 percent of 92 in community B (relative risk in community A as compared with community B, 3.9; 95 percent confidence interval, 1.2 to 12.2). The risk of infection was associated with tick bites, exposure to wildlife, golfing, and among golfers, retrieving lost golf balls from the rough. Persons who never used insect repellent were more likely to have had infection than persons who did. In community A, thousands of Lone Star ticks were found; in community B, only three ticks were found. Conclusions. The high rate of E. chaffeensis infection in community A resulted from its proximity to a wildlife reserve. When outdoor recreational activities are common and concentrations of ticks are high, outbreaks of arthropod-borne zoonoses can be anticipated.	VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37232; NATL CTR INFECT DIS,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA; TENNESSEE DEPT HLTH,NASHVILLE,TN; UNIV TENNESSEE,DEPT ENTOMOL & PLANT PATHOL,KNOXVILLE,TN; TENNESSEE VALLEY AUTHOR,GOLDEN POND,KY	Vanderbilt University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Tennessee Department Health; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Tennessee Valley Authority			Childs, James E/B-4002-2012					ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1993, AM J TROP MED HYG, V49, P239, DOI 10.4269/ajtmh.1993.49.239; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DAWSON JE, 1994, J CLIN MICROBIOL, V32, P2725, DOI 10.1128/JCM.32.11.2725-2728.1994; Dean A. G., 1990, EPI INFO VERSION 5 W; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; Hair J.A., 1986, P406; Harkess J R, 1991, Infect Dis Clin North Am, V5, P37; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; KARDATZKE JT, 1992, J MED ENTOMOL, V29, P669, DOI 10.1093/jmedent/29.4.669; LEDERBERG J, 1992, EMERGING INFECTIONS, P206; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; ROHRBACH BW, 1990, AM J PUBLIC HEALTH, V80, P442, DOI 10.2105/AJPH.80.4.442; SCHWARTZ BS, 1990, AM J EPIDEMIOL, V131, P877, DOI 10.1093/oxfordjournals.aje.a115578; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; Telford S R 3rd, 1991, Infect Dis Clin North Am, V5, P7; TOPPING NH, 1947, NEW YORK STATE J MED, V47, P1585; WALKER DH, 1994, NEW ENGL J MED, V331, P1651, DOI 10.1056/NEJM199412153312410; YEVICH SJ, 1995, J INFECT DIS, V171, P1266, DOI 10.1093/infdis/171.5.1266; 1988, MMWR-MORBID MORTAL W, V37, P270; 1988, MMWR-MORBID MORTAL W, V37, P275	27	93	98	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					420	425		10.1056/NEJM199508173330704	http://dx.doi.org/10.1056/NEJM199508173330704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616991				2022-12-01	WOS:A1995RP24300004
J	TAMURA, T; ISHIHARA, M; LAMPHIER, MS; TANAKA, N; OISHI, I; AIZAWA, S; MATSUYAMA, T; MAK, TW; TAKI, S; TANIGUCHI, T				TAMURA, T; ISHIHARA, M; LAMPHIER, MS; TANAKA, N; OISHI, I; AIZAWA, S; MATSUYAMA, T; MAK, TW; TAKI, S; TANIGUCHI, T			AN IRF-1-DEPENDENT PATHWAY OF DNA DAMAGE-INDUCED APOPTOSIS IN MITOGEN-ACTIVATED T-LYMPHOCYTES	NATURE			English	Article							REGULATORY FACTOR-I; PROGRAMMED CELL-DEATH; GENE CED-3; IRF-1; INDUCTION; HOMOLOG; ENZYME; SYSTEM; GROWTH; BCL-2	LYMPHOCYTES are particularly susceptible to DNA damage-induced apoptosis, a response which may serve as a form of 'altruistic suicide' to counter their intrinsic high potential for mutation and clonal expansion(1). The tumour suppressor p53 has been shown to regulate this type of apoptosis in thymocytes(2,3), but an as yet unknown, p53-independent pathway(s) appears to mediate the same event in mitogen-activated mature T lymphocytes(4). Here we show that DNA damage-induced apoptosis in these T lymphocytes is dependent on the antioncogenic transcription factor interferon regulatory factor (IRF)-1 (refs 5-7). Thus two different anti-oncogenic transcription factors, p53 and IRF-1, are required for distinct apoptotic pathways in T lymphocytes. We also show that mitogen induction of the interleukin-1 beta converting enzyme (ICE) gene(8-10), a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, is IRF-1-dependent. Ectopic overexpression of IRE-1 results in the activation of the endogenous gene for ICE and enhances the sensitivity of cells to radiation-induced apoptosis.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES EMBRYON SCI & TECHNOL,KYOTO 61902,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 860,JAPAN; AMGEN INST,TORONTO,ON M4X 1K9,CANADA	Osaka University; Japan Science & Technology Agency (JST); Kumamoto University	TAMURA, T (corresponding author), UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.		Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349; Tanaka, Nobuyuki/0000-0002-6373-2220; Taki, Shinsuke/0000-0001-5143-3496				CARRETTI DP, 1992, SCIENCE, V256, P97; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUKADA T, 1993, ONCOGENE, V8, P3313; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	414	422	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					596	599		10.1038/376596a0	http://dx.doi.org/10.1038/376596a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637809				2022-12-01	WOS:A1995RP75600052
J	VENANCE, L; PIOMELLI, D; GLOWINSKI, J; GIAUME, C				VENANCE, L; PIOMELLI, D; GLOWINSKI, J; GIAUME, C			INHIBITION BY ANANDAMIDE OF GAP-JUNCTIONS AND INTERCELLULAR CALCIUM SIGNALING IN STRIATAL ASTROCYTES	NATURE			English	Article							SINGLE-CHANNEL CURRENTS; CANNABINOID RECEPTOR; COMMUNICATION; WAVES; PROTEIN; BINDS; CELLS	ANANDAMIDE, an endogenous arachidonic acid derivative that is released from neurons and activates cannabinoid receptors(1), may act as a transcellular cannabimimetic messenger in the central nervous system(2-4). The biological actions of anandamide and the identity of its target cells are, however, still poorly documented(5). Here we show that anandamide is a potent inhibitor of gap-junction conductance and dye permeability in striatal astrocytes. This inhibitory effect is specific for anandamide as compared to coreleased congeners(4) or structural analogues, is sensitive to pertussis toxin and to protein-alkylating agents, and is neither mimicked by cannabinoid-receptor agonists nor prevented by a cannabinoid-receptor antagonist. Glutamate released from neurons evokes calcium waves in astrocytes(6) that propagate via gap junctions(7-9), and may, in turn, activate neurons distant from their initiation sites in astrocytes(10-12). We find that anandamide blocks the propagation of astrocyte calcium waves generated by either mechanical stimulation or local glutamate application. Thus, by regulating gap-junction permeability, anandamide may control intercellular communication in astrocytes and therefore neuron-glial interactions.	COLL FRANCE,INSERM,U114,F-75231 PARIS 05,FRANCE; INST NEUROSCI,LA JOLLA,CA 92037	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Venance, Laurent/E-5840-2016	Venance, Laurent/0000-0003-0738-1662				CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; COMELLBELL AH, 1990, SCIENCE, V247, P470; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DEVANE WA, 1994, TRENDS PHARMACOL SCI, V15, P40, DOI 10.1016/0165-6147(94)90106-6; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIAUME C, 1991, P NATL ACAD SCI USA, V88, P5577, DOI 10.1073/pnas.88.13.5577; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MURPHY NP, 1994, EUR J NEUROSCI, V6, P854, DOI 10.1111/j.1460-9568.1994.tb00995.x; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0	28	309	315	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					590	594		10.1038/376590a0	http://dx.doi.org/10.1038/376590a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637807	Green Submitted			2022-12-01	WOS:A1995RP75600050
J	VESA, J; HELLSTEN, E; VERKRUYSE, LA; CAMP, LA; RAPOLA, J; SANTAVUORI, P; HOFMANN, SL; PELTONEN, L				VESA, J; HELLSTEN, E; VERKRUYSE, LA; CAMP, LA; RAPOLA, J; SANTAVUORI, P; HOFMANN, SL; PELTONEN, L			MUTATIONS IN THE PALMITOYL PROTEIN THIOESTERASE GENE CAUSING INFANTILE NEURONAL CEROID-LIPOFUSCINOSIS	NATURE			English	Article							L-MYC; CHROMOSOME-1; POLYMORPHISM; ASSIGNMENT; JUVENILE; DISEASE; CLONING; MAPS; FORM; 1P32	NEURONAL ceroid lipofuscinoses (NCL) represent a group of common progressive encephalopathies of children which have a global incidence of 1 in 12,500 (ref. 1). These severe brain diseases are divided into three autosomal recessive subtypes, assigned to different chromosomal loci(2-4). The infantile subtype of NCL (INCL), linked to chromosome 1p32, is characterized by early visual loss and rapidly progressing mental deterioration, resulting in a pat electroencephalogram by 3 years of age; death occurs at 8 to 11 years(5), and characteristic storage bodies are found in brain and other tissues at autopsy(6). The molecular pathogenesis underlying the selective loss of neurons of neocortical origin has remained unknown. Here we report the identification, by positional candidate methods, of defects in the palmitoyl-protein thioesterase gene in all 42 Finnish INCL patients and several non-Finnish patients. The most common mutation results in intracellular accumulation of the polypeptide and undetectable enzyme activity in the brain of patients.	NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,SF-00300 HELSINKI,FINLAND; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV HELSINKI,CHILDRENS HOSP,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT CHILD NEUROL,SF-00290 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Helsinki; University of Helsinki								CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; ERLANSON CH, 1970, SCAND J GASTROENTERO, V5, P333; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P928; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JARVELA I, 1991, GENOMICS, V9, P170, DOI 10.1016/0888-7543(91)90235-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PROLA RL, 1984, J BIOL CHEM, V259, P3350; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; Rider J A, 1988, Am J Med Genet Suppl, V5, P21; RILKONEN A, 1994, DNA CELL BIOL, V13, P257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAVUORI P, 1974, DEV MED CHILD NEUROL, V16, P644; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WILLIAMS R, 1993, AM J HUM GENET, V53, P931; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379	30	586	591	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					584	587		10.1038/376584a0	http://dx.doi.org/10.1038/376584a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637805				2022-12-01	WOS:A1995RP75600048
J	WILLIAMS, GV; GOLDMANRAKIC, PS				WILLIAMS, GV; GOLDMANRAKIC, PS			MODULATION OF MEMORY FIELDS BY DOPAMINE D1 RECEPTORS IN PREFRONTAL CORTEX	NATURE			English	Article							PRIMATE CEREBRAL-CORTEX; WORKING MEMORY; PARKINSONS-DISEASE; TARGET-CELLS; NEURONS; RAT; SCHIZOPHRENIA; AMPHETAMINE; INVOLVEMENT; STIMULATION	Dopamine has been implicated in the cognitive process of working memory but the cellular basis of its action has yet to be revealed. By combining iontophoretic analysis of dopamine receptors with single-cell recording during behaviour, we found that D1 antagonists can selectively potentiate the 'memory fields' of prefrontal neurons which subserve working memory. The precision shown for D1 receptor modulation of mnemonic processing Indicates a direct gating of selective excitatory synaptic inputs to prefrontal neurons during cognition.			WILLIAMS, GV (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA.							Amsten A. F., 1995, J NEUROSCI, V15, P3429; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; BAUER RH, 1978, PHARMACOL BIOCHEM BE, V8, P243, DOI 10.1016/0091-3057(78)90311-8; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BERGSON C, 1994, SOC NEUR ABSTR, V20, P275; BRADLEY VA, 1989, J NEUROL NEUROSUR PS, V52, P1228, DOI 10.1136/jnnp.52.11.1228; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; BUSHNELL PJ, 1983, PHARM BIOCH BEHAV, V45, P765; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; CEPEDA C, 1992, SYNAPSE, V11, P330, DOI 10.1002/syn.890110408; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pharmtox.33.1.281; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster JM, 1989, PREFRONTAL CORTEX, P51; GODBOUT R, 1991, J PHARMACOL EXP THER, V258, P728; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; GOLDSTEIN LE, 1994, J NEUROSCI, V14, P4937; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; MILLAR J, 1988, J NEUROSCI METH, V25, P59, DOI 10.1016/0165-0270(88)90120-3; MILLAR J, 1989, J COMP NEUROL, V287, P119, DOI 10.1002/cne.902870109; OSCALAIDHE SP, 1993, SOC NEUR ABSTR, V19, P800; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; SABATER R, 1993, EUR J PHARMACOL, V242, P205, DOI 10.1016/0014-2999(93)90082-S; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SEGUELA P, 1988, BRAIN RES, V442, P11, DOI 10.1016/0006-8993(88)91427-8; SHURTLEFF D, 1994, PHARMACOL BIOCHEM BE, V47, P935, DOI 10.1016/0091-3057(94)90299-2; SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720; TAYLOR LA, 1991, LIFE SCI, V49, P1505, DOI 10.1016/0024-3205(91)90051-C; THIERRY AM, 1988, ANN NY ACAD SCI, V537, P101, DOI 10.1111/j.1749-6632.1988.tb42099.x; VANEDEN CG, 1987, NEUROSCIENCE, V22, P849, DOI 10.1016/0306-4522(87)92964-2; WILSON FAW, 1994, P NATL ACAD SCI USA, V91, P4009, DOI 10.1073/pnas.91.9.4009; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4	45	1293	1309	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	1995	376	6541					572	575		10.1038/376572a0	http://dx.doi.org/10.1038/376572a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637804				2022-12-01	WOS:A1995RP75600044
J	WYNN, TA; CHEEVER, AW; JANKOVIC, D; POINDEXTER, RW; CASPAR, P; LEWIS, FA; SHER, A				WYNN, TA; CHEEVER, AW; JANKOVIC, D; POINDEXTER, RW; CASPAR, P; LEWIS, FA; SHER, A			AN IL-12-BASED VACCINATION METHOD FOR PREVENTING FIBROSIS INDUCED BY SCHISTOSOME INFECTION	NATURE			English	Article							TUMOR NECROSIS FACTOR; MURINE SCHISTOSOMIASIS; IMMUNE-RESPONSE; MESSENGER-RNA; MANSONI; MICE; INFLAMMATION; INDUCTION; INVIVO; BETA	THE harmful fibrosis which often occurs in the context of infectious. disease involves the excessive deposition of connective tissue matrix, particularly collagen, and is mostly resistant to pharmacological and immunological intervention(1). In schistosomiasis, fibrosis is associated with the granulomatous response to parasite eggs trapped in the liver(2). We have previously shown that interleukin (IL)-12 administered peritoneally with eggs prevents subsequent pulmonary granuloma formation on intravenous challenge with eggs(3). Here we show that sensitization with eggs plus IL-12 partly inhibits granuloma formation and dramatically reduces the tissue fibrosis induced by natural infection with Schistosoma mansoni worms. These results are an example of a vaccine against parasites which acts by preventing pathology rather than infection. IL-12, is known to favour the priming of Th1 rather than Th2 cells, and the effects on fibrosis are accompanied by replacement of the Th2-dominated pattern of cytokine expression characteristic of S. mansoni infection with one dominated by Th1 cytokines. Elevated Th2 cytokine expression and fibrosis are common manifestations of a wide variety of infectious diseases and atopic disorders which might be ameliorated by vaccination with antigen and IL-12.	NIAID,PARASIT DIS LAB,HOST PARASITE SECT,BETHESDA,MD 20892; BIOMED RES INST,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	WYNN, TA (corresponding author), NIAID,PARASITOL LAB,IMMUNOBIOL SECT,BETHESDA,MD 20892, USA.		Wynn, Thomas A/AAO-3523-2021; Wynn, Thomas A/C-2797-2011	Wynn, Thomas A/0000-0002-7244-8731; 				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; BERGQUIST NR, 1994, IMMUNOLOGIST, V2, P131; BUTTERWORTH AE, 1992, T ROY SOC TROP MED H, V86, P1, DOI 10.1016/0035-9203(92)90411-5; CAPRON AR, 1992, CURR OPIN IMMUNOL, V4, P419, DOI 10.1016/S0952-7915(06)80033-6; CHEEVER AW, 1992, J IMMUNOL, V148, P3244; CHEEVER AW, 1994, J IMMUNOL, V153, P753; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; DOMINGO EO, 1968, AM J PATHOL, V52, P369; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENDERSON GS, 1992, J IMMUNOL, V148, P2261; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; OSWALD IP, 1994, J IMMUNOL, V153, P1707; PEARCE EJ, 1995, MOL APPROACHES PARAS, V12, P497; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PLAYFAIR JHL, 1991, ACT LEIDENS, V60, P157; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SHER A, 1991, J IMMUNOL, V147, P2713; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; WYNN TA, 1993, J IMMUNOL, V151, P1430; WYNN TA, 1995, J IMMUNOL, V154, P4701; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551; YAMASHITA T, 1992, J IMMUNOL, V149, P3659; ZWINGENBERGER K, 1990, SCAND J IMMUNOL, V31, P205, DOI 10.1111/j.1365-3083.1990.tb02761.x	27	355	375	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					594	596		10.1038/376594a0	http://dx.doi.org/10.1038/376594a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637808				2022-12-01	WOS:A1995RP75600051
J	CORTI, MC; GURALNIK, JM; SALIVE, ME; HARRIS, T; FIELD, TS; WALLACE, RB; BERKMAN, LF; SEEMAN, TE; GLYNN, RJ; HENNEKENS, CH; HAVLIK, RJ				CORTI, MC; GURALNIK, JM; SALIVE, ME; HARRIS, T; FIELD, TS; WALLACE, RB; BERKMAN, LF; SEEMAN, TE; GLYNN, RJ; HENNEKENS, CH; HAVLIK, RJ			HDL CHOLESTEROL PREDICTS CORONARY HEART-DISEASE MORTALITY IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY LIPOPROTEIN; HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; FOLLOW-UP; FRAMINGHAM; PREVALENCE; HEALTH	Objectives.-To examine the relationship of total cholesterol and high-density lipoprotein cholesterol (HDL-C) with coronary heart disease (CHD) mortality and with occurrence of new CHD events in persons aged 71 years and older. Design.-Prospective cohort study with a median of 4.4 years of follow-up. Setting.-East Boston, Mass; New Haven, Conn; and Iowa and Washington counties, Iowa. Participants.-A total of 2527 women and 1377 men who completed an interview, had serum lipid determinations, and survived at least 1 year. New CHD events were evaluated in persons with no CHD history or hospitalization. Main Outcome Measures.-Death due to CHD (ICD-9 codes 410 through 414 as underlying cause of death); new occurrence of CHD events (fatal CHD or hospitalization with CHD [ICD-9 codes 410 through 414]). Results.-After adjustment for established CHD risk factors, the relative risk (RR) of death due to CHD for those with low HDL-C (<0.90 mmol/L [<35 mg/dL]) compared with the reference group (HDL-C greater than or equal to 1.55 mmol/L [greater than or equal to 60 mg/dL]) was 2.5 (95% confidence interval [Cl], 1.6 to 4.0). Elevated risk was present in subgroups aged 71 through 80 years (RR, 4.1; 95% Cl, 1.9 to 8.8) and over 80 years (RR, 1.8; 95% Cl, 0.99 to 3.4), and in men and women. Low HDL-C predicted an increased risk of occurrence of new CHD events (RR, 1.4, 95% Cl, 1.1 to 2.0), with similar but nonsignificant results in subgroups of men and women. Total cholesterol was less consistently associated with CHD mortality than HDL-C. When we compared individuals with total cholesterol of at least 6.20 mmol/L (240 mg/dL) with the reference group with total cholesterol of 4.16 to 5.19 mmol/L (161 to 199 mg/dL), a significant risk of CHD mortality was seen for women (RR, 1.8; 95% Cl, 1.03 to 3.0) but not for men (RR, 1.0; 95% Cl, 0.5 to 2.0). In the total population, for each 1-unit increase in the total cholesterol/HDL-C ratio there was a 17% increase in the risk of CHD death that was statistically significant. Conclusions.-Low HDL-C predicts CHD mortality and occurrence of new CHD events in persons older than 70 years. Elevated total cholesterol was not found to be associated with CHD mortality in older men, but may be a risk factor for CHD in older women.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; UNIV IOWA, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Iowa; Yale University; Harvard University; Harvard T.H. Chan School of Public Health	CORTI, MC (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM, 7201 WISCONSIN AVE, ROOM 3C309, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE ON AGING [N01AG002105, N01AG002107, N01AG002106] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02105, N01-AG-02107, N01-AG-02106] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGNER E, 1983, ACTA MED SCAND, V214, P33; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1994, CIRCULATION, V89, P1329; Barrett-Connor E, 1992, Ann Epidemiol, V2, P77, DOI 10.1016/1047-2797(92)90040-W; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; BRAY GA, 1978, INT J OBESITY, V2, P99; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; JACKSON R, 1988, NEW ZEAL MED J, V101, P658; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LACROIX AZ, 1991, NEW ENGL J MED, V325, P1586; MALENKA DJ, 1988, ARCH INTERN MED, V148, P2247, DOI 10.1001/archinte.148.10.2247; MANOLIO TA, 1992, ANN INTERN MED, V116, P641, DOI 10.7326/0003-4819-116-8-641; MILLERBASS K, 1993, ARCH INTERN MED, V153, P2209; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; Reed D, 1992, Ann Epidemiol, V2, P29, DOI 10.1016/1047-2797(92)90034-N; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; Sorkin J D, 1992, Ann Epidemiol, V2, P59, DOI 10.1016/1047-2797(92)90038-R; STAESSEN J, 1990, J HYPERTENS, V8, P755, DOI 10.1097/00004872-199008000-00010; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Wallace R B, 1992, Ann Epidemiol, V2, P15, DOI 10.1016/1047-2797(92)90032-L; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1991, P217 SAS I INC TECHN; [No title captured]; 1977, JAMA-J AM MED ASSOC, V237, P2385	42	208	212	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					539	544		10.1001/jama.274.7.539	http://dx.doi.org/10.1001/jama.274.7.539			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629981				2022-12-01	WOS:A1995RN46600023
J	HENRARD, DR; PHILLIPS, JF; MUENZ, LR; BLATTNER, WA; WIESNER, D; EYSTER, ME; GOEDERT, JJ				HENRARD, DR; PHILLIPS, JF; MUENZ, LR; BLATTNER, WA; WIESNER, D; EYSTER, ME; GOEDERT, JJ			NATURAL-HISTORY OF HIV-1 CELL-FREE VIREMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; HOMOSEXUAL MEN; VIRAL BURDEN; INFECTION; AIDS; PLASMA; TYPE-1; BLOOD	Objective.-To characterize the natural history of viremia with human immunodeficiency virus type 1 (HIV-1) and its association with disease progression from infection to acquired immunodeficiency syndrome (AIDS). Design.-Prospective cohort study. Annual specimens were tested for quantitative virion-associated HIV-1 RNA, p24 antigen, and CD4(+) lymphocyte levels. Participants.-A total of 42 homosexual men who seroconverted to HIV-1 between 1982 and 1985. Main Outcome Measures.-Trends over time in serum HIV-1 RNA level, correlations between serum HIV-1 RNA and other markers, and prediction of AIDS using these markers. ResuIts.-HIV-1 RNA levels were stable overtime, increasing by 10-fold or more in only six (14%) of the 42 subjects during 3 to 11 years of follow-up. Mean HIV-1 RNA levels were 10(3.8) copies/mL if AIDS occurred in less than 4 years, 10(3.07) copies/mL if AIDS developed within 4 through 9 years, and 10(2.27) copies/mL if AIDS did not develop within 6 through 11 years. In both univariate and multivariate models, initial and subsequent HIV-1 RNA levels, p24 antigenemia, and percentage of CD4(+) lymphocytes were independently predictive of AIDS. Conclusions.-The stability of virion-associated HIV-1 RNA levels suggests that an equilibrium between HIV-1 replication rate and efficacy of immunologic response is established shortly after infection and persists throughout the asymptomatic period of the disease. Thus, defective immunologic control of HIV-1 infection may be as important as the viral replication rate for determining AIDS-free survival. Because individual steady-state levels of viremia were established soon after infection, HIV-1 RNA levels may be useful markers for predicting clinical outcome.	ABBOTT LABS, DEPT MED RES, N CHICAGO, IL 60064 USA; NCI, VIRAL EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT MED, DIV HEMATOL, HERSHEY, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				, M. Elaine Eyster/0000-0001-8248-6793	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095612] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-95612, N01-CP-33060, N01-CP-40521] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; COOMBS RW, 1993, J CLIN MICROBIOL, V31, P1980, DOI 10.1128/JCM.31.8.1980-1986.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARZADEGAN H, 1993, 1ST P NAT C HUM RETR; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; GARRY RF, 1993, NATURE, V365, P301, DOI 10.1038/365301b0; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JOLLERJEMELKA HI, 1994, J HEPATOL, V21, P269, DOI 10.1016/S0168-8278(05)80407-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARIM MR, SAS MACRO GENERALIZE; KOJIMA E, 1994, 10TH P INT C AIDS; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MCLEAN A, 1993, NATURE, V365, P301, DOI 10.1038/365301a0; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PETRICCIANI JC, 1992, AIDS RES HUM RETROV, V8, P1527, DOI 10.1089/aid.1992.8.1527; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRESTON DL, 1990, EPICURE RISK REGRESS; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	199	201	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					554	558						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629984				2022-12-01	WOS:A1995RN46600026
J	MEJIA, RE; POLLACK, MM				MEJIA, RE; POLLACK, MM			VARIABILITY IN BRAIN-DEATH DETERMINATION PRACTICES IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES	Objective.-To investigate variability in practices for determining brain death and organ procurement results in pediatric intensive care units (PICUs). Design.-Prospective cohort study. Setting.-Pediatric ICUs. Patients.-Children undergoing brain death evaluations selected from 5415 consecutive PICU admissions. Main Outcome Measures.-Data from children undergoing brain death evaluations including number of coma examinations, number and duration of apnea tests, Pco(2) measurements at the end of the apnea test, ancillary tests used to confirm brain death, organ procurement, and reasons for nonprocurement. Results.-A total of 93 (37%) of 248 deaths were brain deaths. Compared with the other deaths, children who were classified as brain dead were sicker on admission (mean Pediatric Risk of Mortality [PRISM] score+/-SD: 31+/-11 vs 23+/-12, P<,001; pre-ICU cardiopulmonary resuscitation, 72% vs 40%, P<.001), and had more traumatic injuries (42% vs 12%, P<.001). Variability in apnea testing included lack of apnea testing in 23 patients (25%) and controversial apnea testing practices in 20 patients (22%). Three patients (3%) had brain death evaluations within hours of discontinuing barbiturate infusions, and four of 30 patients younger than 1 year did not have a confirmatory test, Solid organ procurement was successful in 32%, Reasons for nonprocurement included parental refusal (12%), disease state (12%), and medical examiner's case (22%). Conclusions.-Substantial variability exists in the criteria used by clinicians for the diagnosis of brain death. Some practices are contradictory to the Guidelines for the Determination of Brain Death in Children and to recommendations for apnea testing. Organ procurement could be improved by increased medical examiner cooperation.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CHILRENS RES INST,CTR HLTH SERV & CLIN RES,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC	Children's National Health System; Children's National Health System; George Washington University					PHS HHS [MCH-110584] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALJUMAH M, 1992, CRIT CARE MED, V20, P1564; ASHWAL S, 1993, J HEART LUNG TRANSPL, V12, pS176; Ashwal S, 1991, Adv Pediatr, V38, P181; DRAKE B, 1986, PEDIATRICS, V78, P107; EDMONDS JF, 1989, PEDIAT BRAIN DEATH O, P89; FACKLER JC, 1988, AM J DIS CHILD, V142, P999, DOI 10.1001/archpedi.1988.02150090097034; FREEMAN JM, 1988, PEDIATRICS, V81, P301; GONNELLA JS, 1986, DISEASE STAGING CLIN; Hauser J E, 1969, J Forensic Sci, V14, P501; KAUFMAN HH, 1989, NEUROSURGERY, V25, P275, DOI 10.1227/00006123-198908000-00019; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; LEVETOWN M, 1994, JAMA-J AM MED ASSOC, V272, P1271, DOI 10.1001/jama.272.16.1271; NARKEWICZ RM, 1989, PEDIATRICS, V83, P629; POLLACK MM, 1993, CRIT CARE MED, V21, P607, DOI 10.1097/00003246-199304000-00023; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; POWNER DJ, 1976, JAMA-J AM MED ASSOC, V236, P1123, DOI 10.1001/jama.236.10.1123; RIVIELLO JJ, 1988, PEDIATR NEUROL, V4, P213, DOI 10.1016/0887-8994(88)90033-1; SCHAFER JA, 1984, CRIT CARE MED, V12, P357; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P1607, DOI 10.1001/jama.272.20.1607; SHERIDAN F, 1993, J HEART LUNG TRANSPL, V12, pS179; SHEWMON DA, 1988, ANN NEUROL, V24, P789; SHEWMON DA, 1988, NEUROLOGY, V38, P1813, DOI 10.1212/WNL.38.11.1813-b; SQUIRES S, 1993, WASHINGTON POST 1118; SQUIRES S, 1994, WASHINGTON POST 0729; STAWORN D, 1994, CRIT CARE MED, V22, P1301, DOI 10.1097/00003246-199408000-00014; 1984, PEDIATRICS, V74, P505; 1981, JAMA-J AM MED ASSOC, V246, P2184	28	61	63	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					550	553		10.1001/jama.274.7.550	http://dx.doi.org/10.1001/jama.274.7.550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629983				2022-12-01	WOS:A1995RN46600025
J	NELSON, R; NORTON, N; CAUTLEY, E; FURNER, S				NELSON, R; NORTON, N; CAUTLEY, E; FURNER, S			COMMUNITY-BASED PREVALENCE OF ANAL INCONTINENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FECAL INCONTINENCE	Objective.-To determine the prevalence of and Characteristics associated with anal incontinence in the general community. Setting.-Community survey. Participants.-The population of the state of Wisconsin sampled in the Wisconsin Family Health Survey. Subjects were identified by random digit dialing with telephone interview. The individual within each household identified as most knowledgeable about the health status of all other members of the household was asked about the health status of each member of the household. Approximately 200 households were surveyed each month. Main Outcome Measures.-The presence of anal incontinence to solid or liquid feces or gas, who suffered from it, the frequency of anal incontinence, and how the incontinent person coped with it. Results.-A total of 2570 households comprising 6959 individuals were surveyed, and 153 individuals were reported to have anal incontinence, representing 2.2% of the population (95% confidence interval [Cl], +/-0.3%). Thirty percent of the incontinent subjects were older than 65 years, and 63% were women. Of those with anal incontinence, 36% were incontinent to solid feces, 54% to liquid feces, and 60% to gas, In a multivariate analysis, independent associations of the following risk factors with anal incontinence were found: female sex (odds ratio [OR], 1.5, Cl, 1.1 to 2.1), age (continuously adjusted) (OR, 1.01; Cl, 1.01 to 1.02), physical limitations (OR, 1.8; Cl, 1.2 to 2.7), and poor general health (OR, 1.6, Cl, 1.4 to 1.9). Conclusions.-Anal incontinence was reported in 2.2% of the general population. Independent risk factors for incontinence include female sex, advancing age, poor general health, and physical limitations.	UNIV ILLINOIS,COLL MED,DEPT SURG,COLON & RECTAL SURG SECT,CHICAGO,IL; UNIV ILLINOIS,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,CHICAGO,IL; INT FDN BOWEL DYSFUNCT,MILWAUKEE,WI; STATE WISCONSIN DEPT HLTH & SOCIAL SERV,MADISON,WI	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								CAMPBELL AJ, 1985, AGE AGEING, V14, P65, DOI 10.1093/ageing/14.2.65; DEAN AG, 1991, EPI INFO MANUAL VERS; DENIS P, 1992, GASTROEN CLIN BIOL, V16, P344; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; DROSSMAN DA, 1989, AM J GASTROENTEROL, V84, P355; KOK ALM, 1992, AGE AGEING, V21, P211, DOI 10.1093/ageing/21.3.211; LEIGH RJ, 1982, LANCET, V1, P1349; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADOFF RD, 1992, NEW ENGL J MED, V326, P1002; SCHILLER LR, 1982, NEW ENGL J MED, V307, P1666, DOI 10.1056/NEJM198212303072702; SMALL KA, 1990, AUST NZ J OBSTET GYN, V90, P41; Thomas T M, 1984, Community Med, V6, P216; 1994, 1993 WISCONSIN FAMIL; 1989, VITAL HLTH STAT 14, V33; 1994, PROFILE WISCONSIN NU	15	482	499	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					559	561		10.1001/jama.274.7.559	http://dx.doi.org/10.1001/jama.274.7.559			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629985				2022-12-01	WOS:A1995RN46600027
J	DOPPMAN, JL; CHANG, R; FRAKER, DL; NORTON, JA; ALEXANDER, HR; MILLER, DL; COLLIER, E; SKARULIS, MC; GORDEN, P				DOPPMAN, JL; CHANG, R; FRAKER, DL; NORTON, JA; ALEXANDER, HR; MILLER, DL; COLLIER, E; SKARULIS, MC; GORDEN, P			LOCALIZATION OF INSULINOMAS TO REGIONS OF THE PANCREAS BY INTRAARTERIAL STIMULATION WITH CALCIUM	ANNALS OF INTERNAL MEDICINE			English	Article						INSULINOMA; CALCIUM; HEPATIC VEINS; ANGIOGRAPHY; PANCREAS	SELECTIVE INTRAARTERIAL INJECTION; ZOLLINGER-ELLISON SYNDROME; INTRAOPERATIVE ULTRASONOGRAPHY; INFUSION; GASTRINOMAS; SECRETION; RELEASE	Objective: To determine the sensitivity of calcium injected into pancreatic arteries in localizing insulin-secreting tumors to regions of the pancreas. Design and Patients: To stimulate the release of insulin, 25 patients with surgically proven insulinomas (average diameter, 15 mm) had calcium gluconate (0.025 mEq Ca++/kg body weight) injected before surgery into the arteries supplying the pancreatic head (gastroduodenal and superior mesenteric arteries) and the body and tail (splenic artery) of the pancreas. Setting: Tertiary referral hospital. Measurements: Insulin levels were measured in samples taken from the right and left hepatic veins before and 30, 60, and 120 seconds after calcium injection. A twofold increase in insulin level in the sample taken from the right hepatic vein 30 or 60 seconds after injection localized the insulinoma to the segment of the pancreas supplied by the selectively injected artery. Localization done using calcium stimulation was compared with localization done using transcutaneous ultrasonography (n = 22), computed tomography (n = 23), magnetic resonance imaging (n = 21), arteriography (n = 25), and portal venous sampling (n = 9) Results: Calcium stimulation localized 22 of 25 insulinomas (sensitivity, 88% [95% CI, 68% to 97%]) to the correct region of the pancreas. The sensitivities of the other imaging methods were 9% for ultrasonography (CI, 1% to 23%), 17% for computed tomography (CI, 5% to 39%), 43% for magnetic resonance imaging (CI, 22% to 66%), 36% for arteriography (CI, 18% to 57%), and 67% for portal venous sampling (CI, 30% to 93%). Calcium stimulation added only a few minutes to the time needed for pancreatic arteriography and caused no morbid conditions. Conclusion: Intra-arterial calcium stimulation with right hepatic vein sampling for insulin gradients is the most sensitive preoperative test for localizing insulinomas.	NATL NAVAL MED CTR, BETHESDA, MD 20889 USA; WASHINGTON UNIV, ST LOUIS, MO USA	Walter Reed National Military Medical Center; Washington University (WUSTL)	DOPPMAN, JL (corresponding author), NIH, CTR CLIN,DEPT DIAGNOST RADIOL,BLDG 10,ROOM 1C660, 10 CTR DR, MSC 1182, BETHESDA, MD 20892 USA.							BRUNT LM, 1986, J CLIN ENDOCR METAB, V62, P210, DOI 10.1210/jcem-62-1-210; DEPALO C, 1981, J CLIN ENDOCR METAB, V52, P804, DOI 10.1210/jcem-52-4-804; DOHERTY GM, 1991, SURGERY, V110, P989; DOPPMAN JL, 1990, RADIOLOGY, V174, P25, DOI 10.1148/radiology.174.1.2294556; DOPPMAN JL, 1993, WORLD J SURG, V17, P439, DOI 10.1007/BF01655101; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; GAEKE RF, 1975, METABOLISM, V24, P1029, DOI 10.1016/0026-0495(75)90096-7; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GRANT CS, 1988, ARCH SURG-CHICAGO, V123, P843; HARRISON TS, 1981, MIL MED, V146, P103; IMAMURA M, 1987, ANN SURG, V205, P230, DOI 10.1097/00000658-198703000-00003; KAKITA K, 1981, HORM METAB RES, V13, P237, DOI 10.1055/s-2007-1019231; KAPLAN EL, 1979, ANN SURG, V190, P501, DOI 10.1097/00000658-197910000-00009; KING CMP, 1994, CLIN RADIOL, V49, P295, DOI 10.1016/S0009-9260(05)81790-8; MILLER DL, 1992, RADIOLOGY, V182, P235, DOI 10.1148/radiology.182.1.1727289; MILLER JL, 1981, NEW ENGL J MED, V304, P1430; NORTON JA, 1990, ANN SURG, V212, P615, DOI 10.1097/00000658-199011000-00009; POINTEL JP, 1978, HORM METAB RES, V10, P572, DOI 10.1055/s-0028-1096158; ROY BK, 1979, METABOLISM, V28, P246, DOI 10.1016/0026-0495(79)90071-4; THOM AK, 1992, SURGERY, V112, P1002	20	207	216	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					269	273		10.7326/0003-4819-123-4-199508150-00004	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611592				2022-12-01	WOS:A1995RN66500004
J	FENDRICK, AM; CHERNEW, ME; HIRTH, RA; BLOOM, BS				FENDRICK, AM; CHERNEW, ME; HIRTH, RA; BLOOM, BS			ALTERNATIVE MANAGEMENT STRATEGIES FOR PATIENTS WITH SUSPECTED PEPTIC-ULCER DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						PEPTIC ULCER; COST-BENEFIT ANALYSIS; HELICOBACTER PYLORI; HELICOBACTER INFECTIONS; ENDOSCOPY	HELICOBACTER-PYLORI INFECTION; DOUBLE-BLIND TRIAL; DUODENAL-ULCER; CAMPYLOBACTER-PYLORI; NONULCER DYSPEPSIA; BREATH TEST; GASTRIC-CARCINOMA; TRIPLE THERAPY; FOLLOW-UP; H-2-RECEPTOR ANTAGONISTS	Objective: To estimate the clinical and economic effects of available invasive and noninvasive management strategies for peptic ulcer and Helicobacter pylori in persons with symptoms suggesting peptic ulcer disease. Design: Cost-effectiveness analysis using a decision analytic model. Intervention: 2 immediate endoscopy and 3 noninvasive diagnostic and treatment strategies were evaluated: 1) immediate endoscopy for peptic ulcer and biopsy for H. pylori; 2) immediate endoscopy without biopsy; 3) serologic test for H. pylori; 4) empiric treatment with antisecretory therapy; and 5) empiric treatment with antisecretory therapy and antibiotic agents to eradicate H. pylori. Measurements: Cost per ulcer cured and cost per patient treated. Results: The estimated costs per ulcer cured by strategy were as follows: 1) endoscopy and biopsy for H. pylori, $8045; 2) endoscopy without biopsy, $6984; 3) serologic test for H. pylori, $4541; 4) empiric antisecretory therapy, $4835; and 5) empiric antisecretory and antibiotic therapy, $4155. The predicted costs per patient treated were as follows: 1) endoscopy and biopsy for H. pylori, $1584; 2) endoscopy without biopsy, $1375; 3) serologic test for H. pylori, $894; 4) empiric antisecretory therapy, $952; and 5) empiric antisecretory and antibiotic therapy, $818. The cost-effectiveness advantage of the noninvasive strategies diminished as the cost of endoscopy decreased or as the probability of recurrent symptoms increased in patients initially managed without endoscopy. Conclusion: Endoscopy, although costly, precisely guided diagnosis and treatment and thus potentially reduced the number of patients inappropriately treated. However, the safety and effectiveness of less expensive, less invasive diagnostic and treatment strategies strongly support initial noninvasive care of symptomatic persons thought to have peptic ulcer disease.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	FENDRICK, AM (corresponding author), UNIV MICHIGAN, MED CTR, DIV GEN MED, 3116 TAUBMAN CTR, ANN ARBOR, MI 48109 USA.							ARCHAMBAULT AP, 1988, GASTROENTEROLOGY, V94, P1130, DOI 10.1016/0016-5085(88)90003-0; BAMBERG P, 1992, J GASTROEN HEPATOL, V7, P577, DOI 10.1111/j.1440-1746.1992.tb01489.x; BANK S, 1992, AM J GASTROENTEROL, V87, P1365; BARDHAN KD, 1989, J CLIN GASTROENTEROL, V21, P408; BARNES RJ, 1974, BRIT MED J, V4, P214, DOI 10.1136/bmj.4.5938.214; BAYERDORFFER E, 1993, SCAND J GASTROENTERO, V28, P19, DOI 10.3109/00365529309098337; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; BELL GD, 1987, LANCET, V1, P1367; BELL GD, 1992, ALIMENT PHARM THERAP, V6, P427; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1993, INT J CANCER, V55, P799, DOI 10.1002/ijc.2910550518; BLOOM BS, 1989, J CLIN GASTROENTEROL, V11, P615, DOI 10.1097/00004836-198912000-00003; BLOOM BS, 1990, J CLIN GASTROENTEROL, V12, P100, DOI 10.1097/00004836-199002000-00026; BONNEVIE O, 1985, DIGEST DIS SCI, V30, pS8, DOI 10.1007/BF01309380; BORODY TJ, 1989, MED J AUSTRALIA, V151, P431, DOI 10.5694/j.1326-5377.1989.tb101251.x; BURETTE A, 1993, GASTROENTEROLOGY S, V4, pA49; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CADY B, 1977, AM J SURG, V133, P423, DOI 10.1016/0002-9610(77)90126-X; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; COELHO LGV, 1991, AM J GASTROENTEROL, V86, P971; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1986, LANCET, V1, P1022; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P1359; DOBRILLA G, 1988, GUT, V29, P181, DOI 10.1136/gut.29.2.181; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUPONT JB, 1978, CANCER-AM CANCER SOC, V41, P941, DOI 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M; ELASHOFF JD, 1983, J CLIN GASTROENTEROL, V5, P509, DOI 10.1097/00004836-198312000-00008; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FARUP PG, 1992, ALIMENT PHARM THERAP, V6, P179; FISHER JA, 1977, BRIT MED J, V2, P1199, DOI 10.1136/bmj.2.6096.1199; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; FORMAN D, 1993, LANCET, V341, P1359; GEAR MWL, 1980, BRIT MED J, V280, P1136, DOI 10.1136/bmj.280.6223.1136; GLISE H, 1987, AM J MED, V83, P105, DOI 10.1016/0002-9343(87)90838-2; GLUPCZYNSKI Y, 1988, AM J GASTROENTEROL, V83, P365; GOH KL, 1991, SCAND J GASTROENTERO, V26, P1123, DOI 10.3109/00365529108998603; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P1289; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GRAHAM DY, 1993, GASTROENTEROLOGY, V105, P279, DOI 10.1016/0016-5085(93)90038-E; GRAHAM DY, 1990, DIGEST DIS SCI, V35, P66, DOI 10.1007/BF01537225; GREENBERG RE, 1990, ARCH INTERN MED, V150, P2053, DOI 10.1001/archinte.150.10.2053; HANSSON LE, 1993, GASTROENTEROLOGY, V105, P1098, DOI 10.1016/0016-5085(93)90954-B; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOLCOMBE C, 1992, ALIMENT PHARM THERAP, V6, P119; HORROCKS JC, 1978, GUT, V19, P19, DOI 10.1136/gut.19.1.19; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; JENSEN DM, 1986, AM J MED, V81, P42, DOI 10.1016/0002-9343(86)90599-1; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; KAGEVI I, 1989, SCAND J GASTROENTERO, V24, P145, DOI 10.3109/00365528909093029; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; KLEIN PD, 1993, AM J GASTROENTEROL, V88, P1865; LABENZ J, 1993, AM J GASTROENTEROL, V88, P491; LABENZ J, 1993, GUT, V34, P1167, DOI 10.1136/gut.34.9.1167; LAMBERT JR, 1993, GASTROENTEROL CLIN N, V22, P141; LANE MR, 1988, LANCET, V1, P1147; LINDBERG G, 1987, SCAND J GASTROENTERO, V22, P190, DOI 10.3109/00365528709090990; LOGAN RPH, 1992, LANCET, V340, P239, DOI 10.1016/0140-6736(92)90502-T; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALFERTHEINER P, 1993, SCAND J GASTROENTERO, V28, P34, DOI 10.3109/00365529309098341; MANSI C, 1990, DIGEST DIS SCI, V35, P1452, DOI 10.1007/BF01540561; MANSI C, 1993, J CLIN GASTROENTEROL, V16, P149, DOI 10.1097/00004836-199303000-00015; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1991, AM J GASTROENTEROL, V86, P438; MARSHALL RJ, 1985, MED J AUSTRALIA, V82, P192; MCNULTY CAM, 1989, GUT, V30, P1058, DOI 10.1136/gut.30.8.1058; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MOLLMANN KM, 1975, SCAND J GASTROENTERO, V10, P805; MORRISSEY JF, 1988, ANN INTERN MED, V109, P605, DOI 10.7326/0003-4819-109-8-605; MORRISSEY JF, 1976, GASTROINTEST ENDOSC, V23, P13, DOI 10.1016/S0016-5107(76)73567-3; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; OLEARCHYK AS, 1978, AM J GASTROENTEROL, V70, P25; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PATCHETT S, 1991, BMJ-BRIT MED J, V303, P1238, DOI 10.1136/bmj.303.6812.1238; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; RAUWS EAJ, 1989, GUT, V30, P798, DOI 10.1136/gut.30.6.798; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIPPONEN P, 1991, SCAND J GASTROENTERO, V26, P6, DOI 10.3109/00365529109103980; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; TALLEY NJ, 1993, GASTROENTEROL CLIN N, V22, P153; TALLEY NJ, 1992, J CLIN MICROBIOL, V30, P3146, DOI 10.1128/JCM.30.12.3146-3150.1992; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	96	183	183	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					260	268		10.7326/0003-4819-123-4-199508150-00003	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611591				2022-12-01	WOS:A1995RN66500003
J	MORRIS, JG; SHAY, DK; HEBDEN, JN; MCCARTER, RJ; PERDUE, BE; JARVIS, W; JOHNSON, JA; DOWLING, TC; POLISH, LB; SCHWALBE, RS				MORRIS, JG; SHAY, DK; HEBDEN, JN; MCCARTER, RJ; PERDUE, BE; JARVIS, W; JOHNSON, JA; DOWLING, TC; POLISH, LB; SCHWALBE, RS			ENTEROCOCCI RESISTANT TO MULTIPLE ANTIMICROBIAL AGENTS, INCLUDING VANCOMYCIN - ESTABLISHMENT OF ENDEMICITY IN A UNIVERSITY MEDICAL-CENTER	ANNALS OF INTERNAL MEDICINE			English	Article						VANCOMYCIN; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; DRUG RESISTANCE, MICROBIAL; ORGAN TRANSPLANTATION	HIGH-LEVEL RESISTANCE; ANTIBIOTIC SYNERGISM; FAECIUM; INFECTIONS; GENTAMICIN; TRENDS	Objectives: To determine the distribution of and risk factors for colonization and infection with vancomycin-resistant enterococci; to evaluate the molecular epidemiology of these strains; and to assess the effect of interventions, including 1) strict adherence to infection control procedures and 2) restricted use of vancomycin. Design: Problem identification based on descriptive studies, point-prevalence surveys, and case-control studies and followed by specific interventions and evaluation of the response to these interventions. Setting: University medical center. Participants: All patients hospitalized between May 1992 and June 1994 (59 196 admissions). Main Results: 75 active infections attributed to vancomycin-resistant enterococci were identified. Thirty-one patients (41%) had bloodstream infections and 6 (8%) died. The incidence of active infection was highest in the organ transplantation unit (13.2 infections/1000 admissions). In the point-prevalence studies, vancomycin-resistant enterococci were isolated from 20% of a random sample of hospitalized patients in July, August, and September 1993 (adjusted prevalence, 16.9%). Case-control studies showed significant associations between colonization and infection and 1) receipt of antimicrobial agents, particularly vancomycin, and 2) severity of illness. Although several small case clusters had isolates with identical banding patterns on pulsed-field gel electrophoresis, at least 45 different banding patterns were noted among medical center isolates. Interventions took place in November and December 1993. Vancomycin restriction policies resulted in a 59% decrease in intravenous vancomycin use and an 85% decrease in oral vancomycin use. Point-prevalence surveys done in April, May, and June 1994 showed a consistent 20% level of colonization with vancomycin-resistant enterococci strains (adjusted prevalence, 18.7%). No significant changes were seen in rates of vancomycin-resistant enterococci infection. Conclusions: Vancomycin-resistant enterococci are an important cause of illness and death in the study institution, particularly among organ transplant recipients and other seriously ill persons; they have also become a common intestinal colonizer among hospitalized patients. The diversity of isolates (based on molecular typing studies) suggests that resistant organisms have been introduced from multiple sources. Interventions that effectively lower the overall level of colonization with vancomycin-resistant enterococci must still be identified.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; UNIV MARYLAND, MED CTR, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	MORRIS, JG (corresponding author), VET AFFAIRS MED CTR, INFECT DIS SECT, 10 N GREENE ST, BALTIMORE, MD 21201 USA.		Dowling, Thomas/D-2147-2013	Dowling, Thomas/0000-0003-3214-9283; Shay, David/0000-0001-9619-4820				[Anonymous], 1993, METHODS DILUTION ANT; [Anonymous], 1993, PERFORMANCE STANDARD; ARDUINO RC, 1994, PRINCIPLES PRACTICE; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BATES J, 1993, LANCET, V342, P490, DOI 10.1016/0140-6736(93)91613-Q; BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; CHADWICK PR, 1994, LANCET, V344, P685, DOI 10.1016/S0140-6736(94)92119-9; DEAN AG, 1991, EPIINFO VERSION 5 WO; DEAN J, 1994, 94TH GEN M AM SOC MI; DONABEDIAN SM, 1992, J CLIN MICROBIOL, V30, P2757, DOI 10.1128/JCM.30.11.2757-2761.1992; FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731, DOI 10.1128/JCM.27.4.731-734.1989; FRIEDEN TR, 1993, LANCET, V342, P76, DOI 10.1016/0140-6736(93)91285-T; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOERING RV, 1994, 3RD INT M BACT EP MA; GREEN M, 1993, 33RD INT C ANT AG CH; HARIHARAN R, 1993, 33RD INT C ANT AG CH; HERDEN J, 1994, 34TH INT C ANT AG CH; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; JONES R, 1993, 33RD INT C ANT AG CH; JORDENS JZ, 1994, J ANTIMICROB CHEMOTH, V34, P515, DOI 10.1093/jac/34.4.515; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LINDEN P, 1993, 33RD INT C ANT AG CH; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; MOELLERI.RC, 1971, J CLIN INVEST, V50, P2580, DOI 10.1172/JCI106758; MOELLERING RC, 1971, J INFECT DIS, V124, pS207, DOI 10.1093/infdis/124.Supplement_1.S207; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; PRATTRIPIN K, 1992, CLIN MICROBIOLOGY PR; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHWALBE RE, 1991, 91ST ANN M AM SOC MI; SMITH SM, 1994, 34TH INT C ANT AG CH; SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563; STANDIFORD HD, 1970, ARCH INTERN MED, V126, P255, DOI 10.1001/archinte.126.2.255; STROUD L, 1993, SOC HOSPITAL EPIDEMI; UTTLEY AHC, 1988, LANCET, V1, P57; VENUTI E, 1994, 94TH GEN M AM SOC MI; VERMA P, 1994, 94TH GEN M AM SOC MI; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1995, INFECT CONT HOSP EP, V16, P105; 1993, MMWR-MORBID MORTAL W, V42, P5947; 1992, STANDARD METHODS EXA, P69	45	395	404	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					250	259		10.7326/0003-4819-123-4-199508150-00002	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611590				2022-12-01	WOS:A1995RN66500002
J	CLAUSEN, JO; HANSEN, T; BJORBAEK, C; ECHWALD, SM; URHAMMER, SA; RASMUSSEN, S; ANDERSEN, CB; HANSEN, L; ALMIND, K; WINTHER, K; HARALDSDOTTIR, J; BORCHJOHNSEN, K; PEDERSEN, O				CLAUSEN, JO; HANSEN, T; BJORBAEK, C; ECHWALD, SM; URHAMMER, SA; RASMUSSEN, S; ANDERSEN, CB; HANSEN, L; ALMIND, K; WINTHER, K; HARALDSDOTTIR, J; BORCHJOHNSEN, K; PEDERSEN, O			INSULIN-RESISTANCE - INTERACTIONS BETWEEN OBESITY AND A COMMON VARIANT OF INSULIN-RECEPTOR SUBSTRATE-1	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; SENSITIVITY; GLUCOSE; POLYMORPHISMS; PLASMA	We previously discovered two aminoacid polymorphisms in codons 513 and 972 of the protein insulin receptor substrate-1 (IRS-1), which is important in cellular insulin action. We have investigated whether these polymorphisms are associated with changes in insulin sensitivity in a random sample of young healthy adults. Insulin sensitivity and secretion were measured during a combined intravenous glucose and tolbutamide tolerance test in 380 unrelated white subjects aged 18-32. IRS-1 polymorphisms were examined conformation polymorphism and enzyme digestion. No homozygous carrier of the codon-513 variant was identified, but one non-obese man had the codon-972 mutation on both alleles. He had low fasting-serum insulin and C-peptide concentrations and low insulin sensitivity and glucose effectiveness. During a 24 h dexamethasone test, he developed transient diabetes. In their heterozygous forms the codon-513 and codon-972 variants of IRS-1 were found in 3% and 9% of the subjects. Non-obese carriers of either polymorphism had similar insulin sensitivity and pancreatic beta-cell function to non-obese wild-type subjects (no known variants of IRS-1). Analysis of variance showed, however, a significant interaction between obesity (body-mass index greater than or equal to 25 kg/m(2)) and the heterozygous form of the codon-972 variant (p<0.003); obese polymorphism carriers had lower insulin sensitivity than obese non-carriers (mean 6.0 [SD 3.3] vs 12.3 [9.5] x 10(-5) L min(-1) pmol(-1)). The obese carriers of the codon-972 variant were also characterised by a clustering of metabolic cardiovascular risk factors, with raised fasting concentrations of plasma glucose, serum triglyceride, and plasma tissue-plasminogen-activator and its fast-acting inhibitor. With adjustment for known modulators of insulin sensitivity, multivariate analyses showed that the combination of obesity and the codon-972 variant was associated with a 50% reduction in insulin sensitivity (p=0.0008). Our results suggest that the codon-972 IRS-1 gene variant may interact with obesity in the pathogenesis of common insulin-resistant disorders.	STENO DIABET CTR, DK-2820 GENTOFTE, DENMARK; HAGEDORN RES INST, COPENHAGEN, DENMARK; GLOSTRUP POPULAT STUDIES, MED DEPT C, COPENHAGEN, DENMARK; UNIV COPENHAGEN, GLOSTRUP HOSP, DEPT CLIN CHEM, COPENHAGEN, DENMARK; ROYAL VET & AGR UNIV, RES DEPT HUMAN NUTR, COPENHAGEN, DENMARK	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute; University of Copenhagen; University of Copenhagen			Bjorbaek, Christian/S-4727-2019; Pedersen, Oluf/AAG-8015-2020					ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; ANDERSEN L, 1993, CLIN CHEM, V39, P578; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; BEARD JC, 1986, DIABETES, V35, P362, DOI 10.2337/diabetes.35.3.362; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; ECHWALD SM, 1995, DIABETES, V44, P347, DOI 10.2337/diabetes.44.3.347; HAGER J, 1993, LANCET, V342, P1430, DOI 10.1016/0140-6736(93)92793-S; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HITMAN GA, 1995, DIABETOLOGIA, V38, P481, DOI 10.1007/BF00410287; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; IBSEN KK, 1981, ACTA PAEDIATR SCAND, V70, P27, DOI 10.1111/j.1651-2227.1981.tb07168.x; IMAI Y, 1994, J CLIN ENDOCR METAB, V79, P1655, DOI 10.1210/jc.79.6.1655; LAAKSO M, 1994, J CLIN INVEST, V94, P1141, DOI 10.1172/JCI117429; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUNDBAEK K, 1962, BRIT MED J, P1507, DOI 10.1136/bmj.1.5291.1507; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; PACINI G, 1986, COMPUT METH PROG BIO, V23, P113, DOI 10.1016/0169-2607(86)90106-9; RANBY M, 1986, CLIN CHEM, V32, P2160; SHIMOKAWA K, 1994, BIOCHEM BIOPH RES CO, V202, P463, DOI 10.1006/bbrc.1994.1951; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; WHITE MF, 1994, J BIOL CHEM, V269, P1	30	197	206	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					397	402		10.1016/S0140-6736(95)92779-4	http://dx.doi.org/10.1016/S0140-6736(95)92779-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623569				2022-12-01	WOS:A1995RN65600008
J	DWYER, JH				DWYER, JH			GENES, BLOOD-PRESSURE, AND AFRICAN HERITAGE	LANCET			English	Editorial Material							URBAN				DWYER, JH (corresponding author), UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033, USA.							COOPER R, 1994, J HYPERTENS, V12, P215; GILES WH, 1994, AM J MED SCI, V308, P271, DOI 10.1097/00000441-199411000-00003; MBUYAMBAKABANGU JR, 1986, AM J EPIDEMIOL, V124, P957, DOI 10.1093/oxfordjournals.aje.a114485; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; SEEDAT YK, 1982, J EPIDEMIOL COMMUN H, V36, P256, DOI 10.1136/jech.36.4.256; ZARATE AO, 1994, INT MORTALITY CHARTB	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					392	392		10.1016/S0140-6736(95)92777-8	http://dx.doi.org/10.1016/S0140-6736(95)92777-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623567				2022-12-01	WOS:A1995RN65600006
J	ELLIS, LM; FIDLER, IJ				ELLIS, LM; FIDLER, IJ			ANGIOGENESIS AND BREAST-CANCER METASTASIS	LANCET			English	Editorial Material							INDEPENDENT PROGNOSTIC INDICATOR; TUMOR ANGIOGENESIS; CARCINOMA		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	ELLIS, LM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG,HOUSTON,TX 77030, USA.							BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1994, J CLIN ONCOL, V12, P454, DOI 10.1200/JCO.1994.12.3.454; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; Hall N R, 1992, Surg Oncol, V1, P223, DOI 10.1016/0960-7404(92)90068-V; HARRIS JR, 1991, BREAST DISEASES, P327; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; KITADAI Y, IN PRESS CLIN CANCER; OBERMAIR A, 1994, CHIRURG, V65, P611; Paget S., 1889, LANCET, V133, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Singh R. K., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P87; TOI M, 1993, INT J CANCER, V55, P371, DOI 10.1002/ijc.2910550305; VANHOEF MEHM, 1993, EUR J CANCER, V29A, P1141; VISSCHER DW, 1993, ANAL QUANT CYTOL, V15, P88; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	18	58	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					388	390		10.1016/S0140-6736(95)92774-3	http://dx.doi.org/10.1016/S0140-6736(95)92774-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7542721	Bronze			2022-12-01	WOS:A1995RN65600003
J	GRAY, DWR				GRAY, DWR			MYCOPHENOLATE MOFETIL FOR TRANSPLANTATION - NEW DRUG, OLD PROBLEMS	LANCET			English	Editorial Material											GRAY, DWR (corresponding author), OXFORD RADCLIFFE HOSP,OXFORD TRANSPLANT CTR,NUFFIELD DEPT SURG,OXFORD,ENGLAND.							AZUMA H, 1995, TRANSPLANTATION, V59, P460; 1995, LANCET, V345, P1321	2	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					390	390		10.1016/S0140-6736(95)92775-1	http://dx.doi.org/10.1016/S0140-6736(95)92775-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623565				2022-12-01	WOS:A1995RN65600004
J	GRUBB, NR; ELTON, RA; FOX, KAA				GRUBB, NR; ELTON, RA; FOX, KAA			IN-HOSPITAL MORTALITY AFTER OUT-OF-HOSPITAL CARDIAC-ARREST	LANCET			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY RESUSCITATION; HEALTH-PROFESSIONALS; UTSTEIN STYLE; SURVIVAL; DEFIBRILLATION; EMERGENCY; EXPERIENCE; STATEMENT; SCOTLAND	In-hospital management of out-of-hospital cardiac arrest is complicated by uncertainty about prognosis and the need to identify markers of adverse outcome in individuals surviving initial resuscitation. We sought to identify factors that predict in-hospital death among patients who initially survive out-of-hospital cardiac arrest. We investigated 346 consecutive cases of out-of-hospital cardiac arrest received by a single centre in Edinburgh, UK (270 cases examined retrospectively, 76 prospectively). Of the retrospective cohort, 246 cases were thought to be of cardiac origin. There were associations between in-hospital mortality and pre-arrest variables, resuscitation variables, and factors measured during admission. Crew-witnessed arrests were associated with low mortality; arrest rhythm (p<0.001), resuscitation by a health professional (p<0.05), conscious level on admission (p<0.001), and requirement for ventilaton (p<0.05) independently predicted in-hospital mortality. A weighted prognostic scoring system based on three of these variables accurately predicted the likelihood of in-hospital death in the prospective test group. Further assessment of conscious level during admission with the Glasgow coma score predicted mortality rates in the study population, but coma did not predict a hopeless prognosis in individual cases unless it persisted for 72 h or more. Accurate prognostic assessment of out-of-hospital cardiac arrest survivors can be made from information available on admission. Of factors that independently predicted outcome, the skill of the resuscitator is most readily modified. This suggests that public training in resuscitation may reduce mortality rates.	UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,MED STAT UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	GRUBB, NR (corresponding author), UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Fox, keith A A/I-3742-2013	Fox, Keith/0000-0002-0140-2752				AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; BOSSAERT L, 1989, RESUSCITATION, V17, pS57; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1992, CIRCULATION, V85, P98; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUSACK S, 1992, ARCH EMERG MED, V9, P203; DICKEY W, 1992, BRIT HEART J, V67, P334; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; JENNETT B, 1975, LANCET, V1, P480; JUCHEMS R, 1993, RESUSCITATION, V26, P23, DOI 10.1016/0300-9572(93)90159-N; ROWLEY JM, 1990, BRIT HEART J, V64, P309; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; TORPPEDERSEN C, 1991, RESUSCITATION, V21, P283, DOI 10.1016/0300-9572(91)90053-2; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; ZIPES DP, 1992, CIRCULATION, V85, P160	22	94	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					417	421		10.1016/S0140-6736(95)92784-0	http://dx.doi.org/10.1016/S0140-6736(95)92784-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623574				2022-12-01	WOS:A1995RN65600013
J	HAY, J				HAY, J			COMPLICATIONS AT SITE OF INJECTION OF DEPOT NEUROLEPTICS	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT PSYCHIAT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BELANGERANNABLE MC, 1985, CANADIAN NURSE, V81, P1; FOSTER P, 1989, PHARM J, V243, P431; HAMANN GL, 1990, J CLIN PSYCHIAT, V51, P502; SVENDSEN O, 1989, STUDIES TISSUE INJUR; WRIGHT NF, 1990, PSYCHIATRIC B, V14, P594	5	38	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					421	421		10.1136/bmj.311.7002.421	http://dx.doi.org/10.1136/bmj.311.7002.421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640587	Green Published			2022-12-01	WOS:A1995RP55400014
J	LAU, JYN; SIMMONDS, P; URDEA, MS				LAU, JYN; SIMMONDS, P; URDEA, MS			IMPLICATIONS OF VARIATIONS OF CONSERVED REGIONS OF HEPATITIS-C VIRUS GENOME	LANCET			English	Editorial Material									UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CHIRON CORP,EMERYVILLE,CA	University of Edinburgh; Novartis	LAU, JYN (corresponding author), UNIV FLORIDA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,HEPATOBILIARY DIS SECT,GAINESVILLE,FL 32610, USA.			Simmonds, Peter/0000-0002-7964-4700				BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1016/0270-9139(94)90224-0; HAYASHI J, 1995, J INFECTION, V30, P235, DOI 10.1016/S0163-4453(95)90785-8; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LAU JYN, IN PRESS ANN INTERN; ORITO E, 1994, J MED VIROL, V44, P410, DOI 10.1002/jmv.1890440418; POZZATO G, 1995, J MED VIROL, V45, P445, DOI 10.1002/jmv.1890450416; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; TKOHARA K, 1992, J VIROL, V66, P1476; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; YAMADA G, IN PRESS HEPATOLOGY	14	96	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					425	426		10.1016/S0140-6736(95)92786-7	http://dx.doi.org/10.1016/S0140-6736(95)92786-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623576				2022-12-01	WOS:A1995RN65600015
J	LONDON, NJ; FARMERY, SM; WILL, EJ; DAVISON, AM; LODGE, JPA				LONDON, NJ; FARMERY, SM; WILL, EJ; DAVISON, AM; LODGE, JPA			RISK OF NEOPLASIA IN RENAL-TRANSPLANT PATIENTS	LANCET			English	Article							MALIGNANT-TUMORS; RECIPIENTS; CANCER; CYCLOSPORINE; FAILURE	Renal allograft recipients are at an increased risk of neoplasia, although the extent of the problem has not been established in a typical European transplant population. To assess this risk we did a comprehensive, retrospective study of 918 patients transplanted at one centre over 24 years. The centre (Leeds) serves Yorkshire and Humberside, a region in northern England with a population of 3.6 million. The search, which made use of six sources of information, revealed 70 patients (7.6%) who had developed a neoplastic lesion, 10 patients having more than one type. More than half (42) were cutaneous lesions (mostly squamous cell carcinomas). The risk of developing neoplasia in the first 10 years after transplantation was calculated to be 14%. By 20 years this had risen to 40% compared with a 6% cumulative risk of neoplasia in an age-matched control population (p<0.005). The full extent of this problem in the European transplant population has been underestimated and, now that recipients are surviving longer, there is a clear need for both lifelong surveillance and closer investigation of these patients.	ST JAMES UNIV HOSP, ACAD SURG UNIT, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, DEPT RENAL MED, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	Saint James's University Hospital; Saint James's University Hospital								ARMITAGE P, 1971, STATISTICAL METHODS, P414; BIRKELAND SA, 1983, CANCER, V51, P1571, DOI 10.1002/1097-0142(19830501)51:9<1571::AID-CNCR2820510903>3.0.CO;2-S; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; BROYER M, 1985, P EUR DIAL TRANS, V21, P2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIDDINGTON M, 1989, BRIT J SURG, V76, P1002, DOI 10.1002/bjs.1800761005; LONDON NJ, 1994, THESIS U CAMBRIDGE C; MATAS AJ, 1975, LANCET, V1, P883; PECQUEUX JC, 1990, UROL INT, V45, P290, DOI 10.1159/000281722; PENN I, 1991, TRANSPLANT P, V23, P1101; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PENN I, 1994, TRANSPLANT P, V26, P1; PENN I, 1969, TRANSPLANT P, V1, P106; SHEIL AGR, 1977, TRANSPLANT P, V9, P1133; SHEIL AGR, 1993, TRANSPLANT P, V25, P1383; VILARDELL J, 1992, TRANSPLANT P, V24, P1948; WALZ MK, 1992, DTS MED WSCHR, V119, P927	17	297	307	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					403	406		10.1016/S0140-6736(95)92780-8	http://dx.doi.org/10.1016/S0140-6736(95)92780-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623570				2022-12-01	WOS:A1995RN65600009
J	PRENTICE, AM; JEBB, SA				PRENTICE, AM; JEBB, SA			OBESITY IN BRITAIN - GLUTTONY OR SLOTH	BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT; ENERGY-INTAKE; WEIGHT; HUMANS	The prevalence of clinical obesity in Britain has doubled in the past decade. The Health of the Nation initiative has set ambitious targets for reversing the trend in recognition of the serious health burden which will accrue, but efforts to develop prevention and treatment strategies are handicapped by uncertainty as to the aetiology of the problem. It is generally assumed that ready access to highly palatable foods induces excess consumption and that obesity is caused by simple gluttony. There is evidence that a high fat diet does override normal satiety mechanisms, However, average recorded energy intake in Britain has declined substantially as obesity rates have escalated. The implication is that levels of physical activity, and hence energy needs, have declined even faster. Evidence suggests that modern inactive lifestyles are at least as important as diet in the aetiology of obesity and possibly represent the dominant factor.			PRENTICE, AM (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 2DH,ENGLAND.		Prentice, Andrew/AAG-1961-2019	Jebb, Susan/0000-0001-9190-2920				Bennett N, 1995, HLTH SURVEY ENGLAND; Blundell John E., 1993, American Journal of Clinical Nutrition, V57, p772S, DOI 10.1093/ajcn/57.5.772S; BOLTONSMITH C, 1994, INT J OBESITY, V18, P820; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; DIETZ WH, 1985, PEDIATRICS, V75, P807; FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; GIBNEY M J, 1990, Journal of Human Nutrition and Dietetics, V3, P245, DOI 10.1111/j.1365-277X.1990.tb00064.x; Gregory F., 1990, DIETARY NUTR SURVEY; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HILL JO, IN PRESS AM J CLIN N; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LISSNER L, 1987, AM J CLIN NUTR, V46, P886, DOI 10.1093/ajcn/46.6.886; PRENTICE A M, 1989, Journal of Human Nutrition and Dietetics, V2, P95, DOI 10.1111/j.1365-277X.1989.tb00014.x; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROLLS BJ, 1994, AM J CLIN NUTR, V60, P476, DOI 10.1093/ajcn/60.4.476; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; Stubbs R. J., 1993, Proceedings of the Nutrition Society, V52, p35A; White A, 1993, HLTH SURVEY ENGLAND; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]; 1992, REPORT ACTIVITY PATT; 1994, SOCIAL TRENDS, V24; 1940, HOUSEHOLD FOOD CONSU; 1992, HOUSEHOLD FOOD CONSU	29	818	832	2	88	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					437	439		10.1136/bmj.311.7002.437	http://dx.doi.org/10.1136/bmj.311.7002.437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640595	Green Published			2022-12-01	WOS:A1995RP55400023
J	SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM				SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM			RISKS OF OROFACIAL CLEFTS IN CHILDREN BORN TO WOMEN USING MULTIVITAMINS CONTAINING FOLIC-ACID PERICONCEPTIONALLY	LANCET			English	Article							NEURAL-TUBE DEFECTS; VITAMIN SUPPLEMENTATION; PREVENT RECURRENCE; WESTERN-AUSTRALIA; DIETARY-FOLATE; ORAL CLEFTS; PREGNANCY; LIP; SMOKING; PALATE	Women are advised to take folic acid before they conceive as a precaution against neural-tube defects. However, the use of folic acid in preventing orofacial clefts is unknown. We investigated whether a woman's periconceptional use of multivitamins containing folic acid was associated with a reduced risk of orofacial clefts. We derived data from a population-based case-control study of fetuses and liveborn infants with orofacial anomalies among a 1987-89 cohort of births in California. We interviewed 731 (84.7%) of eligible mothers with orofacial cleft case infants and 734 (78.2%) mothers with non-malformed control infants. We found a reduced risk of orofacial clefts if the mother had used multivitamins containing folic acid during the period from one month before through two months after conception. The odds ratios ranged from 0.50-0.73 depending on cleft phenotype. Controlling for the potential influence of other variables did not substantially alter the results. Maternal daily consumption of cereal containing folic acid was also associated with a reduced risk of orofacial clefts. Women who used multivitamins containing folic acid periconceptionally had a 25-50% reduction in risk for offspring with orofacial clefts compared to women who did not use such vitamins. However, this association may not be attributable to folic acid specifically, but may be a consequence of other multivitamin supplement components, or behaviours, that are highly correlated with the use of multivitamins containing folic acid.	CHILDRENS HOSP,DEPT MED GENET,OAKLAND,CA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	SHAW, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA, USA.			Shaw, Gary/0000-0001-7438-4914				BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BOWER C, 1992, AM J MED GENET, V44, P647, DOI 10.1002/ajmg.1320440524; Briggs R M, 1976, Clin Plast Surg, V3, P647; CONWAY H, 1958, Plast Reconstr Surg Transplant Bull, V22, P450, DOI 10.1097/00006534-195811000-00003; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DANSKY LV, 1987, ANN NEUROL, V21, P176, DOI 10.1002/ana.410210210; DOUGLAS B, 1958, Plast Reconstr Surg Transplant Bull, V22, P94, DOI 10.1097/00006534-195808000-00002; HILL L, 1988, J EPIDEMIOL COMMUN H, V42, P1, DOI 10.1136/jech.42.1.1; JORDAN RL, 1977, TERATOLOGY, V15, P73, DOI 10.1002/tera.1420150110; KHOURY MJ, 1989, AM J DIS CHILD, V143, P333, DOI 10.1001/archpedi.1989.02150150091023; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; NELSON MM, 1960, CIBA F S CONGENITAL, P134; PEER LA, 1964, PLAST RECONSTR SURG, V34, P358; PEER LA, 1958, PLAST RECONSTR SURG, V22, P422; SAXEN I, 1975, INT J EPIDEMIOL, V4, P37, DOI 10.1093/ije/4.1.37; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1983, LANCET, V1, P1027; TOLAROVA M, 1982, LANCET, V2, P217; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; WAITZMAN NJ, 1994, INQUIRY-J HEALTH CAR, V31, P188; WEGNER C, 1992, NEUROLOGY, V42, P17; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WITTER FR, 1982, AM J OBSTET GYNECOL, V144, P857, DOI 10.1016/0002-9378(82)90369-6; 1991, STATISTICS EPIIDEMIO; 1991, LANCET, V338, P131; 1989, HLTH HABITS HIST QUE	30	373	387	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					393	396		10.1016/S0140-6736(95)92778-6	http://dx.doi.org/10.1016/S0140-6736(95)92778-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623568				2022-12-01	WOS:A1995RN65600007
J	WANNAMETHEE, G; SHAPER, AG; WHINCUP, PH; WALKER, M				WANNAMETHEE, G; SHAPER, AG; WHINCUP, PH; WALKER, M			LOW SERUM TOTAL CHOLESTEROL CONCENTRATIONS AND MORTALITY IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; CANCER MORTALITY; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; BLOOD-LIPIDS; BODY-WEIGHT; EPIDEMIOLOGY; POPULATION	Objective-To examine the relation between low serum total cholesterol concentrations and causes of mortality. Design-Cohort study of men followed up for an average of 14.8 years (range 13.5-16.0 years). Setting-One general practice in each of 24 British towns. Subjects-7735 men aged 40-59 at screening selected at random from the 24 general practices. Main outcome measures-Deaths from all causes, cardiovascular causes, cancer, and non-cardiovascular, non-cancer causes. Results-During the mean follow up period of 14.8 years there were 1257 deaths from all causes, 640 cardiovascular deaths, 433 cancer deaths, and 184 deaths from other causes. Low serum cholesterol concentrations (<4.8 mmol/l), present in 5% (n=410) of the men, were associated with the highest mortality from all causes, largely due to a significant increase in cancer deaths (age adjusted relative risk 1.6 (95% confidence interval 1.1 to 2.3); <4.8 v 4.8-5.9 mmol/l) and in other non-cardiovascular deaths (age adjusted relative risk 1.9 (1.1 to 3.1)). Low serum cholesterol concentration was associated with an increased prevalence of several diseases and indicators of ill health and with lifestyle characteristics such as smoking and heavy drinking. After adjustment for these factors in the multivariate analysis the increased risk for cancer was attenuated (relative risk 1.4 (0.9 to 2.0)) and the inverse association with other non-cardiovascular, non-cancer causes was no longer significant (relative risk 1.5 (0.9 to 2.6); <4.8 v 4.8-5.9 mmol/l). The excess risks of cancer and of other non-cardiovascular deaths were most pronounced in the first five years and became attenuated and non-significant with longer follow up. By contrast, the positive association between serum total cholesterol concentration and cardiovascular mortality was seen even after more than 10 years of follow up. Conclusion-The association between comparatively low serum total cholesterol concentrations and excess mortality seemed to be due to preclinical cancer and other non-cardiovascular diseases. This suggests that public health programmes encouraging lower average concentrations of serum total cholesterol are unlikely to be associated with increased cancer or other non-cardiovascular mortality.			WANNAMETHEE, G (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Whincup, Peter/0000-0002-5589-4107; Wannamethee, Sasiwarang/0000-0001-9484-9977				ALVAREZ C, 1986, CLIN CHEM, V32, P142; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; COX DR, 1972, J R STAT SOC B, V34, P187; DAVEYSMITH G, 1992, JAMA-J AM MED ASSOC, V267, P70; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; HARRIS T, 1994, J CLIN EPIDEMIOL, V45, P595; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HULLEY SB, 1992, CIRCULATION, V87, P1026; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; JACOBS D, 1993, CIRCULATION, V86, P1046; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1993, EUR HEART J, V14, P581, DOI 10.1093/eurheartj/14.5.581; PHILLIPS A, 1989, LANCET, V2, P1434; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SCHATZKIN A, 1987, LANCET, V2, P298; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WANNAMETHEE G, 1992, J EPIDEMIOL COMMUN H, V46, P197, DOI 10.1136/jech.46.3.197; WANNAMETHEE G, 1993, AM J EPIDEMIOL, V137, P735, DOI 10.1093/oxfordjournals.aje.a116734; 1982, JAMA-J AM MED ASSOC, V248, P2853	34	51	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					409	413		10.1136/bmj.311.7002.409	http://dx.doi.org/10.1136/bmj.311.7002.409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640584	Green Published			2022-12-01	WOS:A1995RP55400011
J	ARCHER, JE; VEGA, LR; SOLOMON, F				ARCHER, JE; VEGA, LR; SOLOMON, F			RBL2P, A YEAST PROTEIN THAT BINDS TO BETA-TUBULIN AND PARTICIPATES IN MICROTUBULE FUNCTION IN-VIVO	CELL			English	Article							CONDITIONAL-LETHAL MUTATIONS; SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; ALPHA-TUBULIN; GAMMA-TUBULIN; ASPERGILLUS-NIDULANS; GENETIC-ANALYSIS; MESSENGER-RNAS; ACTIN; INHIBITION	Genetic configurations resulting in high ratios of beta-tubulin to alpha-tubulin are toxic in S. cerevisiae, causing microtubule disassembly and cell death, We identified three non-tubulin yeast genes that, when overexpressed, rescue cells from excess beta-tubulin, One, RBL2, rescues beta-tubulin lethality as efficiently as does alpha-tubulin. Rbl2p binds to beta-tubulin in vivo, Deficiencies or excesses of either Rbl2p or alpha-tubulin affect microtubule-dependent functions in a parallel fashion, Rbl2p has functional homology with murine cofactor A, a protein important for in vitro assays of beta-tubulin folding. The results suggest that Rbl2p participates in microtubule morphogenesis but not in the assembled polymer.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	ARCHER, JE (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Vega, Leticia/G-1984-2017; Vega, Leticia/AAF-4981-2021	Vega, Leticia/0000-0001-7605-1048				ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1989, GENETICS, V121, P675; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; FLOOR E, 1970, Journal of Molecular Biology, V47, P293, DOI 10.1016/0022-2836(70)90303-7; FULLER MT, 1987, J CELL BIOL, V104, P385, DOI 10.1083/jcb.104.3.385; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KATZ W, 1990, MOL CELL BIOL, V10, P2730; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LIU HP, 1992, GENETICS, V132, P665; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PASQUALONE D, 1994, J CELL BIOL, V127, P1973, DOI 10.1083/jcb.127.6.1973; ROUT MP, 1991, COLD SPRING HARB SYM, V56, P687; SCHATZ PJ, 1988, GENETICS, V120, P681; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SHERMAN F, 1986, LABORATOORY COURSE M; SKOUFIAS DA, 1992, BIOCHEMISTRY-US, V31, P738, DOI 10.1021/bi00118a015; SOLOMON F, 1992, METHODS STUDYING YEA; STERNBERG N, 1976, VIROLOGY, V71, P568, DOI 10.1016/0042-6822(76)90382-2; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WEINSTEIN B, 1992, MOL MICROBIOL, V6, P677, DOI 10.1111/j.1365-2958.1992.tb01515.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	38	76	79	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					425	434		10.1016/0092-8674(95)90431-X	http://dx.doi.org/10.1016/0092-8674(95)90431-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634332	Bronze			2022-12-01	WOS:A1995RP24200012
J	BOGERD, HP; FRIDELL, RA; MADORE, S; CULLEN, BR				BOGERD, HP; FRIDELL, RA; MADORE, S; CULLEN, BR			IDENTIFICATION OF A NOVEL CELLULAR COFACTOR FOR THE REV/REX CLASS OF RETROVIRAL REGULATORY PROTEINS	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; GENE-EXPRESSION REQUIRES; VIRAL MESSENGER-RNA; I REX; BINDING-SITE; NUCLEOLAR LOCALIZATION; TARGET SEQUENCE; DOMAIN; MUTANTS	HIV-1 Rev is the prototype of a class of retroviral regulatory proteins that induce the sequence-specific nuclear export of target RNAs. This function requires the Rev activation domain, which is believed to bind an essential cellular cofactor. We report the identification of a novel human gene product that binds to not only the HIV-1 Rev activation domain in vitro and in vivo but also to functionally equivalent domains in other Rev and Rex proteins. The Rev/Rex activation domain-binding (Rab) protein occupies a binding site on HIV-I Rev that precisely matches that predicted by genetic analysis. Rab binds the Rev activation domain when Rev is assembled onto its RNA target and can significantly enhance Rev activity when overexpressed. We conclude that Rab is the predicted activation domain-specific cofactor for the Rev/Rex class of RNA export factors.	DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710	Duke University	BOGERD, HP (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HARPER JW, 1993, CELL, V75, P805; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUANG JK, 1993, MOL CELL BIOL, V13, P7476, DOI 10.1128/MCB.13.12.7476; IVEYHOYLE M, 1990, MOL CELL BIOL, V10, P6152, DOI 10.1128/MCB.10.12.6152; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KJERNS J, 1992, EMBO J, V11, P1119; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TILEY LS, 1991, J VIROL, V65, P3877, DOI 10.1128/JVI.65.7.3877-3881.1991; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992	41	285	294	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					485	494		10.1016/0092-8674(95)90437-9	http://dx.doi.org/10.1016/0092-8674(95)90437-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634337	Bronze			2022-12-01	WOS:A1995RP24200018
J	BOSE, R; VERHEIJ, M; HAIMOVITZFRIEDMAN, A; SCOTTO, K; FUKS, Z; KOLESNICK, R				BOSE, R; VERHEIJ, M; HAIMOVITZFRIEDMAN, A; SCOTTO, K; FUKS, Z; KOLESNICK, R			CERAMIDE SYNTHASE MEDIATES DAUNORUBICIN-INDUCED APOPTOSIS - AN ALTERNATIVE MECHANISM FOR GENERATING DEATH SIGNALS	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SPHINGANINE N-ACYLTRANSFERASE; NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; HL-60 CELLS; ANTICANCER DRUGS; SPHINGOLIPID BIOSYNTHESIS; CHEMOTHERAPEUTIC AGENTS; FUSARIUM-MONILIFORME; SPHINGOMYELIN	The sphingomyelin pathway, which is initiated by sphingomyelin hydrolysis to generate the second messenger ceramide, signals apoptosis for tu mor necrosis factor alpha, Fas, and ionizing radiation. In the present studies, the anticancer drug daunorubicin also stimulated ceramide elevation and apoptosis in P388 and U937 cells, Cell-permeable analogs of ceramide, but not other lipid second messengers, mimicked daunorubicin in inducing apoptosis. Daunorubicin-stimulated ceramide elevation, however, did not result from sphingomyelin hydrolysis, but rather from de novo synthesis via activation of the enzyme ceramide synthase. An obligatory role for ceramide synthase was defined, since its natural specific inhibitor, fumonisin B1, blocked daunorubicin-induced ceramide elevation and apoptosis. These studies demonstrate that ceramide synthase activity can be regulated in eukaryotes and constitute definitive evidence for a requirement for ceramide elevation in the induction of apoptosis.	MEM SLOAN KETTERING CANC CTR,EUKARYOT TRANSCRIPT LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DIV RADIAT ONCOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	BOSE, R (corresponding author), MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R01CA057400] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA42385, CA57400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96; ANILKUMAR TV, 1992, BRIT J CANCER, V65, P552, DOI 10.1038/bjc.1992.113; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CIFONE MG, 1994, J EXP MED, V177, P1547; DIVE C, 1993, FRONTIERS PHARM CANC, P21; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DYSON JED, 1986, CELL TISSUE KINET, V19, P311, DOI 10.1111/j.1365-2184.1986.tb00683.x; EPSTEIN RJ, 1990, J CLIN ONCOL, V8, P2062, DOI 10.1200/JCO.1990.8.12.2062; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDM.A, 1994, J EXP MED, V180, P525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAREL R, 1993, J BIOL CHEM, V268, P14476; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LING YH, 1993, CANCER RES, V53, P1845; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SMITH PJ, 1994, ANN HEMATOL, V69, pS7, DOI 10.1007/BF01757348; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPETH PAJ, 1989, SEMIN ONCOL, V16, P2; STRUM JC, 1994, J BIOL CHEM, V269, P15493; THAKKAR NS, 1992, BIOCHEM PHARMACOL, V43, P1683, DOI 10.1016/0006-2952(92)90697-H; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZWELLING LA, 1993, BIOCHEM PHARMACOL, V45, P516, DOI 10.1016/0006-2952(93)90091-A	57	764	798	1	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					405	414		10.1016/0092-8674(95)90429-8	http://dx.doi.org/10.1016/0092-8674(95)90429-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634330	Bronze			2022-12-01	WOS:A1995RP24200010
J	CHENG, HJ; NAKAMOTO, M; BERGEMANN, AD; FLANAGAN, JG				CHENG, HJ; NAKAMOTO, M; BERGEMANN, AD; FLANAGAN, JG			COMPLEMENTARY GRADIENTS IN EXPRESSION AND BINDING OF ELF-1 AND MEK4 IN DEVELOPMENT OF THE TOPOGRAPHIC RETINOTECTAL PROJECTION MAP	CELL			English	Article							RETINAL AXONS; VISUAL-SYSTEM; CHICK; RECEPTOR; GUIDANCE; MOLECULE; POSITION; INVITRO; TECTUM; ORDER	Topographic maps with a defined spatial ordering of neuronal connections are a key feature of brain organization. Such maps are believed to develop in response to complementary position-specific labels in presynaptic and postsynaptic fields. However, the complementary labeling molecules are not known. In the well-studied visual map of retinal axons projecting to the tectum, the labels are hypothesized to be in gradients, without needing large numbers of cell-specific molecules. We recently cloned ELF-1 as a ligand for Eph family receptors. Here, RNA hybridization shows matching expression gradients for ELF-1 in the tectum and its receptor Mek4 in the retina. Binding activity detected with alkaline phosphatase fusions of ELF-1 and Mek4 also reveals gradients and provides direct evidence for molecular complementarity of gradients in reciprocal fields, ELF-1 and Mek4 may therefore play roles in retinotectal development and have properties predicted of topographic mapping labels.			CHENG, HJ (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Flanagan, John/AAM-2995-2020; Cheng, Hwai-Jong/AAY-5067-2021	Cheng, Hwai-Jong/0000-0003-0647-0567; Bergemann, Andrew/0000-0002-0027-7662; Nakamoto, Masaru/0000-0001-9356-1189	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD029417, R01HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, IN PRESS MOL CELL BI; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COX EC, 1990, NEURON, V2, P31; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEITCHER DL, 1994, J NEUROSCI, V14, P486; Descartes R., 1664, TREATISE MAN; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; ITASAKI N, 1992, NEURON, V8, P787, DOI 10.1016/0896-6273(92)90099-Y; Jacobson M., 1991, DEV NEUROBIOLOGY; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAVAIL JH, 1971, BRAIN RES, V28, P391, DOI 10.1016/0006-8993(71)90053-9; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MEY J, 1992, J HIRNFORSCH, V33, P673; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NIETO MA, 1992, DEVELOPMENT, V116, P1137; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; SOANS C, 1994, ONCOGENE, V9, P3353; Sperry RW, 1943, J COMP NEUROL, V79, P33, DOI 10.1002/cne.900790104; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SPIRA AW, 1987, J COMP NEUROL, V260, P526, DOI 10.1002/cne.902600406; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	43	630	642	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					371	381		10.1016/0092-8674(95)90426-3	http://dx.doi.org/10.1016/0092-8674(95)90426-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634327	Green Published, Bronze			2022-12-01	WOS:A1995RP24200007
J	CHEUNG, AY; WANG, H; WU, HM				CHEUNG, AY; WANG, H; WU, HM			A FLORAL TRANSMITTING TISSUE-SPECIFIC GLYCOPROTEIN ATTRACTS POLLEN TUBES AND STIMULATES THEIR GROWTH	CELL			English	Article							PROLINE-RICH PROTEIN; ARABINOGALACTAN-PROTEINS; NICOTIANA-ALATA; GENE-EXPRESSION; DAUCUS-CAROTA; EXTENSIN; STIGMA; AXONS; IDENTIFICATION; CHEMOTROPISM	Pollen tubes elongate directionally in the extracellular matrix of pistil tissues to transport the male gametes from the apically located stigma to the basally located ovary for fertilization. The molecular mechanisms underlying directional pollen tube growth in the pistil are poorly understood. We have purified a glycoprotein, TTS, from tobacco stylar transmitting tissue, which supports pollen tube growth between the stigma and the ovary. TTS proteins belong to the arabinogalactan protein family, and they polymerize readily in vitro in a head-to-tail fashion into oligomeric forms. TTS proteins stimulate pollen tube growth in vitro and attract pollen tubes grown in a semi-in vivo culture system. In vivo, the pollen tube growth rate is reduced in transgenic plants that have significantly reduced levels of TTS proteins as a result of either antisense suppression or sense cosuppression. These results identify TTS protein as a pistil component that positively contributes to pollen tube growth.			CHEUNG, AY (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.			Wang, Hong/0000-0003-4130-8741				BALDWIN TC, 1993, PLANT PHYSIOL, V103, P115, DOI 10.1104/pp.103.1.115; CHEN CG, 1993, PLANT MOL BIOL, V21, P391, DOI 10.1007/BF00019955; CHEN CG, 1994, P NATL ACAD SCI USA, V91, P10305, DOI 10.1073/pnas.91.22.10305; CHEN CG, 1992, PLANT CELL, V4, P1053, DOI 10.1105/tpc.4.9.1053; CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; CHEUNG AY, 1993, PLANT J, V3, P151, DOI 10.1111/j.1365-313X.1993.tb00018.x; CLARKE A, 1979, P NATL ACAD SCI USA, V76, P3358, DOI 10.1073/pnas.76.7.3358; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DU H, 1994, PLANT CELL, V6, P1643, DOI 10.1105/tpc.6.11.1643; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; GLEESON PA, 1980, PHYTOCHEMISTRY, V19, P1777, DOI 10.1016/S0031-9422(00)83812-1; GOLDMAN MHD, 1992, PLANT CELL, V4, P1041, DOI 10.1105/tpc.4.9.1041; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HEATH IB, 1990, TIP GROWTH PLANT FUN; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JEFFERIES CJ, 1974, STAIN TECHNOL, V49, P199, DOI 10.3109/10520297409116977; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; KANDASAMY MK, 1987, J PLANT PHYSIOL, V131, P495, DOI 10.1016/S0176-1617(87)80292-4; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIELISZEWSKI MJ, 1992, PLANT PHYSIOL, V99, P538, DOI 10.1104/pp.99.2.538; Knox R. B., 1984, Cellular interactions, P508; KREUGER M, 1993, PLANTA, V189, P243, DOI 10.1007/BF00195083; LABARCA C, 1973, PLANT PHYSIOL, V52, P87, DOI 10.1104/pp.52.2.87; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; MASCARENHAS JP, 1975, BOT REV, V41, P259, DOI 10.1007/BF02860839; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MASCARENHAS JP, 1962, AM J BOT, V49, P482, DOI 10.2307/2439418; MASCARENHAS JP, 1962, NATURE, V196, P292, DOI 10.1038/196292a0; Mulcahy G. B., 1982, J PALYNOL, V18, P61; READ SM, 1993, PROTOPLASMA, V177, P1, DOI 10.1007/BF01403393; REGER BJ, 1992, SEX PLANT REPROD, V5, P201, DOI 10.1007/BF00189812; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROSEN WG, 1961, AM J BOT, V48, P889, DOI 10.2307/2439530; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SHOWALTER AM, 1989, BIOCH PLANTS, V15, P485; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; SOMMERVILLE J, 1987, ELECTRON MICROSCOPY; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; Van Montagu M., 1986, METHOD ENZYMOL, V153, P277; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; VASIL IK, 1987, INT REV CYTOL, V107, P127, DOI 10.1016/S0074-7696(08)61075-X; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; WELK M, 1965, AM J BOT, V52, P774, DOI 10.2307/2439758; WU HM, 1995, CELL, V82, P395, DOI 10.1016/0092-8674(95)90428-X; YARIV J, 1967, BIOCHEM J, V105, P10; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	51	385	438	2	35	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					383	393		10.1016/0092-8674(95)90427-1	http://dx.doi.org/10.1016/0092-8674(95)90427-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634328	hybrid			2022-12-01	WOS:A1995RP24200008
J	DRESCHER, U; KREMOSER, C; HANDWERKER, C; LOSCHINGER, J; NODA, M; BONHOEFFER, F				DRESCHER, U; KREMOSER, C; HANDWERKER, C; LOSCHINGER, J; NODA, M; BONHOEFFER, F			IN-VITRO GUIDANCE OF RETINAL GANGLION-CELL AXONS BY RAGS, A 25 KDA TECTAL PROTEIN RELATED TO LIGANDS FOR EPH RECEPTOR TYROSINE KINASES	CELL			English	Article							GROWTH CONES; ANCHORED PROTEINS; NEURONS INVITRO; COLLAPSE; POSITION; FAMILY; BRAIN; GENE; IDENTIFICATION; RECOGNITION	The results of previous in vitro experiments indicate that a glycosylphosphatidylinositol (GPl)-anchored protein may play an important role in the guidance of temporal retinal axons during the formation of the topographically ordered retinotectal projection. We have purified and cloned a GPl-anchored, 25 kDa glycoprotein that is a good candidate for a molecule involved in this process. During the time of innervation by retinal ganglion cells, this protein is gradedly expressed in the posterior part of the developing tectum, In two different in vitro assay systems, the recombinant protein induces growth cone collapse and repulsion of retinal ganglion cell axons. These phenomena are observed for axons of temporal as well as nasal origin, indicating that an additional activity may be necessary to confer the nasotemporal specificity observed in previous assays, We named the protein RAGS (for repulsive axon guidance signal), The sequence of RAGS shows significant homology to recently identified ligands for receptor tyrosine kinases of the Eph subfamily.			DRESCHER, U (corresponding author), MAX PLANCK INST DEV BIOL, DEPT PHYS BIOL, D-72076 TUBINGEN, GERMANY.		Drescher, Uwe/C-5438-2009; Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X				BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CROWE J, 1992, QUIAEXPRESS INSTRUCT; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; FAWCETT JW, 1989, J CELL SCI, V92, P93; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FLETCHER FA, 1994, ONCOGENE, V9, P3241; FLETCHER FA, 1994, GENOMICS, V24, P127, DOI 10.1006/geno.1994.1589; GILLARDIHEBENST.P, 1992, ONCOGENE, V7, P2499; GLERER A, 1987, DEVELOPMENT, V101, P479; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MOORMAN SJ, 1990, J NEUROSCI, V10, P3158; MULLER B, 1992, THESIS U TUBINGEN TU; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAQUALE EB, 1994, DEV BIOL, V163, P491; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RAPER JA, 1990, EXP NEUROBIOL, V109, P71; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SIMON DK, 1992, NEURON, V9, P977, DOI 10.1016/0896-6273(92)90249-D; STAHL B, 1990, NEURON, V5, P733; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONBOXBERG Y, 1993, NEURON, V10, P345; VONBOXBERG Y, 1988, ANAL BIOCHEM, V169, P372; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; 1992, SEQUENCE ANAL SOFTWA	72	742	759	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					359	370		10.1016/0092-8674(95)90425-5	http://dx.doi.org/10.1016/0092-8674(95)90425-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634326	Bronze			2022-12-01	WOS:A1995RP24200006
J	ENGEL, A; HAYERHARTL, MK; GOLDIE, KN; PFEIFER, G; HEGERL, R; MULLER, S; DASILVA, ACR; BAUMEISTER, W; HARTL, FU				ENGEL, A; HAYERHARTL, MK; GOLDIE, KN; PFEIFER, G; HEGERL, R; MULLER, S; DASILVA, ACR; BAUMEISTER, W; HARTL, FU			FUNCTIONAL-SIGNIFICANCE OF SYMMETRICAL VERSUS ASYMMETRICAL GROEL-GROES CHAPERONIN COMPLEXES	SCIENCE			English	Article							ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; CENTRAL CAVITY; PROTEIN; HYDROLYSIS; SURFACE; BINDING	The Escherichia coli chaperonin GroEL and its regulator GroES are thought to mediate adenosine triphosphate-dependent protein folding as an asymmetrical complex, with substrate protein bound within the GroEL cylinder. In contrast, a symmetrical complex formed between one GroEL and two GroES oligomers, with substrate protein binding to the outer surface of GroEL, was recently proposed to be the functional chaperonin unit. Electron microscopic and biochemical analyses have now shown that unphysiologically high magnesium concentrations and increased pH are required to assemble symmetrical complexes, the formation of which precludes the association of unfolded polypeptide. Thus, the functional significance of GroEL:(GroES)(2) particles remains to be demonstrated.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; MAX PLANCK INST BIOCHEM, D-82150 MARTINSRIED, GERMANY	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Max Planck Society	ENGEL, A (corresponding author), UNIV BASEL, BIOZENTRUM, MAURICE E MULLER INST, CH-4056 BASEL, SWITZERLAND.		Hayer-Hartl, Manajit/V-8078-2017; Hartl, F. Ulrich/Y-8206-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5664	31	81	82	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					832	836		10.1126/science.7638600	http://dx.doi.org/10.1126/science.7638600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638600				2022-12-01	WOS:A1995RN65000043
J	FANKHAUSER, C; REYMOND, A; CERUTTI, L; UTZIG, S; HOFMANN, K; SIMANIS, V				FANKHAUSER, C; REYMOND, A; CERUTTI, L; UTZIG, S; HOFMANN, K; SIMANIS, V			THE S-POMBE CDC15 GENE IS A KEY ELEMENT IN THE REORGANIZATION OF F-ACTIN AT MITOSIS	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION CYCLE; CYTOKINESIS; PROTEIN; CYTOSKELETON; COMPONENTS; SEPTATION; CLEAVAGE; DEFECTS; MYOSIN	The S. pombe cdc15 gene is essential for cell division, cdcl5(ts) mutants do not form a septum, but growth and nuclear division continue, leading to formation of multinucleate cells, The earliest step in septum formation and cytokinesis, rearrangement of actin to the center of the cell, is associated with appearance of hypophosphorylated cdc15p and formation of a cdc15p ring, which colocalizes with actin, Loss of cdc15p function impairs formation of the actin ring, The abundance of cdcl5 mRNA varies through the cell division cycle, peaking in early mitosis before septation, Expression of cdcl5 in G2-arrested cells induces actin rearrangement to the center of the cell, These data implicate cdc15p as a key element in mediating the cytoskeletal rearrangements required for cytokinesis.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND	Swiss Institute Experimental Cancer Research			Fankhauser, Christian/C-4291-2018; Fankhauser, Christian/ABE-8757-2021; Hofmann, Kay/D-6714-2011	Fankhauser, Christian/0000-0003-4719-5901; Fankhauser, Christian/0000-0003-4719-5901; Hofmann, Kay/0000-0002-2289-9083; Reymond, Alexandre/0000-0003-1030-8327				BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; FANKHAUSER C, 1993, MOL BIOL CELL, V4, P531, DOI 10.1091/mbc.4.5.531; Fankhauser Christian, 1994, Trends in Cell Biology, V4, P96, DOI 10.1016/0962-8924(94)90182-1; Fantes P.A., 1989, MOL BIOL FISSION YEA, P127; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KANBE T, 1989, J CELL SCI, V94, P647; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KOHLI J, 1977, GENETICS, V87, P471; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARGOLIS RL, 1993, BIOESSAYS, V15, P201, DOI 10.1002/bies.950150310; MARKS J, 1992, J CELL SCI, V101, P801; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MARKS J, 1986, J CELL SCI, P229; MARKS J, 1987, SPEC PUBL SOC GEN MI, V23, P119; MCCOLLUM D, 1995, IN PRESS J CELL BIOL; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Robinow C, 1989, MOL BIOL FISSION YEA, P273; Sambrook J, 1989, MOL CLONING; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SIMANIS V, 1995, SEMIN CELL BIOL, V6, P79, DOI 10.1016/1043-4682(95)90004-7; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; WOODS A, 1989, J CELL SCI, V93, P491	44	217	220	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					435	444		10.1016/0092-8674(95)90432-8	http://dx.doi.org/10.1016/0092-8674(95)90432-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634333	Bronze			2022-12-01	WOS:A1995RP24200013
J	FISCHER, U; HUBER, J; BOELENS, WC; MATTAJ, IW; LUHRMANN, R				FISCHER, U; HUBER, J; BOELENS, WC; MATTAJ, IW; LUHRMANN, R			THE HIV-1 REV ACTIVATION DOMAIN IS A NUCLEAR EXPORT SIGNAL THAT ACCESSES AN EXPORT PATHWAY USED BY SPECIFIC CELLULAR RNAS	CELL			English	Article							VIRAL MESSENGER-RNA; VIRUS TYPE-1 REV; TRANS-ACTIVATOR; PROTEINS; BINDING; MUTANTS; IDENTIFICATION; LOCALIZATION; EXPRESSION; DEFINITION	HIV-1 Rev protein directs nuclear export of pre-mRNAs and mRNAs containing its binding site, the Rev response element (RRE). To define how Rev acts, we used conjugates between bovine serum albumin (BSA) and peptides comprising the Rev activation domain (BSA-R). BSA-R inhibited Rev-mediated nuclear RNA export, whereas a mutant activation domain peptide conjugate did not. BSA-R did not affect the export of mRNA, tRNA, or ribosomal subunits, but did inhibit export of 5S rRNA and spliceosomal U snRNAs. BSA-R was itself exported from the nucleus in an active, saturable manner. Thus, the Rev activation domain constitutes a nuclear export signal that redirects RRE-containing viral RNAs to a non-mRNA export pathway.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	FISCHER, U (corresponding author), INST MOLEKBIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY.		Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020; Boelens, Wilbert/D-8877-2012	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591; Mattaj, Iain/0000-0002-5537-8284				BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BERGER J, 1991, VIROLOGY, V183, P630, DOI 10.1016/0042-6822(91)90992-K; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1994, J CELL BIOL, V125, P971, DOI 10.1083/jcb.125.5.971; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, IN PRESS NATURE; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, REV CELL, V67, P169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1995, CELL, V79, P931; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	42	963	991	0	30	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					475	483		10.1016/0092-8674(95)90436-0	http://dx.doi.org/10.1016/0092-8674(95)90436-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7543368	Bronze			2022-12-01	WOS:A1995RP24200017
J	GARCIAMORENO, C; TURMEN, T				GARCIAMORENO, C; TURMEN, T			INTERNATIONAL PERSPECTIVES ON WOMENS REPRODUCTIVE HEALTH	SCIENCE			English	Editorial Material											GARCIAMORENO, C (corresponding author), WHO,DIV FAMILY HLTH,CH-1211 GENEVA 27,SWITZERLAND.							ALTHAUS A, 1991, INT FAM PLAN PERSPEC, V17, P145; BONGAARTS J, 1995, STUD FAMILY PLANN, V26, P57, DOI 10.2307/2137932; ELIAS C, 1991, 5 POP COUNC WORK PAP; FONN S, COMMUNICATION; HEISE L, 1994, 255 WORLD BANK DISC; KAY B, 1991, QUALITY CALIDAD QUAL, V3; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232; 1994, WHOGPADIR944 REP; 1995, WHOFHE956; 1994, WHOGPASEF944 GLOB PR; 1994, 1994 INT C POP DEV C	11	8	8	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					790	792		10.1126/science.7638592	http://dx.doi.org/10.1126/science.7638592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638592				2022-12-01	WOS:A1995RN65000030
J	GODOWSKI, PJ; MARK, MR; CHEN, JA; SADICK, MD; RAAB, H; HAMMOND, RG				GODOWSKI, PJ; MARK, MR; CHEN, JA; SADICK, MD; RAAB, H; HAMMOND, RG			REEVALUATION OF THE ROLES OF PROTEIN-S AND GAS6 AS LIGANDS FOR THE RECEPTOR TYROSINE KINASE RSE/TYRO-3	CELL			English	Article							GROWTH		GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	GODOWSKI, PJ (corresponding author), GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080, USA.			Hammonds, Glenn/0000-0003-0727-121X				MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	6	189	201	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					355	358		10.1016/0092-8674(95)90424-7	http://dx.doi.org/10.1016/0092-8674(95)90424-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634325	Bronze			2022-12-01	WOS:A1995RP24200005
J	GRANT, MR; GODIARD, L; STRAUBE, E; ASHFIELD, T; LEWALD, J; SATTLER, A; INNES, RW; DANGL, JL				GRANT, MR; GODIARD, L; STRAUBE, E; ASHFIELD, T; LEWALD, J; SATTLER, A; INNES, RW; DANGL, JL			STRUCTURE OF THE ARABIDOPSIS RPM1 GENE ENABLING DUAL-SPECIFICITY DISEASE RESISTANCE	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; SYRINGAE PV GLYCINEA; YAC CLONES; IDENTIFICATION; AVIRULENCE; LOCUS; DNA; EXPRESSION; PROTEIN; WALKING	Plants can recognize pathogens through the action of disease resistance (R) genes, which confer resistance to pathogens expressing unique corresponding avirulence (avr) genes. The molecular basis of this gene-for-gene specificity is unknown. The Arabidopsis thaliana RPM1 gene enables dual specificity to pathogens expressing either of two unrelated Pseudomonas syringae avr genes. Despite this function, RPM1 encodes a protein sharing molecular features with recently described single-specificity R genes. Surprisingly, RPM1 is lacking from naturally occurring, disease-susceptible Arabidopsis accessions.	MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill			Innes, Roger/A-5244-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046451] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29 GM 46451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1907, CURRENT PROTOCOLS MO; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Crute I, 1994, ARABIDOPSIS, P705; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DANGL JL, 1993, INT REV CYTOL, V144, P53, DOI 10.1016/S0074-7696(08)61513-2; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; DANGL JL, 1992, PLANT J, V2, P3, DOI 10.1111/j.1365-313X.1992.00003.x; DANGL JL, 1994, BACTERIAL PATHOGENES, V192, P99; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; INNES RW, 1993, PLANT J, V4, P813, DOI 10.1046/j.1365-313X.1993.04050813.x; INNES RW, UNPUB; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; LEWALD J, UNPUB; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Matallana E., 1992, Methods in Arabidopsis research., P144; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MOWERY P, UNPUB; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMIDT R, 1994, PLANT J, V5, P735, DOI 10.1111/j.1365-313X.1994.00735.x; SCHMIDT R, 1992, GENOME ANAL, V4, P71; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; TAMAKI S, 1988, J BACTERIOL, V170, P4846, DOI 10.1128/jb.170.10.4846-4854.1988; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	42	717	776	0	58	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					843	846		10.1126/science.7638602	http://dx.doi.org/10.1126/science.7638602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638602				2022-12-01	WOS:A1995RN65000046
J	GRIFFITH, JP; KIM, JL; KIM, EE; SINTCHAK, MD; THOMSON, JA; FITZGIBBON, MJ; FLEMING, MA; CARON, PR; HSIAO, K; NAVIA, MA				GRIFFITH, JP; KIM, JL; KIM, EE; SINTCHAK, MD; THOMSON, JA; FITZGIBBON, MJ; FLEMING, MA; CARON, PR; HSIAO, K; NAVIA, MA			X-RAY STRUCTURE OF CALCINEURIN INHIBITED BY THE IMMUNOPHILIN IMMUNOSUPPRESSANT FKBP12-FK506 COMPLEX	CELL			English	Article							LYMPHOCYTE-T ACTIVATION; CYCLOSPORINE-A; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; FK-506-BINDING PROTEIN; CATALYTIC SUBUNIT; ATOMIC-STRUCTURE; CELL ACTIVATION; PEPTIDE COMPLEX	The X-ray structure of the ternary complex of a calcineurin A fragment, calcineurin B, FKBP12, and the immunosuppressant drug FK506 (also known as tacrolimus) has been determined at 2.5 Angstrom resolution, providing a description of how FK506 functions at the atomic level. In the structure, the FKBP12-FK506 binary complex does not contact the phosphatase active site on calcineurin A that is more than 10 Angstrom removed. Instead, FKBP12-FK506 is so positioned that it can inhibit the dephosphorylation of its macromolecular substrates by physically hindering their approach to the active site. The ternary complex described here represents the three-dimensional structure of a Ser/Thr protein phosphatase and provides a structural basis for understanding calcineurin inhibition by FKBP12-FK506.			GRIFFITH, JP (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.							ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1989, PHARMACOL REV, V41, P259; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Di Padova F. E., 1994, Perspectives in Drug Discovery and Design, V2, P49; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUTER O, 1995, J BIOL CHEM, V270, P18935, DOI 10.1074/jbc.270.32.18935; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Goulet Mark T., 1994, Perspectives in Drug Discovery and Design, V2, P145, DOI 10.1007/BF02171741; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; ITOH S, 1995, IN PRESS BIOORG MED, V5; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAKALIS LT, 1995, FEBS LETT, V362, P55, DOI 10.1016/0014-5793(95)00207-P; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1984, J BIOL CHEM, V259, P8847; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; NARGANG CE, 1994, DNA SEQUENCE, V4, P313, DOI 10.3109/10425179409020857; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cb.10.110194.000415; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILSON KP, 1995, ACTA CRYSTALLOGR D, V51, P511, DOI 10.1107/S0907444994014514; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	75	752	786	5	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					507	522		10.1016/0092-8674(95)90439-5	http://dx.doi.org/10.1016/0092-8674(95)90439-5			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7543369	Bronze			2022-12-01	WOS:A1995RP24200020
J	HAJNOCZKY, G; ROBBGASPERS, LD; SEITZ, MB; THOMAS, AP				HAJNOCZKY, G; ROBBGASPERS, LD; SEITZ, MB; THOMAS, AP			DECODING OF CYTOSOLIC CALCIUM OSCILLATIONS IN THE MITOCHONDRIA	CELL			English	Article							MAMMALIAN MITOCHONDRIA; HEPATOCYTES; METABOLISM; CHANNELS; RECEPTOR; CELLS; IONS	Frequency-modulated oscillations of cytosolic Ca2+ ([Ca2+](c)) are believed to be important in signal transduction, but it has been difficult to correlate [Ca2+](c) oscillations directly with the activity of Ca2+-regulated targets. We have studied the control of Ca2+-sensitive mitochondrial dehydrogenases (CSMDHs) by monitoring mitochondrial Ca2+ ([Ca2+](m)) and the redox state of flavoproteins and pyridine nucleotides simultaneously with [Ca2+](c) in single hepatocytes. Oscillations of [Ca2+](c) induced by IP3-dependent hormones were efficiently transmitted to the mitochondria as [Ca2+](m) oscillations. Each [Ca2+](m) spike was sufficient to cause a maximal transient activation of the CSMDHs and [Ca2+](m) oscillations at frequencies above 0.5 per minute caused a sustained activation of mitochondrial metabolism. By contrast, sustained [Ca2+](c) increases yielded only transient CSMDH activation, and slow or partial [Ca2+](c) elevations were ineffective in increasing [Ca2+](m) or stimulating CSMDHs. We conclude that the mitochondria are tuned to oscillating [Ca2+](c) signals, the frequency of which can control the CSMDHs over the full range of potential activities.			HAJNOCZKY, G (corresponding author), THOMAS JEFFERSON UNIV, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA.		Gaspers, Lawrence/W-8766-2019; Thomas, Andrew/C-6755-2013	Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00180, AA07215] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1994, HEPATOLOGY, V20, P1309, DOI 10.1016/0270-9139(94)90773-0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HOEK JB, 1995, IN PRESS BIOCH BIOPH; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MIX TCH, 1994, BIOPHYS J, V66, pA97; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NICHOLS BJ, 1994, BIOCHEM J, V303, P461, DOI 10.1042/bj3030461; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; RAPP PE, 1981, J EXP BIOL, V93, P119; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHOLZ R, 1969, J BIOL CHEM, V244, P2317; TAKEI K, 1992, J NEUROSCI, V12, P489; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	32	927	945	3	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					415	424		10.1016/0092-8674(95)90430-1	http://dx.doi.org/10.1016/0092-8674(95)90430-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634331	Bronze			2022-12-01	WOS:A1995RP24200011
J	HAYERHARTL, MK; MARTIN, J; HARTL, FU				HAYERHARTL, MK; MARTIN, J; HARTL, FU			ASYMMETRICAL INTERACTION OF GROEL AND GROES IN THE ATPASE CYCLE OF ASSISTED PROTEIN-FOLDING	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; HEAT-SHOCK PROTEINS; CHAPERONIN PROTEINS; CENTRAL CAVITY; HYDROLYSIS; BINDING; MITOCHONDRIA; HSP60	The chaperonins GroEL and GroES of Escherichia coli facilitate protein folding in an adenosine triphosphate (ATP)-dependent reaction cycle, The kinetic parameters for the formation and dissociation of GroEL-GroES complexes were analyzed by surface plasmon resonance. Association of GroES and subsequent ATP hydrolysis in the interacting GroEL toroid resulted in the formation of a stable GroEL:ADP:GroES complex. The complex dissociated as a result of ATP hydrolysis in the opposite GroEL toroid, without formation of a symmetrical GroEL:(GroES)(2) intermediate. Dissociation was accelerated by the addition of unfolded polypeptide. Thus, the functional chaperonin unit is an asymmetrical GroEL:GroES complex, and substrate protein plays an active role in modulating the chaperonin reaction cycle.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hayer-Hartl, Manajit/V-8078-2017; Hartl, F. Ulrich/Y-8206-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HAYERHARTL MK, UNPUB; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5664; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567	42	134	137	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					836	841		10.1126/science.7638601	http://dx.doi.org/10.1126/science.7638601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638601				2022-12-01	WOS:A1995RN65000044
J	MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R				MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R			ULTRASOUND-MEDIATED TRANSDERMAL PROTEIN DELIVERY	SCIENCE			English	Article							INTERFERON-GAMMA; ERYTHROPOIETIN; PHONOPHORESIS; SKIN	Transdermal drug delivery offers a potential method of drug administration. However, its application has been limited to a few low molecular weight compounds because of the extremely low permeability of human skin. Low-frequency ultrasound was shown to increase the permeability of human skin to many drugs, including high molecular weight proteins, by several orders of magnitude, thus making transdermal administration of these molecules potentially feasible. It was possible to deliver and control therapeutic doses of proteins such as insulin, interferon gamma, and erythropoeitin across human skin. Low-frequency ultrasound is thus a potential noninvasive substitute for traditional methods of drug delivery, such as injections.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM44884] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APFEL RE, 1986, IEEE T ULTRASON FERR, P139; BOMMER J, 1988, LANCET, V2, P406; Bronaugh RL, 1989, PERCUTANEOUS ABSORPT, P27; BURNETTE RR, 1989, TRANSDERMAL DRUG DEL, P247; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; ELIAS JJ, 1989, PERCUTANEOUS ABSORPT, P1; FRIDEMAN RM, 1981, INTERFERONS PRIMER; GAERTNER W, 1954, J ACOUST SOC AM, V26, P977, DOI 10.1121/1.1907464; GRUPS JW, 1989, BRIT J UROL, V64, P218, DOI 10.1111/j.1464-410X.1989.tb06000.x; Kost J, 1993, TOPICAL DRUG BIOAVAI, P91; KRALL LP, 1988, WORLD BOOK DIABETES, P160; MITRAGOTRI S, 1995, J PHARM SCI, V84, P697, DOI 10.1002/jps.2600840607; MORIMOTO Y, 1992, J PHARM PHARMACOL, V44, P634, DOI 10.1111/j.2042-7158.1992.tb05484.x; NEWMAN JT, 1992, J AM PODIAT MED ASSN, V82, P432, DOI 10.7547/87507315-82-8-432; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PISHKO MV, 1991, ANAL CHEM, V63, P2268, DOI 10.1021/ac00020a014; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; Quillen WS, 1980, ATHL TRAIN, V15, P109; ROSSEL J, 1988, IEEE T BIOMED ENG, V35, P649; SKAUEN DM, 1984, INT J PHARMACEUT, V20, P235, DOI 10.1016/0378-5173(84)90171-6; STRINGFELLOW D, 1986, CLIN APPLICATIONS IN, P1; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; WALMSLEY AD, 1988, ULTRASOUND MED BIOL, V14; Walters KA., 1989, TRANSDERMAL DRUG DEL, P197; Wester R. C., 1993, TOPICAL DRUG BIOAVAI, P333	25	604	676	11	142	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					850	853		10.1126/science.7638603	http://dx.doi.org/10.1126/science.7638603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638603				2022-12-01	WOS:A1995RN65000048
J	STUTTS, MJ; CANESSA, CM; OLSEN, JC; HAMRICK, M; COHN, JA; ROSSIER, BC; BOUCHER, RC				STUTTS, MJ; CANESSA, CM; OLSEN, JC; HAMRICK, M; COHN, JA; ROSSIER, BC; BOUCHER, RC			CFTR AS A CAMP-DEPENDENT REGULATOR OF SODIUM-CHANNELS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN NASAL EPITHELIUM; FIBROSIS; TRANSPORT; MEMBRANE; CELLS; PROTEIN	Cystic fibrosis transmembrane regulator (CFTR), the gene product that is mutated in cystic fibrosis (CF) patients, has a well-recognized function as a cyclic adenosine 3',5'-monophosphate (cAMP)-regulated chloride channel, but this property does not account for the abnormally high basal rate and cAMP sensitivity of sodium ion absorption in CF airway epithelia. Expression of complementary DNAs for rat epithelial Na+ channel (rENaC) alone in Madin Darby canine kidney (MDCK) epithelial cells generated large amiloride-sensitive sodium currents that were stimulated by cAMP, whereas coexpression of human CFTR with rENaC generated smaller basal sodium currents that were inhibited by cAMP. Parallel studies that measured regulation of sodium permeability in fibroblasts showed similar results. In CF airway epithelia, the absence of this second function of CFTR as a cAMP-dependent regulator likely accounts for abnormal sodium transport.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND; DUKE UNIV, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27710 USA	University of Lausanne	STUTTS, MJ (corresponding author), UNIV N CAROLINA, CYST FIBROSIS PULM RES & TREATMENT CTR, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42384, HL 34322] Funding Source: Medline; PHS HHS [CFF R026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BURCH LH, IN PRESS AM J PHYSL; CANESSA C, UNPUB; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; LAFERTE S, 1992, BIOCHEM J, V283, P193, DOI 10.1042/bj2830193; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ONEAL W, 1994, PEDIATR PULM S, V10, P194; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; STUTTS MJ, 1994, J BIOL CHEM, V269, P8667; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; TALBOT CR, 1995, FASEB J, V9, pA304; USSING HH, 1949, PHYSIOL REV, V29, P127, DOI 10.1152/physrev.1949.29.2.127; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC319, DOI 10.1152/ajpcell.1991.261.2.C319; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332	31	902	921	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					847	850		10.1126/science.7543698	http://dx.doi.org/10.1126/science.7543698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7543698				2022-12-01	WOS:A1995RN65000047
J	STUTZ, F; NEVILLE, M; ROSBASH, M				STUTZ, F; NEVILLE, M; ROSBASH, M			IDENTIFICATION OF A NOVEL NUCLEAR PORE-ASSOCIATED PROTEIN AS A FUNCTIONAL TARGET OF THE HIV-1 REV PROTEIN IN YEAST	CELL			English	Article							VIRUS TYPE-1 REV; VIRAL MESSENGER-RNA; HTLV-I REX; TRANS-ACTIVATOR; MUTATIONAL ANALYSIS; COMPLEX PROTEINS; PREMESSENGER RNA; GENE; ENVELOPE; BINDING	The HIV-1 Rev protein increases the cytoplasm ic levels of unspliced and singly spliced target transcripts in metazoan systems. Based on experiments that indicate a similar function of Rev in the yeast S. cerevisiae, we have identified a yeast protein that interacts with the effector domain of Rev. The protein, Rip1p, is a novel small nucleoporin-like protein, some of which is associated with nuclear pores. Its closest known yeast relative is a nuclear pore component also implicated in mRNA transport from nucleus to cytoplasm. Analysis of strains that overexpress Rip1p or that are deleted for the RIP1 gene show that Rip1p is important for the effect of Rev on gene expression, indicating that the physical interaction is of functional significance in vivo. The results suggest that Rev directly promotes the cytoplasmic transport of suitable transcripts by targeting them to the nuclear pore.	BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University	STUTZ, F (corresponding author), BRANDEIS UNIV, HOWARD HUGHES MED INST, WALTHAM, MA 02254 USA.		Stutz, Françoise C/N-4329-2017	Goodwin, Megan/0000-0001-8506-9944				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DINGWALL C, 1993, CURR BIOL, V3, P297, DOI 10.1016/0960-9822(93)90184-P; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P389; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LESSER CF, 1993, GENETICS, V133, P851; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Maniatis T., 1982, MOL CLONING; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	68	211	216	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					495	506		10.1016/0092-8674(95)90438-7	http://dx.doi.org/10.1016/0092-8674(95)90438-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634338	Bronze			2022-12-01	WOS:A1995RP24200019
J	SU, Y; DOSTMANN, WRG; HERBERG, FW; DURICK, K; XUONG, NH; TENEYCK, L; TAYLOR, SS; VARUGHESE, KI				SU, Y; DOSTMANN, WRG; HERBERG, FW; DURICK, K; XUONG, NH; TENEYCK, L; TAYLOR, SS; VARUGHESE, KI			REGULATORY SUBUNIT OF PROTEIN-KINASE-A - STRUCTURE OF DELETION MUTANT WITH CAMP BINDING DOMAINS	SCIENCE			English	Article							CYCLIC-NUCLEOTIDE ANALOGS; CATALYTIC SUBUNIT; 8-AZIDOADENOSINE 3',5'-MONOPHOSPHATE; ADENOSINE 3'-5'-MONOPHOSPHATE; COVALENT MODIFICATION; R-SUBUNIT; SITE-A; ACTIVATION; AMP; PHOSPHOROTHIOATES	In the molecular scheme of living organisms, adenosine 3',5'-monophosphate (cyclic AMP or cAMP) has been a universal second messenger. In eukaryotic cells, the primary receptors for cAMP are the regulatory subunits of cAMP-dependent protein kinase. The crystal structure of a 1-91 deletion mutant of the type I alpha regulatory subunit was refined to 2.8 Angstrom resolution. Each of the two tandem cAMP binding domains provides an extensive network of hydrogen bonds that buries the cyclic phosphate and the ribose between two beta strands that are linked by a short alpha helix. Each adenine base stacks against an aromatic ring that lies outside the beta barrel. This structure provides a molecular basis for understanding how cAMP binds cooperatively to its receptor protein, thus mediating activation of the kinase.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; SAN DIEGO SUPERCOMP CTR, LA JOLLA, CA 92186 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01644] Funding Source: Medline; NIGMS NIH HHS [GM07313, GM34921] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDRIDGE K, UNPUB; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1985, BIOCHEMISTRY-US, V24, P2163, DOI 10.1021/bi00330a009; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CORBIN JD, 1982, EUR J BIOCHEM, V125, P259, DOI 10.1111/j.1432-1033.1982.tb06677.x; CREIGHTON TE, 1984, PROTEINS, P139; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; JASTORFF B, 1979, EUR J BIOCHEM, V101, P555, DOI 10.1111/j.1432-1033.1979.tb19750.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8483; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KREBS EG, 1993, BIOSCIENCE REP, V13, P127, DOI 10.1007/BF01149958; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EACM; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; NELSON NC, 1983, J BIOL CHEM, V258, P981; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHABB JB, 1991, J BIOL CHEM, V266, P24320; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1993, J MOL BIOL, V230, P1091, DOI 10.1006/jmbi.1993.1224; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WOODFORD TA, 1987, J BIOL CHEM, V262, P13321; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	60	327	334	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					807	813		10.1126/science.7638597	http://dx.doi.org/10.1126/science.7638597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638597				2022-12-01	WOS:A1995RN65000036
J	SUNG, P; ROBBERSON, DL				SUNG, P; ROBBERSON, DL			DNA STRAND EXCHANGE MEDIATED BY A RAD51-SSDNA NUCLEOPROTEIN FILAMENT WITH POLARITY OPPOSITE TO THAT OF RECA	CELL			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; RAD51; RECOMBINATION; PROTEIN; GENE; SEQUENCE; HOMOLOG; REPAIR	Yeast RAD51 gene functions in genetic recombination and DNA double-strand break repair. In vitro, in the presence of ATP and replication protein A, RAD51 protein pairs single-stranded DNA (ssDNA) with homologous double-stranded DNA (dsDNA) and catalyzes strand exchange between the synapsed DNA partners. Electron microscopic analyses show that RAD51 forms helical filaments on both ssDNA and dsDNA, in which the DNA is highly extended. However, results presented here indicate that only the RAD51-ssDNA nucleoprotein filament is functionally relevant. Strand exchange is arrested when heterology is encountered in the duplex partner, and analysis of the configuration of the terminal joint thus formed reveals that pairing and strand exchange initiate at the 5' end of the complementary strand in the linear duplex, a reaction polarity opposite to that of the bacterial prototype RecA.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	SUNG, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ESO7061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; KMIEC EB, 1983, CELL, V33, P857, DOI 10.1016/0092-8674(83)90028-4; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LOVETT ST, 1987, GENETICS, V116, P547; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	26	420	434	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					453	461		10.1016/0092-8674(95)90434-4	http://dx.doi.org/10.1016/0092-8674(95)90434-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634335	Bronze			2022-12-01	WOS:A1995RP24200015
J	WEISSMAN, MM; OLFSON, M				WEISSMAN, MM; OLFSON, M			DEPRESSION IN WOMEN - IMPLICATIONS FOR HEALTH-CARE RESEARCH	SCIENCE			English	Article							PSYCHIATRIC EPIDEMIOLOGY; PUERPERAL PSYCHOSES; MENTAL-DISORDERS; SOCIAL STRESS; PREGNANCY; POSTPARTUM; PREVALENCE; GENDER; PSYCHOTHERAPY; COMMUNITY	Epidemiologic data from around the world demonstrate that major depression is approximately twice as common in women than men and that its first onset peaks during the childbearing years. Progress has been made in understanding the epidemiology of depression and in developing effective treatments. Much remains to be learned about the basic pathogenesis of depression and the specific treatment needs of depressed women and their offspring, especially during the reproductive years.	NEW YORK STATE PSYCHIAT INST & HOSP, DIV CLIN & GENET EPIDEMIOL, NEW YORK, NY 10032 USA	New York State Psychiatry Institute	WEISSMAN, MM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA.		Olfson, Mark/AAA-8547-2021	Weissman, Myrna/0000-0003-3490-3075				[Anonymous], 1993, AM J PSYCHIAT, V150, P1; BALDWIN JA, 1989, ACTA PSYCHIAT SCAND, V80, P37, DOI 10.1111/j.1600-0447.1989.tb07167.x; BRESLAU N, IN PRESS PSYCHIATRY; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BROCKINGTON IF, 1990, BRIT J PSYCHIAT, V157, P331, DOI 10.1192/bjp.157.3.331; CANINO GJ, 1987, ARCH GEN PSYCHIAT, V44, P727; COHEN LS, 1992, CURR AFFECTIVE ILLNE, V11, P5; DAVIDSON J, 1985, ACTA PSYCHIAT SCAND, V71, P451, DOI 10.1111/j.1600-0447.1985.tb05057.x; DIMASCIO A, 1979, ARCH GEN PSYCHIAT, V36, P1450; DOWLATSHAHI D, 1990, PSYCHOL MED, V20, P655, DOI 10.1017/S0033291700017177; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FARAVELLI C, 1990, J AFFECT DISORDERS, V20, P135, DOI 10.1016/0165-0327(90)90127-T; FRANK E, 1988, AM J PSYCHIAT, V145, P41; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GARVEY MJ, 1984, J REPROD MED, V29, P113; GLASSMAN AH, 1977, ARCH GEN PSYCHIAT, V34, P197; GOTLIB IH, 1989, J CONSULT CLIN PSYCH, V57, P269, DOI 10.1037/0022-006X.57.2.269; HOHMANN AA, 1989, MED CARE, V27, P478, DOI 10.1097/00005650-198905000-00004; KARAM E, 1991, OCT M INT TRAUM STRE; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KENDELL RE, 1985, J PSYCHOSOM RES, V29, P3, DOI 10.1016/0022-3999(85)90003-0; KERNS LL, 1986, J NERV MENT DIS, V174, P652, DOI 10.1097/00005053-198611000-00003; KESSLER RC, 1981, J HEALTH SOC BEHAV, V22, P49, DOI 10.2307/2136367; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KITAMURA T, 1993, PSYCHOL MED, V23, P967, DOI 10.1017/S003329170002643X; KLERMAN GL, 1974, AM J PSYCHIAT, V131, P186, DOI 10.1176/ajp.131.2.186; KUMAR R, 1993, PROG NEURO-PSYCHOPH, V17, P571, DOI 10.1016/0278-5846(93)90006-E; LEE CK, 1990, J NERV MENT DIS, V178, P242, DOI 10.1097/00005053-199004000-00004; LEPINE J P, 1989, Psychiatrie and Psychobiologie, V4, P267; MARTIN CJ, 1989, J AFFECT DISORDERS, V16, P283, DOI 10.1016/0165-0327(89)90083-9; Mastroianni AC, 1994, WOMEN HLTH RES ETHIC, VI; Miller L J, 1991, Psychiatr Med, V9, P275; Montgomery Stuart A., 1995, P1043; MORTOLA JF, 1989, PSYCHIAT CLIN N AM, V12, P69; OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801; ORN H, 1988, ACTA PSYCHIAT SCAND, V77, P17, DOI 10.1111/j.1600-0447.1988.tb08543.x; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; ROBINS LN, 1991, PSYCHIATRIC DISORDER; ROHE GH, 1893, JAMA-J AM MED ASSOC, V21, P325; ROHE GH, 1993, JAMA-J AM MED ASSOC, V270, P1180; SARGEANT JK, 1990, ARCH GEN PSYCHIAT, V47, P519; SCHATZBERG AF, 1991, MANUAL CLIN PSYCHOPH, P315; SIMON G, 1995, AM J PSYCHIAT, V152, P352; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TUETH MJ, 1993, JAMA-J AM MED ASSOC, V270, P2177, DOI 10.1001/jama.1993.03510180047018; VIGGEDAL G, 1993, J CHILD PSYCHOL PSYC, V34, P295, DOI 10.1111/j.1469-7610.1993.tb00993.x; Weissman M.M., 1994, WORLD PSYCHIATR ASS, V2, P1; WEISSMAN MM, 1987, ARCH GEN PSYCHIAT, V44, P847; WEISSMAN MM, 1992, JAMA-J AM MED ASSOC, V268, P3098, DOI 10.1001/jama.1992.03490210080039; WELLS JE, 1989, AUST NZ J PSYCHIAT, V23, P315, DOI 10.3109/00048678909068289; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; WISNER KL, 1993, AM J PSYCHIAT, V150, P1541; WITTCHEN HU, 1992, EUR ARCH PSY CLIN N, V241, P247, DOI 10.1007/BF02190261; WOLK SI, 1995, REV PSYCHIATRY, V14, pCH9; YONKERS KA, 1992, AM J PSYCHIAT, V149, P587; YONKERS KA, 1995, REV PSYCHIATRY, V2, P307; ZUCKERMAN B, 1990, J DEV BEHAV PEDIATR, V11, P190; 1993, 930551 US DEP HLTH H; 1980, DIAGNOSTIC STATISTIC	60	346	356	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					799	801		10.1126/science.7638596	http://dx.doi.org/10.1126/science.7638596			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638596	Green Submitted			2022-12-01	WOS:A1995RN65000034
J	WEN, W; MEINKOTH, JL; TSIEN, RY; TAYLOR, SS				WEN, W; MEINKOTH, JL; TSIEN, RY; TAYLOR, SS			IDENTIFICATION OF A SIGNAL FOR RAPID EXPORT OF PROTEINS FROM THE NUCLEUS	CELL			English	Article							SV40 T-ANTIGEN; ESCHERICHIA-COLI; MESSENGER-RNA; PORE COMPLEX; CYCLIC-AMP; 2 STEPS; TRANSPORT; TRANSLOCATION; IMPORT; KINASE	Active nuclear import of protein is controlled by nuclear localization signals (NLSs), but nuclear export is not understood well. Nuclear trafficking of the catalytic (C) subunit of cAMP-dependent protein kinase (cAPK) is critical for regulation of gene expression. The heat-stable inhibitor (PKI) of cAPK contains a nuclear export signal (NES) that triggers rapid, active net extrusion of the C-PKI complex from the nucleus. This NES (residues 35-49), fused or conjugated to heterologous proteins, was sufficient for rapid nuclear export. Hydrophobic residues were critical. The NES is a slightly weaker signal than the SV40 NLS. A sequence containing only residues 37-46, LALKLAGLDI, is also sufficient for nuclear export. This is an example of a protein-based NES having no obvious association with RNA. A similar sequence, LQLPPLERLTL, from Rev, an RNA-binding protein of HIV-1, also is an NES.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of Pennsylvania; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	WEN, W (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.		Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BOHNLEIN E, 1991, J VIROL, V65, P7051; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHON MA, 1994, P NATL ACAD SCI USA, V91, P7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WEN W, 1994, J BIOL CHEM, V269, P32214; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	60	1000	1023	0	44	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					463	473		10.1016/0092-8674(95)90435-2	http://dx.doi.org/10.1016/0092-8674(95)90435-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634336	hybrid			2022-12-01	WOS:A1995RP24200016
J	WU, HM; WANG, H; CHEUNG, AY				WU, HM; WANG, H; CHEUNG, AY			A POLLEN-TUBE GROWTH-STIMULATORY GLYCOPROTEIN IS DEGLYCOSYLATED BY POLLEN TUBES AND DISPLAYS A GLYCOSYLATION GRADIENT IN THE FLOWER	CELL			English	Article							SELF-INCOMPATIBILITY; CELL-WALL; NICOTIANA-ALATA; AXONS; PROTEINS; MOVEMENT; INVITRO; CHEMOTROPISM; POLLINATION; CHEMOTAXIS	In plant sexual reproduction, pollen tubes elongate from the stigma, through the stylar transmitting tissue, to the ovary of the pistil to deliver the male gametes for fertilization. TTS protein is a tobacco transmitting tissue glycoprotein shown to attract pollen tubes and promote their growth. Here, we show TTS proteins adhere to the pollen tube surface and tips, suggesting that they may serve as adhesive substrates for pollen tube growth. TTS proteins are also incorporated into pollen tube walls and are deglycosylated by pollen tubes, suggesting that they may provide nutrients to this process, Within the transmitting tissue, TTS proteins display a gradient of increasing glycosylation from the stigmatic end to the ovarian end of the style, coincident with the direction of pollen tube growth. These results together suggest that the TTS protein-bound sugar gradient may contribute to guiding pollen tubes from the stigma to the ovary.			WU, HM (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.			Wang, Hong/0000-0003-4130-8741				CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DU H, 1994, PLANT CELL, V6, P1643, DOI 10.1105/tpc.6.11.1643; FOOTE HCC, 1994, P NATL ACAD SCI USA, V91, P2265, DOI 10.1073/pnas.91.6.2265; GRAY JE, 1991, PLANT CELL, V3, P271, DOI 10.1105/tpc.3.3.271; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEATH IB, 1990, TIP GROWTH PLANT FUN; HERRERO M, 1980, PLANTA, V148, P217, DOI 10.1007/BF00380030; Heslop-Harrison Y., 1988, Sexual Plant Reproduction, V1, P182, DOI 10.1007/BF00193749; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HESLOPHARRISON Y, 1985, ACTA BOT NEERL, V34, P193, DOI 10.1111/j.1438-8677.1985.tb01879.x; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JAUH GY, 1995, SEX PLANT REPROD, V8, P168, DOI 10.1007/BF00242262; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KANDASARNY MK, 1994, DEVELOPMENT, V20, P3405; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Knox R. B., 1984, Cellular interactions, P508; LI XM, 1994, PLANT CELL, V6, P1923, DOI 10.1105/tpc.6.12.1923; LI YQ, 1992, PLANTA, V188, P532, DOI 10.1007/BF00197045; LI YQ, 1994, SEX PLANT REPROD, V7, P145; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MASCARENHAS JP, 1975, BOT REV, V41, P259, DOI 10.1007/BF02860839; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MASCARENHAS JP, 1962, AM J BOT, V49, P482, DOI 10.2307/2439418; MASCARENHAS JP, 1962, NATURE, V196, P292, DOI 10.1038/196292a0; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NEWBIGIN E, 1993, PLANT CELL, V5, P1315, DOI 10.1105/tpc.5.10.1315; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PLACZEK M, 1990, DEVELOPMENT, V110, P19; REGER BJ, 1992, SEX PLANT REPROD, V5, P201, DOI 10.1007/BF00189812; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROSEN WG, 1961, AM J BOT, V48, P889, DOI 10.2307/2439530; SANDERS LC, 1989, SCIENCE, V243, P1606, DOI 10.1126/science.243.4898.1606; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SOMMERVILLE J, 1987, ELECTRON MICROSCOPY; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TRINKAUS JP, 1985, J NEUROSCI RES, V13, P1, DOI 10.1002/jnr.490130102; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; WANG C, 1989, DEV BIOL, V136, P405, DOI 10.1016/0012-1606(89)90266-2; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; YARIV J, 1967, BIOCHEM J, V105, P10; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	51	217	233	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					395	403		10.1016/0092-8674(95)90428-X	http://dx.doi.org/10.1016/0092-8674(95)90428-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634329	Bronze			2022-12-01	WOS:A1995RP24200009
J	WU, HY; TAN, JY; FANG, M				WU, HY; TAN, JY; FANG, M			LONG-RANGE INTERACTION BETWEEN 2 PROMOTERS - ACTIVATION OF THE LEU-500 PROMOTER BY A DISTANT UPSTREAM PROMOTER	CELL			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; TOPOISOMERASE-I; DNA TOPOISOMERASES; TRANSCRIPTION; GENE; EXPRESSION; MUTATIONS; TEMPLATE; PLASMID	The leu-500 mutation can be suppressed in S. typhimurium topA. Previous studies have demonstrated that the plasmid-borne leu-500 minimal promoter cannot be activated in topA mutants unless adjacent (<250 bp) transcription occurs away from the leu-500 promoter (short-range promoter interaction). To search for a potential upstream promoter responsible for activation of leu-500 in the chromosomal context, we have identified the ilvlH promoter, located 1.9 kb upstream of leu-500 (long-range promoter interaction). Different from short-range promoter interaction, which is abolished by DNA sequence insertions, the long-range promoter interaction is mediated by the intervening DNA sequence. These studies suggest that the long-range interaction between a pair of divergently arrayed promoters is probably mediated by a complex process involving relay of DNA supercoiling by the DNA sequence located between the two promoters.			WU, HY (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201, USA.							BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; CALVO JM, 1969, J BACTERIOL, V97, P1272, DOI 10.1128/JB.97.3.1272-1282.1969; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUBANAU E, 1972, MOL GEN GENET, V117, P91; ECCLES MR, 1994, ONCOGENE, V9, P2059; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GEMMILL RM, 1983, J MOL BIOL, V170, P39, DOI 10.1016/S0022-2836(83)80226-5; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MARGOLIN P, 1963, GENETICS, V48, P441; McKenney K, 1981, Gene Amplif Anal, V2, P383; MENZEL R, 1987, J BACTERIOL, V169, P1272, DOI 10.1128/jb.169.3.1272-1278.1987; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUKAI FH, 1963, P NATL ACAD SCI USA, V50, P140, DOI 10.1073/pnas.50.1.140; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; PLATKO JV, 1990, J BACTERIOL, V172, P4563, DOI 10.1128/jb.172.8.4563-4570.1990; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; SMITH GR, 1981, CELL, V24, P599, DOI 10.1016/0092-8674(81)90085-4; SQUIRES CH, 1983, J BACTERIOL, V154, P1054, DOI 10.1128/JB.154.3.1054-1063.1983; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; UMBARGER HE, 1987, ESCHERICHIA COLI SAL, V1, P352; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	37	42	43	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					445	451		10.1016/0092-8674(95)90433-6	http://dx.doi.org/10.1016/0092-8674(95)90433-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634334	Bronze			2022-12-01	WOS:A1995RP24200014
J	CAI, H; LEVINE, V				CAI, H; LEVINE, V			MODULATION OF ENHANCER-PROMOTER INTERACTIONS BY INSULATORS IN THE DROSOPHILA EMBRYO	NATURE			English	Article							DOMAIN BOUNDARIES; PROTEIN; REPRESSION; EXPRESSION; CONVERSION; SILENCER; ELEMENT; ASSAY; GENE	INSULATOR DNAs, or boundary elements, functionally isolate neighbouring genes by blocking interactions between distal enhancers and inappropriate target promoters(1-5). The best-characterized insulators in Drosophila correspond to a 340-base-pair (bp) fragment from the gypsy retrotransposon(3), and the scs and scs' sequences flanking the 87A1 hsp70 locus(1,2). Here we demonstrate that both insulators block the interaction of defined even-skipped (eve) stripe enhancers(6,7) when positioned between the enhancer and the target promoter. The simultaneous use of two stripe enhancers (eve stripes 2 and 3) provides evidence that enhancers lying distal to the insulator are selectively blocked. The insertion of stripe- insulator-stripe sequences between two divergently transcribed promoters indicates that enhancers barred from acting on one basal promoter are fully accessible to appropriate regulatory factors for activating the other promoter. These results suggest that insulators do not propagate changes in chromatin structure. Finally, we present evidence that the gypsy insulator does not block interactions between a silencer element and a basal promoter, Taken together, these results suggest that insulators might not be restricted to the functional isolation of neighbouring genetic loci. Rather, they might function as flexible regulatory elements that modulate enhancer-promoter interactions within complex promoters and complex genetic loci.			CAI, H (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,PACIFIC HALL,LA JOLLA,CA 92093, USA.			Levine, Michael/0000-0001-7629-0081				CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GINDHART JG, 1995, GENETICS, V139, P781; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SMALL S, 1993, DEVELOPMENT, V119, P767; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1	16	188	190	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					533	536		10.1038/376533a0	http://dx.doi.org/10.1038/376533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637789				2022-12-01	WOS:A1995RN62200051
J	CARROLL, SB				CARROLL, SB			HOMEOTIC GENES AND THE EVOLUTION OF ARTHROPODS AND CHORDATES	NATURE			English	Review							BITHORAX-COMPLEX; HOMEOBOX GENES; LIMB DEVELOPMENT; FOSSIL RECORD; DISTAL-LESS; HOX GENES; WNT GENE; DROSOPHILA; ANTENNAPEDIA; ORIGIN	Clusters of homeotic genes sculpt the morphology of animal body plans and body parts. Different body patterns may evolve through changes in homeotic gene number, regulation or function. Recent evidence suggests that homeotic gene clusters were duplicated early in vertebrate evolution, but the generation of arthropod and tetrapod diversity has largely involved regulatory changes in the expression of conserved arrays of homeotic genes and the evolution of interactions between homeotic proteins and the genes they regulate.			CARROLL, SB (corresponding author), UNIV WISCONSIN, HOWARD HUGHES MED INST, RM BOCK LABS, 1525 LINDEN DR, MADISON, WI 53706 USA.							AHLBERG PE, 1991, NATURE, V354, P298, DOI 10.1038/354298a0; AKAM M, 1994, DEVELOPMENT, P209; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1993, BIOESSAYS, V15, P439, DOI 10.1002/bies.950150702; BIRKETSMITH SJR, 1984, PROLEGS LEGS WINGS I; Bonner JT., 1988, EVOLUTION COMPLEXITY; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; Brusca R.C., 1990, INVERTEBRATES; BURKE AC, 1995, DEVELOPMENT, V121, P333; Carroll RL., 1988, VERTEBRATE PALEONTOL; CARROLL SB, 1995, NATURE, V375, P58, DOI 10.1038/375058a0; CARTWRIGHT P, 1993, MOL PHYLOGENET EVOL, V2, P185, DOI 10.1006/mpev.1993.1019; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; DICKINSON WJ, 1991, EVOLUTIONARY BIOL, P127; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GANS C, 1975, AM ZOOL, V15, P455; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GINDHART JG, 1995, GENETICS, V139, P781; GOLDSCHMIDT RB, 1940, MATERIAL BASIS EVOLU; Gould S.J., 1977, ONTOGENY PHYLOGENY; GRAHAM A, 1994, CURR BIOL, V4, P1135, DOI 10.1016/S0960-9822(00)00256-6; HOGAN BLM, 1994, DEVELOPMENT, P53; HOLLAND PWH, 1994, DEVELOPMENT, P125; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JACOBS DK, 1990, P NATL ACAD SCI USA, V87, P4406, DOI 10.1073/pnas.87.11.4406; KAUFMAN T, 1990, GENETIC REGULATORY H; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOSTRIKEN R, 1992, DEV BIOL, V151, P225, DOI 10.1016/0012-1606(92)90229-A; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANN RS, 1994, DEVELOPMENT, V120, P3205; MASTICK GS, 1995, GENETICS, V139, P349; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1994, SCI AM, V270, P58, DOI 10.1038/scientificamerican0294-58; MCGINNIS W, 1994, GENETICS, V137, P607; MISOF B, 1995, CCE24 YAL U TECH REP; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Nijhout HF., 1991, DEV EVOLUTION BUTTER; Ohno S., 1970, EVOLUTION GENE DUPLI, DOI [10.1007/978-3-642-86659-3_11, DOI 10.1007/978-3-642-86659-3]; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; Raff R.A., 1983, EMBRYOS GENES EVOLUT; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RUDDLE FH, 1994, DEVELOPMENT, P155; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SHANKLAND M, 1991, DEVELOPMENT, P29; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WALLACE B, 1985, Q REV BIOL, V60, P31, DOI 10.1086/414172; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; WHEELER WC, 1993, CLADISTICS, V9, P1, DOI 10.1111/j.1096-0031.1993.tb00207.x; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WILSON AC, 1985, SCI AM, V253, P164, DOI 10.1038/scientificamerican1085-164; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	76	526	543	3	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	1995	376	6540					479	485		10.1038/376479a0	http://dx.doi.org/10.1038/376479a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637779				2022-12-01	WOS:A1995RN62200036
J	CLEMENT, K; VAISSE, C; MANNING, BS; BASDEVANT, A; GUYGRAND, B; RUIZ, J; SILVER, KD; SHULDINER, AR; FROGUEL, P; STROSBERG, AD				CLEMENT, K; VAISSE, C; MANNING, BS; BASDEVANT, A; GUYGRAND, B; RUIZ, J; SILVER, KD; SHULDINER, AR; FROGUEL, P; STROSBERG, AD			GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC RECEPTOR AND AN INCREASED CAPACITY TO GAIN WEIGHT IN PATIENTS WITH MORBID-OBESITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION	Background. The beta(3)-adrenergic receptor, located mainly in adipose tissue, is involved in the regulation of lipolysis and thermogenesis, The potential relevance of this receptor to obesity in humans led us to screen obese French patients for a recently identified mutation in the gene for the receptor. Methods. We used the polymerase chain reaction to amplify a region of the gene for the beta(3)-adrenergic receptor encoding amino acid residues 27 to 110 in genomic DNA extracted from leukocytes from 185 patients with morbid obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], >40) and 94 normal subjects. A mutation resulting in the replacement of tryptophan by arginine at position 64 (Trp64Arg) was detected by an analysis of restriction-fragment-length polymorphisms with the use of the endonuclease BstNI, which discriminates between the normal and mutant sequences. Results. The frequency of the Trp64Arg allele was similar in the morbidly obese patients and the normal subjects (0.08 and 0.10, respectively), However, the patients with morbid obesity who were heterozygous for the Trp64Arg mutation had an increased capacity to gain weight; the mean weight in the 14 heterozygous patients was 140 kg, as compared with 126 kg in the 171 patients without the mutation (P=0.03), There were no homozygotes in this sample, The cumulative 25-year change in weight (from the age of 20 years) was 67 kg in the Trp64Arg heterozygotes, as compared with 51 kg in those without the mutation. The maximal weight differential (the maximal lifetime weight minus the weight at 20 years of age) in the Trp64Arg heterozygotes was 74 kg, as compared with 59 kg in the patients without the mutation (P=0.02), Conclusions. People with the Trp64Arg mutation of the gene for the beta(3)-adrenergic receptor may have an increased capacity to gain weight.	INST PASTEUR,CNRS,UNITE EP10,F-59019 LILLE,FRANCE; UNIV HOSP LILLE,LILLE,FRANCE; HOP HOTEL DIEU,DEPT NUTR,F-75181 PARIS,FRANCE; INST COCHIN GENET MOLEC,IMMUNOPHARMACOL MOLEC LAB,CNRS,UNITE UPR 0415,F-75014 PARIS,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University			Vaisse, Christian/F-1067-2011; Clément, karine/R-1120-2017; FROGUEL, Philippe/O-6799-2017	FROGUEL, Philippe/0000-0003-2972-0784; Shuldiner, Alan/0000-0001-9921-4305				Adams T D, 1993, Obes Res, V1, P261; Arbeeny C. M., 1994, International Journal of Obesity, V18, P4; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BOUCHARD C, 1988, ANNU REV NUTR, V8, P259, DOI 10.1146/annurev.nu.08.070188.001355; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; PRICE RA, 1990, HUM BIOL, V62, P747; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; Sambrook J., 1989, MOL CLONING LAB MANU; Susulic V. S., 1994, International Journal of Obesity, V18, P5; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603	15	581	600	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					352	354		10.1056/NEJM199508103330605	http://dx.doi.org/10.1056/NEJM199508103330605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609752				2022-12-01	WOS:A1995RN08200005
J	CULLEN, PJ; HSUAN, JJ; TRUONG, O; LETCHER, AJ; JACKSON, TR; DAWSON, AP; IRVINE, RF				CULLEN, PJ; HSUAN, JJ; TRUONG, O; LETCHER, AJ; JACKSON, TR; DAWSON, AP; IRVINE, RF			IDENTIFICATION OF A SPECIFIC INS(1,3,4,5)P-4-BINDING PROTEIN AS A MEMBER OF THE GAP1 FAMILY	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; BUD-SITE-SELECTION; YEAST	INOSITOL 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) is produced rapidly from inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) in stimulated cells(1,2). Despite extensive experimentation, no clearly defined cellular function has yet been described for this inositol phosphate. Binding sites specific for Ins(1,3,4,5)P-4 have been identified in several tissues(3,4), and we have purified one such protein to homogeneity(5). Its high affinity for Ins(1,3,4,5)P-4, and its exquisite specificity for this isomeric configuration(5,6), suggest it may be an Ins(1,3,4,5)P-4 receptor. Here we report the cloning and characterization of this protein as a GTPase-activating protein, specifically a member of the GAP family. In vitro it shows GAP activity against both Rap and Ras, but only the Ras GAP activity is inhibited by phospholipids and is specifically stimulated by Ins(1,3,4,5)P-4.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV CAMBRIDGE, BABRAHAM INST, DEPT ZOOL, MOLEC SIGNALLING LAB, CAMBRIDGE CB2 3EJ, ENGLAND	University of East Anglia; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	CULLEN, PJ (corresponding author), BABRAHAM INST, INOSITIDE LAB, BABRAHAM HALL, CAMBRIDGE CB2 4AT, ENGLAND.		Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Cullen, Peter/0000-0002-9070-8349				BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; CORVAZIER E, 1991, BIOCHEM J, V281, P323; CULLEN PJ, 1994, BIOCHEM J, V298, P739, DOI 10.1042/bj2980739; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1992, BIOCHEM J, V288, P149, DOI 10.1042/bj2880149; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HASHII M, 1993, J BIOL CHEM, V268, P19403; IRVINE RF, 1993, CURR BIOL, V3, P540, DOI 10.1016/0960-9822(93)90052-P; IRVINE RF, 1992, INOSITOL PHOSPHATE C, P161; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MANNING DR, 1991, THROMB HAEMOSTASIS, V66, P393; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8846; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914	21	287	289	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					527	530		10.1038/376527a0	http://dx.doi.org/10.1038/376527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637787				2022-12-01	WOS:A1995RN62200049
J	FARNSWORTH, CL; FRESHNEY, NW; ROSEN, LB; GHOSH, A; GREENBERG, ME; FEIG, LA				FARNSWORTH, CL; FRESHNEY, NW; ROSEN, LB; GHOSH, A; GREENBERG, ME; FEIG, LA			CALCIUM ACTIVATION OF RAS MEDIATED BY NEURONAL EXCHANGE FACTOR RAS-GRF	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; PROTEIN; GENE; EXPRESSION; DOMAIN; CDC25; IDENTIFICATION; ASSOCIATION; INHIBITION	TYROSINE kinase receptors stimulate the Ras signalling pathway by enhancing the activity of the SOS nucleotide-exchange factor(1) This occurs, at least in part, by the recruitment of an SOS-GRB2 complex to Ras in the plasma membrane. Here we describe a different signalling pathway to Ras that involves activation of the Ras-GRF exchange factor(2-4) in response to Ca2+-influx, In particular, se show that the ability of Ras-CRF to activate Ras in vivo is markedly enhanced by raised Ca2+ concentrations. Activation is mediated by calmodulin binding to an IQ motif(5) in Ras-GRF, because substitutions in conserved amino acids in this motif prevent both calmodulin binding to Ras-CRF and Ras-GRF activation in vivo, So far, full-length Ras-GRF has been detected only in brain neurons(2,6,7), Our findings implicate Ras-GRF in the regulation of neuronal functions that are influenced by Ca2+ signals.	HARVARD UNIV,CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02111; HARVARD UNIV,CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 01215	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	FARNSWORTH, CL (corresponding author), TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111, USA.		Farnsworth, Christine/Q-5617-2018	Farnsworth, Christine/0000-0001-7615-3749; Freshney, Norman/0000-0002-6342-341X				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1994, MOL CELL BIOL, V13, P7718; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheney R. E., 1994, Molecular Biology of the Cell, V5, p21A; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D	28	379	386	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					524	527		10.1038/376524a0	http://dx.doi.org/10.1038/376524a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637786				2022-12-01	WOS:A1995RN62200048
J	FRITZ, CC; ZAPP, ML; GREEN, MR				FRITZ, CC; ZAPP, ML; GREEN, MR			A HUMAN NUCLEOPORIN-LIKE PROTEIN THAT SPECIFICALLY INTERACTS WITH HIV REV	NATURE			English	Article							VIRUS TYPE-1 REV; PORE COMPLEX PROTEIN; ACTIVATION DOMAIN; I REX; DEFINITION; MOTIF	THE Rev protein of human immunodeficiency virus type I (HIV-1) facilitates the nuclear export of unspliced and partly spliced viral RNAs. Rev contains an RNA binding domain, required for interaction with HIV-1 RNA, and an effector domain, required for RNA-bound Rev to function. The Rev effector domain is believed to interact with a cellular cofactor required for the Rev response and thus HIV-1 replication(1,2). Here we report the use of a yeast two-hybrid screen to clone human Rev interacting protein (hRIP), which specifically interacts with the Rev effector domain. This hRIP protein has hemology with nucleoporins, a class of proteins that mediate nucleocytoplasmic transport(3,4). These and other properties of hRIP are those expected of a Rev cellular cofactor.			FRITZ, CC (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,SUITE 309,WORCESTER,MA 01605, USA.		Williamson, James R/B-2891-2009	Williamson, James R/0000-0002-8772-468X				CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GORSCH LC, 1995, CELL BIOL, V129, P939; Green MR, 1993, AIDS RES REV, V3, P41; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; ZHANG GH, 1994, NATURE, V372, P809	20	238	243	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					530	533		10.1038/376530a0	http://dx.doi.org/10.1038/376530a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637788				2022-12-01	WOS:A1995RN62200050
J	GOSHIMA, Y; NAKAMURA, F; STRITTMATTER, P; STRITTMATTER, SM				GOSHIMA, Y; NAKAMURA, F; STRITTMATTER, P; STRITTMATTER, SM			COLLAPSIN-INDUCED GROWTH CONE COLLAPSE MEDIATED BY AN INTRACELLULAR PROTEIN RELATED TO UNC-33	NATURE			English	Article							AXONAL GUIDANCE; ELEGANS; GAP-43; OUTGROWTH; NEURONS; BRAIN	COLLAPSIN(1), a member of the newly recognized semaphorin family(2-4), contributes to axonal pathfinding during neural development by inhibiting growth cone extension(1-5). The mechanism of collapsin action is poorly understood, Here we use a Xenopus laevis oocyte expression system to identify molecules involved in collapsin signalling, because several experiments have raised the possibility that heterotrimeric GTP-binding proteins might participate in these events(6-9). A collapsin response mediator protein of relative molecular mass (M(r)) 62K (CRMP-62) required for collapsin-induced inward currents in X. laevis oocytes is isolated. CRMP-62 shares homology with UNC-33, a nematode neuronal protein required for appropriately directed axonal extension(10-12), CRMP-62 is localized exclusively in the developing chick nervous system. Introduction of anti-CRMP-62 antibodies into dorsal root ganglion neurons blocks collapsin-induced growth cone collapse. CRMP-62 appears to be an intracellular component of a signalling cascade initiated by an unidentified transmembrane collapsin-binding protein.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT NEUROBIOL,NEW HAVEN,CT 06520	Yale University; Yale University			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BORASIO GD, 1989, NEURON, V2, P1087; DURIEUX ME, 1992, AM J PHYSIOL, V363, pC896; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LAPOINTE G, 1994, APPL ENVIRON MICROB, V60, P888, DOI 10.1128/AEM.60.3.888-895.1994; LI W, 1992, GENETICS, V132, P675; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MORIARTY TM, 1990, G PROTEINS, P479; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RAPER JA, 1990, NEURON, V2, P21; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TYGYL G, 1992, J BIOL CHEM, V267, P21360; YANG YS, 1993, J BIOL CHEM, V268, P10870	22	612	626	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					509	514		10.1038/376509a0	http://dx.doi.org/10.1038/376509a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637782				2022-12-01	WOS:A1995RN62200043
J	GURDON, JB; MITCHELL, A; MAHONY, D				GURDON, JB; MITCHELL, A; MAHONY, D			DIRECT AND CONTINUOUS ASSESSMENT BY CELLS OF THEIR POSITION IN A MORPHOGEN GRADIENT	NATURE			English	Article							MESODERM INDUCTION; XENOPUS; RESPONSES; ACTIVIN; HOMOLOG	ACCORDING to the morphogen gradient concept(1-5), cells in one part of an embryo secrete diffusible molecules (morphogens) that spread to other nearby cells and activate genes at different threshold concentrations, Strong support for the operation of a morphogen gradient mechanism in vertebrate development has come from the biochemical experiments of Green and Smith(6,7), who induced different kinds of gene expression in amphibian blastula cells exposed to small changes in activin concentration, But the interpretation of these experiments has been complicated by recent reports that cells tested for gene expression 3 hours after exposure to activin fail to show the graded response previously reported at 15 hours(6,7), a result suggesting that cells recognize their position in a gradient by an indirect mechanism, Here we conclude from the in situ analysis of blastula tissue containing activin-loaded beads(11) that cells respond directly to changing morphogen concentrations, in a way that resembles a ratchet-like process.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE,ENGLAND	University of Cambridge	GURDON, JB (corresponding author), CANC RES CAMPAIGN,WELLCOME INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRICKELL PM, 1989, BIOESSAYS, V11, P145, DOI 10.1002/bies.950110508; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1995, BIOESSAYS, V17, P93, DOI 10.1002/bies.950170202; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONES EA, 1987, DEVELOPMENT, V101, P557; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [10.1242/dev.200356, DOI 10.1242/DEV.200356]; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SYMES K, 1987, DEVELOPMENT, V101, P339; SYMES K, 1994, DEVELOPMENT, V120, P2339; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VIZE PD, 1994, TRENDS GENET, V10, P371, DOI 10.1016/0168-9525(94)90134-1; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1989, DEVELOPMENT, V107, P3	22	133	133	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					520	521		10.1038/376520a0	http://dx.doi.org/10.1038/376520a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637784				2022-12-01	WOS:A1995RN62200046
J	KOCH, AE; HALLORAN, MM; HASKELL, CJ; SHAH, MR; POLVERINI, PJ				KOCH, AE; HALLORAN, MM; HASKELL, CJ; SHAH, MR; POLVERINI, PJ			ANGIOGENESIS MEDIATED BY SOLUBLE FORMS OF E-SELECTIN AND VASCULAR CELL-ADHESION MOLECULE-1	NATURE			English	Article							HUMAN-ENDOTHELIAL-CELLS; TUMOR NECROSIS FACTOR; EXPRESSION; DISTINCT; EPITOPES; LEWIS	ENDOTHELIAL adhesion molecules facilitate the entry of leukocytes into inflamed tissues. This in turn promotes neovascularization, a process central to the progression of rheumatoid arthritis, tumour growth and wound repair(1). Here we test the hypothesis that soluble endothelial adhesion molecules promote angiogenesis(2-4), Human recombinant soluble E-selectin and soluble vascular cell adhesion molecule-1 induced chemotaxis of human endothelial cells in vitro and were angiogenic in rat cornea. Soluble E-selectin acted on endothelial cells in part through a sialyl Lewis-X-dependent mechanism, while soluble vascular cell adhesion molecule-1 acted on endothelial cells in part through a very late antigen (VLA)-4 dependent mechanism, The chemotactic activity of rheumatoid synovial fluid for endothelial cells, and also its angiogenic activity, were blocked by antibodies to either soluble E-selectin or soluble vascular cell adhesion molecule-1. These results suggest a novel function for soluble endothelial adhesion molecules as mediators of angiogenesis.	LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611; UNIV MICHIGAN,SCH DENT,MOLEC PATHOGENESIS LAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	KOCH, AE (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ARTHRIT & CONNECT TISSUE DIS SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Koch, Alisa E/B-6894-2011; Polverini, Peter/AAJ-8392-2020					BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CARLOS TM, 1990, BLOOD, V76, P965; CARSON CW, 1994, J RHEUMATOL, V21, P605; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; GILLARD BK, 1987, ARCH BIOCHEM BIOPHYS, V256, P435, DOI 10.1016/0003-9861(87)90600-X; JOHNSON BA, 1993, ARTHRITIS RHEUM, V36, P137, DOI 10.1002/art.1780360203; KLAGSBRUN M, 1991, REV PHYSL, V53, P217; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1991, LAB INVEST, V64, P313; KOCH AE, 1993, CLIN IMMUNOL IMMUNOP, V69, P29, DOI 10.1006/clin.1993.1146; KOCH AE, 1994, J IMMUNOL, V152, P149; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LOBB RR, 1991, J IMMUNOL, V147, P124; MASSIA SP, 1992, J BIOL CHEM, V267, P14109; MUNRO JM, 1992, AM J PATHOL, V141, P1392; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PAAVONEN T, 1992, AM J PATHOL, V141, P1259; POBER JS, 1986, J IMMUNOL, V136, P1680; PULIDO R, 1991, J BIOL CHEM, V266, P10241; Winer BJ., 1971, STAT PRINCIPLES EXPT	25	511	551	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					517	519		10.1038/376517a0	http://dx.doi.org/10.1038/376517a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7543654	Green Submitted			2022-12-01	WOS:A1995RN62200045
J	LABARCA, C; NOWAK, MW; ZHANG, HY; TANG, LX; DESHPANDE, P; LESTER, HA				LABARCA, C; NOWAK, MW; ZHANG, HY; TANG, LX; DESHPANDE, P; LESTER, HA			CHANNEL GATING GOVERNED SYMMETRICALLY BY CONSERVED LEUCINE RESIDUES IN THE M2 DOMAIN OF NICOTINIC RECEPTORS	NATURE			English	Article							DESENSITIZATION	IN nicotinic acetylcholine receptors (nAChR), as well as glycine, GABA(A) (gamma-aminobutyric acid), serotonin (5-HT3), and GluCl glutamate receptors, a leucine residue at the approximate midpoint of the M2 transmembrane domain (the 9' position(1)) is conserved across most known subunits(2). Structural data for the nAChR suggest that the Leu 9' residues occupy a 'kink' in each of the five M2 helices and point into the closed channel; in the opening step, the M2 helices rotate so that Leu 9' side chains no longer occlude the conduction pathway(3), Mutation of Leu 9' to one of several other residues slows desensitization and increases sensitivity to agonist(4-6). We have exploited the alpha(2) beta gamma delta stoichiometry of muscle nAChR to express receptors with m(s)* = 0 to 5 Leu 9'Scr mutated subunits. Strikingly, each Leu 9'Ser mutation shifts the dose-response relation for ACh to the left by similar to 10-fold; a nAChR with m(s)* = 4 is 10(4)-fold more sensitive than the wild type, The results suggest that each of the five Leu 9' residues participates independently and symmetrically in a key step in the structural transition between the closed and open states.			LABARCA, C (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.			Nowak, Mark/0000-0001-5097-2682				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; CHARNET P, 1990, NEURON, V2, P87; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SIGURDSON W, 1994, BIOPHYS J, V66, pA212; SIGWORTH FJ, 1987, BIOPHYS J, V52, P147; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WATHEY JC, 1979, BIOPHYS J, V27, P145, DOI 10.1016/S0006-3495(79)85208-X; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030	15	266	269	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					514	516		10.1038/376514a0	http://dx.doi.org/10.1038/376514a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637783				2022-12-01	WOS:A1995RN62200044
J	MADDOX, J				MADDOX, J			DIRECTORY TO THE HUMAN GENOME	NATURE			English	Article																			0	7	7	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					459	460		10.1038/376459a0	http://dx.doi.org/10.1038/376459a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637774				2022-12-01	WOS:A1995RN62200017
J	MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO				MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO			BLUNT IMPACT TO THE CHEST LEADING TO SUDDEN-DEATH FROM CARDIAC-ARREST DURING SPORTS ACTIVITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-QT SYNDROME; COMMOTIO-CORDIS; MYOCARDIAL-INFARCTION; YOUNG-ADULTS	Background. Sudden death from cardiac arrest in a young person may occur during sports play after a blunt blow to the chest in the absence of structural cardiovascular disease or traumatic injury (cardiac concussion or commotio cordis). We studied the clinical features of this apparently uncommon but important phenomenon. Methods. We identified cases from the registries of relevant agencies and organizations, as well as news-media accounts, and developed a clinical profile of 25 children and young adults, 3 to 19 years of age. Results. Each victim collapsed with cardiac arrest immediately after an unexpected blow to the chest, which was usually inflicted by a projectile (such as a baseball or hockey puck), Incidents took place during organized competitive sports in 16 cases and in recreational settings at home, at school, or on the playground in 9, in each instance, the impact to the chest was not judged to be extraordinary for the sport involved and did not appear to have sufficient force to cause death. Twelve victims collapsed virtually instantaneously on impact, whereas 13 remained conscious and physically active for a brief time before cardiac arrest. Cardiopulmonary resuscitation was administered within about three minutes to 19 victims, but normal cardiac rhythm could be restored in only 2 (both incurred irreversible brain damage and died shortly thereafter), Seven victims (28 percent) were wearing some form of protective chest padding. Conclusions. We speculate that most sudden deaths related to impact to the chest (not associated with traumatic injury) are due to ventricular dysrhythmia induced by an abrupt, blunt precordial blow, presumably delivered at an electrically vulnerable phase of ventricular excitability. This profile of blunt chest impact leading to cardiac arrest adds to our understanding of the range of causes of sudden death on the athletic field and may help in the development of preventive measures.	DARTMOUTH COLL SCH MED,DEPT PATHOL,LEBANON,NH; OFF NEW HAMPSHIRE STATE MED EXAMINER,LEBANON,NH; NATL CTR CATASTROPH SPORTS INJURY RES,CHAPEL HILL,NC; UNIV N CAROLINA,CHAPEL HILL,NC 27515	Dartmouth College; University of North Carolina; University of North Carolina Chapel Hill	MARON, BJ (corresponding author), MINNEAPOLIS HEART INST FDN,DIV CARDIOVASC RES,920 E 28TH ST,SUITE 40,MINNEAPOLIS,MN 55407, USA.							ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; COHN PF, 1977, CIRCULATION, V56, P598, DOI 10.1161/01.CIR.56.4.598; Cooper G J, 1989, J R Army Med Corps, V135, P58; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FERSTLE J, 1978, PHYSICIAN SPORTSMED, V6, P21; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; GROSSFELD PD, 1993, MED SCI SPORT EXER, V25, P901; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; Janda DH., 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KING AI, 1986, CPSCC841170 CONS PRO; KULBS F, 1909, MITT GRENZGEB MED CH, V19, P678; LOWN B, 1969, AM J MED, V46, P705, DOI 10.1016/0002-9343(69)90022-9; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1993, CIRCULATION, V88, P50; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; PRINGLE SD, 1987, BRIT HEART J, V57, P375; RAGOSTA M, 1984, MED SCI SPORT EXER, V16, P339; RUTHERFORD G, 1981, OVERVIEW SPORTS RELA; SMIRK FH, 1960, AM J CARDIOL, V6, P620, DOI 10.1016/0002-9149(60)90265-4; SWIFT EM, 1993, SPORTS ILLUSTRA 1206, P66; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VIANO DC, 1978, J TRAUMA, V18, P452, DOI 10.1097/00005373-197806000-00010; Viano DC, 1992, CLIN J SPORT MED, V2, P166; VIANO DC, 1992, CLIN J SPORT MED, V2, P161; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; ZOLL PM, 1976, NEW ENGL J MED, V294, P1274, DOI 10.1056/NEJM197606032942307	36	223	231	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					337	342		10.1056/NEJM199508103330602	http://dx.doi.org/10.1056/NEJM199508103330602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609749	Green Submitted			2022-12-01	WOS:A1995RN08200002
J	PELLEGRINI, L; SONG, T; RICHMOND, TJ				PELLEGRINI, L; SONG, T; RICHMOND, TJ			STRUCTURE OF SERUM RESPONSE FACTOR CORE BOUND TO DNA	NATURE			English	Article							TERNARY COMPLEX-FORMATION; C-FOS; SACCHAROMYCES-CEREVISIAE; BINDING SPECIFICITIES; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; PROTEIN; MCM1; ELEMENT; SRF	The human serum response factor is a transcription factor belonging to the MADS domain protein family with members characterized from the plant and animal kingdoms. The X-ray crystal structure of the serum response factor core in a specific-recognition DNA complex shows that the functions of DNA binding, dimerization and accessory-factor Interaction are compactly Integrated into a novel protein unit. The intrinsic and induced conformation of the serum response element DNA is the principal DNA feature recognized in the specific complex.	ETH ZURICH,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Pellegrini, Luca/AAE-2312-2022	Pellegrini, Luca/0000-0002-9300-497X				AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAGEN DC, 1993, MOL CELL BIOL, V13, P6866, DOI 10.1128/MCB.13.11.6866; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LLANG H, 1994, STRUCT BIOL, V1, P871; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKANO Y, 1991, GENE, V99, P285; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NURRISH SJ, IN PRESS MOL CELL BI; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Sprague G F Jr, 1990, Adv Genet, V27, P33; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRELSMAN R, 1994, CURR OPIN GENE DEV, V4, P96; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	51	291	296	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					490	498		10.1038/376490a0	http://dx.doi.org/10.1038/376490a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637780				2022-12-01	WOS:A1995RN62200038
J	VALLESI, A; GIULI, G; BRADSHAW, RA; LUPORINI, P				VALLESI, A; GIULI, G; BRADSHAW, RA; LUPORINI, P			AUTOCRINE MITOGENIC ACTIVITY OF PHEROMONES PRODUCED BY THE PROTOZOAN CILIATE EUPLOTES-RAIKOVI	NATURE			English	Article							MATING PHEROMONE; STRUCTURAL CHARACTERIZATION; GROWTH-FACTOR; IDENTIFICATION; PURIFICATION; RECOGNITION; CELLS; ER-1	DIFFUSIBLE polypeptide pheromones (formerly referred to as mating-type factors, sex factors or gamones), which distinguish otherwise morphologically identical vegetative cell (mating) types from one another, are produced by some species of ciliates(1,2), Their most striking effect can be observed by exposing cells of one type to a pheromone secreted by another co-specific cell type(3). In the presence of this 'non-self' signal, these cells interrupt their vegetative life to unite temporarily in mating pairs, Thus ciliate pheromones have traditionally been associated only with mating induction(2,4), However, the identification of autocrine pheromone receptors(5,6) suggests a broader role, which is supported by the hypothesis that ciliates evolved their mating-type mechanism for pursuing self-recognition(1). We now report studies, in the cosmopolitan marine sand-dwelling protozoan ciliate Euplotes raikovi, demonstrating that these molecules promote the vegetative reproduction (mitogenic proliferation or growth) of the same cells from which they originate, As, understandably, such autocrine pheromone activity is primary to that of targeting and inducing a foreign cell to mate (paracrine functions), this finding provides an example of how the original function of a molecule can be obscured during evolution by the acquisition of a new one.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine	VALLESI, A (corresponding author), UNIV CAMERINO,DIPARTIMENTO BIOL MOLEC CELLULARE & ANIM,I-62032 CAMERINO MC,ITALY.		Vallesi, Adriana/I-9933-2016; Bradshaw, Ralph A/K-1515-2013	Vallesi, Adriana/0000-0002-4127-090X; 				BEALE G, 1990, TRENDS GENET, V6, P137, DOI 10.1016/0168-9525(90)90132-P; BROWN LR, 1993, J MOL BIOL, V231, P800, DOI 10.1006/jmbi.1993.1327; CONCETTI A, 1986, J BIOL CHEM, V261, P582; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KUHLMANN HW, 1989, J EXP ZOOL, V251, P316, DOI 10.1002/jez.1402510308; LUGINBUHL P, 1994, PROTEIN SCI, V3, P1537, DOI 10.1002/pro.5560030919; LUPORINI P, 1992, DEV GENET, V13, P9, DOI 10.1002/dvg.1020130103; LUPORINI P, 1994, ANN NY ACAD SCI, V712, P195, DOI 10.1111/j.1749-6632.1994.tb33573.x; LUPORINI P, 1986, P NATL ACAD SCI USA, V83, P2889, DOI 10.1073/pnas.83.9.2889; Luporini P., 1986, P263; MICELI C, 1991, EUR J BIOCHEM, V202, P759, DOI 10.1111/j.1432-1033.1991.tb16430.x; MICELI C, 1992, P NATL ACAD SCI USA, V89, P1988, DOI 10.1073/pnas.89.5.1988; Miyake A, 1981, BIOCH PHYSL PROTOZOA, P125; MRONGA S, 1994, PROTEIN SCI, V3, P1527, DOI 10.1002/pro.5560030918; OLINS DE, 1994, INT REV CYTOL, V153, P137, DOI 10.1016/S0074-7696(08)62190-7; ORTENZI C, 1990, J CELL BIOL, V111, P607, DOI 10.1083/jcb.111.2.607; ORTENZI C, 1995, J EUKARYOT MICROBIOL, V42, P242; OTTIGER M, 1994, PROTEIN SCI, V3, P1515, DOI 10.1002/pro.5560030917; PARFENOVA EV, 1989, ACTA PROTOZOOL, V28, P11; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P2071, DOI 10.1073/pnas.89.6.2071; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; STEWART AE, 1992, PROTEIN SCI, V1, P777, DOI 10.1002/pro.5560010609; TAKAGI Y, 1994, ZOOL SCI, V10, P53; TANABE H, 1990, BIOCHEM BIOPH RES CO, V170, P786, DOI 10.1016/0006-291X(90)92160-2; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WHITBREAD JA, 1991, DEV GENET, V12, P78, DOI 10.1002/dvg.1020120114	26	64	66	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					522	524		10.1038/376522a0	http://dx.doi.org/10.1038/376522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637785	Green Submitted			2022-12-01	WOS:A1995RN62200047
J	WALSTON, J; SILVER, K; BOGARDUS, C; KNOWLER, WC; CELI, FS; AUSTIN, S; MANNING, B; STROSBERG, AD; STERN, MP; RABEN, N; SORKIN, JD; ROTH, J; SHULDINER, AR				WALSTON, J; SILVER, K; BOGARDUS, C; KNOWLER, WC; CELI, FS; AUSTIN, S; MANNING, B; STROSBERG, AD; STERN, MP; RABEN, N; SORKIN, JD; ROTH, J; SHULDINER, AR			TIME OF ONSET OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BROWN ADIPOSE-TISSUE; BETA-3-ADRENERGIC RECEPTOR; GLUCOSE-TOLERANCE; METABOLIC-RATE; OBESITY; THERMOGENESIS; MUTATIONS; CHAIN; RISK	Background. The beta(3)-adrenergic receptor is expressed in visceral adipose tissue and is thought to contribute to the regulation of the resting metabolic rate and lipolysis. Methods. To investigate whether mutations in the gene for the beta(3)-adrenergic receptor predispose patients to obesity and non-insulin-dependent diabetes mellitus (NIDDM), we studied this gene in 10 Pima Indians by analysis of single-stranded conformational polymorphisms and dideoxy sequence analysis. Association studies were performed in 642 Pima subjects (390 with NIDDM and 252 without NIDDM). Results. A missense mutation was identified in the gene for the beta(3)-adrenergic receptor that results in the replacement of tryptophan by arginine (Trp64Arg) in the first intracellular loop of the receptor. This mutation was detected with allelic frequencies of 0.31 in Pima Indians, 0.13 in 62 Mexican Americans, 0.12 in 49 blacks, and 0.08 in 48 whites in the United States. Among Pimas, the frequency of the Trp64Arg mutation was similar in nondiabetic and diabetic subjects. However, in subjects homozygous for the mutation the mean (+/-SD) age at the onset of NIDDM was significantly lower (36+/-10 years) than in Trp64Arg heterozygotes (40+/-10 years) or normal homozygotes (41 +/- 11 years; P = 0.02). Furthermore, subjects with the mutation tended to have a lower adjusted resting metabolic rate (P = 0.14 by analysis of covariance). Conclusions. Pima subjects homozygous for the Trp64Arg beta(3)-adrenergic-receptor mutation have an earlier onset of NIDDM and tend to have a lower resting metabolic rate. This mutation may accelerate the onset of NIDDM by altering the balance of energy metabolism invisceral adipose tissue.	JOHNS HOPKINS UNIV, SCH MED, DIV GERIATR MED & GERONTOL, BALTIMORE, MD 21224 USA; JOHNS HOPKINS UNIV, SCH MED, DIV ENDOCRINOL & METAB, BALTIMORE, MD USA; NIDDKD, CLIN DIABET & NUTR SECT, PHOENIX, AZ 85016 USA; NIDDKD, DIABET & ARTHRITIS EPIDEMIOL SECT, PHOENIX, AZ 85016 USA; NIA, CLIN PHYSIOL LAB, BALTIMORE, MD 21224 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; INST COCHIN GENET MOLEC, IMMUNOPHARMACOL MOLEC LAB, F-75014 PARIS, FRANCE; UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV CLIN EPIDEMIOL, SAN ANTONIO, TX 78284 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; University of Texas Health San Antonio				Shuldiner, Alan/0000-0001-9921-4305	NIA NIH HHS [5T32AG00120] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000120] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1989, METABOLISM, V38, P364, DOI 10.1016/0026-0495(89)90126-1; BOUCHARD C, 1993, WORLD REV NUTR DIET, V72, P68; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CIEMENT K, 1995, NEW ENGL J MED, V333, P352; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; CONNACHER AA, 1992, AM J CLIN NUTR, V55, P258; ELBEIN SC, 1994, DIABETES CARE, V17, P1523, DOI 10.2337/diacare.17.12.1523; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GRIFFITHS M, 1990, LANCET, V336, P76, DOI 10.1016/0140-6736(90)91592-X; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LIGGETT SB, 1992, DNA SEQUENCE, V2, P61; LYONS J, 1990, PCR PROTOCOLS GUIDE; MITCHELL BD, 1994, DIABETES CARE, V17, P567, DOI 10.2337/diacare.17.6.567; MITCHELL TH, 1989, INT J OBESITY, V13, P757; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PROCHAZKA M, 1993, DIABETES, V42, P514, DOI 10.2337/diabetes.42.4.514; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; ROTTER JI, 1990, ELLENBERG RIFKINS DI, P378; SHULDINER AR, 1993, HDB ENDOCRINE RES TE, P457; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUSULIC S, 1995, 77TH ANN M END SOC B, P36; TRAYHURN P, 1986, BIOCHEM SOC T, V14, P236, DOI 10.1042/bst0140236; TURNER RC, 1995, DIABETES, V44, P1, DOI 10.2337/diabetes.44.1.1; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; 1985, WHO TECH REP SER, V727, P7	35	566	594	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					343	347		10.1056/NEJM199508103330603	http://dx.doi.org/10.1056/NEJM199508103330603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609750				2022-12-01	WOS:A1995RN08200003
J	WIDEN, E; LEHTO, M; KANNINEN, T; WALSTON, J; SHULDINER, AR; GROOP, LC				WIDEN, E; LEHTO, M; KANNINEN, T; WALSTON, J; SHULDINER, AR; GROOP, LC			ASSOCIATION OF A POLYMORPHISM IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE WITH FEATURES OF THE INSULIN-RESISTANCE SYNDROME IN FINNS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-3-ADRENERGIC RECEPTOR; DIABETES-MELLITUS; MUSCLE; OBESITY; GLUCOSE; TISSUE; MEN	Background, Because visceral obesity predicts insulin resistance, we studied whether alterations in the gene encoding for the beta(3)-adrenergic receptor in visceral fat are associated with insulin resistance. Methods. We studied the frequency of a cytosine-to-thymidine mutation that results in the replacement of tryptophan by arginine at position 64 (Trp64Arg) of the beta(3)-adrenergic receptor by restriction-enzyme digestion with BstOl in 335 subjects from western Finland, 207 of whom were nondiabetic and 128 of whom had non-insulin-dependent diabetes mellitus (NIDDM). We also determined the frequency of the mutation in 156 subjects from southern Finland. Sensitivity to insulin was measured by the hyperinsulinemic-euglycemic clamp technique in 66 randomly selected nondiabetic subjects. Results. In the subjects from western Finland, the frequency of the mutated allele was similar in the nondiabetic subjects and the subjects with NIDDM (12 vs, 11 percent), The mean age of the subjects at the onset of diabetes was lower among those with the mutation than those without it (56 vs. 61 years, P = 0,04). Among the nondiabetic subjects, those with the mutation had a higher ratio of waist to hip circumference (P = 0.02), a greater increase in the serum insulin response after the oral administration of glucose (P = 0.05), a higher diastolic blood pressure (82 vs. 78 mm Hg, P = 0.01), and a lower rate of glucose disposal during the clamp study (5.3 vs, 6.5 mg [29 vs. 36 mu mol] per kilogram of body weight per minute; P = 0.04) than the subjects without the mutated allele. In an analysis of sibling pairs, the siblings with the mutation generally had higher waist:hip ratios (P = 0.05) and higher responses of blood glucose and serum insulin after the oral administration of glucose than their siblings without the mutation (P = 0.02 and P = 0.005, respectively). Conclusions. The Trp64Arg allele of the beta(3)-adrenergic receptor is associated with abdominal obesity acid resistance to insulin and may contribute to the early onset of NIDDM.	LUND UNIV,DEPT ENDOCRINOL,LUND,SWEDEN; HELSINKI UNIV HOSP,DEPT MED 4,SF-00170 HELSINKI,FINLAND; JOHNS HOPKINS UNIV,SCH MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD	Lund University; University of Helsinki; Helsinki University Central Hospital; Johns Hopkins University				Shuldiner, Alan/0000-0001-9921-4305				BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CARO JF, 1991, J CLIN ENDOCR METAB, V73, P691, DOI 10.1210/jcem-73-4-691; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; MARIN P, 1992, METABOLISM, V41, P1242, DOI 10.1016/0026-0495(92)90016-4; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	17	538	563	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					348	351		10.1056/NEJM199508103330604	http://dx.doi.org/10.1056/NEJM199508103330604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609751				2022-12-01	WOS:A1995RN08200004
J	ALPERS, A; LO, B				ALPERS, A; LO, B			PHYSICIAN-ASSISTED SUICIDE IN OREGON - A BOLD EXPERIMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; LIFE; CARE		UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALPERS, A (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM MED ETH,521 PARNASSUS AVE,ROOM C 126,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P474; BELKIN L, 1993, NY TIMES MAGAZI 1114, P75; BELKIN L, 1993, NY TIMES MAGAZI 1114, P74; BELKIN L, 1993, NY TIMES MAGAZI 1114, P63; Belkin Lisa, 1993, N Y Times Mag, P48; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; CHRISTAKIS N, 1993, J GEN INTERN MED, V9, P314; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Doyle D, 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; LO B, 1995, RESOLVING ETHICAL DI, P168; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	22	55	55	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					483	487		10.1001/jama.274.6.483	http://dx.doi.org/10.1001/jama.274.6.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629958				2022-12-01	WOS:A1995RM69900029
J	CHOW, WH; FINKLE, WD; MCLAUGHLIN, JK; FRANKL, H; ZIEL, HK; FRAUMENI, JF				CHOW, WH; FINKLE, WD; MCLAUGHLIN, JK; FRANKL, H; ZIEL, HK; FRAUMENI, JF			THE RELATION OF GASTROESOPHAGEAL REFLUX DISEASE AND ITS TREATMENT TO ADENOCARCINOMAS OF THE ESOPHAGUS AND GASTRIC CARDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BARRETTS-ESOPHAGUS; CIMETIDINE; CANCER	Objective.-To examine the relationship of gastrointestinal disorders and their treatment to the risk of adenocarcinomas of the esophagus and gastric cardia (AEC). Design.-A medical record-based case-control study, with data collected on a standardized form by a trained abstractor, blind to the case-control status. Setting.-A large prepaid health plan. Subjects.-Case patients were plan members newly diagnosed with histologically confirmed AEC from 1986 to 1992. For each of the 196 eligible case patients, one control was selected who matched for membership at time of diagnosis, sex, year of birth, and duration of membership. Main Outcome Measures.-Association between AEC and history of gastroesophageal conditions and their treatment. Conditional logistic regression procedures were used for calculation of odds ratios (ORs) and corresponding 95% confidence intervals (Cls), with adjustment for race, smoking status, and body mass index. Medications were grouped into H-2 antagonists (cimetidine, ranitidine, famotidine, and nizatidine) and anticholinergics (propantheline bromide, dicyclomine hydrochloride, Donnatal [combination of atropine sulfate, hyoscyamine sulfate, phenobarbital, and scopolamine hydrobromide], and Librax [combination of chlordiazepoxide hydrochloride and clidinium bromide]). Results.-Significant twofold or greater risks of AEC were associated with a history of esophageal reflux, hiatal hernia, esophagitis/esophageal ulcer, and difficulty swallowing. The ORs increased with increasing number of these conditions. Although a fourfold risk was linked to four or more prescriptions for H-2 antagonists, the risk was reduced to 1.5 (95% CI, 0.4 to 5.4) after adjusting for the predisposing conditions. Further analysis revealed that the excess risk was restricted to persons with a history of gastroesophageal reflux and related conditions. No association was observed for overall use of anticholinergics. However, after adjustment for predisposing conditions, ORs decreased with increasing number of prescriptions for anticholinergics (P for trend=.08). Conclusions.-This study provides reassuring findings that use of H-2 antagonists and anticholinergics does not increase AEC risk. It also quantifies the elevated risk of AEC associated with gastroesophageal reflux disease. Further research into reflux disease and the production of premalignant epithelial changes may help elucidate carcinogenic mechanisms and measures aimed at early detection and prevention of AEC.	INT EPIDEMIOL INST,ROCKVILLE,MD 20850; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892; SO CALIF PERMANENTE MED GRP,DEPT MED,LOS ANGELES,CA 90027; SO CALIF PERMANENTE MED GRP,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90027	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups					DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095680] Funding Source: NIH RePORTER; NCI NIH HHS [N01 CP 95680] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Breslow NE., 1980, IARC SCI PUBLICATION, V32; BROWN LM, 1994, CANCER CAUSE CONTROL, V5, P333, DOI 10.1007/BF01804984; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; COLINJONES DG, 1991, Q J MED, V78, P13; ELDER JB, 1979, LANCET, V1, P1005, DOI 10.1016/S0140-6736(79)92757-0; GAREWAL HS, 1989, PREV MED, V18, P749, DOI 10.1016/0091-7435(89)90046-7; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Harrison S L, 1992, Eur J Cancer Prev, V1, P271, DOI 10.1097/00008469-199204000-00009; KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153; LAVECCHIA C, 1992, NUTRITION, V8, P177; MACDONALD WC, 1987, CANCER, V60, P1094, DOI 10.1002/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4; Moller H, 1992, Eur J Cancer Prev, V1, P159; MOLLER H, 1992, GUT, V33, P1166, DOI 10.1136/gut.33.9.1166; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; REED PI, 1979, LANCET, V1, P1234; REID BJ, 1991, GASTROENTEROL CLIN N, V20, P817; Schumacher M C, 1990, Epidemiology, V1, P251, DOI 10.1097/00001648-199005000-00012; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; VAUGHAN TL, 1992, RECENT ADV BIOL PREV; WANG HH, 1986, HUM PATHOL, V17, P482, DOI 10.1016/S0046-8177(86)80038-7; WANG HH, 1994, CANCER CAUSE CONTROL, V5, P573, DOI 10.1007/BF01831386; [No title captured]	25	291	297	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					474	477		10.1001/jama.274.6.474	http://dx.doi.org/10.1001/jama.274.6.474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629956				2022-12-01	WOS:A1995RM69900027
J	GILSDORF, JR				GILSDORF, JR			BRAD MISSED THE MIRACLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629936				2022-12-01	WOS:A1995RM69900002
J	LOZANO, P; CONNELL, FA; KOEPSELL, TD				LOZANO, P; CONNELL, FA; KOEPSELL, TD			USE OF HEALTH-SERVICES BY AFRICAN-AMERICAN CHILDREN WITH ASTHMA ON MEDICAID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD ASTHMA; UNITED-STATES; RACE; HOSPITALIZATIONS; PREVALENCE; MORTALITY; TRENDS; EVENTS; SODIUM	Objective.-To determine whether African-American children with asthma use more emergency department (ED) and inpatient medical services and fewer preventive services than white children with similar insurance coverage and family income. Design.-Historical cohort study using Medicaid claims data, Setting.-Aid to Families With Dependent Children enrollees aged 3 through 17 years in the Seattle-Tacoma, Wash, metropolitan area. Patients.-All 576 African-American children and 1369 white children receiving services for asthma between June 1988 and December 1992. Main Outcome Measures.-Utilization of asthma services (ED, inpatient, office visits, and pharmacy) and well-child services and associated Medicaid reimbursements, Results.-African-American children were more likely than white children to make ED visits or to be hospitalized for asthma; adjusted odds ratios (ORs) were 1.70 (95% confidence interval [CI], 1.34 to 2.15) and 1.42 (95% CI, 1.03 to 1.96), respectively, African-American children were less likely to have made an office visit for asthma; the adjusted OR was 0.48 (95% CI, 0.26 to 0.85). The two groups were similarly likely to have filled a prescription for an asthma medication and to have made a well-child visit. Per capita payments for asthma services were 24% higher for African-American children: $436 vs $350 per child-year. Conclusions.-Higher use of ED and inpatient services for asthma among African-American children using Medicaid (compared with white children) cannot be fully explained by poverty or inadequate health insurance. Furthermore, these children appear to make disproportionately few office visits for asthma, suggesting suboptimal use of preventive services for asthma. In contrast, the comparable use of well-child visits in the two groups suggests the problem may not be in access to care in general, but there may be specific problems in the successful management of chronic diseases such as asthma among African-American children.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LOZANO, P (corresponding author), GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,1730 MINOR AVE,SUITE 1600,SEATTLE,WA 98101, USA.		Lozano, Paula Maria/GPP-4090-2022		PHS HHS [MCJ-9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSCO LA, 1993, CHEST, V104, P1727, DOI 10.1378/chest.104.6.1727; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARR W, 1989, SOC SCI MED, V29, P705, DOI 10.1016/0277-9536(89)90149-4; COGSWELL JJ, 1985, ARCH DIS CHILD, V60, P736, DOI 10.1136/adc.60.8.736; CONNELL FA, 1987, ANNU REV PUBL HEALTH, V8, P51, DOI 10.1146/annurev.publhealth.8.1.51; Duan N., 1983, J EC BUSINESS STATIS, V1, P115, DOI [DOI 10.2307/1391852, 10.2307/1391852]; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; FITZPATRICK SB, 1992, J NATL MED ASSOC, V84, P233; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; KLEIN R, 1977, PEDIATRICS, V60, P7; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; ROBINSON JC, 1991, INQUIRY-J HEALTH CAR, V28, P107; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SLY RM, 1988, ANN ALLERGY, V60, P433; TAYLOR WR, 1992, PEDIATRICS, V90, P657; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1991, NIH PHS913042 NAT HE; 1992, STATE AM CHILDREN 19	27	162	163	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					469	473		10.1001/jama.274.6.469	http://dx.doi.org/10.1001/jama.274.6.469			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629955				2022-12-01	WOS:A1995RM69900026
J	MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE				MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE			THE INACCESSIBILITY OF ADVANCE DIRECTIVES ON TRANSFER FROM AMBULATORY TO ACUTE-CARE SETTINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATTITUDES	Objective.-To investigate the accessibility of patients' previously executed advance directives during an acute hospitalization. Design.-Retrospective chart review. Setting.-A large metropolitan teaching hospital, a 514-bed skilled nursing facility, a geriatrics ambulatory care clinic, and a geriatrics group practice office. Patients.-One hundred fourteen geriatric patients who had previously executed an advance directive. Main Outcome Measures.-The medical records of 180 admissions over 3 years, 1991 through 1993, were reviewed for documentation of patients' advance directive status. Results.-Twenty-six percent of patients who had previously executed advance directives had their directives recognized during their hospitalization. Of the subgroup of patients who were judged not to have the capacity to make medical decisions during their admissions, 26% (14/53) had their directives recognized. When the advance directive was recognized, it appeared to influence treatment decisions in 12 (86%) of 14 cases. Conclusions.-Previously executed advance directives are not accessible when patients are admitted to hospitals for acute illness. When such directives are recognized, they are used to influence medical treatment decisions. Further research is needed to define and overcome barriers to this inaccessibility.	JEWISH HOME & HOSP AGED NEW YORK,NEW YORK,NY		MORRISON, RS (corresponding author), MT SINAI MED CTR,DEPT GERIATR & ADULT DEV,BOX 1070,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.							DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GHUSIN HF, 1993, J AM GERIATR SOC S, V41; HIGH DM, 1994, GERONTOLOGIST, V24, P409; LIBOW LS, 1978, GERIATRICS, V33, P92; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LYNN J, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562275; MILLER MB, 1976, J AM GERIATR SOC, V24, P108, DOI 10.1111/j.1532-5415.1976.tb04281.x; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; OUSLANDER J, 1990, PRINCIPLES GERIATRIC, P331; PARIS B, 1992, J AM GERIATR SOC, V40, pA129; PARIS BEC, 1993, ARCH INTERN MED, V153, P1689, DOI 10.1001/archinte.153.14.1689; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SCHMERLING RH, 1988, J GEN INTERN MED, V3, P317; SUGARMAN J, 1994, J CLIN ETHIC, V5, P60; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1992, Q PROGR REPORT ADV D	20	139	139	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					478	482		10.1001/jama.274.6.478	http://dx.doi.org/10.1001/jama.274.6.478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629957				2022-12-01	WOS:A1995RM69900028
J	ASAI, A; FUKUHARA, S; LO, B				ASAI, A; FUKUHARA, S; LO, B			ATTITUDES OF JAPANESE AND JAPANESE-AMERICAN PHYSICIANS TOWARDS LIFE-SUSTAINING TREATMENT	LANCET			English	Article								Doctors in different countries have different approaches to bioethical problems. We studied how attitudes to life-sustaining treatment for terminally ill patients differ in Japan and the USA by administering a questionnaire to Japanese (136) and Japanese-American (77) physicians. In a series of clinical scenarios the questionnaire asked what life-sustaining interventions the doctors would recommend to a patient with metastatic gastric cancer. Most Japanese physicians would recommend blood for transfusions for gastrointestinal bleeding (74%) total parenteral nutrition for malnutrition (67%) and vasopressors for life-threatening hypotension (61%) when the patient did not know of his diagnosis and outlook. Significantly fewer Japanese physicians would want these interventions for themselves: 29% would want transfusion, 36% would want total parenteral nutrition, and 25% would want vasopressors. 36% of Japanese physicians would override the explicit request of a competent moribund cancer patient to withdraw all life-support. By contrast, among Japanese-American physicians only 42% would recommend blood transfusions, 33% total parenteral nutrition, and 34% vasopressors to a terminally ill cancer patient who did not know of his diagnosis or outlook. Cross-cultural studies in medical ethics can help physicians and the public in different countries to take a fresh took at accepted practices and the ethical reasons behind them.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT GEN INTERNAL MED,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,DIV INTERNAL HLTH,TOKYO,JAPAN	University of California System; University of California San Francisco; University of Tokyo					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRAMPTON MW, 1987, J GEN INTERN MED, V2, P394, DOI 10.1007/BF02596364; HADFIELD P, 1993, LANCET, V341, P1141, DOI 10.1016/0140-6736(93)93144-P; LO B, 1995, RESOLVING ETHICAL DI, P141; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 1994, REPORT SURVEY JAPANE	7	81	83	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					356	359		10.1016/S0140-6736(95)92230-X	http://dx.doi.org/10.1016/S0140-6736(95)92230-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM713	7623536				2022-12-01	WOS:A1995RM71300013
J	BENTLEY, E; MACKIE, IC				BENTLEY, E; MACKIE, IC			TRENDS IN PRESCRIPTIONS OF PARACETAMOL FOR CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES		UNIV MANCHESTER,HOSP DENT,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester								BENTLEY EM, 1993, HEALTH EDUC RES, V8, P519, DOI 10.1093/her/8.4.519; MACKIE IC, 1993, BRIT DENT J, V175, P93, DOI 10.1038/sj.bdj.4808242; 1979, BRIT MED J, V1, P1231	3	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					362	362		10.1136/bmj.311.7001.362	http://dx.doi.org/10.1136/bmj.311.7001.362			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640543	Green Published			2022-12-01	WOS:A1995RN46900017
J	DEBERG, JC; PATTYNAMA, PMT; OBERMANN, WR; BODE, PJ; VIELVOYE, GJ; TAMINIAU, AHM				DEBERG, JC; PATTYNAMA, PMT; OBERMANN, WR; BODE, PJ; VIELVOYE, GJ; TAMINIAU, AHM			PERCUTANEOUS COMPUTED-TOMOGRAPHY-GUIDED THERMOCOAGULATION FOR OSTEOID OSTEOMAS	LANCET			English	Note							ELECTRODE	Current treatment for osteoid osteomas is usually surgical excision of the nidus. We treated 18 patients with osteoid osteoma by percutaneous thermocoagulation of the nidus under computed-tomography guidance. The procedure was technically successful in all cases and there were no complications. Patients were discharged on the following morning and resumed normal activities immediately. Air patients but one remained pain free during follow-up (range 3-15 months). A second thermocoagulation treatment relieved the recurrent symptoms in this patient. Percutaneous thermocoagulation appears to be effective for osteoid osteomas, and is a minimally invasive alternative to surgical resection.	UNIV LEIDEN HOSP,DEPT ORTHOPAED SURG,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	DEBERG, JC (corresponding author), UNIV LEIDEN HOSP,DEPT RADIOL,2333 AA LEIDEN,NETHERLANDS.							MARCOVE RC, 1991, CLIN ORTHOP RELAT R, V267, P197; MAZOYER JF, 1991, RADIOLOGY, V181, P269, DOI 10.1148/radiology.181.1.1887046; MULDER JD, 1993, RADIOLOGIC ATLAS BON, P385; NORMAN A, 1975, CLIN ORTHOP RELAT R, V110, P233; Picci P, 1989, BONE TUMORS CLIN RAD, P226; ROSENTHAL DI, 1992, RADIOLOGY, V183, P29, DOI 10.1148/radiology.183.1.1549690; TILLOTSON CL, 1989, INVEST RADIOL, V24, P888, DOI 10.1097/00004424-198911000-00009	7	103	107	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					350	351		10.1016/S0140-6736(95)92228-8	http://dx.doi.org/10.1016/S0140-6736(95)92228-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623534				2022-12-01	WOS:A1995RM71300011
J	FRYATT, RJ				FRYATT, RJ			FOREIGN-AID AND TB CONTROL POLICY IN NEPAL	LANCET			English	Editorial Material											FRYATT, RJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON,ENGLAND.							Chan S. L., 1994, P141; 1995, STOP TB SOURCE WHO R; 1994, NATIONAL TUBERCULOSI; 1993, WORLD HLTH, V4, P2	4	7	7	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					328	328		10.1016/S0140-6736(95)92223-7	http://dx.doi.org/10.1016/S0140-6736(95)92223-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623529				2022-12-01	WOS:A1995RM71300006
J	GEDDES, JR; JUSZCZAK, E				GEDDES, JR; JUSZCZAK, E			PERIOD TRENDS IN RATE OF SUICIDE IN FIRST 28 DAYS AFTER-DISCHARGE FROM PSYCHIATRIC-HOSPITAL IN SCOTLAND, 1968-92	BRITISH MEDICAL JOURNAL			English	Article							AFTER-DISCHARGE; INPATIENT CARE; PREVENTION; RISK	Objective-To examine period trends in the rate of suicide in the first 28 days after discharge from psychiatric hospital. Design-Cohort study of patients discharged from psychiatric hospital. Setting-Scotland. Subjects-Ah patients aged 15-84 who were discharged from Scottish psychiatric hospitals during 1968 to 1992. Outcome measure-The rate of suicide (classified as codes E950-9 and E980-9 according to the International Classification of Diseases, Ninth Revision) within 28 days of discharge per 100 000 person years at risk for five year periods during 1968 to 1992. Crude, within cohort rates and externally standardised rates were calculated. Results-Overall, 196 male patients committed suicide in 20 520 person years at risk, and 171 female patients committed suicide in 24 114 person years at risk. A significant Linear trend was seen in period effect on externally standardised mortality ratios in both sexes: a decrease in male patients (P=0.008) and an increase in female patients (P=0.0001). The adjusted standardised mortality ratio in 1988-92 compared with 1968-72 was 0.62 (95% confidence interval 0.39 to 0.98) in male patients and 2.73 (1.64 to 4.56) in female patients. Conclusion-The increase in the rate of suicide in the 28 days after discharge in female psychiatric patients makes this an increasingly important period to target. The rise has occurred against the background of a reduction of 60% in the number of psychiatric beds for adults.	ROYAL EDINBURGH & ASSOCIATED HOSP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; NATL HLTH SERV SCOTLAND,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; NHS National Services Scotland				Geddes, John/0000-0002-5281-5960				ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; BAKER RJ, 1978, GLIM SYSTEM; Breslow N. E., 1987, STATISTICAL METHODS, VII; Charlton J., 1992, Population Trends, P10; Clayton DHM, 1993, STATISTICAL METHODS; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P1347; DIEKSTRA RFW, 1993, ACTA PSYCHIATR SCA S, V371, P9; ENGBERG M, 1994, ACTA PSYCHIAT SCAND, V89, P35, DOI 10.1111/j.1600-0447.1994.tb01482.x; FLOOD RA, 1968, BRIT J PSYCHIAT, V114, P443, DOI 10.1192/bjp.114.509.443; FULLEN I, 1993, BRIT MED J, V306, P710; GEDDES JR, 1994, BRIT J PSYCHIAT, V164, P564, DOI 10.1192/S0007125000051989; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; ISOMETSA E, 1993, LANCET, V342, P1055, DOI 10.1016/0140-6736(93)92913-E; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KING E, 1994, BRIT J PSYCHIAT, V165, P658, DOI 10.1192/bjp.165.5.658; KING EA, 1993, LANCET, V342, P744; KREITMAN N, 1994, HLTH B EDINB, V52, P300; MCGONIGAL G, 1992, Health Bulletin (Edinburgh), V50, P309; MORGAN HG, 1992, BRIT J PSYCHIAT, V160, P149, DOI 10.1192/bjp.160.2.149; VASSILAS CA, 1993, BRIT MED J, V307, P300, DOI 10.1136/bmj.307.6899.300; 1978, MENTAL DISORDERS GLO; 1986, MAKING REALITY COMMU; 1992, HLTH NATION STRATEGY; 1991, EGRET EPIDEMIOLOGICA	26	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					357	360		10.1136/bmj.311.7001.357	http://dx.doi.org/10.1136/bmj.311.7001.357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640540	Green Published			2022-12-01	WOS:A1995RN46900014
J	HARMER, M; DAVIES, KA; LUNN, JN				HARMER, M; DAVIES, KA; LUNN, JN			A SURVEY OF ACUTE PAIN SERVICES IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article											HARMER, M (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT ANAESTHET & INTENS CARE MED,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							CARTWRIGHT PD, 1991, ANAESTHESIA, V46, P188, DOI 10.1111/j.1365-2044.1991.tb09406.x; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; 1990, PAIN SURGERY; 1992, PAIN DISCOMFORT PALL	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					360	361		10.1136/bmj.311.7001.360	http://dx.doi.org/10.1136/bmj.311.7001.360			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640541	Green Published			2022-12-01	WOS:A1995RN46900015
J	STEEL, KP				STEEL, KP			HAIR-CELL REGENERATION - CURE FOR DEAFNESS	LANCET			English	Editorial Material							ACOUSTIC TRAUMA; INNER-EAR				STEEL, KP (corresponding author), MRC, INST HEARING RES, UNIV PK, NOTTINGHAM, ENGLAND.							CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; KESSLER J, 1995, CIBA F S, V196; LEFEBVRE PP, 1993, SCIENCE, V260, P692, DOI 10.1126/science.8480180; LEWIS J, 1991, CIBA F SYMP, V160, P25, DOI 10.4171/RMI/104; RUBEL EW, 1995, SCIENCE, V267, P701, DOI 10.1126/science.7839150; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; STAECKER H, 1995, SCIENCE, V267, P709, DOI 10.1126/science.267.5198.709; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285	10	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					325	326		10.1016/S0140-6736(95)92220-2	http://dx.doi.org/10.1016/S0140-6736(95)92220-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623526				2022-12-01	WOS:A1995RM71300003
J	WATTERS, JK				WATTERS, JK			HIV TEST-RESULTS, PARTNER NOTIFICATION, AND PERSONAL CONDUCT	LANCET			English	Editorial Material							INFECTION		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143, USA.							BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; GREEN J, 1995, LANCET, V345, P1508; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MASON HRC, 1995, HEALTH PSYCHOL, V14, P6, DOI 10.1037/0278-6133.14.1.6; NORTH RL, 1993, NEW ENGL J MED, V329, P1194, DOI 10.1056/NEJM199310143291612; PAVIA AT, 1993, AM J PUBLIC HEALTH, V83, P1418, DOI 10.2105/AJPH.83.10.1418; SIGNORILE M, 1995, NY TIMES        0226, V15; TEMMERMAN M, 1995, LANCET, V345, P969, DOI 10.1016/S0140-6736(95)90707-6; 1995, MMWR-MORBID MORTAL W, V44, P202; 1994, HIV AIDS SURVEILLANC, V6, P17; 1995, MMWR-MORBID MORTAL W, V44, P401	14	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					326	327		10.1016/S0140-6736(95)92221-0	http://dx.doi.org/10.1016/S0140-6736(95)92221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623527				2022-12-01	WOS:A1995RM71300004
J	WEILERRAVELL, D; SHUPAK, A; GOLDENBERG, I; HALPERN, P; SHOSHANI, O; HIRSCHHORN, G; MARGULIS, A				WEILERRAVELL, D; SHUPAK, A; GOLDENBERG, I; HALPERN, P; SHOSHANI, O; HIRSCHHORN, G; MARGULIS, A			PULMONARY-EDEMA AND HEMOPTYSIS INDUCED BY STRENUOUS SWIMMING	BRITISH MEDICAL JOURNAL			English	Article									IDF,MED CORPS,ISRAEL NAVAL MED INST,IL-31080 HAIFA,ISRAEL									NORSK P, 1986, EUR J APPL PHYSIOL O, V54, P608, DOI 10.1007/BF00943349; PASCOE JR, 1981, AM J VET RES, V42, P703; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U; WILMSHURST PT, 1989, LANCET, V1, P62	4	93	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					361	362		10.1136/bmj.311.7001.361	http://dx.doi.org/10.1136/bmj.311.7001.361			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640542	Green Published			2022-12-01	WOS:A1995RN46900016
J	BELL, TW; HOU, Z; LUO, Y; DREW, MGB; CHAPOTEAU, E; CZECH, BP; KUMAR, A				BELL, TW; HOU, Z; LUO, Y; DREW, MGB; CHAPOTEAU, E; CZECH, BP; KUMAR, A			DETECTION OF CREATININE BY A DESIGNED RECEPTOR	SCIENCE			English	Article							TORANDS; ASSAY	An artificial receptor has been designed to bind creatinine with a color change (chromogenic response) caused by proton transfer from one end of the receptor to the other. The receptor was synthesized and found to extract creatinine from water into chlorocarbon solvents. The color change in the organic layer is specific for creatinine relative to other organic solutes, and it is selective far creatinine relative to sodium, potassium, and ammonium ions. The chromogenic mechanism is revealed by x-ray crystal structures of creatinine, the free receptor, and the complex, showing ''induced fit'' binding resulting from electronic complementarity between host and guest.	SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; UNIV READING,DEPT CHEM,READING RG6 2AD,BERKS,ENGLAND; BAYER CORP,DIV DIAGNOST,TARRYTOWN,NY 10591	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Reading; Bayer AG								BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; BECKLES DL, 1995, TETRAHEDRON, V51, P363, DOI 10.1016/0040-4020(94)00902-7; BELL TW, 1993, PURE APPL CHEM, V65, P361, DOI 10.1351/pac199365030361; BELL TW, 1994, NATURE, V367, P441, DOI 10.1038/367441a0; BELL TW, 1986, J AM CHEM SOC, V108, P8109, DOI 10.1021/ja00285a049; BELL TW, 1993, FLUORESCENT CHEMOSEN, P85; BELL TW, 1993, ORG SYNTH, V8, P87; BUHLMANN P, 1993, TETRAHEDRON, V49, P7627, DOI 10.1016/S0040-4020(01)87238-0; BUTLER AR, 1985, J CHEM SOC PERK T 2, P1465, DOI 10.1039/p29850001465; CALABRESE GS, 1988, TOP CURR CHEM, V143, P49; CRAM DJ, 1986, ANGEW CHEM INT EDIT, V25, P1039, DOI 10.1002/anie.198610393; DUPRE S, 1955, ACTA CRYSTALLOGR, V8, P311, DOI 10.1107/S0365110X55000972; FOSSATI P, 1983, CLIN CHEM, V29, P1494; FREE HM, 1991, MODERN URINE CHEM; HIRSHFELD FL, 1980, ACTA CRYSTALLOGR B, V36, P406, DOI 10.1107/S0567740880003366; JAYNES PK, 1982, CLIN CHEM, V28, P114; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; Johnson D., 1989, CLIN CHEM, P55; KENYON GL, 1971, J AM CHEM SOC, V93, P5552, DOI 10.1021/ja00750a039; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; MAJEWICZ TG, 1974, J ORG CHEM, V39, P720, DOI 10.1021/jo00919a033; NARAYANAN S, 1980, CLIN CHEM, V26, P1119; SHELDRICK GM, 1993, SHELXI PROGRAM CRYST; Stewart J. J. P., 1993, MOPAC93; VANLENTE F, 1990, CLIN CHEM NEWS   OCT, P8	26	101	106	2	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					671	674		10.1126/science.7624796	http://dx.doi.org/10.1126/science.7624796			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624796				2022-12-01	WOS:A1995RM70200027
J	HANKS, M; WURST, W; ANSONCARTWRIGHT, L; AUERBACH, AB; JOYNER, AL				HANKS, M; WURST, W; ANSONCARTWRIGHT, L; AUERBACH, AB; JOYNER, AL			RESCUE OF THE EN-1 MUTANT PHENOTYPE BY REPLACEMENT OF EN-1 WITH EN-2	SCIENCE			English	Article							HOMEO BOX; MOUSE; EXPRESSION; MICE; SEQUENCE; GENES; RECOMBINATION; VERTEBRAE; DELETION; CHICKEN	The related mouse Engrailed genes En-1 and En-2 are expressed from the one- and approximately five-somite stages, respectively, in a similar presumptive mid-hindbrain domain. However, mutations in En-1 and En-2 produce different phenotypes. En-1 mutant mice die at birth with a large mid-hindbrain deletion, whereas En-2 mutants are viable, with cerebellar defects. To determine whether these contrasting phenotypes reflect differences in temporal expression or biochemical activity of the En proteins, En-1 coding sequences were replaced with En-2 sequences by gene targeting. This rescued all En-1 mutant defects, demonstrating that the difference between En-1 and En-2 stems from their divergent expression patterns.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute				Wurst, Wolfgang/0000-0003-4422-7410				CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; HANKS M, UNPUB; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Joyner Alexandra L., 1991, Seminars in Developmental Biology, V2, P435; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; LOGAN C, 1993, DEVELOPMENT, V117, P905; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; WURST W, 1994, DEVELOPMENT, V120, P2065; Wurst W., 1993, Gene targeting: a practical approach., P33; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	24	342	360	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	1995	269	5224					679	682		10.1126/science.7624797	http://dx.doi.org/10.1126/science.7624797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624797				2022-12-01	WOS:A1995RM70200030
J	HASHIMOTO, K; HIRAI, M; KUROSAWA, Y				HASHIMOTO, K; HIRAI, M; KUROSAWA, Y			A GENE OUTSIDE THE HUMAN MHC RELATED TO CLASSICAL HLA CLASS-I GENES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGENS; SEQUENCE; ASSIGNMENT; CDNA; ZN-ALPHA-2-GLYCOPROTEIN; EXPRESSION; XENOPUS; CLONING; FAMILY	By presenting antigenic peptides to T lymphocytes, major histocompatibility complex (MHC) class I molecules play important roles in the human immune system. Knowledge is limited on the evolutionary history of human MHC class I-related molecules. An expressed class I gene, MRI, has now been identified on human chromosome 1q25, outside the MHC. In contrast to other known human divergent class I genes, MR1 encodes peptide-binding domains similar to those encoded by human leukocyte antigen (HLA) class I genes on chromosome 6 and by nonmammalian classical MHC class I genes. This gene may thus contribute to understanding the evolution of the MHC.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	HASHIMOTO, K (corresponding author), FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN.							ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; ARUFFO A, 1989, J IMMUNOL, V143, P1723; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; BRILES WE, 1993, IMMUNOGENETICS, V37, P408, DOI 10.1007/BF00222464; BRUNS GA, 1991, CYTOGENET CELL GENET, V58, P103, DOI 10.1159/000133161; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; ELLIS SA, 1990, J IMMUNOL, V144, P731; FLAJNIK MF, 1993, EMBO J, V12, P4385, DOI 10.1002/j.1460-2075.1993.tb06123.x; GRIMHOLT U, 1993, IMMUNOGENETICS, V37, P469, DOI 10.1007/BF00222473; GROSSBERGER D, 1992, IMMUNOGENETICS, V36, P166, DOI 10.1007/BF00661093; GUILD BC, 1983, P NATL ACAD SCI-BIOL, V80, P2894, DOI 10.1073/pnas.80.10.2894; GUILLEMOT F, 1988, EMBO J, V7, P2775, DOI 10.1002/j.1460-2075.1988.tb03132.x; HASHIMOTO K, 1992, P NATL ACAD SCI USA, V89, P2209, DOI 10.1073/pnas.89.6.2209; HASHIMOTO K, 1990, P NATL ACAD SCI USA, V87, P6863, DOI 10.1073/pnas.87.17.6863; HASHIMOTO K, 1991, MOL EVOLUTION MAJOR, P103; ICHIHARA Y, 1992, IMMUNOL LETT, V33, P277, DOI 10.1016/0165-2478(92)90073-W; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MILLER MM, 1994, P NATL ACAD SCI USA, V91, P4397, DOI 10.1073/pnas.91.10.4397; OKAMURA K, 1993, J IMMUNOL, V151, P188; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SHUM BP, 1993, J IMMUNOL, V151, P5376; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UEYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P696, DOI 10.1016/0006-291X(91)91844-3; WATKINS DI, 1990, NATURE, V346, P60, DOI 10.1038/346060a0; WATTS S, 1989, IMMUNOGENETICS, V30, P390, DOI 10.1007/BF02425281; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2; ZEMMOUR J, 1991, IMMUNOGENETICS, V33, P310, DOI 10.1007/BF00216690	32	146	147	2	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					693	695		10.1126/science.7624800	http://dx.doi.org/10.1126/science.7624800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624800				2022-12-01	WOS:A1995RM70200035
J	JACKMAN, RJ; WILBUR, JL; WHITESIDES, GM				JACKMAN, RJ; WILBUR, JL; WHITESIDES, GM			FABRICATION OF SUBMICROMETER FEATURES ON CURVED SUBSTRATES BY MICROCONTACT PRINTING	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; GOLD	Microcontact printing (mu CP) has been used to produce patterned self-assembled monolayers (SAMs) with submicrometer features on curved substrates with radii of curvature as small as 25 micrometers. Wet-chemical etching that uses the patterned SAMs as resists transfers the patterns formed by mu CP into gold. At present, there is no comparable method for microfabrication on curved surfaces.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016511] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-F32 GM16511-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Feely W. E., 1988, 1988 Solid State Sensor and Actuator Workshop. Technical Digest (Cat. No.88TH0215-4), P13, DOI 10.1109/SOLSEN.1988.26421; JACOBSEN SC, 1991, IEEE MICRO ELECTRO MECHANICAL SYSTEMS, P45; JACOBSEN SC, 1989, 1989 IEEE INT C ROBA, V3, P1536; JACOBSEN SC, 1989, FEB P IEEE MICR EL M, P17; KIM E, 1995, J ELECTROCHEM SOC, V142, P628, DOI 10.1149/1.2044112; KUMAR A, 1992, J AM CHEM SOC, V114, P9188, DOI 10.1021/ja00049a061; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; LOPEZ GP, 1993, LANGMUIR, V9, P1513, DOI 10.1021/la00030a015; Puddephatt R.J., 1978, CHEM GOLD; WILBUR JL, 1994, ADV MATER, V6, P600, DOI 10.1002/adma.19940060719; WILBUR JL, IN PRESS ADV MAT; XIA Y, UNPUB; XIA Y, 1994, J AM CHEM SOC, V117, P3274; XIA YN, 1995, ADV MATER, V7, P471, DOI 10.1002/adma.19950070513	15	364	410	3	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					664	666		10.1126/science.7624795	http://dx.doi.org/10.1126/science.7624795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624795				2022-12-01	WOS:A1995RM70200024
J	MACDONALD, SM; RAFNAR, T; LANGDON, J; LICHTENSTEIN, LM				MACDONALD, SM; RAFNAR, T; LANGDON, J; LICHTENSTEIN, LM			MOLECULAR-IDENTIFICATION OF AN IGE-DEPENDENT HISTAMINE-RELEASING FACTOR	SCIENCE			English	Article							HUMAN BASOPHILS; TRANSLATIONAL CONTROL; ACTIVATING FACTOR; RESPONSES; CHALLENGE; SEQUENCE; AIRWAYS; TUMOR; RNA	An immunoglobulin E (IgE)-dependent histamine-releasing factor (HRF) produced by lymphocytes of atopic children and present in biological fluids of allergic patients has been identified and purified. Amino-terminal sequencing revealed extensive homology to a mouse protein, p21, and its human homolog, p23. Both recombinant proteins caused histamine release from the human basophils of a subpopulation of donors, and this release was dependent on IgE. Polyclonal antibodies recognized and removed the biological activity of recombinant and native HRF. HRF identifies a heterogeneity of IgE and is believed to play a prominent role in chronic allergic disease processes.			MACDONALD, SM (corresponding author), JOHNS HOPKINS UNIV,JOHNS HOPKINS ASTHMA & ALLERGY CTR,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032651, R01AI032651] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07290, AI 32651] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BOHM H, 1989, BIOCHEM INT, V19, P277; BOHM H, 1991, BIOMED BIOCHIM ACTA, V12, P1193; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; DAHLNDEN CA, 1994, J EXP MED, V179, P751; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DA, 1966, J IMMUNOL, V97, P203; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1993, ALLERGY PRINCIPLES P, P1; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THUESON DO, 1979, J IMMUNOL, V123, P633; WARNER JA, 1986, J IMMUNOL, V136, P2583; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233	27	298	323	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					688	690		10.1126/science.7542803	http://dx.doi.org/10.1126/science.7542803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7542803				2022-12-01	WOS:A1995RM70200033
J	MATSUMOTO, Y; KIM, K				MATSUMOTO, Y; KIM, K			EXCISION OF DEOXYRIBOSE PHOSPHATE RESIDUES BY DNA-POLYMERASE-BETA DURING DNA-REPAIR	SCIENCE			English	Article							SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; HUMAN-CELLS; NOVIKOFF HEPATOMA; MESSENGER-RNA; DAMAGED DNA; IDENTIFICATION; ACID; DOMAIN	Eukaryotic DNA polymerase beta (pol beta) can catalyze DNA synthesis during base excision DNA repair. It is shown here that pol beta also catalyzes release of 5'-terminal deoxyribose phosphate (dRP) residues from incised apurinic-apyrimidinic sites, which are common intermediate products in base excision repair. The catalytic domain for this activity resides within an amino-terminal 8-kilodalton fragment of pol beta, which comprises a distinct structural domain of the enzyme. Magnesium is required for the release of dRP from double-stranded DNA but not from a single-stranded oligonucleotide. Analysis of the released products indicates that the excision reaction occurs by beta-elimination rather than hydrolysis.			MATSUMOTO, Y (corresponding author), FOX CHASE CANC CTR,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19111, USA.			Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL CANCER INSTITUTE [R01CA063154, R29CA063154, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA63154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HADI SM, 1971, BIOCHEMISTRY-US, V10, P4986, DOI 10.1021/bi00802a024; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Matsumoto Y., UNPUB; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; PRASAD R, 1994, J BIOL CHEM, V269, P18096; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; THOMAS DC, 1982, BIOCHEMISTRY-US, V21, P5060, DOI 10.1021/bi00263a033; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	34	616	629	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					699	702		10.1126/science.7624801	http://dx.doi.org/10.1126/science.7624801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624801				2022-12-01	WOS:A1995RM70200037
J	MCADAMS, HH; SHAPIRO, L				MCADAMS, HH; SHAPIRO, L			CIRCUIT SIMULATION OF GENETIC NETWORKS	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-LAMBDA; PHAGE-LAMBDA; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; LOGICAL ANALYSIS; RIGHT OPERATOR; ANTISENSE RNA; REPRESSOR; INFECTION	Genetic networks with tens to hundreds of genes are difficult to analyze with currently available techniques. Because of the many parallels in the function of these biochemically based genetic circuits and electrical circuits, a hybrid modeling approach is proposed that integrates conventional biochemical kinetic modeling within the framework of a circuit simulation. The circuit diagram of the bacteriophage lambda lysis-lysogeny decision circuit represents connectivity in signal paths of the biochemical components. A key feature of the lambda genetic circuit is that operons function as active integrated logic components and introduce signal time delays essential for the in vivo behavior of phage lambda.			MCADAMS, HH (corresponding author), STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.							ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; CAMPBELL A, 1983, LAMBDA, V2, P365; Casjens S, 1992, SEMINARS VIROLOGY, V3, P383; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; ECHOLS H, 1983, LAMBDA, V2, P75; Friedman DI, 1992, CURR OPIN GENET DEV, V2, P727, DOI 10.1016/S0959-437X(05)80133-9; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HARTWELL LH, 1991, GENETICS, V129, P975; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; Hendrix R.W., 1983, LAMBDA, VII; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HO YS, 1985, J BIOL CHEM, V260, P1838; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; KAUFMAN M, 1985, J THEOR BIOL, V114, P527, DOI 10.1016/S0022-5193(85)80042-4; KIM SK, 1992, ANNU REV MICROBIOL, V46, P117, DOI 10.1146/annurev.mi.46.100192.001001; KORNBERG A, 1992, DNA REPLICATION, P246; KOURILSKY P, 1973, MOL GEN GENET, V122, P183, DOI 10.1007/BF00435190; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KRINKE L, 1990, GENE DEV, V4, P2223, DOI 10.1101/gad.4.12a.2223; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEONG JM, 1986, J MOL BIOL, V189, P603, DOI 10.1016/0022-2836(86)90491-2; LEVINE A, 1979, J MOL BIOL, V131, P655, DOI 10.1016/0022-2836(79)90014-7; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LUK KC, 1983, J GEN VIROL, V64, P183, DOI 10.1099/0022-1317-64-1-183; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCFALLNGAI MJ, 1991, SCIENCE, V254, P1491, DOI 10.1126/science.1962208; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; NOBLE JA, 1993, P NATL ACAD SCI USA, V90, P10866, DOI 10.1073/pnas.90.22.10866; PTASHNE M, 1992, GENETIC SWITCH GENE; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROBERTS JW, 1983, LAMBDA, V2, P123; SCHMEISSNER U, 1980, P NATL ACAD SCI-BIOL, V77, P3191, DOI 10.1073/pnas.77.6.3191; SHEA MA, 1985, J MOL BIOL, V181, P211, DOI 10.1016/0022-2836(85)90086-5; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; Wulff DL, 1983, LAMBDA, VII, P53; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; ZAMBETTI GP, 1984, MOL GEN GENET, V193, P322, DOI 10.1007/BF00330688	51	365	388	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	1995	269	5224					650	656		10.1126/science.7624793	http://dx.doi.org/10.1126/science.7624793			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624793				2022-12-01	WOS:A1995RM70200022
J	NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK				NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK			STRUCTURE OF BAM-HI ENDONUCLEASE BOUND TO DNA - PARTIAL FOLDING AND UNFOLDING ON DNA-BINDING	SCIENCE			English	Article							REPRESSOR OPERATOR COMPLEX; CRYSTAL-STRUCTURE; RESTRICTION ENDONUCLEASE; WEISSENBERG CAMERA; DIFFRACTION DATA; RESOLUTION; CRYSTALLOGRAPHY; RECOGNITION; REFINEMENT; ECORI	The crystal structure of restriction endonuclease Bam HI complexed to DNA has been determined at 2.2 angstrom resolution. The DNA binds in the cleft and retains a B-DNA type of conformation. The enzyme, however, undergoes a series of conformational changes, including rotation of subunits and folding of disordered regions. The most striking conformational change is the unraveling of carboxyl-terminal alpha helices to form partially disordered ''arms.'' The arm from one subunit fits into the minor groove while the arm from the symmetry related subunit follows the DNA sugar-phosphate backbone. Recognition of DNA base pairs occurs primarily in the major groove, with a few interactions occurring in the minor groove. Tightly bound water molecules play an equally important role as side chain and main chain atoms in the recognition of base pairs. The complex also provides new insights into the mechanism by which the enzyme catalyzes the hydrolysis of DNA phosphodiester groups.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRUNGER AT, 1992, XPLOR V3 0 MANUAL; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; Creighton TE, 1993, PROTEINS STRUCTURES; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; FITAGERALD PMD, 1988, J APPL CRYSTALLOGR, V20, P383; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P993; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; JORDAN SR, 1988, SCIENCE, V242, P893; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Roberts R, 1993, NUCLEASES, P35; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEITZ T, NIH GM44006 GRAN; STRZELECKA T, 1994, J MOL BIOL, V239, P430, DOI 10.1006/jmbi.1994.1383; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XUONG NH, 1978, ACTA CRYSTALLOGR A, V34, P289, DOI 10.1107/S0567739478000546	38	295	297	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					656	663		10.1126/science.7624794	http://dx.doi.org/10.1126/science.7624794			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624794				2022-12-01	WOS:A1995RM70200023
J	PAGANO, M; TAM, SW; THEODORAS, AM; BEERROMERO, P; DELSAL, G; CHAU, V; YEW, PR; DRAETTA, GF; ROLFE, M				PAGANO, M; TAM, SW; THEODORAS, AM; BEERROMERO, P; DELSAL, G; CHAU, V; YEW, PR; DRAETTA, GF; ROLFE, M			ROLE OF THE UBIQUITIN-PROTEASOME PATHWAY IN REGULATING ABUNDANCE OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P27	SCIENCE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; DEGRADATION; ASSOCIATION; PROTEIN; CLONING; SYSTEM; YEAST; GENE; P53	The p27 mammalian cell cycle protein is an inhibitor of cyclin-dependent kinases. Both in vivo and in vitro, p27 was found to be degraded by the ubiquitin-proteasome pathway. The human ubiquitin-conjugating enzymes Ubc2 and Ubc3 were specifically involved in the ubiquitination of p27. Compared with proliferating cells, quiescent cells exhibited a smaller amount of p27 ubiquitinating activity, which accounted for the marked increase of p27 half-life measured in these cells. Thus, the abundance of p27 in cells is regulated by degradation. The specific proteolysis of p27 may represent a mechanism for regulating the activity of cyclin-dependent kinases.	WAYNE STATE UNIV, DEPT PHARMACOL, DETROIT, MI 48201 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Wayne State University; Harvard University; Harvard Medical School	PAGANO, M (corresponding author), MITOTIX INC, 1 KENDALL SQ, BLDG 600, CAMBRIDGE, MA 02139 USA.			DEL SAL, GIANNINO/0000-0003-2185-6003; pagano, michele/0000-0003-3210-2442				CHAU V, UNPUB; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KAISER P, 1994, J BIOL CHEM, V269, P8797; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LIU Z, 1992, J BIOL CHEM, V267, P15829; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; Murray A., 1993, CELL CYCLE INTRO; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1995, CELL CYCLE MATERIALS, pCH24; PAGANO M, UNPUB; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TAM SC, UNPUB; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	1722	1770	3	67	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					682	685		10.1126/science.7624798	http://dx.doi.org/10.1126/science.7624798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624798				2022-12-01	WOS:A1995RM70200031
J	PELLIZZER, G; SARGENT, P; GEORGOPOULOS, AP				PELLIZZER, G; SARGENT, P; GEORGOPOULOS, AP			MOTOR CORTICAL ACTIVITY IN A CONTEXT-RECALL TASK	SCIENCE			English	Article							SINGLE CELL; DIRECTION; CORTEX; VISUOMOTOR; MOVEMENTS	A monkey was trained to respond on the basis of the serial position of a test stimulus in a sequence. First, three stimuli were presented successively on a circle. Then one of them (except the last) changed color (test stimulus) and served as the go signal: The monkey was required to produce a motor response in the direction of the stimulus that followed the test stimulus. When the test stimulus was the second in the sequence, there was a change in motor cortical activity from a pattern reflecting the direction of this stimulus to the pattern associated with the direction of the motor response. This change was abrupt, occurred 100 to 150 milliseconds after the go signal, and was evident both in the activity of single cells and in the time-varying neuronal population vector. These findings identify the neural correlates of a switching process that is different from a mental rotation described previously.	VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Pellizzer, Giuseppe/B-7540-2017	Pellizzer, Giuseppe/0000-0002-9254-5555	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017413] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17413] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; GAZZANIGA MS, 1995, COGNITIVE NEUROSCLEN; GEORGOPOULOS AP, 1991, EXP BRAIN RES, V83, P453; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1993, SCIENCE, V260, P47, DOI 10.1126/science.8465199; Kosslyn S. M., 1992, FRONTIERS COGNITIVE; LURITO JT, 1991, EXP BRAIN RES, V87, P562; MARDIA KV, 1972, STATISTICS DIRECTION; PELLIZZER G, 1993, EXP BRAIN RES, V93, P165; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; Snedecor G. W, 1989, STAT METHODS, V8th; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; Zar JH., 1999, BIOSTAT ANAL, V4	16	55	55	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					702	705		10.1126/science.7624802	http://dx.doi.org/10.1126/science.7624802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624802				2022-12-01	WOS:A1995RM70200038
J	STOYANOV, B; VOLINIA, S; HANCK, T; RUBIO, I; LOUBTCHENKOV, M; MALEK, D; STOYANOVA, S; VANHAESEBROECK, B; DHAND, R; NURNBERG, B; GIERSCHIK, P; SEEDORF, K; HSUAN, JJ; WATERFIELD, MD; WETZKER, R				STOYANOV, B; VOLINIA, S; HANCK, T; RUBIO, I; LOUBTCHENKOV, M; MALEK, D; STOYANOVA, S; VANHAESEBROECK, B; DHAND, R; NURNBERG, B; GIERSCHIK, P; SEEDORF, K; HSUAN, JJ; WATERFIELD, MD; WETZKER, R			CLONING AND CHARACTERIZATION OF A G-PROTEIN-ACTIVATED HUMAN PHOSPHOINOSITIDE-3 KINASE	SCIENCE			English	Article							PHOSPHOLIPASE-C ISOZYMES; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATED ACCUMULATION; BINDING-SITE; YEAST; CELLS	Phosphoinositide-3 kinase activity is implicated in diverse cellular responses triggered by mammalian cell surface receptors and in the regulation of protein sorting in yeast. Receptors with intrinsic and associated tyrosine kinase activity recruit heterodimeric phosphoinositide-3 kinases that consist of p110 catalytic subunits and p85 adaptor molecules containing Src homology 2 (SH2) domains. A phosphoinositide-3 kinase isotype, p110 gamma, was cloned and characterized. The p110 gamma enzyme was activated in vitro by both the alpha and beta gamma subunits of heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) and did not interact with p85. A potential pleckstrin homology domain is located near its amino terminus. The p110 gamma isotype may link signaling through G protein-coupled receptors to the generation of phosphoinositide second messengers phosphorylated in the D-3 position.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WCE 6BT, ENGLAND; UNIV JENA, FAC MED, MAX PLANCK RES UNIT GROWTH FACTOR SIGNAL TRANSDUC, D-07747 JENA, GERMANY; UNIV ULM, DEPT PHARMACOL & TOXICOL, D-89069 ULM, GERMANY; UNIV JENA, FAC MED, INST BIOCHEM 2, D-07747 JENA, GERMANY; FREE UNIV BERLIN, INST PHARMACOL, D-14195 BERLIN, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Ludwig Institute for Cancer Research; University of London; University College London; Friedrich Schiller University of Jena; Max Planck Society; Ulm University; Friedrich Schiller University of Jena; Free University of Berlin; Max Planck Society			Volinia, Stefano/A-3029-2010; Hsuan, Justin/C-8825-2009; Wetzker, Reinhard/AAD-8713-2019; Volinia, Stefano/AAA-9264-2019	Volinia, Stefano/0000-0003-0910-3893; Hsuan, Justin/0000-0001-6083-7564; Volinia, Stefano/0000-0003-0910-3893; Nurnberg, Bernd/0000-0002-5995-6555				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIERSCHIK P, 1994, METHOD ENZYMOL, V238, P181; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; NURNBERG B, 1994, BIOCHEM J, V300, P387; OKADA T, 1994, J BIOL CHEM, V269, P3568; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; VOLINIA S, IN PRESS EMBO J; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YANO H, 1993, J BIOL CHEM, V268, P25846	32	631	673	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					690	693		10.1126/science.7624799	http://dx.doi.org/10.1126/science.7624799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624799				2022-12-01	WOS:A1995RM70200034
J	AVEROF, M; AKAM, M				AVEROF, M; AKAM, M			HOX GENES AND THE DIVERSIFICATION OF INSECT AND CRUSTACEAN BODY PLANS	NATURE			English	Article							DROSOPHILA EMBRYO; HOMEOTIC GENES; EXPRESSION; COMPLEX; SEGMENT; ARTEMIA	CRUSTACEANS and insects share a common origin of segmentation(1,2), but the specialization of trunk segments appears to have arisen independently in insects and various crustacean subgroups(3'4). Such macroevolutionary changes in body architecture may be investigated by comparative studies of conserved genetic markers(5-7). The Hox genes are well suited for this purpose, as they determine positional identity along the body axis in a wide range of animals. Here we examine the expression of four Hox genes in the branchiopod crustacean Artemia franciscana, and compare this with Hox expression patterns from insects. In Artemia the three 'trunk' genes Antp, Ubx and abdA are expressed in largely overlapping domains in the uniform thoracic region, whereas in insects they specify distinct segment types within the thorax and abdomen. Our comparisons suggest a multistep process for the diversification of these Hox gene functions, involving early differences in tissue specificity and the later acquisition of a role in defining segmental differences within the trunk. We propose that the branchiopod thorax may be homologous to the entire pregenital (thoracic and abdominal) region of the insect trunk.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE,ENGLAND	University of Cambridge	AVEROF, M (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			Averof, Michalis/0000-0002-6803-7251	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM M, 1994, DEVELOPMENT S, V120, P209; ANDERSON D. T., 1967, AUST J ZOOL, V15, P47, DOI 10.1071/ZO9670047; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; BEEMAN RW, 1993, BIOESSAYS, V15, P439, DOI 10.1002/bies.950150702; CALMAN WT, 1909, CRUSTACEA; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; DOHLE W, 1988, DEVELOPMENT, V104, P147; DOHLE W, 1988, MYRIAPODA ANCESTRY I; Jurgens G., 1993, DEV DROSOPHILA MELAN, P687; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P567; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MAHAFFEY JW, 1989, DEVELOPMENT, V105, P167; MANZANARES M, 1993, DEVELOPMENT, V118, P1209; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCNAMARA KJ, 1993, PALAEONTOLOGY, V36, P319; PATEL NH, 1989, DEVELOPMENT, V107, P201; RIEK E F, 1968, Records of the Australian Museum, V27, P313; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; Scourfield DJ, 1926, PHILOS T R SOC LON B, V214, P153, DOI 10.1098/rstb.1926.0005; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Snodgrass R. E., 1951, COMP STUDIES HEAD MA; TEAR G, 1990, DEVELOPMENT, V110, P915; UENO K, 1992, DEVELOPMENT, V114, P555; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Walossek Dieter, 1993, Fossils and Strata, V32, P1; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0	30	211	223	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					420	423		10.1038/376420a0	http://dx.doi.org/10.1038/376420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630416				2022-12-01	WOS:A1995RM63900050
J	AVERY, AC; ZHAO, ZS; RODRIGUEZ, A; BIKOFF, EK; SOHEILIAN, M; FOSTER, CS; CANTOR, H				AVERY, AC; ZHAO, ZS; RODRIGUEZ, A; BIKOFF, EK; SOHEILIAN, M; FOSTER, CS; CANTOR, H			RESISTANCE TO HERPES STROMAL KERATITIS CONFERRED BY AN IGG2A-DERIVED PEPTIDE	NATURE			English	Article							T-CELL CLONES; SIMPLEX KERATITIS; ANTIGEN; MICE; MHC; UNRESPONSIVENESS; SUSCEPTIBILITY; DETERMINANTS; LYMPHOCYTES; ALLOTYPE	NOT all peripheral tissue antigens enter the thymus and it is unclear how the immune system remains tolerant to this class of self antigen. As tolerance to self peptides can generate gaps in the T-cell repertoire for cross-reactive foreign antigens(1,2), we investigated whether this mechanism might also diminish autoimmune reactions to similar peptides expressed by peripheral tissues. Herpes stromal keratitis (HSK) is a virally induced autoimmune reaction against corneal tissues mediated by T cells(3-5), and is a leading cause of human blindness(6). Resistance to HSK in mice is associated with allotypic variation in immunoglobulin genes(7,8), possibly because circulating immunoglobin-derived peptides can cross-tolerize T cells specific for corneal tissue autoantigens. Here we show that HSK is mediated by T-cell clones specific for corneal self antigens which also recognize an allotype-bearing peptide derived from IgG2a, and that exposure of HSK-susceptible mice to a soluble form of this peptide confers resistance to HSK. Shared expression of peptide subsequences between sequestered tissue proteins and circulating proteins may be important for maintenance of self-tolerance and prevention of autoimmunity.	HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM,SCH MED, DEPT OPHTHALMOL,HILLES IMMUNOL LAB, BOSTON, MA 02114 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University	AVERY, AC (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT PATHOL, IMMUNOPATHOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Rodriguez-Garcia, Alejandro/AAI-1045-2019; Avery, Anne/J-8405-2017; Soheilian, Masoud/AAW-4743-2020	Rodriguez-Garcia, Alejandro/0000-0002-1419-2109; Soheilian, Masoud/0000-0001-7508-426X				ABROMSONLEEMAN S, 1995, J IMMUNOL, V154, P388; AKOVA YA, 1993, CURR EYE RES, V12, P1093, DOI 10.3109/02713689309033507; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; BARTNES K, 1991, EUR J IMMUNOL, V21, P2365, DOI 10.1002/eji.1830211011; BIKOFF E, 1986, J IMMUNOL, V137, P28; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1411, DOI 10.1002/eji.1830210613; BIKOFF EK, 1989, EUR J IMMUNOL, V19, P1903, DOI 10.1002/eji.1830191022; CALLANAN D, 1988, TRANSPLANTATION, V45, P437, DOI 10.1097/00007890-198802000-00039; CLAVERIE JM, 1988, EUR J IMMUNOL, V18, P1547, DOI 10.1002/eji.1830181012; DAWSON C, 1976, SURV OPHTHALMOL, V21, P11; DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9; FELLER DC, 1991, NATURE, V349, P720, DOI 10.1038/349720a0; FOSTER CS, 1986, CLIN IMMUNOL IMMUNOP, V40, P313, DOI 10.1016/0090-1229(86)90036-X; FRIEDMAN S, 1987, IMMUNOGENETICS, V26, P193, DOI 10.1007/BF00346512; GARCHON HJ, 1991, HUM IMMUNOL, V32, P1, DOI 10.1016/0198-8859(91)90113-N; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; MARSHAKROTHSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P1120, DOI 10.1073/pnas.77.2.1120; MATZINGER P, 1981, NATURE, V292, P497, DOI 10.1038/292497a0; MERCADAL CM, 1993, J VIROL, V67, P3404, DOI 10.1128/JVI.67.6.3404-3408.1993; METCALF JF, 1979, INFECT IMMUN, V26, P1164, DOI 10.1128/IAI.26.3.1164-1171.1979; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; Niederkorn J Y, 1990, Adv Immunol, V48, P191, DOI 10.1016/S0065-2776(08)60755-5; OPREMCAK EM, 1990, INVEST OPHTH VIS SCI, V31, P305; OPREMCAK EM, 1988, INVEST OPHTH VIS SCI, V29, P749; ROSS J, 1989, Investigative Ophthalmology and Visual Science, V30, P442; RUSSELL RG, 1984, INVEST OPHTH VIS SCI, V25, P938; VIDOVIC D, 1988, NATURE, V336, P222, DOI 10.1038/336222a0	27	99	101	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					431	434		10.1038/376431a0	http://dx.doi.org/10.1038/376431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630419				2022-12-01	WOS:A1995RM63900053
J	CHARNOV, EL; DOWNHOWER, JF				CHARNOV, EL; DOWNHOWER, JF			A TRADE-OFF-INVARIANT LIFE-HISTORY RULE FOR OPTIMAL OFFSPRING SIZE	NATURE			English	Article							NUMBER	OPTIMIZATION models have been widely and successfully used in evolutionary ecology to predict the attributes of organisms(1-6) Most such models maximize darwinian fitness (or a component of fitness) in the face of trade-offs and constraints; the numerical results usually depend on the exact form of the trade-offs/constraints. Here we report the first (to our knowledge) numerical optimum for life-history evolution which is independent of the details of the underlying trade-off, for a large array for trade-off forms. The rule is that at small litter sizes, the range in offspring size is inversely proportional to the size of the litter. Details of the offspring-survival/offspring-size trade-off(7-10) set the value of the proportionality constant, but the -1 exponent, the inverse proportionality itself, is universal. Studies of life histories have yielded many empirical examples of universality for various scaling exponents (for example, adult lifespan scales as approximate to 0.25 with adult body mass within many taxa); this is an example of the numerical value of an exponent (here -1) emerging from a life-history model as independent of all but a few general features of the underlying economic structure.	OHIO STATE UNIV, DEPT ZOOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University	CHARNOV, EL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							BEVERTON RJH, 1992, J FISH BIOL, V41, P137, DOI 10.1111/j.1095-8649.1992.tb03875.x; Bulmer M., 1994, THEORETICAL EVOLUTIO; CHARNOV E L, 1982; CHARNOV EL, 1995, EVOL ECOL, V9, P57, DOI 10.1007/BF01237697; CHARNOV EL, 1990, EVOL ECOL, V4, P273, DOI 10.1007/BF02214335; Charnov Eric L., 1993, P1; Clutton-Brock T, 1991, EVOLUTION PARENTAL C, DOI [10.1515/9780691206981, DOI 10.1515/9780691206981]; Gadgil M., 1975, ECOLOGY EVOLUTION CO, P142; GODFRAY HCJ, 1994, PARASITOIDS; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; SHINE R, 1995, OIKOS, V72, P343, DOI 10.2307/3546119; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Stearns S.C., 1992, pi; Stephens D.W., 1986, pi; WOOTTON RJ, 1994, J FISH BIOL, V45, P1067	16	60	61	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					418	419		10.1038/376418a0	http://dx.doi.org/10.1038/376418a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630415	Green Submitted			2022-12-01	WOS:A1995RM63900049
J	FRANK, J; ZHU, J; PENCZEK, P; LI, YH; SRIVASTAVA, S; VERSCHOOR, A; RADERMACHER, M; GRASSUCCI, R; LATA, RK; AGRAWAL, RK				FRANK, J; ZHU, J; PENCZEK, P; LI, YH; SRIVASTAVA, S; VERSCHOOR, A; RADERMACHER, M; GRASSUCCI, R; LATA, RK; AGRAWAL, RK			A MODEL OF PROTEIN-SYNTHESIS BASED ON CRYOELECTRON MICROSCOPY OF THE E-COLI RIBOSOME	NATURE			English	Article							3-DIMENSIONAL RECONSTRUCTION; IMAGE-RECONSTRUCTION; ESCHERICHIA-COLI; SINGLE PARTICLES; RNA; SUBUNIT; TUNNEL; ICE	THE ribosome is formed by assembly of proteins and nucleic acids, and synthesizes proteins according to genetic instructions in all organisms. Many of the biochemical steps of this fundamental process are known, but a detailed understanding requires a well-defined structural model of the ribosome. Electron microscopy combined with image reconstruction of two-dimensional crystals or single ribosomes(4) has been the most promising technique, but the resolution of the resulting models has been insufficient. Here we report a 25-Angstrom reconstruction of the ribosome from Escherichia coli, obtained by combining 4,300 projections of ice-embedded single particles. Our new reconstruction reveals a channel in the small ribosomal subunit and a bifurcating tunnel in the large subunit which may constitute pathways for the incoming message and the nascent polypeptide chain, respectively. Based on these new findings, a three-dimensional model of the basic framework of protein synthesis is presented.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222; SUNY ALBANY,DEPT COMP SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	FRANK, J (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,BOX 509,ALBANY,NY 12201, USA.							AVILASAKAR AJ, 1994, J MOL BIOL, V239, P689, DOI 10.1006/jmbi.1994.1406; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; EASTERWOOD TR, 1994, NUCLEIC ACIDS RES, V22, P3779, DOI 10.1093/nar/22.18.3779; EISENSTEIN M, 1991, BIOCHIMIE, V73, P879, DOI 10.1016/0300-9084(91)90129-O; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1990, RIBOSOME, P107; GILBERT P, 1972, J THEOR BIOL, V36, P105, DOI 10.1016/0022-5193(72)90180-4; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MONTESANORODITIS L, 1994, J BIOL CHEM, V269, P6458; OAKES MI, 1990, J MOL BIOL, V211, P897, DOI 10.1016/0022-2836(90)90082-W; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; SCHRODER RR, 1990, J STRUCT BIOL, V105, P28, DOI 10.1016/1047-8477(90)90095-T; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; SUNDARALINGAM M, 1975, P101; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	24	353	363	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					441	444		10.1038/376441a0	http://dx.doi.org/10.1038/376441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630422				2022-12-01	WOS:A1995RM63900057
J	MCEACHERN, MJ; BLACKBURN, EH				MCEACHERN, MJ; BLACKBURN, EH			RUNAWAY TELOMERE ELONGATION CAUSED BY TELOMERASE RNA GENE-MUTATIONS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HUMAN FIBROBLASTS; BINDING-PROTEIN; YEAST; DNA; SENESCENCE; RAP1; IDENTIFICATION; SEQUENCES; STABILITY	The ribonucleoprotein enzyme telomerase adds telomeric DNA onto chromosome ends and is normally regulated so that telomeric DNA lengths are kept within defined bounds. In the telomerase RNA gene from the yeast Kluyveromyces lactis, specific mutations that alter telomeric DNA sequences result in telomeres elongating to up to 100 times their normal length and Impair cell growth. Some mutations cause immediate elongation whereas others behave like genetic time bombs, causing elongation only after a latent period of hundreds of generations.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	MCEACHERN, MJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, BOX 0414, SAN FRANCISCO, CA 94143 USA.							BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1993, MOL CELL BIOL, V13, P551, DOI 10.1128/MCB.13.1.551; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PARDUE ML, 1994, CURR OPIN GENET DEV, V4, P845, DOI 10.1016/0959-437X(94)90069-8; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J, 1989, MOL CLONING; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHAY JW, 1993, ONCOGENE, V8, P1407; SHIPPEN DE, 1994, P NATL ACAD SCI USA, V91, P405, DOI 10.1073/pnas.91.1.405; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; VESELKOV AG, 1993, NATURE, V364, P496, DOI 10.1038/364496a0; WILLIAMSON JR, 1994, REV BIOPHYS BIOMOL S, V23, P703; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	43	305	316	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					403	409		10.1038/376403a0	http://dx.doi.org/10.1038/376403a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630414				2022-12-01	WOS:A1995RM63900045
J	NAKAO, S; TAKENAKA, T; MAEDA, M; KODAMA, C; TANAKA, A; TAHARA, M; YOSHIDA, A; KURIYAMA, M; HAYASHIBE, H; SAKURABA, H; TANAKA, H				NAKAO, S; TAKENAKA, T; MAEDA, M; KODAMA, C; TANAKA, A; TAHARA, M; YOSHIDA, A; KURIYAMA, M; HAYASHIBE, H; SAKURABA, H; TANAKA, H			AN ATYPICAL VARIANT OF FABRYS-DISEASE IN MEN WITH LEFT-VENTRICULAR HYPERTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GALACTOSIDASE-A; POINT MUTATIONS; CARDIOMYOPATHY; GENE; MANIFESTATIONS; HEMIZYGOTES; IDENTIFICATION; HETEROZYGOTES; REGION	Background. Fabry's disease is an x-linked recessive disorder that results from a deficiency of alpha-galactosidase. Left ventricular hypertrophy is one of the common manifestations in men with classic hemizygous disease. Recently, several cases of an atypical variant of hemizygous Fabry's disease, with manifestations limited to the heart, have been reported. Therefore, we assessed the incidence of hemizygosity for Fabry's disease among male patients with left ventricular hypertrophy. Methods. We measured plasma alpha-galactosidase activity in 230 consecutive male patients with left ventricular hypertrophy. Clinical manifestations were assessed, endomyocardial biopsies were performed, and the patients were screened for mutations in the alpha-galactosidase gene. Results. Seven of the 230 patients with left ventricular hypertrophy (3 percent) had low plasma alpha-galactosidase activity (4 to 14 percent of the mean value in normal controls). These seven unrelated patients, ranging in age from 55 to 72 years, did not have angiokeratoma, acroparesthesias, hypohidrosis, or corneal opacities, which are typical manifestations of Fabry's disease. Endomyocardial biopsy was performed in five patients and revealed marked sarcoplasmic vacuolization in all five. Samples from four patients were examined by electron microscopy and revealed typical lysosomal inclusions with a concentric lamellar configuration in all four. Two patients had novel missense mutations in exon 1 and exon 6. The remaining five had no mutations in the coding region of the alpha-galactosidase gene, but the amounts of the alpha-galactosidase messenger RNA were markedly lower than normal. Conclusions. Seven unrelated patients with atypical variants of hemizygous Fabry's disease were found among 230 men with left ventricular hypertrophy. Fabry's disease should be considered as a cause of unexplained left ventricular hypertrophy.	KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 1, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT PATHOL 1, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 3, KAGOSHIMA 890, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT CLIN GENET, TOKYO 113, JAPAN	Kagoshima University; Kagoshima University; Kagoshima University; Tokyo Metropolitan Institute of Medical Science								ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BASS JL, 1980, AM HEART J, V100, P807, DOI 10.1016/0002-8703(80)90060-5; BECKER AE, 1975, AM J CARDIOL, V36, P829, DOI 10.1016/0002-9149(75)90468-3; BISHOP DF, 1988, P NATL ACAD SCI USA, V85, P3903, DOI 10.1073/pnas.85.11.3903; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; COLUCCI WS, 1982, NEW ENGL J MED, V307, P926, DOI 10.1056/NEJM198210073071505; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; DESNICK RJ, 1976, CIRCULATION, V54, P818, DOI 10.1161/01.CIR.54.5.818; DESNICK RJ, 1995, METABOLIC MOL BASIS, V2, P2741; ELLEDER M, 1990, VIRCHOWS ARCH A, V417, P449, DOI 10.1007/BF01606034; ENG CM, 1993, AM J HUM GENET, V53, P1186; FELNER JM, 1990, HEART, P1990; FERRANS VJ, 1969, AM J CARDIOL, V24, P95, DOI 10.1016/0002-9149(69)90055-1; FISHER EA, 1992, ANN INTERN MED, V117, P221, DOI 10.7326/0003-4819-117-3-221; GOLDMAN ME, 1986, J AM COLL CARDIOL, V7, P1157, DOI 10.1016/S0735-1097(86)80238-8; HENRY WL, 1973, CIRCULATION, V47, P225, DOI 10.1161/01.CIR.47.2.225; IKARI Y, 1992, BRIT HEART J, V68, P323; ISHII S, 1992, HUM GENET, V89, P29, DOI 10.1007/BF00207037; ISHII S, 1994, BBA-PROTEIN STRUCT M, V1204, P265, DOI 10.1016/0167-4838(94)90017-5; KOIDE T, 1990, FEBS LETT, V259, P353, DOI 10.1016/0014-5793(90)80046-L; KUHN H, 1982, CIRCULATION, V66, P117; MATSUI S, 1977, JPN CIRC J, V41, P1023, DOI 10.1253/jcj.41.1023; MAYES JS, 1981, CLIN CHIM ACTA, V112, P247, DOI 10.1016/0009-8981(81)90384-3; MEHTA J, 1977, AM HEART J, V93, P699, DOI 10.1016/S0002-8703(77)80064-1; NAGAO Y, 1991, CLIN GENET, V39, P233; OGAWA K, 1990, HUM PATHOL, V21, P1067, DOI 10.1016/0046-8177(90)90258-7; ROUDEBUSH CP, 1973, NEW ENGL J MED, V289, P357, DOI 10.1056/NEJM197308162890709; SAKURABA H, 1986, CLIN GENET, V29, P276; SAKURABA H, 1990, AM J HUM GENET, V47, P784; Sambrook J., 1989, MOL CLONING LAB MANU; VONSCHEIDT W, 1991, NEW ENGL J MED, V324, P395, DOI 10.1056/NEJM199102073240607; WEBB JG, 1990, J AM COLL CARDIOL, V15, P83, DOI 10.1016/0735-1097(90)90180-W; YANAGAWA Y, 1988, Acta Paediatrica Japonica, V30, P38	34	568	609	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					288	293		10.1056/NEJM199508033330504	http://dx.doi.org/10.1056/NEJM199508033330504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596372	Bronze			2022-12-01	WOS:A1995RL69400004
J	NEGISHI, I; MOTOYAMA, N; NAKAYAMA, K; NAKAYAMA, K; SENJU, S; HATAKEYAMA, S; ZHANG, Q; CHAN, AC; LOH, DY				NEGISHI, I; MOTOYAMA, N; NAKAYAMA, K; NAKAYAMA, K; SENJU, S; HATAKEYAMA, S; ZHANG, Q; CHAN, AC; LOH, DY			ESSENTIAL ROLE FOR ZAP-70 IN BOTH POSITIVE AND NEGATIVE SELECTION OF THYMOCYTES	NATURE			English	Article							PROTEIN-TYROSINE KINASE; KILLER-CELLS; T-CELLS; APOPTOSIS; COMPLEX; INVIVO; MICE	DURING thymic development, T cells that can recognize foreign antigen in association with self major histocompatibility complex (MHC) are selected for survival (positive selection) and autoreactive T cells are eliminated (negative selection). Both of these selective events are mediated by interaction between the T-cell receptor (TCR) and the peptid-MHC complex(1) But the signalling pathways that lead to cell survival or to cell death are still unclear. ZAP-70 is a protein tyrosine kinase (PTK) that is associated with the TCR signalling subunits (CD3 and zeta) and is expressed in T cells and natural killer cell(2). It has been shown that ZAP-70 plays a crucial role in T-cell activation(2-5) and development(6-8). Here we show that mice lacking ZAP-70 had neither CD4 nor CD8 single-positive T cells, but human ZAP-70 reconstituted both CD4 and CDS single-positive populations. Moreover, ZAP-70(-/-) thomocytes were not deleted by peptide antigens. Natural killer cell function was intact in the absence of ZAP-70. These data suggest that ZAP-70 is a central signalling molecule during thymic selection for CD4 and CD8 lineage.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV RHEUMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CONE JC, 1993, EUR J IMMUNOL, V23, P2488; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GUNJI Y, 1989, J IMMUNOL, V142, P1748; IWABUCHI K, 1992, P NATL ACAD SCI USA, V89, P9000, DOI 10.1073/pnas.89.19.9000; MADRENAS J, 1994, SCIENCE, V267, P515; MOMBAERTS P, 1994, INT IMMUNOL, V6, P1061, DOI 10.1093/intimm/6.7.1061; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VIVLER E, 1993, EUR J IMMUNOL, V23, P1872	25	460	463	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					435	438		10.1038/376435a0	http://dx.doi.org/10.1038/376435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630421				2022-12-01	WOS:A1995RM63900055
J	SIMMONDS, AJ; BROOK, WJ; COHEN, SM; BELLE, JB				SIMMONDS, AJ; BROOK, WJ; COHEN, SM; BELLE, JB			DISTINGUISHABLE FUNCTIONS FOR ENGRAILED AND INVECTED IN ANTERIOR-POSTERIOR PATTERNING IN THE DROSOPHILA WING	NATURE			English	Article							GENE; EXPRESSION; DISK; MELANOGASTER; DIRECTS; LOCUS	SUBDIVISION Of the limb primordia into compartments initiates pattern formation in the developing limbs(1,2). Interaction between distinctly specific cells in adjacent compartments leads to localized expression of the secreted signalling molecules Wingless (Wg) or Decapentaplegic (Dpp) which in turn organize pattern and control growth of the limbs The homeobox gene engrailed has been implicated in specification of posterior cell fate(9-12), whereas the LIM/homeobox gene, apterous, specifies dorsal fate(3). Removing apterous activity causes a complete transformation from dorsal to ventral fate and leads to the formation of an ectopic dorsal-ventral boundary organizer(3,13). By contrast, removing engrailed activity causes incomplete morphological transformation from posterior to anterior fate in the wing(10,14,15), and fails to produce an ectopic anterior-posterior organizer (reviewed in ref, 2). Complete transformation can only be effected by simultaneously eliminating activity of engrailed and its homologue invected(16-18). Here we show that invected functions principally to specify posterior cell fate. Thus establishment of the anterior-posterior organizer and control of compartment identity are genetically distinguishable, and invected may perform a discrete subset of functions previously ascribed to engrailed.	UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	University of Alberta; European Molecular Biology Laboratory (EMBL)			Simmonds, Andrew J/D-3675-2009; Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Simmonds, Andrew/0000-0001-7165-9302				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Eker R, 1929, HEREDITAS, V12, P217; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GUBB D, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P236, DOI 10.1007/BF00848252; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LAWRENCE PA, 1982, EMBO J, V7, P827; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; SANICOLA M, 1995, GENETICS, V139, P745; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; SERRANO N, 1995, DEVELOPMENT, V121, P1691; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, IN PRESS DEVELOPMENT; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1990, GENETICS, V125, P833; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WURST W, 1994, DEVELOPMENT, V120, P2065	31	103	106	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					424	427		10.1038/376424a0	http://dx.doi.org/10.1038/376424a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630417				2022-12-01	WOS:A1995RM63900051
J	SKEATH, JB; ZHANG, Y; HOLMGREN, R; CARROLL, SB; DOE, CQ				SKEATH, JB; ZHANG, Y; HOLMGREN, R; CARROLL, SB; DOE, CQ			SPECIFICATION OF NEUROBLAST IDENTITY IN THE DROSOPHILA EMBRYONIC CENTRAL-NERVOUS-SYSTEM BY GOOSEBERRY-DISTAL	NATURE			English	Article							GENES; EXPRESSION; ACHAETE; SEGREGATION; COMPLEX; REGION	THE Drosophila central nervous system develops from a segmentally reiterated array of 30 unique neural precursors, called neuroblasts. Each neuroblast goes through a stereotyped cell lineage to produce an invariant clone of neural progeny. It is critical to identify the genes that specify neuroblast identity as these genes control the time of formation, gene expression profile, and cell lineage characteristics of each neuroblast. Here we show that the Pax-type gooseberry-distal gene specifies row 5 neuroblast identity. Initially, four rows of neuroblasts form per segment (1, 3, 5, 7) and gooseberry-distal is expressed in row 5 neuroblasts(1-3). By using 10 molecular markers, and by following the number and orientation of neuroblast divisions, we show that lack of gooseberry-distal transforms row 5 neuroblasts into row 3 neuroblasts, whereas ubiquitous gooseberry-distal generates the reciprocal transformation. Thus, gooseberry-distal is necessary and sufficient to specify row 5 neuroblast identity autonomously, The 10 genes coordinately regulated by gooseberry-distal are prime candidates for controlling specific aspects of neuroblast identity.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI	University of Illinois System; University of Illinois Urbana-Champaign; Northwestern University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	SKEATH, JB (corresponding author), UNIV ILLINOIS,HOWARD HUGHES MED INST,URBANA,IL 61801, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DOE CQ, 1988, SCIENCE, V239, P190; DOE CQ, 1992, DEVELOPMENT, V119, P855; Goodman Corey S., 1993, P1131; GUTJAHR T, 1993, DEVELOPMENT, V119, P21; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; MARTINBERMUDO MD, 1991, DEVELOPMENT, V119, P1003; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; SKEATH JB, 1992, DEVELOPMENT, V114, P939; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; ZHANG Y, 1994, DEVELOPMENT, V120, P1151	18	81	81	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					427	430		10.1038/376427a0	http://dx.doi.org/10.1038/376427a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630418				2022-12-01	WOS:A1995RM63900052
J	TANAKA, T; AMES, JB; HARVEY, TS; STRYER, L; IKURA, M				TANAKA, T; AMES, JB; HARVEY, TS; STRYER, L; IKURA, M			SEQUESTRATION OF THE MEMBRANE-TARGETING MYRISTOYL GROUP OF RECOVERIN IN THE CALCIUM-FREE STATE	NATURE			English	Article							BINDING PROTEIN; NERVOUS-SYSTEM; TRANSLOCATION; HIPPOCALCIN; TERMINUS; CLONING; FAMILY; RODS	RECOVERIN, a retinal calcium-binding protein of relative molecular mass (M(r)) 23K, participates In the recovery phase of visual excitation and in adaptation to background light(1-3) The Ca2+-bound form of recoverin prolongs the photoresponse(4), probably by blocking phosphorylation of photoexcited rhodopsin. Retinal recoverin contains a covalently attached myristoyl group or related acyl group at its amino terminus(6) and two Ca2+-binding sites(7). Ca2+ binding to myristoylated, but not unmyristoylated, recoverin induces its translocation to bilayer membranes, indicating that the myristoyl group is essential to the read-out of calcium signals (calcium-myristoyl switch)(8,9). Here we present the solution structure of Ca2+-free, myristoylated recombinant recoverin obtained by heteronuclear multidimensional NMR spectroscopy. The myristoyl group is sequestered in a deep hydrophobic pocket formed by many aromatic and other hydrophobic residues from five flanking helices.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	TANAKA, T (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.		Harvey, Timothy S/F-9863-2013	Harvey, Timothy S/0000-0001-6270-1943; Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BABU YS, 1988, J MOL BIOL, V24, P191; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; Brunger AT, 1993, X PLOR VERSION 3 1 S; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KIM JY, 1994, J BIOL CHEM, V269, P28214; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LADANT D, 1995, J BIOL CHEM, V270, P3179; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; STRYER L, 1991, J BIOL CHEM, V266, P10711; WALKER F, 1993, J BIOL CHEM, V268, P19552; YAMAGATA K, 1990, NEURON, V2, P469; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	32	278	282	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					444	447		10.1038/376444a0	http://dx.doi.org/10.1038/376444a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630423				2022-12-01	WOS:A1995RM63900058
J	TATEISHI, J; BROWN, P; KITAMOTO, T; HOQUE, ZM; ROOS, R; WOLLMAN, R; CERVENAKOVA, L; GAJDUSEK, DC				TATEISHI, J; BROWN, P; KITAMOTO, T; HOQUE, ZM; ROOS, R; WOLLMAN, R; CERVENAKOVA, L; GAJDUSEK, DC			FIRST EXPERIMENTAL TRANSMISSION OF FATAL FAMILIAL INSOMNIA	NATURE			English	Article							CREUTZFELDT-JAKOB DISEASE; PRION PROTEIN ACCUMULATION; CODON-178; GENE; MICE	ORIGINALLY described by Lugaresi et al, in 1986 (ref. 1), fatal familial insomnia (FFI) is a rare inherited neurological disease characterized by the subacute progression of intractable insomnia and other autonomic abnormalities, cerebellar and pyramidal signs; myoclonus and dementia; neuropathologically, the major feature is severe neuronal loss with associated gliosis in the ventral and mediodorsal thalamic nuclei. The disease has been related to the group of spongiform encephalopathies by virtue of the presence of low levels of proteinase-resistant amyloid protein (PrPres) in the brain(2-4), and of a pathogenic single-allele mutation at codon 178 of the PRNP gene that encodes PrPres (refs 2, 5). Here rye report the successful transmission of the disease to experimental animals, placing FFI within the group of infectious cerebral amyloidoses.	NINCDS,CNS STUDIES LAB,BETHESDA,MD 20892; UNIV CHICAGO,MED CTR,DEPT NEUROL,CHICAGO,IL 60637; UNIV CHICAGO,MED CTR,DEPT PATHOL,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	TATEISHI, J (corresponding author), KYUSHU UNIV,INST NEUROL,DEPT NEUROPATHOL,FUKUOKA 812,JAPAN.							BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; BROWN P, 1995, ANN NEUROL, V38, P245, DOI 10.1002/ana.410380218; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; LITTLE BW, 1986, ANN NEUROL, V20, P231, DOI 10.1002/ana.410200209; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MURAMOTO T, 1992, BRAIN RES, V599, P309, DOI 10.1016/0006-8993(92)90406-Y; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; TATEISHI J, 1981, ACTA NEUROPATHOL, V53, P161, DOI 10.1007/BF00689997	12	110	111	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					434	435		10.1038/376434a0	http://dx.doi.org/10.1038/376434a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630420				2022-12-01	WOS:A1995RM63900054
J	BOICE, JD; MANDEL, JS; DOODY, MM				BOICE, JD; MANDEL, JS; DOODY, MM			BREAST-CANCER AMONG RADIOLOGIC TECHNOLOGISTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; RISK; RADIATION; THERAPY; MORTALITY; WORKERS; TUBERCULOSIS; EPIDEMIOLOGY; RADIOTHERAPY; CHILDHOOD	Objective.-To evaluate the risk of breast cancer among women occupationally ex Design.-Case-control study. Participants.-A health survey of 105 385 women radiologic technologists certified by the American Registry of Radiologic Technologists since 1926. Among 79016 respondents, 600 breast cancer cases were identified. Each of 528 eligible subjects with breast cancer was matched to five control subjects based on age, year of certification, and follow-up time. Main Outcome Measures.-Relative risk (RR) estimated as the relative odds ratio for breast cancer over categories of years worked as a radiologic technologist and according to personal and occupational exposure characteristics. Results.-Study subjects had been certified for a mean of 29 years; 63.8% of cases and 62.6% of controls worked as radiologic technologists for 10 years or more. Significant increased risks for breast cancer were associated with early age at menarche (for <11 years of age: RR=1.79; 95% confidence interval [CI], 1.09 to 2.94), nulliparity (RR=1.36; 95% CI, 1.04 to 1.78), first-degree relative with history of breast cancer(RR=2.07; 95% CI, 1.56 to 2.74), prior breast biopsy (RR=1.53; 95% CI, 1.17 to 2.00), alcohol consumption (for >14 alcoholic drinks per week: RR=2.12; 95% CI, 1.06 to 4.27), thyroid cancer (RR=5.36; 95% CI, 1.64 to 17.5), hyperthyroidism (RR=1.66; 95% CI, 1.02 to 2.71), and residence in the northeastern United States (RR=1.66; 95% CI, 1.19 to 2.30). Jobs involving radiotherapy, radioisotopes, or fluoroscopic equipment, however, were not linked to breast cancer risk, nor were personal exposures to fluoroscopy or multifilm procedures. Use of birth control pills, postmenopausal estrogens, or permanent hair dyes also were not risk factors. Based on dosimetry records for 35% of study subjects, cumulative exposures appeared low. Among women who worked more than 20 years, the RR for breast cancer was 1.13 (95% CI, 0.79 to 1.64). Conclusions.-More than 50% of the reported breast cancers could be explained by established risk factors. Employment as a radiologic technologist, however, was not found to increase the risk of breast cancer. The contribution of prolonged exposure to relatively low doses of ionizing radiation to breast cancer risk was too small to be detectable at this time.	UNIV MINNESOTA, SCH PUBL HLTH, DIV ENVIRONM & OCCUPAT HLTH, MINNEAPOLIS, MN USA	University of Minnesota System; University of Minnesota Twin Cities	BOICE, JD (corresponding author), NCI, RADIAT EPIDEMIOL BRANCH, 6130 EXECUT BLVD, EPN ROOM 408, BETHESDA, MD 20892 USA.				NCI NIH HHS [N01-CP0-5609, N01-CP8-5604, N01-CP9-5614] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP005609, N01CP095614, N01CP085604] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		[Anonymous], 1994, SOURCES EFFECTS IONI; BAVERSTOCK KF, 1989, BIR REPORT, P72; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BOICE JD, 1992, CANCER, V69, P586, DOI 10.1002/1097-0142(19920115)69:2<586::AID-CNCR2820690251>3.0.CO;2-3; BOICE JD, 1989, INT J CANCER, V44, P7, DOI 10.1002/ijc.2910440103; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; FURST CJ, 1988, JNCI-J NATL CANCER I, V80, P1387, DOI 10.1093/jnci/80.17.1387; GILBERT ES, 1993, RADIAT RES, V136, P408, DOI 10.2307/3578555; GREEN A, 1987, JNCI-J NATL CANCER I, V79, P253; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HIDRETH NG, 1989, NEW ENGL J MED, V321, P1281; HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; KEREIAKES JG, 1980, HDB RAD DOSES NUCLEA; LI FP, 1983, CANCER, V51, P521, DOI 10.1002/1097-0142(19830201)51:3<521::AID-CNCR2820510325>3.0.CO;2-U; LONDON S J, 1989, Journal of the American Medical Association, V262, P2853, DOI 10.1001/jama.262.20.2853; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; LUCAS JN, 1992, INT J RADIAT BIOL, V62, P53, DOI 10.1080/09553009214551821; MACKENZI.I, 1965, BRIT J CANCER, V19, P1, DOI 10.1038/bjc.1965.1; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679; MCLAUGHLIN JR, 1993, INT J EPIDEMIOL, V22, P584, DOI 10.1093/ije/22.4.584; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STEBBINGS JH, 1984, AM J IND MED, V5, P435, DOI 10.1002/ajim.4700050604; STRAUME T, 1992, HEALTH PHYS, V62, P122, DOI 10.1097/00004032-199202000-00001; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; WANEBO CK, 1968, NEW ENGL J MED, V279, P667, DOI 10.1056/NEJM196809262791301; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WEISS HA, 1994, INT J CANCER, V59, P327, DOI 10.1002/ijc.2910590307; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505	42	52	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					394	401		10.1001/jama.274.5.394	http://dx.doi.org/10.1001/jama.274.5.394			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616635				2022-12-01	WOS:A1995RL41600025
J	LAND, CE				LAND, CE			STUDIES OF CANCER AND RADIATION-DOSE AMONG ATOMIC-BOMB SURVIVORS - THE EXAMPLE OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IONIZING-RADIATION; MORTALITY; THERAPY; WOMEN; RISK	A comprehensive program of medical follow-up of survivors of the atomic bombings of Hiroshima and Nagasaki, Japan, by the Radiation Effects Research Foundation (RERF) has produced quantitative estimates of cancer risk from exposure to ionizing radiation. For breast cancer in women, in particular, the strength of the radiation dose response and the generally low level of population risk in the absence of radiation exposure have led to a clear description of excess risk and its variation by age at exposure and over time following exposure. Comparisons of RERF data with data from medically irradiated populations have yielded additional information on the influence of population and underlying breast cancer rates on radiation-related risk. Epidemiological investigations of breast cancer cases and matched controls among atomic bomb survivors have clarified the role of reproductive history as a modifier of the carcinogenic effects of radiation exposure. Finally, a pattern of radiation-related risk by attained age among the survivors exposed during childhood or adolescence suggests the possible existence of a radiation-susceptible subgroup. The hypothetical existence of such a group is lent plausibility by the results of recent family studies suggesting that heritable mutations in certain genes are associated with familial aggregations of breast cancer. The recent isolation and cloning of one such gene, BRCA1, makes it likely that the hypothesis can be tested using molecular assays of archival and other tissue obtained from atomic bomb survivor cases and controls.			LAND, CE (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EPN 408,6130 EXECUT BLVD,MS 7362,BETHESDA,MD 20892, USA.							BOICE JD, 1990, RADIAT RES, V125, P214; CLIFTON KH, 1975, J NATL CANCER I, V55, P485; CLIFTON KH, 1978, CANCER RES, V38, P1507; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HANCOCK SL, 1993, J NATL CANCER I, V181, P25; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; LAND CE, 1993, LANCET, V342, P237, DOI 10.1016/0140-6736(93)92324-M; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P157, DOI 10.1007/BF01830262; LAND CE, 1980, J NATL CANCER I, V65, P353; MABUCHI K, 1994, RADIAT RES, V137, P51; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Neel J V, 1991, CHILDREN ATOMIC BOMB; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PUTNAM FW, 1994, PERSPECT BIOL MED, V37, P515; RALL JE, 1985, NIH852748 PUBL; Roesch WC, 1987, US JAPAN JOINT REASS; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; THOMPSON DE, 1994, RADIAT RES, V137, P517; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; ZIEGLER RG, 1993, J NATL CANCER I, V22, P1819; 1994, SOURCES EFFECTS IONI, P115	33	92	97	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					402	407						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616636				2022-12-01	WOS:A1995RL41600026
J	SHIGEMATSU, I; MENDELSOHN, ML				SHIGEMATSU, I; MENDELSOHN, ML			THE RADIATION-EFFECTS-RESEARCH-FOUNDATION-OF-HIROSHIMA-AND-NAGASAKI - PAST, PRESENT, AND FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									RADIAT EFFECTS RES FDN,NAGASAKI,JAPAN	Radiation Effects Research Foundation - Japan	SHIGEMATSU, I (corresponding author), RADIAT EFFECTS RES FDN,MINAMI KU,5-2 HIJIYAMA PK,HIROSHIMA 732,JAPAN.							Neel J V, 1991, CHILDREN ATOMIC BOMB; PUTNAM FW, 1994, PERSPECT BIOL MED, V37, P515; ROESCH WE, 1987, US JAPAN REASSESSMEN, V1; SHIGEMATSU I, 1995, EFFECT A BOMB RAD HU; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; YOSHIMOTO Y, 1994, LANCET, V344, P345, DOI 10.1016/S0140-6736(94)91389-7; 1995, R95096 US DEP EN	7	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					425	426						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616640				2022-12-01	WOS:A1995RL41600031
J	WEINBERG, AD; KRIPALANI, S; MCCARTHY, PL; SCHULL, WJ				WEINBERG, AD; KRIPALANI, S; MCCARTHY, PL; SCHULL, WJ			CARING FOR SURVIVORS OF THE CHERNOBYL DISASTER - WHAT THE CLINICIAN SHOULD KNOW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW TRANSPLANTATION; A-BOMB SURVIVORS; POST-CHERNOBYL; NUCLEAR ACCIDENTS; INDUCED ABORTIONS; BIRTH-DEFECTS; CANCER; CONSEQUENCES; MORTALITY; RADIATION	The health status of approximately 1 million immigrants in the United States and Israel may have been adversely affected by radiation exposure as a result of the Chernobyl nuclear power plant disaster and cleanup efforts. Many of these immigrants suffer from significant psychological distress, fearing that they have a radiation-induced illness. Based on a review of the literature and our experience from the US National Chernobyl Registry Coordinating Center, we recommend that medical management of these immigrants include routine physical examination, with particular attention to the thyroid gland. Adults should receive regular cancer screening as well as routine blood chemistry tests, thyroid function tests, complete blood cell count, and urinalysis. Children should be examined regularly, with attention to the thyroid and overall body growth. It is reasonable for children to undergo thyroid studies, a complete blood cell count, or neuropsychiatric testing if there is clinical suspicion of a disorder. Given the long latency period for disease induction by radiation exposure, it is still too early to fully assess and draw conclusions concerning the possible health effects of the Chernobyl disaster, and long-term follow-up of all potentially affected individuals is important.	UNIV TEXAS, HLTH SCI CTR, CTR HUMAN GENET, SCH PUBL HLTH, HOUSTON, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	WEINBERG, AD (corresponding author), BAYLOR COLL MED, CTR CANC CONTROL RES, DEPT MED, 1 BAYLOR PLAZA, ST924, HOUSTON, TX 77030 USA.							ABELIN T, 1994, SOZ PRAVENTIV MED, V39, P189, DOI 10.1007/BF01309218; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1991, INT CHERNOBYL PROJEC; AUVINEN A, 1994, BRIT MED J, V309, P151, DOI 10.1136/bmj.309.6948.151; BARANOV A, 1989, NEW ENGL J MED, V321, P205, DOI 10.1056/NEJM198907273210401; Baverstock K F, 1993, World Health Stat Q, V46, P204; BEHAR A, 1990, Journal of Environmental Pathology Toxicology and Oncology, V10, P281; BERTOLLINI R, 1990, SCAND J WORK ENV HEA, V16, P96, DOI 10.5271/sjweh.1803; BOICE J, 1994, BRIT MED J, V309, P139, DOI 10.1136/bmj.309.6948.139; BOLSHOVA EV, 1993, ACTA ENDOCRINOL-COP, V129, P594, DOI 10.1530/acta.0.1290594; BONTE FJ, 1988, SEMIN NUCL MED, V18, P16, DOI 10.1016/S0001-2998(88)80016-3; BUTTURINI A, 1994, BRIT MED J, V309, P1299; CASTRONOVO FP, 1987, J NUCL MED, V28, P535; CHAMPLIN R, 1987, SEMIN HEMATOL, V24, P1; CHAMPLIN RE, 1988, ANN INTERN MED, V109, P730, DOI 10.7326/0003-4819-109-9-730; DERUIG WG, 1992, ANALYST, V117, P545, DOI 10.1039/an9921700545; DEWALS P, 1988, INT J EPIDEMIOL, V17, P230, DOI 10.1093/ije/17.1.230; EMERIT I, 1994, J CANCER RES CLIN, V120, P558, DOI 10.1007/BF01221035; ERICSON A, 1994, ENVIRON RES, V67, P149, DOI 10.1006/enrs.1994.1070; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GALE RP, 1987, JAMA-J AM MED ASSOC, V258, P625, DOI 10.1001/jama.258.5.625; GEIGER HJ, 1986, JAMA-J AM MED ASSOC, V256, P609, DOI 10.1001/jama.256.5.609; GINZBURG HM, 1993, PUBLIC HEALTH REP, V108, P184; GOLD SJ, 1994, AM JEWISH YB, V94, P3; GUVENC H, 1993, J EPIDEMIOL COMMUN H, V47, P40, DOI 10.1136/jech.47.1.40; HAEUSLER MCH, 1992, AM J OBSTET GYNECOL, V167, P1025, DOI 10.1016/S0002-9378(12)80032-9; HARJULEHTO T, 1989, BRIT MED J, V298, P995, DOI 10.1136/bmj.298.6679.995; HARJULEHTOMERVAALA T, 1992, MUTAT RES, V275, P81, DOI 10.1016/0921-8734(92)90011-D; HJALMARS U, 1994, BRIT MED J, V309, P154, DOI 10.1136/bmj.309.6948.154; HOLOWINSKY IZ, 1993, MENT RETARD, V31, P35; JENSEN RH, 1995, RADIAT RES, V141, P129, DOI 10.2307/3579040; KAMPMANN B, 1994, BRIT MED J, V309, P1299; KATO H, 1982, RADIAT RES, V91, P243, DOI 10.2307/3575833; KATO H, 1982, RADIAT RES, V90, P395, DOI 10.2307/3575716; KNUDSEN LB, 1991, BIOMED PHARMACOTHER, V45, P229, DOI 10.1016/0753-3322(91)90022-L; KUCHUK AA, 1994, TOXICOL LETT, V72, P213, DOI 10.1016/0378-4274(94)90031-0; LIE RT, 1992, AM J EPIDEMIOL, V136, P377, DOI 10.1093/oxfordjournals.aje.a116510; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; LIKHTAREV IA, 1994, RADIAT ENVIRON BIOPH, V33, P149, DOI 10.1007/BF01219338; LINNEMANN RE, 1987, JAMA-J AM MED ASSOC, V258, P637; LITTELL FH, 1993, HOLOCAUST GENOCIDE S, V7, P121, DOI 10.1093/hgs/7.1.121; Mettler FA, 1995, MED EFFECTS IONIZING; Mould R F, 1987, Br J Radiol, V60, pB29; Nazarov A. N., 1992, Problemy Endokrinologii, V38, P58; Neel J V, 1991, CHILDREN ATOMIC BOMB; NENOT JC, 1990, INT J RADIAT BIOL, V57, P1073, DOI 10.1080/09553009014551201; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; PARAZZINI F, 1988, BRIT MED J, V296, P136, DOI 10.1136/bmj.296.6615.136-a; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; Perry A R, 1990, Radiol Technol, V61, P290; PETER RU, 1994, J AM ACAD DERMATOL, V30, P719, DOI 10.1016/S0190-9622(08)81501-0; PETRIDOU E, 1994, SCAND J SOC MED, V22, P127, DOI 10.1177/140349489402200208; RAYMOND L, 1991, SOZ PRAVENTIV MED, V36, P304, DOI 10.1007/BF01359163; RON E, 1992, NATURE, V360, P113, DOI 10.1038/360113a0; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SJOBERG L, 1987, MED ONCOL TUMOR PHAR, V4, P259; SOUCHKEVITCH G, 1995, PARTICIPANTS CLEAN U; SPERLING K, 1994, BRIT MED J, V309, P158, DOI 10.1136/bmj.309.6948.158; STOLL C, 1990, AM J MED GENET, P79; TAJTAKOVA M, 1993, HORM METAB RES, V25, P644, DOI 10.1055/s-2007-1002197; TRICHOPOULOS D, 1987, BRIT MED J, V295, P1100, DOI 10.1136/bmj.295.6606.1100; YARILIN AA, 1993, INT J RADIAT BIOL, V63, P519, DOI 10.1080/09553009314550681; 1977, 5 NAT COUNC RAD PROT; 1995, CANCER FACTS FIGURES; 1988, 37TH SESS ANN VIENN; 1985, 35TH SESS UNSCEAR NE; 1988, PAEDIATR PERINAT EP, V2, P253	67	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					408	412		10.1001/jama.274.5.408	http://dx.doi.org/10.1001/jama.274.5.408			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616637				2022-12-01	WOS:A1995RL41600027
J	MCDANIEL, DO; ALARCON, GS; PRATT, PW; REVEILLE, JD				MCDANIEL, DO; ALARCON, GS; PRATT, PW; REVEILLE, JD			MOST AFRICAN-AMERICAN PATIENTS WITH RHEUMATOID-ARTHRITIS DO NOT HAVE THE RHEUMATOID ANTIGENIC DETERMINANT (EPITOPE)	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; BLACKS; HLA-DR ANTIGENS; ANTIGENIC DETERMINANTS	HLA-DR ANTIGENS; DISEASE SEVERITY; D REGION; ASSOCIATION; SUSCEPTIBILITY; GENES; BLACKS; HYPOTHESIS; POPULATION; SEQUENCE	Objective: To evaluate the relation between the presence of the ''rheumatoid epitope,'' defined by a sequence motif in the HLA-DRB1 alleles, and disease severity in African-American patients with rheumatoid arthritis. Design: Cross-sectional study. Setting: Rheumatology outpatient clinics at two university medical centers. Patients: 86 African-American patients with rheumatoid arthritis (66 seropositive and 20 seronegative for the rheumatoid factor) attending the clinics and 88 healthy African-American persons. Measurements: HLA-DRB1 alleles were determined by restriction fragment length polymorphism and by allele-specific oligonucleotide typing of polymerase chain reaction-amplified HLA-DRB1 second exons. Results: With the exception of an increased frequency of HLA-DRB1*04 alleles in seropositive patients with rheumatoid arthritis (27.3%) compared with controls (13.1%) (P = 0.02), the frequencies of HLA-DRB1 alleles were similar in patients and controls. Most seropositive (48 of 66) and seronegative (15 of 20) patients were HLA-DR4 negative, but some (7 of 48 seropositive patients and 3 of 15 seronegative persons) inherited the rheumatoid epitope on a non-DR4 allele. Disease features, including severity, were similar for patients without the epitope and for those with either a single or a double dose of an epitope-positive allele. Positivity for rheumatoid factor, but not for the rheumatoid epitope, was weakly associated with severity in these patients. Conclusion: Most African-American patients with rheumatoid arthritis did not express the rheumatoid epitope. The predisposition to and severity of rheumatoid arthritis in African-Americans appears to be independent of the presence and dose of the shared rheumatoid epitope.	UNIV TEXAS, HLTH SCI CTR, DIV RHEUMATOL & CLIN IMMUNOGENET, HOUSTON, TX 77225 USA; UNIV ALABAMA, DIV CLIN IMMUNOL & RHEUMATOL, BIRMINGHAM, AL 35294 USA	University of Texas System; University of Texas Health Science Center Houston; University of Alabama System; University of Alabama Birmingham					NIAMS NIH HHS [AR39325, P0-AR 20614] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614, R29AR039325] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON GS, 1983, J RHEUMATOL, V10, P579; ALARCON GS, 1982, ARTHRITIS RHEUM, V25, P502, DOI 10.1002/art.1780250503; ALARIF LI, 1983, J RHEUMATOL, V10, P297; ANGELINI G, 1992, HUM IMMUNOL, V34, P135, DOI 10.1016/0198-8859(92)90039-P; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOKI KA, 1992, ARTHRITIS RHEUM, V35, P749, DOI 10.1002/art.1780350706; CASTRO F, 1994, B ASS PERUAN RHEUM, V13, P14; DEJUAN MD, 1994, TISSUE ANTIGENS, V43, P320; DEVRIES N, 1993, TISSUE ANTIGENS, V41, P26; GAO XJ, 1991, ARTHRITIS RHEUM, V34, P1310, DOI 10.1002/art.1780341016; GAO XJ, 1990, ARTHRITIS RHEUM, V33, P939, DOI 10.1002/art.1780330704; GORONZY J, 1986, J CLIN INVEST, V77, P1042, DOI 10.1172/JCI112358; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; KARR RW, 1980, ARTHRITIS RHEUM-US, V23, P1241, DOI 10.1002/art.1780231102; LONG EO, 1983, EMBO J, V2, P389, DOI 10.1002/j.1460-2075.1983.tb01435.x; LOPEZMENDEZ A, 1989, J RHEUMATOL, V16, P1197; MARSAL S, 1994, ARTHRITIS RHEUM, V37, P504, DOI 10.1002/art.1780370410; MARTELL RW, 1989, TISSUE ANTIGENS, V36, P1326; MCDANIEL DO, 1989, TISSUE ANTIGENS, V34, P299, DOI 10.1111/j.1399-0039.1989.tb01746.x; MCDANIEL DO, 1993, BIOTECHNIQUES, V15, P140; MODY GM, 1989, J RHEUMATOL, V16, P1326; NELSON JL, 1991, TISSUE ANTIGENS, V38, P145, DOI 10.1111/j.1399-0039.1991.tb01888.x; NELSON JL, 1994, ARTHRITIS RHEUM, V37, P673; NEPOM GT, 1986, LANCET, V2, P1002; OHTA N, 1982, HUM IMMUNOL, V5, P123, DOI 10.1016/0198-8859(82)90057-X; PERDRIGER A, 1992, TISSUE ANTIGENS, V39, P14, DOI 10.1111/j.1399-0039.1992.tb02149.x; PILE KD, 1992, TISSUE ANTIGENS, V39, P138, DOI 10.1111/j.1399-0039.1992.tb01924.x; RENNINGEN KS, 1990, TISSUE ANTIGENS, V36, P235, DOI 10.1111/j.1399-0039.1990.tb01834.x; Reveille J. D., 1994, Arthritis and Rheumatism, V37, pS359; SILMAN AJ, 1993, J RHEUMATOL, V20, P618; SINGAL DP, 1994, CLIN EXP RHEUMATOL, V12, P29; SINGAL DP, 1987, LANCET, V2, P1118; STASTNY P, 1976, J CLIN INVEST, V57, P1148, DOI 10.1172/JCI108382; STEPHENS HAF, 1989, IMMUNOGENETICS, V30, P119, DOI 10.1007/BF02421540; TAN PLJ, 1993, ARTHRITIS RHEUM, V36, P15, DOI 10.1002/art.1780360104; TANEJA V, 1993, ARTHRITIS RHEUM, V36, P1380, DOI 10.1002/art.1780361009; VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519; WATANABE Y, 1989, J EXP MED, V169, P2263, DOI 10.1084/jem.169.6.2263; WEYAND CM, 1994, B RHEUM DIS, V43, P5; WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WEYAND CM, 1989, IMMUNOBIOLOGY HLA IM, P422; WILLKENS RF, 1991, ARTHRITIS RHEUM, V34, P43, DOI 10.1002/art.1780340107; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049; YELAMOS J, 1993, ARTHRITIS RHEUM-US, V36, P811, DOI 10.1002/art.1780360611; ZOSCHKE D, 1986, HUM IMMUNOL, V15, P118, DOI 10.1016/0198-8859(86)90322-8; [No title captured]	48	72	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					181	187		10.7326/0003-4819-123-3-199508010-00004	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598299				2022-12-01	WOS:A1995RL10400004
J	SALVARANI, C; GABRIEL, SE; OFALLON, WM; HUNDER, GG				SALVARANI, C; GABRIEL, SE; OFALLON, WM; HUNDER, GG			THE INCIDENCE OF GIANT-CELL ARTERITIS IN OLMSTED COUNTY, MINNESOTA - APPARENT FLUCTUATIONS IN A CYCLIC PATTERN	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMYALGIA-RHEUMATICA; TEMPORAL ARTERITIS; INTERMEDIATE FILAMENTS; EPIDEMIOLOGY; ANTIBODIES; 10-YEAR; VIRUS	Objective: To investigate trends in the incidence of giant cell arteritis over Design: Population-based incidence study. Setting: Olmsted County, Minnesota. Methods: All incidence cases of giant cell arteritis first diagnosed between 1950 and 1991 were identified using the unified record system at Mayo Clinic. Age- and sex-specific incidence rates were calculated using the number of incidence cases as the numerator and population estimates as the denominator. Overall rates were age- and sex-adjusted to the 1980 United States. white population. The annual incidence rates were graphically illustrated using a 3-year centered moving average. Results: Between 1950 and 1998, 125 Olmsted County residents (103 women and 22 men) were diagnosed with giant cell arteritis. The age- and sex-adjusted incidence per 100 000 persons 50 years of age or older was 17.8 (95% CI, 14.1 to 21.0); incidence was significantly higher in women (24.2 [CI, 19.5 to 28.9]) than in men (8.2 [CI, 4.8 to 11.6]). Age-specific incidence rates increased with age (P < 0.0001). The annual incidence rates increased significantly over the study period (P = 0.002) and appear to have clustered in five peak periods, which occurred about every 7 years. A significant calendar-time effect was identified; it predicted an increase in incidence of 2.6% (CI, 0.9% to 4.3%) every 5 years. Conclusions: Our observation of a regular cyclic pattern in incidence rates over time supports the hypothesis of an infectious cause for giant cell arteritis. Similar studies in other populations are needed to confirm our findings.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV RHEUMATOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic			Salvarani, Carlo/K-2431-2018	Salvarani, Carlo/0000-0001-5426-5133	NIAMS NIH HHS [AR 30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DW, 1991, NEUROEPIDEMIOLOGY TR, P239; BARRIER JH, 1988, J RHEUMATOL, V15, P383; BENGTSSON BA, 1982, ACTA MED SCAND, P1; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; CIMMINO MA, 1993, CLIN EXP RHEUMATOL, V11, P309; DASGUPTA B, 1987, ANN RHEUM DIS, V46, P746, DOI 10.1136/ard.46.10.746; ELLING H, 1980, ANN RHEUM DIS, V39, P511, DOI 10.1136/ard.39.5.511; FESSEL WJ, 1969, LANCET, V2, P1249; FRANZEN P, 1992, J RHEUMATOL, V19, P273; FRIEDMAN G, 1982, ISRAEL J MED SCI, V18, P241; GONZALEZGAY MA, 1992, J RHEUMATOL, V19, P277; HICKSTEIN DD, 1981, ARTHRITIS RHEUM, V24, P1448, DOI 10.1002/art.1780241122; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MATHEWSON JA, 1986, J RHEUMATOL, V13, P190; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; NORDBORG E, 1990, J INTERN MED, V227, P233, DOI 10.1111/j.1365-2796.1990.tb00150.x; OBRIEN JP, 1992, ARTHRITIS RHEUM, V35, P794, DOI 10.1002/art.1780350713; SALVARANI C, 1991, ARTHRITIS RHEUM, V34, P351, DOI 10.1002/art.1780340313; SMITH CA, 1983, ARTHRITIS RHEUM, V26, P1214, DOI 10.1002/art.1780261007; TOH BH, 1979, CLIN EXP IMMUNOL, V37, P76	24	246	249	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					192	194		10.7326/0003-4819-123-3-199508010-00006	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598301				2022-12-01	WOS:A1995RL10400006
J	BAKOULA, CG; KAFRITSA, YJ; KAVADIAS, GD; LAZOPOULOU, DD; THEODORIDOU, MC; MARAVELIAS, KP; MATSANIOTIS, NS				BAKOULA, CG; KAFRITSA, YJ; KAVADIAS, GD; LAZOPOULOU, DD; THEODORIDOU, MC; MARAVELIAS, KP; MATSANIOTIS, NS			OBJECTIVE PASSIVE-SMOKING INDICATORS AND RESPIRATORY MORBIDITY IN YOUNG-CHILDREN	LANCET			English	Note							ENVIRONMENTAL TOBACCO-SMOKE; URINARY COTININE; EXPOSURE	Exposure to environmental tobacco smoke is associated with increased respiratory morbidity in young children, but few studies have assessed such exposure objectively by urinary cotinine measurements. 501 children aged 1-5 years, a random 5% sample of children attending an outpatient clinic, were classified as exposed or nonexposed to environmental tobacco smoke with a cut-off of 10 ng cotinine per mg creatinine in urine. Exposed children were 3.5 times (95% Cl 1.56-7.90, p<0.0024) more likely to have increased respiratory morbidity (three or more episodes during the previous 12 months) than non-exposed children after adjustment for potential confounding factors.	UNIV ATHENS,DEPT PAEDIAT 1,ATHENS,GREECE; UNIV ATHENS,DEPT FORENS MED & TOXICOL,ATHENS,GREECE	National & Kapodistrian University of Athens; National & Kapodistrian University of Athens								CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; DALLAVORGIA P, 1990, SCAND J SOC MED, V18, P81, DOI 10.1177/140349489001800201; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V788, P696; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; MARBURY MC, 1993, AM J EPIDEMIOL, V137, P1089, DOI 10.1093/oxfordjournals.aje.a116612; REESE AC, 1992, AM REV RESPIR DIS, V146, P66, DOI 10.1164/ajrccm/146.1.66; RICHARDSON MA, 1988, J ALLERGY CLIN IMMUN, V81, P1032, DOI 10.1016/0091-6749(88)90175-3; RUBIN DH, 1988, YALE J BIOL MED, V61, P401; STRACHAN DP, 1990, AM REV RESPIR DIS, V142, P147, DOI 10.1164/ajrccm/142.1.147; WALD NJ, 1984, LANCET, V1, P230	10	46	50	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					280	281		10.1016/S0140-6736(95)92167-2	http://dx.doi.org/10.1016/S0140-6736(95)92167-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL757	7630249				2022-12-01	WOS:A1995RL75700012
J	BLAMEY, A; MUTRIE, N; AITCHISON, T				BLAMEY, A; MUTRIE, N; AITCHISON, T			HEALTH PROMOTION BY ENCOURAGED USE OF STAIRS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,INST BIOMED & LIFE SCI,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow	BLAMEY, A (corresponding author), GREATER GLASGOW HLTH BOARD,GLASGOW G2 4JT,LANARK,SCOTLAND.							BROWNELL KD, 1980, AM J PSYCHIAT, V137, P1540; CAMPBELL MJ, 1993, MED STAT COMMONSENSE, P126; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; 1992, ALLIED DUNBAR NATION	4	114	116	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					289	290		10.1136/bmj.311.7000.289	http://dx.doi.org/10.1136/bmj.311.7000.289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633234	Green Published			2022-12-01	WOS:A1995RM71900021
J	BROMBERG, JEC; RINKEL, GJE; ALGRA, A; GREEBE, P; VANDUYN, CM; HASAN, D; LIMBURG, M; TERBERG, HWM; WIJDICKS, EFM; VANGIJN, J				BROMBERG, JEC; RINKEL, GJE; ALGRA, A; GREEBE, P; VANDUYN, CM; HASAN, D; LIMBURG, M; TERBERG, HWM; WIJDICKS, EFM; VANGIJN, J			SUBARACHNOID HEMORRHAGE IN FIRST-DEGREE AND 2ND-DEGREE RELATIVES OF PATIENTS WITH SUBARACHNOID HEMORRHAGE	BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL ANEURYSMS; HEMORRHAGE		UNIV ROTTERDAM,DEPT NEUROL,ROTTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,1105 AZ AMSTERDAM,NETHERLANDS; SITTARD HOSP,DEPT NEUROL,SITTARD,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam	BROMBERG, JEC (corresponding author), UNIV UTRECHT,DEPT NEUROL,POB 85500,3508 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008	Hasan, Djo/0000-0003-4610-5433				BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; RONKAINEN A, 1993, NEUROSURGERY, V33, P787; TERBERG HWM, 1992, STROKE, V23, P1024, DOI 10.1161/01.STR.23.7.1024; WANG PS, 1995, ARCH NEUROL-CHICAGO, V52, P202, DOI 10.1001/archneur.1995.00540260108026	5	134	136	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					288	289		10.1136/bmj.311.7000.288	http://dx.doi.org/10.1136/bmj.311.7000.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633233	Green Published			2022-12-01	WOS:A1995RM71900020
J	FLEMING, DM; CHAKRAVERTY, P; SADLER, C; LITTON, P				FLEMING, DM; CHAKRAVERTY, P; SADLER, C; LITTON, P			COMBINED CLINICAL AND VIROLOGICAL SURVEILLANCE OF INFLUENZA IN WINTERS OF 1992-3 AND 1993-4	BRITISH MEDICAL JOURNAL			English	Article									CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND	Public Health England	FLEMING, DM (corresponding author), ROYAL COLL GEN PRACTITIONERS,BIRMINGHAM RES UNIT,BIRMINGHAM B17 9DB,W MIDLANDS,ENGLAND.							DAISY JA, 1979, J CLIN MICROBIOL, V5, P688; HANNOUN C, 1989, EUR J EPIDEMIOL, V5, P285, DOI 10.1007/BF00144828; VANCASTEREN V, 1992, METHOD INFORM MED, V31, P147; WEBSTER RG, 1994, BRIT MED J, V309, P1179, DOI 10.1136/bmj.309.6963.1179; 1977, J R COLL GEN PRACT, V27, P544	5	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					290	291		10.1136/bmj.311.7000.290	http://dx.doi.org/10.1136/bmj.311.7000.290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633235	Green Published			2022-12-01	WOS:A1995RM71900022
J	JONES, JK; GORKIN, L; LIAN, JF; STAFFA, JA; FLETCHER, AP				JONES, JK; GORKIN, L; LIAN, JF; STAFFA, JA; FLETCHER, AP			DISCONTINUATION OF AND CHANGES IN TREATMENT AFTER START OF NEW COURSES OF ANTIHYPERTENSIVE DRUGS - A STUDY OF A UNITED-KINGDOM POPULATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; HYPERTENSION	Objective-To evaluate the incidence of discontinuation of and changes in treatment after newly prescribed courses of antihypertensive drugs of the four primary therapeutic classes: beta blocker, calcium channel blocker, and angiotensin converting enzyme inhibitor. Design-A retrospective analysis of patients on an automated database of 1.2 million patients was conducted on visits between 1 October 1992 and 30 September 1993. Setting-General practices in the United Kingdom. Subjects-37 643 patients with hypertension receiving a relevant drug in the time period were identified. A new course of treatment in at least one of the four therapeutic classes, defined as a drug not prescribed in the previous four months, was observed in 10 222 patients aged greater than or equal to 40 years. Main outcome measures-Patients changing to other treatment or discontinuing after initiating a new course of treatment, defined as the absence of a refill prescription for the new drug or another in its category within a six month observation period. Results-Changes in or discontinuation of treatment were frequently observed, and by month six continuation rates ranged between 40% to 50% for all four classes of drugs. Conclusion-Low rates of continuation with a newly prescribed antihypertensive drug exist regardless of which drug is prescribed.	IMS INT, LONDON, ENGLAND		JONES, JK (corresponding author), DEGGE GRP, 1616 N FT MYER DR, SUITE 1430, ARLINGTON, VA 22209 USA.							[Anonymous], 1991, JAMA, V265, P3255; BLACK DM, 1987, J GERONTOL, V42, P552, DOI 10.1093/geronj/42.5.552; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAVIS CE, 1990, HDB HLTH BEHAVIOR CH; GORKIN L, 1990, HDB HLTH BEHAVIOR CH; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; MCCOMBS JS, 1994, MED CARE, V32, P214, DOI 10.1097/00005650-199403000-00003; MOSS AJ, 1989, CIRCULATION, V80, P102; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; SHULMAN N, 1982, CONTROL CLIN TRIALS, V3, P13, DOI 10.1016/0197-2456(82)90016-2; SWALES JD, 1994, LANCET, V344, P380; 1979, JAMA-J AM MED ASSOC, V22, P2562	15	226	231	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 29	1995	311	7000					293	295		10.1136/bmj.311.7000.293	http://dx.doi.org/10.1136/bmj.311.7000.293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633238	Green Published			2022-12-01	WOS:A1995RM71900026
J	RICHARDSON, R; HURWITZ, B				RICHARDSON, R; HURWITZ, B			DONORS ATTITUDES TOWARDS BODY DONATION FOR DISSECTION	LANCET			English	Article								We report a survey in the UK of potential whole-body donors for dissection. 218 people (age range 19-97 years) answered a postal questionnaire, giving information about themselves, their reasons for donation, attitudes towards the dead body, funeral preferences and medical giving and receiving. In addition to altruism, motives included the wish to avoid funeral ceremonies, to avoid waste, and in a few cases, to evade the expense of a funeral. 44% understood that their bodies would be used as teaching material, 42% for experiments. Whilst 69% believed in one or more supernatural phenomena, only 39% said they were religious. 69% requested cremation after dissection; 2% wanted to be buried. The notion of money incentives to promote donation was overwhelmingly rejected.	ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON, ENGLAND	Imperial College London	RICHARDSON, R (corresponding author), UCL, DEPT ANAT, LONDON WC1 6BT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Dooley D, 1973, Ann R Coll Surg Engl, V53, P13; Druce M, 1994, CLIN ANAT, V7, P42, DOI [10.1002/ca.980070108, DOI 10.1002/CA.980070108]; FENNELL S, 1992, NEW ZEAL MED J, V105, P472; HORNE DJD, 1990, ACAD MED, V65, P645, DOI 10.1097/00001888-199010000-00011; HUMPHREY DC, 1973, B NEW YORK ACAD MED, V49, P819; MURRAY TH, 1994, JAMA-J AM MED ASSOC, V272, P814, DOI 10.1001/jama.272.10.814; MURRAY TH, 1987, HASTINGS CENT REP, V17, P30, DOI 10.2307/3562041; RICHARDSON R, 1989, DEATH DISSECTION DES, P95	8	86	86	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 29	1995	346	8970					277	279		10.1016/S0140-6736(95)92166-4	http://dx.doi.org/10.1016/S0140-6736(95)92166-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630248				2022-12-01	WOS:A1995RL75700011
J	RODRIGUES, JJ; MEHENDALE, SM; SHEPHERD, ME; DIVEKAR, AD; GANGAKHEDKAR, RR; QUINN, TC; PARANJAPE, RS; RISBUD, AR; BROOKMEYER, RS; GADKARI, DA; GOKHALE, MR; ROMPALO, AM; DESHPANDE, SG; KHALANDKAR, MM; MAWAR, N; BOLLINGER, RC				RODRIGUES, JJ; MEHENDALE, SM; SHEPHERD, ME; DIVEKAR, AD; GANGAKHEDKAR, RR; QUINN, TC; PARANJAPE, RS; RISBUD, AR; BROOKMEYER, RS; GADKARI, DA; GOKHALE, MR; ROMPALO, AM; DESHPANDE, SG; KHALANDKAR, MM; MAWAR, N; BOLLINGER, RC			RISK-FACTORS FOR HIV-INFECTION IN PEOPLE ATTENDING CLINICS FOR SEXUALLY-TRANSMITTED DISEASES IN INDIA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the risk factors for HIV infection in patients attending clinics for sexually transmitted diseases in India. Design-Descriptive study of HN serology, risk behaviour, and findings on physical examination. Subjects-2800 patients presenting to outpatient clinics between 13 May 1993 and 15 July 1994. Setting-Two clinics and the National AIDS Research Institute, in Pune, Maharashtra State, India. Main outcome measure-HIV status, presence of sexually transmitted diseases, and sexual behaviour. Results-The overall proportion of patients infected with HIV was 23.4% (655/2800); 34% (184) of the women and 21% (459) of the men were positive for HN infection. Of the 560 women screened, 338 (60%) had a reported history of sex working, of whom 153 (45%) were infected with HIV-1. The prevalence of HIV-1 infection in the 222 women who were not sex workers was 14%. The significant independent characteristics associated with HIV infection based on a logistic regression analysis included being a female sex worker, sexual contact with a sex worker, lack of formal education, receptive anal sex in the previous three months, lack of condom use in the previous three months, current or previous genital ulcer or genital discharge, and a positive result of a Venereal Disease Research Laboratory test. Conclusions-In India the prevalence of HIV infection is alarmingly high among female sex workers and men attending clinics for sexually transmitted diseases, particularly in those who had recently had contact with sex workers. A high prevalence of HIV infection was also found in monogamous, married women presenting to the clinics who denied any history of sex working. The HIV epidemic in India is primarily due to heterosexual transmission of HIV-1 and, as in other countries, HIV infection is associated with ulcerative and non-ulcerative sexually transmitted diseases.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; NATL AIDS RES INST,POONA,MAHARASHTRA,INDIA; NIAID,BETHESDA,MD 20892; BJ MED COLL,POONA,MAHARASHTRA,INDIA; SASSOON GEN HOSP,POONA,MAHARASHTRA,INDIA; PUNE MUNICIPAL CORP,DR KOTNIS HLTH CTR,POONA,MAHARASHTRA,INDIA	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); B.J. Govt. Medical College & Sassoon General Hospitals, Pune				Bollinger, Robert/0000-0002-6798-6834; Paranjape, Ramesh/0000-0003-2948-9148	FOGARTY INTERNATIONAL CENTER [N01TW000000] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW0000] Funding Source: Medline; NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NIAID NIH HHS [AI 33879-02] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAVE GG, 1992, 8TH INT C AIDS AMST; BHAVE GG, 1990, 6TH INT C AIDS SAN F; BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; HASMUKH S, 1992, 8TH INT C AIDS AMST; JACOB M, 1992, 8 INT C AIDS AMST; JAIN MK, 1994, J ACQ IMMUN DEF SYND, V7, P1185; JOSHI SH, 1992, 8 INT C AIDS AMST; KULKARNI S, 1992, INDIAN J MED RES-A, V95, P213; Kumar B, 1990, Int J STD AIDS, V1, P438; MANIAR JK, 1992, 8 INT C AIDS AMST; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; SIMOES EAF, 1987, INDIAN J MED RES, V85, P335; THAKUR T S, 1991, Indian Journal of Medical Sciences, V45, P332; THAKUR T S, 1991, Journal of Communicable Diseases, V23, P38; TRIPATHY S, 1993, 9TH INT C AIDS BERL; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1993, OVERVIEW HIV TRENDS	17	98	101	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					283	286		10.1136/bmj.311.7000.283	http://dx.doi.org/10.1136/bmj.311.7000.283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633230	Green Published			2022-12-01	WOS:A1995RM71900017
J	STERN, RC; DOERSHUK, CF; DRUMM, MI				STERN, RC; DOERSHUK, CF; DRUMM, MI			3849+10 KB C-]T MUTATION AND DISEASE SEVERITY IN CYSTIC-FIBROSIS	LANCET			English	Article							GENE; FORM; DNA	50% of patients with cystic fibrosis (CF) are homozygous for the Delta F508 mutation, but the remainder have at least one of many other less common mutations. The 3849+10 kb C-->T splice mutation seems to be associated with less severe disease. We report ten CF patients who are hemizygous for this mutation. Three male patients do not have azoospermia (sperm counts 12, 53, and 198x10(6)/mL). Another boy died before CF was diagnosed; his genital tract appeared normal at necropsy. All patients had clinically sufficient exocrine pancreatic function. Pulmonary disease was delayed in onset in most of these patients (range <1 to 16; median 9 years), but then became severe in some, progressing to death (in two) and need for transplantation in one. Sweat chloride concentration was abnormal (80 mmol/L) in one patient but in others was in the intermediate range (45-65 mmol/L). There was substantial variation in pulmonary disease severity within sibships. These observations suggest some dissociation in genetically determined severity between different organs. There was some evidence among these patients of a tendency for disease of the genital tract to become progressively more severe. Perhaps sperm banking should be offered to male patients. We speculate that some normal CF transmembrane conductance regulator is made in patients with this splice abnormality.	CASE WESTERN RESERVE UNIV,LEROY W MATTHEWS CYST FIBROSIS CTR,DEPT PEDIAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,LEROY W MATTHEWS CYST FIBROSIS CTR,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University	STERN, RC (corresponding author), UNIV CLEVELAND HOSP,RAINBOW BABIES & CHILDRENS HOSP,11100 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; DEAN M, 1994, HUM GENET, V93, P364; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KEREM BS, 1989, AM J HUM GENET, V44, P827; LANDING BH, 1969, ARCH PATHOL, V88, P569; LIEBERMAN J, 1990, INTERNAL MED, V11, P105; MERCIER B, 1995, AM J HUM GENET, V56, P272; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHUBER AP, 1993, HUM MOL GENET, V2, P153, DOI 10.1093/hmg/2.2.153; STERN RC, 1982, LANCET, V1, P1401; TAMAGNINI GP, 1983, BRIT J HAEMATOL, V54, P189, DOI 10.1111/j.1365-2141.1983.tb02087.x; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; 1994, HUM MUTAT, V4, P167	16	44	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					274	276		10.1016/S0140-6736(95)92165-6	http://dx.doi.org/10.1016/S0140-6736(95)92165-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630247				2022-12-01	WOS:A1995RL75700010
J	TOMLINSON, P; SUGARMAN, ID				TOMLINSON, P; SUGARMAN, ID			COMPLICATIONS WITH SHUNTS IN ADULTS WITH SPINA-BIFIDA	BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL-PRESSURE; CHILDREN	Objective-To assess the incidence of malfunction of shunts in adults with spina bifida who have shunts to control hydrocephalus. Design-A retrospective review of the medical notes and contact by questionnaire of adults with spina bifida to assess symptoms, function of shunts, frequency of operative procedures, and follow up. Subjects-110 patients with shunts who attended Lord Mayor Treloar College for the physically disabled between 1978 and 1993. Results-The average (range) number of revisions of shunts per person was 3.6 (0-28). Although 37 patients underwent an emergency operation for revision in their first year of life, there was a continuing low incidence, increasing in the early teenage years, which persisted into the third decade. Intervals between emergency revisions varied:. 202/ 320 occurred within one year of the last shunt operation, 56 occurred after five years, 24 after 10 years, and 15 after 15 or more years. Fifteen patients had chronic intermittent headaches, of whom four died and three suffered severe morbidity. Thirteen died; three had raised intracranial pressure, and four died suddenly; these deaths were presumed to be related to their shunts. Up to the age of 16 there was 100% hospital follow up, but after that only 40% of young adults underwent review, including review of their shunt function. Conclusion-Shunts to control hydrocephalus may fail after many years without symptoms, This is difficult to diagnose and if missed may lead to chronic morbidity and death. As hospital follow up of this group is falling, both general practitioners and hospital doctors must be aware that a shunt may malfunction after prolonged quiescent periods.	LORD MAYOR TRELOAR COLL,ALTON,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT CHILD HLTH,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton								BRYDON HL, 1994, EUR J PEDIATR SURG, V4, P37; DOYLE J, 1992, J CLIN MONITOR, V8, P81, DOI 10.1007/BF01618093; DRAKE JM, 1991, J NEUROSURG, V75, P535, DOI 10.3171/jns.1991.75.4.0535; EPSTEIN F, 1982, MONOGR NEURAL SCI, V8, P105; HEMMER R, 1976, DEV MED CHILD NEUROL, V18, P69; HEMMER R, 1982, MONOGR NEURAL SCI, V8, P227; LORBER J, 1982, MONOGR NEUROL SCI, V8, P134; MOSS SM, 1991, EUR J PEDIATR SURG, V1, P25, DOI 10.1055/s-2008-1042533; PIATT JH, 1993, PEDIATR NEUROSURG, V19, P233, DOI 10.1159/000120738; POPLE IK, 1992, CHILD NERV SYST, V8, P124, DOI 10.1007/BF00298265; RICHMOND TS, 1993, CLIN ISSUES CRITICAL, V4, P148; UVEBRANT P, 1992, CHILD NERV SYST, V8, P76, DOI 10.1007/BF00298444	12	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					286	287		10.1136/bmj.311.7000.286	http://dx.doi.org/10.1136/bmj.311.7000.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633231	Green Published			2022-12-01	WOS:A1995RM71900018
J	BAKER, SM; BRONNER, CE; ZHANG, L; PLUG, AW; ROBATZEK, M; WARREN, G; ELLIOTT, EA; YU, JA; ASHLEY, T; ARNHEIM, N; FLAVELL, RA; LISKAY, RM				BAKER, SM; BRONNER, CE; ZHANG, L; PLUG, AW; ROBATZEK, M; WARREN, G; ELLIOTT, EA; YU, JA; ASHLEY, T; ARNHEIM, N; FLAVELL, RA; LISKAY, RM			MALE-MICE DEFECTIVE IN THE DNA MISMATCH REPAIR GENE PMS2 EXHIBIT ABNORMAL CHROMOSOME SYNAPSIS IN MEIOSIS	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; MEIOTIC SYNAPSIS; ESCHERICHIA-COLI; RECOMBINATION; CONVERSION; YEAST; INITIATION; MUTATIONS; SEQUENCE	Using gene targeting in embryonic stem cells, we have derived mice with a null mutation in a DNA mismatch repair gene homolog, PMS2. We observed microsatellite instability in the male germline, in tail, and in tumor DNA of PMS2-deficient animals. We therefore conclude that PMS2 is involved in DNA mismatch repair in a variety of tissues. PMS2-deficient animals appear prone to sarcomas and lymphomas, PMS2-deficient males are infertile, producing only abnormal spermatozoa. Analysis of axial element and synaptonemal complex formation during prophase of meiosis I indicates abnormalities in chromosome synapsis. These observations suggest links among mismatch repair, genetic recombination, and chromosome synapsis in meiosis.	OREGON HLTH SCI UNIV, DEPT MOLEC MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; UNIV SO CALIF, PROGRAM MOLEC BIOL, LOS ANGELES, CA 90089 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; AGR UNIV WAGENINGEN, DEPT GENET, 6703 HA WAGENINGEN, NETHERLANDS	Oregon Health & Science University; University of Southern California; Yale University; Howard Hughes Medical Institute; Yale University; Wageningen University & Research	BAKER, SM (corresponding author), OREGON HLTH SCI UNIV, DEPT MED & MOLEC GENET, PORTLAND, OR 97201 USA.		Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Arnheim, Norman/0000-0003-1247-1347	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032741, R01GM049779, R37GM032741, R01GM045413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45413-05, GM49779, GM32741-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1994, GENETICS, V137, P19; ASHLEY T, 1988, GENETICS, V118, P307; ASHLEY T, 1990, GENETICA, V83, P1; AU KG, 1992, J BIOL CHEM, V267, P12142; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Boer P. de, 1989, Fertility and chromosome pairing: recent studies in plants and animals., P37; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; DETLOFF P, 1992, GENETICS, V132, P113; DIETRICH W, 1992, GENETICS, V131, P423; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOREJT J, 1985, EXP CLIN IMMUNOGENET, V2, P106; GOETZ P, 1984, J CELL SCI, V65, P249; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HOEKSTRA MF, 1991, METHOD ENZYMOL, V194, P329; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEEFLANG PE, 1994, CURRENT PROTOCOLS HU, V1; LI FP, 1988, CANCER RES, V48, P5358; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Moses MJ, 1980, ANIMAL MODELS HUMAN, P169; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PETIT MA, 1991, GENETICS, V129, P327; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Russell L, 1990, HISTOLOGICAL HISTOPA; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SELVA EM, 1995, GENETICS, V139, P1175; SHERMAN JD, 1992, GENOME, V35, P907, DOI 10.1139/g92-140; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; Speed R.M., 1989, FERTILITY CHROMOSOME, P1; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WILLIAMSON MS, 1985, GENETICS, V110, P609; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; [No title captured]	52	469	494	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					309	319		10.1016/0092-8674(95)90318-6	http://dx.doi.org/10.1016/0092-8674(95)90318-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628019	hybrid			2022-12-01	WOS:A1995RL76000018
J	CAMPFIELD, LA; SMITH, FJ; GUISEZ, Y; DEVOS, R; BURN, P				CAMPFIELD, LA; SMITH, FJ; GUISEZ, Y; DEVOS, R; BURN, P			RECOMBINANT MOUSE OB PROTEIN - EVIDENCE FOR A PERIPHERAL SIGNAL LINKING ADIPOSITY AND CENTRAL NEURAL NETWORKS	SCIENCE			English	Article							DIABETES-OBESITY SYNDROMES; MICE; RODENTS; ANIMALS	The recent positional cloning of the mouse ob gene and its human homolog has provided the basis to investigate the potential role of the ob gene product in body weight regulation. A biologically active form of recombinant mouse OB protein was overexpressed and purified to near homogeneity from a bacterial expression system. Peripheral and central administration of microgram doses of OB protein reduced food intake and body weight of ob/ob and diet-induced obese mice but not in db/db obese mice. The behavioral effects after brain administration suggest that OB protein can act directly on neuronal networks that control feeding and energy balance.	ROCHE RES GENT,B-9000 GHENT,BELGIUM		CAMPFIELD, LA (corresponding author), HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110, USA.							BJORNTORP P, 1992, OBESITY; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRAY GA, 1975, METABOLISM, V24, P99, DOI 10.1016/0026-0495(75)90011-6; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; Coleman D L, 1981, Prog Clin Biol Res, V45, P145; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1982, DIABETES, V31, P1; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COLEMAN DL, 1982, DIABETES, V31, P24, DOI 10.2337/diab.31.1.S24; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GUISEZ Y, UNPUB; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALS AM, 1950, J HERED, V17, P317; KEESEY RE, 1989, MED CLIN N AM, V73, P15, DOI 10.1016/S0025-7125(16)30689-7; Le Magnen J, 1992, NEUROBIOLOGY FEEDING; LEIBEL RL, 1993, CRIT REV FOOD SCI, V33, P351, DOI 10.1080/10408399309527632; LEIBEL RL, 1995, NEW ENGL J MED, V232, P621; MOKHTARIAN A, 1993, PHYSIOL BEHAV, V54, P895, DOI 10.1016/0031-9384(93)90298-T; MORLEY JE, 1987, AM J PHYSIOL, V253, pR516, DOI 10.1152/ajpregu.1987.253.3.R516; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Schwartz MW, 1994, ENDOCR REV, V2, P109; Snedecor G. W, 1989, STAT METHODS, V8th; Thomas PR, 1995, WEIGHING OPTIONS CRI; WEST DB, 1994, MAMM GENOME, V5, P546, DOI 10.1007/BF00354928; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	2907	3047	3	135	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					546	549		10.1126/science.7624778	http://dx.doi.org/10.1126/science.7624778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624778				2022-12-01	WOS:A1995RL49500030
J	CHEN, JJ; REID, CE; BAND, V; ANDROPHY, EJ				CHEN, JJ; REID, CE; BAND, V; ANDROPHY, EJ			INTERACTION OF PAPILLOMAVIRUS E6 ONCOPROTEINS WITH A PUTATIVE CALCIUM-BINDING PROTEIN	SCIENCE			English	Article							MAMMARY EPITHELIAL-CELLS; BOVINE PAPILLOMAVIRUS; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; P53 PROTEIN; HPV-16 E6; TYPE-16; DEGRADATION; DNA; TRANSACTIVATION	Human papillomaviruses (HPVs) are associated with the majority of cervical cancers and encode a transforming protein, E6, that interacts with the tumor suppressor protein p53. Because E6 has p53-independent transforming activity, the yeast two-hybrid system was used to search for other EG-binding proteins. One such protein, E6BP, interacted with cancer-associated HPV E6 and with bovine papillomavirus type 1 (BPV-1) E6. The transforming activity of BPV-1 E6 mutants correlated with their E6BP-binding ability. E6BP is identical to a putative calcium-binding protein, ERC-55, that appears to be localized in the endoplasmic reticulum.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT DERMATOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT RADIAT ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT BIOCHEM, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center				Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [R29CA56803, R01CA44174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044174, R29CA056803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen J., UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DOSHI N, UNPUB; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KEEN N, 1994, ONCOGENE, V9, P1493; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIANG XH, 1993, ONCOGENE, V8, P2645; MANSUR CP, 1995, ONCOGENE, V10, P457; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, DNA TUMOR VIRUSES CO, P571; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHMITT A, 1994, ONCOGENE, V68, P7051; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	40	245	255	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					529	531		10.1126/science.7624774	http://dx.doi.org/10.1126/science.7624774			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624774				2022-12-01	WOS:A1995RL49500024
J	CROVELLO, CS; FURIE, BC; FURIE, B				CROVELLO, CS; FURIE, BC; FURIE, B			HISTIDINE PHOSPHORYLATION OF P-SELECTIN UPON STIMULATION OF HUMAN PLATELETS - A NOVEL PATHWAY FOR ACTIVATION-DEPENDENT SIGNAL-TRANSDUCTION	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; LABILE HISTONE PHOSPHATES; PHYSARUM-POLYCEPHALUM; DEHYDROGENASE KINASE; SEQUENCE SIMILARITY; MOLECULAR-CLONING; NUCLEAR PROTEINS; PLASMA-MEMBRANE; RAT-LIVER; ADHESION	Transient phosphorylation of histidine characterizes the two-component systems in prokaryotes that control important physiological functions, but analogous events have not been implicated in signal transduction in mammalian cells. To explore histidine phosphorylation during activation of human cells, stimulated platelets were analyzed for the formation of protein phosphohistidine in a model system employing P-selectin. P-selectin, a leukocyte adhesion molecule, undergoes rapid phosphorylation and selective dephosphorylation of tyrosine, serine, and threonine. We now establish that phosphorylation following platelet activation with thrombin or collagen generates phosphohistidine at histidines on the cytoplasmic tail of P-selectin. With thrombin stimulation, the kinetics of phosphohistidine appearance and disappearance on P-selectin are very rapid. Platelets exhibit a novel ligand-induced signaling pathway to generate phosphohistidine. These results provide direct biochemical evidence for the induction of rapid and reversible histidine phosphorylation in mammalian cells upon cell activation and represent a novel paradigm for mammalian cell signaling.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University; Tufts University	CROVELLO, CS (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051926] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51926] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; CHONG BH, 1994, BLOOD, V83, P1535; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; CROVELLO CS, 1993, J BIOL CHEM, V268, P14590; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KIM YH, 1993, J BIOL CHEM, V268, P18513; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; MOTOJIMA K, 1994, J BIOL CHEM, V269, P9030; OHMORI H, 1993, J BIOL CHEM, V268, P7625; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; Sheridan R. C., 2007, INORG SYN, P23; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALINDER O, 1969, J BIOL CHEM, V244, P1065; WALINDER O, 1968, J BIOL CHEM, V243, P3947; WATSON SP, 1985, BIOCHEM J, V226, P831, DOI 10.1042/bj2260831; WEI YF, 1993, METHOD ENZYMOL, V200, P388; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WIELAND T, 1993, J BIOL CHEM, V268, P18111; WONG C, 1993, BIOCHEM J, V296, P293, DOI 10.1042/bj2960293; ZETTERQVIST O, 1967, BIOCHIM BIOPHYS ACTA, V136, P279, DOI 10.1016/0304-4165(67)90073-6; ZHANG J, 1993, J BIOL CHEM, V268, P22251	53	88	90	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					279	286		10.1016/0092-8674(95)90315-1	http://dx.doi.org/10.1016/0092-8674(95)90315-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543025	Bronze			2022-12-01	WOS:A1995RL76000015
J	DEWIND, N; DEKKER, M; BERNS, A; RADMAN, M; RIELE, HT				DEWIND, N; DEKKER, M; BERNS, A; RADMAN, M; RIELE, HT			INACTIVATION OF THE MOUSE MSH2 GENE RESULTS IN MISMATCH REPAIR DEFICIENCY, METHYLATION TOLERANCE, HYPERRECOMBINATION, AND PREDISPOSITION TO CANCER	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; BASE-PAIR MISMATCHES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GENOMIC INSTABILITY; ESCHERICHIA-COLI; DNA-DAMAGE; EXTRACTS; BINDING; MUTATIONS	To investigate the role of the presumed DNA mismatch repair (MMR) gene Msh2 in genome stability and tumorigenesis, we have generated cells and mice that are deficient for the gene. Msh2-deficient cells have lost mismatch binding and have acquired microsatellite instability, a mutator phenotype, and tolerance to methylating agents. Moreover, in these cells, homologous recombination has lost dependence on complete identity between interacting DNA sequences, suggesting that Msh2 is involved in safeguarding the genome from promiscuous recombination. Msh2-deficient mice display no major abnormalities, but a significant fraction develops lymphomas at an early age. Thus, Msh2 is involved in MMR, controlling several aspects of genome stability; loss of MMR-controlled genome stability predisposes to cancer.	NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS; INST JACQUES MONOD, MUTAGENESIS LAB, F-75251 PARIS 5, FRANCE	Netherlands Cancer Institute; UDICE-French Research Universities; Universite Paris Cite	DEWIND, N (corresponding author), NETHERLANDS CANC INST, DIV MOLEC CARCINOGENESIS, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.		; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				AALTONEN LA, 1994, CANCER RES, V54, P1645; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; AQUILINA G, 1993, CARCINOGENESIS, V14, P2097, DOI 10.1093/carcin/14.10.2097; BEIJERSBERGEN RL, 1995, IN PRESS GENES DEV; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROSIUS J, 1992, P NATL ACAD SCI USA, V89, P10706, DOI 10.1073/pnas.89.22.10706; CHONG JM, 1994, CANCER RES, V54, P4595; COHEN PR, 1991, AM J MED, V90, P606; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; HAN HJ, 1993, CANCER RES, V53, P5087; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; JASS JR, 1994, MUTAT RES-FUND MOL M, V310, P125, DOI 10.1016/0027-5107(94)90016-7; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KOLODNER RD, 1995, CANCER RES, V55, P242; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LOEB LA, 1994, CANCER RES, V54, P5059; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MICHEJDA CJ, 1994, DNA ADDUCTS IDENTIFI, P323; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PETIT MA, 1991, GENETICS, V129, P327; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; RISINGER JI, 1993, CANCER RES, V53, P5100; Sambrook J., 1989, MOL CLONING LAB MANU; SELVA EM, 1995, GENETICS, V139, P1175; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SUZUKI H, 1994, CANCER RES, V54, P4841; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VARLET I, 1994, NUCLEIC ACIDS RES, V22, P5723, DOI 10.1093/nar/22.25.5723; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	88	693	720	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					321	330		10.1016/0092-8674(95)90319-4	http://dx.doi.org/10.1016/0092-8674(95)90319-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628020	Bronze			2022-12-01	WOS:A1995RL76000019
J	FLEISCHMANN, RD; ADAMS, MD; WHITE, O; CLAYTON, RA; KIRKNESS, EF; KERLAVAGE, AR; BULT, CJ; TOMB, JF; DOUGHERTY, BA; MERRICK, JM; MCKENNEY, K; SUTTON, G; FITZHUGH, W; FIELDS, C; GOCAYNE, JD; SCOTT, J; SHIRLEY, R; LIU, LI; GLODEK, A; KELLEY, JM; WEIDMAN, JF; PHILLIPS, CA; SPRIGGS, T; HEDBLOM, E; COTTON, MD; UTTERBACK, TR; HANNA, MC; NGUYEN, DT; SAUDEK, DM; BRANDON, RC; FINE, LD; FRITCHMAN, JL; FUHRMANN, JL; GEOGHAGEN, NSM; GNEHM, CL; MCDONALD, LA; SMALL, KV; FRASER, CM; SMITH, HO; VENTER, JC				FLEISCHMANN, RD; ADAMS, MD; WHITE, O; CLAYTON, RA; KIRKNESS, EF; KERLAVAGE, AR; BULT, CJ; TOMB, JF; DOUGHERTY, BA; MERRICK, JM; MCKENNEY, K; SUTTON, G; FITZHUGH, W; FIELDS, C; GOCAYNE, JD; SCOTT, J; SHIRLEY, R; LIU, LI; GLODEK, A; KELLEY, JM; WEIDMAN, JF; PHILLIPS, CA; SPRIGGS, T; HEDBLOM, E; COTTON, MD; UTTERBACK, TR; HANNA, MC; NGUYEN, DT; SAUDEK, DM; BRANDON, RC; FINE, LD; FRITCHMAN, JL; FUHRMANN, JL; GEOGHAGEN, NSM; GNEHM, CL; MCDONALD, LA; SMALL, KV; FRASER, CM; SMITH, HO; VENTER, JC			WHOLE-GENOME RANDOM SEQUENCING AND ASSEMBLY OF HAEMOPHILUS-INFLUENZAE RD	SCIENCE			English	Article							ESCHERICHIA-COLI GENOME; HEMOPHILUS TRANSFORMATION; DNA-SEQUENCE; GENE; PROTEIN; ORGANIZATION; PROJECT; RECOGNITION; COMPETENCE; COMPUTER	An approach for genome analysis based on sequencing and assembly of unselected pieces of DNA from the whole chromosome has been applied to obtain the complete nucleotide sequence (1,830,137 base pairs) of the genome from the bacterium Haemophilus influenzae Rd. This approach eliminates the need for initial mapping efforts and is therefore applicable to the vast array of microbial species for which genome maps are unavailable. The H. influenzae Rd genome sequence (Genome Sequence DataBase accession number L42023) represents the only complete genome sequence from a free-living organism.	INST GENOM RES, GAITHERSBURG, MD 20878 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA; NIST, GAITHERSBURG, MD 20878 USA	J. Craig Venter Institute; Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institute of Standards & Technology (NIST) - USA			Puigbò, Pere/A-2214-2008	Fraser, Claire/0000-0003-1462-2428; Fields, Chris/0000-0002-4812-0744; Kerlavage, Anthony/0000-0002-3954-9653				Adams M. D., 1994, AUTOMATED DNA SEQUEN; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMS MD, IN PRESS NATURE; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BAROUKI R, 1985, J BACTERIOL, V163, P629, DOI 10.1128/JB.163.2.629-634.1985; BODMER WF, 1994, REV INVEST CLIN S, P3; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CHANDLER MS, 1992, P NATL ACAD SCI USA, V89, P1626, DOI 10.1073/pnas.89.5.1626; CLAVERIE JM, 1993, J MOL BIOL, V234, P1140, DOI 10.1006/jmbi.1993.1666; DANNER DB, 1980, GENE, V11, P311, DOI 10.1016/0378-1119(80)90071-2; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; DOROCICZ IR, 1993, J BACTERIOL, V175, P7142, DOI 10.1128/JB.175.22.7142-7149.1993; DOUGHERTY B, UNPUB; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HARTL DL, 1993, GENOME RES MOL MED V, P115; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HONG GF, 1982, J MOL BIOL, V162, P72; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KAHN ME, 1984, J MEMBRANE BIOL, V138, P155; KERLAVAGE A, 1993, 26TH P HAW INT C SYS, P585; KERLAVAGE AR, IN PRESS IEEE COMPUT; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KLEIN RD, 1979, J GEN MICROBIOL, V113, P409, DOI 10.1099/00221287-113-2-409; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER E S, 1988, Genomics, V2, P231; LEE JJ, 1989, J BACTERIOL, V171, P3016, DOI 10.1128/jb.171.6.3016-3024.1989; LEVY J, 1994, YEAST, V10, P1689, DOI 10.1002/yea.320101304; LEWIN B, 1994, GENES, V5, pCH18; LEWIN B, 1994, GENES, V5, pCH19; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REDFIELD RJ, 1991, J BACTERIOL, V173, P5612, DOI 10.1128/jb.173.18.5612-5618.1991; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; TOMB JF, 1992, P NATL ACAD SCI USA, V89, P10252, DOI 10.1073/pnas.89.21.10252; TTOMB JF, UNPUB; UTTERBACK TR, UNPUB; VANHAM SM, 1994, MOL MICROBIOL, V13, P673; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; WILCOX KW, 1975, J BACTERIOL, V122, P443, DOI 10.1128/JB.122.2.443-453.1975; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	57	4331	6344	1	348	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					496	512		10.1126/science.7542800	http://dx.doi.org/10.1126/science.7542800			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542800				2022-12-01	WOS:A1995RL49500017
J	GUNDERSON, KL; KOPITO, RR				GUNDERSON, KL; KOPITO, RR			CONFORMATIONAL STATES OF CFTR ASSOCIATED WITH CHANNEL GATING - THE ROLE OF ATP BINDING AND HYDROLYSIS	CELL			English	Article							SITE-DIRECTED MUTAGENESIS; CYSTIC-FIBROSIS; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; CHLORIDE CHANNEL; TRIPHOSPHATE CONFORMATION; CRYSTAL-STRUCTURE; TRANSPORT; PROTEINS	CFTR is a member of the traffic ATPase superfamily and a C1(-) ion channel that appears to require ATP hydrolysis for gating. Analysis of single CFTR C1(-) channels reconstituted into planar lipid bilayers revealed the presence of two open conductance states that are connected to each other and to the closed state by an asymmetric cycle of gating events. We show here that the transition between the two open conductance states is directly coupled to ATP hydrolysis by one of the consensus nucleotide-binding folds, designated NBF2. Moreover, the transition between the closed state and one of the open states is linked to the binding of ATP. This analysis permits real-time visualization of conformational changes associated with a single cycle of ATP hydrolysis by a single protein molecule and suggests a model describing a role for ATP in CFTR gating.	STANFORD UNIV,BIOPHYS PROGRAM,STANFORD,CA 94305	Stanford University	GUNDERSON, KL (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43994] Funding Source: Medline; NIGMS NIH HHS [GM08294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGGINS CF, 1990, RES MICROBIOL, V141, P353, DOI 10.1016/0923-2508(90)90011-E; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHN J, 1993, J BIOL CHEM, V268, P923; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; REDDY M, 1994, PEDIATR PULM S, V10, P183; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD CL, 1994, J BIOL CHEM, V269, P26710	47	184	187	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					231	239		10.1016/0092-8674(95)90310-0	http://dx.doi.org/10.1016/0092-8674(95)90310-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543023	Bronze			2022-12-01	WOS:A1995RL76000010
J	HALAAS, JL; GAJIWALA, KS; MAFFEI, M; COHEN, SL; CHAIT, BT; RABINOWITZ, D; LALLONE, RL; BURLEY, SK; FRIEDMAN, JM				HALAAS, JL; GAJIWALA, KS; MAFFEI, M; COHEN, SL; CHAIT, BT; RABINOWITZ, D; LALLONE, RL; BURLEY, SK; FRIEDMAN, JM			WEIGHT-REDUCING EFFECTS OF THE PLASMA-PROTEIN ENCODED BY THE OBESE GENE	SCIENCE			English	Article							RATS	The gene product of the ob locus is important in the regulation of body weight. The ob product was shown to be present as a 16-kilodalton protein in mouse and human plasma but was undetectable in plasma from C57BL/6J ob/ob mice. Plasma levels of this protein were increased in diabetic (db) mice, a mutant thought to be resistant to the effects of ab. Daily intraperitoneal injections of either mouse or human recombinant OB protein reduced the body weight of ob/ob mice by 30 percent after 2 weeks of treatment with no apparent toxicity but had no effect on db/db mice. The protein reduced food intake and increased energy expenditure in ob/ob mice. Injections of wild-type mice twice daily with the mouse protein resulted in a sustained 12 percent weight loss, decreased food intake, and a reduction of body fat from 12.2 to 0.7 percent. These data suggest that the OB protein serves an endocrine function to regulate body fat stores.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,GENET MOLEC LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOPHYS LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT STAT,NEW YORK,NY 10027; BROOKWOOD BIOMED CTR,BIRMINGHAM,AL 35209	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Columbia University				Burley, Stephen/0000-0002-2487-9713	NCRR NIH HHS [RR00862] Funding Source: Medline; NIDDK NIH HHS [DK41096] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTTIST; HALAAS JL, UNPUB; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS RBS, 1987, INT J OBESITY, V11, P275; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HERVEY GR, 1976, P PHYSL SOC, V266, pP65; KEESEY RC, 1984, ASS RES NERVOUS MENT, V62, P87; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEIBELT RA, 1965, ANN NY ACAD SCI, V131, P559; PARAMESWARAN SV, 1977, AM J PHYSIOL, V232, pR150, DOI 10.1152/ajpregu.1977.232.5.R150; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	3944	4167	6	237	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					543	546		10.1126/science.7624777	http://dx.doi.org/10.1126/science.7624777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624777				2022-12-01	WOS:A1995RL49500029
J	HUMPEL, C; LINDQVIST, E; SODERSTROM, S; KYLBERG, A; EBENDAL, T; OLSON, L				HUMPEL, C; LINDQVIST, E; SODERSTROM, S; KYLBERG, A; EBENDAL, T; OLSON, L			MONITORING RELEASE OF NEUROTROPHIC ACTIVITY IN THE BRAINS OF AWAKE RATS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; EXPRESSION; ANTIBODIES	Intracerebral microdialysis of awake rats was used to monitor the possible release of neurotrophic factors from brain cells in response to injury and excitation. Perfusates were tested with ganglia bioassays and enzyme immunoassay. Trophic activity was released after implantation of the microdialysis probe into the hippocampus but not into the striatum, as assessed by increased nerve fiber outgrowth from Remak's ganglion. Kainic acid treatment significantly increased the release of trophic activity from hippocampal sites. These findings suggest that the brain responds to mechanical injury as well as to certain excitatory stimuli by regional extracellular release of neurotrophic activity that is not identical to the actions of known neurotrophic factors.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN; UNIV INNSBRUCK, DEPT PSYCHIAT, NEUROCHEM UNIT, A-6020 INNSBRUCK, AUSTRIA; UNIV UPPSALA, CTR BIOMED, DEPT DEV NEUROSCI, S-75123 UPPSALA, SWEDEN	Karolinska Institutet; University of Innsbruck; Uppsala University								AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; EBENDAL T, 1978, ZOON, V6, P235; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EBENDAL T, 1989, NERVE GROWTH FACTORS, P81; EBENDAL T, UNPUB; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Lapchak P A, 1992, Rev Neurosci, V3, P1, DOI [10.1515/REVNEURO.1992.3.2.109, 10.1515/REVNEURO.1992.3.1.1]; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; LEVIMONTALCINI R, 1987, BIOSCIENCE REP, V7, P681, DOI 10.1007/BF01116861; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; WETMORE C, 1991, P NATL ACAD SCI USA, V88, P9843, DOI 10.1073/pnas.88.21.9843; WETMORE CJ, 1993, J HISTOCHEM CYTOCHEM, V41, P521, DOI 10.1177/41.4.8450192	15	19	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					552	554		10.1126/science.7624780	http://dx.doi.org/10.1126/science.7624780			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624780				2022-12-01	WOS:A1995RL49500032
J	JUNGNICKEL, B; RAPOPORT, TA				JUNGNICKEL, B; RAPOPORT, TA			A POSTTARGETING SIGNAL SEQUENCE RECOGNITION EVENT IN THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							PROTEIN TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; NASCENT POLYPEPTIDES; SUPPRESSOR MUTATIONS; MICROSOMAL-MEMBRANES; PARTICLE RECEPTOR; ESCHERICHIA-COLI; ER MEMBRANE; COMPONENTS; PEPTIDES	We have analyzed early phases of the cotranslational transport of the secretory protein preprolactin through the mammalian endoplasmic reticulum (ER) membrane. Following recognition of the signal sequence of the nascent polypeptide chain in the cytosol by the SRP, the chain is transferred into the membrane, where a second signal sequence recognition step takes place for which the presence in the lipid bilayer of the Sec61p complex is essential and sufficient. This step leads to a tight junction between the ribosome-nascent chain complex and the Sec61p complex, and to the productive insertion of the nascent chain into the translocation site, These results show that a translocation substrate is subjected to two recognition events before being allowed to cross the ER membrane.	MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	JUNGNICKEL, B (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.							ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1992, J CELL BIOL, V95, P470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1993, FEBS LETT, V329, P268, DOI 10.1016/0014-5793(93)80235-M; KALLES KU, 1994, J CELL BIOL, V126, P925; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PREHN S, 1980, EUR J BIOCHEM, V107, P185, DOI 10.1111/j.1432-1033.1980.tb04639.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; [No title captured]	30	232	234	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					261	270		10.1016/0092-8674(95)90313-5	http://dx.doi.org/10.1016/0092-8674(95)90313-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628015	Bronze			2022-12-01	WOS:A1995RL76000013
J	KATZ, WS; HILL, RJ; CLANDININ, TR; STERNBERG, PW				KATZ, WS; HILL, RJ; CLANDININ, TR; STERNBERG, PW			DIFFERENT LEVELS OF THE C-ELEGANS GROWTH-FACTOR LIN-3 PROMOTE DISTINCT VULVAR PRECURSOR FATES	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; CELL LINEAGES; EXPRESSION; INDUCTION; AUTONOMY; ENCODES; MUTANTS; PATTERN; SIGNAL	An invariant spatial pattern of three cell fates (3 degrees-3 degrees 2 degrees-1 degrees-2 degrees-3 degrees) is generated from a field of multipotent precursor cells during C. elegans vulval development. We demonstrate that the epidermal growth factor-like domain of the LIN-3 protein can induce either of two distinct vulval cell fates: a high dose of LIN-3 induces a 1 degrees fate; a lower dose of LIN-3 induces a 2 degrees fate. A high dose of LIN-3 can also induce adjacent vulval precursor cells to assume 1 degrees fates; thus, high levels of LIN-3 can override the lateral signaling that normally inhibits formation of adjacent 1 degrees fates. We propose that the invariant pattern of vulval cell fates is generated by a graded distribution of LIN-3 that promotes different vulval fates according to local concentration and by a lateral signal that reinforces this initial bias.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	KATZ, WS (corresponding author), CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125, USA.			Katz, Wendy/0000-0003-3038-6314; Sternberg, Paul/0000-0002-7699-0173	NICHD NIH HHS [HD23690] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023690] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREYD G, 1991, THESIS MIT CAMBRIDGE; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, GENETICS, V126, P899; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOGA M, 1995, IN PRESS DEVELOPMENT; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, METHODS CELL BIOL C; PEIFER M, 1994, SCIENCE, V266, P192; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; Sambrook J., 1989, MOL CLONING LAB MANU; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STJOHNSTON D, 1992, CELL, V68, P201; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1976, PHILOS T ROY SOC B, V275, P287, DOI 10.1098/rstb.1976.0084; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	49	167	177	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					297	307		10.1016/0092-8674(95)90317-8	http://dx.doi.org/10.1016/0092-8674(95)90317-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628018	Bronze			2022-12-01	WOS:A1995RL76000017
J	KOUNNAS, MZ; MOIR, RD; REBECK, GW; BUSH, AI; ARGRAVES, WS; TANZI, RE; HYMAN, BT; STRICKLAND, DK				KOUNNAS, MZ; MOIR, RD; REBECK, GW; BUSH, AI; ARGRAVES, WS; TANZI, RE; HYMAN, BT; STRICKLAND, DK			LDL RECEPTOR-RELATED PROTEIN, A MULTIFUNCTIONAL APOE RECEPTOR, BINDS SECRETED BETA-AMYLOID PRECURSOR PROTEIN AND MEDIATES ITS DEGRADATION	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; SPORADIC ALZHEIMERS-DISEASE; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; PLASMINOGEN-ACTIVATOR; MESSENGER-RNA; NEXIN-II; CELL; PURIFICATION	The secreted form of beta-amyloid precursor protein (APP) containing the Kunitz proteinase inhibitor (KPI) domain, also called protease nexin II, is internalized and degraded by cells. We show that the low density lipoprotein (LDL) receptor-related protein (LRP) is responsible for the endocytosis of secreted APP. APP(S)770 degradation is inhibited by an LRP antagonist called the receptor-associated protein (RAP) and by LRP antibodies and is greatly diminished in fibroblasts genetically deficient in LRP. APP(S)695, which lacks the KPI domain, isa poor LRP ligand, Since LRP also binds apolipoprotein E (apoE)-enriched lipoproteins and inheritance of the epsilon 4 allele of the apoE gene is a risk factor for Alzheimer's disease (AD), these data link in a single metabolic pathway two molecules strongly implicated in the pathophysiology of AD.	AMER RED CROSS,HOLLAND LABS,DEPT BIOCHEM,ROCKVILLE,MD 20855; MASSACHUSETTS GEN HOSP,GENET & AGING LAB,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114	American Red Cross; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Bush, Ashley I/A-1186-2007; Moir, Robert D./M-7612-2017; Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Rebeck, George William/J-2192-2012	Bush, Ashley I/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Rebeck, George William/0000-0001-6276-248X	NHLBI NIH HHS [HL50787] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BREEN KC, 1992, MOL CHEM NEUROPATHOL, V16, P109, DOI 10.1007/BF03159964; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HERZ J, 1991, J BIOL CHEM, V266, P21232; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; JIN LW, 1994, J NEUROSCI, V14, P5461; JOHNSONWOOD KL, 1994, BIOCHEM BIOPH RES CO, V200, P1685, DOI 10.1006/bbrc.1994.1646; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNAUER DJ, 1982, P NATL ACAD SCI-BIOL, V79, P2310, DOI 10.1073/pnas.79.7.2310; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; KOO EH, 1990, NEURON, V2, P97; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOUNNAS MZ, 1994, IN VIVO, V8, P342; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, IN PRESS APOLIPOPROT; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; QUI WQ, 1995, J NEUROSCI, V15, P2157; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1995, IN PRESS FASEB J; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	76	435	457	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					331	340		10.1016/0092-8674(95)90320-8	http://dx.doi.org/10.1016/0092-8674(95)90320-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543026	Bronze			2022-12-01	WOS:A1995RL76000020
J	LEE, SL; WESSELSCHMIDT, RL; LINETTE, GP; KANAGAWA, O; RUSSELL, JH; MILBRANDT, J				LEE, SL; WESSELSCHMIDT, RL; LINETTE, GP; KANAGAWA, O; RUSSELL, JH; MILBRANDT, J			UNIMPAIRED THYMIC AND PERIPHERAL T-CELL DEATH IN MICE LACKING THE NUCLEAR RECEPTOR NGFI-B (NUR77)	SCIENCE			English	Article							CLONAL DELETION; THYMOCYTES; APOPTOSIS; ANTIBODIES; HYBRIDOMAS; INVIVO; GENE	T cell hybridomas require the immediate-early gene NGFI-B (nur77) for T cell receptor (TCR)-mediated apoptosis, a model for negative selection of self-reactive T cells. TCR-mediated death was examined in mice bearing an NGFI-B loss-of-function mutation, either by administration of antibodies to CD3 (anti-CD3) or in two well-characterized transgenic models expressing self-reactive TCRs. Both the extent and the rate of thymocyte death were unimpaired. Anti-CD3-induced death was normal in CD4+ peripheral T cells, in which death is mediated predominantly by the Fas signaling pathway. Thus, no unique requirement for NGFI-B is observed for thymic or peripheral T cell death.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Milbrandt, Jeffrey/0000-0002-5477-7689; Russell, John/0000-0002-3680-9587	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KISLELOW P, 1988, NATURE, V333, P742; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Lee S. A., UNPUB; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WATSON MA, UNPUB; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	28	221	224	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					532	535		10.1126/science.7624775	http://dx.doi.org/10.1126/science.7624775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624775				2022-12-01	WOS:A1995RL49500025
J	MAEDA, T; TAKEKAWA, M; SAITO, H				MAEDA, T; TAKEKAWA, M; SAITO, H			ACTIVATION OF YEAST PBS2 MAPKK BY MAPKKKS OR BY BINDING OF AN SH3-CONTAINING OSMOSENSOR	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PATHWAY; ALLELE	The role of mitogen-activated protein (MAP) kinase cascades in integrating distinct upstream signals was studied in yeast. Mutants that were not able to activate PBS2 MAP kinase kinase (MAPKK; Pbs2p) at high osmolarity were characterized. Pbs2p was activated by two independent signals that emanated from distinct cell-surface osmosensors. Pbs2p was activated by MAP kinase kinase kinases (MAPKKKs) Ssk2p and Ssk22p that are under the control of the SLN1-SSK1 two-component osmosensor. Alternatively, Pbs2p was activated by a mechanism that involves the binding of its amino terminal proline-rich motif to the Src homology 3 (SH3) domain of a putative transmembrane osmosensor Sho1p.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019; Maeda, Tatsuya/L-5540-2019	Saito, Haruo/0000-0001-7891-1689; Takekawa, Mutsuhiro/0000-0002-8027-3847				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, UNPUB; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; VOFTEK AB, 1993, CELL, V74, P205	23	536	564	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					554	558		10.1126/science.7624781	http://dx.doi.org/10.1126/science.7624781			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624781				2022-12-01	WOS:A1995RL49500033
J	MING, M; EWEN, ME; PEREIRA, MEA				MING, M; EWEN, ME; PEREIRA, MEA			TRYPANOSOME INVASION OF MAMMALIAN-CELLS REQUIRES ACTIVATION OF THE TGF-BETA SIGNALING PATHWAY	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; II RECEPTOR; CRUZI; INHIBITION; PROTEIN; KINASE; TRYPOMASTIGOTES; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Trypanosoma cruzi invades most nucleated mammalian cells by as yet unknown mechanisms, We report here that while T. cruzi attaches to epithelial cells lacking signaling transforming growth factor beta (TGF beta) receptor I or II, the adherent parasites cannot penetrate and replicate inside the mutant cells, as they do in parental cells, Invasion of the mutants is restored by transfection with the TGF beta receptor genes, as are biological responses to TGF beta. Similar rescue of both TGF beta antiproliferative response and T. cruzi invasion was demonstrated in a hybrid of TGF beta-resistant bladder and colon carcinoma cells. In addition, T. cruzi did not efficiently invade epithelial cells with dysfunction of the intracellular signaling cascade caused by the constitutive expression of the cyclin-dependent kinase cdk4 or of the oncogene H-ras. Treatment with TGF beta, but not with other antiproliferative agents of nonphagocytic cells, greatly enhances T. cruzi invasion. Moreover, infective, but not noninfective, trypanosomes strongly induce a TGF beta-responsive reporter gene in TGF beta-sensitive, but not in TGF beta-insensitive, cell lines. Thus, T. cruzi itself may directly trigger activation of the TGF beta signaling pathway required for parasite entry into the mammalian cells.	TUFTS UNIV,NEW ENGLAND MED CTR,TUPPER RES INST,DIV GEOG MED & INFECT DIS,TROP DIS RES UNIT,BOSTON,MA 02111; HARVARD UNIV,SCH MED,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute								ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANDRADE Z, 1983, CYTOPATHOLOGY PARASI, P228; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; Brener Z., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P247; CAVALLESCO R, 1988, J IMMUNOL, V140, P617; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DVORAK JA, 1981, SCIENCE, V214, P1034, DOI 10.1126/science.7029713; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOODING LR, 1992, CELL, V71, P5; HENRIQUEZ D, 1981, MOL BIOCHEM PARASIT, V2, P359, DOI 10.1016/0166-6851(81)90087-6; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MING M, 1993, MOL BIOCHEM PARASIT, V59, P243, DOI 10.1016/0166-6851(93)90222-J; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PEREIRA MEA, 1994, BAILLIERE CLIN INF D, V1, P305; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROWIN KS, 1983, P NATL ACAD SCI-BIOL, V80, P6390, DOI 10.1073/pnas.80.20.6390; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCUDDER P, 1993, J BIOL CHEM, V268, P9886; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; WAHL SM, 1988, J IMMUNOL, V140, P3026; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAKUBU MA, 1994, MOL BIOCHEM PARASIT, V66, P119, DOI 10.1016/0166-6851(94)90042-6	50	128	132	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					287	296		10.1016/0092-8674(95)90316-X	http://dx.doi.org/10.1016/0092-8674(95)90316-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628017	Bronze			2022-12-01	WOS:A1995RL76000016
J	MOHRIG, JR; MOERKE, KA; CLOUTIER, DL; LANE, BD; PERSON, EC; ONASCH, TB				MOHRIG, JR; MOERKE, KA; CLOUTIER, DL; LANE, BD; PERSON, EC; ONASCH, TB			IMPORTANCE OF HISTORICAL CONTINGENCY IN THE STEREOCHEMISTRY OF HYDRATASE-DEHYDRATASE ENZYMES	SCIENCE			English	Article							STEREOSPECIFICITY; ANALOGS; EVOLUTION; FUMARASE	There are two stereochemical classes of hydratase-dehydratase enzymes. Those that catalyze the addition of water to alpha,beta-unsaturated thioesters give syn addition-elimination stereochemistry, whereas those that catalyze the addition of water to conjugated carboxylate substrates give anti stereochemistry. This dichotomy could reflect different adaptive advantages or contingencies of separate evolutionary histories. Determination of the nonenzymatic stereochemistry of deuterium oxide addition to fumarate and to S-crotonyl N-acetylcysteamine has provided direct evidence for the importance of the contingencies of evolutionary history, rather than chemical efficiency, in the pathways of these hydratase-dehydratase enzymes.			MOHRIG, JR (corresponding author), CARLETON COLL, DEPT CHEM, NORTHFIELD, MN 55057 USA.		MOHRIG, JERRY/V-8908-2019; Onasch, Tim/AAY-4998-2020	Onasch, Tim/0000-0001-7796-7840				AMYES TL, 1992, J AM CHEM SOC, V114, P10297, DOI 10.1021/ja00052a028; ANDERSON SR, 1994, BIOCHEMISTRY-US, V33, P10545, DOI 10.1021/bi00200a041; ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; BAHNSON BJ, 1991, BIOCHEMISTRY-US, V30, P5894, DOI 10.1021/bi00238a013; BAHNSON BJ, 1989, BIOCHEMISTRY-US, V28, P4173, DOI 10.1021/bi00436a008; BENNER SA, 1989, CHEM REV, V89, P789, DOI 10.1021/cr00094a004; BENNER SA, 1989, TOP STEREOCHEM, V19, P127; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; CLELAND WW, 1975, ACCOUNTS CHEM RES, V8, P145, DOI 10.1021/ar50089a001; CREIGHTON DJ, 1990, ENZYMES, V19, pCH7; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ERICKSON LE, 1959, J PHYS CHEM-US, V63, P705, DOI 10.1021/j150575a014; GAWRON O, 1961, J AM CHEM SOC, V83, P3634, DOI 10.1021/ja01478a021; GERIT JA, 1992, J AM CHEM SOC, V114, P5928; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GLASFELD A, 1990, J BIOL CHEM, V265, P11692; HANSON KR, 1975, ACCOUNTS CHEM RES, V8, P1, DOI 10.1021/ar50085a001; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MOHRIG JR, 1990, J AM CHEM SOC, V112, P3665, DOI 10.1021/ja00165a065; MOHRIG JR, 1981, J ORG CHEM, V46, P4655, DOI 10.1021/jo00336a003; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; SAUNDERS WH, 1973, MECHANISMS ELIMINATI, pCH3; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5304, DOI 10.1021/ja00277a040; SPEIR TW, 1971, BIOCHEM J, V125, P267, DOI 10.1042/bj1250267	28	54	54	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					527	529						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	RL495	7624773				2022-12-01	WOS:A1995RL49500023
J	NEUMANN, H; CAVALIE, A; JENNE, DE; WEKERLE, H				NEUMANN, H; CAVALIE, A; JENNE, DE; WEKERLE, H			INDUCTION OF MHC CLASS-I GENES IN NEURONS	SCIENCE			English	Article							EXPRESSION; ANTIGENS; CELLS	Whether neurons express major histocompatibility complex (MHC) class I genes has not been firmly established. The techniques of confocal laser microscopy, patch clamp electrophysiology, and reverse transcriptase-polymerase chain reaction were combined here to directly examine the inducibility of MHC class I genes in individual cultured rat hippocampal neurons. Transcription of MHC class I genes was very rare in neurons with spontaneous action potentials. In electrically silent neurons, transcription was noted, with expression of beta(2)-microglobulin under tighter control than in class I heavy chain molecules. Surface expression of class I molecules occurred only in electrically silent neurons treated with interferon gamma. Immunosurveillance by cytotoxic T cells may be focused on functionally impaired neurons.	MAX PLANCK INST PSYCHIAT,DEPT NEUROIMMUNOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Jenne, Dieter Erich/AAP-1414-2020; Neumann, Harald/A-9718-2010	Neumann, Harald/0000-0002-5071-5202				BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; HAMILL OP, 1991, PFLUEGERS ARCH, V391, P85; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MASSA PT, 1993, GLIA, V8, P201, DOI 10.1002/glia.440080307; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	10	354	360	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					549	552		10.1126/science.7624779	http://dx.doi.org/10.1126/science.7624779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624779				2022-12-01	WOS:A1995RL49500031
J	PELES, E; NATIV, M; CAMPBELL, PL; SAKURAI, T; MARTINEZ, R; LEV, S; CLARY, DO; SCHILLING, J; BARNEA, G; PLOWMAN, GD; GRUMET, M; SCHLESSINGER, J				PELES, E; NATIV, M; CAMPBELL, PL; SAKURAI, T; MARTINEZ, R; LEV, S; CLARY, DO; SCHILLING, J; BARNEA, G; PLOWMAN, GD; GRUMET, M; SCHLESSINGER, J			THE CARBONIC-ANHYDRASE DOMAIN OF RECEPTOR TYROSINE PHOSPHATASE-BETA IS A FUNCTIONAL LIGAND FOR THE AXONAL CELL RECOGNITION MOLECULE CONTACTIN	CELL			English	Article							ADHESION MOLECULE; NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; MULTIFUNCTIONAL PROTEIN; NEUROTROPHIN RECEPTORS; GLYCOPROTEIN; EXPRESSION; IMMUNOGLOBULIN; BINDING; GROWTH	Receptor-type protein tyrosine phosphatase beta (RPTP beta) is expressed in the developing nervous system and contains a carbonic anhydrase (CAH) domain as well as a fibronectin type III repeat in its extracellular domain. Fusion proteins containing these domains were used to search for ligands of RPTP beta. The CAH domain bound specifically to a 140 kDa protein expressed on the surface of neuronal cells. Expression cloning in COS7 cells revealed that this protein is contactin, a GPI membrane-anchored neuronal cell recognition molecule. The CAH domain of RPTP beta induced cell adhesion and neurite growth of primary tectal neurons, and differentiation of neuroblastoma cells. These responses were blocked by antibodies against contactin, demonstrating that contactin is a neuronal receptor for RPTP beta. These experiments show that an individual domain of RPTP beta acts as a functional ligand for the neuronal receptor contactin. The Interaction between contactin and RPTP beta may generate unidirectional or bidirectional signals during neural development.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	PELES, E (corresponding author), SUGEN INC,515 GALVESTON DR,REDWOOD CITY,CA 94063, USA.		grumet, martin/ABC-6462-2020; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330; Peles, Elior/0000-0002-3325-0597	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021629] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21629] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARNEA G, 1994, CELL, V76, P205, DOI 10.1016/0092-8674(94)90328-X; BERGLUND EO, 1994, GENOMICS, V21, P571, DOI 10.1006/geno.1994.1316; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BRUMMENDORF T, 1993, NEURON, V10, P711; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; FAIVRESARRAILH C, 1992, J NEUROSCI, V12, P257; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GENNARINI G, 1989, J CELL BIOL, V109, P755; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HAWROT E, 1979, METHOD ENZYMOL, V58, P547; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAMMERS R, 1993, J BIOL CHEM, V168, P24456; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LUDECKE G, 1990, CANCER, V65, P2270, DOI 10.1002/1097-0142(19900515)65:10<2270::AID-CNCR2820651019>3.0.CO;2-4; MAA JS, 1990, J BIOL CHEM, V265, P1569; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; REID RA, 1994, MOL BRAIN RES, V21, P1, DOI 10.1016/0169-328X(94)90372-7; ROUGON G, 1994, J MED BIOL RES, V2, P409; SAHIN M, 1995, J COMP NEUROL, V351, P617, DOI 10.1002/cne.903510410; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; SHITARA K, 1994, J BIOL CHEM, V269, P20189; SHOCK LP, 1995, MOL BRAIN RES, V28, P110, DOI 10.1016/0169-328X(94)00190-P; THEVENIAU M, 1992, J CELL BIOCHEM, V48, P61, DOI 10.1002/jcb.240480110; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WALSH FS, 1991, CELL BIOL INT REP, V15, P1151, DOI 10.1016/0309-1651(91)90061-M; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	56	353	363	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					251	260		10.1016/0092-8674(95)90312-7	http://dx.doi.org/10.1016/0092-8674(95)90312-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628014	Bronze			2022-12-01	WOS:A1995RL76000012
J	PELLEYMOUNTER, MA; CULLEN, MJ; BAKER, MB; HECHT, R; WINTERS, D; BOONE, T; COLLINS, F				PELLEYMOUNTER, MA; CULLEN, MJ; BAKER, MB; HECHT, R; WINTERS, D; BOONE, T; COLLINS, F			EFFECTS OF THE OBESE GENE-PRODUCT ON BODY-WEIGHT REGULATION IN OB/OB MICE	SCIENCE			English	Article								C57BL/6J mice with a mutation in the obese (ob) gene are obese, diabetic, and exhibit reduced activity, metabolism, and body temperature. Daily intraperitoneal injection of these mice with recombinant OB protein lowered their body weight, percent body fat, food intake, and serum concentrations of glucose and insulin. In addition, metabolic rate, body temperature, and activity levels were increased by this treatment. None of these parameters was altered beyond the level observed in lean controls, suggesting that the OB protein normalized the metabolic status of the ob/ob mice. Lean animals injected with OB protein maintained a smaller weight loss throughout the 28-day study and showed no changes in any of the metabolic parameters. These data suggest that the OB protein regulates body weight and fat deposition through effects on metabolism and appetite.	AMGEN INC,DEPT RECOVERY PROC DEV,THOUSAND OAKS,CA 91320	Amgen	PELLEYMOUNTER, MA (corresponding author), AMGEN INC,DEPT NEUROBIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRITTON DR, 1989, PHARMACOL BIOCHEM BE, V34, P779, DOI 10.1016/0091-3057(89)90274-8; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; LESHNER AI, 1972, PHYSIOL BEHAV, V9, P281, DOI 10.1016/0031-9384(72)90251-X; LU H, 1993, PROTEIN FOLDING IN V, V526, pCH15; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	7	3678	3887	3	238	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					540	543		10.1126/science.7624776	http://dx.doi.org/10.1126/science.7624776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624776				2022-12-01	WOS:A1995RL49500028
J	SMITH, HO; TOMB, JF; DOUGHERTY, BA; FLEISCHMANN, RD; VENTER, JC				SMITH, HO; TOMB, JF; DOUGHERTY, BA; FLEISCHMANN, RD; VENTER, JC			FREQUENCY AND DISTRIBUTION OF DNA UPTAKE SIGNAL SEQUENCES IN THE HAEMOPHILUS-INFLUENZAE RD GENOME	SCIENCE			English	Article							HEMOPHILUS TRANSFORMATION; RECOGNITION SITES; SPECIFICITY	The naturally transformable, Gram-negative bacterium Haemophilus influenzae Rd preferentially takes up DNA of its own species by recognizing a 9-base pair sequence, 5'-AAGTGCGGT, carried in multiple copies in its chromosome. With the availability of the complete genome sequence, 1465 copies of the 9-base pair uptake site have been identified. Alignment of these sites unexpectedly reveals an extended consensus region of 29 base pairs containing the core 9-base pair region and two downstream 6- base pair A/T-rich regions, each spaced about one helix turn apart. Seventeen percent of the sites are in inverted repeat pairs, many of which are located downstream to gene termini and are capable of forming stem-loop structures in messenger RNA that might function as signals for transcription termination.	INST GENOM RES,GAITHERSBURG,MD 20878	J. Craig Venter Institute	SMITH, HO (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; DANNER DB, 1980, GENE, V11, P311, DOI 10.1016/0378-1119(80)90071-2; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; FITZMAURICE WP, 1984, GENE, V31, P187, DOI 10.1016/0378-1119(84)90209-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIEDMAN EA, 1972, J BIOL CHEM, V247, P2846; GOODGAL SH, 1990, J BACTERIOL, V172, P5924, DOI 10.1128/jb.172.10.5924-5928.1990; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; KAHN ME, 1984, J MEMBRANE BIOL, V81, P89, DOI 10.1007/BF01868974; KAUC L, 1990, GENE, V95, P149, DOI 10.1016/0378-1119(90)90427-S; REDFIELD RJ, 1991, NATURE, V352, P25, DOI 10.1038/352025b0; SCOCCA JJ, 1974, J BACTERIOL, V118, P369, DOI 10.1128/JB.118.2.369-373.1974; SISCO KL, 1979, P NATL ACAD SCI USA, V76, P972, DOI 10.1073/pnas.76.2.972; SMITH GR, 1994, EXPERIENTIA, V50, P234, DOI 10.1007/BF01924006; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; WILCOX KW, 1976, J BIOL CHEM, V251, P6127	17	167	174	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					538	540		10.1126/science.7542802	http://dx.doi.org/10.1126/science.7542802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542802				2022-12-01	WOS:A1995RL49500027
J	TARAKHOVSKY, A; KANNER, SB; HOMBACH, J; LEDBETTER, JA; MULLER, W; KILLEEN, N; RAJEWSKY, K				TARAKHOVSKY, A; KANNER, SB; HOMBACH, J; LEDBETTER, JA; MULLER, W; KILLEEN, N; RAJEWSKY, K			A ROLE FOR CD5 IN TCR-MEDIATED SIGNAL-TRANSDUCTION AND THYMOCYTE SELECTION	SCIENCE			English	Article							RECEPTOR TRANSGENIC MICE; PROTEIN-TYROSINE KINASES; T-CELL; POSITIVE SELECTION; CD4+8+ THYMOCYTES; ANTIGEN; ACTIVATION; COMPLEX; PHOSPHORYLATION; STIMULATION	CD5 is a transmembrane protein that is expressed on the surface of T cells and a subset of B cells. The absence of CD5 rendered thymocytes hyperresponsive to stimulation through the T cell antigen receptor (TCR) in vitro. Selection of T cells expressing three distinct transgenic TCRs was also abnormal in CD5-deficient mice. These observations indicate that CD5 can influence the fate of developing thymocytes by acting as a negative regulator of TCR-mediated signal transduction.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,CH-8091 ZURICH,SWITZERLAND; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Bristol-Myers Squibb; University of Zurich; University of California System; University of California San Francisco	TARAKHOVSKY, A (corresponding author), UNIV COLOGNE,INST GENET,D-50937 COLOGNE,GERMANY.		Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Rajewsky, Klaus/0000-0002-6633-6370				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CROMPTON T, 1993, P NATL ACAD SCI USA, V90, P8982, DOI 10.1073/pnas.90.19.8982; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KANNER SB, 1992, J IMMUNOL, V148, P2023; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1992, IMMUNOLOGY, V75, P441; KEARSE KP, 1965, J EXP MED, V181, P193; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; MCATEER MJ, 1988, EUR J IMMUNOL, V18, P1111, DOI 10.1002/eji.1830180721; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1994, EUR J IMMUNOL, V24, P1982, DOI 10.1002/eji.1830240907; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TARAKHOVSKY A, 1994, EUR J IMMUNOL, V24, P1678, DOI 10.1002/eji.1830240733; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1986, P NATL ACAD SCI USA, V83, P6998, DOI 10.1073/pnas.83.18.6998; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	35	360	363	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					535	537		10.1126/science.7542801	http://dx.doi.org/10.1126/science.7542801			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542801				2022-12-01	WOS:A1995RL49500026
J	WEEKS, KM; CECH, TR				WEEKS, KM; CECH, TR			PROTEIN FACILITATION OF GROUP-I INTRON SPLICING BY ASSEMBLY OF THE CATALYTIC CORE AND THE 5'-SPLICE-SITE DOMAIN	CELL			English	Article							BASE-PAIRING INTERACTION; GUANOSINE-BINDING-SITE; TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; RIBONUCLEASE-P; RIBOSOMAL-RNA; SECONDARY STRUCTURE; GUIDE SEQUENCE; MESSENGER-RNA; CBP2 PROTEIN	The yeast mitochondrial group 1 intron b15 undergoes self-splicing at high Mg2+ concentrations, but requires the splicing factor CBP2 for reaction under physiological conditions. Chemical accessibility and UV crosslinking experiments now reveal that self-processing is slow because functional elements are not properly positioned in an active tertiary structure. Folding anergy provided by CBP2 drives assembly of two RNA domains that comprise the catalytic core and meditates association of an similar to 100 nt 5' domain that contains the 5' splice site. Thus, the protein assembles RNA secondary structure elements into a specific three-dimensional array while the RNA provides the catalytic center. The division of labor between RNA and protein illustrated by this simple system reveals principles applicable to complex ribonucleoprotein assemblies such as the spliceosome and ribosome.			WEEKS, KM (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.biochem.59.1.543; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P102; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; GUO QB, 1991, J BIOL CHEM, V266, P1809; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER TS, 1988, P NATL ACAD SCI USA, V88, P11105; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)80118-E; JANDROSITZ A, 1995, EMBO J, V14, P820, DOI 10.1002/j.1460-2075.1995.tb07060.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1991, NATURE, V347, P578; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PARTONO S, 1990, P NATL ACAD SCI USA, V87, P8192, DOI 10.1073/pnas.87.21.8192; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RITCHINGS BW, 1992, NUCLEIC ACIDS RES, V20, P2349, DOI 10.1093/nar/20.9.2349; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WOLLENZIEN PL, 1983, CELL, V32, P397, DOI 10.1016/0092-8674(83)90459-2; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	49	103	106	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					221	230		10.1016/0092-8674(95)90309-7	http://dx.doi.org/10.1016/0092-8674(95)90309-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628013	Bronze			2022-12-01	WOS:A1995RL76000009
J	FRIEDEN, TR; FUJIWARA, PI; WASHKO, RM; HAMBURG, MA				FRIEDEN, TR; FUJIWARA, PI; WASHKO, RM; HAMBURG, MA			TUBERCULOSIS IN NEW-YORK-CITY - TURNING THE TIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INFECTION; CHEMOTHERAPY	Background. From 1978 through 1992, the number of patients with tuberculosis in New York City nearly tripled, and the proportion of such patients who had drug-resistant isolates of Mycobacterium tuberculosis more than doubled. Methods. We reviewed, confirmed, and analyzed data obtained during the surveillance of patients with tuberculosis. Results. From 1992 through 1994, there was a 21 percent decrease in reported cases of tuberculosis in New York City. An evaluation of the surveillance system revealed very few unreported cases. The number of cases decreased by more than 20 percent among blacks and Hispanics, persons with documented human immunodeficiency virus infection, homeless persons, and patients with multidrug-resistant tuberculosis; in all these groups, tuberculosis is likely to result from recent transmission. In contrast, the number of cases of tuberculosis increased among elderly and foreign-born persons, in whom the disease is likely to result from the reactivation of an infection acquired many years earlier. Enrollment in a program of directly observed therapy, in which health workers watch patients take their medications, increased from fewer than 100 patients to nearly 1300, with more than 32,000 patient-months of observation from 1992 through 1994. Conclusions. Epidemiologic patterns strongly suggest that the decrease in cases resulted from an interruption in the ongoing spread of M. tuberculosis infection, primarily because of better rates of completion of treatment and expanded use of directly observed therapy. Another contributing factor may have been efforts to reduce the spread of tuberculosis in institutional settings, such as hospitals, shelters, and jails. Expansion of measures to prevent and control tuberculosis and support of international control efforts are needed to ensure continued progress.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; CTR DIS CONTROL & PREVENT, NATL CTR PREVENT SERV, DIV TB ELIMINAT, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x; AZMEH W, 1993, 33RD INT C ANT AG CH, P229; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BIGGS HM, 1908, BRIEF HIST CAMPAIGN; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRICKNER PW, 1993, TUBERCULOSIS COMPREH, P433; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; LOWELL AM, 1961, TUBERCULOSIS NEW YOR; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STYBLO K, 1991, SELECTED PAPERS ROYA, V24, P52; VALWAY S, 1993, 33RD INT C ANT AG CH, P230; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1994, WHOTB94177; 1992, NEW YORK CITY TASK F; 1993, TUBERCULOSIS NEW YOR; 1990, MMWR-MORBID MORTAL W, V39, P9; 1995, MMWR-MORBID MORTAL W, V44, P81; 1994, AIDS SURVEILLANCE UP	35	580	593	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					229	233		10.1056/NEJM199507273330406	http://dx.doi.org/10.1056/NEJM199507273330406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791840				2022-12-01	WOS:A1995RK42300006
J	GIAID, A; SALEH, D				GIAID, A; SALEH, D			REDUCED EXPRESSION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELAXING FACTOR; RELAXATION; IMPAIRMENT; CLONING; DISEASE	Background. Pulmonary hypertension is characterized by abnormal thickening of the pulmonary arteries and increased pulmonary vascular resistance. Nitric oxide is a potent endothelium-derived vasorelaxant substance and an inhibitor of smooth-muscle-cell growth. Nitric oxide is produced in various cell types by the action of an enzyme, nitric oxide synthase. We compared the expression of endothelial nitric oxide synthase in the lungs of control subjects with that in the lungs of patients with pulmonary hypertension. Methods. We investigated the expression of endothelial nitric oxide synthase by histochemical and immunohistochemical analysis, in situ hybridization, and Northern blot analysis in the lungs of 22 patients with plexogenic pulmonary arteriopathy (arteriopathy of grades 4 through 6), 24 patients with secondary pulmonary hypertension (arteriopathy of grades 1 through 3), and 23 control subjects. Results. In the lungs of the control subjects, nitric oxide synthase was expressed at a high level in the vascular endothelium of all types of vessels and in the pulmonary epithelium. In contrast, little or no expression of the enzyme was found in the vascular endothelium of pulmonary arteries with severe histologic abnormalities (i.e., plexiform lesions) in patients with pulmonary hypertension. The intensity of the enzyme immunoreactivity correlated inversely with the severity of histologic changes. There was an inverse correlation between the arterial expression of the enzyme and total pulmonary resistance in patients with plexogenic pulmonary arteriopathy (r = -0.766, P = 0.004). Conclusions. Pulmonary hypertension is associated with diminished expression of endothelial nitric oxide synthase. It is possible that decreased expression of nitric oxide synthase may contribute to pulmonary vasoconstriction and to the excessive growth of the tunica media observed in this disease.	MCGILL UNIV, MONTREAL, PQ, CANADA	McGill University	GIAID, A (corresponding author), MONTREAL GEN HOSP, DEPT PATHOL, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.							BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DINHXUAN AT, 1993, BRIT J PHARMACOL, V109, P587, DOI 10.1111/j.1476-5381.1993.tb13611.x; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; FINEMAN JR, 1994, J CLIN INVEST, V93, P2675, DOI 10.1172/JCI117281; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; GOLDIE RG, 1990, TRENDS PHARMACOL SCI, V11, P67, DOI 10.1016/0165-6147(90)90320-8; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HEATH D, 1993, EUR RESPIR REV, V3, P555; HIGENBOTTAM T, 1993, EUR RESPIR J, V6, P1207; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVY DD, 1994, AM J CARDIOL, V74, P414, DOI 10.1016/0002-9149(94)90420-0; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JANSSENS SP, 1992, J BIOL CHEM, V267, P22964; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; LAMONTAGNE D, 1992, CIRC RES, V70, P123, DOI 10.1161/01.RES.70.1.123; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MILLER VM, 1992, AM J PHYSIOL, V263, pH103, DOI 10.1152/ajpheart.1992.263.1.H103; MONCADA S, 1978, PHARMACOL REV, V30, P293; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAGASAKA Y, 1984, CIRC RES, V54, P90, DOI 10.1161/01.RES.54.1.90; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P835, DOI 10.1006/bbrc.1994.1119; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; STUARTSMITH K, 1987, J APPL PHYSIOL, V63, P2510, DOI 10.1152/jappl.1987.63.6.2510; WAGENVOORT CA, 1981, HISTOPATHOLOGY, V5, P595, DOI 10.1111/j.1365-2559.1981.tb01826.x; WOOD P, 1958, BRIT HEART J, V20, P557; ZAPOL WM, 1994, AM J RESP CRIT CARE, V149, P1375, DOI 10.1164/ajrccm.149.5.8173780	38	1009	1061	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					214	221		10.1056/NEJM199507273330403	http://dx.doi.org/10.1056/NEJM199507273330403			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7540722				2022-12-01	WOS:A1995RK42300003
J	HELD, W; ROLAND, J; RAULET, DH				HELD, W; ROLAND, J; RAULET, DH			ALLELIC EXCLUSION OF LY49-FAMILY GENES ENCODING CLASS-I MHC-SPECIFIC RECEPTORS ON NK CELLS	NATURE			English	Article							NATURAL-KILLER-CELLS; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; MULTIGENE FAMILY; ANTIGEN; LY-49; IDENTIFICATION; COMPLEX; CLONING; NKR-P1	AN important feature of natural killer (NK) cell activity is the lysis of cells that have extinguished expression of some or all class I major histocompatibility (MHC) molecules(1-7). Accordingly, the Ly49A NK-cell antigen receptor has been shown to deliver an inhibitory signal to NK cells on encounter with D-d or D-k class I MHC on target cells(4). Ly49A belongs to a family of eight or more highly related, tightly linked genes(2,8-10). Expression of Ly49A and Ly49C, another member of the Ly49 family with distinct MHC specificity, define subpopulations of NK cells that are only partly overlapping(10-12). The mechanisms regulating the expression of Ly49 family members are unknown. We show here that the Ly49A and Ly49C NK-cell receptors are each subject to allelic exclusion. Because Ly49 genes are not thought to undergo DNA rearrangement(13,14), allelic exclusion of Ly49 genes could involve a mechanism distinct from that used by B and T lymphocytes(15,16) and is likely to play an important role in the genesis of a putative NK-cell repertoire specific for class I molecules.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; INST PASTEUR,DEPT IMMUNOL,F-75724 PARIS,FRANCE	University of California System; University of California Berkeley; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HELD, W (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Raulet, David/0000-0002-1257-8649				BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; Casanova J L, 1993, Methods Mol Biol, V23, P191; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAN PY, 1989, J IMMUNOL, V142, P1727; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CORREA I, 1994, EUR J IMMUNOL, V24, P1323, DOI 10.1002/eji.1830240613; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; KARLHOFER FM, 1994, J IMMUNOL, V153, P2407; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; NAGASAWA R, 1987, J IMMUNOL, V138, P815; RAULET D, IN PRESS SEMIN IMMUN, V7; RAULET DH, 1980, J IMMUNOL, V125, P1136; ROLAND J, 1992, INT IMMUNOL, V4, P699, DOI 10.1093/intimm/4.6.699; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; SMITH HRC, 1994, J IMMUNOL, V153, P1068; STONEMAN E, 1993, J IMMUNOL, V150, pA1465; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TAKEI F, 1983, J IMMUNOL, V130, P2794; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; WONG S, 1991, J IMMUNOL, V147, P1417; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	30	175	176	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					355	358		10.1038/376355a0	http://dx.doi.org/10.1038/376355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630404				2022-12-01	WOS:A1995RL44300051
J	JEFFREY, PD; RUSO, AA; POLYAK, K; GIBBS, E; HURWITZ, J; MASSAGUE, J; PAVLETICH, NP				JEFFREY, PD; RUSO, AA; POLYAK, K; GIBBS, E; HURWITZ, J; MASSAGUE, J; PAVLETICH, NP			MECHANISM OF CDK ACTIVATION REVEALED BY THE STRUCTURE OF A CYCLINA-CDK2 COMPLEX	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PHOSPHORYLATION; CYCLINS; BINDING; YEAST; LOCALIZATION; INVITRO; PROGRAM	The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 Angstrom resolution. CyclinA binds to one side of CDK2's catalytic cleft, inducing large conformational changes in its PSTAIRE helix and T-loop. These changes activate the kinase by realigning active site residues and relieving the steric blockade at the entrance of the catalytic cleft.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	JEFFREY, PD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Massague, Joan/0000-0001-9324-8408; Jeffrey, Philip/0000-0002-4351-5341				BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P273; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STANDART N, 1990, GENE DEV, V4, P1257; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; 1979, SERC4 DAR LAB COLL C	50	1188	1225	2	109	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					313	320		10.1038/376313a0	http://dx.doi.org/10.1038/376313a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630397				2022-12-01	WOS:A1995RL44300040
J	KLINE, SE; HEDEMARK, LL; DAVIES, SF				KLINE, SE; HEDEMARK, LL; DAVIES, SF			OUTBREAK OF TUBERCULOSIS AMONG REGULAR PATRONS OF A NEIGHBORHOOD BAR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; ADULT; HOMELESS; SEQUENCE; SHELTER; COMPLEX	Background. Outbreaks of tuberculosis have been reported in prisons, nursing homes, urban homeless shelters, and other crowded settings. We report a nonresidential outbreak of tuberculosis that originated in a neighborhood bar. Methods. A homeless patient with highly infectious pulmonary tuberculosis was a regular patron of a neighborhood bar during a long symptomatic interval before diagnosis. We investigated 97 other regular customers and employees of the bar through interviews, tuberculin skin testing, and chest roentgenography, We performed DNA fingerprinting on isolates from the index patient and 11 other patients. Results. The index patient apparently infected 41 of 97 contacts (42 percent), resulting in 14 cases of active tuberculosis and 27 cases of infection but no disease (indicated by positive tuberculin skin tests). Four other cases of active tuberculosis occurred among regular customers of the bar who were missed by the contact investigation. There were also two secondary cases. Radiographic findings in active cases included upper-lobe disease in seven cases (three cavitary) and negative chest films at the time of diagnosis in four cases. All 12 culture isolates we tested had the same chromosomal-DNA restriction pattern. Conclusions. The spread of tuberculosis in a neighborhood bar can be a major public health problem. The high rate of infection and disease among the contacts was unexpected and was not due to coinfection with the human immunodeficiency virus. Possible explanations include heavy alcohol use among the contacts, high infectivity of the index case, or both. Sputum cultures must be performed in tuberculin-positive contacts who have symptoms, even if the chest films are normal.	HENNEPIN CTY MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; TB CONTROL CLIN HENNEPIN CTY,MINNEAPOLIS,MN; UNIV MINNESOTA HOSP & CLIN,DEPT MED,DIV INFECT DIS,MINNEAPOLIS,MN	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital								ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARZA M, 1972, POSTGRAD MED, V51, P143, DOI 10.1080/00325481.1972.11698136; BROWN KE, 1961, BRIT J DIS CHEST, V55, P150, DOI 10.1016/S0007-0971(61)80109-5; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHOYKE PL, 1983, RADIOLOGY, V148, P357, DOI 10.1148/radiology.148.2.6867325; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FEINGOLD AO, 1976, SOUTHERN MED J, V69, P1336, DOI 10.1097/00007611-197610000-00024; FRIEDMAN L H, 1992, American Review of Respiratory Disease, V145, pA107; FRIEDMAN LN, 1987, AM REV RESPIR DIS, V136, P1188, DOI 10.1164/ajrccm/136.5.1188; HADLOCK FP, 1980, AM J ROENTGENOL, V134, P1015, DOI 10.2214/ajr.134.5.1015; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; KHAN MA, 1977, AM J MED, V62, P31, DOI 10.1016/0002-9343(77)90346-1; MILLER W T, 1978, AJR (American Journal of Roentgenology), V130, P867; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P109, DOI 10.1016/S0037-198X(05)80100-2; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; OLIN JS, 1966, CAN MED ASSOC J, V94, P999; PEDROBOTET J, 1992, AIDS, V6, P91, DOI 10.1097/00002030-199201000-00012; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; SIDDIQUI F, 1989, BACTEC SYSTEM PRODUC; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STEAD WW, 1981, ANN INTERN MED, V94, P606, DOI 10.7326/0003-4819-94-5-606; TABET SR, 1994, J INFECT DIS, V169, P189, DOI 10.1093/infdis/169.1.189; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WOODRING JH, 1986, AM J ROENTGENOL, V146, P497, DOI 10.2214/ajr.146.3.497; 1991, MMWR-MORBID MORTAL W, V40, P869; 1990, AM REV RESPIR DIS, V142, P725; 1990, AM REV RESPIR DIS, V142, P1470; 1992, MMWR-MORBID MORTAL W, V41, P507	31	185	186	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					222	227		10.1056/NEJM199507273330404	http://dx.doi.org/10.1056/NEJM199507273330404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791838				2022-12-01	WOS:A1995RK42300004
J	MIETTINEN, PJ; BERGER, JE; MENESES, J; PHUNG, Y; PEDERSEN, RA; WERB, Z; DERYNCK, R				MIETTINEN, PJ; BERGER, JE; MENESES, J; PHUNG, Y; PEDERSEN, RA; WERB, Z; DERYNCK, R			EPITHELIAL IMMATURITY AND MULTIORGAN FAILURE IN MICE LACKING EPIDERMAL GROWTH-FACTOR RECEPTOR	NATURE			English	Article							FACTOR EXPRESSION; LUNG MATURATION; MOUSE; GENE; ALPHA; MILK; EGF	SINCE the discovery that epidermal growth factor (EGF) can accelerate opening of the eyelids(1), the EGF receptor (EGF-R) has been extensively studied and is now considered to be a prototype tyrosine kinase receptor(2). Binding of EGF or of transforming growth factor-alpha (TGF-alpha) or other related factors activates the receptor and induces cell proliferation and differentiation. Although it is not found on haematopoietic cells, the EGF-R is widely expressed in mammals and has been implicated in various stages of embryonic development(3). Here we investigate the developmental and physiological roles of this receptor and its ligands by inactivating the gene encoding EGF-R. We find that EGF-R(-/-) mice survive for up to 8 days after birth and suffer from impaired epithelial development in several organs, including skin, lung and gastrointestinal tract.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEV BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	MIETTINEN, PJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143, USA.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BEARDMORE JM, 1983, PEDIATR RES, V17, P825, DOI 10.1203/00006450-198310000-00012; CATTERTON WZ, 1979, PEDIATR RES, V13, P104, DOI 10.1203/00006450-197902000-00004; COHEN S, 1962, J BIOL CHEM, V237, P1555; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FONDACCI C, 1994, J CLIN INVEST, V93, P1149, DOI 10.1172/JCI117067; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FUJITA Y, 1991, J CLIN ENDOCR METAB, V72, P1340, DOI 10.1210/jcem-72-6-1340; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GOETZMAN BW, 1993, PEDIATR RES, V35, P30; Hogan B., 1994, MANIPULATING MOUSE E; JOBE AH, 1991, ANN MED, V23, P687, DOI 10.3109/07853899109148104; Joyner AL, 1993, GENE TARGETING PRACT; LUETTEKE NC, 1994, GENE DEV, V6, P399; LUETTEKE NC, 1993, CELL, V73, P249; MALO C, 1982, GASTROENTEROLOGY, V83, P28; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MENARD D, 1988, GASTROENTEROLOGY, V94, P656, DOI 10.1016/0016-5085(88)90236-3; MIETTINEN PJ, 1993, PEDIATR RES, V33, P481, DOI 10.1203/00006450-199305000-00012; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; OKADA M, 1991, LIFE SCI, V48, P1151, DOI 10.1016/0024-3205(91)90452-H; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PLOPPER CG, 1992, AM J PHYSIOL, V262, pL313, DOI 10.1152/ajplung.1992.262.3.L313; RAABERG L, 1995, PEDIATR RES, V37, P175, DOI 10.1203/00006450-199502000-00009; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIBILLIA M, IN PRESS SCIENCE; SUNDELL HW, 1980, AM J PATHOL, V100, P707; THREADGILL DW, IN PRESS SCIENCE; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; YASUI S, 1993, PEDIATR PULM, V15, P251, DOI 10.1002/ppul.1950150412	32	819	841	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					337	341		10.1038/376337a0	http://dx.doi.org/10.1038/376337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630400				2022-12-01	WOS:A1995RL44300046
J	MORI, I; OHSHIMA, Y				MORI, I; OHSHIMA, Y			NEURAL REGULATION OF THERMOTAXIS IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; CHEMOSENSORY NEURONS; CELL LINEAGE; MUTANT; CHEMOTAXIS	THERMAL stimulus is an important environmental factor influencing animal behaviour(1). However, the mechanisms underlying thermosensation and thermal adaptation are poorly understood. The nematode Caenorhabditis elegans can sense a range of environmental temperatures and migrate towards the cultivation temperature on a thermal gradient(2). This modifiable thermotactic response provides an ideal system for studying the cellular and molecular processes involved in thermosensation and thermal information storage. We have identified neurons critical for thermotaxis by killing individual cells in live animals. The results indicate that an amphid sensory neuron, AFD, is a major thermosensory neuron. Some of the genetically defined cryophilic and thermophilic mutant phenotypes were mimicked when amphid interneurons AIY and AIZ, respectively, were killed, indicating that AIY is responsible for thermophilic movement and AIZ for cryophilic movement. We propose a neural model in which regulation of the activities of the two interneurons in opposite directions, depending on the cultivation temperature, is essential for thermotaxis.			MORI, I (corresponding author), KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN.							AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BRENNER S, 1974, GENETICS, V77, P71; Eckert R, 1988, ANIMAL PHYSL; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	14	397	413	1	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					344	348		10.1038/376344a0	http://dx.doi.org/10.1038/376344a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630402				2022-12-01	WOS:A1995RL44300048
J	PETRIJ, F; GILES, RH; DAUWERSE, HG; SARIS, JJ; HENNEKAM, RCM; MASUNO, M; TOMMERUP, N; VANOMMEN, GJB; GOODMAN, RH; PETERS, DJM; BREUNING, MH				PETRIJ, F; GILES, RH; DAUWERSE, HG; SARIS, JJ; HENNEKAM, RCM; MASUNO, M; TOMMERUP, N; VANOMMEN, GJB; GOODMAN, RH; PETERS, DJM; BREUNING, MH			RUBINSTEIN-TAYBI SYNDROME CAUSED BY MUTATIONS IN THE TRANSCRIPTIONAL COACTIVATOR CBP	NATURE			English	Article							DENOVO RECIPROCAL TRANSLOCATION; PAIRED BOX GENE; CYCLIC-AMP; SHORT ARM; PROTEIN; DNA; 16P13.3	THE Rubinstein-Taybi syndrome (RTS) is a well-defined syndrome with facial abnormalities, broad thumbs, broad big toes and mental retardation as the main clinical features(1-3). Many patients with RTS have been shown to have breakpoints in, and microdeletions of, chromosome 16p13.3 (refs 4-8). Here we report that all these breakpoints are restricted to a region that contains the gene for the human CREB binding protein (CBP), a nuclear protein participating co-activator in cyclic-AMP-regulated gene expression(9-12). We show that RTS results not only from gross chromosomal rearrangements of chromosome 16p, but also from point mutations in the CBP gene itself. Because the patients are heterozygous for the mutations, we propose that the loss of one functional copy of the CBP gene underlies the developmental abnormalities in RTS and possibly the propensity for malignancy.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,1105 AZ AMSTERDAM,NETHERLANDS; KANAGAWA CHILDRENS MED CTR,DIV MED GENET,YOKOHAMA,KANAGAWA,JAPAN; JOHN F KENNEDY INST,DANISH CTR HUMAN GENOME RES,DK-2600 GLOSTRUP,DENMARK; ULLEVAL UNIV HOSP,DEPT MED GENET,OSLO,NORWAY; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Aarhus University; University of Oslo; Oregon Health & Science University	PETRIJ, F (corresponding author), LEIDEN UNIV,SYLVIUS LABS,DEPT HUMAN GENET,LEIDEN,NETHERLANDS.		Breuning, Martijn H/E-3429-2010; Peters, Dorien/AFH-8507-2022; Tommerup, Niels/T-8776-2017	Peters, Dorien/0000-0001-6974-7143; Tommerup, Niels/0000-0003-2304-0112; Giles, Rachel/0000-0001-9133-2008				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BREUNING MH, 1993, AM J HUM GENET, V52, P249; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAUWERSE JG, 1992, BLOOD, V79, P1299; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GFIBBONS RJ, 1995, CELL, V80, P837; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HENNEKAM RCM, 1990, AM J MED GENET S, V6, P17; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOTH CF, 1993, AM J HUM GENET, V52, P455; IMAIZUMI K, 1991, AM J MED GENET, V38, P636, DOI 10.1002/ajmg.1320380430; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LACOMBE D, 1992, AM J MED GENET, V44, P126; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MASUNO M, 1994, AM J MED GENET, V53, P352, DOI 10.1002/ajmg.1320530409; MICHAIL J, 1957, Rev Chir Orthop Reparatrice Appar Mot, V43, P142; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010; SIRAGANIAN PA, 1989, MED PEDIATR ONCOL, V17, P485; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TOMMERUP N, 1992, AM J MED GENET, V44, P237, DOI 10.1002/ajmg.1320440223; WESSELS JW, 1991, BLOOD, V77, P1555	28	929	964	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					348	351		10.1038/376348a0	http://dx.doi.org/10.1038/376348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630403				2022-12-01	WOS:A1995RL44300049
J	RICKERT, RC; RAJEWSKY, K; ROES, J				RICKERT, RC; RAJEWSKY, K; ROES, J			IMPAIRMENT OF T-CELL-DEPENDENT B-CELL RESPONSES AND B-1 CELL-DEVELOPMENT IN CD19-DEFICIENT MICE	NATURE			English	Article							COMPLEMENT RECEPTOR TYPE-2; HUMAN LYMPHOCYTES-B; ANTIGEN RECEPTOR; IMMUNE-RESPONSE; ANTIBODY; INVIVO; CD19; LIGANDS; GROWTH; IGM	CD19 is the hallmark differentiation antigen of the B lineage. Its early expression has implicated a role for CD19 during the antigen-independent phases of B-cell development, whereas in mature B cells CD19 can act synergistically with surface immunoglobulin to induce activation(1). We have generated CD19-deficient mice and found that development of conventional B cells is unperturbed. However, mature CD19(-/-) B cells show a profound deficiency in responding to protein antigens that require T-cell help. This is accompanied by a lack of germinal centre formation and affinity maturation of serum antibodies. Thus CD19 is crucial for both initial B-cell activation by T-cell-dependent antigens and the maturation and/or selection of the activated cells into the memory compartment. An impairment in ligand-driven selection may also be responsible for the observation of a striking reduction in the B-1 (formerly Ly-1) B-cell subset, thought to develop under the control of self-antigens and bacterial antigens (reviewed in ref. 2).			RICKERT, RC (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,D-50931 COLOGNE,GERMANY.			Roes, Jurgen/0000-0003-3235-2345; Rajewsky, Klaus/0000-0002-6633-6370				BOHNSACK JF, 1988, J IMMUNOL, V141, P2569; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1988, J IMMUNOL, V141, P457; CARTER RH, 1989, J IMMUNOL, V143, P1755; CUMANO A, 1986, EMBO J, P2459; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HEYMAN B, 1994, NEW ASPECTS COMPLEME, P59; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MCHEYZERWILLIAM.MG, 1993, J EXP MED, V178, P295; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; MERCOLINO TJ, 1988, J EXP MED, V168, P687, DOI 10.1084/jem.168.2.687; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; TORRES R, IN PRESS COLOGNE GUI; TSOKOS GC, 1990, J IMMUNOL, V144, P1640; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WELLS SM, 1994, J IMMUNOL, V153, P5503; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519	29	573	590	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					352	355		10.1038/376352a0	http://dx.doi.org/10.1038/376352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7543183				2022-12-01	WOS:A1995RL44300050
J	SASAI, Y; LU, B; STEINBEISSER, H; DEROBERTIS, EM				SASAI, Y; LU, B; STEINBEISSER, H; DEROBERTIS, EM			REGULATION OF NEURAL INDUCTION BY THE CHD AND BMP-4 ANTAGONISTIC PATTERNING SIGNALS IN XENOPUS	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL PATTERN; MESODERM INDUCTION; DROSOPHILA EMBRYO; GENE-EXPRESSION; PLATE; LAEVIS	IN Drosophila the amount of neurogenic ectoderm, from which the central nervous system (CNS) derives, is regulated by a dorsal-ventral system of positional information in which two secreted molecules of antagonistic functions, decapentaplegic (dpp) and short-gastrulation (sog), play fundamental roles(1-4). The vertebrate homologue of dpp is either bmp-4 or bmp-2 (ref. 5), and the homologue of sog is chd(4,6,7) (s-chordin). In Xenopus the CNS is induced by signals emanating from the organizer(8), and two proteins secreted by the organizer, noggin(9) and follistatin(10), have been shown to induce neural tissue in animal-cap assays. Here we report that Chd, another organizer-specific secreted factor(6), has neuralizing activity and that this activity can be antagonized by Bmp-4. Inhibition of the function of the endogenous Bmp-4 present in the animal cap(1)1 also leads to neural differentiation. We suggest that conserved molecular mechanisms involving chd/sog and bmp-4/dpp gene products pattern the ectoderm in Xenopus and in Drosophila.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869				ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JAMRICH M, 1989, DEVELOPMENT, V105, P779; JONES CM, 1992, DEVELOPMENT, V115, P639; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; PADGETT RW, 1994, P NATL ACAD SCI USA, V90, P2905; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHARPE CR, 1989, DEVELOPMENT, V107, P701; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; ZARAISKY AG, 1992, DEV BIOL, V152, P373, DOI 10.1016/0012-1606(92)90144-6	28	542	566	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					333	336		10.1038/376333a0	http://dx.doi.org/10.1038/376333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630399				2022-12-01	WOS:A1995RL44300045
J	SCHILLER, PH				SCHILLER, PH			EFFECT OF LESIONS IN VISUAL CORTICAL AREA V4 ON THE RECOGNITION OF TRANSFORMED OBJECTS	NATURE			English	Article							STATE DEPENDENT ACTIVITY; BROAD-BAND CHANNELS; COLOR-OPPONENT; RHESUS-MONKEY; CORTEX; MACAQUE; DISCRIMINATION; PERCEPTION; VISION; DEPTH	THE primate visual system has a remarkable capability for recognizing objects irrespective of the multitude of images they form on the retinal surface by virtue of changes in size, perspective, contrast, colour and partial obstruction by other stimuli in the visual scene. There is increasing evidence that this remarkable capacity is brought about by processes that occur earlier in the visual system than had previously been thought(1-14). Here I show that after ablation of area V4 in the rhesus monkey, major deficits arise in the recognition of objects that have been transformed in size, in the degree of occlusion, and in the amount of contour information provided. The ability to detect these objects when presented individually was unaffected by these lesions.			SCHILLER, PH (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-634,CAMBRIDGE,MA 02139, USA.							DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HEYWOOD CA, 1992, J NEUROSCI, V12, P4056; HEYWOOD CA, 1987, J NEUROSCI, V7, P2601; HUBEL DH, 1970, NATURE, V225, P41, DOI 10.1038/225041a0; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2190; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1991, SCIENCE, V251, P1251, DOI 10.1126/science.2006413; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; SCHILLER PH, IN PRESS BEHAV BRAIN; WALSH V, 1992, BEHAV BRAIN RES, V50, P115, DOI 10.1016/S0166-4328(05)80293-1; WEISKRANTZ L, 1984, BRAIN, V107, P1033, DOI 10.1093/brain/107.4.1033; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0; ZEKI SM, 1973, BRAIN RES, V53, P422, DOI 10.1016/0006-8993(73)90227-8	20	64	64	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					342	344		10.1038/376342a0	http://dx.doi.org/10.1038/376342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630401				2022-12-01	WOS:A1995RL44300047
J	SHAMOO, Y; FRIEDMAN, AM; PARSONS, MR; KONIGSBERG, WH; STEITZ, TA				SHAMOO, Y; FRIEDMAN, AM; PARSONS, MR; KONIGSBERG, WH; STEITZ, TA			CRYSTAL-STRUCTURE OF A REPLICATION FORK SINGLE-STRANDED-DNA BINDING-PROTEIN (T4 GP32) COMPLEXED TO DNA	NATURE			English	Article							GENE 32 PROTEIN; H-1-NMR 500 MHZ; ESCHERICHIA-COLI; BACTERIOPHAGE-T4; SITE; IDENTIFICATION; MUTAGENESIS; RESIDUES	THE single-stranded DNA (ssDNA) binding protein gp32 from bacteriophage T4 is essential for T4 DNA replication, recombination and repair. In vivo gp32 binds ssDNA as the replication fork advances and stimulates repulsion processivity and accuracy by a factor of several hundred(1). Gp32 binding affects nearly every major aspect of DNA metabolism. Among its important functions are: (1) configuring ssDNA templates for efficient use by the replisome including DNA polymerase; (2) melting out adventitious secondary structures; (3) protecting exposed ssDNA from nucleases; and (4) facilitating homologous recombination by binding ssDNA during strand displacement. We have determined the crystal structure of the gp32 DNA binding domain complexed to ssDNA at 2.2 Angstrom resolution. The ssDNA binding cleft comprises regions from three structural subdomains and includes a positively charged surface that runs parallel to a series of hydrophobic pockets formed bg clusters of aromatic side chains. Although only weak electron density is seen for the ssDNA, it indicates that the phosphate backbone contacts an electropositive cleft of the protein, placing the bases in contact with the hydrophobic pockets. The DNA mobility implied by the weak electron density may reflect the role of gp32 as a sequence-independent ssDNA chaperone allowing the largely unstructured ssDNA to slide freely through the cleft.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	SHAMOO, Y (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA.		Friedman, Alan M/J-2696-2012; Steitz, Thomas A./C-6559-2009	Shamoo, Yousif/0000-0001-9241-8962				ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, X PLOR VERSION 2 2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; DELIUS H, 1972, J MOL BIOL, V67, P341, DOI 10.1016/0022-2836(72)90454-8; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KHAMIS MI, 1986, BIOCHEMISTRY-US, V25, P5865, DOI 10.1021/bi00368a005; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P50; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAN T, 1989, BIOCHEMISTRY-US, V28, P8833, DOI 10.1021/bi00448a023; PRIGODICH RV, 1984, BIOCHEMISTRY-US, V23, P522, DOI 10.1021/bi00298a019; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SPICER EK, 1979, J BIOL CHEM, V254, P6433; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VANAMERONGEN H, 1990, BIOCHEMISTRY-US, V29, P5619, DOI 10.1021/bi00475a029; YANG W, 1990, J BIOL CHEM, V265, P13553; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	29	221	230	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 27	1995	376	6538					362	366		10.1038/376362a0	http://dx.doi.org/10.1038/376362a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630406				2022-12-01	WOS:A1995RL44300053
J	TERADA, Y; TATSUKA, M; JINNO, S; OKAYAMA, H				TERADA, Y; TATSUKA, M; JINNO, S; OKAYAMA, H			REQUIREMENT FOR TYROSINE PHOSPHORYLATION OF CDK4 IN G1 ARREST INDUCED BY ULTRAVIOLET-IRRADIATION	NATURE			English	Article							ATAXIA TELANGIECTASIA; DNA-REPLICATION; PROTEIN-KINASE; CELLS; MITOSIS; INDUCTION; MUTATION; GENE	EXPOSURE to ultraviolet light arrests the function of mammalian fibroblasts in the G1 phase of the cell cycle, as well as the S and G2 phases. Although p21, an inhibitor of cyclin-dependent kinase (Cdk) that is induced by DNA damage mag partly account for the arrest in G1 (ref. 1), the mechanism is little understood. Here we show that tyrosine phosphorylation of Cdk4 is required for this arrest. In rat fibroblast, Cdk4 is tyrosine-phosphorylated during G1 progression, and its dephosphorylation is required for S phase. When cells are ultraviolet-irradiated, their arrest in G1 is accompanied by an increase in phosphorylation level. Conversely, cells expressing unphosphorylatable Cdk4(F17) fail to arrest in G1, and suffer significantly elevated chromosomal aberrations and cell death.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN; UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Kanazawa University; University of Tokyo	TERADA, Y (corresponding author), RES DEV CORP JAPAN, ERATO, OKAYAMA CELL SWITCHING PROJECT, SAKYO KU, KYOTO 606, JAPAN.			Terada, Yasuhiko/0000-0003-4784-5273				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NAGATA A, 1991, NEW BIOL, V3, P959; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TATSUKA M, 1989, MUTAT RES, V214, P321; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	27	169	169	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 27	1995	376	6538					358	362		10.1038/376358a0	http://dx.doi.org/10.1038/376358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630405				2022-12-01	WOS:A1995RL44300052
J	WILSON, PA; HEMMATIBRIVANLOU, A				WILSON, PA; HEMMATIBRIVANLOU, A			INDUCTION OF EPIDERMIS AND INHIBITION OF NEURAL FATE BY BMP-4	NATURE			English	Article							XENOPUS-LAEVIS; MESODERM INDUCTION; DROSOPHILA EMBRYO; EARLY RESPONSE; EXPRESSION; ECTODERM; HOMOLOG; PATTERN; NOGGIN; RNA	DURING gastrulation in vertebrates, ectodermal cells choose between two fates, neural and epidermal. The nervous system forms in response to signals from the Spemann organizer(1,2); ectoderm that does not receive these signals becomes epidermis. Unexpectedly, however, in Xenopus, neural tissue also forms when cell-cell communication within the ectoderm is disrupted by cell dissociation(3,4) or by antagonists of the growth factor activin(5-7). These observations suggest that epidermal specification depends on local signalling, by activin or a close relative, and that neural tissue forms when this communication is blocked(6). Here we report that bone morphogenesis protein 4 (Bmp-4), a relative of activin that is expressed in the embryo at the time of ectodermal fate determination(8,9), is a potent epidermal inducer and neural inhibitor, the first reported in any vertebrate. Activin can inhibit neuralization by inducing mesoderm, but does not induce epidermis. Moreover, the dominant-negative activin receptor, which stimulates neuralization when expressed in the embryo(5,6), blocks Bmp-4 in our assay. Our findings demonstrate that epidermal fate can be induced, and thus provide further evidence that neural specification is under inhibitory control in vertebrates.			WILSON, PA (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							AKERS RM, 1986, SCIENCE, V231, P613, DOI 10.1126/science.3945801; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, IN PRESS DEV GENET; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WITTA SE, 1995, DEVELOPMENT, V121, P721; YAMADA T, 1950, BIOL BULL-US, V98, P98, DOI 10.2307/1538572	31	628	654	4	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					331	333		10.1038/376331a0	http://dx.doi.org/10.1038/376331a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630398				2022-12-01	WOS:A1995RL44300044
J	BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A				BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A			PREVENTABLE HOSPITALIZATIONS AND ACCESS TO HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CITY; POOR	Objective. To examine whether the higher hospital admission rates for chronic medical conditions such as asthma, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and diabetes in low-income communities resulted from community differences in access to care, prevalence of the diseases, propensity to seek care, or physician admitting style. Design.-Analysis of California hospital discharge data. We calculated the hospitalization rates for these five chronic conditions for the 250 ZIP code clusters that define urban California. We performed a random-digit telephone survey among adults residing in a random sample of 41 of these urban ZIP code clusters stratified by admission rates and a mailed survey of generalist and emergency physicians who practiced in the same 41 areas. Setting.-Community based. Participants.-A total of 6674 English- and Spanish-speaking adults aged 18 through 64 years residing in the 41 areas were asked about their access to care, their chronic medical conditions, and their propensity to seek health care. Physician admitting style was measured with written clinical vignettes among 723 generalist and emergency physicians practicing in the same communities. Main Outcome Measures.-We compared respondents' reports of access to medical care in an area with the area's cumulative admission rate for these five chronic conditions. We then tested whether access to medical care remained independently associated with preventable hospitalization rates after controlling for the prevalence of the conditions, health care seeking, and physician practice style. Results.-Access to care was inversely associated with the hospitalization rates for the five chronic medical conditions (R(2)=0.50; P<.001). In a multivariate analysis that included a measure of access, the prevalence of conditions, health care seeking, and physician practice style to predict cumulative hospitalization rates for chronic medical conditions, both self-rated access to care (P<.002) and the prevalence of the conditions (P<.03) remained independent predictors. Conclusion.-Communities where people perceive poor access to medical care have higher rates of hospitalization for chronic diseases. Improving access to care is more likely than changing patients' propensity to seek health care or eliminating variation in physician practice style to reduce hospitalization rates for chronic conditions.	SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH & AGING,SAN FRANCISCO,CA 94143; UNIV MINNESOTA,SCH MED,HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; NYU,ROBERT F WAGNER GRAD SCH PUBL SERV,NEW YORK,NY 10003	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; New York University	BINDMAN, AB (corresponding author), SAN FRANCISCO GEN HOSP,PRIMARY CARE RES CTR,WARD 95,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.		Grumbach, Kevin/L-9222-2016		AHRQ HHS [HSO7373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; CAPER P, 1993, HEALTH AFFAIR, V12, P174, DOI 10.1377/hlthaff.12.1.174; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GRISWOLD PR, 1992, HLTH CARE COSTS MASS; GRUMBACH K, 1995, CALIFORNIA POLICY SE; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; Komaromy Miriam, 1995, JGIM, V10, P70; MEUX E, 1994, HEALTH SERV RES, V29, P247; MEUX EF, 1990, REPORT RESULTS OSHPD; NEWACHECK PW, 1988, HEALTH SERV RES, V23, P401; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SMELOFF EA, 1981, PUBLIC HEALTH REP, V96, P310; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; 1993, CD ROM SERIES 10, V4; 1990, STATISTICAL ANAL SAM; 1992, US DEPT HLTH HUMA 10, V4; 1992, 1990 CALIFORNIA HOSP	20	686	691	0	54	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					305	311		10.1001/jama.274.4.305	http://dx.doi.org/10.1001/jama.274.4.305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609259				2022-12-01	WOS:A1995RJ89800032
J	GREENBERGER, P				GREENBERGER, P			ALLERGIC RHINITIS IN AN ALLERGY CLINIC NURSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GREENBERGER, P (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609269				2022-12-01	WOS:A1995RJ89800042
J	HIRSCH, DR; INGENITO, EP; GOLDHABER, SZ				HIRSCH, DR; INGENITO, EP; GOLDHABER, SZ			PREVALENCE OF DEEP VENOUS THROMBOSIS AMONG PATIENTS IN MEDICAL INTENSIVE GALE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							VEIN-THROMBOSIS	Objective.-To determine the frequency of deep venous thrombosis (DVT) in medical intensive care unit (MICU) patients. Design.-Prospective ultrasound case series. Setting.-An MICU in a large tertiary care hospital in Boston, Mass. Subjects.-Patients older than 18 years of age admitted to the MICU with an anticipated stay of more than 48 hours. Main Outcome Measure.-Deep venous thrombosis as detected by ultrasonography with color Doppler imaging performed twice weekly in the MICU and once within 1 week of discharge from the MICU. Results.-Deep venous thrombosis was detected in 33% (95% confidence interval, 24% to 43%) of 100 eligible patients during the 8-month study period. Forty-eight percent (16/33) were proximal lower extremity DVT, and 15% (5/33) were upper extremity DVT associated with central venous catheters, with one patient having both upper and proximal lower extremity DVT. Ultrasound examination results led to inferior vena cava filter placement in three patients, initiation of full-dose anticoagulation in four patients, initiation or continuation of low-dose subcutaneous heparin in 10 patients, follow-up ultrasound studies in three patients, central line removal in one patient, and no intervention in 10 patients due to active bleeding, prior filter, or heparin-induced thrombocytopenia. Two patients remained anticoagulated for other reasons. In this series, there was no difference in age, gender, body mass index, diagnosis of cancer, recent surgery, duration of hospitalization prior to DVT detection, and DVT prophylaxis between patients with DVT and those without. Conclusions.-An unexpectedly high rate of DVT was detected by ultrasound in these MICU patients despite prophylaxis in 61%. Traditionally recognized DVT risk factors failed to identify patients who developed DVT. Routine ultrasound surveillance or more intensive prophylaxis regimens may be warranted in this patient population if these DVT rates are confirmed in other settings.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR02635] Funding Source: Medline; NHLBI NIH HHS [HL 02663] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; BICK RL, 1992, SEMIN THROMB HEMOST, V18, P267, DOI 10.1055/s-2007-1002434; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DIEBOLD J, 1991, PATHOL RES PRACT, V187, P260; GARDNER MJ, 1989, BRIT MED J CONFIDENC; Hirst D., 1993, PREVENTION VENOUS TH, P51; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; KEANE MG, 1994, CHEST, V106, P13, DOI 10.1378/chest.106.1.13; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; POLAK JF, 1992, PERIPHERAL VASCULAR, P162; SIMONS GR, 1995, AM J MED, V99, P1; SIOSON ER, 1988, ARCH PHYS MED REHAB, V69, P183; 1991, EPI INFO VERSION 5 0	15	223	238	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					335	337		10.1001/jama.274.4.335	http://dx.doi.org/10.1001/jama.274.4.335			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609264				2022-12-01	WOS:A1995RJ89800037
J	KREDER, KJ				KREDER, KJ			COMBINATION-DRUG THERAPY FOR BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KREDER, KJ (corresponding author), UNIV IOWA,IOWA CITY,IA 52242, USA.			Kreder, Karl/0000-0002-8981-5286					0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					359	359		10.1001/jama.274.4.359	http://dx.doi.org/10.1001/jama.274.4.359			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7541871				2022-12-01	WOS:A1995RJ89800045
J	MEHTA, M; SCHILLER, JH				MEHTA, M; SCHILLER, JH			PROGNOSIS WITH ASYMPTOMATIC PULMONARY NODULES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MEHTA, M (corresponding author), UNIV WISCONSIN,MADISON,WI 53706, USA.							BERLIN NI, 1984, AM REV RESPIR DIS, V30, P565; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; GINSBERG RJ, 1993, CANCER PRINCIPLES PR; HARVEY JC, 1993, SEMIN SURG ONCOL, V9, P32; SAAD R, 1989, REV ASSOC MED BRAS, V35, P23; STEELE JD, 1964, SOLITARY PULMONARY N	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609270				2022-12-01	WOS:A1995RJ89800044
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEM RULE TO PROTECT IDENTITIES OF REPORTERS OF ADVERSE EVENTS AND PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					292	292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609246				2022-12-01	WOS:A1995RJ89800008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW INFORMATION ADDED TO THEOPHYLLINE LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					292	292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609246				2022-12-01	WOS:A1995RJ89800009
J	SILBER, JH; ROSENBAUM, PR; SCHWARTZ, JS; ROSS, RN; WILLIAMS, SV				SILBER, JH; ROSENBAUM, PR; SCHWARTZ, JS; ROSS, RN; WILLIAMS, SV			EVALUATION OF THE COMPLICATION RATE AS A MEASURE OF QUALITY OF CARE IN CORONARY-ARTERY BYPASS GRAFT-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-HOSPITAL MORTALITY; SURGICAL-PROCEDURES; ADMISSION SEVERITY; ADVERSE EVENTS; DATA-BASES; ILLNESS; MEDISGROUPS; DEATH; RISK; VOLUME	Objective.-To determine whether hospital rankings based on complication rates provide the same information as hospital rankings based on mortality rates. Design.-A retrospective study of in-hospital death, complication, and death following complication (failure to rescue). Hospitals were ranked using residuals based on the difference between the observed and the expected number of events (from logistic regression models); rankings were compared using Spearman rank correlations. Setting.-Hospitals performing coronary artery bypass graft (CABG) surgery in the 1991 and 1992 MedisGroups National Comparative Data Bases. Patients and Data Sets,-Record abstraction data for 16 673 patients who underwent CABG procedures at 57 hospitals, linked with data from the 1991 American Hospital Association Annual Survey. Results.-After adjusting for patient admission severity of illness, there were low correlations between hospital rankings based on death or failure to rescue and those rankings based on complication (death vs complication, r=0.07, P=.58; failure to rescue vs complication, r=-0.22, P=.11). In addition, many hospital characteristics that are generally associated with a higher quality of care were associated with higher complication rates but with expected or lower-than-expected mortality rates. Conclusions.-HospitaI rankings based on complication rates provide different information than those based on mortality rates. Until more is known about these differences, complication rates should not be used to judge hospital quality of care in CABG surgery.	UNIV PENN, SCH MED, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, DEPT STAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Rosenbaum, Paul R/H-8687-2012		AHRQ HHS [R01-HS06560] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; DESHARNAIS S, 1991, HEALTH SERV RES, V26, P425; FLOOD AF, 1987, HOSPITAL STRUCTURE P, P174; HABERMAN SJ, 1976, 9TH P INT BIOM C BOS, P104; HABERMAN SJ, 1974, ANAL FREQUENCY DATA, P138; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HANNAN EL, 1989, AM J PUBLIC HEALTH, V79, P430, DOI 10.2105/AJPH.79.4.430; Hartz A J, 1992, Int J Technol Assess Health Care, V8, P524; HARTZ AJ, 1994, AM J PUBLIC HEALTH, V84, P1609, DOI 10.2105/AJPH.84.10.1609; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HARTZ AJ, 1992, AM J PUBLIC HEALTH, V82, P1631, DOI 10.2105/AJPH.82.12.1631; HARTZ AJ, 1993, HEALTH SERV RES, V27, P765; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; IEZZONI LI, 1994, INQUIRY-J HEALTH CAR, V31, P40; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; KRAKAUER H, 1993, INQUIRY-J HEALTH CAR, V30, P115; KUHN EM, 1991, MED CARE, V29, P1028, DOI 10.1097/00005650-199110000-00008; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; Mosteller F, 1977, DATA ANAL REGRESSION, P299; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; ROSEN AK, 1992, MED CARE, V30, P753, DOI 10.1097/00005650-199209000-00001; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004; SILBER JH, 1995, J AM STAT ASSOC, V90, P7, DOI 10.2307/2291124; SILBER JH, 1993, CLIN RES, V41, pA181; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; WEISBERG S, 1985, APPL LINEAR REGRESSI, P179; WRIGHT JG, 1987, CHEST, V91, P394, DOI 10.1378/chest.91.3.394	41	250	252	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					317	323		10.1001/jama.274.4.317	http://dx.doi.org/10.1001/jama.274.4.317			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609261				2022-12-01	WOS:A1995RJ89800034
J	BEREK, JS				BEREK, JS			OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME	LANCET			English	Editorial Material							TUMORS				BEREK, JS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNAECOL,LOS ANGELES,CA 90024, USA.							CHILDERS JM, 1994, OBSTET GYNECOL, V84, P765; DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263; GLEESON NC, 1993, AM J OBSTET GYNECOL, V169, P522, DOI 10.1016/0002-9378(93)90611-L; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; HERRMANN UJ, 1987, OBSTET GYNECOL, V69, P777; HULKA J, 1992, J REPROD MED, V7, P599; MAIMAN M, 1991, OBSTET GYNECOL, V77, P563; PARKER WH, 1990, AM J OBSTET GYNECOL, V163, P1574, DOI 10.1016/0002-9378(90)90630-P; PARKER WH, 1994, J AM COLL SURGEONS, V179, P733; SEVELDA P, 1989, GYNECOL ONCOL, V35, P321, DOI 10.1016/0090-8258(89)90071-1; SJOVALL K, 1994, INT J GYNECOL CANCER, V4, P333, DOI 10.1046/j.1525-1438.1994.04050333.x; WEBB MJ, 1973, AM J OBSTET GYNECOL, V116, P222, DOI 10.1016/0002-9378(73)91054-5	12	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					200	200		10.1016/S0140-6736(95)91264-9	http://dx.doi.org/10.1016/S0140-6736(95)91264-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616797				2022-12-01	WOS:A1995RK41900006
J	DAVIDSON, PT				DAVIDSON, PT			MANAGING TUBERCULOSIS DURING PREGNANCY	LANCET			English	Editorial Material									UNIV SO CALIF,SCH MED,LOS ANGELES,CA	University of Southern California	DAVIDSON, PT (corresponding author), TB CONTROL PROGRAM LOS ANGELES CTY,LOS ANGELES,CA, USA.		Addis, Antonio/K-1865-2019	Addis, Antonio/0000-0003-0962-9959				CARTER EJ, 1994, CHEST, V106, P1466, DOI 10.1378/chest.106.5.1466; DAUTZENBERG B, 1988, REV MAL RESPIR, V5, P279; DEMARCH P, 1974, CHEST, V68, P800; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; GOOD JT, 1981, AM J OBSTET GYNECOL, V140, P492, DOI 10.1016/0002-9378(81)90222-2; HAMADEH MA, 1992, CHEST, V101, P1114, DOI 10.1378/chest.101.4.1114; JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7; MARGONO F, 1994, OBSTET GYNECOL, V83, P911, DOI 10.1097/00006250-199406000-00001; SCHAEFER G, 1975, OBSTET GYNECOL, V46, P706; SNIDER DE, 1980, AM REV RESPIR DIS, V122, P65; 1994, AM J RESP CRIT CARE, V149, P1359; 1994, REPORTED TUBERCULOSI, P1	12	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					199	200		10.1016/S0140-6736(95)91263-0	http://dx.doi.org/10.1016/S0140-6736(95)91263-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616796				2022-12-01	WOS:A1995RK41900005
J	FOSTER, S; BUVE, A				FOSTER, S; BUVE, A			BENEFITS OF HIV SCREENING OF BLOOD-TRANSFUSIONS IN ZAMBIA	LANCET			English	Article								Blood transfusion continues to be an important route of transmission of HIV in developing countries, especially for young children following the perinatal period, Testing for HIV is costly and reliable donor support for the purchase of test kits is often essential, yet difficult to secure. The costs of screening of transfusions for HIV and the financial benefits in terms of savings on treatment costs averted were calculated for a district hospital in Zambia where seroprevalence among donors was 15.9%. Financial benefits exceed costs by a factor of 2.7-3.5. In 1991, 1073 transfusions were given and an estimated 150 cases of transfusion-related AIDS were prevented by screening, of which 59% were in children aged 5 years or under and 31% were in women. The total cost of HIV screening was pound 3061 ($4745), and the cost per case of HIV infection prevented was pound 20.40 ($31.62); the cost of this protection for the population served by the hospital was pound 0.02 ($0.03) per person. An estimated 3625 undiscounted healthy years of life were saved, of which nearly 69% were in children under 6, at a cost of pound 0.85 ($1.32) per year of life saved. It is essential that financial and political support for HIV screening of blood for transfusion is maintained,	INST TROP MED,B-2000 ANTWERP,BELGIUM	Institute of Tropical Medicine (ITM)	FOSTER, S (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND.							BEAL R, 1992, SAFE BLOOD DEV COUNT; BUVE A, 1993, 9TH C AIDS BERL; EISENSTAEDT RS, 1988, AM J PUBLIC HEALTH, V78, P450, DOI 10.2105/AJPH.78.4.450; Gibbs WN, 1992, GUIDELINES ORG BLOOD; GUMODOKA B, 1993, AIDS, V7, P387, DOI 10.1097/00002030-199303000-00013; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; KASLOW RA, 1989, EPIDEMIOLOGY AIDS; MILLS A, 1993, COSTS HIV AIDS PREVE; OVER M, 1988, GLOBAL IMPACT AIDS; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SODERLUND N, 1993, B WORLD HEALTH ORGAN, V71, P595	11	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					225	227		10.1016/S0140-6736(95)91272-X	http://dx.doi.org/10.1016/S0140-6736(95)91272-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616804				2022-12-01	WOS:A1995RK41900014
J	FRENCH, RR; HAMBLIN, TJ; BELL, AJ; TUTT, AL; GLENNIE, MJ				FRENCH, RR; HAMBLIN, TJ; BELL, AJ; TUTT, AL; GLENNIE, MJ			TREATMENT OF B-CELL LYMPHOMAS WITH COMBINATION OF BISPECIFIC ANTIBODIES AND SAPORIN	LANCET			English	Note							IMMUNOTOXIN	We report the use of a bispecific F(ab')(2) antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody response to mouse Fab' and saporin. All patients showed rapid and beneficial responses to treatment with improvements in most disease sites and in peripheral blood cytopenia. The responses were short-lived (less than 28 days) but further study of this targeting system is warranted.	ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND; SOUTHAMPTON GEN HOSP,TENOVUS RES LAB,SOUTHAMPTON,HANTS,ENGLAND; POOLE GEN HOSP,POOLE,DORSET,ENGLAND	University of Southampton; Poole Hospital								AMLOT PL, 1993, BLOOD, V82, P2624; BONARDI MA, 1993, CANCER RES, V53, P3015; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FRENCH RR, 1991, CANCER RES, V51, P2353; GLENNIE MJ, 1993, TUMOUR IMMUNOBIOLOGY, P225; GROSSBARD ML, 1991, BLOOD, V78, P174; STANSFELD AG, 1988, LANCET, V1, P292; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; 1979, WHO OFFSET PUBLICATI, V48	9	37	38	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					223	224		10.1016/S0140-6736(95)91271-1	http://dx.doi.org/10.1016/S0140-6736(95)91271-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7542357				2022-12-01	WOS:A1995RK41900013
J	HANSEN, JG; SCHMIDT, H; ROSBORG, J; LUND, E				HANSEN, JG; SCHMIDT, H; ROSBORG, J; LUND, E			PREDICTING ACUTE MAXILLARY SINUSITIS IN A GENERAL-PRACTICE POPULATION	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-EXAMINATION; DIAGNOSIS; HISTORY; ULTRASONOGRAPHY; SYMPTOMS; SIGNS; NASAL	Objective-To evaluate the diagnostic value of symptoms, signs, erythrocyte sedimentation rate, and C reactive protein for acute maxillary sinusitis. Design-Prospective cohort study. Setting-Danish general practice in cooperation with the otorhinolaryngology and neuroradiology department at Aalborg County Hospital. Subjects-174 patients aged 18-65 years who were suspected by the general practitioner of having acute maxillary sinusitis. Main outcome measure-The independent association of symptoms, signs, erythrocyte sedimentation rate, and concentration of C reactive protein in patients with acute maxillary sinusitis defined as purulent or mucopurulent antral aspirate. Results-Only raised erythrocyte sedimentation rate (P=0.01) and raised C reactive protein (P=0.007) were found to be independently associated with a diagnosis of acute maxillary sinusitis. The combination of the two variables had a sensitivity of 0.82 and a specificity of 0.57. Conclusion-Erythrocyte sedimentation rate and C reactive protein are useful diagnostic criteria for acute maxillary sinusitis.	AALBORG CTY HOSP,DEPT OTORHINOLARYNGOL,AALBORG,DENMARK; AALBORG CTY HOSP,DEPT NEURORADIOL,AALBORG,DENMARK	Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital								Antila J., 1993, Rhinology (Utrecht), V31, P145; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BERG O, 1985, LARYNGOSCOPE, V95, P851; BERG O, 1981, ANN OTO RHINOL LARYN, V90, P272, DOI 10.1177/000348948109000316; Bro F, 1986, Ugeskr Laeger, V148, P2540; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; FLINN J, 1994, CLIN OTOLARYNGOL, V19, P287, DOI 10.1111/j.1365-2273.1994.tb01232.x; Hansen J G, 1994, Ugeskr Laeger, V156, P1934; HJORTDAHL P, 1991, Scandinavian Journal of Primary Health Care, V9, P3, DOI 10.3109/02813439109026574; Hovelius B, 1986, INFEKTIONER PRIMARVA, P75; JANNERT M, 1982, ACTA OTOLARYNGOL S, V389, P29; KATHOLM M, 1984, ACTA OTOLARYNGOL S S, V412, P88; KAY NJ, 1984, ANN OTO RHINOL LARYN, V93, P37, DOI 10.1177/000348948409300109; Lindbaek Morten, 1993, Tidsskrift for den Norske Laegeforening, V113, P700; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; UNGER JM, 1984, LARYNGOSCOPE, V94, P1319; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705	20	131	138	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					233	236		10.1136/bmj.311.6999.233	http://dx.doi.org/10.1136/bmj.311.6999.233			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627042	Green Published			2022-12-01	WOS:A1995RL44100025
J	JAMES, JA; LAING, GJ; LOGAN, S				JAMES, JA; LAING, GJ; LOGAN, S			CHANGING PATTERNS OF IRON-DEFICIENCY ANEMIA IN THE 2ND YEAR OF LIFE	BRITISH MEDICAL JOURNAL			English	Article									ST LEONARDS HOSP,DEPT COMMUNITY CHILD HLTH,LONDON N1 5LZ,ENGLAND; INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1 1EH,ENGLAND	University of London; University College London	JAMES, JA (corresponding author), MONTPELIER HLTH CTR,BATH BLDG,BRISTOL BS6 5PT,AVON,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; HALL DMB, 1991, HLTH ALL CHILDREN PR; IDRADINATA P, 1993, LANCET, V341, P1; JAMES J, 1989, BRIT MED J, V299, P838, DOI 10.1136/bmj.299.6703.838; LOZOFF B, 1994, J PEDIATR-US, V125, P577	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					230	230		10.1136/bmj.311.6999.230	http://dx.doi.org/10.1136/bmj.311.6999.230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627036	Green Published			2022-12-01	WOS:A1995RL44100019
J	REILLY, JT; TOH, CH				REILLY, JT; TOH, CH			SHEAR-STRESS AND PLATELET-FUNCTION - A THERAPEUTIC CHALLENGE	LANCET			English	Editorial Material							AGGREGATION				REILLY, JT (corresponding author), NO GEN HOSP,DEPT HAEMATOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							BEURLINGHARBURY C, 1978, BLOOD, V52, P13; CAPPELL MS, 1986, ANN INTERN MED, V105, P54, DOI 10.7326/0003-4819-105-1-54; DARDIK R, 1993, THROMB HAEMOSTASIS, V70, P522; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; MOAKE JL, 1988, BLOOD, V71, P1366; OBRIEN JR, 1992, THROMB RES, V65, P821, DOI 10.1016/0049-3848(92)90121-P; OBRIEN JR, 1995, PLATELETS, V6, P242, DOI 10.3109/09537109509078461; OBRIEN JR, 1994, THROMB RES, V76, P103, DOI 10.1016/0049-3848(94)90212-7; ROTH GJ, 1991, BLOOD, V77, P5	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					196	197		10.1016/S0140-6736(95)91261-4	http://dx.doi.org/10.1016/S0140-6736(95)91261-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616794				2022-12-01	WOS:A1995RK41900003
J	SIVARAJASINGAM, V; LASZLO, J; OGDEN, GR				SIVARAJASINGAM, V; LASZLO, J; OGDEN, GR			EXTENT OF HEPATITIS-B IMMUNIZATION AMONG MEDICAL AND DENTAL STUDENTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,DEPT DENT SURG & PERIODONTOL,DUNDEE DD1 4HR,SCOTLAND	University of Dundee			Ogden, Graham/U-6774-2019	Ogden, Graham/0000-0003-3394-4537				KINGMAN S, 1994, BRIT MED J, V308, P876, DOI 10.1136/bmj.308.6933.876; OATES BC, 1993, BRIT MED J, V307, P301, DOI 10.1136/bmj.307.6899.301; TONKS A, 1993, BRIT MED J, V307, P522; 1992, IMMUNISATION INFECTI, P110	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					231	231		10.1136/bmj.311.6999.231	http://dx.doi.org/10.1136/bmj.311.6999.231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627037	Green Published			2022-12-01	WOS:A1995RL44100020
J	TOWERS, CV				TOWERS, CV			GROUP-B STREPTOCOCCUS - THE US CONTROVERSY	LANCET			English	Editorial Material							SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS; EARLY-ONSET DISEASE; PREGNANCY; CARRIAGE				TOWERS, CV (corresponding author), LONG BEACH MEM WOMENS HOSP,CTR PERINATAL,LONG BEACH,CA, USA.							BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; BOYER KM, 1983, J INFECT DIS, V148, P802, DOI 10.1093/infdis/148.5.802; BOYER KM, 1983, J INFECT DIS, V148, P795, DOI 10.1093/infdis/148.5.795; DILLON HC, 1982, J INFECT DIS, V145, P794, DOI 10.1093/infdis/145.6.794; LEWIN EB, 1981, AM J OBSTET GYNECOL, V139, P512, DOI 10.1016/0002-9378(81)90509-3; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; TOWERS CV, 1990, AM J OBSTET GYNECOL, V163, P965, DOI 10.1016/0002-9378(90)91105-L; YANCEY MK, 1992, OBSTET GYNECOL, V80, P1038; 1992, ACOG TECH B, V170, P1; 1993, ACOG NEWSL, V37, P2; 1992, PEDIATRICS, V90, P775	11	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					197	199		10.1016/S0140-6736(95)91262-2	http://dx.doi.org/10.1016/S0140-6736(95)91262-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616795				2022-12-01	WOS:A1995RK41900004
J	WAGNER, JE; KERNAN, NA; STEINBUCH, M; BROXMEYER, HE; GLUCKMAN, E				WAGNER, JE; KERNAN, NA; STEINBUCH, M; BROXMEYER, HE; GLUCKMAN, E			ALLOGENEIC SIBLING UMBILICAL-CORD-BLOOD TRANSPLANTATION IN CHILDREN WITH MALIGNANT AND NONMALIGNANT DISEASE	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; VERSUS-HOST DISEASE; HEMATOPOIETIC STEM; RISK-FACTORS; APLASTIC-ANEMIA; CELLS; LEUKEMIA; PATIENT; RECONSTITUTION; ENGRAFTMENT	Allogeneic bone marrow transplantation is limited by the availability of suitable marrow donors and risk of graft-versus-host disease (GVHD) and opportunistic infection. In an attempt to ameliorate these limitations, umbilical cord blood has been postulated as an alternative source of allogeneic haemopoietic stem cells for transplantation. From September, 1994, umbilical cord blood from sibling donors has been used to reconstitute haemapoiesis in 44 children with acquired or congenital lympho-haemapoietic disorders, neuroblastoma, or metabolic diseases. Patients who had HLA-identical and HLA-1 antigen disparate grafts, had a probability of engraftment at 50 days after transplantation of 85%. No patient had late graft failure. The probability of grade II-IV GVHD at 100 days was 3% and the probability of chronic GVHD at one year was 6%. With a median follow-up of 1.6 years, the probability of survival for recipients of HLA-identical or HLA-1 antigen disparate grafts is 72%. We conclude that umbilical cord blood is a sufficient source of transplantable haemopoietic stem cells for children with HLA-identical or HLA-1 antigen disparate sibling donors with very low risk of acute or extensive chronic GVHD. The feasibility of umbilical-cord-blood transplantation with HLA-2 and HLA-3 antigen disparate sibling donors remains to be determined.	UNIV MINNESOTA,SCH MED,DIV EPIDEMIOL & CLIN RES,MINNEAPOLIS,MN 55455; MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,BONE MARROW TRANSPLANTAT SERV,NEW YORK,NY 10021; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,DEPT IMMUNOL,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; HOP ST LOUIS,SERV GREFE MOELLE,FEDERAT HEMATOL,PARIS,FRANCE	University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	WAGNER, JE (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PEDIAT,DIV BONE MARROW TRANSPLANTAT,MINNEAPOLIS,MN 55455, USA.				NCI NIH HHS [P01-CA21737, P01-CA23766] Funding Source: Medline; NIAID NIH HHS [P01-AI32918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023766, P01CA021737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI032918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; BENSUSSAN A, 1994, P NATL ACAD SCI USA, V91, P9136, DOI 10.1073/pnas.91.19.9136; Bertolini F, 1995, J Hematother, V4, P29, DOI 10.1089/scd.1.1995.4.29; BOGDANIC V, 1993, TRANSPLANTATION, V56, P477; BROXMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109, DOI 10.1073/pnas.89.9.4109; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BROXMEYER HE, 1991, BLOOD CELLS, V17, P313; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHANG RS, 1979, LANCET, V2, P201; CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377; DEACOCK SJ, 1992, TRANSPLANTATION, V53, P1128, DOI 10.1097/00007890-199205000-00028; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V11, P199; HALL J, 1994, BLOOD, V84, pA97; ISSARAGRISIL S, 1995, NEW ENGL J MED, V332, P367, DOI 10.1056/NEJM199502093320605; KALIA A, 1988, TRANSPLANTATION, V46, P70, DOI 10.1097/00007890-198807000-00012; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOHLIKUMAR M, 1993, BRIT J HAEMATOL, V85, P419, DOI 10.1111/j.1365-2141.1993.tb03192.x; LINCH DC, 1989, NATURE, V340, P676, DOI 10.1038/340676a0; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; NATHAN DG, 1989, NEW ENGL J MED, V321, P1190, DOI 10.1056/NEJM198910263211710; PAHWA RN, 1994, P NATL ACAD SCI USA, V91, P4485, DOI 10.1073/pnas.91.10.4485; RISDON G, 1994, CELL IMMUNOL, V154, P14, DOI 10.1006/cimm.1994.1053; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; RUBINSTEIN P, 1993, BLOOD, V81, P1679; SOCIE G, 1994, BLOOD, V83, P340; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STORB R, 1983, BRIT J HAEMATOL, V55, P573, DOI 10.1111/j.1365-2141.1983.tb02839.x; THIERRY D, 1992, BONE MARROW TRANSPL, V9, P101; Traineau R, 1993, J Hematother, V2, P231, DOI 10.1089/scd.1.1993.2.231; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; VILMER E, 1992, TRANSPLANTATION, V53, P1155; VOWELS MR, 1993, NEW ENGL J MED, V329, P1623, DOI 10.1056/NEJM199311253292205; Wagner J E, 1992, J Hematother, V1, P167, DOI 10.1089/scd.1.1992.1.167; WAGNER JE, 1992, BLOOD, V79, P1874; WEISDORF D, 1991, TRANSPLANTATION, V51, P1197, DOI 10.1097/00007890-199106000-00010	37	511	524	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					214	219		10.1016/S0140-6736(95)91268-1	http://dx.doi.org/10.1016/S0140-6736(95)91268-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616801				2022-12-01	WOS:A1995RK41900010
J	BOCZKO, EM; BROOKS, CL				BOCZKO, EM; BROOKS, CL			FIRST-PRINCIPLES CALCULATION OF THE FOLDING FREE-ENERGY OF A 3-HELIX BUNDLE PROTEIN	SCIENCE			English	Article							MOLTEN GLOBULE STATE; THERMODYNAMIC ANALYSIS; STAPHYLOCOCCUS-AUREUS; MOLECULAR-DYNAMICS; SIMULATIONS; DENATURATION; SEQUENCE; PEPTIDE	The folding and unfolding of a three-helix bundle protein were explored with molecular-dynamics simulations, cluster analysis, and weighted-histogram techniques. The folding-unfolding process occurs by means of a ''folding funnel,'' in which a uniform and broad distribution of conformational states is accessible outside of the native manifold. This distribution narrows near a transition region and becomes compact within the native manifold. Key thermodynamic steps in folding include initial interactions around the amino-terminal helix-turn-helix motif, interactions between helices I and II, and, finally, the docking of helix III onto the helix I-II subdomain. A metastable minimum in the calculated free-energy surface is observed at approximately 1.5 times the native volume. Folding-unfolding thermodynamics are dominated by the opposing influences of protein-solvent energy, which favors unfolding, and the overall entropy, which favors folding by means of the hydrophobic effect.			BOCZKO, EM (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048807] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48807] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Allen M.P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BOCZKO EM, 1993, J PHYS CHEM-US, V97, P4509, DOI 10.1021/j100119a043; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1993, CURR OPIN STRUC BIOL, V3, P92, DOI 10.1016/0959-440X(93)90207-2; BROOKS CL, 1985, J CHEM PHYS, V83, P5897, DOI 10.1063/1.449621; BROOKS CL, 1993, CHEM REV, V93, P2487, DOI 10.1021/cr00023a008; BROOKS CL, 1992, J MOL BIOL, V227, P375, DOI 10.1016/0022-2836(92)90893-O; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; DAGGETT V, 1994, CURR OPIN STRUC BIOL, V4, P291, DOI 10.1016/S0959-440X(94)90322-0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1995, PROTEIN SCI, V4, P561; GILL SJ, 1988, ADV PROTEIN CHEM, V39, P191; GORDON AD, 1987, J ROY STAT SOC A STA, V150, P119, DOI 10.2307/2981629; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; HONIG B, 1994, OCT COLD SPRING HARB; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KOLINSKI A, 1994, PROTEINS, V18, P353, DOI 10.1002/prot.340180406; KUMAR S, 1992, J COMPUT CHEM, V13, P169; KURITA T, 1991, PATTERN RECOGN, V24, P205, DOI 10.1016/0031-3203(91)90062-A; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAZARIDIS T, 1992, J PHYS CHEM-US, V96, P3847, DOI 10.1021/j100188a051; LEOPOLD PE, 1992, P NATL ACAD SCI USA, V89, P8721, DOI 10.1073/pnas.89.18.8721; LIEBERMAN M, 1994, J AM CHEM SOC, V116, P5035, DOI 10.1021/ja00091a002; LUTHEYSCHULTEN Z, 1995, J PHYS CHEM-US, V99, P2177, DOI 10.1021/j100007a057; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SKOLNICK J, 1991, J MOL BIOL, V221, P499, DOI 10.1016/0022-2836(91)80070-B; SKOLNICK J, 1993, CURR BIOL, V3, P414, DOI 10.1016/0960-9822(93)90348-R; TADDEI N, 1994, EUR J BIOCHEM, V225, P811, DOI 10.1111/j.1432-1033.1994.0811b.x; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, FEBS LETT, V321, P15; VALLEAU JP, 1977, GUIDE MONTE CARLO ST, V2, P169; VEITH M, 1994, J MOL BIOL, V237, P361; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; XU S, 1993, PATTERN RECOGN LETT, V14, P7, DOI 10.1016/0167-8655(93)90127-Y; YU HA, 1988, J CHEM PHYS, V89, P2366, DOI 10.1063/1.455080	45	357	360	1	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					393	396		10.1126/science.7618103	http://dx.doi.org/10.1126/science.7618103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618103				2022-12-01	WOS:A1995RK42700046
J	COHN, M; BLACKBURN, EH				COHN, M; BLACKBURN, EH			TELOMERASE IN YEAST	SCIENCE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; PRIMER SPECIFICITY; DNA-SEQUENCES; TETRAHYMENA; IDENTIFICATION; SENESCENCE; RNA; RIBONUCLEOPROTEIN; CHROMOSOMES; ELONGATION	The ribonucleoprotein enzyme telomerase synthesizes telomeric DNA by copying an internal RNA template sequence. The telomerase activities of the yeasts Saccharomyces castellii and Saccharomyces cerevisiae-with regular and irregular telomeric sequences, respectively-have now been identified and characterized. The S. cerevisiae activity required the telomerase RNA gene TLC1 but not the EST1 gene, both of which are required for normal telomere maintenance in vivo. This activity exhibited low processivity and produced no regularly repeated products. An inherently high stalling frequency of the S. cerevisiae telomerase may account for its in vitro properties and for the irregular telomeric sequences of this yeast.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Cohn, Marita/0000-0002-3370-2864	NIGMS NIH HHS [GM26259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; COHN M, UNPUB; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; GILLEY D, IN PRESS GENES DEV; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MCEACHERN MJ, IN PRESS NATURE; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	30	251	261	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					396	400		10.1126/science.7618104	http://dx.doi.org/10.1126/science.7618104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618104				2022-12-01	WOS:A1995RK42700047
J	DUYAO, MP; AUERBACH, AB; RYAN, A; PERSICHETTI, F; BARNES, GT; MCNEIL, SM; GE, P; VONSATTEL, JP; GUSELLA, JF; JOYNER, AL; MACDONALD, ME				DUYAO, MP; AUERBACH, AB; RYAN, A; PERSICHETTI, F; BARNES, GT; MCNEIL, SM; GE, P; VONSATTEL, JP; GUSELLA, JF; JOYNER, AL; MACDONALD, ME			INACTIVATION OF THE MOUSE HUNTINGTONS-DISEASE GENE HOMOLOG HDH	SCIENCE			English	Article							FRAGILE-X-SYNDROME; EXPRESSION; FMR-1; CELLS; MICE	Huntington's disease (HD) is a dominant neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding huntingtin, a protein of unknown function. To distinguish between ''loss of function'' and ''gain of function'' models of HD, the murine HD homolog Hdh was inactivated by gene targeting. Mice heterozygous for Hdh inactivation were phenotypically normal, whereas homozygosity resulted in embryonic death. Homozygotes displayed abnormal gastrulation at embryonic day 7.5 and were resorbing by day 8.5. Thus, huntingtin is critical early in embryonic development, before the emergence of the nervous system. That Hdh inactivation does not mimic adult HD neuropathology suggests that the human disease involves a gain of function.	MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129; MT SINAI HOSP,DIV MOLEC & DEV BIOL,TORONTO,ON M5G 1X5,CANADA; MASSACHUSETTS GEN HOSP,MOLEC NEUROPATHOL LAB,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Harvard University; Massachusetts General Hospital				Persichetti, Francesca/0000-0002-9804-644X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016367, P50NS016367, R01NS032765] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16367, NS32765] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; [Anonymous], 1994, CELL, V78, P23; BARNES GT, 1994, SOMAT CELL MOLEC GEN, V20, P87, DOI 10.1007/BF02290678; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE; GUSELLA JF, 1995, SEMIN CELL BIOL, V6, P21, DOI 10.1016/1043-4682(95)90011-X; GUSELLA JF, 1993, ARCH NEUROL-CHICAGO, V50, P1157, DOI 10.1001/archneur.1993.00540110037003; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Joyner AL, 1993, GENE TARGETING PRACT; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; WURST W, 1993, GENE TARGETING PRACT, P31; 1993, CELL, V72, P971	31	514	531	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					407	410		10.1126/science.7618107	http://dx.doi.org/10.1126/science.7618107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618107				2022-12-01	WOS:A1995RK42700050
J	EKLAND, EH; SZOSTAK, JW; BARTEL, DP				EKLAND, EH; SZOSTAK, JW; BARTEL, DP			STRUCTURALLY COMPLEX AND HIGHLY-ACTIVE RNA LIGASES DERIVED FROM RANDOM RNA SEQUENCES	SCIENCE			English	Article							RIBOZYMES; SUBSTRATE	Seven families of RNA ligases, previously isolated from random RNA sequences, fall into three classes on the basis of secondary structure and regiospecificity of ligation. Two of the three classes of ribozymes have been engineered to act as true enzymes, catalyzing the multiple-turnover transformation of substrates into products. The most complex of these ribozymes has a minimal catalytic domain of 93 nucleotides. An optimized version of this ribozyme has a k(cat), exceeding one per second, a value far greater than that of most natural RNA catalysts and approaching that of comparable protein enzymes. The fact that such a large and complex ligase emerged from avery limited sampling of sequence space implies the existence of a large number of distinct RNA structures of equivalent complexity and activity.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	EKLAND, EH (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BARTEL DP, UNPUB; CHAPMAN KB, 1995, CHEM BIOL, V2, P325, DOI 10.1016/1074-5521(95)90051-9; Ekland E. H., UNPUB; EKLAND EH, IN PRESS NUCLEIC ACI; HARADA K, 1993, NUCLEIC ACIDS RES, V21, P2287, DOI 10.1093/nar/21.10.2287; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; LLANGASEKARE M, 1995, SCIENCE, V267, P643; LOHMANN R, 1977, J MOL BIOL, V113, P193; LOHRMANN R, 1978, TETRAHEDRON, V34, P853, DOI 10.1016/0040-4020(78)88129-0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; LUCIA J S JR, 1990, Biochemistry, V29, P8813; MODRICH P, 1973, J BIOL CHEM, V21, P7502; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROHATGI R, UNPUB; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	23	277	291	1	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					364	370		10.1126/science.7618102	http://dx.doi.org/10.1126/science.7618102			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618102				2022-12-01	WOS:A1995RK42700038
J	HENSEL, M; SHEA, JE; GLEESON, C; JONES, MD; DALTON, E; HOLDEN, DW				HENSEL, M; SHEA, JE; GLEESON, C; JONES, MD; DALTON, E; HOLDEN, DW			SIMULTANEOUS IDENTIFICATION OF BACTERIAL VIRULENCE GENES BY NEGATIVE SELECTION	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; MUTANTS; AVIRULENT; CELLS; MICE	An insertional mutagenesis system that uses transposons carrying unique DNA sequence tags was developed for the isolation of bacterial virulence genes. The tags from a mixed population of bacterial mutants representing the inoculum and bacteria recovered from infected hosts were detected by amplification, radiolabeling, and hybridization analysis. When applied to a murine model of typhoid fever caused by Salmonella typhimurium, mutants with attenuated virulence were revealed by use of tags that were present in the inoculum but not in bacteria recovered from infected mice. This approach resulted in the identification of new virulence genes, some of which are related to, but functionally distinct from, the inv/spa family of S. typhimurium.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London				Hensel, Michael/0000-0001-6604-6253; Dalton, Emma/0000-0002-3517-0742				BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x; CARTER PB, 1974, J EXP MED, V139, P1189, DOI 10.1084/jem.139.5.1189; Davis R., 1980, ADV BACTERIAL GENETI; DELORENZO V, 1994, METHOD ENZYMOL, V264, P386; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; GROISMAN EA, 1990, TRENDS BIOCHEM SCI, V15, P30, DOI 10.1016/0968-0004(90)90128-X; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; Groisman Eduardo A., 1994, Trends in Microbiology, V2, P289, DOI 10.1016/0966-842X(94)90006-X; HENSEL M, UNPUB; HOLDEN DW, 1989, EMBO J, V8, P1927, DOI 10.1002/j.1460-2075.1989.tb03596.x; LEE JC, 1987, J INFECT DIS, V156, P741, DOI 10.1093/infdis/156.5.741; LU SW, 1994, P NATL ACAD SCI USA, V91, P12649, DOI 10.1073/pnas.91.26.12649; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MILLER I, 1989, INFECT IMMUN, V57, P2758, DOI 10.1128/IAI.57.9.2758-2763.1989; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; REED L. J., 1938, AMER JOUR HYG, V27, P493; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8	22	955	1135	1	78	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					400	403		10.1126/science.7618105	http://dx.doi.org/10.1126/science.7618105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618105				2022-12-01	WOS:A1995RK42700048
J	KORN, SJ; IKEDA, SR				KORN, SJ; IKEDA, SR			PERMEATION SELECTIVITY BY COMPETITION IN A DELAYED RECTIFIER POTASSIUM CHANNEL	SCIENCE			English	Article							CALCIUM CHANNELS; ION CONDUCTANCE; K+ CHANNEL; NEURONS; MUSCLE; CELLS	Permeation selectivity was studied in two human potassium channels, Kv2.1 and Kv1.5, expressed in a mouse cell line. With normal concentrations of potassium and sodium, both channels were highly selective for potassium. On removal of potassium, Kv2.1 displayed a large sodium conductance that was inhibited by low concentrations of potassium. The channel showed a competition mechanism of selectivity similar to that of calcium channels. In contrast, Kv1.5 displayed a negligible sodium conductance on removal of potassium. The observation that structurally similar potassium channels show different abilities to conduct sodium provides a basis for understanding the structural determinants of potassium channel selectivity.	MED COLL GEORGIA,DEPT PHARMACOL & TOXICOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University	KORN, SJ (corresponding author), UNIV CONNECTICUT,DEPT PHYSIOL & NEUROBIOL,BOX U-156,STORRS,CT 06269, USA.			Ikeda, Stephen/0000-0002-4088-9508				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BLATZ AL, 1984, J GEN PHYSIOL, V84, P1, DOI 10.1085/jgp.84.1.1; CALLAHAN MJ, 1994, J GEN PHYSIOL, V104, P747, DOI 10.1085/jgp.104.4.747; HAMILL OP, 1981, PFLUGERS ARCH, V381, P85; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1993, BIOPHYS J, V65, P2089, DOI 10.1016/S0006-3495(93)81244-X; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; IKEDA SR, 1995, J PHYSIOL-LONDON, V486, P267, DOI 10.1113/jphysiol.1995.sp020809; KORN SJ, UNPUB; LEVITT DG, 1978, BIOPHYS J, V22, P209, DOI 10.1016/S0006-3495(78)85485-X; REUTER H, 1980, J MEMBRANE BIOL, V57, P103, DOI 10.1007/BF01868997; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZHU Y, 1993, J PHYSIOL-LONDON, V468, P441, DOI 10.1113/jphysiol.1993.sp019781	18	83	85	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					410	412		10.1126/science.7618108	http://dx.doi.org/10.1126/science.7618108			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618108				2022-12-01	WOS:A1995RK42700051
J	MARTIN, PT; ETTINGER, AJ; SANES, JR				MARTIN, PT; ETTINGER, AJ; SANES, JR			A SYNAPTIC LOCALIZATION DOMAIN IN THE SYNAPTIC CLEFT PROTEIN LAMININ BETA-2 (S-LAMININ)	SCIENCE			English	Article							BASAL LAMINA; NEUROMUSCULAR-JUNCTION; ACETYLCHOLINE-RECEPTORS; MOUSE MUSCLE; ADHESION; CELLS; DIFFERENTIATION; EXPRESSION; VARIANTS; SEQUENCE	The basal lamina that ensheaths skeletal muscle fibers traverses the synaptic cleft at the neuromuscular junction. Synaptic and extrasynaptic portions of the basal lamina contain different laminin beta chains: beta 2 (or s) at synapses and beta 1 (or beta 1) extrasynaptically. Laminin beta 2 is also confined to synapselike parches on myotube surfaces in vitro, whereas beta 1 is present throughout the extracellular matrix. This differential localization of laminin beta chains was analyzed by expression of chimeric beta 1-beta 2 molecules in cultured mouse myotubes. A 16-amino acid carboxyl-terminal sequence in beta 2 was necessary for synaptic localization, and an amino-terminal domain in beta 1 promoted association with extracellular fibrils. The synaptic targeting sequence of beta 2 contains a site previously shown to be adhesive for motor neurons.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Martin, Paul/0000-0002-0674-6191				ABRAHAMSON DR, 1989, J CELL BIOL, V109, P3477, DOI 10.1083/jcb.109.6.3477; Apel Elizabeth D., 1995, Current Opinion in Neurobiology, V5, P62, DOI 10.1016/0959-4388(95)80088-3; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHIU AY, 1984, DEV BIOL, V103, P4556; COHEN MW, 1980, J EXP BIOL, V89, P43; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FAMBROUGH DM, 1979, PHYSIOL REV, V59, P165, DOI 10.1152/physrev.1979.59.1.165; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1991, J NEUROSCI, V11, P3960; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; REING J, 1992, J BIOL CHEM, V267, P23143; SANES JR, 1983, DEV BIOL, V97, P123, DOI 10.1016/0012-1606(83)90070-2; SANES JR, 1984, J NEUROSCI, V4, P464; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCHITTNY JC, 1993, EUR J BIOCHEM, V216, P437, DOI 10.1111/j.1432-1033.1993.tb18161.x; SILBERSTEIN L, 1982, NATURE, V295, P143, DOI 10.1038/295143a0; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; UTANI A, 1994, J BIOL CHEM, V269, P19167; WEWER UM, 1994, LAB INVEST, V71, P719; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0	38	84	84	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					413	416		10.1126/science.7618109	http://dx.doi.org/10.1126/science.7618109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618109				2022-12-01	WOS:A1995RK42700052
J	WHITMARSH, AJ; SHORE, P; SHARROCKS, AD; DAVIS, RJ				WHITMARSH, AJ; SHORE, P; SHARROCKS, AD; DAVIS, RJ			INTEGRATION OF MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS AT THE SERUM RESPONSE ELEMENT	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; ETS-RELATED PROTEIN; FACTOR P62TCF; DNA-BINDING; ELK-1; PHOSPHORYLATION; EXPRESSION; GENE	The ternary complex factor (TCF) subfamily of ETS-domain transcription factors bind with serum response factor (SRF) to the serum response element (SRE) and mediate increased gene expression. The TCF protein Elk-1 is phosphorylated by the JNK and ERK groups of mitogen-activated protein (MAP) kinases causing increased DNA binding, ternary complex formation, and transcriptional activation. Activated SRE-dependent gene expression is induced by JNK in cells treated with interleukin-1 and by ERK after treatment with phorbol ester. The Elk-1 transcription factor therefore integrates MAP kinase signaling pathways in vivo to coordinate biological responses to different extracellular stimuli.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Newcastle University - UK				Whitmarsh, Alan/0000-0003-1184-6610; Shore, Paul/0000-0002-1832-5976				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BUSCHER M, 1988, ONCOGENE, V3, P301; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERLJARD B, 1994, CELL, V76, P1025; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; SETH A, 1992, J BIOL CHEM, V267, P24796; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHARROCKS AD, IN PRESS FEBS LETT; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMARSH AJ, UNPUB; YAN MH, 1994, NATURE, V372, P798	43	887	904	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					403	407		10.1126/science.7618106	http://dx.doi.org/10.1126/science.7618106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618106				2022-12-01	WOS:A1995RK42700049
J	BENNETT, SN; MCNEIL, MM; BLAND, LA; ARDUINO, MJ; VILLARINO, ME; PERROTTA, DM; BURWEN, DR; WELBEL, SF; PEGUES, DA; STROUD, L; ZEITZ, PS; JARVIS, WR				BENNETT, SN; MCNEIL, MM; BLAND, LA; ARDUINO, MJ; VILLARINO, ME; PERROTTA, DM; BURWEN, DR; WELBEL, SF; PEGUES, DA; STROUD, L; ZEITZ, PS; JARVIS, WR			POSTOPERATIVE INFECTIONS TRACED TO CONTAMINATION OF AN INTRAVENOUS ANESTHETIC, PROPOFOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; STAPHYLOCOCCUS-AUREUS; ENDOTOXIN PRODUCTION; CANDIDA-ALBICANS; MICROBIAL-GROWTH; BACTERIAL-GROWTH; SYRINGES; INFUSION; OUTBREAK	Background. Between June 1990 and February 1993, the Centers for Disease Control and Prevention conducted investigations at seven hospitals because of unusual outbreaks of bloodstream infections, surgical-site infections, and acute febrile episodes after surgical procedures. Methods. We conducted case-control or cohort studies, or both, to identify risk factors. A case patient was defined as any patient who had an organism-specific infection or acute febrile episode after a surgical procedure during the study period in that hospital. The investigations also included reviews of procedures, cultures, and microbiologic studies of infecting, contaminating, and colonizing strains. Results. Sixty-two case patients were identified, 49 (79 percent) of whom underwent surgery during an epidemic period. Postoperative complications were more frequent during the epidemic period than before it. Only exposure to propofol, a lipid-based anesthetic agent, was significantly associated with the postoperative complications at all seven hospitals. In six of the outbreaks, an etiologic agent (Staphylococcus aureus, Candida albicans, Moraxella osloensis, Enterobacter agglomerans, or Serratia marcescens) was identified, and the same strains were isolated from the case patients. Although cultures of unopened containers of propofol were negative, at two hospitals cultures of propofol from syringes currently in use were positive. At one hospital, the recovered organism was identical to the organism isolated from the case patients. Interviews with and observation of anesthesiology personnel documented a wide variety of lapses in aseptic techniques. Conclusions. With the increasing use of lipid-based medications, which support rapid bacterial growth at room temperature, strict aseptic techniques are essential during the handling of these agents to prevent extrinsic contamination and dangerous infectious complications.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; TEXAS DEPT HLTH, AUSTIN, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Texas Department of State Health Services			Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; McNeil, Michael/0000-0003-0713-8312; Zeitz, Paul/0000-0002-0865-088X				ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; ARDUINO MJ, 1991, INFECT CONT HOSP EP, V12, P535; BERRY CB, 1993, ANAESTHESIA, V48, P30; BLAIR JE, 1961, B WORLD HEALTH ORGAN, V24, P771; CORBETT JJ, 1971, NEUROLOGY, V21, P946, DOI 10.1212/WNL.21.9.946; CROCKER KS, 1984, JPEN-PARENTER ENTER, V8, P391, DOI 10.1177/0148607184008004391; Dean A. G., 1990, EPI INFO VERSION 5 W; EDWARDS PR, 1986, IDENTIFICATION ENTER, P431; FROGGATT JW, 1991, 31ST INT C ANT AG CH; Garner J. S., 1985, GUIDELINE PREVENTION; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GREENE ES, 1990, ANESTHESIOLOGY, V73, pA1061; HARRISON CA, 1990, ANAESTHESIA, V45, P831, DOI 10.1111/j.1365-2044.1990.tb14564.x; JACKSON PG, 1981, TUBERCLE, V62, P277, DOI 10.1016/S0041-3879(81)80008-6; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; JARVIS WR, 1984, J CLIN MICROBIOL, V19, P17, DOI 10.1128/JCM.19.1.17-20.1984; KANTOR RJ, 1983, AM J MED, V74, P449, DOI 10.1016/0002-9343(83)90978-6; KEMPEN P M, 1989, Anesthesiology (Hagerstown), V71, pA948, DOI 10.1097/00000542-198909001-00948; KEMPEN PM, 1989, CAN J ANAESTH, V36, P730, DOI 10.1007/BF03005435; KEMPEN PM, 1990, ANESTH ANALG       S, V70, pS199; KOEPKE JW, 1985, ANN ALLERGY, V55, P776; KOEPKE JW, 1984, NEW ENGL J MED, V311, P1188; LASKER BA, 1989, NUCLEIC ACIDS RES, V17, P3783, DOI 10.1093/nar/17.10.3783; LUTZ CT, 1984, NEW ENGL J MED, V310, P1335, DOI 10.1056/NEJM198405173102024; MAKI DG, 1974, APPL MICROBIOL, V28, P778, DOI 10.1128/AEM.28.5.778-784.1974; Maniatis T., 1982, MOL CLONING; MASON MM, 1987, J CLIN MICROBIOL, V25, P563, DOI 10.1128/JCM.25.3.563-566.1987; MASTRO TD, 1990, NEW ENGL J MED, V323, P968, DOI 10.1056/NEJM199010043231406; NORTH JB, 1979, AUST NZ J SURG, V49, P484, DOI 10.1111/j.1445-2197.1979.tb05847.x; ODONNELL NG, 1992, ANAESTHESIA, V47, P923, DOI 10.1111/j.1365-2044.1992.tb03191.x; PARLOW JL, 1989, CAN J ANAESTH, V36, pS61; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; REMILLARD JF, 1987, DETECTION BACTERIAL, V231, P197; ROSENBERG A D, 1989, Anesthesiology (Hagerstown), V71, pA949, DOI 10.1097/00000542-198909001-00949; ROSENBERG AD, 1991, ANESTH ANALG, V72, pS228; RUDNICK JR, 1992, 2ND ANN M SOC HOSP E; SCHAFFNER W, 1969, NEW ENGL J MED, V280, P1224, DOI 10.1056/NEJM196905292802209; SOSIS MB, 1993, ANESTH ANALG, V77, P766; STEERE AC, 1978, TRANSFUSION, V18, P102, DOI 10.1046/j.1537-2995.1978.18178118551.x; TESSLER M, 1992, CAN J ANAESTH, V39, P509, DOI 10.1007/BF03008718; THOMAS DV, 1991, BRIT J ANAESTH, V66, P274, DOI 10.1093/bja/66.2.274-a; TRAUB WH, 1977, J CLIN MICROBIOL, V5, P115; TREPANIER CA, 1990, CAN J ANAESTH, V37, P156, DOI 10.1007/BF03005462; WEINSTEIN RA, 1991, AM J MED, V91, pS179, DOI 10.1016/0002-9343(91)90366-6; ZACHER AN, 1991, ANESTHESIOLOGY, V75, P893, DOI 10.1097/00000542-199111000-00022; 1993, RECOMMENDATIONS INFE; 1985, US PHARMACOPEIA, P1165; 1976, MMWR-MORBID MORTAL W, V25, P141; 1990, MMWR-MORBID MORTAL W, V39, P426; 1993, INFECTION CONTROL GU; 1993, DIPRIVAN INJECTION; 1985, STANDARD METHODS EXA, P869	52	362	374	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					147	154		10.1056/NEJM199507203330303	http://dx.doi.org/10.1056/NEJM199507203330303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791816				2022-12-01	WOS:A1995RK91700003
J	CHRISTENSEN, K; SCHMIDT, MM; VETH, M; OLSEN, J				CHRISTENSEN, K; SCHMIDT, MM; VETH, M; OLSEN, J			ABSENCE OF AN ENVIRONMENTAL-EFFECT ON THE RECURRENCE OF FACIAL-CLEFT DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALATE; LIP; GENE	Background. The rate of of a broad range of birth defects may decrease among women who change residence after the birth of their first infant, The aim of the present study was to determine the effect of changing residence on the recurrence of congenital facial-cleft defects. Methods. We identified 4189 women who had had infants with facial-cleft defects by linking a data base comprising the records of children with facial clefts born between 1952 and 1987 with the Central Person Registry in Denmark, Among the 4189 mothers, 1902 each had additional children after the first child with a facial-cleft defect. A total of 2692 younger siblings were identified. We compared the proportion of infants with facial-cleft defects among the younger siblings between mothers who had changed municipalities or sexual partners and those who had not. Results. Changing the municipality of residence did not decrease the frequency with which facial-cleft defects recurred in younger siblings. Among the 907 infants of mothers who changed municipalities but not partners, 29 (3.2 percent) had facial-cleft defects, as compared with 48 (3.4 percent) of 1425 infants of mothers who changed neither municipality nor partner (relative risk, 0.9; 95 percent confidence interval, 0.6 to 1.5), However, a change of partner reduced the recurrence risk significantly. Among 236 infants of mothers who changed partners, 1 (0.4 percent) had a facial-cleft defect, as compared with 77 (3.3 percent) of 2350 infants of mothers who did not change partners (relative risk, 0.1; 95 percent confidence interval, 0.02 to 0.9). Conclusions. Recurrence of facial-cleft defects is not linked to the residence of the mother, but having a different partner reduced a woman's risk of having a second child with this defect.	ODENSE UNIV, SCH MED, ODENSE, DENMARK; AARHUS UNIV, DEPT BIOSTAT, AARHUS, DENMARK	University of Southern Denmark; Aarhus University	CHRISTENSEN, K (corresponding author), STENO INST PUBL HLTH, DEPT EPIDEMIOL & SOCIAL MED, DANISH EPIDEMIOL SCI CTR, RES UNIT, DK-8000 AARHUS C, DENMARK.		Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292				ARDINGER HH, 1989, AM J HUM GENET, V45, P348; BAIRD PA, 1994, TERATOLOGY, V49, P448, DOI 10.1002/tera.1420490604; CARTER CO, 1982, J MED GENET, V19, P246, DOI 10.1136/jmg.19.4.246; CHENEVIXTRENCH G, 1992, AM J HUM GENET, V51, P1377; CHRISTENSEN K, 1993, AM J MED GENET, V47, P910, DOI 10.1002/ajmg.1320470620; CHRISTENSEN K, 1992, AM J HUM GENET, V51, P654; CHRISTENSEN K, 1994, CLIN GENET, V46, P329; FRIIS ML, 1989, ACTA NEUROL SCAND, V79, P433, DOI 10.1111/j.1600-0404.1989.tb03814.x; GOLDBERG R, 1993, AM J MED GENET, V45, P313, DOI 10.1002/ajmg.1320450307; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; KHOURY MJ, 1987, AM J PUBLIC HEALTH, V77, P623, DOI 10.2105/AJPH.77.5.623; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; MARAZITA ML, 1986, J CRAN GENET DEV BIO, P89; MOORE GE, 1987, NATURE, V326, P91, DOI 10.1038/326091a0; OLSEN J, 1982, UGESKRIFT LAEGER, V4, P1333; PRADAT P, 1994, GENET EPIDEMIOL, V11, P131, DOI 10.1002/gepi.1370110204; WALD N, 1991, LANCET, V338, P131; WANG JH, 1988, AM J HUM GENET, V42, P772; WERLER MM, 1991, AM J EPIDEMIOL, V134, P691, DOI 10.1093/oxfordjournals.aje.a116145	19	45	45	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					161	164		10.1056/NEJM199507203330305	http://dx.doi.org/10.1056/NEJM199507203330305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791818	Bronze			2022-12-01	WOS:A1995RK91700005
J	COCKS, BG; CHANG, CCJ; CARBALLIDO, JM; YSSEL, H; DEVRIES, JE; AVERSA, G				COCKS, BG; CHANG, CCJ; CARBALLIDO, JM; YSSEL, H; DEVRIES, JE; AVERSA, G			A NOVEL RECEPTOR INVOLVED IN T-CELL ACTIVATION	NATURE			English	Article							MONOCLONAL-ANTIBODIES; B-CELLS; PROLIFERATION; CLONES; CD28; CD4+; ANTIGEN; CLONING; CTLA-4; GAMMA	OPTIMAL T-cell activation and T-cell expansion require triggering by T-cell antigen receptors and co-stimulatory signals provided by accessory cells(1-3). A major co-stimulatory pathway involves crosslinking the CD28 molecule on T cells by its ligands CD80 or CD86 expressed on antigen-presenting cells(4-7). But recent studies(8,9) on CD28-deficient mice have indicated that CD28 is not required for all T-cell responses and that additional T-cell costimulatory pathways exist. Here we describe a novel glycoprotein, of relative molecular mass 70,000 (M(r) 70K), designated SLAM, that belongs to the immunoglobulin gene superfamily, which is involved in T-cell stimulation. SLAM is constitutively expressed on peripheral-blood CD45RO(high) memory T cells, T-cell clones, immature thymocytes, and a proportion of B cells, and is rapidly induced on naive T cells after activation. Engagement of SLAM enhances antigen-specific proliferation and cytokine production by T cells carrying the CD4 antigen (CD4(+)). Particularly, the production of interferon-gamma (IFN-gamma) is strongly upregulated, even in T helper type 2 (Th2) CD4(+) T-cell clones, whereas no induction of interleukin(IL)-4 or IL-5 production was observed in Th1 clones. In addition, the engagement of SLAM induces directly the proliferation of CD4(+) T-cell clones and preactivated T cells, in the absence of any other stimuli, and without CD28 involvement. Thus SLAM is a novel receptor on T cells that, when engaged, potentiates T-cell expansion in a CD28-independent manner and induces a Th0/Th1 cytokine production profile.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yssel, Hans/C-6406-2009; Yssel, Hans/AFV-2907-2022	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836				AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; AZUMA M, 1909, J EXP MED, V177, P845; BACCHETTA R, 1990, J IMMUNOL, V144, P902; Bierer B E, 1993, Semin Immunol, V5, P249, DOI 10.1006/smim.1993.1029; CHRETIEN I, 1989, J IMMUNOL METHODS, V117, P67, DOI 10.1016/0022-1759(89)90120-8; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; FAVRE C, 1989, MOL IMMUNOL, V26, P17, DOI 10.1016/0161-5890(89)90015-1; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MATHEW PA, 1993, J IMMUNOL, V151, P5328; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Sambrook J., 1989, MOL CLONING; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STAUNTON DE, 1989, J EXP MED, V169, P187; YSSEL H, 1992, J IMMUNOL, V148, P738; YSSEL H, 1984, J IMMUNOL METHODS, V72, P21; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	416	448	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					260	263		10.1038/376260a0	http://dx.doi.org/10.1038/376260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617038				2022-12-01	WOS:A1995RK33100048
J	COLLINS, JJ; CHOW, CC; IMHOFF, TT				COLLINS, JJ; CHOW, CC; IMHOFF, TT			STOCHASTIC RESONANCE WITHOUT TUNING	NATURE			English	Article							BISTABLE SYSTEMS; NOISE; INFORMATION; SIMULATION; DYNAMICS; NEURONS	STOCHASTIC resonance(1-4) (SR) is a phenomenon wherein the response of a nonlinear system to a weak periodic input signal is optimized by the presence of a particular, non-zero level of noises(5-7). SR has been proposed as a means for improving signal detection in a wide variety of systems, including superconducting quantum interference devices(8), and may be used in some natural systems such as sensory neurons(9-15). But for SR to be effective in a single-unit system (such as a sensory neuron or a single ion channel), the optimal intensity of the noise must be adjusted as the nature of the signal to be detected changes(15). This has been thought to impose a limitation on the practical and natural uses of SR. Here we show that the ability of a summing network of excitable units to detect a range of weak (sub-threshold) signals (either periodic or aperiodic) can be optimized by a fixed level of noise, irrespective of the nature of the input signal. We also show that this noise does not significantly degrade the ability of the network to detect suprathreshold signals. Thus, large nonlinear networks do not suffer from the limitations of SR in single units, and might be able to use a single noise level, such as that provided by the intrinsic noise of the individual components, to enhance the system's sensitivity to weak inputs. This suggests a functional role for neuronal noise(14,16-18) in sensory systems.	BOSTON UNIV, DEPT BIOMED ENGN, BOSTON, MA 02215 USA	Boston University	COLLINS, JJ (corresponding author), BOSTON UNIV, NEUROMUSCULAR RES CTR, 44 CUMMINGTON ST, BOSTON, MA 02215 USA.		Chow, Carson C/A-7970-2009					BENZI R, 1982, TELLUS, V34, P10; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; BULSARA AR, 1993, PHYS REV E, V47, P3734, DOI 10.1103/PhysRevE.47.3734; CHIALVO DR, 1993, J STAT PHYS, V70, P375, DOI 10.1007/BF01053974; COLLINS JJ, UNPUB PHYS REV LETT; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DE LUCA CJ, 1982, J PHYSIOL-LONDON, V329, P113, DOI 10.1113/jphysiol.1982.sp014293; DENK W, 1989, PHYS REV LETT, V63, P207, DOI 10.1103/PhysRevLett.63.207; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; HIBBS AD, 1995, J APPL PHYS, V77, P2582, DOI 10.1063/1.358720; INCHIOSA ME, 1995, PHYS LETT A, V200, P283, DOI 10.1016/0375-9601(95)00198-C; INCHIOSA ME, IN PRESS 3RD P TECHN; INCHIOSA ME, IN PRESS PHYS REV E; JUNG P, 1992, PHYS REV A, V46, pR1709, DOI 10.1103/PhysRevA.46.R1709; JUNG P, 1993, PHYS REP, V234, P175, DOI 10.1016/0370-1573(93)90022-6; KISS LB, 1993, J STAT PHYS, V70, P451, DOI 10.1007/BF01053981; KISS LB, 3RD P TECHN C NONL D; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LINDNER JF, IN PRESS PHYS REV LE; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; MANNELLA R, 1989, PHYS REV A, V40, P3381, DOI 10.1103/PhysRevA.40.3381; MOSS F, 1993, ANN NY ACAD SCI, V706, P26, DOI 10.1111/j.1749-6632.1993.tb24679.x; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; NEIMAN A, 1995, PHYS LETT A, V197, P379, DOI 10.1016/0375-9601(94)01008-I; NICOLIS C, 1982, TELLUS, V34, P1, DOI 10.1111/j.2153-3490.1982.tb01786.x; PANTAZELOU E, 1993, AIP CONF PROC, P549; SHEPHERD GM, 1988, NEUROBIOLOGHY; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	35	670	693	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					236	238		10.1038/376236a0	http://dx.doi.org/10.1038/376236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617033				2022-12-01	WOS:A1995RK33100040
J	HIROSE, K; LOCKHART, A; CROSS, RA; AMOS, LA				HIROSE, K; LOCKHART, A; CROSS, RA; AMOS, LA			NUCLEOTIDE-DEPENDENT ANGULAR CHANGE IN KINESIN MOTOR DOMAIN BOUND TO TUBULIN	NATURE			English	Article							MICROTUBULES; MICROSCOPY; IMAGES	KINESIN is a 'motor' molecule, consisting of two head domains, an alpha-helical coiled coil rod, and a tail part that binds to its cargo(1,2). When expressed in a bacterial system, the head domain is functional(3), and can bind to microtubules with the stoichiometry of one head per tubulin dimer. Kinesin moves along microtubules by means of a cyclic process of nucleotide binding, hydrolysis and product release(4,5). We have used negative-stain electron microscopy and image analysis to study the structures of microtubules and tubulin sheets decorated with the motor domain (bead) of kinesin in three states: in the presence of an unhydrolysable ATP analogue, 5'-adenylylimidodiphosphate (AMP-PNP); without nucleotides; and with adenosine 5'-diphosphate (ADP). A single kinesin head bound to a microtubule has a pear-shaped structure, with the broader end towards the 'plus' end of the microtubule under all conditions; the reverse motor, ncd, is similarly oriented. Three-dimensional maps reveal that kinesin heads have a spike that is assumed to form the attachment to the tail of a complete kinesin molecule. This spike is perpendicular to the microtubule axis in the presence of ADP, but points towards the plus end (similar to 45 degrees) in the presence of AMP-PNP or absence of nucleotides. Our results provide direct evidence for a conformational change of the kinesin motor domain during the ATPase cycle.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; MARIE CURIE INST, OXTED RH8 0TL, SURREY, ENGLAND	MRC Laboratory Molecular Biology			Cross, Robert A/F-1798-2011; Hirose, Keiko/M-5429-2018	Cross, Robert A/0000-0002-0004-7832; Hirose, Keiko/0000-0003-4587-8346; Amos, Linda/0000-0001-8305-5346				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; DALLAI R, 1990, J STRUCT BIOL, V103, P164, DOI 10.1016/1047-8477(90)90020-D; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROSE K, IN PRESS J MOL BIOL; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; KUO SC, 1991, J CELL SCI, P135; LANZAVECCHIA S, 1994, J STRUCT BIOL, V113, P225, DOI 10.1006/jsbi.1994.1057; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MIKKAWA M, 1994, J CELL BIOL, V127, P1965; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WADE RH, 1993, J STRUCT BIOL, V110, P1, DOI 10.1006/jsbi.1993.1001; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	25	110	111	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					277	279		10.1038/376277a0	http://dx.doi.org/10.1038/376277a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617042				2022-12-01	WOS:A1995RK33100053
J	HOENGER, A; SABLIN, EP; VALE, RD; FLETTERICK, RJ; MILLIGAN, RA				HOENGER, A; SABLIN, EP; VALE, RD; FLETTERICK, RJ; MILLIGAN, RA			3-DIMENSIONAL STRUCTURE OF A TUBULIN-MOTOR-PROTEIN COMPLEX	NATURE			English	Article							ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; MICROTUBULE DYNAMICS; SURFACE LATTICE; DROSOPHILA; KINESIN; RECONSTRUCTION; SEGREGATION; MOLECULE; CRYSTALS	THE kinesin superfamily is a class of microtubule-based mechanoenzymes involved in intracellular transport and chromosome movements. Molecules that move towards either the plus end or the minus end of microtubules are represented within the family. The motor domains of these molecules exhibit considerable sequence homology and contain both the ATP- and microtubule-binding sites (reviewed in refs 1, 2). Here we focus on non-claret disjunctional (ncd), a minus-end-directed motor involved in chromosome segregation in meiosis and early mitosis in Drosophila(3-6). We have calculated a three-dimensional map of tubulin sheets decorated with monomeric recombinant ncd motor domains(7) by negative-stain electron microscopy and image analysis. Comparisons with a control structure of tubulin alone reveal that each motor domain binds to the crest of a single protofilament, making extensive contacts with both the alpha and beta tubulin monomers. Binding of the motor domain results in significant conformational changes in both of the tubulin monomers.	UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS & BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	HOENGER, A (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Hoenger, Andreas/0000-0001-9176-6658				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CREPEAU RH, 1978, P NATL ACAD SCI USA, V75, P5006, DOI 10.1073/pnas.75.10.5006; CREPEAU RH, 1977, J MOL BIOL, V116, P301, DOI 10.1016/0022-2836(77)90218-2; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUSER JE, 1986, J CELL BIOL, V103, P2209, DOI 10.1083/jcb.103.6.2209; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SABLIN EP, 1995, PROTEINS, V21, P68, DOI 10.1002/prot.340210108; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; SHIMIZU T, 1993, METHOD CELL BIOL, V39, P167, DOI 10.1016/S0091-679X(08)60169-7; SIMON JR, 1990, J CELL SCI, V96, P571; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; TAMM LK, 1979, J MOL BIOL, V130, P473, DOI 10.1016/0022-2836(79)90435-2; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	27	100	100	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					271	274		10.1038/376271a0	http://dx.doi.org/10.1038/376271a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617040				2022-12-01	WOS:A1995RK33100051
J	HOLLEY, SA; JACKSON, PD; SASAI, Y; LU, B; DEROBERTIS, EM; HOFFMANN, FM; FERGUSON, EL				HOLLEY, SA; JACKSON, PD; SASAI, Y; LU, B; DEROBERTIS, EM; HOFFMANN, FM; FERGUSON, EL			A CONSERVED SYSTEM FOR DORSAL-VENTRAL PATTERNING IN INSECTS AND VERTEBRATES INVOLVING SOG AND CHORDIN	NATURE			English	Article							DROSOPHILA EMBRYO; XENOPUS; GRADIENT; POLARITY; DOMINANT; GENES; TOLL	DORSAL-VENTRAL patterning within the ectoderm of the Drosophila embryo requires seven zygotic genes, including short gastrulation (sog)(1). Here we demonstrate that sog, which is expressed in the ventrolateral region of the embryo that gives rise to the nerve cord(2), is functionally homologous to the chordin gene of Xenopus, which is expressed in the dorsal blastopore lip of the embryo and in dorsal mesoderm, in particular the notochord(3). We show by injections of messenger RNA that both sog and chordin can promote ventral development in Drosophila, and that sog, like chordin(3), can promote dorsal development in Xenopus. In Drosophila, sog antagonizes the dorsalizing effects of decapentaplegic (dpp)(1,2,4), member of the transforming growth factor-beta family. One of the dpp homologues in vertebrates, bmp-4, is expressed ventrally in Xenopus(5) and promotes ventral development(6,7). We show that dpp can promote ventral fates in Xenopus, and that injection of sog mRNA counteracts the ventralizing effects of dpp. These results suggest the molecular conservation of dorsoventral patterning mechanisms during evolution.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	HOLLEY, SA (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Ferguson, Edwin/0000-0003-4125-4253; Hoffmann, F. Michael/0000-0002-2770-9656				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Geoffroy Saint-Hilaire uU., 1822, MEM MUS HIST NAT, V9, P89; JONES CM, 1992, DEVELOPMENT, V115, P39; LACALLI TC, 1995, NATURE, V373, P110, DOI 10.1038/373110c0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; PETERSON KJ, 1995, NATURE, V373, P112; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1991, ROUX ARCH DEV BIOL, V199, P341, DOI 10.1007/BF01705927; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WHARTON KA, 1993, DEVELOPMENT, V117, P807; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	24	362	370	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					249	253		10.1038/376249a0	http://dx.doi.org/10.1038/376249a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617035				2022-12-01	WOS:A1995RK33100045
J	KESSLER, DA				KESSLER, DA			NICOTINE ADDICTION IN YOUNG-PEOPLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.							BANTLE LF, 1968, JAN MIN SNUFF CHEW T, P3; CUMMINGS KM, 1994, AM J PUBLIC HEALTH, V84, P300, DOI 10.2105/AJPH.84.2.300; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FREEDMAN AM, 1994, WALL ST J       0603, pA1; GIOVINO GA, 1994, AUG FOOD DRUG ADM DR; HILTS PJ, 1994, NY TIMES        1127, P1; LYNCH BS, 1994, GROWING TOBACCO FREE, P8; LYNCH BS, 1994, GROWING UP TOBACCO F; LYNCH BS, 1994, GROWING TOBACCO FREE, P3; MCMAHON JP, 1990, COMMUNICATION   0110; MOSS AJ, 1992, ADV DATA VITAL HLTH, V221; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; SHAPIRO E, 1994, WALL STREET J   1006; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P3; WARLICK RG, 1990, COMMUNICATION   0405; 1994, REPORT C PURSUANT FE, P3; 1991, J NATL CANCER I, V83, P1620; 1992, 1992 GALLUP SURVEY, P59; 1995, NATIONS 1ST SURVEY R; 1988, OVERALL MARKET CONDI, P6; 1994, MONITORING FUTURE ST; 1988, HLTH CONSEQUENCES SM, P7; 1995, FINDINGS SURVEY APPR, P4; 1993, MMWR-MORBID MORTAL W, V42, P645; 1994, MMWR-MORBID MORTAL W, V43, P580; 1994, PREVENTING TOBACCO U, P124; 1994, PREVENTING TOBACCO U, V5, P58; 1994, MMWR-MORBID MORTAL W, V43, P577; 1982, PROJECT PLUS MINUS 3, P1; 1988, HLTH CONSEQUENCES SM, P9; 1994, PREVENTING TOBACCO U, P249; 1989, REDUCING HLTH CONSEQ, P131; 1994, PREVENTING TOBACCO U, P192; 1977, 16 KWECH MARK RES PR, pR6; 1992, TEENAGE ATTITUDES BE, P54; 1994, PREVENTING TOBACCO U, P70; 1986, NIH 862874 DEP HLTH, pR7	37	91	92	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					186	189		10.1056/NEJM199507203330311	http://dx.doi.org/10.1056/NEJM199507203330311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK917	7791824				2022-12-01	WOS:A1995RK91700011
J	KIKKAWA, M; ISHIKAWA, T; WAKABAYASHI, T; HIROKAWA, N				KIKKAWA, M; ISHIKAWA, T; WAKABAYASHI, T; HIROKAWA, N			3-DIMENSIONAL STRUCTURE OF THE KINESIN HEAD-MICROTUBULE COMPLEX	NATURE			English	Article							CRYO-ELECTRON MICROSCOPY; SURFACE LATTICE; RECONSTRUCTION; DECORATION; TUBULIN; SYSTEM; IMAGES	KINESIN is a microtubule (MT)-associated 'motor' molecule fundamental to organelle transport(1,2). Recently, various kinesin superfamily members (KIFs) have also been identified and suggested as being responsible for the transport of specific organelles(3-5). Kinesin is a heterotetramer composed of two heavy chains and two light chains. The heavy chains form two globular heads, a rod and a fan-like tail completed by the light chains(6,7). The globular head, which is composed of approximately 340 amino-terminal residues of the heavy chain, includes both ATP-binding and MT-binding domains, and its recombinant protein also has these properties(8). To improve the understanding of the mechanism of force generation by an MT-based molecular motor, kinesin, we report here the three-dimensional structure of the complex of a recombinant kinesin head and MTs, as revealed by helical reconstruction from cryoelectron micrographs. A kinesin head is a globular teardrop-like structure binding to the ridge of one protofilament of MTs. We have determined the polarity of the structure of the complex of MTs and the kinesin head in relation to MT polarity.	UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC SCI, DEPT PHYS, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Kikkawa, Masahide/A-6692-2010; Ishikawa, Takashi/E-5023-2017	Kikkawa, Masahide/0000-0001-7656-8194; Ishikawa, Takashi/0000-0002-1976-7477				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; ISHIKAWA T, 1994, BIOCHEM BIOPH RES CO, V203, P951, DOI 10.1006/bbrc.1994.2274; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Vale Ronald D., 1993, P175; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	30	88	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					274	277		10.1038/376274a0	http://dx.doi.org/10.1038/376274a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617041				2022-12-01	WOS:A1995RK33100052
J	LIN, HH; GROSSCHEDL, R				LIN, HH; GROSSCHEDL, R			FAILURE OF B-CELL DIFFERENTIATION IN MISE LACKING THE TRANSCRIPTION FACTOR EBF	NATURE			English	Article							GENE-TRANSCRIPTION; IMMUNOGLOBULIN HEAVY; ANTIGEN RECEPTOR; BONE-MARROW; EXPRESSION; LINEAGE; REARRANGEMENT; MB-1; REGULATOR; CLONING	EARLY B-cell factor (EBF) is a cell type-specific transcription factor that is expressed at all antigen-independent stages of B-lymphocyte differentiation and participates in the regulation of the mb-1 gene(1-4). Here we show, by targeted gene disruption in mice, that EBF is necessary for the generation of immunoglobulin-expressing B cells. EBF-deficient mice lack B cells that have rearranged their immunoglobulin D and J(H) gene segments, but contain B220(+)CD43(+) progenitor cells that express germline mu and IL-7 receptor transcripts. Various non-lymphoid tissues that express EBF are apparently normal in homozygous mutant mice, including olfactory neurons in which EBF was identified as Olf-1 (refs 5, 6). Together, these data suggest that EBF plays a specific and important role in the transcriptional control of B-cell differentiation at a stage before Ig (immunoglobulin) gene rearrangement but after commitment of cells to the B-lymphoid lineage.			LIN, HH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.							BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.iy.11.040193.002441; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V255, P855; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; URBANEK P, 1994, CELL, V7, P901; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHANG Y, 1994, CELL, V79, P875	30	515	525	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					263	267		10.1038/376263a0	http://dx.doi.org/10.1038/376263a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7542362				2022-12-01	WOS:A1995RK33100049
J	RIVERAPOMAR, R; LU, XG; PERRIMON, N; TAUBERT, H; JACKLE, H				RIVERAPOMAR, R; LU, XG; PERRIMON, N; TAUBERT, H; JACKLE, H			ACTIVATION OF POSTERIOR GAP DENE EXPRESSION IN THE DROSOPHILA BLASTODERM	NATURE			English	Article							CAUDAL GENE; PATTERN; PROTEIN; EMBRYO; GRADIENT; RNA; EMBRYOGENESIS; LOCALIZATION	THE process of body prepatterning during Drosophila blastoderm formation relies on the localized activities of zygotic segmentation genes, which are controlled by asymmetrically distributed maternal determinants(1,2). The anterior determinant bicoid, a homeodomain transcription factor(3,4), forms an anterior-to-posterior concentration gradient(1-4). It interacts with the maternal transcription factor hunchback(5) to activate the anterior zygotic patterning genes, including the central gap gene Kruppel (Kr)(6). In contrast, the posterior maternal system(1,2) does not provide such a decisive transcription factor, but rather prevents the repressor hunchback from acting in the posterior half so that the gap genes giant (gt) and knirps (kni) are activated by an as yet unknown transcription factor(2,7). Here we show that caudal, a conserved homeodomain protein that forms a posterior-to-anterior concentration gradient(8,9), and the anterior determinant bicoid cooperate to form a partly redundant activator system in the posterior region of the embryo.	HARVARD UNIV, SCH MED, DEPT GENET, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Kansas	RIVERAPOMAR, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ENTWICKLUNGSBIOL ABT, POSTFACH 2841, D-37018 GOTTINGEN, GERMANY.			Perrimon, Norbert/0000-0001-7542-472X				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOUS XS, 1995, CELL, V81, P63; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEHMANN R, 1988, DEVELOPMENT, V104, P17; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MIODZIK M, 1987, DEVELOPMENT, V101, P421; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Pankratz Michael J., 1993, P467; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1992, CELL, V68, P201; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; XU X, 1994, DEVELOPMENT, V120, P277	29	153	153	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					253	256		10.1038/376253a0	http://dx.doi.org/10.1038/376253a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617036				2022-12-01	WOS:A1995RK33100046
J	RUWENDE, C; KHOO, SC; SNOW, AW; YATES, SNR; KWIATKOWSKI, D; GUPTA, S; WARN, P; ALLSOPP, CEM; GILBERT, SC; PESCHU, N; NEWBOLD, CI; GREENWOOD, BM; MARSH, K; HILL, AVS				RUWENDE, C; KHOO, SC; SNOW, AW; YATES, SNR; KWIATKOWSKI, D; GUPTA, S; WARN, P; ALLSOPP, CEM; GILBERT, SC; PESCHU, N; NEWBOLD, CI; GREENWOOD, BM; MARSH, K; HILL, AVS			NATURAL-SELECTION OF HEMIZYGOTES AND HETEROZYGOTES FOR G6PD DEFICIENCY IN AFRICA BY RESISTANCE TO SEVERE MALARIA	NATURE			English	Article							PLASMODIUM-FALCIPARUM; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; VARIANT; DEHYDROGENASE; SEQUENCE; CHILDREN; ENZYME	GLUCOSE-6-PHOSPHATE dehydrogenase (G6PD) deficiency, the most common enzymopathy of humans, affects over 400 million people(1). The geographical correlation of its distribution with the historical endemicity of malaria suggests that this disorder has risen in frequency through natural selection by malaria(2.3). However, attempts to confirm that G6PD deficiency is protective in case-control studies of malaria have yielded conflicting results(4-8). Hence, for this X-linked disorder, it is unclear whether both male hemizygotes and female heterozygotes are protected or, as frequently suggested, only females(1,5-11). Furthermore, how much protection may be afforded is unknown. Here we report that, in two large case-control studies of over 2,000 African children, the common African form of G6PD deficiency (G6PD A-) is associated with a 46-58% reduction in risk of severe malaria for both female heterozygotes and male hemizygotes. A mathematical model incorporating the measured selective advantage against malaria suggests that a counterbalancing selective disadvantage, associated with this enzyme deficiency, has retarded its rise in frequency in malaria-endemic regions. Although G6PD deficiency is now regarded as a generally benign disorder, in earlier environmental conditions it could have been significantly disadvantageous.	UNIV OXFORD, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7BN, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; KEMRI, CLIN RES CTR, KILIFI UNIT, KILIFI, KENYA; MRC LABS, BANJUL, GAMBIA; UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; MRC Laboratory Molecular Biology; University of Oxford			Gilbert, Sarah C./H-2857-2019; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; Snow, Robert/0000-0003-3725-6088; Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0; BEUTLER E, 1989, BLOOD, V74, P2550; BEUTLER E, 1990, SEMIN HEMATOL, V27, P137; BIENZLE U, 1972, LANCET, V1, P107; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; GILLES HM, 1967, LANCET, V1, P138; GREENBERG DR, 1993, SOLID STATE ELECTRON, V36, P53, DOI 10.1016/0038-1101(93)90068-2; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; HELLER P, 1979, NEW ENGL J MED, V300, P1001, DOI 10.1056/NEJM197905033001801; HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; KURDIHAIDAR B, 1990, MOL BIOCHEM PARASIT, V41, P83, DOI 10.1016/0166-6851(90)90099-8; LING IT, 1988, MOL BIOCHEM PARASIT, V31, P47, DOI 10.1016/0166-6851(88)90144-2; Livingstone F. B., 1985, FREQUENCIES HEMOGLOB; Luzzato L, 1989, METABOLIC BASIS INHE, P2237; LUZZATTO L, 1979, LANCET, V1, P1183; LUZZATTO L, 1985, ADV HUM GENET, V14, P217; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARTIN SK, 1979, LANCET, V1, P524; MARTIN SK, 1994, PARASITOL TODAY, V10, P251, DOI 10.1016/0169-4758(94)90133-3; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MILLER LH, 1988, MALARIA PRINCIPLES P, P493; MOTULSKY AG, 1961, LANCET, V1, P1168; MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28; ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298; USANGA EA, 1985, NATURE, V313, P793, DOI 10.1038/313793a0; VULLIAMY TJ, 1991, P NATL ACAD SCI USA, V88, P8568, DOI 10.1073/pnas.88.19.8568	29	408	425	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					246	249		10.1038/376246a0	http://dx.doi.org/10.1038/376246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617034				2022-12-01	WOS:A1995RK33100044
J	THOMAS, SM; SORIANO, P; IMAMOTO, A				THOMAS, SM; SORIANO, P; IMAMOTO, A			SPECIFIC AND REDUNDANT ROLES OF SRC AND FYN IN ORGANIZING THE CYTOSKELETON	NATURE			English	Article							TYROSINE PHOSPHORYLATION; CELLS; GENE; MICE; KINASES; IDENTIFICATION; OSTEOPETROSIS; DISRUPTION; SUBSTRATE; ENCODES	MOUSE embryos lacking Csk, a negative regulator of Src family kinases, exhibit defects in neurulation and die at mid-gestation(1,2). To determine the role of activated Src family kinases in the csk(-) phenotype, we have introduced mutations in the src and fyn genes(3,4) into the csk(-) mutant background. Genetic analysis reveals that src, but not fyn, is partly epistatic to the csk gene. Biochemical analysis indicates that several cytoskeletal proteins are hyperphosphorylated an tyrosine residues in csk(-) cells. Regulation of cortactin and tensin hyperphosphorylation is Src-dependent, whereas focal adhesion kinase and paxillin hyperphosphorylation is partly dependent on both Src and Fyn. Furthermore, the src(-) mutation can restore the normal distribution of cortactin and partly correct filamentous actin organization in csk(-) cells. Thus, Src family kinases have both specific and overlapping functions in regulation of the cytoskeleton. The disturbance of these functions may be a molecular basis for the phenotype exhibited by csk(-) mutants.			THOMAS, SM (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV MOLEC MED, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IMAMOTO A, 1994, CURR OPIN GENET DEV, V4, P40, DOI 10.1016/0959-437X(94)90089-2; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARTANEN J, 1991, ONCOGENE, V6, P2013; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TURNER CE, 1994, J CELL SCI, V107, P1583; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAGI T, 1994, ONCOGENE, V9, P2433; YANG JT, 1993, DEVELOPMENT, V119, P1093	30	301	302	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					267	271		10.1038/376267a0	http://dx.doi.org/10.1038/376267a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617039				2022-12-01	WOS:A1995RK33100050
J	WALTER, MR; WINDSOR, W; NAGABHUSHAN, TL; LUNDELL, DJ; LUNN, CA; ZAUODNY, PJ; NARULA, SK				WALTER, MR; WINDSOR, W; NAGABHUSHAN, TL; LUNDELL, DJ; LUNN, CA; ZAUODNY, PJ; NARULA, SK			CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN INTERFERON-GAMMA AND ITS SOLUBLE HIGH-AFFINITY RECEPTOR	NATURE			English	Article							EXTRACELLULAR DOMAIN; ACCESSORY FACTOR; C-TERMINUS; HUMAN CD4; PROTEIN; EXPRESSION; RESOLUTION; FRAGMENT; CLONING	The crystal structure of interferon-gamma bound to the extracellular fragment of its high-affinity cell-surface receptor reveals the first view of a class-2 cytokine receptor-ligand complex. In the complex, one interferon-gamma homodimer binds two receptor molecules. Unlike the class-1 growth hormone receptor complex, the two interferon-gamma receptors do not interact with one another and are separated by 27 Angstrom. Upon receptor binding, the flexible As loop of interferon-gamma undergoes a conformational change that includes the formation of a 3(10) helix.	UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, BIRMINGHAM, AL 35294 USA; SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA	University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation	WALTER, MR (corresponding author), UNIV ALABAMA, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1016/S0022-2836(84)71582-8; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GRIGGS ND, 1992, J IMMUNOL, V149, P517; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JARPE MA, 1993, J INTERFERON RES, V13, P99, DOI 10.1089/jir.1993.13.99; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LUNDELL D, 1994, J BIOL CHEM, V269, P16159; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; LUNN CA, 1992, PROTEIN ENG, V5, P253, DOI 10.1093/protein/5.3.253; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	337	353	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					230	235		10.1038/376230a0	http://dx.doi.org/10.1038/376230a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617032				2022-12-01	WOS:A1995RK33100039
J	WEISSKOPF, MG; NICOLL, RA				WEISSKOPF, MG; NICOLL, RA			PRESYNAPTIC CHANGES DURING MOSSY FIBER LTP REVEALED BY NMDA RECEPTOR-MEDIATED SYNAPTIC RESPONSES	NATURE			English	Article							LONG-TERM POTENTIATION; GUINEA-PIG HIPPOCAMPUS; RAT HIPPOCAMPUS; MECHANISMS; PROBABILITY; NEURONS; RELEASE; SLICES; FORMS; BRAIN	ACTIVITY-DEPENDENT changes in synaptic strength are important for learning and memory. Long-term potentiation (LTP) of glutamatergic excitatory synapses following brief repetitive stimulation provides a compelling cellular model for such plasticity(1-4). In the CA1 region of the hippocampus, anatomical studies have revealed large numbers of NMDA (N-methyl-D-aspartate) receptor sites at excitatory synapses(5,6), which express primarily an NMDA receptor-dependent form of LTP(7). In contrast, these studies(5,6) have suggested that messy fibre synapses activate primarily or exclusively alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and, indeed, these synapses express a form of LTP that is entirely independent of NMDA receptors(8,9). Here we present physiological data demonstrating that messy fibres activate a substantial NMDA receptor synaptic component that expresses LTP. The presence of an NMDA receptor response allowed us to use the open-channel NMDA receptor antagonist MK-801 to establish directly that the probability of transmitter release is enhanced during the expression of messy fibre LTP.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; GUSTAFSSON B, 1991, SEMIN NEUROSCI, V2, P321; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ISAACSON JS, 1990, SOC NEUR ABSTR, V20, P468; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHARFMAN HE, 1994, NEUROPHYSIOL, V72, P2167; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; YAMAMOTO C, 1983, EXP BRAIN RES, V51, P128; YAMAMOTO C, 1992, NEUROSCI LETT, V138, P111, DOI 10.1016/0304-3940(92)90484-O; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	27	153	155	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					256	259		10.1038/376256a0	http://dx.doi.org/10.1038/376256a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617037				2022-12-01	WOS:A1995RK33100047
J	YELAMOS, J; KLIX, N; GOYENECHEA, B; LOZANO, F; CHUI, YL; FERNANDEZ, AG; PANNELL, R; NEUBERGER, MS; MILSTEIN, C				YELAMOS, J; KLIX, N; GOYENECHEA, B; LOZANO, F; CHUI, YL; FERNANDEZ, AG; PANNELL, R; NEUBERGER, MS; MILSTEIN, C			TARGETING OF NON-LG SEQUENCES IN-PLACE OF THE V-SEGMENT BY SOMATIC HYPERMUTATION	NATURE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; IMMUNOGLOBULIN GENES; PASSENGER TRANSGENES; AFFINITY MATURATION; MUTATION; KAPPA; MUTAGENESIS; MECHANISM; PROMOTER	Affinity maturation of antibodies is characterized by localized hypermutation of the DNA around the V segment. Here we show, using mice containing single or multiple transgene constructs, that an immunoglobulin V-kappa segment can be replaced by human beta-globin or prokaryotic neo or gpt genes without affecting the rate of hypermutation; the V gene itself is not necessary for recruiting hypermutation. The ability to target hypermutation to heterologous genes in vivo could find more general applications in biology.			YELAMOS, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		González-Fernández, África/E-2641-2012; Yelamos, Jose/N-2842-2016	González-Fernández, África/0000-0002-9226-4825; LOZANO, FRANCISCO/0000-0003-1119-4368; Chui, Yiu-Loon/0000-0002-3441-9729; Yelamos, Jose/0000-0003-1195-1496				AZUMA T, 1993, INT IMMUNOL, V5, P121, DOI 10.1093/intimm/5.2.121; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOTH GW, 1990, MOL CELL BIOL, V10, P5187, DOI 10.1128/MCB.10.10.5187; CHUI YL, 1995, J MOL BIOL, V249, P555, DOI 10.1006/jmbi.1995.0318; CLACKSON T, 1989, NUCLEIC ACIDS RES, V17, P10163, DOI 10.1093/nar/17.24.10163; Galfre G, 1981, Methods Enzymol, V73, P3; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GONZALEZFERNAND.A, 1994, P NATL ACAD SCI USA, V91, P12614; GONZALEZFERNANDEZ, 1993, P NATL ACAD SCI USA, V90, P9862; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MANSER T, 1990, SOMATIC HYPERMUTATIO, P20; MOTOYAMA N, 1991, P NATL ACAD SCI USA, V88, P7933, DOI 10.1073/pnas.88.18.7933; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Pettersson S, 1989, Int Immunol, V1, P509, DOI 10.1093/intimm/1.5.509; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RADA C, 1994, EUR J IMMUNOL, V24, P1453, DOI 10.1002/eji.1830240632; ROGERSON B, 1991, EMBO J, V10, P4331, DOI 10.1002/j.1460-2075.1991.tb05011.x; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROTHENFLUH HS, 1993, EUR J IMMUNOL, V23, P2152, DOI 10.1002/eji.1830230916; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; STEELE EJ, 1992, IMMUNOL CELL BIOL, V70, P129, DOI 10.1038/icb.1992.18; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; WEBER JS, 1991, J IMMUNOL, V146, P3652; WEBER JS, 1994, J IMMUNOL, V153, P3594; WEIGERT M, 1986, PROG IMMUNOL, V6, P139	40	208	247	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					225	229						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617031				2022-12-01	WOS:A1995RK33100038
J	BARNES, DE; HANAUER, P; SLADE, J; BERO, LA; GLANTZ, SA				BARNES, DE; HANAUER, P; SLADE, J; BERO, LA; GLANTZ, SA			ENVIRONMENTAL TOBACCO-SMOKE - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PASSIVE SMOKING; LUNG-CANCER; HEART-DISEASE	Objective.-To examine the tobacco industry's public and private responses to rising concern over the health effects of environmental tobacco smoke (ETS). Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-Privately, B&W and BAT began conducting research related to ETS in the mid 1970s. BAT researchers appear to have determined that sidestream smoke produces irritation, that it contains toxic substances including N-nitrosamines, and that it is ''biologically active'' (eg, carcinogenic) in laboratory tests. During the 1980s, the primary purpose of BAT's research related to ETS was to develop a new cigarette that emitted less irritating and less biologically active sidestream smoke. Publicly, the tobacco industry has denied that exposure to ETS has been proven dangerous to health. It has criticized the methodology of published research on ETS, even when some of its own consultants have privately acknowledged that the research was valid, In addition, the industry has funded scientific research with the stated purpose of anticipating and refuting the evidence against ETS. The tobacco industry's strategy regarding passive smoking has been remarkarbly similar to its strategy regarding active smoking. it has privately conducted internal research, at least some of which has supported the conclusion that passive smoking is dangerous to health, while it has publicly denied that the hazards have been proven.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN L, 1977, NY TIMES        0918, P29; [Anonymous], 1986, ENV TOBACCO SMOKE ME; BECKER CG, 1979, AM J PATHOL, V96, P249; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BECKER CG, 1976, P NATL ACAD SCI USA, V73, P1712, DOI 10.1073/pnas.73.5.1712; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; Brunnemann K D, 1978, IARC Sci Publ, P343; BRUNNEMANN KD, 1977, CANCER RES, V37, P3218; CUDDEBACK JE, 1976, AM IND HYG ASSOC J, V37, P263, DOI 10.1080/0002889768507453; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FRIEDMAN A, 1993, WALL STREET J   0211, pA1; GARFINKEL L, 1981, JNCI-J NATL CANCER I, V66, P1061, DOI 10.1093/jnci/66.6.1061; GIDDING SS, 1994, CIRCULATION, V90, P2582; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1992, J CLIN EPIDEMIOL, V45, P815, DOI 10.1016/0895-4356(92)90063-S; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; GLANTZ SA, 1983, 12TH P WORLD C TOB H, P287; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; HOFFMANN D, 1994, J TOXICOL ENV HEALTH, V41, P1, DOI 10.1080/15287399409531825; Levin M, 1993, NATION          0809, P168; LEVY D, 1994, USA TODAY       0621, pD1; RUSSELL MAH, 1973, LANCET, V1, P576; Taylor Peter, 1984, SMOKE RING TOBACCO M; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TURNER S, 1992, ENVIRON INT, V18, P19, DOI 10.1016/0160-4120(92)90207-K; 1992, EPA600690006F; 1993, ANN REV SUMMARY FINA; 1981, BRIT MED J, V283, P914; 1994, ENV TOBACCO SMOKE IN; 1994, OVERSIGHT HEARING TO; 1986, PHS CDC878398 US DEP; 1986, TOBACCO SMOKE NONSMO	34	65	65	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					248	253		10.1001/jama.274.3.248	http://dx.doi.org/10.1001/jama.274.3.248			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609234				2022-12-01	WOS:A1995RH93700031
J	BERO, L; BARNES, DE; HANAUER, P; SLADE, J; GLANTZ, SA				BERO, L; BARNES, DE; HANAUER, P; SLADE, J; GLANTZ, SA			LAWYER CONTROL OF THE TOBACCO INDUSTRYS EXTERNAL RESEARCH-PROGRAM - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the involvement of tobacco industry lawyers in the selection of tobacco industry scientific research projects and to examine how the research was used to influence public policy. Data Sources.-Documents from Brown and Williamson Tobacco Corporation, the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-The involvement of tobacco industry lawyers in the selection of scientific projects to be funded is in sharp contrast to the industry's public statements about its review process for its external research program. Scientific merit played little role in the selection of external research projects, The results of the projects were used to generate good publicity for the industry, to deflect attention away from tobacco use as a health danger, and to attempt, sometimes surreptitiously, to influence policymakers.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BERO LA, 1993, TOB CONTROL, V2, P103; DURBIN R, 1993, TOB CONTROL, V2, P8; FRIEDMAN GD, 1979, NEW ENGL J MED, V300, P213, DOI 10.1056/NEJM197902013000501; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; 1992, EPA600690006F; 1964, US DHEW PHS PUBLICAT, V1103; 1992, 1992 COUNC TOB RES R	13	76	76	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					241	247		10.1001/jama.274.3.241	http://dx.doi.org/10.1001/jama.274.3.241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609233				2022-12-01	WOS:A1995RH93700030
J	GLANTZ, SA; BARNES, DE; BERO, L; HANAUER, P; SLADE, J				GLANTZ, SA; BARNES, DE; BERO, L; HANAUER, P; SLADE, J			LOOKING THROUGH A KEYHOLE AT THE TOBACCO INDUSTRY - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To introduce a series of papers discussing previously undocumented tobacco industry activities regarding strategies to avoid products liability litigation, understand nicotine addiction, and manipulate both internal and external scientific research on the effects of both active and passive smoking. Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-These documents provide our first look at the inner workings of the tobacco industry during the crucial period in which the scientific case that smoking is addictive and kills smokers solidified. The documents show a sophisticated legal and public relations strategy to avoid liability for the diseases induced by tobacco use. The documents show that lawyers steered scientists away from particular research avenues, which is inconsistent with the company's purported disbelief in the causation and addiction claims; if the company had been genuinely unconvinced by the causation and addiction hypotheses, then it should have had no concern that new research would provide ammunition for the enemy. Quite the contrary, the documents show that B&W and BAT recognized more than 30 years ago that nicotine is addictive and that tobacco smoke is ''biologically active'' (leg, carcinogenic).	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ 08903	University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center	GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,DIV CARDIOL,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HILTS P, 1994, NY TIMES        0310, pA10; HILTS PJ, 1994, NY TIMES        0507, pA1; KING W, 1976, NY TIMES        1030, pA8; MAXWELL JJ, 1993, HIST SALES TRENDS CI; MAXWELL JJ, 1993, MAXWELL CONSUMER REP; MILLHISER RR, 1978, NY TIMES        0112, pA19; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; WEISZ P, 1995, BRANDWEEK       0606, P20; WOLINSKY H, 1985, NEW YORK STATE J MED, V85, P451; 1964, US DHEW PHS1103 PUBL; 1988, PHS CDC888406 US DEP; 1989, PHS DHHS CDC898411 U; 1981, DHHS PHS8150156 US D; 1982, DHHS PHS8550179 US D; 1979, NY TIMES        0922, pA6; 1972, PHS DHEW HSM727516 H; 1979, DHEW PHS7950066 OFF; 1985, ORG POLICY STATEMENT; 1986, PHS DHHS CDC878398 U; 1986, TOBACCO SMOKE NONSMO	23	91	92	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					219	224		10.1001/jama.274.3.219	http://dx.doi.org/10.1001/jama.274.3.219			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609230				2022-12-01	WOS:A1995RH93700027
J	GRAHAM, T				GRAHAM, T			THE BROWN-AND-WILLIAMSON DOCUMENTS - THE COMPANY RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GRAHAM, T (corresponding author), TRIVALLEY HERALD,4770 WILLOW RD,PLEASANTON,CA 94588, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					254	255						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609235				2022-12-01	WOS:A1995RH93700032
J	HANAUER, P; SLADE, J; BARNES, DE; BERO, L; GLANTZ, SA				HANAUER, P; SLADE, J; BARNES, DE; BERO, L; GLANTZ, SA			LAWYER CONTROL OF INTERNAL SCIENTIFIC-RESEARCH TO PROTECT AGAINST PRODUCTS-LIABILITY LAWSUITS - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To understand how attorneys for the tobacco industry in general, and Brown and Williamson Tobacco Corporation (B&W) in particular, have responded to the threat of products liability litigation arising from smoking-induced diseases. Data Sources.-Documents from B&W, the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, or received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-She documents demonstrate that the tobacco industry in general, and B&W in particular, were very concerned about the threat of products liability lawsuits, and they illustrate some of the steps taken by lawyers at one company to avoid the discovery of documents that might be useful to a plaintiff in such a lawsuit, These steps included efforts to control the language of scientific discourse on issues related to smoking and health, to bring all potentially damaging internal scientific documents under attorney work product and attorney-client privilege to avoid discovery, to remove ''deadwood'' documents, and to insulate B&W from knowledge of potentially damaging scientific information from other BAT companies.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; RABIN RL, 1992, STANFORD LAW REV, V44, P853, DOI 10.2307/1229002; Taylor Peter, 1984, SMOKE RING TOBACCO M; WAGNER S, 1971, CIGARETTE COUNTRY TO	4	40	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					234	240						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609232				2022-12-01	WOS:A1995RH93700029
J	SLADE, J; BERO, LA; HANAUER, P; BARNES, DE; GLANTZ, SA				SLADE, J; BERO, LA; HANAUER, P; BARNES, DE; GLANTZ, SA			NICOTINE AND ADDICTION - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTES; BLOCKING; VENTS	Objective.-To learn how nicotine has been regarded by a major tobacco company. Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-During a period of 22 years (1962 to 1984), employees of B&W and BAT conducted research and commented on the pharmacology of nicotine. They consistently regarded nicotine as the pharmacological agent that explained tobacco use, In the early part of the period under study, officials of the companies wrote about nicotine addiction explicitly. Inhalation of cigarette smoke by the consumer was recognized throughout the period as necessary for the normal function of a cigarette. The documents contain little indication that research was conducted on either the taste or the flavor of nicotine, The documents reveal an intention on the part of B&W and its corporate parent to affect the function of the body with nicotine.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1962, SMOKING HLTH REPORT; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; Ellis C., 1966, US Patent, Patent No. [3 258 015, 3258015]; Ellis Charles, 1967, US Patent, Patent No. [3 356 094, 3356094]; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; GRUNBERG NE, 1982, ADDICT BEHAV, V7, P317, DOI 10.1016/0306-4603(82)90001-6; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HENNINGFIELD JE, 1992, J CONSULT CLIN PSYCH, V61, P743; JOHNSON R, 1990, Patent No. 4955397; Kessler David A., 1994, TOB CONTROL, V3, P150, DOI DOI 10.1136/TC.3.2.148; KOZLOWSKI LT, 1988, AM J PUBLIC HEALTH, V78, P694, DOI 10.2105/AJPH.78.6.694; KOZLOWSKI LT, 1989, PHARMACOL BIOCHEM BE, V33, P815, DOI 10.1016/0091-3057(89)90476-0; LITZINGER E, 1990, Patent No. 4924886; MARTINI L, 1966, NEUROENDOCRINOLOGY; MEDVEI V, 1992, HIST CLIN ENDOCRINOL; OCKENE J, 1982, PREV MED, V10, P476; PORENSKI H, 1994, Patent No. 5327915; SLADE J, 1993, NICOTINE ADDICTION P, P3; 1988, DHHS CDC888406 US DE; 1989, DHHS CDC898411 US DE; 1964, US DHEW PHS1103 PUBL, V1103; 1980, BRIT MED J, V280, P972	22	85	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					225	233		10.1001/jama.274.3.225	http://dx.doi.org/10.1001/jama.274.3.225			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609231				2022-12-01	WOS:A1995RH93700028
J	ANDERSON, NE; BROAD, JB; BONITA, R				ANDERSON, NE; BROAD, JB; BONITA, R			DELAYS IN-HOSPITAL ADMISSION AND INVESTIGATION IN ACUTE STROKE	BRITISH MEDICAL JOURNAL			English	Article							TIME		AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; SCH MED AUCKLAND,GERIATR MED SECT,AUCKLAND,NEW ZEALAND	Auckland City Hospital; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ALBERTS MJ, 1990, JAMA-J AM MED ASSOC, V263, P65, DOI 10.1001/jama.263.1.65; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; BONITA R, 1995, INT J EPIDEMIOL, V24, P535, DOI 10.1093/ije/24.3.535; BONITA R, 1993, LANCET, V342, P470; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835	5	51	53	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					162	162		10.1136/bmj.311.6998.162	http://dx.doi.org/10.1136/bmj.311.6998.162			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613428	Green Published			2022-12-01	WOS:A1995RK15900022
J	BAUER, TM; RITZ, R; HABERTHUR, C; HA, HR; HUNKELER, W; SLEIGHT, AJ; SCOLLOLAVIZZARI, G; HAEFELI, WE				BAUER, TM; RITZ, R; HABERTHUR, C; HA, HR; HUNKELER, W; SLEIGHT, AJ; SCOLLOLAVIZZARI, G; HAEFELI, WE			PROLONGED SEDATION DUE TO ACCUMULATION OF CONJUGATED METABOLITES OF MIDAZOLAM	LANCET			English	Article							MORPHINE-6-GLUCURONIDE; PLASMA	Midazolam is a short-acting benzodiazepine routinely used in intensive-care medicine. Conjugates of its main metabolite, alpha-hydroxymidazolam, have been shown to accumulate in renal failure but have not previously been related to the prolonged sedative effects commonly observed in critically ill patients. We report five patients with severe renal failure who had prolonged sedation after administration of midazolam. In all five patients, the comatose state was immediately reversed by the benzodiazepine-receptor antagonist flumazenil. Serum concentration monitoring showed high concentrations of conjugated alpha-hydroxymidazolam when concentrations of the unconjugated metabolite and the parent drug were below the therapeutic range. In-vitro binding studies showed that the affinity of binding to the cerebral benzodiazepine receptor of glucuronidated alpha-hydroxymidazolam was only about ten times weaker (affinity constant 16 nmol/L) than that of midazolam (1 . 4 nmol/L) or unconjugated alpha-hydroxymidazolam (2 . 2 nmol/L). Conjugated metabolites of midazolam have substantial pharmacological activity. Physicians should be aware that these metabolites can accumulate in patients with renal failure.	UNIV BASEL HOSP,DEPT INTERNAL MED,DIV CLIN PHARMACOL,CH-4031 BASEL,SWITZERLAND; UNIV BASEL HOSP,DEPT INTERNAL MED,DIV INTENS CARE,CH-4031 BASEL,SWITZERLAND; UNIV BASEL HOSP,DEPT NEUROL,CH-4031 BASEL,SWITZERLAND; UNIV ZURICH HOSP,CARDIOVASC THERAPY RES UNIT,CH-8091 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	University of Basel; University of Basel; University of Basel; University of Zurich; University Zurich Hospital; Roche Holding			Haefeli, Walter Emil/AAJ-3024-2020	Haefeli, Walter Emil/0000-0003-0672-6876				BYATT CM, 1984, BRIT MED J, V289, P799, DOI 10.1136/bmj.289.6448.799; DREISSEN JJ, 1991, ACTA ANAESTH BELG, V42, P149; HA HR, 1993, THER DRUG MONIT, V15, P338, DOI 10.1097/00007691-199308000-00013; HAND CW, 1987, LANCET, V2, P1207; HEISMANN P, 1983, BR J CLIN PHARM, V16, pS43; KROEMER HK, 1992, CLIN PHARMACOKINET, V23, P292, DOI 10.2165/00003088-199223040-00005; MOHLER H, 1981, NATURE, V294, P763, DOI 10.1038/294763a0; MOHLER H, 1981, J NEUROCHEM, V37, P714; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; OSBORNE R, 1988, LANCET, V1, P828; PERSSON MP, 1988, CLIN PHARMACOL THER, V43, P324; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SCOLLOLAVIZZARI G, 1987, EUR NEUROL, V26, P161, DOI 10.1159/000116329	14	207	224	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					145	147		10.1016/S0140-6736(95)91209-6	http://dx.doi.org/10.1016/S0140-6736(95)91209-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603229				2022-12-01	WOS:A1995RJ03100009
J	BUCHWALD, D; UMALI, P; UMALI, J; KITH, P; PEARLMAN, T; KOMAROFF, AL				BUCHWALD, D; UMALI, P; UMALI, J; KITH, P; PEARLMAN, T; KOMAROFF, AL			CHRONIC FATIGUE AND THE CHRONIC-FATIGUE-SYNDROME - PREVALENCE IN A PACIFIC-NORTHWEST HEALTH-CARE SYSTEM	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE; FATIGUE SYNDROME, CHRONIC; HEALTH STATUS INDICATORS; LYMPHADENITIS; PSYCHOPHYSIOLOGICAL DISORDERS	GENERAL-PRACTICE; FOLLOW-UP; SYMPTOMS; EPIDEMIOLOGY; DEFINITION; POPULATION	Objectives: To investigate the point prevalence of the chronic fatigue syndrome and unexplained debilitating chronic fatigue in a community-based sample of persons and to describe demographic, clinical, and psychosocial differences among those with the chronic fatigue syndrome, those with chronic fatigue, and healthy controls. Design: Prospective cohort study. Setting: A health maintenance organization in Seattle, Washington. Participants: A random sample of 4000 members of the health maintenance organization was surveyed by mail for the presence of chronic fatigue. Measurements: Persons with chronic fatigue were evaluated using a questionnaire that requested information about medical history and fatigue and related symptoms; validated measures of functional status and psychological distress; a physical examination; and standardized blood tests. A structured psychiatric interview was done in persons who appeared to meet the original Centers for Disease Control and Prevention (CDC) criteria for the chronic fatigue syndrome. Participants completed self-report measures at 12 and 24 months. Those with chronic fatigue were reevaluated in person 1 year after study enrollment. Results. 3066 (77%) of the 4000 members surveyed responded. Chronic fatigue was reported by 590 persons (19%). Of these, 388 (66%) had a medical or psychiatric condition that could account for the fatigue. Of the 74 persons (37%) with chronic fatigue who were enrolled in the study, only 3 met the CDC criteria for the chronic fatigue syndrome. The remaining 71 persons were designated as having chronic fatigue alone. Seventy-four healthy, age- and sex-matched controls who were drawn from the same sample but who denied having chronic fatigue were also studied. Demographic characteristics were similar in persons with the chronic fatigue syndrome, persons with chronic fatigue atone, and controls. Those with the chronic fatigue syndrome or chronic fatigue alone had more frequent cervical and axillary adenopathy, poorer functional status, and greater psychological distress than controls. Women and minorities were not overrepresented among cases with chronic fatigue. Conclusions: Using different assumptions about the likelihood that persons who did not participate in the study had the chronic fatigue syndrome, the estimated crude point prevalence of the syndrome in this community ranged from 75 to 267 cases per 100 000 persons. The point prevalence of chronic fatigue alone was strikingly higher; it ranged from 1775 to 6321 cases per 100 000 persons.	HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BUCHWALD, D (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR, 325 9TH AVE ZA-60, SEATTLE, WA 98104 USA.				NIAID NIH HHS [R01 AI27314, R01 AI26788, UO1 AI32246] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026788, U01AI032246, R01AI027314] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHEN MK, 1986, PREV MED, V15, P74, DOI 10.1016/0091-7435(86)90037-X; CLARK MR, 1995, AM J MED, V98, P187, DOI 10.1016/S0002-9343(99)80403-3; Cox B.D., 1987, HLTH LIFESTYLE SURVE; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; GUNN WJ, 1993, CIBA F SYMP, V173, P83; HAMMOND EC, 1964, AM J PUBLIC HEALTH N, V54, P11, DOI 10.2105/AJPH.54.1.11; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOYEN DO, 1991, BRIT J GEN PRACT, V41, P324; HOYEN DO, 1988, SCOT MED J, V33, P368, DOI 10.1177/003693308803300607; JERRETT WA, 1981, PRACTITIONER, V225, P731; KELLNER R, 1973, AM J PSYCHIAT, V130, P102, DOI 10.1176/ajp.130.1.102; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MATTHEWS DA, 1990, CLIN RES, V38, pA699; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; MORRISON JD, 1980, J FAM PRACTICE, V10, P795; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PRICE RK, 1992, PUBLIC HEALTH REP, V107, P514; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; Robins L.N., 1985, DIAGNOSTIC INTERVIEW; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARNOPOLSKY A, 1980, PSYCHOL MED, V10, P683, DOI 10.1017/S0033291700054982; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; 1987, DIAGNOSTIC STATISTIC	34	173	177	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					81	88		10.7326/0003-4819-123-2-199507150-00001	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM435	7778839				2022-12-01	WOS:A1995RM43500001
J	COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; SHORVON, SD				COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; SHORVON, SD			REMISSION OF EPILEPSY - RESULTS FROM THE NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY	LANCET			English	Article							1ST SEIZURE; PROGNOSIS; POPULATION; ROCHESTER; MINNESOTA; NGPSE	Remission of seizures is a crucial measure of outcome in epilepsy. The National General Practice Study of Epilepsy (NGPSE) aimed to investigate the remission of patients with epilepsy and the effect of various factors on the likelihood of remission. The NGPSE is a prospective population-based study free from major selection bias. We enrolled 1091 patients with newly diagnosed or suspected epilepsy who attended one of 275 general practices throughout the UK between 1984 and 1987, Remission was analysed in those patients who were classified after 6 months as having definite epilepsy (n=564) or possible epilepsy (n=228). After 9 years from the index seizure, 86% (95% CI 81-90) of patients with definite epilepsy had achieved a remission of 3 years and 68% (61-75) a remission of 5 years. For the complete cohort, including those with possible epilepsy, the remission rates at 9 years were 87% (83-91) for 3-year remission and 71% (65-77) for 5-year remission. The proportion of patients with definite epilepsy who were still in remission at 9 years' follow-up (terminal remission) was 68% (62-74) for 3-year and 54% (48-60) for 5-year remission. 61% (56-68) of patients with idiopathic seizures and 61% (46-75) of those with remote symptomatic epilepsy had achieved 5-year remission by 9 years. Overall, age and seizure type had little effect on the chances of achieving remission, This study confirms the good outcome for seizure control in the majority of patients.	CHALFONT CTR EPILEPSY, CHALFONT ST PETER, BUCKS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	MRC Biostatistics Unit; University of Cambridge	COCKERELL, OC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Shorvon, Simon D/A-2019-2009; Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; BEGHI E, 1992, EPILEPSIA, V33, P45; CHADWICK D, 1991, LANCET, V337, P1175; CHADWICK D, 1993, BRIT MED J, V306, P1374; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; CROMBIE DL, 1960, BRIT MED J, V2, P416; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; JANZ D, 1990, COMPREHENSIVE EPILEP, P171; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANFORD M, 1992, NEUROLOGY, V42, P1911; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; RODIN EA, 1968, PROGNOSIS PATIENTS E; SANDER JWAS, 1993, LANCET, V342, P874, DOI 10.1016/0140-6736(93)92737-E; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267	23	290	294	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					140	144		10.1016/S0140-6736(95)91208-8	http://dx.doi.org/10.1016/S0140-6736(95)91208-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603228				2022-12-01	WOS:A1995RJ03100008
J	DALE, DC				DALE, DC			WHERE NOW FOR COLONY-STIMULATING FACTORS	LANCET			English	Editorial Material							GRANULOCYTE; NEUTROPENIA				DALE, DC (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.							BENSINGER WI, 1993, BLOOD, V81, P1883, DOI 10.1182/blood.V81.7.1883.1883; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; DALE DC, 1993, BLOOD, V81, P2496; DALE DC, 1995, STEM CELLS, V13, P94, DOI 10.1002/stem.5530130201; Demirer T, 1995, Curr Opin Hematol, V2, P219; ESCHBACH JW, 1994, KIDNEY INT, V45, pS70; Jones E A, 1993, JAMA, V270, P1132, DOI 10.1001/jama.270.9.1132; Kaushansky K, 1995, Curr Opin Hematol, V2, P172; KUHNS DB, 1995, J INFECT DIS, V171, P145, DOI 10.1093/infdis/171.1.145; NELSON S, 1994, CLIN INFECT DIS, V18, pS197, DOI 10.1093/clinids/18.Supplement_2.S197; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; TO LB, 1994, BLOOD, V84, P2930; WELTE K, 1990, BLOOD, V75, P1056	13	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					135	136		10.1016/S0140-6736(95)91206-1	http://dx.doi.org/10.1016/S0140-6736(95)91206-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7541497				2022-12-01	WOS:A1995RJ03100006
J	FLAHAULT, A; GARNERIN, P; CHAUVIN, P; FARRAN, N; SAIDI, Y; DIAZ, C; TOUBIANA, L; DRUCKER, J; VALLERON, AJ				FLAHAULT, A; GARNERIN, P; CHAUVIN, P; FARRAN, N; SAIDI, Y; DIAZ, C; TOUBIANA, L; DRUCKER, J; VALLERON, AJ			SENTINELLE TRACES OF AN EPIDEMIC OF ACUTE GASTROENTERITIS IN FRANCE	LANCET			English	Article									HOP NATL ST MAURICE,RESEAU NATL SANTE PUBL,F-75571 PARIS 12,FRANCE		FLAHAULT, A (corresponding author), INSERM,U263,F-75571 PARIS 12,FRANCE.		Chauvin, Pierre/S-2981-2019; Toubiana, Laurent/L-6840-2017; Chauvin, Pierre/G-1095-2015	Chauvin, Pierre/0000-0002-9183-6406; Toubiana, Laurent/0000-0002-1849-9829; Chauvin, Pierre/0000-0002-9183-6406				COSTAGLIOLA D, 1994, EUR J EPIDEMIOL, V10, P475, DOI 10.1007/BF01719680; Valleron A.-J., 1992, Morbidity and Mortality Weekly Report, V41, P101	2	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					162	163		10.1016/S0140-6736(95)91214-2	http://dx.doi.org/10.1016/S0140-6736(95)91214-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603234				2022-12-01	WOS:A1995RJ03100014
J	FOREYT, J; GOODRICK, K				FOREYT, J; GOODRICK, K			THE ULTIMATE TRIUMPH OF OBESITY	LANCET			English	Editorial Material											FOREYT, J (corresponding author), BAYLOR COLL MED,DEPT MED,NUTR RES CLIN,HOUSTON,TX 77030, USA.							BENNETT WI, 1995, NEW ENGL J MED, V332, P673, DOI 10.1056/NEJM199503093321009; Foreyt J P, 1994, Obes Res, V2, P378; FOREYT JP, 1994, LIVING DIETING; KIRSCHENBAUM DS, 1995, BEHAV THER, V26, P43, DOI 10.1016/S0005-7894(05)80082-6; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LISSNER L, 1994, PHARMACOECONOMICS, V5, P8, DOI 10.2165/00019053-199400051-00004; Logue A. W., 2014, PSYCHOL EATING DRINK; POWELL KE, 1994, MED SCI SPORT EXER, V26, P851; RESNICOW K, 1993, ANN NY ACAD SCI, V699, P154, DOI 10.1111/j.1749-6632.1993.tb18847.x; Seligman, 1994, WHAT YOU CAN CHANGE; THOMAS PR, 1995, WEIGHTING OPTIONS CR; VANITALLIE TB, 1994, PHARMACOECONOMICS, V5, P1, DOI 10.2165/00019053-199400051-00003; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007; 1994, MMWR-MORBID MORTAL W, V43, P116; 1994, SHAPE UP AM EXECUTIV	16	58	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					134	135		10.1016/S0140-6736(95)91205-3	http://dx.doi.org/10.1016/S0140-6736(95)91205-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603226				2022-12-01	WOS:A1995RJ03100005
J	LEAN, MEJ; HAN, TS; MORRISON, CE				LEAN, MEJ; HAN, TS; MORRISON, CE			WAIST CIRCUMFERENCE AS A MEASURE FOR INDICATING NEED FOR WEIGHT MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							BODY-FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; OBESE WOMEN; ADIPOSE-TISSUE; RISK-FACTORS; FOLLOW; PARTICIPANTS; CHOLESTEROL; OVERWEIGHT; REDUCTION	Objective-To test the hypothesis that a single measurement, waist circumference, might be used to identify people at health risk both from being overweight and from having a central fat distribution. Design-A community derived random sample of men and women and a second, validation sample. Setting-North Glasgow. Subjects-904 men and 1014 women (first sample); 86 men and 202 women (validation sample). Main outcome measures-Waist circumference, body mass index, waist:hip ratio. Results-Waist circumference greater than or equal to 94 cm for men and greater than or equal to 80 cm for women identified subjects with high body mass index (greater than or equal to 25 kg/m(2)) and those with lower body mass index but high waist:hip ratio (greater than or equal to 0.95 for men, greater than or equal to 0.80 women) with a sensitivity of > 96% and specificity > 97.5%. Waist circumference greater than or equal to 102 cm for men or greater than or equal to 88 cm for women identified subjects with body mass index greater than or equal to 30 and those with lower body mass index but high waist:hip ratio with a sensitivity of > 96% and specificity > 98%, with only about 2% of the sample being misclassified. Conclusions-Waist circumference could be used in health promotion programmes to identify individuals who should seek and be offered weight management. Men with waist circumference greater than or equal to 94 cm and women with waist circumference greater than or equal to 80 cm should gain no further weight; men with waist circumference greater than or equal to 102 cm and women with waist circumference greater than or equal to 88 cm should reduce their weight.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND	University of Glasgow	LEAN, MEJ (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT HUMAN NUTR,GLASGOW G31 2ER,LANARK,SCOTLAND.			Han, Thang/0000-0003-2570-0938				Bennett N, 1995, HLTH SURVEY ENGLAND; BJORNTORP P, 1987, AM J CLIN NUTR, V45, P1120, DOI 10.1093/ajcn/45.5.1120; CASIMIRRI F, 1989, ANN NUTR METAB, V33, P79, DOI 10.1159/000177524; CHAN JM, 1994, DIABETES CARE, V9, P961; DENBESTEN C, 1988, AM J CLIN NUTR, V47, P840, DOI 10.1093/ajcn/47.5.840; DENNIS KE, 1993, ARTERIOSCLER THROMB, V13, P1487, DOI 10.1161/01.ATV.13.10.1487; FLODMARK CE, 1994, ACTA PAEDIATR, V83, P941, DOI 10.1111/j.1651-2227.1994.tb13177.x; Gregory F., 1990, DIETARY NUTR SURVEY; HANSON P, 1988, RESOURCE MANUAL GUID; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HOUMARD JA, 1994, INT J OBESITY, V18, P243; KANALEY JA, 1993, AM J CLIN NUTR, V57, P20, DOI 10.1093/ajcn/57.1.20; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NORUSIS MJ, 1993, BASE SYSTEM USERS GU; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; SEIDELL JC, 1989, INFUSIONSTHERAPIE, V16, P276; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SONNICHSEN AC, 1992, METABOLISM, V41, P1035, DOI 10.1016/0026-0495(92)90134-V; VANDERKOOY K, 1993, AM J CLIN NUTR, V58, P853, DOI 10.1093/ajcn/58.6.853; VANGAAL LF, 1990, BODY FAT DISTRIBUTIO; WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086; YUDKIN JS, 1993, BMJ-BRIT MED J, V306, P1313, DOI 10.1136/bmj.306.6888.1313; 1992, SCOTLANDS HLTH CHALL; 1989, WHO UD EURICPNUT125; 1991, OBESITY OVERWEIGHT; 1994, NUTRITIONAL ASPECTS; 1991, CM1583	31	1077	1136	0	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					158	161		10.1136/bmj.311.6998.158	http://dx.doi.org/10.1136/bmj.311.6998.158			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613427	Green Published			2022-12-01	WOS:A1995RK15900021
J	MATSUMOTO, A; OGURA, K; HIRATA, Y; KAKOKI, M; WATANABE, F; TAKENAKA, K; SHIRATORI, Y; MOMOMURA, S; OMATA, M				MATSUMOTO, A; OGURA, K; HIRATA, Y; KAKOKI, M; WATANABE, F; TAKENAKA, K; SHIRATORI, Y; MOMOMURA, S; OMATA, M			INCREASED NITRIC-OXIDE IN THE EXHALED AIR OF PATIENTS WITH DECOMPENSATED LIVER-CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							SYNTHASE; EXPRESSION; ENDOTOXIN; CYTOKINES; CELLS; RATS	Objective: To determine if nitric oxide output in exhaled air is increased in patients with liver cirrhosis. Design: Cross-sectional study. Setting: A university hospital. Patients: 50 patients with liver cirrhosis, 6 patients with chronic hepatitis, and 15 healthy controls. Measurements: Nitric oxide in exhaled air was measured using a chemiluminescence analyzer. Cardiac index was determined using echocardiography. Results: Patients with decompensated liver cirrhosis had higher levels of exhaled nitric oxide output (Child C patients, 190 +/- 11 nL/min per m(2) body surface area) than controls (97 +/- 8 nL/min per m(2) body surface area; P < 0.001), whereas patients with compensated liver cirrhosis or chronic hepatitis had levels of nitric oxide output similar to those found in controls. Cardiac index was greater in patients with liver cirrhosis (Child C patients, 4.3 +/- 0.3 L/min per m(2) body surface area) than in controls (2.9 +/- 0.2 L/min per m(2) body surface area; P < 0.001). Cardiac index correlated with nitric oxide levels (r = 0.621; P < 0.001). Conclusions: Increased nitric oxide output in exhaled air is associated with systemic circulatory disturbances in patients with liver cirrhosis.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GUARNER C, 1993, HEPATOLOGY, V18, P1139; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1002/hep.1840130211; LEE FY, 1992, HEPATOLOGY, V16, P1043, DOI 10.1002/hep.1840160430; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; MATSUMOTO A, 1994, LANCET, V343, P849, DOI 10.1016/S0140-6736(94)92047-8; MIDGLEY S, 1991, LANCET, V338, P1590, DOI 10.1016/0140-6736(91)92407-S; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROLLA G, 1994, NEW ENGL J MED, V331, P1098, DOI 10.1056/NEJM199410203311617; SPITZER JA, 1994, HEPATOLOGY, V19, P217, DOI 10.1016/0270-9139(94)90074-4; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7	21	99	103	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					110	113		10.7326/0003-4819-123-2-199507150-00005	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778822				2022-12-01	WOS:A1995RM43500005
J	PHILLIPS, S; DONALDSON, L; GEISLER, K; PERA, A; KOCHAR, R				PHILLIPS, S; DONALDSON, L; GEISLER, K; PERA, A; KOCHAR, R			STOOL COMPOSITION IN FACTITIAL DIARRHEA - A 6-YEAR EXPERIENCE WITH STOOL ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						FACTITIOUS DISORDERS; DIARRHEA; FECES; BODY WATER; CATHARTICS	LAXATIVE ABUSE; OSMOTIC GAP; MALABSORPTION; PREVALENCE	Objective: To evaluate the utility of stool water analysis in the management of patients with chronic diarrhea. Design: Retrospective analysis of 6 years of experience. Setting: A specialized laboratory in a major referral center, Patients: 325 patients with diarrhea who were referred for stool chemistry analysis. Fecal analysis was requested by many internists and gastroenterologists. Patient records were reviewed to establish the final and most likely cause of diarrhea. Results: One third of patients provided samples that were inappropriate for analysis, but data from 202 persons were available, The usefulness of the general separation of cases of chronic diarrhea into those in which patients had predominantly osmotic pathophysiologies and those in which patients had predominantly secretory pathophysiologies was confirmed, but overlap and intra-individual variability limited the usefulness of this approach in individual patients. Thirty-five patients (17%) had a diagnosis of factitial diarrhea (30 because of laxative use and 5 because of fluid added to stools). Conclusions: Among selected subpopulations, the chemical analysis of fresh stools has a role in the evaluation of obscure examples of chronic diarrhea. It is especially useful in identifying factitial diarrhea.			PHILLIPS, S (corresponding author), MAYO CLIN & MAYO FDN, GASTROENTEROL RES UNIT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BINDER HJ, 1992, GASTROENTEROLOGY, V103, P702, DOI 10.1016/0016-5085(92)90870-5; BYTZER P, 1990, SCAND J GASTROENTERO, V25, P572, DOI 10.3109/00365529009095532; BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; DALY JA, 1972, CLIN CHEM, V18, P263; DEWOLFF FA, 1983, HUM TOXICOL, V2, P385, DOI 10.1177/096032718300200235; EARNEST DL, 1993, GASTROINTESTINAL DIS, P1563; EHERER AJ, 1992, GASTROENTEROLOGY, V103, P545, DOI 10.1016/0016-5085(92)90845-P; FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; FINE KD, 1991, NEW ENGL J MED, V324, P1012, DOI 10.1056/NEJM199104113241502; FINE KD, 1993, GASTROINTESTINAL DIS, P1043; GALATOLA G, 1992, EUR J GASTROEN HEPAT, V4, P533; Grindler E., 1971, CLIN CHEM, V17, P662; HAMMER HF, 1990, J CLIN INVEST, V86, P1936, DOI 10.1172/JCI114927; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; HARVEY RF, 1983, LANCET, V1, P632; KACERE RD, 1993, MAYO CLIN PROC, V68, P355, DOI 10.1016/S0025-6196(12)60130-X; KASPI T, 1978, LANCET, V1, P1162; LADEFOGED K, 1987, SCAND J GASTROENTERO, V22, P813, DOI 10.3109/00365528708991920; MORRISON G, 1987, CLIN DISORDERS FLUID; PHILLIPS SF, 1972, GASTROENTEROLOGY, V63, P495; TALLEY NJ, 1989, ANN INTERN MED, V111, P671, DOI 10.7326/0003-4819-111-8-671; VALENTZAS CG, 1971, JAMA-J AM MED ASSOC, V217, P966	22	29	30	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					97	100		10.7326/0003-4819-123-2-199507150-00003	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778841				2022-12-01	WOS:A1995RM43500003
J	ROSENBERG, J				ROSENBERG, J			METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS (MRSA) IN THE COMMUNITY - WHOS WATCHING	LANCET			English	Editorial Material							MICROBIOLOGY; INFECTIONS				ROSENBERG, J (corresponding author), CALIF DEPT HLTH SERV,DIV COMMUNICABLE DIS CONTROL,INFECT CONTROL PROGRAM,BERKELEY,CA 94704, USA.							BERMAN DS, 1994, NEW ENGL J MED, V330, P1247; DECKER MD, 1992, HOSP INFECT, P221; EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; LINNEMANN CC, 1991, AM J MED, V91, pS238, DOI 10.1016/0002-9343(91)90375-8; MCGOWAN JE, 1995, INFECT CONT HOSP EP, V16, P67, DOI 10.1086/647058; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NETTLEMAN MD, 1991, AM J MED S3B, V1, pS228; SARAVOLATZ LD, 1982, ANN INTERN MED, V97, P325, DOI 10.7326/0003-4819-97-3-325; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	12	54	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					132	133		10.1016/S0140-6736(95)91203-7	http://dx.doi.org/10.1016/S0140-6736(95)91203-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603224				2022-12-01	WOS:A1995RJ03100002
J	TEDDER, RS; ZUCKERMAN, MA; GOLDSTONE, AH; HAWKINS, AE; FIELDING, A; BRIGGS, EM; IRWIN, D; BLAIR, S; GORMAN, AM; PATTERSON, KG; LINCH, DC; HEPTONSTALL, J; BRINK, NS				TEDDER, RS; ZUCKERMAN, MA; GOLDSTONE, AH; HAWKINS, AE; FIELDING, A; BRIGGS, EM; IRWIN, D; BLAIR, S; GORMAN, AM; PATTERSON, KG; LINCH, DC; HEPTONSTALL, J; BRINK, NS			HEPATITIS-B TRANSMISSION FROM CONTAMINATED CRYOPRESERVATION TANK	LANCET			English	Article								Over a 25-month period, six multiply transfused patients undergoing cytotoxic treatment for haematological or other malignant disorders developed icteric acute hepatitis B virus (HBV) infection. Bone marrow or peripheral-blood stem cells had been harvested from all six patients and stored in the same cryopreservation tank for possible future transplantation. Human DNA, HBsAg, and HBV DNA with sequences identical to those from four patients with related infections were subsequently found in the liquid nitrogen. Leakage of the cryopreservation bags used to store bone marrow harvested from the first patient when acutely infected with HBV led to contamination of the tank and its contents with HBV and subsequent transmission to patients after transplantation. This incident emphasises the continuing need to screen donors of tissue to be cryopreserved for bloodborne virus infections. It also reinforces the requirement for primary containers used to cryopreserve human tissue to be sealed in a way which prevents exchange of material between the specimen and the liquid nitrogen.	UCL HOSP, DEPT HAEMATOL, LONDON, ENGLAND; ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; NE THAMES REG TRANSFUS CTR, BRENTWOOD, ESSEX, ENGLAND; PUBL HLTH LAB SERV, LONDON, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; Public Health England	TEDDER, RS (corresponding author), UCL, SCH MED, DIV VIROL, WINDEYER BLDG, 46 CLEVELAND ST, LONDON W1P 6DB, ENGLAND.			Tedder, Richard/0000-0002-9672-5721				ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; HAWKINS AE, 1994, J MED VIROL, V44, P13, DOI 10.1002/jmv.1890440105; KOIKE K, 1992, UNPUB PCR CLIN DIAGN; TEDDER RS, 1980, J MED VIROL, V6, P323, DOI 10.1002/jmv.1890060407; VOAK D, 1994, TRANSFUSION MED, V4, P165; ZUCKERMAN MA, 1994, OCT MO LBIOL HEP B V	6	327	338	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					137	140		10.1016/S0140-6736(95)91207-X	http://dx.doi.org/10.1016/S0140-6736(95)91207-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603227				2022-12-01	WOS:A1995RJ03100007
J	VALLANCE, P; PATTON, S; BHAGAT, K; MACALLISTER, R; RADOMSKI, M; MONCADA, S; MALINSKI, T				VALLANCE, P; PATTON, S; BHAGAT, K; MACALLISTER, R; RADOMSKI, M; MONCADA, S; MALINSKI, T			DIRECT MEASUREMENT OF NITRIC-OXIDE IN HUMAN-BEINGS	LANCET			English	Note							HUMAN VEINS INVIVO; ENDOTHELIUM; ACETYLCHOLINE; RELEASE	Nitric oxide is a short-lived radical involved in various biological processes. We have used an electrochemical microsensor to detect nitric oxide signals in blood vessels of healthy volunteers. The sensor was inserted into a hand vein, and the vessel was stimulated with acetylcholine or bradykinin. Dose-dependent signals were detected and were attenuated by an inhibitor of nitric oxide synthase. The results provide further evidence that endothelium-derived relaxing factor is nitric oxide and demonstrate a method for monitoring the L-arginjne/nitric-oxide pathway in human beings.	OAKLAND UNIV, DEPT PHARMACOL, ROCHESTER, MI 48309 USA; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PHARMACOL & CLIN PHARMACOL, LONDON SW17 0RE, ENGLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND	Oakland University; St Georges University London; GlaxoSmithKline; Wellcome Research Laboratories			Radomski, Marek W/C-5195-2014					COLLIER J, 1990, CLIN SCI, V78, P101, DOI 10.1042/cs0780101; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; KIECHLE FL, 1993, AM J CLIN PATHOL, V100, P567, DOI 10.1093/ajcp/100.5.567; MALINSKI T, 1994, INT CONGR SER, V1058, P207; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1994, J ROY COLL PHYS LOND, V28, P209; VALLANCE P, 1989, LANCET, V2, P997	9	131	137	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 15	1995	346	8968					153	154		10.1016/S0140-6736(95)91211-8	http://dx.doi.org/10.1016/S0140-6736(95)91211-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603231				2022-12-01	WOS:A1995RJ03100011
J	WILCOX, CM; SCHWARTZ, DA; CLARK, WS				WILCOX, CM; SCHWARTZ, DA; CLARK, WS			ESOPHAGEAL ULCERATION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - CAUSES, RESPONSE TO THERAPY, AND LONG-TERM OUTCOME	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; AVIUM COMPLEX INFECTION; CYTOMEGALOVIRUS VIREMIA; CD4 COUNT; SURVIVAL; AIDS; TRANSPLANTATION; HYBRIDIZATION; ZIDOVUDINE; SYMPTOMS	Objective: To determine the causes of esophageal ulceration, the response rate to currently available therapies, and the long-term outcome in patients with human immunodeficiency virus (HIV) infection. Design: Prospective cohort study. Setting: An urban county hospital. Patients: Consecutive patients with HIV infection and endoscopically detected esophageal ulceration during a 4-year period, Intervention: Causes of ulcers were determined from clinical, endoscopic, and pathologic findings. Standard medical therapies for the identified causes were instituted, and ulcer healing was endoscopically confirmed when possible. Measurements: Symptomatic and endoscopic response to therapy and long-term outcome, including survival. Results: 100 patients with esophageal ulcer were identified. Ulcers caused by cytomegalovirus alone were the most common (n = 45); idiopathic ulcers were almost as frequent (n = 40). Herpes simplex Virus esophagitis alone was identified as a cause in only 5 patients. Several potential causes of ulcer were found in 5 patients, including Candida esophagitis in 27 patients. Ten patients developed more than one cause of ulceration during long-term follow-up. Eighty-five patients had specific medical therapy for their identified disorders and had an overall response rate of 98%. Median survival from time of diagnosis was 8.9 months (range, 2 days to > 42 months). A difference in median survival was found between patients with cytomegalovirus esophagitis and those with idiopathic esophageal ulcer (7.6 months compared with 13.1 months; P = 0.03). Conclusions: Given I)the broad spectrum of causes of esophageal ulceration, 2) that each of these causes requires specific therapy, and 3) the apparent high response rate, it is important to do endoscopic evaluation with mucosal biopsy in patients with HIV infection so that a diagnosis can be established and appropriate therapy instituted. Despite effective therapy, long-term survival is poor; however, long-term remission and survival may occur in some patients.	EMORY UNIV, SCH MED, ATLANTA, GA USA; EMORY UNIV, SCH PUBL HLTH, ATLANTA, GA USA; GRADY MEM HOSP, ATLANTA, GA USA	Emory University; Emory University								ALEXANDER JA, 1988, DIGEST DIS SCI, V33, P1121, DOI 10.1007/BF01535788; BLANSHARD C, 1992, Q J MED, V85, P813; BONACINI M, 1991, ARCH INTERN MED, V151, P1567, DOI 10.1001/archinte.151.8.1567; CASABONA J, 1993, EUR J CANCER, V29A, P877, DOI 10.1016/S0959-8049(05)80430-7; CLAYTON F, 1989, ARCH PATHOL LAB MED, V113, P1124; CONNOLLY GM, 1989, GUT, V30, P1033, DOI 10.1136/gut.30.8.1033; DEGRUTTOLA V, 1993, J ACQ IMMUN DEF SYND, V6, P359; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; EDWARDS P, 1990, ANN INTERN MED, V112, P65, DOI 10.7326/0003-4819-112-1-65; GERNA G, AIDS, V190, P1027; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; INDORF AS, 1992, ANN INTERN MED, V117, P133, DOI 10.7326/0003-4819-117-2-133; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; KOTLER DP, 1992, J CLIN GASTROENTEROL, V15, P284, DOI 10.1097/00004836-199212000-00004; KUITERT LM, 1991, AIDS, V5, P1036, DOI 10.1097/00002030-199108000-00023; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE DS, 1991, GASTROINTEST ENDOSC, V37, P332, DOI 10.1016/S0016-5107(91)70726-8; MCDONALD GB, 1985, GASTROENTEROLOGY, V88, P1111, DOI 10.1016/S0016-5085(85)80068-8; MILES SA, 1994, J CLIN ONCOL, V12, P1910, DOI 10.1200/JCO.1994.12.9.1910; NELSON MR, 1991, AM J GASTROENTEROL, V86, P876; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; RAGNI MV, 1993, BLOOD, V81, P1889; SALMON D, 1990, J MED VIROL, V32, P160, DOI 10.1002/jmv.1890320306; SCHWARTZ DA, 1992, HUM PATHOL, V23, P1019, DOI 10.1016/0046-8177(92)90263-3; SEGONDY M, 1990, SCAND J INFECT DIS, V22, P653, DOI 10.3109/00365549009027117; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; WILCOX CM, 1995, AM J MED, V98, P169, DOI 10.1016/S0002-9343(99)80400-8; WILCOX CM, 1994, AM J GASTROENTEROL, V89, P2163; WILCOX CM, 1994, GASTROINTEST ENDOSC, V40, P481, DOI 10.1016/S0016-5107(94)70215-2; WILCOX CM, 1993, J CLIN GASTROENTEROL, V16, P251, DOI 10.1097/00004836-199304000-00019; WILCOX CM, 1993, AM J GASTROENTEROL, V88, P1459; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184	34	69	75	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					143	149		10.7326/0003-4819-123-2-199507150-00010	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778827				2022-12-01	WOS:A1995RM43500010
J	ASHAR, HR; FEJZO, MS; TKACHENKO, A; ZHOU, X; FLETCHER, JA; WEREMOWICZ, S; MORTON, CC; CHADA, K				ASHAR, HR; FEJZO, MS; TKACHENKO, A; ZHOU, X; FLETCHER, JA; WEREMOWICZ, S; MORTON, CC; CHADA, K			DISRUPTION OF THE ARCHITECTURAL FACTOR HMGI-C - DNA-BINDING AT HOOK MOTIFS FUSED IN LIPOMAS TO DISTINCT TRANSCRIPTIONAL REGULATORY DOMAINS	CELL			English	Article							PULMONARY CHONDROID HAMARTOMA; NF-KAPPA-B; DIAGNOSTIC RELEVANCE; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; INSULIN GENE; ALL-1 GENE; PROTEINS; TRANSLOCATION; TUMORS	Lipomas are one of the most common mesenchymal neoplasms in humans. They are characterized by consistent cytogenetic aberrations involving chromosome 12 in bands q14-15. Interestingly, this region is also the site of rearrangement for other mesenchymally derived tumors. This study demonstrates that HMGI-C, an architectural factor that functions in transcriptional regulation, has been disrupted by rearrangement at the 12q14-15 chromosomal breakpoint in lipomas. Chimeric transcripts were isolated from two lipomas in which HMGI-C DNA-binding domains (AT hook motifs) are fused to either a LIM or an acidic transactivation domain. These results, identifying a gene rearranged in a benign neoplastic process that does not proceed to a malignancy, suggest a role for HMGI-C in adipogenesis and mesenchyme differentiation.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	ASHAR, HR (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Fejzo, Marlena/0000-0001-6800-687X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030498] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038731] Funding Source: NIH RePORTER; NCI NIH HHS [1K11 CA 01498] Funding Source: Medline; NICHD NIH HHS [HD30498] Funding Source: Medline; NIGMS NIH HHS [GM38731] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIDGE JA, 1995, GENE CHROMOSOME CANC, V12, P70, DOI 10.1002/gcc.2870120113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DALCIN P, 1993, GENE CHROMOSOME CANC, V8, P131; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FEJZO MS, 1995, GENOMICS, V26, P265, DOI 10.1016/0888-7543(95)80210-D; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FLETCHER JA, 1993, GENE CHROMOSOME CANC, V6, P24, DOI 10.1002/gcc.2870060106; FLETCHER JA, 1992, CANCER RES, V52, P6224; FLETCHER JA, 1990, CANCER RES, V50, P4092; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P218; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JENKINS RB, 1989, CYTOGENET CELL GENET, V51, P1019; JUSTICE MJ, 1990, GENETICS, V125, P855; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MacArthur JW, 1944, AM NAT, V78, P142, DOI 10.1086/281181; MANDAHL N, 1993, CANCER, V71, P3009, DOI 10.1002/1097-0142(19930515)71:10<3009::AID-CNCR2820711020>3.0.CO;2-Y; MANDAHL N, 1988, HUM GENET, V79, P203, DOI 10.1007/BF00366238; MANDAHL N, 1989, CANCER, V65, P242; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; NOGUERA R, 1989, VIRCHOWS ARCH A, V415, P377, DOI 10.1007/BF00718640; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROGERS P, 1980, BRIT J NUTR, V43, P83, DOI 10.1079/BJN19800066; ROHEN C, 1993, CANCER GENET CYTOGEN, V69, P68, DOI 10.1016/0165-4608(93)90117-5; ROTHER RP, 1992, BIOTECHNIQUES, V13, P524; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOH Y, 1994, CELL, V75, P609; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SREEKANTAIAH C, 1991, CANCER RES, V51, P422; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANNI R, 1993, CANCER GENET CYTOGEN, V68, P32, DOI 10.1016/0165-4608(93)90070-3; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YUSPA SH, 1989, GENETIC MECHANISMS C, P115	69	395	408	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					57	65						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606786				2022-12-01	WOS:A1995RK42400009
J	BAI, YW; SOSNICK, TR; MAYNE, L; ENGLANDER, SW				BAI, YW; SOSNICK, TR; MAYNE, L; ENGLANDER, SW			PROTEIN-FOLDING INTERMEDIATES - NATIVE-STATE HYDROGEN-EXCHANGE	SCIENCE			English	Article							CYTOCHROME-C; GUANIDINIUM CHLORIDE; FERROCYTOCHROME-C; FREE-ENERGY; HEMOGLOBIN; RESOLUTION; FRAGMENT; COMPLEX; MODEL; CORE	The hydrogen exchange behavior of native cytochrome c in low concentrations of denaturant reveals a sequence of metastable, partially unfolded forms that occupy free energy levels reaching up to the fully unfolded state. The step from one form to another is accomplished by the unfolding of one or more cooperative units of structure. The cooperative units are entire omega loops or mutually stabilizing pairs of whole helices and loops. The partially unfolded forms detected by hydrogen exchange appear to represent the major intermediates in the reversible, dynamic unfolding reactions that occur even at native conditions and thus may define the major pathway for cytochrome c folding.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104	University of Pennsylvania			Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31847, R01 GM031847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI Y, 1994, THESIS U PENNSYLVANI; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; BREMS DN, 1983, J BIOL CHEM, V258, P3655; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P10271; ENGLANDER SW, 1992, SCIENCE, V256, P1684, DOI 10.1126/science.256.5064.1684; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; ENGLANDER SW, 1984, Q REV BIOPHYS, V15, P521; FERSHT AR, 1994, CURR OPIN STRUC BIOL, V4, P67, DOI 10.1016/S0959-440X(94)90061-2; FISHER A, 1992, ARCH BIOCHEM BIOPHYS, V296, P1, DOI 10.1016/0003-9861(92)90538-8; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; JENG MF, 1992, J MOL BIOL, V221, P1045; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9609, DOI 10.1021/bi00088a013; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA Y, 1993, BIOCHEMISTRY-US, V32, P1219, DOI 10.1021/bi00056a004; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LINDERSTROMLANG KU, 1955, CHEM SOC SPEC PUBL, V2, P1; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MAYO SL, 1993, SCIENCE, V262, P873, DOI 10.1126/science.8235609; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; NALL BT, 1986, BIOCHEMISTRY-US, V25, P2974, DOI 10.1021/bi00358a036; Pace C N, 1986, Methods Enzymol, V131, P266; PTITSYN OB, 1975, BIOPHYS CHEM, V3, P1, DOI 10.1016/0301-4622(75)80033-0; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; QIAN H, 1994, BIOCHEMISTRY-US, V33, P8167, DOI 10.1021/bi00193a001; RIDGE JA, 1981, BIOCHEMISTRY-US, V20, P1662; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROSENBERG A, 1968, J BIOL CHEM, V243, P5193; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; Schechter E, 1967, BIOPOLYMERS, V5, P788; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WAND AJ, 1989, BIOCHEMISTRY-US, V28, P186, DOI 10.1021/bi00427a026; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; WOODWARD C, 1993, TRENDS BIOCHEM SCI, V18, P359, DOI 10.1016/0968-0004(93)90086-3; WU LC, 1993, BIOCHEMISTRY-US, V32, P10271, DOI 10.1021/bi00089a050	43	999	1008	2	83	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					192	197		10.1126/science.7618079	http://dx.doi.org/10.1126/science.7618079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618079	Green Accepted			2022-12-01	WOS:A1995RJ02900030
J	BARUCH, DI; PASLOSKE, BL; SINGH, HB; BI, XH; MA, XC; FELDMAN, M; TARASCHI, TF; HOWARD, RJ				BARUCH, DI; PASLOSKE, BL; SINGH, HB; BI, XH; MA, XC; FELDMAN, M; TARASCHI, TF; HOWARD, RJ			CLONING THE PLASMODIUM-FALCIPARUM GENE ENCODING PFEMP1, A MALARIAL VARIANT ANTIGEN AND ADHERENCE RECEPTOR ON THE SURFACE OF PARASITIZED HUMAN ERYTHROCYTES	CELL			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; MEMBRANE; EXPRESSION; PROTEINS; CELLS; CD36; SEQUESTRATION; ASSOCIATION; PHENOTYPES	Plasmodium falciparum-infected human erythrocytes evade host immunity by expression of a cell-surface variant antigen and receptors for adherence to endothelial cells. These properties have been ascribed to P. falciparum erythrocyte membrane protein 1 (PfEMP1), an antigenically diverse malarial protein of 200-350 kDa on the surface of parasitized erythrocytes (PEs). We describe the cloning of two related PfEMP1 genes from the Malayan Camp (MC) parasite strain. Antibodies generated against recombinant protein fragments of the genes were specific for MC strain PfEMP1 protein. These antibodies reacted only with the surface of MC strain PEs and blocked adherence of these cells to CD36 but without effect on adherence to thrombospondin. Multiple forms of the PfEMP1 gene are apparent in MC parasites. The molecular basis for antigenic variation in malaria and adherence of infected erythrocytes to host cells can now be pursued.	AFFYMAX RES INST, SANTA CLARA, CA 95051 USA; JEFFERSON MED COLL, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NIAID NIH HHS [AI 27247] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027247, R22AI027247] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUIAR JC, 1992, AM J TROP MED HYG, V47, P621; ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; [Anonymous], REFORMA MED; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BRANNAN LR, 1994, P ROY SOC B-BIOL SCI, V256, P71, DOI 10.1098/rspb.1994.0051; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; GIBBONS IR, 1991, P NATL ACAD SCI USA, V88, P8563, DOI 10.1073/pnas.88.19.8563; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371, DOI 10.4269/ajtmh.1992.46.371; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOWARD RJ, 1989, BLOOD, V74, P2603; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MENDIS KN, 1988, AM J TROP MED HYG, V38, P42, DOI 10.4269/ajtmh.1988.38.42; MILLER LH, 1969, AM J TROP MED HYG, V18, P860, DOI 10.4269/ajtmh.1969.18.860; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; NAKAMURA KI, 1992, J HISTOCHEM CYTOCHEM, V40, P1419, DOI 10.1177/40.9.1380530; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; PASLOSKE BL, 1993, MOL BIOCHEM PARASIT, V59, P59, DOI 10.1016/0166-6851(93)90007-K; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PATNAIK JK, 1994, AM J TROP MED HYG, V51, P642, DOI 10.4269/ajtmh.1994.51.642; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; VANSCHRAVENDIJK MR, 1993, AM J TROP MED HYG, V49, P552, DOI 10.4269/ajtmh.1993.49.552; VANSCHRAVENDIJK MR, 1991, BLOOD, V78, P226	39	843	853	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					77	87		10.1016/0092-8674(95)90054-3	http://dx.doi.org/10.1016/0092-8674(95)90054-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7541722	Bronze			2022-12-01	WOS:A1995RK42400011
J	CASTANO, AR; TANGRI, S; MILLER, JEW; HOLCOMBE, HR; JACKSON, MR; HUSE, WD; KRONENBERG, M; PETERSON, PA				CASTANO, AR; TANGRI, S; MILLER, JEW; HOLCOMBE, HR; JACKSON, MR; HUSE, WD; KRONENBERG, M; PETERSON, PA			PEPTIDE BINDING AND PRESENTATION BY MOUSE CD1	SCIENCE			English	Article							LYMPHOCYTES-T; MOLECULES; CELLS; RECOGNITION; SPECIFICITY; ANTIGENS; AFFINITY; HLA-DR1; GENES	CD1 molecules are distantly related to the major histocompatibility complex (MHC) class proteins. They are of unknown function. Screening random peptide phage display libraries with soluble empty mouse CD1 (mCD1) identified a peptide binding motif. It consists of three anchor positions occupied by aromatic or bulky hydrophobic amino acids, Equilibrium binding studies demonstrated that mCD1 binds peptides containing the appropriate motif with relatively high affinity. However, in contrast to classical MHC class I molecules, strong binding to mCD1 required relatively long peptides. Peptide-specific, mCD1-restricted T cell responses can be raised, which suggests that the findings are of immunological significance.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; IXSYS, SAN DIEGO, CA 92121 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Castaño, A. Raul/A-5905-2012	Castaño, A. Raul/0000-0003-2107-8862				BALK SP, 1991, J IMMUNOL, V146, P768; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V268, P83; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CASTANO AM, UNPUB; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FANG TAT, 1990, J IMMUNOL, V144, P1744; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HARBOW E, 1988, ANTIBODIES LABORATOR, P336; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; MILLER JA, UNPUB; MULLER R, 1983, METHOD ENZYMOL, V92, P589; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TANGRI S, UNPUB; TEITELL M, UNPUB; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; VANDERIJN M, 1984, HUM IMMUNOL, V9, P201, DOI 10.1016/0198-8859(84)90025-9; WANG CB, IN PRESS	33	223	236	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					223	226		10.1126/science.7542403	http://dx.doi.org/10.1126/science.7542403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542403				2022-12-01	WOS:A1995RJ02900040
J	DENZIN, LK; CRESSWELL, P				DENZIN, LK; CRESSWELL, P			HLA-DM INDUCES CLIP DISSOCIATION FROM MHC CLASS-II ALPHA-BETA DIMERS AND FACILITATES PEPTIDE LOADING	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; DR MOLECULES; CELL LINE; BINDING; COMPLEX; EXPRESSION; TRANSPORT; GENES; COMPARTMENTS	Human leukocyte antigen DM (HLA-DM) molecules are structurally related to classical MHC class II molecules and reside in the lysosome-like compartment where class II-restricted antigen processing is thought to occur. Mutant cell lines lacking HLA-DM are defective in antigen processing and accumulate class II molecules associated with a nested set of invariant chain-derived peptides (class II-associated invariant chain peptides, CLIP). Here we show that HLA-DM catalyzes the dissociation of CLIP from MHC class II-CLIP complexes in vitro and facilitates the binding of antigenic peptides. The reaction has an acidic pH optimum, consistent with its occurrence in a lysosome-like compartment in vivo. Antibody blocking experiments suggest that a transient interaction between HLA-DM and the MHC class II-CLIP complex is required.			DENZIN, LK (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023081, R37AI023081] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23081] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; CEMAN S, 1992, J IMMUNOL, V149, P754; CHERVONSKY AV, 1994, INT IMMUNOL, V6, P1973; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GELUK A, 1992, EUR J IMMUNOL, V22, P107, DOI 10.1002/eji.1830220117; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; NEWCOMB JR, 1993, J IMMUNOL, V151, P499; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RIBERDY JM, 1994, J CELL BIOL, V1125, P1225; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677	39	612	616	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					155	165		10.1016/0092-8674(95)90061-6	http://dx.doi.org/10.1016/0092-8674(95)90061-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606781	Bronze			2022-12-01	WOS:A1995RK42400018
J	DOODY, GM; JUSTEMENT, LB; DELIBRIAS, CC; MATTHEWS, RJ; LIN, JJ; THOMAS, ML; FEARON, DT				DOODY, GM; JUSTEMENT, LB; DELIBRIAS, CC; MATTHEWS, RJ; LIN, JJ; THOMAS, ML; FEARON, DT			A ROLE IN B-CELL ACTIVATION FOR CD22 AND THE PROTEIN-TYROSINE-PHOSPHATASE SHP	SCIENCE			English	Article							ANTIGEN RECEPTOR; ADHESION MOLECULE; MOTH-EATEN; EXPRESSION; CD40; MICE; LYMPHOCYTES; KINASES; DOMAINS; CD19	CD22 is a membrane immunoglobulin (mlg)-associated protein of B cells. CD22 is tyrosine-phosphorylated when mlg is ligated. Tyrosine-phosphorylated CD22 binds and activates SHP, a protein tyrosine phosphatase known to negatively regulate signaling through mlg. Ligation of CD22 to prevent its coaggregation with mlg lowers the threshold at which mlg activates the B cell by a factor of 100. In secondary lymphoid organs, CD22 may be sequestered away from mlg through interactions with counterreceptors on T cells. Thus, CD22 is a molecular switch for SHP that may bias mlg signaling to anatomic sites rich in T cells.	UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,WELLCOME TRUST IMMUNOL UNIT,CAMBRIDGE CB2 2SP,ENGLAND; UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77555; WASHINGTON UNIV,SCH MED,DEPT PATHOL,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	University of Cambridge; University of Texas System; University of Texas Medical Branch Galveston; Howard Hughes Medical Institute; Washington University (WUSTL)			Doody, Gina/AAN-8246-2021	Doody, Gina/0000-0003-0665-6759; Justement, Louis/0000-0001-7058-867X	NIGMS NIH HHS [GM-46524] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046524, R01GM046524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOUE DR, 1988, J IMMUNOL, V140, P192; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ENGEL P, 1993, J IMMUNOL, V150, P4719; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LIN JJ, 1992, J IMMUNOL, V149, P1548; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POWELL LD, 1993, J BIOL CHEM, V268, P7019; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TORRES RM, 1992, J IMMUNOL, V149, P2641; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	32	487	491	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					242	244		10.1126/science.7618087	http://dx.doi.org/10.1126/science.7618087			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618087				2022-12-01	WOS:A1995RJ02900046
J	HALL, CL; YANG, BH; YANG, XW; ZHANG, SW; TURLEY, M; SAMUEL, S; LANGE, LA; WANG, C; CURPEN, GD; SAVANI, RC; GREENBERG, AH; TURLEY, EA				HALL, CL; YANG, BH; YANG, XW; ZHANG, SW; TURLEY, M; SAMUEL, S; LANGE, LA; WANG, C; CURPEN, GD; SAVANI, RC; GREENBERG, AH; TURLEY, EA			OVEREXPRESSION OF THE HYALURONAN RECEPTOR RHAMM IS TRANSFORMING AND IS ALSO REQUIRED FOR H-RAS TRANSFORMATION	CELL			English	Article							CELL-MATRIX INTERACTIONS; DOMINANT NEGATIVE MUTATION; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR; BINDING PROTEINS; CARCINOMA-CELLS; GENE-EXPRESSION; GROWTH	Overexpression of the RHAMM gene by transfection into fibroblasts is transforming and causes spontaneous metastases in the lung. H-ras-transformed fibrosarcomas transfected with a dominant suppressor mutant of RHAMM exhibit a so-called revertant phenotype end are completely nontumorigenic and nonmetastatic. Conversely, fibroblasts stably expressing low levels of RHAMM as a result of antisense transfection are resistant to res transformation. Collectively, these results indicate that RHAMM acts downstream of res. The loss of functional RHAMM ablates signaling within focal adhesions, in particular changes in focal adhesion kinase phosphorylation, and as a result these focal adhesions are unable to turn over in response to hyaluronan. These results provide evidence of the oncogenic potential of a novel extracellular matrix receptor and establish a functional link between transformation by ras and signaling within focal adhesions that are required for transformation by this oncogene.	UNIV MANITOBA, DEPT PEDIAT, WINNIPEG, MB R3E 0V9, CANADA	University of Manitoba	HALL, CL (corresponding author), UNIV MANITOBA, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA.		Rashmin C. Savani, MBChB/AAG-2041-2021	Rashmin C. Savani, MBChB/0000-0002-9533-5422				ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BEHREND EI, 1994, CANCER RES, V54, P832; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BRAND T, 1993, J BIOL CHEM, V268, P11500; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cellbio.4.1.487; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CHONG ASF, 1992, CELL IMMUNOL, V144, P69, DOI 10.1016/0008-8749(92)90226-F; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ENTWISTLE J, 1995, IN PRESS GENE; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FRASER R, 1993, FASEB J, V6, P2397; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HIRO D, 1986, BIOCHEM BIOPH RES CO, V140, P715, DOI 10.1016/0006-291X(86)90790-4; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KARIKO K, 1993, CANCER RES, V53, P3109; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LIEBL EC, 1992, ONCOGENE, V7, P2417; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RATNER S, 1992, INVAS METAST, V12, P82; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TURLEY E, 1987, JNCI-J NATL CANCER I, V78, P787; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1985, CANCER RES, V45, P5098; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; VARNER JA, 1992, MOL BIOL CELL, V3, pA232; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODS A, 1988, COLLAGEN REL RES, V8, P155; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	62	250	266	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					19	28		10.1016/0092-8674(95)90048-9	http://dx.doi.org/10.1016/0092-8674(95)90048-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7541721	Bronze			2022-12-01	WOS:A1995RK42400005
J	JOHNSON, RE; KOVVALI, GK; PRAKASH, L; PRAKASH, S				JOHNSON, RE; KOVVALI, GK; PRAKASH, L; PRAKASH, S			REQUIREMENT OF THE YEAST RTH1 5' TO 3' EXONUCLEASE FOR THE STABILITY OF SIMPLE REPETITIVE DNA	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; INSTABILITY; MUTATIONS; REPLICATION; MECHANISM; PROTEINS; HOMOLOG; HISTORY	Simple repetitive DNA sequences are unstable in human colorectal cancers and a variety of other cancers. Mutations in the DNA mismatch repair genes MSH2, MLH1, and PMS1 result in elevated rates of spontaneous mutation and cause a marked increase in the instability of simple repeats. Compared with the wild type, a null mutation in the yeast RTH1 gene, which encodes a 5' to 3' exonuclease, was shown to increase the rate of instability of simple repetitive DNA by as much as 280 times and to increase the spontaneous mutation rate by 30 times. Epistasis analyses were consistent with the hypothesis that this RTH1-encoded nuclease has a role in the MSH2-MLH1-PMS1 mismatch repair pathway.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NCI NIH HHS [CA 41261] Funding Source: Medline; NIGMS NIH HHS [GM 19261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GLEBOV OK, 1994, CANCER RES, V54, P3703; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HAN HJ, 1993, CANCER RES, V53, P5087; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KIM HG, 1994, AM J PATHOL, V145, P148; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WAGA S, 1994, J BIOL CHEM, V269, P10923; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0	38	172	181	1	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					238	240		10.1126/science.7618086	http://dx.doi.org/10.1126/science.7618086			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618086				2022-12-01	WOS:A1995RJ02900044
J	KNAUS, UG; MORRIS, S; DONG, HJ; CHERNOFF, J; BOKOCH, GM				KNAUS, UG; MORRIS, S; DONG, HJ; CHERNOFF, J; BOKOCH, GM			REGULATION OF HUMAN-LEUKOCYTE P21-ACTIVATED KINASES THROUGH G-PROTEIN-COUPLED RECEPTORS	SCIENCE			English	Article							NEUTROPHIL NADPH OXIDASE; ACTIVATION; PHOSPHORYLATION; GTP; TRANSLOCATION; STIMULATION; REQUIREMENT; COMPONENTS	The Rac guanosine 5'-triphosphate (GTP)-binding proteins regulate oxidant production by phagocytic leukocytes. Two Ste20-related p21-activated kinases (PAKs) were identified as targets of Rac in human neutrophils. Activity of the similar to 65- and similar to 68-kilodalton PAKs was rapidly stimulated by chemoattractants acting through pertussis toxin-sensitive heterotrimeric GTP-binding proteins (G proteins). Native and recombinant PAKs phos phorylated the p47(phox) reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase component in a Rac-GTP-dependent manner. The action of PAKs during phagocyte activation by G protein-coupled pathways may contribute to regulation of NADPH oxidase activity.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Fox Chase Cancer Center	KNAUS, UG (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIAMS NIH HHS [P60 AR40770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, V35, P65; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DING JB, 1993, J BIOL CHEM, V268, P17326; DORSEUIL O, IN PRESS J LEUKOCYTE; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUANG CK, 1988, J BIOL CHEM, V263, P13144; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, UNPUB; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIANG L, 1995, J LEUKOCYTE BIOL, V57, P326, DOI 10.1002/jlb.57.2.326; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NAUSEEF WM, 1990, BLOOD, V76, P2622; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SELLS MA, UNPUB; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; XU XM, 1994, J BIOL CHEM, V269, P23569	31	356	365	1	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					221	223		10.1126/science.7618083	http://dx.doi.org/10.1126/science.7618083			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618083				2022-12-01	WOS:A1995RJ02900039
J	METZ, T; HARRIS, AW; ADAMS, JM				METZ, T; HARRIS, AW; ADAMS, JM			ABSENCE OF P53 ALLOWS DIRECT IMMORTALIZATION OF HEMATOPOIETIC-CELLS BY THE MYC AND RAF ONCOGENES	CELL			English	Article							WILD-TYPE P53; RECOMBINANT MURINE RETROVIRUS; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; GENE AMPLIFICATION; BONE-MARROW; ERB-B; V-RAF; TRANSFORMATION; INVITRO	The p53 tumor suppressor is implicated here as a crucial barrier to unlimited cell proliferation. Its role in transformation of hematopoietic cells was studied by infecting fetal liver cells from wild-type or p53(-/-) mice with oncogenic retroviruses. Transformed colonies arose with a raf and a myc-raf virus. Absence of p53 did not affect their frequency but proved critical for their continued propagation. Colonies of p53(-/-) cells bearing both myc and raf readily yielded continuous cell lines without apparent requirement for genetic alteration. The lines, mainly of erythroid or myelomonocytic origin, were diploid but highly tumorigenic from their inception. These findings imply that p53 loss contributes directly to immortalization and tumorigenesis, probably by abrogating an intrinsic senescence program.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA12421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOND JA, 1994, ONCOGENE, V9, P1885; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; METCALF D, 1984, CLONAL CULTURES HAEM; METZ T, 1994, SEMIN CANCER BIOL, V5, P125; MILLER M, 1990, ONCOGENE, V5, P1125; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RITTLING SR, 1992, ONCOGENE, V7, P935; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; ROVINSKI B, 1988, ONCOGENE, V2, P445; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUKADA T, 1993, ONCOGENE, V8, P3313; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	51	114	115	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					29	36		10.1016/0092-8674(95)90049-7	http://dx.doi.org/10.1016/0092-8674(95)90049-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606782	Bronze			2022-12-01	WOS:A1995RK42400006
J	PERNIS, A; GUPTA, S; GOLLOB, KJ; GARFEIN, E; COFFMAN, RL; SCHINDLER, C; ROTHMAN, P				PERNIS, A; GUPTA, S; GOLLOB, KJ; GARFEIN, E; COFFMAN, RL; SCHINDLER, C; ROTHMAN, P			LACK OF INTERFERON-GAMMA RECEPTOR-BETA CHAIN AND THE PREVENTION OF INTERFERON-GAMMA SIGNALING IN T(H)1 CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; LYMPHOCYTE-T CLONES; IFN-GAMMA; TRANSCRIPTION FACTOR; IMMUNE REGULATION; TH1; PHOSPHORYLATION; ACTIVATION; SUBSETS; ANTIBODIES	The ability of interferon gamma (IFN-gamma) to inhibit the proliferation of type 2 T helper cells (T(H)2), but not that of type 1 (T(H)1) cells, suggests that helper cell subsets might differ in their activation of the IFN-gamma signaling pathway. The IFN-gamma-inducible signal transducing factor (STF-IFN gamma) was activated in murine T(H)2 but not in T(H)1 cell clones, because in the latter the second chain of the IFN-gamma receptor (accessory factor 1 or IFN-gamma R beta) was absent. Thus, T(H)1 cells use receptor modification to prevent the activation of STF-IFN gamma and achieve an IFN-gamma-resistant state.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Columbia University; Columbia University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Gollob, Kenneth J/GPX-8434-2022; Gollob, Kenneth J/C-1341-2008	Gollob, Kenneth J/0000-0003-4184-3867				BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK JR, 1994, J BIOL CHEM, V269, P7013; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.iy.11.040193.000333; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; LEDERER JA, 1994, J IMMUNOL, V152, P77; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERNIS A, UNPUB; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1992, SCIENCE, V258, P1808, DOI 10.1126/science.1281555; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YANG XJ, 1993, J NEUROSCI, V13, P3006	42	265	269	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					245	247		10.1126/science.7618088	http://dx.doi.org/10.1126/science.7618088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618088				2022-12-01	WOS:A1995RJ02900047
J	RAO, Z; HANDFORD, P; MAYHEW, M; KNOTT, V; BROWNLEE, GG; STUART, D				RAO, Z; HANDFORD, P; MAYHEW, M; KNOTT, V; BROWNLEE, GG; STUART, D			THE STRUCTURE OF A CA2+-BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAIN - ITS ROLE IN PROTEIN-PROTEIN INTERACTIONS	CELL			English	Article							HUMAN FACTOR-IX; FACTOR HOMOLOGY REGION; COAGULATION FACTOR-X; FACTOR-LIKE MODULE; EGF-LIKE DOMAINS; CALCIUM-BINDING; CRYSTAL-STRUCTURE; DROSOPHILA-NOTCH; SECONDARY STRUCTURE; MARFAN-SYNDROME	Various diverse extracellular proteins possess Ca2+-binding epidermal growth factor (EGF)-like domains, the function of which remains uncertain. We have determined, at high resolution (1.5 Angstrom), the crystal structure of such a domain, from human clotting factor IX, as a complex with Ca2+. The Ca2+ ligands form a classic pentagonal bipyramid with six ligands contributed by one polypeptide chain and the seventh supplied by a neighboring EGF-like domain. The crystal structure identifies the role of Ca2+ in maintaining the conformation of the N-terminal region of the domain, but more importantly demonstrates that Ca2+ can directly mediate protein-protein contacts. The observed crystal packing of the domains provides a plausible model for the association of multiple tandemly linked EGF-like domains in proteins such as fibrillin-1, Notch, and protein S. This model is consistent with the known functional data and suggests a general biological role for these domains.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford	RAO, Z (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Rao, Zihe/HCH-6944-2022					ACHARYA KR, 1991, J MOL BIOL, V221, P571; ARLAUD GJ, 1989, BEHRING I MITT, V84, P56; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARON M, 1992, PROTEIN SCI, V1, P81; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAY AJ, 1993, BEHRING I MITT, V93, P31; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; RAO Z, 1995, ACTA CRYSTALLOGR D, V51, P402, DOI 10.1107/S0907444994009881; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERH.M, 1994, THESIS U LUND SWEDEN; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1991, BLOOD, V78, P1637; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THIELENS NM, 1990, BIOCHEMISTRY-US, V29, P3570, DOI 10.1021/bi00466a021; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	64	307	314	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					131	141		10.1016/0092-8674(95)90059-4	http://dx.doi.org/10.1016/0092-8674(95)90059-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606779	Bronze			2022-12-01	WOS:A1995RK42400016
J	REINISCH, KM; CHEN, L; VERDINE, GL; LIPSCOMB, WN				REINISCH, KM; CHEN, L; VERDINE, GL; LIPSCOMB, WN			THE CRYSTAL-STRUCTURE OF HAEIII METHYLTRANSFERASE COVALENTLY COMPLEXED TO DNA - AN EXTRAHELICAL CYTOSINE AND REARRANGED BASE-PAIRING	CELL			English	Article							TARGET-RECOGNIZING DOMAINS; MACROMOLECULAR CRYSTALLOGRAPHY; CPG ISLAND; FRAGILE-X; PROTEIN; REFINEMENT; MECHANISM; METHYLATION; BINDING; SITE	Many organisms expand the information content of their genome through enzymatic methylation of cytosine residues. Here we report the 2.8 Angstrom crystal structure of a bacterial DNA (cytosine-5)-methyltransferase (DCMtase), M. HaeIII, bound covalently to DNA. In this complex, the substrate cytosine is extruded from the DNA helix and inserted into the active site of the enzyme, as has been observed for another DCMtase, M. HhaI. The DNA is bound in a cleft between the two domains of the protein and is distorted from the characteristic B-form conformation at its recognition sequence. A comparison of structures shows a variation in the mode of DNA recognition: M. HaeIII differs from M. HhaI in that the remaining bases in its recognition sequence undergo an extensive rearrangement in their pairing. In this process, the bases are unstacked, and a gap 8 Angstrom long opens in the DNA.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University	REINISCH, KM (corresponding author), HARVARD UNIV,GIBBS CHEM LAB,CAMBRIDGE,MA 02138, USA.		chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199	NIGMS NIH HHS [GM 44853, GM06920] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853, R01GM006920, R37GM006920] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BEHRENS B, 1987, EMBO J, V6, P1137, DOI 10.1002/j.1460-2075.1987.tb04869.x; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CUNIASSE P, 1989, BIOCHEMISTRY-US, V28, P2018, DOI 10.1021/bi00431a009; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1985, METHOD ENZYMOL, V115, P359; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P801; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; NICHOLIS RD, 1995, SEMIN DEV BIOL, V3, P139; NOLLING J, 1992, J BACTERIOL, V174, P5719; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REINISCH K, 1995, THESIS HARVARD U CAM; REINISCH KM, 1994, J MOL BIOL, V238, P626, DOI 10.1006/jmbi.1994.1319; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHHUMACHER MA, 1994, SCIENCE, V266, P763; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; VERDINE GL, 1994, CELL, V76, P197, DOI 10.1016/0092-8674(94)90326-3; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG W, 1995, IN PRESS CELL, V82	64	366	370	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					143	153		10.1016/0092-8674(95)90060-8	http://dx.doi.org/10.1016/0092-8674(95)90060-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606780	Bronze			2022-12-01	WOS:A1995RK42400017
J	ROBERGE, JY; BEEBE, X; DANISHEFSKY, SJ				ROBERGE, JY; BEEBE, X; DANISHEFSKY, SJ			A STRATEGY FOR A CONVERGENT SYNTHESIS OF N-LINKED GLYCOPEPTIDES ON A SOLID SUPPORT	SCIENCE			English	Article							OLIGOSACCHARIDES; GLYCOBIOLOGY; GLYCALS; ROUTE	Oligosaccharides and glycopeptides are of considerable importance in molecular biology and pharmacology. However, their synthesis is complicated by the large number of different linking sites between each saccharide unit, the need for stereochemical control, the chemical sensitivity of the glycopeptide bonds, and the need to harmonize diverse protecting groups. Here, an efficient solid-phase synthesis of three N-linked glycopeptides based on glycal assembly is presented. The peptide domain can be extended while the ensemble remains bound to the polymer. The glycopeptides synthesized here are among the largest M-linked glycopeptides ever accessed by either solution- or solid-phase synthesis.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University	ROBERGE, JY (corresponding author), SLOAN KETTERING INST CANC RES,BIOORGAN CHEM LAB,1275 YORK AVE,BOX 106,NEW YORK,NY 10021, USA.		Roberge, Jacques Y./B-2412-2013	Roberge, Jacques Y./0000-0002-7810-4139	NCI NIH HHS [T32 CA62948] Funding Source: Medline; NIAID NIH HHS [AI 16943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA062948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANISFELD ST, 1990, J ORG CHEM, V55, P5560, DOI 10.1021/jo00308a009; BAHL OP, 1992, GLYCOCONJUGATES COMP, P1; BERKOWITZ DB, 1992, J AM CHEM SOC, V114, P4518, DOI 10.1021/ja00038a011; BLACKBURN GM, 1990, NUCLEIC ACIDS CHEM B; BRAY AM, 1994, J ORG CHEM, V59, P2197, DOI 10.1021/jo00087a041; COHENANISFELD ST, 1993, J AM CHEM SOC, V115, P10531, DOI 10.1021/ja00076a010; DANISHEFSKY J, IN PRESS GLYCOPEPTID; Danishefsky S.J., 1989, CHEMTRACTS, P273; DANISHEFSKY SJ, 1993, SCIENCE, V260, P1307, DOI 10.1126/science.8493573; DANISHEFSKY SJ, 1995, SCHERING LECTURE SER; DANISHEFSKY SJ, 1994, POLYM PREPR, V35, P977; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; FEIZI T, 1994, CURR OPIN STRUC BIOL, V4, P673, DOI 10.1016/S0959-440X(94)90164-3; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; JONES D A JR, 1977, Tetrahedron Letters, V33, P2853; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KOBATA A, 1993, ACCOUNTS CHEM RES, V26, P319, DOI 10.1021/ar00030a004; KUNZ H, 1992, SYNLETT, P591; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEHRMAN MA, 1993, Patent No. 5272070; LEMIEUX RU, 1964, CAN J CHEM, V42, P1473, DOI 10.1139/v64-222; MATSUURA S, 1976, J CHEM SOC CHEM COMM, P451, DOI 10.1039/c39760000451; MCDONALD FE, 1992, J ORG CHEM, V57, P7001, DOI 10.1021/jo00052a001; McPherson M. J., 1991, PCR PRACTICAL APPROA; MELDAL M, 1994, CURR OPIN STRUC BIOL, V4, P710, DOI 10.1016/S0959-440X(94)90169-4; Meldal Morten, 1994, P145; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; PAULSEN H, 1985, LIEBIGS ANN CHEM, P2028; RANDOLPH JT, 1994, ANGEW CHEM INT EDIT, V33, P1470, DOI 10.1002/anie.199414701; ROBINSON AJ, 1993, TETRAHEDRON, V49, P11329, DOI 10.1016/S0040-4020(01)81815-9; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; UNVERZAGT C, 1993, BIOORGAN MED CHEM, V3, P197; VETTER D, 1995, ANGEW CHEM INT EDIT, V34, P60, DOI 10.1002/anie.199500601; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227	36	84	188	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					202	204		10.1126/science.7618080	http://dx.doi.org/10.1126/science.7618080			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618080				2022-12-01	WOS:A1995RJ02900032
J	SALINAS, F; KODADEK, T				SALINAS, F; KODADEK, T			PHAGE-T4 HOMOLOGOUS STRAND EXCHANGE - A DNA HELICASE, NOT THE STRAND TRANSFERASE, DRIVES POLAR BRANCH MIGRATION	CELL			English	Article							ESCHERICHIA-COLI RECA; PROTEIN-PROTEIN INTERACTIONS; BINDING-PROTEIN; RUVB PROTEINS; BACTERIOPHAGE-T4 UVSX; HOLLIDAY JUNCTIONS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; GENE-32 PROTEINS; PURIFICATION	Homologous strand exchange is a central step in general genetic recombination. A multiprotein complex composed of five purified bacteriophage T4 proteins (the products of the uvsX, uvsY, 32, 41, and 59 genes) that mediates strand exchange under physiologically relevant conditions has been reconstituted. One of these proteins, the product of the uvsY gene, is required for homologous pairing but strongly inhibits branch migration catalyzed by UvsX protein, the phage RecA analog. Branch migration is completely dependent on the gene 41 protein, a DNA helicase that also functions in phage replication. The helicase is delivered to the strand exchange complex by the gene 59 accessory protein in a strand-specific fashion through direct interactions between the gene 59 and gene 32 proteins. These data suggest that strand transferases such as UvsX protein are essential for homologous pairing in vivo, but that a DNA helicase drives polar branch migration.	UNIV TEXAS, INST MOLEC BIOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	SALINAS, F (corresponding author), UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA.				NIGMS NIH HHS [GM-39393] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Challberg M D, 1980, Methods Enzymol, V65, P39; CONKLING MA, 1984, GENETICS, V107, P505; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; FORMOSA T, 1985, THESIS SAN FRANCISCO; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HINTON DM, 1986, J BIOL CHEM, V261, P5663; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JIANG H, 1993, J BIOL CHEM, V268, P7904; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KODADEK T, 1990, BIOCHEM BIOPH RES CO, V172, P804, DOI 10.1016/0006-291X(90)90746-A; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P28; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LIU CC, 1981, J BIOL CHEM, V256, P2813; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Mosig G, 1983, BACTERIOPHAGE, V4, P120; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1994, EXPERIENTIA, V50, P216; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SPICER EK, 1979, J BIOL CHEM, V254, P6433; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, GENETICS, V138, P247; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	63	57	57	2	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					111	119		10.1016/0092-8674(95)90057-8	http://dx.doi.org/10.1016/0092-8674(95)90057-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606776	Bronze			2022-12-01	WOS:A1995RK42400014
J	SHEN, XT; YU, LL; WEIR, JW; GOROVSKY, MA				SHEN, XT; YU, LL; WEIR, JW; GOROVSKY, MA			LINKER HISTONES ARE NOT ESSENTIAL AND AFFECT CHROMATIN CONDENSATION IN-VIVO	CELL			English	Article							TETRAHYMENA-THERMOPHILA; CELL-CYCLE; SEQUENCE; PHOSPHORYLATION; TRANSFORMATION; GENE; H1; HYBRIDIZATION; MICRONUCLEI; MACRONUCLEI	We have (separately) disrupted all of the expressed macronuclear copies of the HHO gene encoding macronuclear histone H1 and of the micronuclear linker histone (MLH) gene encoding the protein MicLH in Tetrahymena thermophila. These disruptions are shown to eliminate completely the expression of each protein. Strains without either linker histone grow at normal rates and reach near-normal cell densities, demonstrating that linker histones are not essential for cell survival. Histone H1 knockout (Delta H1) cells have enlarged DAPI-stained macronuclei and normal-sized micronuclei, while MicLH knockout (Delta MicLH) cells have enlarged micronuclei and normal-sized macronuclei. Delta MicLH cells undergo mitosis normally. However, the micronuclear mitotic chromosome structure is less condensed. These studies provide evidence that linker histones are nonessential and are involved in chromatin packaging and condensation in vivo.			SHEN, XT (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.			Shen, Xuetong/0000-0002-4267-5298	NIGMS NIH HHS [GM26973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALLIS CD, 1984, J CELL BIOL, V99, P1669, DOI 10.1083/jcb.99.5.1669; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHICOINE LG, 1985, DEV BIOL, V109, P1, DOI 10.1016/0012-1606(85)90339-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; ELLIOTT AM, 1963, CELL MITOSIS, P107; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; GARRARD WT, 1991, BIOESSAYS, V13, P87, DOI 10.1002/bies.950130208; GLOVER CVC, 1981, CELL, V23, P73, DOI 10.1016/0092-8674(81)90271-3; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; Gorovsky M.A., 1986, P227; GOROVSKY MA, 1974, J CELL BIOL, V61, P134, DOI 10.1083/jcb.61.1.134; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cb.06.110190.003235; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; IWAMURA Y, 1979, BIOCHEMISTRY-US, V18, P5289, DOI 10.1021/bi00591a004; JOHMANN CA, 1976, J CELL BIOL, V71, P89, DOI 10.1083/jcb.71.1.89; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Maniatis T., 1982, MOL CLONING; Nanney D.L., 1980, EXPT CILIATOLOGY; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Orias E., 1986, P45; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROTH SY, 1991, EMBO J, V10, P2069, DOI 10.1002/j.1460-2075.1991.tb07738.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; SWEET MT, 1993, CHROMOSOMA, V102, P637, DOI 10.1007/BF00352312; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; THOMA F, 1979, J CELL BIOL, V83, P407; TONDRAVI MM, 1986, P NATL ACAD SCI USA, V83, P4369, DOI 10.1073/pnas.83.12.4369; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; Van Holde K.E., 1989, CHROMATIN; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHITE EM, 1988, NUCLEIC ACIDS RES, V16, P179, DOI 10.1093/nar/16.1.179; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU M, 1988, P NATL ACAD SCI USA, V85, P2205, DOI 10.1073/pnas.85.7.2205; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; WU M, 1989, THESIS U ROCHESTER R; YAO MC, 1991, P NATL ACAD SCI USA, V88, P9493, DOI 10.1073/pnas.88.21.9493; ZLATANOVA J, 1992, J CELL SCI, V103, P889	63	247	256	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					47	56		10.1016/0092-8674(95)90051-9	http://dx.doi.org/10.1016/0092-8674(95)90051-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606784	Bronze			2022-12-01	WOS:A1995RK42400008
J	SIBILIA, M; WAGNER, EF				SIBILIA, M; WAGNER, EF			STRAIN-DEPENDENT EPITHELIAL DEFECTS IN MICE LACKING THE EGF RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; EMBRYONIC STEM-CELLS; FACTOR-ALPHA; TGF-ALPHA; MOUSE DEVELOPMENT; NULL MUTATION; SELF-RENEWAL; DIFFERENTIATION; PLACENTA; CULTURE	Mice and cells lacking the epidermal growth factor receptor (EGFR) were generated to examine its physiological role in vivo. Mutant fetuses are retarded in growth and die at mid-gestation in a 129/Sv genetic background, whereas in a 129/Sv x C57BL/6 cross some survive until birth and even to postnatal day 20 in a 129/Sv x C57BL/6 x MF1 background. Death in utero probably results from a defect in the spongiotrophoblast layer of the placenta. Newborn mutant mice have open eyes, rudimentary whiskers, immature lungs, and defects in the epidermis, correlating with the expression pattern of the EGFR as monitored by beta-galactosidase activity, These defects are probably cell-autonomous because chimeric mice generated with EGFR(-/-) embryonic stem cells contribute small amounts of mutant cells to some organs. These results indicate that the EGFR regulates epithelial proliferation and differentiation and that the genetic background influences the resulting phenotype.			SIBILIA, M (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Sibilia, Maria/0000-0001-6129-5613; Wagner, Erwin F/0000-0001-7872-0196				Adamson E D, 1990, Curr Top Dev Biol, V24, P1, DOI 10.1016/S0070-2153(08)60082-4; AVIVI A, 1991, ONCOGENE, V6, P673; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BREIER G, IN PRESS DEV DYNAMIC; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DAS SK, 1994, DEVELOPMENT, V120, P1071; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONDACCI C, 1994, J CLIN INVEST, V93, P1149, DOI 10.1172/JCI117067; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P407; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LESCISIN KR, 1989, GENE DEV, V2, P1639; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; MUNTENER M, 1977, ACTA ANAT, V98, P241; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROSSANT J, 1985, J EMBRYOL EXP MORPH, V86, P177; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIBILIA M, UNPUB; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VONRUDEN T, 1992, BLOOD, V12, P3145; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	41	818	829	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					234	238		10.1126/science.7618085	http://dx.doi.org/10.1126/science.7618085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618085				2022-12-01	WOS:A1995RJ02900043
J	SIELING, PA; CHATTERJEE, D; PORCELLI, SA; PRIGOZY, TI; MAZZACCARO, RJ; SORIANO, T; BLOOM, BR; BRENNER, MB; KRONENBERG, M; BRENNAN, PJ; MODLIN, RL				SIELING, PA; CHATTERJEE, D; PORCELLI, SA; PRIGOZY, TI; MAZZACCARO, RJ; SORIANO, T; BLOOM, BR; BRENNER, MB; KRONENBERG, M; BRENNAN, PJ; MODLIN, RL			CD1-RESTRICTED T-CELL RECOGNITION OF MICROBIAL LIPOGLYCAN ANTIGENS	SCIENCE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; LIPOARABINOMANNAN; GLYCOPEPTIDES; LYMPHOCYTES; CD1B	It has long been the paradigm that T cells recognize peptide antigens presented by major histocompatibility complex (MHC) molecules. However, nonpeptide antigens can be presented to T cells by human CD1b molecules, which are not encoded by the MHC. A major class of microbial antigens associated with pathogenicity are lipoglycans. It is shown here that human CD1b presents the defined mycobacterial lipoglycan lipoarabinomannan (LAM) to alpha beta T cell receptor-bearing lymphocytes. Presentation of these lipoglycan antigens required internalization and endosomal acidification. The T cell recognition required mannosides with alpha(1-->2) linkages and a phosphatidylinositol unit. T cells activated by LAM produced interferon gamma and were cytolytic. Thus, an important class of microbial molecules, the lipoglycans, is a part of the universe of foreign antigens recognized by human T cells.	UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Colorado State University; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NIAID NIH HHS [AI 18357, AI 07118, AI 28973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018357, R37AI028973, R01AI028973, R37AI018357, R22AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BRODSKY FM, 1982, J IMMUNOL, V128, P129; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chatterjee D., UNPUB; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; HARDING CV, 1993, J IMMUNOL, V151, P2419; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; HUNTER SW, 1982, J BIOL CHEM, V257, P5072; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; PORCELI S, UNPUB; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; SIELING PA, UNPUB; WOO J, 1995, EUR J BIOCHEM, V207, P383; XU SM, 1994, J IMMUNOL, V153, P2568	27	673	684	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					227	230		10.1126/science.7542404	http://dx.doi.org/10.1126/science.7542404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542404				2022-12-01	WOS:A1995RJ02900041
J	SMITH, WC; MCKENDRY, R; RIBISI, S; HARLAND, RM				SMITH, WC; MCKENDRY, R; RIBISI, S; HARLAND, RM			A NODAL-RELATED GENE DEFINES A PHYSICAL AND FUNCTIONAL DOMAIN WITHIN THE SPEMANN ORGANIZER	CELL			English	Article							XENOPUS-LAEVIS; NEURAL INDUCTION; MESODERM INDUCTION; DORSAL MESODERM; INJECTED XWNT-8; EARLY RESPONSE; CELL MOTILITY; ACTIVIN; EMBRYOS; EXPRESSION	A functional screen for gene products that rescue dorsal development in ventralized Xenopus embryos has yielded Xenopus nodal-related 3 (Xnr3), a diverged member of the TGF beta superfamily. Xnr3 is specifically expressed in the Spemann organizer and is only expressed in the epithelial layer of the organizer immediately preceding and extending through gastrulation, Like noggin, Xnr3 can induce muscle in ventral mesoderm explants, consistent with a role in patterning the gastrula, In other ways, the activity of Xnr3 is different from noggin. Embryos receiving injections of Xnr3, particularly in the animal pole, send out tube-like extensions of tissue from the site of injection. These protrusions usually contain no axial mesoderm and only occasionally are positive for neural markers. It has previously been proposed that the epithelial layer of the organizer initiates and coordinates the morphogenetic movements at gastrulation. The protrusions observed may reflect an activity of Xnr3 in promoting morphogenesis.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								AMAYA E, 1993, DEVELOPMENT, V118, P477; BOLCE ME, 1992, DEVELOPMENT, V115, P681; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CONLON FL, 1991, DEVELOPMENT, V118, P969; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HARLAND R, 1988, DEVELOPMENT, V102, P837; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JOHNSON AD, 1994, GENE, V147, P233; JONES EA, 1989, DEVELOPMENT, V107, P785; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KNECHT AK, 1995, DEVELOPMENT, V121, P1911; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LETTICE LA, 1993, DEVELOPMENT, V117, P263; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; PIERCE SB, 1995, DEVELOPMENT, V121, P755; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHIH J, 1992, DEVELOPMENT, V116, P887; SHIH J, 1992, DEVELOPMENT, V116, P901; SHIH J, 1992, DEVELOPMENT, V116, P915; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; WILSON P, 1991, DEVELOPMENT, V112, P289; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	46	289	294	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					37	46		10.1016/0092-8674(95)90050-0	http://dx.doi.org/10.1016/0092-8674(95)90050-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606783	Bronze			2022-12-01	WOS:A1995RK42400007
J	SU, XZ; HEATWOLE, VM; WERTHEIMER, SP; GUINET, F; HERRFELDT, JA; PETERSON, DS; RAVETCH, JA; WELLEMS, TE				SU, XZ; HEATWOLE, VM; WERTHEIMER, SP; GUINET, F; HERRFELDT, JA; PETERSON, DS; RAVETCH, JA; WELLEMS, TE			THE LARGE DIVERSE GENE FAMILY VAR ENCODES PROTEINS INVOLVED IN CYTOADHERENCE AND ANTIGENIC VARIATION OF PLASMODIUM-FALCIPARUM-INFECTED ERYTHROCYTES	CELL			English	Article							HISTIDINE-RICH PROTEIN; PARASITIZED ERYTHROCYTES; MALARIA PARASITES; HOMOLOGOUS RECOMBINATION; ADHESION MOLECULE-1; MELANOMA-CELLS; P-FALCIPARUM; EXPRESSION; SEQUESTRATION; MEMBRANE	The human malaria parasite Plasmodium falciparum evades host immunity by varying the antigenic and adhesive character of infected erythrocytes. We describe a large and extremely diverse family of P. falciparum genes (var) that encode 200-350 kDa proteins having the expected properties of antigenically variant adhesion molecules. Predicted amino acid sequences of var genes show a variable extracellular segment with domains having receptor-binding features, a transmembrane sequence, and a terminal segment that is a probable submembrane anchor. There are 50-150 var genes on multiple parasite chromosomes, and some are in clustered arrangements. var probes detect two classes of transcripts in steady-state RNA: 7-9 kb var transcripts, and an unusual family of 1.8-2.4 kb transcripts that may be involved in expression or rearrangements of var genes.	SLOAN KETTERING INST, DEWITT WALLACE RES LAB, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	SU, XZ (corresponding author), NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Su, Xinzhuan/0000-0003-3246-3248				ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARDESHIR F, 1987, EMBO J, V6, P1421, DOI 10.1002/j.1460-2075.1987.tb02383.x; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BLOOM BR, 1979, NATURE, V279, P21, DOI 10.1038/279021a0; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; BROWN KN, 1973, NATURE, V242, P49, DOI 10.1038/242049a0; CARCY B, 1994, MOL BIOCHEM PARASIT, V68, P221, DOI 10.1016/0166-6851(94)90167-8; CHAIYAROJ SC, 1994, MOL BIOCHEM PARASIT, V67, P21, DOI 10.1016/0166-6851(94)90092-2; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN SA, 1993, MOL BIOCHEM PARASIT, V61, P137, DOI 10.1016/0166-6851(93)90166-U; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; ELLIS J, 1987, MOL BIOCHEM PARASIT, V26, P203, DOI 10.1016/0166-6851(87)90144-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HAYNES RO, 1992, CELL, V69, P11; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOMMEL M, 1985, IMMUNOL TODAY, V6, P28, DOI 10.1016/0167-5699(85)90165-3; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; HYNES RO, 1994, BIOESSAYS, V16, P663, DOI 10.1002/bies.950160912; LANGRETH SG, 1979, J EXP MED, V150, P1241, DOI 10.1084/jem.150.5.1241; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; LUSE SA, 1971, AM J TROP MED HYG, V20, P655, DOI 10.4269/ajtmh.1971.20.655; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Okada A, 1994, Semin Immunol, V6, P185, DOI 10.1006/smim.1994.1024; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1995, IN PRESS P NATL ACAD, V92; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SHARMA YD, 1987, MOL BIOCHEM PARASIT, V26, P11, DOI 10.1016/0166-6851(87)90124-1; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; SINNIS P, 1988, GENOMICS, V3, P287, DOI 10.1016/0888-7543(88)90117-6; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1994, GENE, V151, P225, DOI 10.1016/0378-1119(94)90661-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1987, EMBO J, V6, P1413, DOI 10.1002/j.1460-2075.1987.tb02382.x; UDEINYA IJ, 1983, NATURE, V303, P429, DOI 10.1038/303429a0; WEBER JL, 1988, MOL BIOCHEM PARASIT, V29, P117, DOI 10.1016/0166-6851(88)90066-7; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382	71	957	977	0	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					89	100		10.1016/0092-8674(95)90055-1	http://dx.doi.org/10.1016/0092-8674(95)90055-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606788	Bronze			2022-12-01	WOS:A1995RK42400012
J	THREADGILL, DW; DLUGOSZ, AA; HANSEN, LA; TENNENBAUM, T; LICHTI, U; YEE, D; LAMANTIA, C; MOURTON, T; HERRUP, K; HARRIS, RC; BARNARD, JA; YUSPA, SH; COFFEY, RJ; MAGNUSON, T				THREADGILL, DW; DLUGOSZ, AA; HANSEN, LA; TENNENBAUM, T; LICHTI, U; YEE, D; LAMANTIA, C; MOURTON, T; HERRUP, K; HARRIS, RC; BARNARD, JA; YUSPA, SH; COFFEY, RJ; MAGNUSON, T			TARGETED DISRUPTION OF MOUSE EGF RECEPTOR - EFFECT OF GENETIC BACKGROUND ON MUTANT PHENOTYPE	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; HAIR FOLLICLE; EXPRESSION; DIFFERENTIATION; ALPHA; SKIN; IMPLANTATION; ANTIBODIES; EMBRYOS; INVITRO	Gene targeting was used to create a null allele at the epidermal growth factor receptor locus (Egfr). The phenotype was dependent on genetic background. EGFR deficiency on a CF-1 background resulted in peri-implantation death due to degeneration of the inner cell mass. On a 129/Sv background, homozygous mutants died at mid-gestation due to placental defects; on a CD-1 background, the mutants lived for up to 3 weeks and showed abnormalities in skin, kidney, brain, liver, and gastrointestinal tract. The multiple abnormalities associated with EGFR deficiency indicate that the receptor is involved in a wide range of cellular activities.	CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,DEPT NEUROL,ALZHEIMER RES LAB,CLEVELAND,OH 44106; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University; Vanderbilt University; Vanderbilt University; Vanderbilt University			Threadgill, David W/N-4425-2013; Herrup, Karl/C-5313-2014	Threadgill, David W/0000-0003-3538-1635; Herrup, Karl/0000-0001-7786-5844	NICHD NIH HHS [HD26722, HD07104] Funding Source: Medline; NIGMS NIH HHS [GM14630] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014630] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON ED, 1990, MOL REPROD DEV, V27, P16, DOI 10.1002/mrd.1080270106; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; BRICE EC, 1993, DEV GENET, V14, P174, DOI 10.1002/dvg.1020140304; CAREY TE, 1992, MONOGR NATL CANCER I, V20, P75; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PARIA BC, 1990, P NATL ACAD SCI USA, V87, P4756, DOI 10.1073/pnas.87.12.4756; POIRIER F, 1991, DEVELOPMENT, V113, P1105; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; SASSOON D, 1993, GUIDE TECHNIQUES MOU, P384; TENHAVEOPBROEK AAW, 1988, ANAT REC, V221, P846, DOI 10.1002/ar.1092210409; TENNENBAUM T, 1992, CANCER RES, V52, P2966; THREADGILL DW, UNPUB; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; WOOD SA, 1989, J REPROD FERTIL, V85, P575, DOI 10.1530/jrf.0.0850575; ZELLER R, 1989, CUR PROT MOL BIOL	25	1194	1217	1	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					230	234		10.1126/science.7618084	http://dx.doi.org/10.1126/science.7618084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618084				2022-12-01	WOS:A1995RJ02900042
J	WODARZ, A; HINZ, U; ENGELBERT, M; KNUST, E				WODARZ, A; HINZ, U; ENGELBERT, M; KNUST, E			EXPRESSION OF CRUMBS CONFERS APICAL CHARACTER ON PLASMA-MEMBRANE DOMAINS OF ECTODERMAL EPITHELIA OF DROSOPHILA	CELL			English	Article							ADHESION MOLECULE UVOMORULIN; CELL-SURFACE POLARITY; FASCICLIN-III; ORGANIZATION; MELANOGASTER; PROTEIN; PATHWAYS; RECEPTOR; PRODUCT; ENCODES	The crumbs protein of Drosophila is an integral membrane protein, with 30 EGF-like and 4 laminin A G domain-like repeats in its extracellular segment, which is expressed on the apical plasma membrane of all ectodermally derived epithelia. Here, we present evidence to show that the insertion of crumbs into the plasma membrane is necessary and sufficient to confer apical character on a membrane domain. Overexpression of crumbs results in an enormous expansion of the apical plasma membrane and the concomitant reduction of the basolateral domain. This is followed by the redistribution of beta(Heavy)-spectrin, a component of the membrane cytoskeleton, and by the ectopic deposition of cuticle and other apical components into these areas. Strikingly, overexpression of the membrane-bound cytoplasmic portion of crumbs alone is sufficient to produce this dominant phenotype. Our results suggest that crumbs plays a key role in specifying the apical plasma membrane domain of ectodermal epithelial cells of Drosophila.	UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY	University of Cologne			Wodarz, Andreas/D-4642-2013; Knust, Elisabeth/B-4338-2017	Wodarz, Andreas/0000-0002-0007-6289; 				BRAND AH, 1993, DEVELOPMENT, V118, P401; Campos-Ortega JAVH, 1985, EMBRYONIC DEV DROSOP; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fleming Tom P., 1992, P111; Foe Victoria E., 1993, P149; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KNUST E, 1994, TRENDS GENET, V10, P275, DOI 10.1016/0168-9525(90)90010-4; KNUST E, 1993, DEVELOPMENT S, V119, P261; KORNEZOS A, 1992, MOL GEN GENET, V235, P397, DOI 10.1007/BF00279386; LAFONT F, 1994, NATURE, V372, P801; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; McNeill Helen, 1992, P53; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATTHY L, 1991, FEBS LETT, V289, P99, DOI 10.1016/0014-5793(91)80917-R; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P443; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHONBAUM CP, 1992, DEV BIOL, V151, P431, DOI 10.1016/0012-1606(92)90183-H; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; WARN RM, 1992, EPITHELIAL ORG DEV, P136; Wieschaus E., 1986, P199; WILEY LM, 1990, BIOESSAYS, V12, P67, DOI 10.1002/bies.950120204; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7	41	548	551	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 14	1995	82	1					67	76		10.1016/0092-8674(95)90053-5	http://dx.doi.org/10.1016/0092-8674(95)90053-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606787	Bronze			2022-12-01	WOS:A1995RK42400010
J	ZHENG, XF; FIORENTINO, D; CHEN, J; CRABTREE, GR; SCHREIBER, SL				ZHENG, XF; FIORENTINO, D; CHEN, J; CRABTREE, GR; SCHREIBER, SL			TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN	CELL			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN PHOSPHATASE; YEAST; MUTATIONS; VECTORS; TARGET	The rapamycin-sensitive signaling pathway is required to transduce specific mitogenic signals to the cell cycle machinery responsible for G1 progression. Genetic studies in yeast identified two related genes on this pathway, TOR1 and TOR2, thought to encode novel phosphatidylinositol kinases. We now show that an intact kinase domain is required for the G1 cell cycle functions of both proteins, for the ability of a mutation in a neighboring FKBP12-rapamycin-binding domain of the TOR1 protein to inhibit the growth of yeast cells when overexpressed, and for the essential function of the TOR2 protein. The G1 function of both TOR proteins is sensitive to rapamycin, but the essential function of TOR2 is not. Thus, FKBP12-rapamycin does not appear to inhibit the kinase activity of TOR proteins in a general way; instead, it may interfere selectively with TOR protein binding to or phosphorylation of G1 effecters.	HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Stanford University; Stanford University	ZHENG, XF (corresponding author), HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA.			Fiorentino, David/0000-0001-7951-3674; Chen, Jie/0000-0002-7887-3747	NCI NIH HHS [CA-39612] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039612, R37CA039612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11149; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; GUTHRIE C, 1991, METH ENZYMOL, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLOW E, 1988, ANTIBODIES; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIKORSKI RS, 1989, GENETICS, V122, P19; STACK JH, 1994, J BIOL CHEM, V269, P31552; STAN R, 1994, J BIOL CHEM, V269, P32027	22	244	254	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					121	130		10.1016/0092-8674(95)90058-6	http://dx.doi.org/10.1016/0092-8674(95)90058-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7606777	Bronze			2022-12-01	WOS:A1995RK42400015
J	ZHOU, JS; NOCEK, JM; DEVAN, ML; HOFFMAN, BM				ZHOU, JS; NOCEK, JM; DEVAN, ML; HOFFMAN, BM			INHIBITOR-ENHANCED ELECTRON-TRANSFER - COPPER CYTOCHROME-C AS A REDOX-INERT PROBE OF TERNARY COMPLEXES	SCIENCE			English	Article							CRYSTAL-STRUCTURE; EMISSION-SPECTRA; PEROXIDASE; BINDING; PROTEINS; PLASTOCYANIN; ABSORPTION	Copper-substituted cytochrome c (CuCc) has been used as a structurally faithful, redox-inert inhibitor to probe the mechanism of electron transfer (ET) between Cc molecules and cytochrome c peroxidase (CcP). This inhibitor enhances photoinduced ET quenching of the triplet excited state of a zinc-substituted protein (ZnCcP or ZnCc) by its iron(lll) partner (Fe(3+)Cc or Fe(3+)CcP). These results show that CcP and Cc form a ternary complex in which one Cc molecule binds tightly at a surface domain of CcP having low ET reactivity, whereas the second Cc molecule binds weakly to the 1:1 complex at a second domain I with markedly greater (similar to 10(3)) reactivity. These results also rule out the possibility that Cc bound at the second domain cooperatively enhances ET to Cc at the first domain. The multiphasic kinetics observed for the photoproduced ET intermediate do not reflect electron self-exchange between two Cc molecules within the ternary complex.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University			Nocek, Judith/D-1254-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013531, R01HL013531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13531] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNI H, 1995, BIOCHEMISTRY-US, V34, P5744, DOI 10.1021/bi00017a006; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; CHURCH WB, 1986, J BIOL CHEM, V261, P234; CLARKE MJ, 1991, STRUCT BONDING BERLI, V75; DIXON DW, 1989, BIOPHYS J, V56, P339, DOI 10.1016/S0006-3495(89)82680-3; ENGESETH HR, 1984, J BIOL CHEM, V259, P4822; FINDLAY MC, 1977, J AM CHEM SOC, V99, P5168, DOI 10.1021/ja00457a043; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; KANG CH, 1977, J BIOL CHEM, V252, P919; LIU RQ, 1995, BIOCHEMISTRY-US, V34, P973, DOI 10.1021/bi00003a032; MAUK MR, 1994, BIOCHEMISTRY-US, V33, P12609, DOI 10.1021/bi00208a011; MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/ja00062a035; MOORE GR, 1980, J INORG BIOCHEM, V12, P1, DOI 10.1016/S0162-0134(00)80039-2; MOSER CC, 1988, BIOCHEMISTRY-US, V27, P2450, DOI 10.1021/bi00407a031; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; Sigel H., 1991, METAL IONS BIOL SYST, V27; SILVERMAN RB, 1988, MECHANISM BASED ENZY; STEMP EDA, 1993, BIOCHEMISTRY-US, V32, P10848, DOI 10.1021/bi00091a041; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; VANDERKOOI JM, 1975, EUR J BIOCHEM, V60, P199, DOI 10.1111/j.1432-1033.1975.tb20992.x; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; WALLIN SA, 1991, J AM CHEM SOC, V113, P1842, DOI 10.1021/ja00005a065; ZHANG QP, 1991, MOL CRYST LIQ CRYST, V194, P343, DOI 10.1080/00268949108041186; Zhou J.-S., UNPUB; ZHOU JS, 1993, J AM CHEM SOC, V115, P10796, DOI 10.1021/ja00076a042; ZHOU JS, 1993, J AM CHEM SOC, V115, P11008, DOI 10.1021/ja00076a076; ZHOU JS, 1994, SCIENCE, V265, P1693, DOI 10.1126/science.8085152	33	56	57	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 14	1995	269	5221					204	207		10.1126/science.7618081	http://dx.doi.org/10.1126/science.7618081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618081				2022-12-01	WOS:A1995RJ02900033
